doc_id,sentence,biomarker,medium,prediction
PMC5042010A,"For enrichment of ccfDNA from the recovered plasma, the QIAamp Circulating Nucleic Acid Kit was used along with the QIAVAC system as recommended by the manufacturer (Qiagen, Valencia, CA).",QIAVAC,plasma,1
PMC4096804A,"For the TCGA dataset, we analyzed RNA-seq data from 134 cases of OSCC with sufficient annotation to determine regional lymph node involvement.",TCGA,lymph,1
PMC4096804A,"For the TCGA dataset, we analyzed RNA-seq data from 134 cases of OSCC with sufficient annotation to determine regional lymph node involvement.",OSCC,lymph,1
PMC4096804A,"For the TCGA dataset, we analyzed RNA-seq data from 134 cases of OSCC with sufficient annotation to determine regional lymph node involvement.",RNA,lymph,1
PMC5458215A,"Cells were cultured at 37degC in 5% CO2 in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin and streptomycin in a 10-ml culture dish.",CO2,serum,1
PMC5458215A,"Cells were cultured at 37degC in 5% CO2 in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin and streptomycin in a 10-ml culture dish.",RPMI-1640,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",SMAD4,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",AR,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",SMAD3,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",AR,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",AR,serum,1
PMC4202120A,"While SMAD3 contributes to activation of AR transcriptional activity, SMAD4, together with SMAD3 can also interact with AR and repress AR mediated transcription [195].Radiation therapy frequently employed for treatment of PCa can increase levels of serum TGFb and promote distant metastasis.",SMAD3,serum,1
PMC5378227A,Serum p53 antibodies had the highest sensitivity among TAAs in our panel: 15.0% in the test cohort and 16.5% in the validation cohort.,p53,Serum,1
PMC3476529A,"In blood, typical CD141+ DCs are a distinct population with lower CD11c expression.",CD141,blood,-1
PMC3476529A,"In blood, typical CD141+ DCs are a distinct population with lower CD11c expression.",CD11c,blood,-1
PMC3476529A,"CD141hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14+ DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages.",FLT3,blood,1
PMC3476529A,"CD141hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14+ DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages.",CD14,blood,1
PMC3476529A,"CD141hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14+ DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages.",CSFR,blood,1
PMC3476529A,"CD141hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14+ DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages.",CLEC9A,blood,1
PMC3476529A,"CD141hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14+ DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages.",CX3CR1,blood,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",TGFBI,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",TGFBI,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",TGFBI,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",CENPF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",CENPF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",CENPF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",UNC45A,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",UNC45A,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",UNC45A,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RPLP0,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",SH3GL1,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",SH3GL1,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",SH3GL1,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",MIF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",MIF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",MIF,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3548755A,"Characteristics of screening serum setsThe levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).The levels of serum antibodies to SH3GL1 were significantly higher in patients with low-grade glioma than those with high-grade glioma (P = 0.0243) and healthy volunteers (P = 0.0045) (Figure2A).",RIP,serum,1
PMC3266428A,"Although RNA and DNA were extracted from peripheral blood and not adipose tissue, the gene expression profiles, in terms of pathways perturbed, have been shown to have considerable overlap (43).",RNA,blood,-1
PMC3266428A,"Although RNA and DNA were extracted from peripheral blood and not adipose tissue, the gene expression profiles, in terms of pathways perturbed, have been shown to have considerable overlap (43).",DNA,blood,-1
PMC3476529A,Parallel phenotypic analysis suggests that they are potentially related to blood CD141+ DCs.,CD141,blood,-1
PMC3476529A,"To clarify that CD141hi DCs were tissue residents and not contaminating blood cells, we estimated their frequency relative to CD45+ mononuclear cells.",CD45,blood,-1
PMC3494970A,"These YFP+ bile ducts were identified by co-staining for YFP and SOX9, osteopontin (OPN) or cytokeratin 19 (CK19)1 (Figure 3A).A number of hepatocytes also expressed YFP in the postnatal period.",OPN,bile,1
PMC3494970A,"These YFP+ bile ducts were identified by co-staining for YFP and SOX9, osteopontin (OPN) or cytokeratin 19 (CK19)1 (Figure 3A).A number of hepatocytes also expressed YFP in the postnatal period.",YFP,bile,1
PMC3494970A,"These YFP+ bile ducts were identified by co-staining for YFP and SOX9, osteopontin (OPN) or cytokeratin 19 (CK19)1 (Figure 3A).A number of hepatocytes also expressed YFP in the postnatal period.",SOX9,bile,1
PMC3494970A,"These YFP+ bile ducts were identified by co-staining for YFP and SOX9, osteopontin (OPN) or cytokeratin 19 (CK19)1 (Figure 3A).A number of hepatocytes also expressed YFP in the postnatal period.",YFP,bile,1
PMC4523269A,"After ablation of bulge cells (red X's), hair germ (HG) cells (green) recolonize the bulge niche and mediate hair regeneration (16).View larger versionFig. 6.",X,hair,-1
PMC4523269A,"After ablation of bulge cells (red X's), hair germ (HG) cells (green) recolonize the bulge niche and mediate hair regeneration (16).View larger versionFig. 6.",X,hair,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD14,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD14,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CLEC9A,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CLEC9A,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",XCR1,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",XCR1,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD141,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD141,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD14,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD14,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",TLR3,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",TLR3,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CADM1,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CADM1,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD141,blood,-1
PMC3476529A,"Mindful that CD141 expression was also found on CD14+ DCs and some CD1c+ DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A).As expected, XCR1, TLR3, CLEC9A, and CADM1 were upregulated on blood CD141+ DCs compared with blood CD1c+ DCs and CD14+ monocytes (Figure 2B).",CD141,blood,-1
PMC5505023A,"The cells were then washed three times for 5 min with PBS, permeabilised with 0.1% Triton X-100 in PBS for 10 min and blocked with 6% rat serum in PBS for 30 min at room temperature.",X-100,serum,1
PMC5505023A,"The cells were then washed three times for 5 min with PBS, permeabilised with 0.1% Triton X-100 in PBS for 10 min and blocked with 6% rat serum in PBS for 30 min at room temperature.",PBS,serum,1
PMC5505023A,"The cells were then washed three times for 5 min with PBS, permeabilised with 0.1% Triton X-100 in PBS for 10 min and blocked with 6% rat serum in PBS for 30 min at room temperature.",PBS,serum,1
PMC5505023A,"The cells were then washed three times for 5 min with PBS, permeabilised with 0.1% Triton X-100 in PBS for 10 min and blocked with 6% rat serum in PBS for 30 min at room temperature.",PBS,serum,1
PMC3548755A,"The serum antibody levels to SH3GL1 mut-1 and mut-3 in the patients with low-grade glioma were still significantly higher than those in other groups (Figures4B and D), while the levels of anti-SH3GL1 mut-2 showed no difference among the groups (Figure4C).",SH3GL1,serum,1
PMC3548755A,"The serum antibody levels to SH3GL1 mut-1 and mut-3 in the patients with low-grade glioma were still significantly higher than those in other groups (Figures4B and D), while the levels of anti-SH3GL1 mut-2 showed no difference among the groups (Figure4C).",SH3GL1,serum,1
PMC2441949A,Diagnostic accuracies of cancer-associated genes for detection of metastatic disease in lymph nodes derived from CRC patientsSee full tableTable 3.,CRC,lymph,1
PMC1523209A,"Ep-CAM expression is used to identify single tumor cells that have disseminated to lymph nodes and are associated with a poor prognosis [24,30,31].",CAM,lymph,-1
PMC4253434A,We generated conditioned media from Trop2 knockdown and control cells by growing cells in serum-free media for twenty-four hours and added this media to the different cell populations that had been serum starved for two hours.,Trop2,serum,1
PMC4253434A,We generated conditioned media from Trop2 knockdown and control cells by growing cells in serum-free media for twenty-four hours and added this media to the different cell populations that had been serum starved for two hours.,Trop2,serum,1
PMC5513028A,e Conditioned media were prepared by incubating vector-control or Trop2-knockdown cells in serum-free media for 24 h. MMP2 activities are analyzed by gelatin zymography.,MMP2,serum,1
PMC3126726A,"PBL, peripheral blood lymphocyte.",PBL,blood,-1
PMC3885479A,"In contrast, no significant correlation was discovered between TIMP-1 expression and other clinical items, such as gender, age, tobacco and alcohol consumption, TNM stage and lymph node metastasis.",TIMP-1,lymph,1
PMC3885479A,"In contrast, no significant correlation was discovered between TIMP-1 expression and other clinical items, such as gender, age, tobacco and alcohol consumption, TNM stage and lymph node metastasis.",TNM,lymph,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",BST2,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",TROP2,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",SPSS,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",TSPAN6,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",CRC,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",NGFR,plasma,1
PMC4606116A,"All analyses were performed using the statistical software, Statistical Package for the Social Sciences (Version 13.0, SPSS Inc., Chicago, IL).Four candidate proteins, including TROP2, TSPAN6, BST2, and NGFR, were selected for initial verification by ELISA in plasma samples from 32 CRC patients and 32 healthy controls.",ELISA,plasma,1
PMC3474961A,"Zhang et al. have demonstrated that overexpression of CCL2 by bone marrow osteoblasts, endothelial cells, stromal cells, as well as PCa cells leads to protection of PCa cells from death through autophagy, and is mediated through activation of protein kinase B or Akt/PI3K survival pathways.",CCL2,bone marrow,1
PMC3474961A,"Zhang et al. have demonstrated that overexpression of CCL2 by bone marrow osteoblasts, endothelial cells, stromal cells, as well as PCa cells leads to protection of PCa cells from death through autophagy, and is mediated through activation of protein kinase B or Akt/PI3K survival pathways.",PI3,bone marrow,1
PMC4650945A,Cholestatic liver injury was induced by ligation of the common bile duct (CBDL) and toxic liver injury by injection of carbon tetrachloride in mice.,CBDL,bile,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IFN,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IFN,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IFN,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SB431542,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SB431542,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SB431542,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",FLT3L,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",FLT3L,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",FLT3L,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",CSF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",CSF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",Gas6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",Gas6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",Gas6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",CSF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TPO,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TPO,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TPO,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-6,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SCF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SCF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",SCF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",GM,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",RD,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",RD,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",RD,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TNF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TNF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TNF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",TGF,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-4,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-4,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",IL-4,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",LY2109761,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",LY2109761,CSF,1
PMC3478937A,"Human stem cell factor (SCF), thrombopoietin (TPO), TNF, GM-CSF, fms-related tyrosine kinase 3 ligand (FLT3L), IL-6, IL-4, and human/mouse M-CSF were obtained from PeproTech; TGF-b1, IFN-g, IL-1b, and recombinant human Gas6 were purchased from RD Systems; mouse GM-CSF was from Akron Biotech, TGF-b receptor I/II inhibitor LY2109761 was provided by Eli Lilly and Company, and TGF-b receptor I inhibitor SB431542 was from GlaxoSmithKline.",LY2109761,CSF,1
PMC5513028A,"f Gelaltin zymography analysis of serum-free conditioned medium from FTC-133-vector, FTC-133-Trop2 cellsTo investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown.",MMP2,serum,1
PMC5513028A,"f Gelaltin zymography analysis of serum-free conditioned medium from FTC-133-vector, FTC-133-Trop2 cellsTo investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown.",AP1,serum,1
PMC5513028A,"f Gelaltin zymography analysis of serum-free conditioned medium from FTC-133-vector, FTC-133-Trop2 cellsTo investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown.",Trop2,serum,1
PMC5513028A,"f Gelaltin zymography analysis of serum-free conditioned medium from FTC-133-vector, FTC-133-Trop2 cellsTo investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown.",MMP2,serum,1
PMC5513028A,"f Gelaltin zymography analysis of serum-free conditioned medium from FTC-133-vector, FTC-133-Trop2 cellsTo investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown.",Trop2,serum,1
PMC2722670A,"(clone F25) (ras-NIH3T3) [27,28] were cultured in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 5% heat-inactivated bovine serum.",NIH3T3,serum,1
PMC2722670A,"(clone F25) (ras-NIH3T3) [27,28] were cultured in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 5% heat-inactivated bovine serum.",F25,serum,1
PMC4606116A,"The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 +- 3.00 ng/mL versus 63.05 +- 5.61 ng/mL (p = 0.02), 68.15 +- 1.02 pg/mL versus 65.02 +- 0.01 pg/mL (p  0.01), 2.23 +- 0.20 ng/mL versus 1.13 +- 0.06 ng/mL (p  0.01), and 140.00 +- 3.85 pg/mL versus 314.40 +- 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)).",BST2,plasma,1
PMC4606116A,"The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 +- 3.00 ng/mL versus 63.05 +- 5.61 ng/mL (p = 0.02), 68.15 +- 1.02 pg/mL versus 65.02 +- 0.01 pg/mL (p  0.01), 2.23 +- 0.20 ng/mL versus 1.13 +- 0.06 ng/mL (p  0.01), and 140.00 +- 3.85 pg/mL versus 314.40 +- 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)).",CRC,plasma,1
PMC4606116A,"The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 +- 3.00 ng/mL versus 63.05 +- 5.61 ng/mL (p = 0.02), 68.15 +- 1.02 pg/mL versus 65.02 +- 0.01 pg/mL (p  0.01), 2.23 +- 0.20 ng/mL versus 1.13 +- 0.06 ng/mL (p  0.01), and 140.00 +- 3.85 pg/mL versus 314.40 +- 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)).",TSPAN6,plasma,1
PMC4606116A,"The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 +- 3.00 ng/mL versus 63.05 +- 5.61 ng/mL (p = 0.02), 68.15 +- 1.02 pg/mL versus 65.02 +- 0.01 pg/mL (p  0.01), 2.23 +- 0.20 ng/mL versus 1.13 +- 0.06 ng/mL (p  0.01), and 140.00 +- 3.85 pg/mL versus 314.40 +- 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)).",TROP2,plasma,1
PMC4606116A,"The plasma levels of TROP2, TSPAN6, BST2, and NGFR in CRC patients and healthy controls were determined to be 48.88 +- 3.00 ng/mL versus 63.05 +- 5.61 ng/mL (p = 0.02), 68.15 +- 1.02 pg/mL versus 65.02 +- 0.01 pg/mL (p  0.01), 2.23 +- 0.20 ng/mL versus 1.13 +- 0.06 ng/mL (p  0.01), and 140.00 +- 3.85 pg/mL versus 314.40 +- 137.00 pg/mL (p = 0.20), respectively (Figure 1(a)).",NGFR,plasma,1
PMC4777741A,"Taken together, these results suggest that P. aeruginosa induced activated PKC translocate to the plasma membrane.",PKC,plasma,1
PMC5437009A,"We identified three prognostic factors, including FIGO stage, Lymph node metastasis and CKAP2 expression, can served as independent prognostic factors for poor overall survival.",CKAP2,Lymph,1
PMC5437009A,"We identified three prognostic factors, including FIGO stage, Lymph node metastasis and CKAP2 expression, can served as independent prognostic factors for poor overall survival.",FIGO,Lymph,1
PMC3443948A,"Cubas et al (2010) demonstrated that mouse Trop-2 could activate ERK and promote cell proliferation in pancreatic and colon CL in low serum condition and in a mouse animal model (Cubas et al, 2010).",Trop-2,serum,1
PMC3443948A,"Cubas et al (2010) demonstrated that mouse Trop-2 could activate ERK and promote cell proliferation in pancreatic and colon CL in low serum condition and in a mouse animal model (Cubas et al, 2010).",ERK,serum,1
PMC3551651A,"Tissue sections were incubated with mouse anti-aB-crystallin antibody (Stressgen, Victoria, Canada; 1:300) in TBS containing 1% bovine serum albumin for 1 h. After washing, sections were incubated with EnVision goat anti-mouse/horseradish peroxidase antibody (EB-2305, ZhongShan, Godbridge, China; 1:2000) for 1 h. The replacement of the primary antibody with PBS served as negative controls.",EB-2305,serum,1
PMC3551651A,"Tissue sections were incubated with mouse anti-aB-crystallin antibody (Stressgen, Victoria, Canada; 1:300) in TBS containing 1% bovine serum albumin for 1 h. After washing, sections were incubated with EnVision goat anti-mouse/horseradish peroxidase antibody (EB-2305, ZhongShan, Godbridge, China; 1:2000) for 1 h. The replacement of the primary antibody with PBS served as negative controls.",PBS,serum,1
PMC3551651A,"Tissue sections were incubated with mouse anti-aB-crystallin antibody (Stressgen, Victoria, Canada; 1:300) in TBS containing 1% bovine serum albumin for 1 h. After washing, sections were incubated with EnVision goat anti-mouse/horseradish peroxidase antibody (EB-2305, ZhongShan, Godbridge, China; 1:2000) for 1 h. The replacement of the primary antibody with PBS served as negative controls.",TBS,serum,1
PMC5000705A,"Interestingly, and also in contrast to the primary tumor, E-cadherin expression is high, EMT-transcription factors are upregulated, while Ki67-rates are decreased in lymph nodes, which might be kind of a survival strategy [39].",EMT,lymph,-1
PMC5000705A,"Interestingly, and also in contrast to the primary tumor, E-cadherin expression is high, EMT-transcription factors are upregulated, while Ki67-rates are decreased in lymph nodes, which might be kind of a survival strategy [39].",cadherin,lymph,-1
PMC4606116A,"This analysis suggests that the plasma levels of TROP2 and BST2 might have been significantly altered in CRC patients, which deserves further verification in a large sample set.",BST2,plasma,1
PMC4606116A,"This analysis suggests that the plasma levels of TROP2 and BST2 might have been significantly altered in CRC patients, which deserves further verification in a large sample set.",CRC,plasma,1
PMC4606116A,"This analysis suggests that the plasma levels of TROP2 and BST2 might have been significantly altered in CRC patients, which deserves further verification in a large sample set.",TROP2,plasma,1
PMC4275355A,"Recent lineage tracing revealed that the expression of oncogenic Kras (KrasG12D) and the conditional deletion of tumor suppressor p53 in hair follicle ASCs (through the use of the K15-CrePR allele) resulted in the initiation of tumors, while no tumors were observed in its descendent TACs (through the use of the Shh-CreER allele), which were also exposed to the same oncogenic mutation [75,76].",p53,hair,-1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",YKL-40,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",YKL-40,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",HMGA1,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",HMGA1,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",hTERT,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",hTERT,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",ELISA,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",ELISA,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",TIMP-1,serum,1
PMC5480073A,"Concentrations were measured as absorbance at 450 nm for hTERT and YKL-40 and for TIMP-1 using correction wavelength of 540 nm in ELISA Reader (Bio-Rad, United States).HMGA-1 by Western blot: To estimate circulating HMGA1 protein in serum of the patient using minimal sample volume, 10 mL serum was subjected to protein extraction using a spin column for removing high abundance proteins, yielding = 30 mg/mL of total protein.",TIMP-1,serum,1
PMC3569867A,"As previously suggested, low calcium, serum free culture conditions that support human prostate stem/progenitor growth appears to select exclusively for normal cells, since the TMPRSS-ERG fusion was never observed in the prostaspheres derived from fusion positive tissue specimens [11,12,24].Human prostate tissue was obtained from 59 patients (ages 41-76), undergoing prostate surgery (radical prostatectomy or cystoprostatectomy).",TMPRSS,serum,1
PMC3569867A,"As previously suggested, low calcium, serum free culture conditions that support human prostate stem/progenitor growth appears to select exclusively for normal cells, since the TMPRSS-ERG fusion was never observed in the prostaspheres derived from fusion positive tissue specimens [11,12,24].Human prostate tissue was obtained from 59 patients (ages 41-76), undergoing prostate surgery (radical prostatectomy or cystoprostatectomy).",ERG,serum,1
PMC5042010A,Typically the amount of ccfDNA and ctcDNA recovered per blood draw is sufficient to produce patient matched NGS libraries.,NGS,blood,-1
PMC4096804A,"Towards independent confirmation of OCAMP-B performance, we used a 22 patient OSCC dataset from UPENN (30) and saw excellent stratification (21/22 tumors correct) with respect to lymph node metastatic status (Figure 5A, Table S18).",OCAMP,lymph,1
PMC4096804A,"Towards independent confirmation of OCAMP-B performance, we used a 22 patient OSCC dataset from UPENN (30) and saw excellent stratification (21/22 tumors correct) with respect to lymph node metastatic status (Figure 5A, Table S18).",S18,lymph,1
PMC4096804A,"Towards independent confirmation of OCAMP-B performance, we used a 22 patient OSCC dataset from UPENN (30) and saw excellent stratification (21/22 tumors correct) with respect to lymph node metastatic status (Figure 5A, Table S18).",OSCC,lymph,1
PMC4096804A,"Towards independent confirmation of OCAMP-B performance, we used a 22 patient OSCC dataset from UPENN (30) and saw excellent stratification (21/22 tumors correct) with respect to lymph node metastatic status (Figure 5A, Table S18).",UPENN,lymph,1
PMC3786374A,"However, secreted TGFb1 in the serum was higher as early at age 3 months and persistently higher at 5 months in ThrbPV/PV mice than in WT mice (Figure 3C).",TGFb1,serum,1
PMC3548755A,"Serum antibody levels were examined by ELISA with SH3GL1 muta-1 (B), mut-2 (C), mut-3 (D) and mut-4 (E), and the 10-20 amino acids at the C-terminal end were indicated as the epitope site.",SH3GL1,Serum,1
PMC3548755A,"Serum antibody levels were examined by ELISA with SH3GL1 muta-1 (B), mut-2 (C), mut-3 (D) and mut-4 (E), and the 10-20 amino acids at the C-terminal end were indicated as the epitope site.",ELISA,Serum,1
PMC5085135A,"The cells in RPIM-1640 medium containing 10% fetal calf serum were plated at 2x103 cells per well in 96-well tissue culture plates, and grew for 6 days.",RPIM-1640,serum,1
PMC4606116A,"We then performed extended verification of TROP2 and BST2 in another independent plasma sample set, consisting of 120 CRC patients and 120 controls.",BST2,plasma,1
PMC4606116A,"We then performed extended verification of TROP2 and BST2 in another independent plasma sample set, consisting of 120 CRC patients and 120 controls.",CRC,plasma,1
PMC4606116A,"We then performed extended verification of TROP2 and BST2 in another independent plasma sample set, consisting of 120 CRC patients and 120 controls.",TROP2,plasma,1
PMC5505023A,"It has been found that hepatic progenitor cells (HPCs) become activated in patients with chronic hepatitis C or B, HCC or other severe liver diseases, and damage occurs to liver cells and bile duct epithelial cells (7).",HCC,bile,-1
PMC4882422A,"E, serum GPT levels in the Ptenfl/fl and the PtenDhep mice stimulated with LPS after treated with or without the anti-oxidant N-acetyl-l-cysteine.",LPS,serum,1
PMC4882422A,"E, serum GPT levels in the Ptenfl/fl and the PtenDhep mice stimulated with LPS after treated with or without the anti-oxidant N-acetyl-l-cysteine.",GPT,serum,1
PMC5480073A,"Longitudinal changes in plasma levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have also been seen to be associated with prognosis of GBM (grade-IV) patients[12], reflecting the role of TIMP-1 in invasive growth pattern resulting from degradation of extracellular matrix.",TIMP-1,plasma,1
PMC5480073A,"Longitudinal changes in plasma levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have also been seen to be associated with prognosis of GBM (grade-IV) patients[12], reflecting the role of TIMP-1 in invasive growth pattern resulting from degradation of extracellular matrix.",TIMP-1,plasma,1
PMC5480073A,"Longitudinal changes in plasma levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have also been seen to be associated with prognosis of GBM (grade-IV) patients[12], reflecting the role of TIMP-1 in invasive growth pattern resulting from degradation of extracellular matrix.",GBM,plasma,1
PMC5289527A,"Subsequently, using an acute KD whole blood transcriptome data set, eQTL analysis of the common SNVs suggested decreased transcript levels of IL6 and higher ESR at diagnosis in individuals homozygous for the risk allele.",eQTL,blood,-1
PMC5289527A,"Subsequently, using an acute KD whole blood transcriptome data set, eQTL analysis of the common SNVs suggested decreased transcript levels of IL6 and higher ESR at diagnosis in individuals homozygous for the risk allele.",ESR,blood,-1
PMC5289527A,"Subsequently, using an acute KD whole blood transcriptome data set, eQTL analysis of the common SNVs suggested decreased transcript levels of IL6 and higher ESR at diagnosis in individuals homozygous for the risk allele.",IL6,blood,-1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",Tween-20,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",PBS,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",T,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",T,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",PBS,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",PBS,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",PBS,serum,1
PMC4344740A,"The plates were blocked with 150 ml of 1% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h, washed 4 times with 0.1% Tween-20 in PBS (PBS-T) and incubated with 50 ml of purified antigens (10 mg/ml) in PBS-T. Plates were left overnight at 4degC. After 4 washes with PBS-T, 50 ml of serum diluted at 1:200 in a blocking buffer were added to each well and incubated for 2 h.",PBS,serum,1
PMC1523209A,"In SCC of the lung, strong Ep-CAM expression was positively correlated to lymph node metastasis and larger tumors, however a correlation to survival could not been demonstrated [29].Several lines of evidence point to the importance of this molecule in the early phase of squamous cell cancer progression.",CAM,lymph,1
PMC1523209A,"In SCC of the lung, strong Ep-CAM expression was positively correlated to lymph node metastasis and larger tumors, however a correlation to survival could not been demonstrated [29].Several lines of evidence point to the importance of this molecule in the early phase of squamous cell cancer progression.",SCC,lymph,1
PMC4344740A,Each blood sample was tested in duplicate against GST-antigen fusion protein or control GST alone from a non-recombinant pGEX vector.,pGEX,blood,1
PMC4344740A,Each blood sample was tested in duplicate against GST-antigen fusion protein or control GST alone from a non-recombinant pGEX vector.,GST,blood,1
PMC4344740A,Each blood sample was tested in duplicate against GST-antigen fusion protein or control GST alone from a non-recombinant pGEX vector.,GST,blood,1
PMC5467782A,Tian et al (39) characterized the expression profiles of miRNAs in sera and in tissues collected from NSCLC patients and found that miR-181b-5p was upregulated in serum and tissue of SCC patients.,NSCLC,sera,1
PMC5467782A,Tian et al (39) characterized the expression profiles of miRNAs in sera and in tissues collected from NSCLC patients and found that miR-181b-5p was upregulated in serum and tissue of SCC patients.,NSCLC,serum,1
PMC5467782A,Tian et al (39) characterized the expression profiles of miRNAs in sera and in tissues collected from NSCLC patients and found that miR-181b-5p was upregulated in serum and tissue of SCC patients.,SCC,sera,1
PMC5467782A,Tian et al (39) characterized the expression profiles of miRNAs in sera and in tissues collected from NSCLC patients and found that miR-181b-5p was upregulated in serum and tissue of SCC patients.,SCC,serum,1
PMC3478937A,DCs were generated from mouse BM in the presence of GM-CSF with or without TGF-b1.,GM,CSF,1
PMC3478937A,DCs were generated from mouse BM in the presence of GM-CSF with or without TGF-b1.,TGF,CSF,1
PMC3478937A,"Epidermis was fixed in acetone, blocked with PBS containing 10% goat serum and 4% BSA, and stained with Abs against I-A/I-E (PE conjugated, 1:400; BioLegend) and CD207 (Alexa Fluor 488 conjugated, 1:300; Dendritics) to visualize LCs and Abs against gd-TCR (PE-conjugated, 1:400; BD) to visualize dendritic-epidermal T cells, respectively.",PBS,serum,1
PMC3478937A,"Epidermis was fixed in acetone, blocked with PBS containing 10% goat serum and 4% BSA, and stained with Abs against I-A/I-E (PE conjugated, 1:400; BioLegend) and CD207 (Alexa Fluor 488 conjugated, 1:300; Dendritics) to visualize LCs and Abs against gd-TCR (PE-conjugated, 1:400; BD) to visualize dendritic-epidermal T cells, respectively.",BSA,serum,1
PMC3478937A,"Epidermis was fixed in acetone, blocked with PBS containing 10% goat serum and 4% BSA, and stained with Abs against I-A/I-E (PE conjugated, 1:400; BioLegend) and CD207 (Alexa Fluor 488 conjugated, 1:300; Dendritics) to visualize LCs and Abs against gd-TCR (PE-conjugated, 1:400; BD) to visualize dendritic-epidermal T cells, respectively.",CD207,serum,1
PMC3478937A,"Epidermis was fixed in acetone, blocked with PBS containing 10% goat serum and 4% BSA, and stained with Abs against I-A/I-E (PE conjugated, 1:400; BioLegend) and CD207 (Alexa Fluor 488 conjugated, 1:300; Dendritics) to visualize LCs and Abs against gd-TCR (PE-conjugated, 1:400; BD) to visualize dendritic-epidermal T cells, respectively.",T,serum,1
PMC3478937A,"Epidermis was fixed in acetone, blocked with PBS containing 10% goat serum and 4% BSA, and stained with Abs against I-A/I-E (PE conjugated, 1:400; BioLegend) and CD207 (Alexa Fluor 488 conjugated, 1:300; Dendritics) to visualize LCs and Abs against gd-TCR (PE-conjugated, 1:400; BD) to visualize dendritic-epidermal T cells, respectively.",TCR,serum,1
PMC3476529A,"Cells bearing related markers have previously been reported in the T cell areas of lymphoid tissues, bone marrow (Jongbloed et al., 2010), and in the spleen (Galibert et al., 2005; Poulin et al., 2010",T,bone marrow,1
PMC3418405A,"Notably, persistent inflammation in infected lymph nodes (LNs) leads to the deposition of collagen (6), a phenomenon that has been attributed in part to increased levels of TGF-b1 (7).",TGF,lymph,1
PMC3378878A,"(A) Chromatin from immortalized MEFs cultured in isotonic (300 mOsm/kg) or hypertonic medium (500 mOsm/kg, upon addition of 100 mM NaCl) without or with Torin1 (100 nM) was immunoprecipitated with preimmune rabbit serum (Pre) or a mixture of two rabbit polyclonal antibodies specific for NFAT5 (NFAT5).",NFAT5,serum,1
PMC3378878A,"(A) Chromatin from immortalized MEFs cultured in isotonic (300 mOsm/kg) or hypertonic medium (500 mOsm/kg, upon addition of 100 mM NaCl) without or with Torin1 (100 nM) was immunoprecipitated with preimmune rabbit serum (Pre) or a mixture of two rabbit polyclonal antibodies specific for NFAT5 (NFAT5).",Torin1,serum,1
PMC3378878A,"(A) Chromatin from immortalized MEFs cultured in isotonic (300 mOsm/kg) or hypertonic medium (500 mOsm/kg, upon addition of 100 mM NaCl) without or with Torin1 (100 nM) was immunoprecipitated with preimmune rabbit serum (Pre) or a mixture of two rabbit polyclonal antibodies specific for NFAT5 (NFAT5).",NFAT5,serum,1
PMC5437009A,"Weak expression of FAK in patients with cervical cancer is specifically correlated with pelvic lymph node metastasis and recurrent disease, resulting in a poor disease outcome32.",FAK,lymph,1
PMC3906064A,"A 0.2 mL aliquot of unprocessed blood was reserved and red blood cells (RBC) were removed with VersaLyse (Beckman Coulter, Brea, CA).",RBC,blood,-1
PMC3906064A,"A 0.2 mL aliquot of unprocessed blood was reserved and red blood cells (RBC) were removed with VersaLyse (Beckman Coulter, Brea, CA).",RBC,blood,-1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",CI,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",HR,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",PVTT,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",HR,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",CI,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",AFP,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",CI,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",CI,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",HR,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",CI,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",HR,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",HR,serum,1
PMC3981717A,"Univariate Cox regression analyses showed a significant poorer overall survival in patients with high level of serum AFP (HR, 1.63; 95% CI, 1.31-2.03, P0.0001), in patients with larger size of tumor (HR, 2.53; 95% CI, 1.96-3.27; P0.0001), in patients with multiple lesions (HR, 1.40; 95% CI, 1.12-1.75; P = 0.003), in patients with higher degree of BCLC stage (HR, 2.18; 95% CI, 1.75-2.71, P0.0001), and in patients with existence of PVTT (HR, 2.43; 95% CI, 1.93-3.05; P0.0001) when compared with corresponding control patients groups.",BCLC,serum,1
PMC3548755A,"In contrast, the lower serum autoantibody levels against these determined SEREX-antigens in patients with high-grade glioma as opposed to those with low-grade glioma and healthy volunteers suggest that the existence of some immunosuppressive mechanisms in high-grade gliomas.",SEREX,serum,1
PMC3476529A,Our transcriptomic analysis indicates that CD14+ DCs are related to blood monocytes rather than the cross-presenting DCs of mouse tissues and human blood.,CD14,blood,-1
PMC3476529A,Our transcriptomic analysis indicates that CD14+ DCs are related to blood monocytes rather than the cross-presenting DCs of mouse tissues and human blood.,CD14,blood,-1
PMC5386687A,"On the day of transfection, a 6:1 ratio volume of Fugene (Promega E2691) to DNA amount was added to 800 uL of serum-free DMEM and incubated for 15 minutes at room temperature.",E2691,serum,1
PMC5386687A,"On the day of transfection, a 6:1 ratio volume of Fugene (Promega E2691) to DNA amount was added to 800 uL of serum-free DMEM and incubated for 15 minutes at room temperature.",DNA,serum,1
PMC5386687A,"On the day of transfection, a 6:1 ratio volume of Fugene (Promega E2691) to DNA amount was added to 800 uL of serum-free DMEM and incubated for 15 minutes at room temperature.",DMEM,serum,1
PMC5289527A,"In a study of African children, higher levels of TNFa were produced following in vitro stimulation with a specific TLR2/6 ligand in a whole blood assay when compared to children of European descent [34].We found 41 TLR6 variants located in the promoter, intron 1, exon 2, and the 3'UTR associated with KD susceptibility.",TLR6,blood,-1
PMC3929731A,"A, UHPLC-MS-MS chromatograms showing BPA and BPA-G in mouse serum from animals receiving 250 mg of BPA/kg BW in oil (solid line) or oil vehicle as a control (dashed line).",BPA,serum,1
PMC3929731A,"A, UHPLC-MS-MS chromatograms showing BPA and BPA-G in mouse serum from animals receiving 250 mg of BPA/kg BW in oil (solid line) or oil vehicle as a control (dashed line).",UHPLC,serum,1
PMC3929731A,"A, UHPLC-MS-MS chromatograms showing BPA and BPA-G in mouse serum from animals receiving 250 mg of BPA/kg BW in oil (solid line) or oil vehicle as a control (dashed line).",BPA,serum,1
PMC3929731A,"A, UHPLC-MS-MS chromatograms showing BPA and BPA-G in mouse serum from animals receiving 250 mg of BPA/kg BW in oil (solid line) or oil vehicle as a control (dashed line).",BPA,serum,1
PMC5494437A,"The wide spread glial plasticity between cell and tissue interactions of NCCs and non-NC derivatives of perivascular muscle, bone marrow and mesentery during development, injury and malignancy implicates NCC stem cell-like cells in diseases and neoplasia.",NCC,bone marrow,1
PMC3548755A,The level of anti-SH3GL1 autoantibody could be a novel low-grade glioma-specific serum marker.,SH3GL1,serum,1
PMC4707334A,"However, PW1+/Pax7- populations are negative for endothelial markers as proved by CD31 negative staining [38].Another muscle-resident population of nonsatellite progenitor cells is bipotent fibro/adipogenic progenitors (FAPs) localized in the muscle interstitium and neighboring to muscle-associated blood vessels.",CD31,blood,-1
PMC3561800A,"(E) The indicated cells were synchronized by a double block with 1 mM hydroxyurea; deprived of growth factors; treated with serum-free medium (-), 10% FBS, 10 ng/ml HGF, or 10 ng/ml NRG for 10 hours; and subjected to BrdU incorporation assay.",HGF,serum,1
PMC3561800A,"(E) The indicated cells were synchronized by a double block with 1 mM hydroxyurea; deprived of growth factors; treated with serum-free medium (-), 10% FBS, 10 ng/ml HGF, or 10 ng/ml NRG for 10 hours; and subjected to BrdU incorporation assay.",NRG,serum,1
PMC3561800A,"(E) The indicated cells were synchronized by a double block with 1 mM hydroxyurea; deprived of growth factors; treated with serum-free medium (-), 10% FBS, 10 ng/ml HGF, or 10 ng/ml NRG for 10 hours; and subjected to BrdU incorporation assay.",FBS,serum,1
PMC4882422A,"A histological assessment of inflammation, the serum GPT levels, and the gene expression of proinflammatory cytokines were suppressed in the PtenDhep/Tlr4-/- mice versus the PtenDhep mice (Fig. 1, B and C). Liver fibrosis became evident as inflammation persisted.",GPT,serum,1
PMC3369113A,"After three washes with serum-free RPMI/1% BSA, cells were maintained in suspension for 30 min at 37degC.",BSA,serum,1
PMC3963546A,"miR-141 expression strongly correlated with K19 expression in HCCs, and in the bile ducts (asterisk)/hepatic progenitor cells  (arrow) of the surrounding.",K19,bile,1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",CD14,blood,-1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",CD14,blood,-1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",FACS,blood,-1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",FACS,blood,-1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",DNA,blood,-1
PMC3476529A,"Representative data from two blood and skin donors for ""spiking"" experiment and five donors for skin explant migration are shown.(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs.",DNA,blood,-1
PMC3476529A,"Representative data from three skin donors are shown.(D) CD1c and CD1a expression by FACS-purified, Qtracker605-labeled blood CD141+ DCs cultured in medium (-Dermis) or with digesting dermis (+Dermis) and migrated CD141hi cells from 60 hr skin explants cultured ex vivo (Migrants).",FACS,blood,1
PMC3476529A,"Representative data from three skin donors are shown.(D) CD1c and CD1a expression by FACS-purified, Qtracker605-labeled blood CD141+ DCs cultured in medium (-Dermis) or with digesting dermis (+Dermis) and migrated CD141hi cells from 60 hr skin explants cultured ex vivo (Migrants).",CD141,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(C) Relative expression of CD80, CD83, CD86, and CCR7 (blue) to isotype control (gray) by CD1a+CD1c+ and CD1a-CD1c- fractions of CD141hi cells in the skin (shown with their relative percentages).",CD83,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(C) Relative expression of CD80, CD83, CD86, and CCR7 (blue) to isotype control (gray) by CD1a+CD1c+ and CD1a-CD1c- fractions of CD141hi cells in the skin (shown with their relative percentages).",CCR7,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(C) Relative expression of CD80, CD83, CD86, and CCR7 (blue) to isotype control (gray) by CD1a+CD1c+ and CD1a-CD1c- fractions of CD141hi cells in the skin (shown with their relative percentages).",CD86,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(C) Relative expression of CD80, CD83, CD86, and CCR7 (blue) to isotype control (gray) by CD1a+CD1c+ and CD1a-CD1c- fractions of CD141hi cells in the skin (shown with their relative percentages).",CD80,blood,1
PMC3476529A,Composite data from four blood and seven skin donors are shown with mean +- SEM.,SEM,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,T,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,CD8,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,HLA,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,T,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,IFN,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,DC,blood,-1
PMC3476529A,CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91 CD8+ T cell clones at a DC:T cell ratio of 1:2.5.,s183,blood,-1
PMC5442765A,"We adopted and modified a culture system (i.e., WIT, a serum-free defined medium originally optimized for the robust culture of human primary mammary luminal progenitor cells [13]) to greatly enrich functional human prostatic luminal progenitors that can regenerate prostatic glands and can be tumorigenically transformed to generate prostate tumors in vivo.",WIT,serum,1
PMC3369113A,"Briefly, cells were starved in serum-free RPMI for 24h, then IGF-I was added at 100 ng/ml for 3 min.",RPMI,serum,1
PMC3369113A,"Briefly, cells were starved in serum-free RPMI for 24h, then IGF-I was added at 100 ng/ml for 3 min.",IGF,serum,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD14,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD14,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",FITC,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",FITC,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD14,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD14,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD141,blood,1
PMC3476529A,"*p  0.05, Mann-Whitney U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141hi DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple).",CD141,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",GIEMSA,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",GIEMSA,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",CD141,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",CD141,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",CD14,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",CD14,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",FACS,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",FACS,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",X100,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",X100,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",SEM,blood,1
PMC3476529A,"Representative data from three blood, skin, and lung donors are shown.(E and F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ DCs and monocytes (E) visualized by GIEMSA staining of cytospin preparations (X100) and (F) by SEM.",SEM,blood,1
PMC4596896A,High levels of CD33 expression have been reported in the bone marrow of AML patients while substantially lower levels of expression have been observed in normal bone marrow (21).,CD33,bone marrow,1
PMC4596896A,High levels of CD33 expression have been reported in the bone marrow of AML patients while substantially lower levels of expression have been observed in normal bone marrow (21).,CD33,bone marrow,1
PMC4596896A,High levels of CD33 expression have been reported in the bone marrow of AML patients while substantially lower levels of expression have been observed in normal bone marrow (21).,AML,bone marrow,1
PMC4596896A,High levels of CD33 expression have been reported in the bone marrow of AML patients while substantially lower levels of expression have been observed in normal bone marrow (21).,AML,bone marrow,1
PMC3476529A,"*p  0.05, Mann-Whitney U test.(D) Relative expression of FLT3, CLEC9A, MCSFR, and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray) from blood, skin, and lung.",CLEC9A,blood,-1
PMC3476529A,"*p  0.05, Mann-Whitney U test.(D) Relative expression of FLT3, CLEC9A, MCSFR, and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray) from blood, skin, and lung.",CD14,blood,-1
PMC3476529A,"*p  0.05, Mann-Whitney U test.(D) Relative expression of FLT3, CLEC9A, MCSFR, and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray) from blood, skin, and lung.",FLT3,blood,-1
PMC3476529A,"*p  0.05, Mann-Whitney U test.(D) Relative expression of FLT3, CLEC9A, MCSFR, and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray) from blood, skin, and lung.",CX3CR1,blood,-1
PMC3476529A,"*p  0.05, Mann-Whitney U test.(D) Relative expression of FLT3, CLEC9A, MCSFR, and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray) from blood, skin, and lung.",MCSFR,blood,-1
PMC5289527A,"IL6, a key cytokine controlled by the transcription factors NFKB and AP1 among others, is reported to be high in the serum of acute KD patients [35].",IL6,serum,-1
PMC5289527A,"IL6, a key cytokine controlled by the transcription factors NFKB and AP1 among others, is reported to be high in the serum of acute KD patients [35].",NFKB,serum,-1
PMC5289527A,"IL6, a key cytokine controlled by the transcription factors NFKB and AP1 among others, is reported to be high in the serum of acute KD patients [35].",AP1,serum,-1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",MAOA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",PSA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",MAOA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",MAOA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",PSA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",MAOA,serum,1
PMC4157741A,"In 18 of the 31 cases (58%) MAOA expression increased following treatment, and corresponding increases in MAOA protein levels were observed in three of three cases with elevated MAOA transcripts and sufficient tumor material in both pre- and post-treatment samples (Figure 1C,D).We incorporated the magnitude of MAOA mRNA alterations in a univariate Cox Proportional Hazard Model to estimate hazard ratios of several risk factors including age, baseline serum PSA before chemotherapy, pathologic stage, and histological Gleason grade, using time to PSA relapse as the clinical outcome.",mRNA,serum,1
PMC4621003A,"Flow cytometry analysis was performed to detect anti-D2F2/E2 (HER-2-positive cell line) specific (n = 5) or anti-D2F2 (HER-2-negative cell line) specific (n = 15) IgG antibodies by using 1:200 diluted serum and 250,000 cells per well.",D2F2,serum,1
PMC3548755A,"In the combined population of the first sampling test and the validation test, there was a significant difference between low-grade gliomas and high-grade gliomas (p = 0.0351).The same results of both ELISA based on the independent serum sets support the possibility that SH3GL1 is aberrantly expressed and efficiently elicits a systemic immune response in low-grade glioma patients.",SH3GL1,serum,1
PMC3548755A,"In the combined population of the first sampling test and the validation test, there was a significant difference between low-grade gliomas and high-grade gliomas (p = 0.0351).The same results of both ELISA based on the independent serum sets support the possibility that SH3GL1 is aberrantly expressed and efficiently elicits a systemic immune response in low-grade glioma patients.",ELISA,serum,1
PMC4621003A,(C) Influenza VLPs protein transferred with or without GPI-HER-2 induce similar levels of VLP-specific serum IgG antibodies.,VLP,serum,1
PMC4621003A,(C) Influenza VLPs protein transferred with or without GPI-HER-2 induce similar levels of VLP-specific serum IgG antibodies.,GPI,serum,1
PMC4621003A,(C) Influenza VLPs protein transferred with or without GPI-HER-2 induce similar levels of VLP-specific serum IgG antibodies.,HER-2,serum,1
PMC3718634A,"The serum responses in CRC patients to MMP7 were higher than serum responses in controls (mean 1.74 +- 0.3 ug/ml vs. 0.43 +- 0.1 ug/ml, p 0.0001) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to MMP7 were higher than serum responses in controls (mean 1.74 +- 0.3 ug/ml vs. 0.43 +- 0.1 ug/ml, p 0.0001) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to MMP7 were higher than serum responses in controls (mean 1.74 +- 0.3 ug/ml vs. 0.43 +- 0.1 ug/ml, p 0.0001) (Fig.",MMP7,serum,1
PMC3718634A,"The serum responses in CRC patients to MMP7 were higher than serum responses in controls (mean 1.74 +- 0.3 ug/ml vs. 0.43 +- 0.1 ug/ml, p 0.0001) (Fig.",MMP7,serum,1
PMC4606475A,"The increased DR and fibrosis was not explained by increased susceptibility to TAA-induced injury, as liver injury was comparable in LysM-Wls mice and littermate controls, as assessed by serum ALT and liver histology (Fig.",ALT,serum,1
PMC4606475A,"The increased DR and fibrosis was not explained by increased susceptibility to TAA-induced injury, as liver injury was comparable in LysM-Wls mice and littermate controls, as assessed by serum ALT and liver histology (Fig.",TAA,serum,1
PMC3929731A,"To address these concerns, in the present study, we used 2 in vivo oral BPA doses, which accurately model internal dose levels of unconjugated or free BPA observed in human fetal cord blood, fetal serum, and infants, in the adult host mice (16, 60-62).",BPA,blood,1
PMC3929731A,"To address these concerns, in the present study, we used 2 in vivo oral BPA doses, which accurately model internal dose levels of unconjugated or free BPA observed in human fetal cord blood, fetal serum, and infants, in the adult host mice (16, 60-62).",BPA,serum,1
PMC3929731A,"To address these concerns, in the present study, we used 2 in vivo oral BPA doses, which accurately model internal dose levels of unconjugated or free BPA observed in human fetal cord blood, fetal serum, and infants, in the adult host mice (16, 60-62).",BPA,blood,1
PMC3929731A,"To address these concerns, in the present study, we used 2 in vivo oral BPA doses, which accurately model internal dose levels of unconjugated or free BPA observed in human fetal cord blood, fetal serum, and infants, in the adult host mice (16, 60-62).",BPA,serum,1
PMC3914674A,The stratification of patient's tumors to determine outcome have included serum prostate specific antigen (PSA) levels and clinical staging with histopathological criterion including the Gleason grade (2).,PSA,serum,1
PMC4519179A,"It is important to note that human fetal exposures to BPA, determined by monitoring mid gestational umbilical cord blood, found a geometric mean of 0.16 ng/ml free BPA (0.64 nM) with a small subset of fetuses having high levels of unconjugated BPA (18 ng/ml) [22].",BPA,blood,-1
PMC4519179A,"It is important to note that human fetal exposures to BPA, determined by monitoring mid gestational umbilical cord blood, found a geometric mean of 0.16 ng/ml free BPA (0.64 nM) with a small subset of fetuses having high levels of unconjugated BPA (18 ng/ml) [22].",BPA,blood,-1
PMC4519179A,"It is important to note that human fetal exposures to BPA, determined by monitoring mid gestational umbilical cord blood, found a geometric mean of 0.16 ng/ml free BPA (0.64 nM) with a small subset of fetuses having high levels of unconjugated BPA (18 ng/ml) [22].",BPA,blood,-1
PMC4275355A,"By contrast, another group suggested that hair follicle stem cells are the CCO for BCC in a model that used heterozygous loss of function in Ptch1 via either the Keratin 15 or Keratin 14 Cre and ionizing radiation as a mutagen [80].",CCO,hair,1
PMC4275355A,"By contrast, another group suggested that hair follicle stem cells are the CCO for BCC in a model that used heterozygous loss of function in Ptch1 via either the Keratin 15 or Keratin 14 Cre and ionizing radiation as a mutagen [80].",Ptch1,hair,1
PMC4275355A,"By contrast, another group suggested that hair follicle stem cells are the CCO for BCC in a model that used heterozygous loss of function in Ptch1 via either the Keratin 15 or Keratin 14 Cre and ionizing radiation as a mutagen [80].",BCC,hair,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",PBS,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",X-100,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",BSA,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",PBS,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",A12381,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",DAPI,serum,1
PMC4327780A,"For staining of the cysts, cysts were recovered from the Geltrex Matrix by incubating in Cell Recovery Solution (BD Biosciences 354253) on ice for 1 h. After centrifugation at 300g for 5 min, the pellet containing the cysts was washed with PBS and fixed with 4% paraformaldehyde for 20 min at 22degC. After washing in PBS, cysts were stained with Alexa Fluor 594 phalloidin (Invitrogen A12381, 1:25) and DAPI in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 at 4degC overnight.",PBS,serum,1
PMC5467782A,"3C-E), demonstrating that miR-181b-5p is one of several regulators involved in TGF-b1-dependent EMT.Finally, we compared the levels of miR-181b-5p in peripheral blood of healthy humans and in patients with NSCLC.",TGF,blood,-1
PMC5467782A,"3C-E), demonstrating that miR-181b-5p is one of several regulators involved in TGF-b1-dependent EMT.Finally, we compared the levels of miR-181b-5p in peripheral blood of healthy humans and in patients with NSCLC.",NSCLC,blood,-1
PMC3551651A,"Multivariate analysis revealed that strong expression of aB-crystallin could be considered as an independent factor for poor prognosis of LSCC patients, as well as pTNM stage and lymph node metastasis.",LSCC,lymph,1
PMC3551651A,"Multivariate analysis revealed that strong expression of aB-crystallin could be considered as an independent factor for poor prognosis of LSCC patients, as well as pTNM stage and lymph node metastasis.",pTNM,lymph,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",IMMU-132,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",SN-38,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",SN-38,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",SN-38,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",IMMU-132,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",SN-38,serum,1
PMC4673178A,"After IMMU-132 administration, concentrations of SN-38G were very low in our animal and clinical studies (e.g., in the serum of patients given IMMU-132, only 20-40% of the free SN-38 levels are in the form of SN-38G), providing strong evidence that SN-38 bound to IgG is largely protected from glucuronidation, even though the 10-hydroxy position of the SN-38 is available.",SN-38,serum,1
PMC3135497A,"Serum antibody levels against ECSA proteins or peptides examined by ELISA.Next, we evaluated the relationship between clinicopathological parameters and the presence of s-ECSA-Abs.",ECSA,Serum,1
PMC3135497A,"Serum antibody levels against ECSA proteins or peptides examined by ELISA.Next, we evaluated the relationship between clinicopathological parameters and the presence of s-ECSA-Abs.",ECSA,Serum,1
PMC5378227A,"Although the prognostic impacts of other antigens have not been precisely evaluated, except for p53, expression of HSP70 was associated with reduced survival in patients with esophageal cancer.45 Serum HSP70 autoantibody reaction might reflect this biological effect.",HSP70,Serum,1
PMC5378227A,"Although the prognostic impacts of other antigens have not been precisely evaluated, except for p53, expression of HSP70 was associated with reduced survival in patients with esophageal cancer.45 Serum HSP70 autoantibody reaction might reflect this biological effect.",p53,Serum,1
PMC5378227A,"Although the prognostic impacts of other antigens have not been precisely evaluated, except for p53, expression of HSP70 was associated with reduced survival in patients with esophageal cancer.45 Serum HSP70 autoantibody reaction might reflect this biological effect.",HSP70,Serum,1
PMC4958526A,"(b) Absolute numbers of lymph node DC prior to, and following, topical immunization with Ova.",DC,lymph,1
PMC5000705A,"CSCs and EMT-CTCs have a flexible cytoskeleton and anoikis resistance, so they can survive in the blood stream, and additionally the expression of vimentin leads to a formation of microtentacles, which help the cells to reattach to new tissue sites.",EMT,blood,-1
PMC4118235A,"In addition, the inhibitory action of mibefradil and Ni2+ suggested that plasma membrane Ca2+ channels are involved.",Ni2,plasma,1
PMC4118235A,"In addition, the inhibitory action of mibefradil and Ni2+ suggested that plasma membrane Ca2+ channels are involved.",Ca2,plasma,1
PMC4118235A,"Most interestingly, this process seems to be mediated by [Ca2+]i through the opening of plasma membrane Ca2+ channels, as shown by prevention of ROS increase in cells preloaded with BAPTA-AM or pre-incubated with mibefradil.",ROS,plasma,1
PMC4118235A,"Most interestingly, this process seems to be mediated by [Ca2+]i through the opening of plasma membrane Ca2+ channels, as shown by prevention of ROS increase in cells preloaded with BAPTA-AM or pre-incubated with mibefradil.",BAPTA,plasma,1
PMC4118235A,"Most interestingly, this process seems to be mediated by [Ca2+]i through the opening of plasma membrane Ca2+ channels, as shown by prevention of ROS increase in cells preloaded with BAPTA-AM or pre-incubated with mibefradil.",AM,plasma,1
PMC4118235A,"Most interestingly, this process seems to be mediated by [Ca2+]i through the opening of plasma membrane Ca2+ channels, as shown by prevention of ROS increase in cells preloaded with BAPTA-AM or pre-incubated with mibefradil.",Ca2,plasma,1
PMC4118235A,"Further evidence supporting this mechanism was the observation of DTT- and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells directly exposed to H2O2.It is known that oxidative processes can lead to Ca2+ leakage, by acting on either plasma membrane or intracellular Ca2+ channels [65,66].",ROS,plasma,1
PMC4118235A,"Further evidence supporting this mechanism was the observation of DTT- and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells directly exposed to H2O2.It is known that oxidative processes can lead to Ca2+ leakage, by acting on either plasma membrane or intracellular Ca2+ channels [65,66].",Ca2,plasma,1
PMC4118235A,"Further evidence supporting this mechanism was the observation of DTT- and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells directly exposed to H2O2.It is known that oxidative processes can lead to Ca2+ leakage, by acting on either plasma membrane or intracellular Ca2+ channels [65,66].",DTT-,plasma,1
PMC4118235A,"Further evidence supporting this mechanism was the observation of DTT- and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells directly exposed to H2O2.It is known that oxidative processes can lead to Ca2+ leakage, by acting on either plasma membrane or intracellular Ca2+ channels [65,66].",Ca2,plasma,1
PMC4118235A,"Further evidence supporting this mechanism was the observation of DTT- and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells directly exposed to H2O2.It is known that oxidative processes can lead to Ca2+ leakage, by acting on either plasma membrane or intracellular Ca2+ channels [65,66].",REN,plasma,1
PMC5109830A,323/A3-800CW showed to be stable in human serum with more than 60% of the conjugate still free to bind EpCAM after 96 h with the remaining 40% aggregated or bound to albumin cIn vivo specificity of 323/A3-800CW was shown by competition with unconjugated antibody.,323/A3,serum,1
PMC5109830A,323/A3-800CW showed to be stable in human serum with more than 60% of the conjugate still free to bind EpCAM after 96 h with the remaining 40% aggregated or bound to albumin cIn vivo specificity of 323/A3-800CW was shown by competition with unconjugated antibody.,323/A3,serum,1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",GA,Blood,-1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",GA,blood,-1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",DNA,Blood,-1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",DNA,blood,-1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",DNA,Blood,-1
PMC3981717A,"Leukocyte genomic DNA was extracted from blood samples using the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA).",DNA,blood,-1
PMC3494970A,"Interlobular bile ducts expressed YFP in the postnatal period, confirming the presumed ductal plate origin of the bile ducts.",YFP,bile,1
PMC3494970A,"Interlobular bile ducts expressed YFP in the postnatal period, confirming the presumed ductal plate origin of the bile ducts.",YFP,bile,1
PMC4882422A,Serum GPT levels and Sirius red-positive areas are shown in the right panel.,GPT,Serum,1
PMC3906064A,"A key feature of the LiquidBiopsy platform is the ability to process relatively large volumes of whole blood, while recovering whole CTCs in a PCR tube at purities consistently greater than 1%.",PCR,blood,-1
PMC3548755A,The results of the ELISA based on the newly collected serum set showed that the levels of serum autoantibodies to SH3GL1 were significantly higher than those of healthy donors (P = 0.0189) (Figure2B).,SH3GL1,serum,1
PMC3548755A,The results of the ELISA based on the newly collected serum set showed that the levels of serum autoantibodies to SH3GL1 were significantly higher than those of healthy donors (P = 0.0189) (Figure2B).,SH3GL1,serum,1
PMC3548755A,The results of the ELISA based on the newly collected serum set showed that the levels of serum autoantibodies to SH3GL1 were significantly higher than those of healthy donors (P = 0.0189) (Figure2B).,ELISA,serum,1
PMC3548755A,The results of the ELISA based on the newly collected serum set showed that the levels of serum autoantibodies to SH3GL1 were significantly higher than those of healthy donors (P = 0.0189) (Figure2B).,ELISA,serum,1
PMC4868745A,"High expression of Trop2 in GC was associated with increased differentiation (kh2 = 9.192, p = 0.027), Tumor Node Metastasis (TNM) stage (kh2 = 38.939, p  0.001), tumor size (kh2 = 35.576, p  0.001), lymph node metastases (kh2 = 17.638, p  0.001), distant metastases (kh2 = 9.728, p = 0.001), and H. pylori infection (kh2 = 7.549, p = 0.005).",TNM,lymph,1
PMC4868745A,"High expression of Trop2 in GC was associated with increased differentiation (kh2 = 9.192, p = 0.027), Tumor Node Metastasis (TNM) stage (kh2 = 38.939, p  0.001), tumor size (kh2 = 35.576, p  0.001), lymph node metastases (kh2 = 17.638, p  0.001), distant metastases (kh2 = 9.728, p = 0.001), and H. pylori infection (kh2 = 7.549, p = 0.005).",GC,lymph,1
PMC4868745A,"High expression of Trop2 in GC was associated with increased differentiation (kh2 = 9.192, p = 0.027), Tumor Node Metastasis (TNM) stage (kh2 = 38.939, p  0.001), tumor size (kh2 = 35.576, p  0.001), lymph node metastases (kh2 = 17.638, p  0.001), distant metastases (kh2 = 9.728, p = 0.001), and H. pylori infection (kh2 = 7.549, p = 0.005).",Trop2,lymph,1
PMC3135497A,ELISA using purified recombinant ECSA-1 and -3 proteins revealed that serum antibody levels against ECSA-1 and -3 also were significantly higher in patients with esophageal SCC than in healthy donors (Table 3).View larger versionFigure 3.,ELISA,serum,1
PMC3135497A,ELISA using purified recombinant ECSA-1 and -3 proteins revealed that serum antibody levels against ECSA-1 and -3 also were significantly higher in patients with esophageal SCC than in healthy donors (Table 3).View larger versionFigure 3.,ECSA-1,serum,1
PMC3135497A,ELISA using purified recombinant ECSA-1 and -3 proteins revealed that serum antibody levels against ECSA-1 and -3 also were significantly higher in patients with esophageal SCC than in healthy donors (Table 3).View larger versionFigure 3.,ECSA-1,serum,1
PMC3135497A,ELISA using purified recombinant ECSA-1 and -3 proteins revealed that serum antibody levels against ECSA-1 and -3 also were significantly higher in patients with esophageal SCC than in healthy donors (Table 3).View larger versionFigure 3.,SCC,serum,1
PMC4108928A,"Univariate analysis showed that ROR1 expression, FIGO stage, and lymph node metastasis were correlated with life span (both in disease-free survival and overall survival) of ovarian cancer patients.",ROR1,lymph,1
PMC4108928A,"Univariate analysis showed that ROR1 expression, FIGO stage, and lymph node metastasis were correlated with life span (both in disease-free survival and overall survival) of ovarian cancer patients.",FIGO,lymph,1
PMC3476529A,Double-negative cells on the plot of CD141 versus CD11c in blood correspond to CD123+ pDCs and CD34+ progenitor cells (Figure S1).,CD11c,blood,-1
PMC3476529A,Double-negative cells on the plot of CD141 versus CD11c in blood correspond to CD123+ pDCs and CD34+ progenitor cells (Figure S1).,CD34,blood,-1
PMC3476529A,Double-negative cells on the plot of CD141 versus CD11c in blood correspond to CD123+ pDCs and CD34+ progenitor cells (Figure S1).,CD123,blood,-1
PMC3476529A,Double-negative cells on the plot of CD141 versus CD11c in blood correspond to CD123+ pDCs and CD34+ progenitor cells (Figure S1).,S1,blood,-1
PMC3476529A,Double-negative cells on the plot of CD141 versus CD11c in blood correspond to CD123+ pDCs and CD34+ progenitor cells (Figure S1).,CD141,blood,-1
PMC3906064A,"The average non target recovery by the LiquidBiopsy platform from a 7.5 mL whole blood sample is 55 cells/mL. Most CTC purification systems do not report purity numbers but of those that do ""high"" purity is described as 500-1500 leukocytes/mL [22], [25].",CTC,blood,-1
PMC4882422A,"Serum GPT levels, the gene expression of proinflammatory cytokines and profibrogenic factors in the non-tumor liver tissue, and the Sirius red-positive areas are shown in the right panel (48 weeks of age, n = 8-10).",GPT,Serum,1
PMC4646304A,"a, 105 MDA-MB-231 cells were labeled with 50 nm biotinylated m7e6 IgG (orange), 50 nm biotinylated m7e6 Fab (cyan), or nude (blue) in buffer PBS plus 1 g/L bovine serum albumin for 30 min at room temperature.",MB-231,serum,1
PMC4646304A,"a, 105 MDA-MB-231 cells were labeled with 50 nm biotinylated m7e6 IgG (orange), 50 nm biotinylated m7e6 Fab (cyan), or nude (blue) in buffer PBS plus 1 g/L bovine serum albumin for 30 min at room temperature.",PBS,serum,1
PMC4646304A,"a, 105 MDA-MB-231 cells were labeled with 50 nm biotinylated m7e6 IgG (orange), 50 nm biotinylated m7e6 Fab (cyan), or nude (blue) in buffer PBS plus 1 g/L bovine serum albumin for 30 min at room temperature.",MDA,serum,1
PMC5378268A,"In some cases, the serum-free culture conditions of tumor-derived spheroids were used for MCTS cultures to faithfully reproduce stem cell-like states.",MCTS,serum,1
PMC3476529A,"CD141hi DCs were enriched relative to CD141+ DCs in blood in all tissues, especially the skin (Figure 1D).From these results, we conclude that CD141hi DCs may be identified as a discrete population of HLA-DR+lineage-CD14-CD141hiCD11clo-int cells of skin, lung, and liver.",HLA,blood,1
PMC3476529A,"CD141hi DCs were enriched relative to CD141+ DCs in blood in all tissues, especially the skin (Figure 1D).From these results, we conclude that CD141hi DCs may be identified as a discrete population of HLA-DR+lineage-CD14-CD141hiCD11clo-int cells of skin, lung, and liver.",CD141,blood,1
PMC5494437A,"Since the gyrus lacks a ventricle, Domain I in the gyrus is the Hilus, a deep region of intermediate progenitor cells (IPC) and blood vessels.",IPC,blood,-1
PMC5000705A,Blood from patients with gastritic cancer was infected with this agent and green fluorescent cells could be detected easily and were recognized as a prognostic marker for overall survival (OAS) [38].,OAS,Blood,-1
PMC4251850A,"The proteins marked with asterisks were tested by specific antibodies in the immune blots (see Additional file 1: Figure S8).Of special interest is the protein ARRDC1, which was discussed as a protein responsible for the budding of microvesicles from the plasma membrane [23,24], called ARMMs (ARRDC1-mediated microvesicles).",ARRDC1,plasma,1
PMC2441949A,"The tumour-node-metastasis system, as defined by the American Joint Committee on Cancer, is the most commonly used cancer staging system and classifies colon cancer into four stages based on the depth of invasion of the bowel wall (T), extent of regional lymph node involvement (N), and presence of distant sites of metastatic disease (M) (Greene et al, 2002).",T,lymph,1
PMC3326512A,"However, additional studies suggest that LC do promote the T-helper (Th) cell-selective effector responses [e.g., Th2-predominant Ab responses after gene gun immunization (17) and Th17 responses to fungus-associated antigens that are encountered in skin (18)].Functions of LC are predicated on the ability of LC to localize and persist in epidermis and to traffic from skin to lymph nodes (LN) in a carefully controlled fashion at baseline and after activation.",Th17,lymph,1
PMC3326512A,"However, additional studies suggest that LC do promote the T-helper (Th) cell-selective effector responses [e.g., Th2-predominant Ab responses after gene gun immunization (17) and Th17 responses to fungus-associated antigens that are encountered in skin (18)].Functions of LC are predicated on the ability of LC to localize and persist in epidermis and to traffic from skin to lymph nodes (LN) in a carefully controlled fashion at baseline and after activation.",T,lymph,1
PMC4621003A,The unbound VLPs were removed and then the wells were blocked with PBS containing 0.05% Tween-20 and 3% bovine serum albumin.,Tween-20,serum,1
PMC4621003A,The unbound VLPs were removed and then the wells were blocked with PBS containing 0.05% Tween-20 and 3% bovine serum albumin.,PBS,serum,1
PMC4165776A,We further validated the clinical feasibility of anti-EpCAM-coated biotin/Ppy-microfluidics using artificial blood samples in which EpCAM-positive MCF7 cells (breast cancer cells) were spiked into healthy donor's blood in accordance with NCC Institutional Review Board Approval.,NCC,blood,-1
PMC4165776A,We further validated the clinical feasibility of anti-EpCAM-coated biotin/Ppy-microfluidics using artificial blood samples in which EpCAM-positive MCF7 cells (breast cancer cells) were spiked into healthy donor's blood in accordance with NCC Institutional Review Board Approval.,NCC,blood,-1
PMC4165776A,We further validated the clinical feasibility of anti-EpCAM-coated biotin/Ppy-microfluidics using artificial blood samples in which EpCAM-positive MCF7 cells (breast cancer cells) were spiked into healthy donor's blood in accordance with NCC Institutional Review Board Approval.,MCF7,blood,-1
PMC4165776A,We further validated the clinical feasibility of anti-EpCAM-coated biotin/Ppy-microfluidics using artificial blood samples in which EpCAM-positive MCF7 cells (breast cancer cells) were spiked into healthy donor's blood in accordance with NCC Institutional Review Board Approval.,MCF7,blood,-1
PMC4588827A,"BPA has been shown to increase the stem cell pool in the mammary gland (35, 36), neural cells (37, 38), and human umbilical cord blood (39) and modify the spermatogonial stem cell pool (40) indicating a common enhancement of stem cell self-renewal in multiple structures by this xenoestrogens.",BPA,blood,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",b4-WT,lymph,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",b4-WT,lymph,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",T,lymph,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",T,lymph,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",T,lymph,1
PMC3561800A,"Since most metastatic lesions in both PB-TAg; b4-WT and PB-TAg; b4-1355T mice were poorly differentiated (WT mice, 14 out of 14 lymph node, 14 out of 14 lung, and 8 out of 9 liver lesions; 1355T mice, 4 out of 5 lymph node, 6 out of 8 lung, and 6 out of 7 liver lesions), the delay in the outgrowth of metastases in b4 mutant mice likely reflects the slower histological progression of their primary tumors.",T,lymph,1
PMC4606475A,"non-significantIn healthy livers, b-catenin localised to hepatocyte membranes and bile duct epithelia, whereas after 12 weeks TAA treatment, b-catenin stained hepatocyte membranes and some nuclei, as well as HPC, in both LysM-Wls mice and littermate controls (Fig. 2a).",TAA,bile,1
PMC4606475A,"non-significantIn healthy livers, b-catenin localised to hepatocyte membranes and bile duct epithelia, whereas after 12 weeks TAA treatment, b-catenin stained hepatocyte membranes and some nuclei, as well as HPC, in both LysM-Wls mice and littermate controls (Fig. 2a).",HPC,bile,1
PMC4586470A,"The presentation of many epitopes in close proximity might favor such cross-linking, leading to the proliferation of B lymphocytes, presentation of epitopes to T cells, and differentiation of B lymphocytes into antibody-producing plasma cells [17].",T,plasma,-1
PMC3100619A,"To assess prostasphere clonality, single PrEC cell suspensions were stained with high concentration H342 (5 mg/ml) in PrEGM for 45 min, washed, and mixed with equal amounts of unstained PrEC cells followed by 3D culture for 4-7 d. Prostaspheres were fixed, mounted in propidium iodide, and H342 signal was monitored using fluorescent microscopy.Serum T and E2 levels",H342,Serum,1
PMC3100619A,"To assess prostasphere clonality, single PrEC cell suspensions were stained with high concentration H342 (5 mg/ml) in PrEGM for 45 min, washed, and mixed with equal amounts of unstained PrEC cells followed by 3D culture for 4-7 d. Prostaspheres were fixed, mounted in propidium iodide, and H342 signal was monitored using fluorescent microscopy.Serum T and E2 levels",E2,Serum,1
PMC3100619A,"To assess prostasphere clonality, single PrEC cell suspensions were stained with high concentration H342 (5 mg/ml) in PrEGM for 45 min, washed, and mixed with equal amounts of unstained PrEC cells followed by 3D culture for 4-7 d. Prostaspheres were fixed, mounted in propidium iodide, and H342 signal was monitored using fluorescent microscopy.Serum T and E2 levels",T,Serum,1
PMC3100619A,"To assess prostasphere clonality, single PrEC cell suspensions were stained with high concentration H342 (5 mg/ml) in PrEGM for 45 min, washed, and mixed with equal amounts of unstained PrEC cells followed by 3D culture for 4-7 d. Prostaspheres were fixed, mounted in propidium iodide, and H342 signal was monitored using fluorescent microscopy.Serum T and E2 levels",H342,Serum,1
PMC4253434A,"To further investigate the role of growth factors in Trop2-loss induced p-ErbB3 activation, we asked whether reducing Trop2 levels results in the secretion of an ErbB3-activating ligand that could replace the ability of growth factor-containing serum to stimulate ErbB3 activity in shLacZ control cells.",ErbB3,serum,1
PMC4253434A,"To further investigate the role of growth factors in Trop2-loss induced p-ErbB3 activation, we asked whether reducing Trop2 levels results in the secretion of an ErbB3-activating ligand that could replace the ability of growth factor-containing serum to stimulate ErbB3 activity in shLacZ control cells.",ErbB3,serum,1
PMC4253434A,"To further investigate the role of growth factors in Trop2-loss induced p-ErbB3 activation, we asked whether reducing Trop2 levels results in the secretion of an ErbB3-activating ligand that could replace the ability of growth factor-containing serum to stimulate ErbB3 activity in shLacZ control cells.",Trop2,serum,1
PMC3478937A,(C) BM from WT and TAM KO mice was cultured in the presence of M-CSF +- 0.25 ng/ml TGF-b1 for 7 d and analyzed for Axl and Mer expression by Western blot.,KO,CSF,1
PMC3478937A,(C) BM from WT and TAM KO mice was cultured in the presence of M-CSF +- 0.25 ng/ml TGF-b1 for 7 d and analyzed for Axl and Mer expression by Western blot.,TAM,CSF,1
PMC3478937A,(C) BM from WT and TAM KO mice was cultured in the presence of M-CSF +- 0.25 ng/ml TGF-b1 for 7 d and analyzed for Axl and Mer expression by Western blot.,TGF,CSF,1
PMC4708083A,"This effect correlated with elevated serum AST levels, delayed proliferation of hepatocytes, and increased parenchymal necrosis in Foxl1-/- mice compared to the control mice.",AST,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",AJCC,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",AJCC,lymph,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",CRC,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",CRC,lymph,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",CEA,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",CEA,lymph,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",TNM,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",TNM,lymph,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",T,serum,1
PMC4465473A,"Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20].",T,lymph,1
PMC4253434A,"Importantly, only conditioned media from Trop2 knockdown cells was able to activate serum-starved shLacZ control cells, indicating release of an ErbB3-stimulating ligand upon Trop2 loss (Figure 4A).",Trop2,serum,1
PMC4253434A,"Importantly, only conditioned media from Trop2 knockdown cells was able to activate serum-starved shLacZ control cells, indicating release of an ErbB3-stimulating ligand upon Trop2 loss (Figure 4A).",Trop2,serum,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",PAGE,plasma,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",GST,plasma,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",SDS,plasma,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",GST,plasma,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",SDS,plasma,1
PMC4344740A,"The expression of the GST-fusion proteins was induced by treating the transformed E. coli with 0.1 mM isopropyl-b-D-thiogalactoside for 3 h. The GST recombinant proteins were purified by glutathione-Sepharose column chromatography according to the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against 1 mM Tris-HCl (pH 7.5) and 1 mM EDTA.To confirm the recombinant proteins to be the GST-tagged one that react with autologous plasma, the proteins were lysed in a SDS sample buffer, incubated at 100degC for 3 min, resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotted.",GST,plasma,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",BRL,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",BRL,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",RPMI,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",MDA,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",BRL,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",MB-468,serum,1
PMC3250983A,"The MDA-MB-468 cell line was cultured in adherent-cell monolayers in RPMI medium (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% bovine calf serum (Gibco BRL), 1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1% antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml; Gibco BRL).",BRL,serum,1
PMC4251850A,"An example of proteins enriched in affinity pure EVs of both cancer cell lines was NT5E/CD73, ecto-5'-nucleotidase, which is a plasma membrane protein that catalyses the conversion of extracellular nucleotides to membrane-permeable nucleosides (especially the adenosine release from AMP).",CD73,plasma,1
PMC4251850A,"An example of proteins enriched in affinity pure EVs of both cancer cell lines was NT5E/CD73, ecto-5'-nucleotidase, which is a plasma membrane protein that catalyses the conversion of extracellular nucleotides to membrane-permeable nucleosides (especially the adenosine release from AMP).",AMP,plasma,1
PMC4251850A,"An example of proteins enriched in affinity pure EVs of both cancer cell lines was NT5E/CD73, ecto-5'-nucleotidase, which is a plasma membrane protein that catalyses the conversion of extracellular nucleotides to membrane-permeable nucleosides (especially the adenosine release from AMP).",NT5E,plasma,1
PMC4186637A,"In this approach, unlabeled TF12 is injected intravenously, and when it has localized in the tumor and cleared from the blood, a diHSG-substituted radiolabeled hapten-peptide is injected.",TF12,blood,-1
PMC3975176A,iFGFR1-induced prostate cancer presents higher nuclear EMT-associated Sox9 expression and liver and lymph node metastases [38].,Sox9,lymph,1
PMC3975176A,iFGFR1-induced prostate cancer presents higher nuclear EMT-associated Sox9 expression and liver and lymph node metastases [38].,EMT,lymph,1
PMC5505023A,"Colonies containing 50 cells were quantified after 2 weeks using a binocular inverted microscope (Nikon Eclipse Ti-U).The cells were seeded into a 25 cm2 plastic culture bottle coated with a low concentration of type I collagen at a density of 2x105 viable cells/ml in serum-free medium; spherical cells (10,27) were collected by gentle centrifugation at 30 x g after 5-7 days and replated onto type I collagen-coated 6-well plates as FHPC clonal cells.",FHPC,serum,1
PMC5109830A,"Conjugation, serum stability and EpCAM specificity: Conjugation of IRDye 800CW to 323/A3 and MOPC21 was done through NHS ester conjugation.",NHS,serum,1
PMC5109830A,"Conjugation, serum stability and EpCAM specificity: Conjugation of IRDye 800CW to 323/A3 and MOPC21 was done through NHS ester conjugation.",MOPC21,serum,1
PMC5109830A,"Conjugation, serum stability and EpCAM specificity: Conjugation of IRDye 800CW to 323/A3 and MOPC21 was done through NHS ester conjugation.",323/A3,serum,1
PMC4718644A,Recent data suggests that Serum LPS levels are obviously elevated in patients with chronic hepatitis and cirrhosis [9-10],LPS,Serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",A-1,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",A-1,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",OS,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",OS,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",mRCC,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",mRCC,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",TLR4,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",TLR4,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",5T4,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",5T4,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",IMA-901,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",IMA-901,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",NLR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",NLR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",IRS,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",IRS,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",HR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",HR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",S100A9,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",S100A9,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",TAA,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",TAA,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",NLR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",NLR,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",ApoA1,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",ApoA1,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",CCL17,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",CCL17,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",mRCC,serum,1
PMC4485845A,"Tasquinimod, a TLR4 agonist with anti-angiogenic activity, targets S100A9 protein and affects regulatory myeloid cell function.74 A phase II trial of tasquinimod in several cancers including mRCC is ongoing (NCT01743469).Several potential biomarkers have emerged during trials of vaccines against RCC.Hematologic impairment (low hemoglobin level, high neutrophil count and low lymphocyte count) predicted a poor response to TroVax.49-50 The neutrophil-lymphocyte ratio (NLR) has also shown prognostic value in mRCC (HR = 1.59 [1.10-2.31], p = 0.014 for NLR 3.3).75 An Immune Response Surrogate (IRS) predictive score for vaccine efficiency (anti-5T4 antibody, hemoglobin, and hematocrit) has been proposed but needs validation.49Among potential serum biomarkers, serum apolipoprotein A-1 (ApoA1) and chemokine (C-C motif) ligand 17 (CCL17) predicted immune response to TAA and OS in the IMA-901 trial.",mRCC,serum,1
PMC5000705A,"The CTCscope method, which was published in 2012, is based on an RNA-ISH detecting epithelial as well as EMT-markers from blood samples.",RNA,blood,-1
PMC5000705A,"The CTCscope method, which was published in 2012, is based on an RNA-ISH detecting epithelial as well as EMT-markers from blood samples.",EMT,blood,-1
PMC5000705A,"The CTCscope method, which was published in 2012, is based on an RNA-ISH detecting epithelial as well as EMT-markers from blood samples.",ISH,blood,-1
PMC5085135A,"Our iTRAQ results showed that RAN expression levels increased in NPC tissues with metastasis compared with ones without metastasis, and were positively associated with lymph node and distant metastasis, and clinical stage in NPC patients, supporting that RAN is a metastasis-promoted protein.",iTRAQ,lymph,1
PMC5085135A,"Our iTRAQ results showed that RAN expression levels increased in NPC tissues with metastasis compared with ones without metastasis, and were positively associated with lymph node and distant metastasis, and clinical stage in NPC patients, supporting that RAN is a metastasis-promoted protein.",RAN,lymph,1
PMC5085135A,"Our iTRAQ results showed that RAN expression levels increased in NPC tissues with metastasis compared with ones without metastasis, and were positively associated with lymph node and distant metastasis, and clinical stage in NPC patients, supporting that RAN is a metastasis-promoted protein.",NPC,lymph,1
PMC5085135A,"Our iTRAQ results showed that RAN expression levels increased in NPC tissues with metastasis compared with ones without metastasis, and were positively associated with lymph node and distant metastasis, and clinical stage in NPC patients, supporting that RAN is a metastasis-promoted protein.",RAN,lymph,1
PMC5085135A,"Our iTRAQ results showed that RAN expression levels increased in NPC tissues with metastasis compared with ones without metastasis, and were positively associated with lymph node and distant metastasis, and clinical stage in NPC patients, supporting that RAN is a metastasis-promoted protein.",NPC,lymph,1
PMC4292049A,"The SPECT/CT image (A), acquired 24 h after injection of 111In-IMP288 (185 MBq, 25 mg), pretargeted with 75 mg TF2 (1-day interval), in a 38-year-old patient (cohort 4), shows very clear tumor targeting of an axillary lymph-node metastasis, with very low concentrations of radioactivity in normal tissues.",IMP288,lymph,1
PMC4292049A,"The SPECT/CT image (A), acquired 24 h after injection of 111In-IMP288 (185 MBq, 25 mg), pretargeted with 75 mg TF2 (1-day interval), in a 38-year-old patient (cohort 4), shows very clear tumor targeting of an axillary lymph-node metastasis, with very low concentrations of radioactivity in normal tissues.",SPECT,lymph,1
PMC4292049A,"The SPECT/CT image (A), acquired 24 h after injection of 111In-IMP288 (185 MBq, 25 mg), pretargeted with 75 mg TF2 (1-day interval), in a 38-year-old patient (cohort 4), shows very clear tumor targeting of an axillary lymph-node metastasis, with very low concentrations of radioactivity in normal tissues.",CT,lymph,1
PMC4292049A,"The SPECT/CT image (A), acquired 24 h after injection of 111In-IMP288 (185 MBq, 25 mg), pretargeted with 75 mg TF2 (1-day interval), in a 38-year-old patient (cohort 4), shows very clear tumor targeting of an axillary lymph-node metastasis, with very low concentrations of radioactivity in normal tissues.",TF2,lymph,1
PMC4275355A,"A constitutively active allele of the Gli2 transcription factor, which mimics the activation of the Shh pathway, led to the formation of two different BCC subtypes from either the interfollicular epidermis or the hair follicle [81].",Gli2,hair,-1
PMC4275355A,"A constitutively active allele of the Gli2 transcription factor, which mimics the activation of the Shh pathway, led to the formation of two different BCC subtypes from either the interfollicular epidermis or the hair follicle [81].",BCC,hair,-1
PMC4202120A,"Either or both p63 and miR-205 are absent in lymph nodes or distant metastases of PCa patients [247].MYC amplification is very common in CRPC, found in at least a third of these tumors.",CRPC,lymph,1
PMC4202120A,"Either or both p63 and miR-205 are absent in lymph nodes or distant metastases of PCa patients [247].MYC amplification is very common in CRPC, found in at least a third of these tumors.",p63,lymph,1
PMC3781731A,"Despite this extraordinary ability of myeloid cells to rescue the phenotype of FAH-/- hepatocytes, such phenomenon was not (or very rarely) observed in response to other types of liver injury (CCl4, bile duct ligation [BDL]), suggesting that hematopoietic cells have a limited contribution to hepatocyte population under physiological conditions or in response to injury.72,73",CCl4,bile,1
PMC3781731A,"Despite this extraordinary ability of myeloid cells to rescue the phenotype of FAH-/- hepatocytes, such phenomenon was not (or very rarely) observed in response to other types of liver injury (CCl4, bile duct ligation [BDL]), suggesting that hematopoietic cells have a limited contribution to hepatocyte population under physiological conditions or in response to injury.72,73",BDL,bile,1
PMC2743239A,Specific knockdown of IQGAP1 by siRNA significantly reduces both serum-dependent proliferation and anchorage-independent growth in soft agar.,IQGAP1,serum,1
PMC3967411A,Serum-free culture medium from BPH1 cells was used as a control for active MMPs.,BPH1,Serum,1
PMC3250983A,This low level of CD138 expression explains the relatively low tumor/blood ratio found in the biodistribution analysis of the B-B4 antibody and the relatively high injected activity (22.2 MBq) required to cure mice from their tumor in the RIT assay.,CD138,blood,1
PMC3250983A,This low level of CD138 expression explains the relatively low tumor/blood ratio found in the biodistribution analysis of the B-B4 antibody and the relatively high injected activity (22.2 MBq) required to cure mice from their tumor in the RIT assay.,B4,blood,1
PMC3250983A,This low level of CD138 expression explains the relatively low tumor/blood ratio found in the biodistribution analysis of the B-B4 antibody and the relatively high injected activity (22.2 MBq) required to cure mice from their tumor in the RIT assay.,RIT,blood,1
PMC3781731A,"Thus, human umbilical cord blood-derived cells transplanted into non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice generated clusters of donor-derived hepatocytes in response to CCl4.79 Although transplantation of MSCs often results in attenuation or improvement of liver disease, current studies have not provided a definitive proof for MSC differentiation into functional hepatocytes in vivo.14,77,79-81 Even more controversial is the role of MSCs in fibrosis.",NOD,blood,1
PMC3781731A,"Thus, human umbilical cord blood-derived cells transplanted into non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice generated clusters of donor-derived hepatocytes in response to CCl4.79 Although transplantation of MSCs often results in attenuation or improvement of liver disease, current studies have not provided a definitive proof for MSC differentiation into functional hepatocytes in vivo.14,77,79-81 Even more controversial is the role of MSCs in fibrosis.",SCID,blood,1
PMC3781731A,"Thus, human umbilical cord blood-derived cells transplanted into non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice generated clusters of donor-derived hepatocytes in response to CCl4.79 Although transplantation of MSCs often results in attenuation or improvement of liver disease, current studies have not provided a definitive proof for MSC differentiation into functional hepatocytes in vivo.14,77,79-81 Even more controversial is the role of MSCs in fibrosis.",MSC,blood,1
PMC5410259A,"The prostate epithelial cells were washed with Dulbecco's PBS and treated with trypsin-EDTA for 3 to 5 minutes at 37 C. The prostate epithelial cells were detached by gentle tapping, and trypsin was neutralized by adding Dulbecco's PBS containing 10% fetal bovine serum.",EDTA,serum,1
PMC5410259A,"The prostate epithelial cells were washed with Dulbecco's PBS and treated with trypsin-EDTA for 3 to 5 minutes at 37 C. The prostate epithelial cells were detached by gentle tapping, and trypsin was neutralized by adding Dulbecco's PBS containing 10% fetal bovine serum.",PBS,serum,1
PMC5410259A,"The prostate epithelial cells were washed with Dulbecco's PBS and treated with trypsin-EDTA for 3 to 5 minutes at 37 C. The prostate epithelial cells were detached by gentle tapping, and trypsin was neutralized by adding Dulbecco's PBS containing 10% fetal bovine serum.",PBS,serum,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CD3,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CD3,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",TILS,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",TILS,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",T,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",T,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CD3,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CD3,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CRC,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CRC,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CRC,lymph,1
PMC3039945A,"In addition, although the presence of high density CD3+ TILS in primary tumours has been associated with good prognosis in patients with lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and absence of post-surgical metastases in patients with lymph node-positive CRC [75].Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with high ratios [59,76].",CRC,lymph,1
PMC4606116A,Verifying candidates of categories A and B as clinically useful blood biomarkers for CRC are our prior concern.,CRC,blood,-1
PMC3224189A,Representative cytotoxicity experiments adding human serum to hRS7 against cervical carcinoma cell lines to assess the feasibility of hRS7 ADCC in the presence of irrelevant human immunoglobulins.,hRS7,serum,1
PMC3224189A,Representative cytotoxicity experiments adding human serum to hRS7 against cervical carcinoma cell lines to assess the feasibility of hRS7 ADCC in the presence of irrelevant human immunoglobulins.,hRS7,serum,1
PMC3224189A,Representative cytotoxicity experiments adding human serum to hRS7 against cervical carcinoma cell lines to assess the feasibility of hRS7 ADCC in the presence of irrelevant human immunoglobulins.,ADCC,serum,1
PMC3548755A,"The patients with higher serum level of anti-SH3GL1 autoantibody (solid line) survived significantly longer than those with lower levels (gray line) (p = 0.0124).To determine the accurate immuno-reactive site, an ELISA using 4 deletion mutants of SH3GL1 cDNA was performed.",SH3GL1,serum,1
PMC3548755A,"The patients with higher serum level of anti-SH3GL1 autoantibody (solid line) survived significantly longer than those with lower levels (gray line) (p = 0.0124).To determine the accurate immuno-reactive site, an ELISA using 4 deletion mutants of SH3GL1 cDNA was performed.",cDNA,serum,1
PMC3548755A,"The patients with higher serum level of anti-SH3GL1 autoantibody (solid line) survived significantly longer than those with lower levels (gray line) (p = 0.0124).To determine the accurate immuno-reactive site, an ELISA using 4 deletion mutants of SH3GL1 cDNA was performed.",SH3GL1,serum,1
PMC3548755A,"The patients with higher serum level of anti-SH3GL1 autoantibody (solid line) survived significantly longer than those with lower levels (gray line) (p = 0.0124).To determine the accurate immuno-reactive site, an ELISA using 4 deletion mutants of SH3GL1 cDNA was performed.",ELISA,serum,1
PMC3224189A,"In fact, in some cell lines (i.e. CVX-SCC-1), an increase in cytotoxicity was noted in the presence of effector cells and non-heat-inactivated human serum.",SCC-1,serum,1
PMC3224189A,"In fact, in some cell lines (i.e. CVX-SCC-1), an increase in cytotoxicity was noted in the presence of effector cells and non-heat-inactivated human serum.",CVX,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",ADCC,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",ADCC,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",ADCC,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",ADCC,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",hRS7,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",hRS7,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",IL-2,serum,1
PMC3224189A,"However, the presence of IL-2 did not significantly increase cytotoxicity in the absence of hRS7 or in the presence of rituximab (Figure 4).To assess the feasibility of hRS7-mediated ADCC functioning in vivo, we evaluated the effects of physiological serum IgG concentrations and serum complement on hRS7-mediated ADCC.",IL-2,serum,1
PMC4882422A,Blood samples were collected 6 h after the LPS injection and measured glutamic pyruvic transaminase (GPT) concentration.,LPS,Blood,-1
PMC4882422A,Blood samples were collected 6 h after the LPS injection and measured glutamic pyruvic transaminase (GPT) concentration.,GPT,Blood,-1
PMC3476529A,Full gating strategy and percentage of DC populations in blood and tissues are shown in Figure S1 available online.,S1,blood,-1
PMC3476529A,Full gating strategy and percentage of DC populations in blood and tissues are shown in Figure S1 available online.,DC,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",CD16,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",CD11c,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",CD141,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",CD14,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",DC,blood,-1
PMC3476529A,"Antibodies to CD14 and CD16 were put in separate channels to identify monocyte subsets, and CD11c, CD1c, and CD141 markers were added to map tissue DC subsets to the parameter space of blood DC analysis.",DC,blood,-1
PMC3476529A,"Compared with CD1c+ DCs, blood CD141+ DCs exhibit specialized cross-presenting function and express a number of markers associated with mouse CD8+ DCs (Jongbloed et al.",CD8,blood,-1
PMC3476529A,"Compared with CD1c+ DCs, blood CD141+ DCs exhibit specialized cross-presenting function and express a number of markers associated with mouse CD8+ DCs (Jongbloed et al.",CD141,blood,-1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",hRS7,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",hRS7,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",SCC-1,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",SCC-1,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",PBL,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",PBL,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",CVX,serum,1
PMC3224189A,"In one squamous cervical cancer line (CVX-SCC-1), the addition of serum lead to a significant increase in killing (p=0.03), while the addition of heat-inactivated serum with hRS7 and PBL to the same cell line resulted in a decrease in killing (Figure 5).",CVX,serum,1
PMC3474961A,Nelson et al. have reported high ET-1 levels in plasma of patients with metastatic PCa [124].,ET-1,plasma,1
PMC2828486A,"Nkx3.1-MYC transgenic mice were generated by pronuclear injection of single-cell FVB embryos essentially as previously described [60].Mouse-tail DNA was isolated using the DNeasy Blood  Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for genotyping.",PCR,Blood,-1
PMC2828486A,"Nkx3.1-MYC transgenic mice were generated by pronuclear injection of single-cell FVB embryos essentially as previously described [60].Mouse-tail DNA was isolated using the DNeasy Blood  Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for genotyping.",MYC,Blood,-1
PMC2828486A,"Nkx3.1-MYC transgenic mice were generated by pronuclear injection of single-cell FVB embryos essentially as previously described [60].Mouse-tail DNA was isolated using the DNeasy Blood  Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for genotyping.",QIAGEN,Blood,-1
PMC2828486A,"Nkx3.1-MYC transgenic mice were generated by pronuclear injection of single-cell FVB embryos essentially as previously described [60].Mouse-tail DNA was isolated using the DNeasy Blood  Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for genotyping.",FVB,Blood,-1
PMC2828486A,"Nkx3.1-MYC transgenic mice were generated by pronuclear injection of single-cell FVB embryos essentially as previously described [60].Mouse-tail DNA was isolated using the DNeasy Blood  Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for genotyping.",DNA,Blood,-1
PMC3476529A,"This still presented a technical challenge, because the frequency of CD141hi DCs is only 1% of CD45+ cells, or fewer than 500 cells per cm2.We tested the cross-presentation ability of CD141hi DCs, CD1c+ DCs, CD14+ cells, and epidermal Langerhans cells from the skin in comparison to CD141+ DCs, CD1c+ DCs, CD14+ monocytes, and in vitro monocyte-derived DCs (mo-DCs) and monocyte-derived LCs (mo-LCs) obtained from blood.",CD14,blood,-1
PMC3476529A,"This still presented a technical challenge, because the frequency of CD141hi DCs is only 1% of CD45+ cells, or fewer than 500 cells per cm2.We tested the cross-presentation ability of CD141hi DCs, CD1c+ DCs, CD14+ cells, and epidermal Langerhans cells from the skin in comparison to CD141+ DCs, CD1c+ DCs, CD14+ monocytes, and in vitro monocyte-derived DCs (mo-DCs) and monocyte-derived LCs (mo-LCs) obtained from blood.",CD45,blood,-1
PMC3476529A,"This still presented a technical challenge, because the frequency of CD141hi DCs is only 1% of CD45+ cells, or fewer than 500 cells per cm2.We tested the cross-presentation ability of CD141hi DCs, CD1c+ DCs, CD14+ cells, and epidermal Langerhans cells from the skin in comparison to CD141+ DCs, CD1c+ DCs, CD14+ monocytes, and in vitro monocyte-derived DCs (mo-DCs) and monocyte-derived LCs (mo-LCs) obtained from blood.",CD141,blood,-1
PMC3476529A,"This still presented a technical challenge, because the frequency of CD141hi DCs is only 1% of CD45+ cells, or fewer than 500 cells per cm2.We tested the cross-presentation ability of CD141hi DCs, CD1c+ DCs, CD14+ cells, and epidermal Langerhans cells from the skin in comparison to CD141+ DCs, CD1c+ DCs, CD14+ monocytes, and in vitro monocyte-derived DCs (mo-DCs) and monocyte-derived LCs (mo-LCs) obtained from blood.",CD14,blood,-1
PMC4966842B,"Nearly all cytokines were elevated indicating a cytokine storm, in particular IL-6, IL-1a, IL-1b, and neutrophil-related factors such as G-CSF and MIP-2, causing inflammation and tumor killing through activation of intratumoral NK cells and intratumoral CD8+ T cells.",IL-6,CSF,1
PMC4966842B,"Nearly all cytokines were elevated indicating a cytokine storm, in particular IL-6, IL-1a, IL-1b, and neutrophil-related factors such as G-CSF and MIP-2, causing inflammation and tumor killing through activation of intratumoral NK cells and intratumoral CD8+ T cells.",T,CSF,1
PMC4966842B,"Nearly all cytokines were elevated indicating a cytokine storm, in particular IL-6, IL-1a, IL-1b, and neutrophil-related factors such as G-CSF and MIP-2, causing inflammation and tumor killing through activation of intratumoral NK cells and intratumoral CD8+ T cells.",MIP-2,CSF,1
PMC4966842B,"Nearly all cytokines were elevated indicating a cytokine storm, in particular IL-6, IL-1a, IL-1b, and neutrophil-related factors such as G-CSF and MIP-2, causing inflammation and tumor killing through activation of intratumoral NK cells and intratumoral CD8+ T cells.",CD8,CSF,1
PMC5018629A,The patient had been on steroids for 24 h prior to surgery and did not present clinical signs of sepsis at the time of blood sampling for NLR.,NLR,blood,-1
PMC4588827A,"Although BPA is rapidly metabolized and excreted, conjugated BPA is detectable in greater than 93% of Americans older than 6 years (19), and unconjugated BPA is present in fetal cord blood at approximately 0.2-1 ng/mL (20).",BPA,blood,-1
PMC4588827A,"Although BPA is rapidly metabolized and excreted, conjugated BPA is detectable in greater than 93% of Americans older than 6 years (19), and unconjugated BPA is present in fetal cord blood at approximately 0.2-1 ng/mL (20).",BPA,blood,-1
PMC4588827A,"Although BPA is rapidly metabolized and excreted, conjugated BPA is detectable in greater than 93% of Americans older than 6 years (19), and unconjugated BPA is present in fetal cord blood at approximately 0.2-1 ng/mL (20).",BPA,blood,-1
PMC4294274A,"SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum.",SCC4,serum,1
PMC4294274A,"SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum.",SCC15,serum,1
PMC4294274A,"SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum.",SCC9,serum,1
PMC4294274A,"SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum.",SCC25,serum,1
PMC4294274A,"SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum.",DMEM,serum,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",TNM,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",TNM,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",Trop2,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",Trop2,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",TNM,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",TNM,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",Trop2,lymph,1
PMC5029744A,"High Trop2 expression in cytoplasm was significantly correlated with tumor location (p = 0.046), lymph nodes metastasis (p = 0.027), and TNM stage (p = 0.031), while high Trop2 expression in stroma was remarkably associated with perineural invasion (p = 0.024), vascular invasion (p = 0.047), lymph nodes metastasis (p = 0.020) and TNM stage (p = 0.003).See full tableTable 1.",Trop2,lymph,1
PMC5312042A,"Cell medium (10% fetal bovine serum, Dulbec-co's modified Eagle's medium) was supplemented with murine epidermal growth factor, murine hepatocyte growth factor (both at 10 ng/mL; Peprotech, Inc.), Ix insulin-transferrin-selenium-ethanolamine (Life Technologies Corp.), and dexamethasone (10-7 mol/L; Sigma) and changed 24 hours after plating and every 3 days thereafter.",mol,serum,1
PMC3049439A,"There are other examples of well-described adult stem cells--such as muscle satellite cells--that asymmetrically segregate their DNA strands (Shinin et al, 2006), whereas other adult stem cells--such as HSCs and hair follicle stem cells--have been shown not to use this mechanism (Kiel et al, 2007; Waghmare et al, 2008).Overall, it is clear that cell-cycle properties differ between stem cells and should not be used as principal determinants of stemness.",DNA,hair,-1
PMC4558321A,"HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is 4.5-fold higher than SN-38 (18).",SN-38,serum,1
PMC4558321A,"HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is 4.5-fold higher than SN-38 (18).",SN-38,serum,1
PMC4558321A,"HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is 4.5-fold higher than SN-38 (18).",HPLC,serum,1
PMC4558321A,"HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is 4.5-fold higher than SN-38 (18).",AUC,serum,1
PMC4558321A,"HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is 4.5-fold higher than SN-38 (18).",SN-38,serum,1
PMC4449166A,"Sections were sequentially blocked for 10 minutes with a serum-free blocking reagent (Biocare) then incubated with rabbit polyclonal anti-keratin 14 (Krt14) antibody (1:80,000, AF64, Biolegend) for 1 hour at room temperature.",AF64,serum,1
PMC4449166A,"Sections were sequentially blocked for 10 minutes with a serum-free blocking reagent (Biocare) then incubated with rabbit polyclonal anti-keratin 14 (Krt14) antibody (1:80,000, AF64, Biolegend) for 1 hour at room temperature.",Krt14,serum,1
PMC4294274A,"Detroit 562, FaDu and CAL 27 cell lines were cultured as monolayers in DMEM, supplemented with 10% fetal bovine serum, 0.075% sodium bicarbonate, 0.6 mg/ml l-glutamine and kept at 37 1C in humidified atmosphere with 5% CO2 in air.",CO2,serum,1
PMC4294274A,"Detroit 562, FaDu and CAL 27 cell lines were cultured as monolayers in DMEM, supplemented with 10% fetal bovine serum, 0.075% sodium bicarbonate, 0.6 mg/ml l-glutamine and kept at 37 1C in humidified atmosphere with 5% CO2 in air.",DMEM,serum,1
PMC4294274A,"Detroit 562, FaDu and CAL 27 cell lines were cultured as monolayers in DMEM, supplemented with 10% fetal bovine serum, 0.075% sodium bicarbonate, 0.6 mg/ml l-glutamine and kept at 37 1C in humidified atmosphere with 5% CO2 in air.",CAL,serum,1
PMC5000705A,"Second, during the process of detachment from the primary tumor and invasion of the blood stream these cells undergo a number of phenotypical changes. CTCs which are in fact of epithelial origin change their properties, like cell adhesion, cell mobility, and invasiveness, and loss of epithelial markers, so they become mesenchymal-like cells in a process called epithelial-to-mesenchymal transition (EMT) [15,16].",EMT,blood,1
PMC3249013A,"Additionally, an inverse relation was found between serum TCDD levels and serum testosterone in chemical production workers (Egeland et al., 1994).",TCDD,serum,1
PMC3249013A,"Additionally, an inverse relation was found between serum TCDD levels and serum testosterone in chemical production workers (Egeland et al., 1994).",TCDD,serum,1
PMC3816821A,"Tissue sections were incubated with a primary anti-SHIP2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS containing 1% bovine serum albumin for 1 hour.",SHIP2,serum,1
PMC3816821A,"Tissue sections were incubated with a primary anti-SHIP2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS containing 1% bovine serum albumin for 1 hour.",USA,serum,1
PMC3816821A,"Tissue sections were incubated with a primary anti-SHIP2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS containing 1% bovine serum albumin for 1 hour.",TBS,serum,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",PSA,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",SF,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",IL-23,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",IL-23,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",MMP-3,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",CCL20,sera,1
PMC4473102A,"SF IL-23 levels were higher in PSA patients (37.17+-18.13 pg/mL) than in controls (14.12+-7.23 pg/mL) (p0.01)The analysis of gene expression profiles was paralleled by the detection of some of the corresponding soluble mediators in the sera of patients with PsA. We decided to analyse the levels of osteopontin, osteoactivin, CCL20, CCL18, MMP-3 and IL-23.",CCL18,sera,1
PMC4485845A,IMA-901(r) is a 10 tumor-associated peptide (TUMAP) pool combined with granulocyte macrophage colony-stimulating factor (GM-CSF) injected after a single low dose of cyclophosphamide.,GM,CSF,1
PMC4485845A,IMA-901(r) is a 10 tumor-associated peptide (TUMAP) pool combined with granulocyte macrophage colony-stimulating factor (GM-CSF) injected after a single low dose of cyclophosphamide.,TUMAP,CSF,1
PMC4253434A,"As Trop2 resides in large part at the cell surface (in addition to the cytosol), we reasoned that Trop2 is likely to modify signals originating at the plasma membrane and chose to globally interrogate signaling changes caused by Trop2 loss using an unbiased phospho-proteomic approach.",Trop2,plasma,1
PMC4253434A,"As Trop2 resides in large part at the cell surface (in addition to the cytosol), we reasoned that Trop2 is likely to modify signals originating at the plasma membrane and chose to globally interrogate signaling changes caused by Trop2 loss using an unbiased phospho-proteomic approach.",Trop2,plasma,1
PMC4253434A,"As Trop2 resides in large part at the cell surface (in addition to the cytosol), we reasoned that Trop2 is likely to modify signals originating at the plasma membrane and chose to globally interrogate signaling changes caused by Trop2 loss using an unbiased phospho-proteomic approach.",Trop2,plasma,1
PMC4344740A,"Baseline characteristics of subjects in 1st, 2nd and validation cohortBlood samples were collected both with and without EDTA from each patient upon admission, centrifuged at 3000 x g for 10 min at room temperature and the supernatant was stored at -80degC. Plasma and serum were used in the screening of the 1st and the 2nd/validation cohorts, respectively.",EDTA,serum,1
PMC4344740A,"Baseline characteristics of subjects in 1st, 2nd and validation cohortBlood samples were collected both with and without EDTA from each patient upon admission, centrifuged at 3000 x g for 10 min at room temperature and the supernatant was stored at -80degC. Plasma and serum were used in the screening of the 1st and the 2nd/validation cohorts, respectively.",EDTA,Plasma,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",MgCl2,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",MgCl2,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",T,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",Tween-20,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",Tween-20,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako) in TBS-T for 1 h. The membranes were exposed in 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated with 1:5000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG and making it react for 1 h. Positive reactions were detected by incubation in color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako).",TBS,serum,1
PMC2722670A,"Escherichia coli lysate was then subjected to SDS-PAGE followed by western blotting using sera of 73 patients with esophageal cancer, 14 with breast cancer, 9 with gastric cancer, and 16 with colorectal cancer.",SDS,sera,1
PMC2722670A,"Escherichia coli lysate was then subjected to SDS-PAGE followed by western blotting using sera of 73 patients with esophageal cancer, 14 with breast cancer, 9 with gastric cancer, and 16 with colorectal cancer.",PAGE,sera,1
PMC3266428A,"For cohort 2, DNA samples derived from cord blood (n = 148) and age 7 years whole blood (n = 161) with postnatal growth data were analyzed.",DNA,blood,-1
PMC3266428A,"For cohort 2, DNA samples derived from cord blood (n = 148) and age 7 years whole blood (n = 161) with postnatal growth data were analyzed.",DNA,blood,-1
PMC3566310A,"Again, serum biochemical analyses showed decreased levels of both hepatocyte injury and cholestasis markers, although the difference was not statistically significant with regard to ALP (Supplemental Fig.",ALP,serum,1
PMC3843273A,"None of the other parameters (patient age, tumor location, depth of invasion, lymph-node metastasis, lymphatic invasion, vascular invasion, or pathological stage) was associated with positive survivin expression.",survivin,lymph,1
PMC5000705A,"After the isolation of CTCs from blood of patients with pancreatic ductal adenocarcinoma (PDAC) via size-based filtration device and an immunofluorescence staining of the isolated cells for the EMT-marker ZEB1 and the epithelial marker CK, the cells were analyzed for KRAS (proto-onkogene) mutations.",PDAC,blood,1
PMC5000705A,"After the isolation of CTCs from blood of patients with pancreatic ductal adenocarcinoma (PDAC) via size-based filtration device and an immunofluorescence staining of the isolated cells for the EMT-marker ZEB1 and the epithelial marker CK, the cells were analyzed for KRAS (proto-onkogene) mutations.",KRAS,blood,1
PMC5000705A,"After the isolation of CTCs from blood of patients with pancreatic ductal adenocarcinoma (PDAC) via size-based filtration device and an immunofluorescence staining of the isolated cells for the EMT-marker ZEB1 and the epithelial marker CK, the cells were analyzed for KRAS (proto-onkogene) mutations.",ZEB1,blood,1
PMC5000705A,"After the isolation of CTCs from blood of patients with pancreatic ductal adenocarcinoma (PDAC) via size-based filtration device and an immunofluorescence staining of the isolated cells for the EMT-marker ZEB1 and the epithelial marker CK, the cells were analyzed for KRAS (proto-onkogene) mutations.",EMT,blood,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",MMP7,sera,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",MMP7,serum,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",CDH3,sera,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",CDH3,serum,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",ELISA,sera,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",ELISA,serum,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",KRT23,sera,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",KRT23,serum,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",CLDN1,sera,1
PMC3718634A,"Specifically, siCDH3 reduced protein expression by 38.8 +- 9.7% to 53.1 +- 3.8%, siCLDN1 by 33 +- 1.1% to 73.4 +- 2.8%, siKRT23 by 19.8 +- 5.3% to 33.8 +- 1.9%, and siMMP7 by 33 +- 7.9% to 76.5 +- 9.3%.Indirect ELISA was performed as previously described (22) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23 and MMP7 were diluted with carbonate buffer to a concentration of 1.0 ug/ml. A sample was defined as positive when serum IgG value was greater than the mean and two standard deviations of the control sera (n=25) evaluated for each protein (Fig.",CLDN1,serum,1
PMC3233648A,The addition of untreated serum in the absence of PBL with or without hRS7 was not able to induce significant cytotoxicity against EEC-ARK-1 (data not shown).,PBL,serum,1
PMC3233648A,The addition of untreated serum in the absence of PBL with or without hRS7 was not able to induce significant cytotoxicity against EEC-ARK-1 (data not shown).,hRS7,serum,1
PMC3233648A,The addition of untreated serum in the absence of PBL with or without hRS7 was not able to induce significant cytotoxicity against EEC-ARK-1 (data not shown).,EEC,serum,1
PMC3233648A,The addition of untreated serum in the absence of PBL with or without hRS7 was not able to induce significant cytotoxicity against EEC-ARK-1 (data not shown).,ARK-1,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",ADCC,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",ADCC,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",PBL,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",PBL,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",ARK-1,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",ARK-1,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",hRS7,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",hRS7,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",PBL,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",PBL,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",EEC,serum,1
PMC3233648A,"All cell lines were resistant to incubation with rituximab control antibody in the presence of PBL (Figure 3).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as the potential inhibition of hRS7 activity by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to EEC-ARK-1 during 51Cr release assays in the presence or absence of PBL.",EEC,serum,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",DCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",DCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",DCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",PHCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",PHCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",PHCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",FBXW7,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",FBXW7,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",FBXW7,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",CCA,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHCC,bile,1
PMC4467439A,"To verify our observations and define the clinical significance of FBXW7 in CCA, immunohistochemical (IHC) staining was performed in a cohort of 160 CCA specimens (43 IHCC, 64 PHCC and 53 DCC), 28 of them with paired tumor adjacent nontumorous tissues (10 intrahepatic bile duct tissues, 10 perihilar bile duct tissues and 8 distal bile duct tissues).",IHCC,bile,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,Serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,Serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",hRS7,Serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,Serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",PBL,Serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",ADCC,plasma,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",ADCC,serum,1
PMC3233648A,"Importantly, as representatively demonstrated in Figure 4, the addition of endogenous IgG (i.e., heat-inactivated plasma (diluted 1:2) to PBLs or untreated serum (diluted 1:2) in the presence of hRS7) did not significantly alter the degree of ADCC (figure 4) (hRS7 + PBL vs. hRS7 + PBL + Serum: p= 0.773).Endometrial cancer is the most common gynecologic malignancy in developed countries and it is generally considered a neoplasm with good prognosis.",ADCC,Serum,1
PMC3843273A,"None of the other parameters (patient gender, tumor location, depth of invasion, lymph-node metastasis, vascular invasion, or pathological stage) was associated with positive survivin expression.",survivin,lymph,1
PMC5386687A,The supernatant was removed and particles were resuspended into 1 mL of serum-free RPMI or T-media.,RPMI,serum,1
PMC5386687A,The supernatant was removed and particles were resuspended into 1 mL of serum-free RPMI or T-media.,T,serum,1
PMC3754468A,"Each single stage-specific tumor cell suspension was seeded according to the NSA (i.e., in serum-free medium containing EGF and FGF2 as mitogens) [42].",EGF,serum,1
PMC3754468A,"Each single stage-specific tumor cell suspension was seeded according to the NSA (i.e., in serum-free medium containing EGF and FGF2 as mitogens) [42].",FGF2,serum,1
PMC3754468A,"Each single stage-specific tumor cell suspension was seeded according to the NSA (i.e., in serum-free medium containing EGF and FGF2 as mitogens) [42].",NSA,serum,1
PMC3478937A,"Because it has previously been shown that the TAM ligands Protein S and Gas6 are present in cell culture media, because of Protein S-rich serum and autocrine secretion (Anderson et al., 2003), we next studied functional consequences of the continuous presence of Axl-blocking Abs during LC cultures initiated by CD14+ monocytes (Anderson et al., 2003).",CD14,serum,1
PMC3478937A,"Because it has previously been shown that the TAM ligands Protein S and Gas6 are present in cell culture media, because of Protein S-rich serum and autocrine secretion (Anderson et al., 2003), we next studied functional consequences of the continuous presence of Axl-blocking Abs during LC cultures initiated by CD14+ monocytes (Anderson et al., 2003).",Gas6,serum,1
PMC3478937A,"Because it has previously been shown that the TAM ligands Protein S and Gas6 are present in cell culture media, because of Protein S-rich serum and autocrine secretion (Anderson et al., 2003), we next studied functional consequences of the continuous presence of Axl-blocking Abs during LC cultures initiated by CD14+ monocytes (Anderson et al., 2003).",TAM,serum,1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",IL-4,blood,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",IL-4,CSF,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",CD115,blood,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",CD115,CSF,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",GM,blood,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",GM,CSF,-1
PMC5538449A,"However, LC development is dependent on macrophage colony-stimulating factor receptor (CD115, c-fms), and blood monocytes can differentiate into LCs.9-12Human monocytes can also differentiate into monocyte-derived dendritic cells (moDCs; induced by GM-CSF and IL-4), resembling inflammatory DCs in vivo (eg, inflammatory dendritic epidermal cells [IDECs]), or into macrophages.",CSF,blood,-1
PMC4329473A,"Along the same line, cleavage of murine EpCAM was reported to be fulfilled by ADAM proteases at the plasma membrane but additionally, by the b-secretase BACE-1 (48).",BACE-1,plasma,1
PMC4329473A,"Along the same line, cleavage of murine EpCAM was reported to be fulfilled by ADAM proteases at the plasma membrane but additionally, by the b-secretase BACE-1 (48).",ADAM,plasma,1
PMC5042010A,"For instance, sample CYN-026 described a TP53 (C182Y) mutation in a bone marrow derived biopsy sample.",CYN-026,bone marrow,1
PMC5042010A,"For instance, sample CYN-026 described a TP53 (C182Y) mutation in a bone marrow derived biopsy sample.",C182Y,bone marrow,1
PMC5042010A,"For instance, sample CYN-026 described a TP53 (C182Y) mutation in a bone marrow derived biopsy sample.",TP53,bone marrow,1
PMC5042010A,"For these applications, the most important result is the demonstration that the informative template from a blood sample may now be defined molecularly as related to the disease process by orthogonal characterization of DNA alterations.",DNA,blood,-1
PMC4807992A,"PC incidence increases during aging, when serum testosterone levels decline but estrogen levels remain constant, suggesting that the estradiol/testosterone ratio, rather than serum levels of each steroid, is critical in PC development [63].",PC,serum,1
PMC4807992A,"PC incidence increases during aging, when serum testosterone levels decline but estrogen levels remain constant, suggesting that the estradiol/testosterone ratio, rather than serum levels of each steroid, is critical in PC development [63].",PC,serum,1
PMC4807992A,"PC incidence increases during aging, when serum testosterone levels decline but estrogen levels remain constant, suggesting that the estradiol/testosterone ratio, rather than serum levels of each steroid, is critical in PC development [63].",PC,serum,1
PMC4807992A,"PC incidence increases during aging, when serum testosterone levels decline but estrogen levels remain constant, suggesting that the estradiol/testosterone ratio, rather than serum levels of each steroid, is critical in PC development [63].",PC,serum,1
PMC3478937A,"Unlike CD34+ cell-derived LC generation cultures (Strobl et al., 1997), these monocyte-derived LC (moLC) cultures crucially depend on serum supplementation (not depicted).",CD34,serum,1
PMC4673178A,C.In vitro serum stability of IMMU-132 in monkey or human serum.,IMMU-132,serum,1
PMC4673178A,C.In vitro serum stability of IMMU-132 in monkey or human serum.,IMMU-132,serum,1
PMC3443948A,It is reasonable because Trop-2 contains an EGF-like domain that may likely activate EGFR signalling and ERK activation in serum-free condition.,ERK,serum,1
PMC3443948A,It is reasonable because Trop-2 contains an EGF-like domain that may likely activate EGFR signalling and ERK activation in serum-free condition.,EGFR,serum,1
PMC3443948A,It is reasonable because Trop-2 contains an EGF-like domain that may likely activate EGFR signalling and ERK activation in serum-free condition.,Trop-2,serum,1
PMC3443948A,It is reasonable because Trop-2 contains an EGF-like domain that may likely activate EGFR signalling and ERK activation in serum-free condition.,EGF,serum,1
PMC5109830A,"Fluorescence-guided surgery (FGS) is a technique based on near-infrared (NIR) light, which has been widely investigated for sentinel lymph node procedures, anastomosis and during cholecystectomies [5-7].",FGS,lymph,-1
PMC5109830A,"Fluorescence-guided surgery (FGS) is a technique based on near-infrared (NIR) light, which has been widely investigated for sentinel lymph node procedures, anastomosis and during cholecystectomies [5-7].",NIR,lymph,-1
PMC4473102A,"OPN is biosynthesized by a variety of cells including fibroblasts, osteoblasts, osteocytes, chondrocytes, some bone marrow cells, dendritic cells, endothelial cells.",OPN,bone marrow,-1
PMC4275355A,"Furthermore, the coupling of DMBA/TPA chemical carcinogenesis to lineage tracing demonstrated that the vast majority of SCC tumors derived from hair follicle ASCs, even when all cells of the epidermis received a carcinogenic insult [77].",SCC,hair,-1
PMC4275355A,"Furthermore, the coupling of DMBA/TPA chemical carcinogenesis to lineage tracing demonstrated that the vast majority of SCC tumors derived from hair follicle ASCs, even when all cells of the epidermis received a carcinogenic insult [77].",DMBA,hair,-1
PMC4275355A,"Furthermore, the coupling of DMBA/TPA chemical carcinogenesis to lineage tracing demonstrated that the vast majority of SCC tumors derived from hair follicle ASCs, even when all cells of the epidermis received a carcinogenic insult [77].",TPA,hair,-1
PMC4485845A,The phase I and II trials had two objectives.21 The first was to identify strong immunogenic TUMAPs (using the XPRESIDENT platform to screen for overexpressed genes corresponding to HLA ligands) and specific anti-TUMAPS T-cells in blood.,TUMAPS,blood,-1
PMC4485845A,The phase I and II trials had two objectives.21 The first was to identify strong immunogenic TUMAPs (using the XPRESIDENT platform to screen for overexpressed genes corresponding to HLA ligands) and specific anti-TUMAPS T-cells in blood.,HLA,blood,-1
PMC4485845A,The phase I and II trials had two objectives.21 The first was to identify strong immunogenic TUMAPs (using the XPRESIDENT platform to screen for overexpressed genes corresponding to HLA ligands) and specific anti-TUMAPS T-cells in blood.,XPRESIDENT,blood,-1
PMC4485845A,The phase I and II trials had two objectives.21 The first was to identify strong immunogenic TUMAPs (using the XPRESIDENT platform to screen for overexpressed genes corresponding to HLA ligands) and specific anti-TUMAPS T-cells in blood.,T,blood,-1
PMC5437520A,"However, there were a number of DEGs associated with interferon (e.g. interferon-activated gene 205 (IFI205), interferon-induced transmembrane protein 1 (IFITM1) and interferon gamma inducible protein 30 (IFI30)), which were not members of the top 100 list (data not shown).Different angiogenic factors have been related to metastasis formation because they promote primary tumour growth and increase the likelihood that tumour cells come into contact with blood and thus disseminate [27].",IFI205,blood,-1
PMC5437520A,"However, there were a number of DEGs associated with interferon (e.g. interferon-activated gene 205 (IFI205), interferon-induced transmembrane protein 1 (IFITM1) and interferon gamma inducible protein 30 (IFI30)), which were not members of the top 100 list (data not shown).Different angiogenic factors have been related to metastasis formation because they promote primary tumour growth and increase the likelihood that tumour cells come into contact with blood and thus disseminate [27].",IFITM1,blood,-1
PMC5437520A,"However, there were a number of DEGs associated with interferon (e.g. interferon-activated gene 205 (IFI205), interferon-induced transmembrane protein 1 (IFITM1) and interferon gamma inducible protein 30 (IFI30)), which were not members of the top 100 list (data not shown).Different angiogenic factors have been related to metastasis formation because they promote primary tumour growth and increase the likelihood that tumour cells come into contact with blood and thus disseminate [27].",IFI30,blood,-1
PMC5437520A,"However, there were a number of DEGs associated with interferon (e.g. interferon-activated gene 205 (IFI205), interferon-induced transmembrane protein 1 (IFITM1) and interferon gamma inducible protein 30 (IFI30)), which were not members of the top 100 list (data not shown).Different angiogenic factors have been related to metastasis formation because they promote primary tumour growth and increase the likelihood that tumour cells come into contact with blood and thus disseminate [27].",gamma,blood,-1
PMC5289527A,"Whole blood samples or Scope(r) mouthwash rinses were obtained from family members and 10 mg of genomic DNA was extracted and submitted to Illumina Clinical Services Laboratory in San Diego, CA, USA for sequencing using HiSeq 2000.",USA,blood,-1
PMC5289527A,"Whole blood samples or Scope(r) mouthwash rinses were obtained from family members and 10 mg of genomic DNA was extracted and submitted to Illumina Clinical Services Laboratory in San Diego, CA, USA for sequencing using HiSeq 2000.",San,blood,-1
PMC5289527A,"Whole blood samples or Scope(r) mouthwash rinses were obtained from family members and 10 mg of genomic DNA was extracted and submitted to Illumina Clinical Services Laboratory in San Diego, CA, USA for sequencing using HiSeq 2000.",DNA,blood,-1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",DM4,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",DM4,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",SPP,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",SPP,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",Q3W,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",Q3W,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",IMGN242,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",IMGN242,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",DM1,serum,1
PMC4596896A,"The serum half-life in humans for the huC242-SPP-DM1 (Cantuzumab Mertansine), using a Q3W dosing schedule, ranged between 18 and 48.5 hrs while the serum half-life for huC242-SPDB-DM4 (IMGN242) was between 60 and 120 hrs (56).",DM1,serum,1
PMC5467782A,"Circulating microRNA in peripheral blood was isolated using the mirVana PARIS Kit (Ambion, USA).",PARIS,blood,-1
PMC5467782A,"Circulating microRNA in peripheral blood was isolated using the mirVana PARIS Kit (Ambion, USA).",USA,blood,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",SDC4,sera,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",MMP3,sera,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",SDC2,sera,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",ECM,sera,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",MMP3,sera,-1
PMC4473102A,"The upregulation of the MMP3 gene is particularly interesting, since its overexpression has been reported in PsA synovium [125] and increased MMP3 levels have been detected in sera of PsA patients by several investigators [126] including ourselves (Fig 4).Among genes coding for ECM components, the upregulation of the two syndecans transcribing genes (SDC2 and SDC4) is remarkable since these molecules are involved in the retention and activation of leukocytes in inflamed synovium [127,128] and can induce synovial fibroblasts to produce cartilage matrix degrading enzymes such as ADAMTS5 [129].Another aspect associated to synovial hyperplasia is neoangiogenesis, considered a typical feature of the early phase of PsA [130,131].",ADAMTS5,sera,-1
PMC5357254A,"In addition, it has been noted that CD45 is found in MSCs isolated from testis biopsies, ovary, hair follicle and UC Wharton's jelly [37], and CD14 at a low level in non-myeloid lineage cells [38], implying that these two molecules may express in some of this newly identified MSCs from some donors which, however, remains further investigation.",CD14,hair,1
PMC5357254A,"In addition, it has been noted that CD45 is found in MSCs isolated from testis biopsies, ovary, hair follicle and UC Wharton's jelly [37], and CD14 at a low level in non-myeloid lineage cells [38], implying that these two molecules may express in some of this newly identified MSCs from some donors which, however, remains further investigation.",CD45,hair,1
PMC4673178A,"Animals given IMMU-132 had much lower concentrations of free SN-38 in the serum, but it was detected through 48 h. Free SN-38G was detected only at 1 and 6 h, and was 3- to 7-times lower than free SN-38.View larger versionFigure 7.",IMMU-132,serum,1
PMC4673178A,"Animals given IMMU-132 had much lower concentrations of free SN-38 in the serum, but it was detected through 48 h. Free SN-38G was detected only at 1 and 6 h, and was 3- to 7-times lower than free SN-38.View larger versionFigure 7.",SN-38,serum,1
PMC4673178A,"Animals given IMMU-132 had much lower concentrations of free SN-38 in the serum, but it was detected through 48 h. Free SN-38G was detected only at 1 and 6 h, and was 3- to 7-times lower than free SN-38.View larger versionFigure 7.",SN-38,serum,1
PMC3128671A,"In contrast, in USPC ARK-3 cell line, the addition of serum led to a significant increase in killing (p=0.02) (Figure 5).",USPC,serum,1
PMC3128671A,"In contrast, in USPC ARK-3 cell line, the addition of serum led to a significant increase in killing (p=0.02) (Figure 5).",ARK-3,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ADCC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ADCC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",hRS7,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",hRS7,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",PBL,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",PBL,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",PBL,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",PBL,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-6,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-6,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-3,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-3,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ADCC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ADCC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",USPC,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-2,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",ARK-2,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",hRS7,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",hRS7,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",Trop-2,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",Trop-2,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",IL-2,serum,1
PMC3128671A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of Rituximab control antibody (Figure 4).In order to evaluate the effect of complement on the hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1 : 2 (with and without heat inactivation) was added to high Trop-2 expressing USPC cell lines (i.e., USPC ARK-2, USPC ARK-3 and USPC ARK-6) during standard 5-hrs 51Cr release assays in the presence of PBL.",IL-2,serum,1
PMC3906064A,Graphs show number of targets spiked per mL of blood against the yield +/-1 SD from an average of between 7 and 27 experiments.Density adjusted buffers isolate the sample in a sheath flow.,SD,blood,-1
PMC3126726A,"The cellular effect of KIAA0247 is very similar to that of 14-3-3s, whose overexpression could also cause G2/M cell cycle arrest, although 14-3-3s is a p53-dependent inhibitor of G2/M progression [26].In the group's previous studies of fecal gene expression, advanced microarray technology defined global changes in gene expression detectable in feces [18,38].",KIAA0247,feces,-1
PMC3126726A,These results suggest that fecal KIAA0247 provides a more useful therapeutic reference for early-stage CRC patients than blood KIAA0247.,KIAA0247,blood,-1
PMC3126726A,These results suggest that fecal KIAA0247 provides a more useful therapeutic reference for early-stage CRC patients than blood KIAA0247.,CRC,blood,-1
PMC3126726A,These results suggest that fecal KIAA0247 provides a more useful therapeutic reference for early-stage CRC patients than blood KIAA0247.,KIAA0247,blood,-1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,serum,1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,bone marrow,1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,lymph,1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,serum,1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,bone marrow,1
PMC3754468A,"Metastatic spread occurs by exploiting both the lymphatic and the circulatory system, and metastases can be retrieved primarily in bone, pelvic lymph nodes, and bone marrow, and less frequently in lungs and liver [6].A variety of experimental models, including transgenic mouse models and serum-dependent human PC cell lines, have been exploited to investigate PC pathogenesis.",PC,lymph,1
PMC3250983A,"CD138 is expressed by about 75% of ER-negative forms of breast cancer [39], and it is associated with a high histological grade, Ki 67 index, tumor size, and lymph node involvement [8,40].",ER,lymph,1
PMC3250983A,"CD138 is expressed by about 75% of ER-negative forms of breast cancer [39], and it is associated with a high histological grade, Ki 67 index, tumor size, and lymph node involvement [8,40].",Ki,lymph,1
PMC3250983A,"CD138 is expressed by about 75% of ER-negative forms of breast cancer [39], and it is associated with a high histological grade, Ki 67 index, tumor size, and lymph node involvement [8,40].",CD138,lymph,1
PMC3718634A,"Stage 1 (40%) and stage 2 (60%) CRC patient sera were included (HSD# 19394, University of Washington, Seattle, WA and Innovative Research, Novi, MI).",MI,sera,1
PMC3718634A,"Stage 1 (40%) and stage 2 (60%) CRC patient sera were included (HSD# 19394, University of Washington, Seattle, WA and Innovative Research, Novi, MI).",HSD,sera,1
PMC3718634A,"Stage 1 (40%) and stage 2 (60%) CRC patient sera were included (HSD# 19394, University of Washington, Seattle, WA and Innovative Research, Novi, MI).",CRC,sera,1
PMC3224774A,"This suggests that in the presence of effector PBL, human plasma may augment hRS7-mediated cytotoxicity against carcinosarcomas.",PBL,plasma,1
PMC2441949A,"Area under the curve (AUC) measurements were performed for single gene analysis using MedCalc software (Mariakerke, Belgium); patients were dichotomised according to lymph node metastasis status.",AUC,lymph,1
PMC3110956A,"At times of sacrifice, livers were rinsed in phosphate-buffered saline (PBS) and placed in 4% paraformaldehyde for 45 min, rinsed in PBS, and cryoprotected in 10%, 20%, and 30% sucrose/PBS overnight at 4degC. Frozen sections were warmed to room temperature for 3 min, rinsed in PBS, and blocked with PBS/0.25% Trion X-100/3% donkey serum for 1 h at room temperature.",PBS,serum,1
PMC3110956A,"At times of sacrifice, livers were rinsed in phosphate-buffered saline (PBS) and placed in 4% paraformaldehyde for 45 min, rinsed in PBS, and cryoprotected in 10%, 20%, and 30% sucrose/PBS overnight at 4degC. Frozen sections were warmed to room temperature for 3 min, rinsed in PBS, and blocked with PBS/0.25% Trion X-100/3% donkey serum for 1 h at room temperature.",PBS,serum,1
PMC3110956A,"At times of sacrifice, livers were rinsed in phosphate-buffered saline (PBS) and placed in 4% paraformaldehyde for 45 min, rinsed in PBS, and cryoprotected in 10%, 20%, and 30% sucrose/PBS overnight at 4degC. Frozen sections were warmed to room temperature for 3 min, rinsed in PBS, and blocked with PBS/0.25% Trion X-100/3% donkey serum for 1 h at room temperature.",PBS,serum,1
PMC3110956A,"At times of sacrifice, livers were rinsed in phosphate-buffered saline (PBS) and placed in 4% paraformaldehyde for 45 min, rinsed in PBS, and cryoprotected in 10%, 20%, and 30% sucrose/PBS overnight at 4degC. Frozen sections were warmed to room temperature for 3 min, rinsed in PBS, and blocked with PBS/0.25% Trion X-100/3% donkey serum for 1 h at room temperature.",PBS,serum,1
PMC4426451A,"Whereas conventional microscopy of human samples (smears, aspirates, biopsies, blood) is the most widely used to diagnose cancer, its POC adaptation is limited by inherent drawbacks such as bulky optics, requirements for trained microscopists, and operator-dependent variability.",POC,blood,-1
PMC3110956A,Cells were incubated with APC-conjugated anti-CD45 for 20 min and washed several times in PBS with 2% fetal bovine serum.,PBS,serum,1
PMC3110956A,Cells were incubated with APC-conjugated anti-CD45 for 20 min and washed several times in PBS with 2% fetal bovine serum.,APC,serum,1
PMC3110956A,Cells were incubated with APC-conjugated anti-CD45 for 20 min and washed several times in PBS with 2% fetal bovine serum.,CD45,serum,1
PMC4712003A,"Sections were incubated with blocking solution (5% bovine serum albumin [BSA] in PBS) for 30 min and then incubated with a mouse monoclonal anti-integrina6 antibody (ITGA6; 1 mg/ml; Abd Serotec, Bio-Rad Laboratories) or a rabbit monoclonal anti-PTGS1 antibody (0.3 mg/ml; Abcam) diluted in blocking solution at room temperature for 1 hr. Sections were washed three times with PBS-Tween and subsequently incubated with an anti-mouse Alexa 594 (red; Life Technologies) or an anti-rabbit Alexa 488 (green; Life Technologies) -conjugated secondary antibody (2 mg/ml) at room temperature for 30 min in blocking buffer containing a Hoechst blue dye (1 mg/ml; Biotium).",BSA,serum,1
PMC4712003A,"Sections were incubated with blocking solution (5% bovine serum albumin [BSA] in PBS) for 30 min and then incubated with a mouse monoclonal anti-integrina6 antibody (ITGA6; 1 mg/ml; Abd Serotec, Bio-Rad Laboratories) or a rabbit monoclonal anti-PTGS1 antibody (0.3 mg/ml; Abcam) diluted in blocking solution at room temperature for 1 hr. Sections were washed three times with PBS-Tween and subsequently incubated with an anti-mouse Alexa 594 (red; Life Technologies) or an anti-rabbit Alexa 488 (green; Life Technologies) -conjugated secondary antibody (2 mg/ml) at room temperature for 30 min in blocking buffer containing a Hoechst blue dye (1 mg/ml; Biotium).",PTGS1,serum,1
PMC4712003A,"Sections were incubated with blocking solution (5% bovine serum albumin [BSA] in PBS) for 30 min and then incubated with a mouse monoclonal anti-integrina6 antibody (ITGA6; 1 mg/ml; Abd Serotec, Bio-Rad Laboratories) or a rabbit monoclonal anti-PTGS1 antibody (0.3 mg/ml; Abcam) diluted in blocking solution at room temperature for 1 hr. Sections were washed three times with PBS-Tween and subsequently incubated with an anti-mouse Alexa 594 (red; Life Technologies) or an anti-rabbit Alexa 488 (green; Life Technologies) -conjugated secondary antibody (2 mg/ml) at room temperature for 30 min in blocking buffer containing a Hoechst blue dye (1 mg/ml; Biotium).",ITGA6,serum,1
PMC4712003A,"Sections were incubated with blocking solution (5% bovine serum albumin [BSA] in PBS) for 30 min and then incubated with a mouse monoclonal anti-integrina6 antibody (ITGA6; 1 mg/ml; Abd Serotec, Bio-Rad Laboratories) or a rabbit monoclonal anti-PTGS1 antibody (0.3 mg/ml; Abcam) diluted in blocking solution at room temperature for 1 hr. Sections were washed three times with PBS-Tween and subsequently incubated with an anti-mouse Alexa 594 (red; Life Technologies) or an anti-rabbit Alexa 488 (green; Life Technologies) -conjugated secondary antibody (2 mg/ml) at room temperature for 30 min in blocking buffer containing a Hoechst blue dye (1 mg/ml; Biotium).",PBS,serum,1
PMC4712003A,"Sections were incubated with blocking solution (5% bovine serum albumin [BSA] in PBS) for 30 min and then incubated with a mouse monoclonal anti-integrina6 antibody (ITGA6; 1 mg/ml; Abd Serotec, Bio-Rad Laboratories) or a rabbit monoclonal anti-PTGS1 antibody (0.3 mg/ml; Abcam) diluted in blocking solution at room temperature for 1 hr. Sections were washed three times with PBS-Tween and subsequently incubated with an anti-mouse Alexa 594 (red; Life Technologies) or an anti-rabbit Alexa 488 (green; Life Technologies) -conjugated secondary antibody (2 mg/ml) at room temperature for 30 min in blocking buffer containing a Hoechst blue dye (1 mg/ml; Biotium).",PBS,serum,1
PMC5414739A,"Human CD34+ bone marrow cells have been proposed to express the PRLR, potentially supporting the fact that PRL stimulation in colony assays enhances the growth of granulocytic and erythrocytic progenitors (135).",CD34,bone marrow,1
PMC5414739A,"Human CD34+ bone marrow cells have been proposed to express the PRLR, potentially supporting the fact that PRL stimulation in colony assays enhances the growth of granulocytic and erythrocytic progenitors (135).",PRL,bone marrow,1
PMC5414739A,"Human CD34+ bone marrow cells have been proposed to express the PRLR, potentially supporting the fact that PRL stimulation in colony assays enhances the growth of granulocytic and erythrocytic progenitors (135).",PRLR,bone marrow,1
PMC4972371A,"Negative CD24 tumours had a longer median time to progression compared to positive CD24 tumours (12.1 months vs 5.5 months, p = 0.008).10 S100A4 negative tumours also had a longer median time to progression compared to S100A4 positive tumours (16.9 months vs 6.3 months, p = 0.004).FOXC1 and Smad4/Dpc4 were the highest ranking biomarkers when considering lymph node involvement.",S100A4,lymph,1
PMC4972371A,"Negative CD24 tumours had a longer median time to progression compared to positive CD24 tumours (12.1 months vs 5.5 months, p = 0.008).10 S100A4 negative tumours also had a longer median time to progression compared to S100A4 positive tumours (16.9 months vs 6.3 months, p = 0.004).FOXC1 and Smad4/Dpc4 were the highest ranking biomarkers when considering lymph node involvement.",CD24,lymph,1
PMC4972371A,"Negative CD24 tumours had a longer median time to progression compared to positive CD24 tumours (12.1 months vs 5.5 months, p = 0.008).10 S100A4 negative tumours also had a longer median time to progression compared to S100A4 positive tumours (16.9 months vs 6.3 months, p = 0.004).FOXC1 and Smad4/Dpc4 were the highest ranking biomarkers when considering lymph node involvement.",S100A4,lymph,1
PMC4972371A,"Negative CD24 tumours had a longer median time to progression compared to positive CD24 tumours (12.1 months vs 5.5 months, p = 0.008).10 S100A4 negative tumours also had a longer median time to progression compared to S100A4 positive tumours (16.9 months vs 6.3 months, p = 0.004).FOXC1 and Smad4/Dpc4 were the highest ranking biomarkers when considering lymph node involvement.",CD24,lymph,1
PMC4972371A,"Negative CD24 tumours had a longer median time to progression compared to positive CD24 tumours (12.1 months vs 5.5 months, p = 0.008).10 S100A4 negative tumours also had a longer median time to progression compared to S100A4 positive tumours (16.9 months vs 6.3 months, p = 0.004).FOXC1 and Smad4/Dpc4 were the highest ranking biomarkers when considering lymph node involvement.",6.3,lymph,1
PMC3474961A,"Collectively these studies have shown that while ADT decreases serum testosterone levels by approximately 95%, intra-tumor androgen levels combined with overexpressed AR may be sufficient to drive the progression of PCa in AR-dependent manner.",ADT,serum,1
PMC3474961A,"Collectively these studies have shown that while ADT decreases serum testosterone levels by approximately 95%, intra-tumor androgen levels combined with overexpressed AR may be sufficient to drive the progression of PCa in AR-dependent manner.",AR,serum,1
PMC3474961A,"Collectively these studies have shown that while ADT decreases serum testosterone levels by approximately 95%, intra-tumor androgen levels combined with overexpressed AR may be sufficient to drive the progression of PCa in AR-dependent manner.",AR,serum,1
PMC5538449A,"Conversely, addition of TGF-b1 alone (ie, without Delta-1) to GM-CSF-supplemented cultures resulted in the generation of macrophages (CD14+CD11b+CD1a-) exhibiting marked upregulation of KLF4 protein (Fig 2, A).",KLF4,CSF,1
PMC5538449A,"Conversely, addition of TGF-b1 alone (ie, without Delta-1) to GM-CSF-supplemented cultures resulted in the generation of macrophages (CD14+CD11b+CD1a-) exhibiting marked upregulation of KLF4 protein (Fig 2, A).",TGF,CSF,1
PMC5538449A,"Conversely, addition of TGF-b1 alone (ie, without Delta-1) to GM-CSF-supplemented cultures resulted in the generation of macrophages (CD14+CD11b+CD1a-) exhibiting marked upregulation of KLF4 protein (Fig 2, A).",Delta-1,CSF,1
PMC5538449A,"Conversely, addition of TGF-b1 alone (ie, without Delta-1) to GM-CSF-supplemented cultures resulted in the generation of macrophages (CD14+CD11b+CD1a-) exhibiting marked upregulation of KLF4 protein (Fig 2, A).",GM,CSF,1
PMC3929731A,"In a study of 2500 US adults, 93% had detectable urine BPA, indicating that humans are chronically exposed to this compound during routine daily activity (17).",BPA,urine,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",CA-125,lymph,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",CA-125,ascites,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",CA-125,serum,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",FIGO,lymph,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",FIGO,ascites,1
PMC4108928A,"The original clinical data were obtained from hospital medical records, including patient age, tumor size, FIGO stage, tumor grade, histological type, serum CA-125 level, ascites, lymph node metastasis, relapse status, disease-free survival and overall survival.",FIGO,serum,1
PMC3474961A,"Stanbrough and colleagues compared gene expression profiles of androgen-independent PCa bone marrow metastases (N=33) with primary PCa samples (N=22) and reported that while AR expression was upregulated in metastatic samples, additional genes including the aldo-keto reductase family 1 member C3 (AKR1C3), a key prostatic enzyme that reduces adrenal androstenedione to testosterone, was also overexpressed [70].",AR,bone marrow,1
PMC3474961A,"Stanbrough and colleagues compared gene expression profiles of androgen-independent PCa bone marrow metastases (N=33) with primary PCa samples (N=22) and reported that while AR expression was upregulated in metastatic samples, additional genes including the aldo-keto reductase family 1 member C3 (AKR1C3), a key prostatic enzyme that reduces adrenal androstenedione to testosterone, was also overexpressed [70].",C3,bone marrow,1
PMC3474961A,"Stanbrough and colleagues compared gene expression profiles of androgen-independent PCa bone marrow metastases (N=33) with primary PCa samples (N=22) and reported that while AR expression was upregulated in metastatic samples, additional genes including the aldo-keto reductase family 1 member C3 (AKR1C3), a key prostatic enzyme that reduces adrenal androstenedione to testosterone, was also overexpressed [70].",AKR1C3,bone marrow,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",TBS,plasma,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",Tween-20,plasma,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",BSA,plasma,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",T,plasma,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",TBS,plasma,1
PMC4344740A,"The membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and non-specific binding was blocked by incubation with 1% protease-free BSA (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted plasma for 1 h.",T,plasma,1
PMC3929731A,"Although levels of unconjugated or free BPA in adult human serum are typically low (undetectable to ~0.5 ng/mL), higher levels have been reported in amniotic fluid, fetal circulation, and neonates (19-22).",BPA,serum,1
PMC2634835A,"Src kinase inhibition using either a dominant-negative approach or small molecule inhibitors, decreased growth and invasion of HNSCC cells, regardless of EGFR stimulation.50,51 HNSCC invasion is associated in part with the development of invadopodia, a phenomenon whereby cancer cells form plasma membrane-like protrusions that make contact with and facilitate degradation of the extracellular matrix and subsequent invasion invasion2.",EGFR,plasma,1
PMC2634835A,"Src kinase inhibition using either a dominant-negative approach or small molecule inhibitors, decreased growth and invasion of HNSCC cells, regardless of EGFR stimulation.50,51 HNSCC invasion is associated in part with the development of invadopodia, a phenomenon whereby cancer cells form plasma membrane-like protrusions that make contact with and facilitate degradation of the extracellular matrix and subsequent invasion invasion2.",HNSCC,plasma,1
PMC2634835A,"Src kinase inhibition using either a dominant-negative approach or small molecule inhibitors, decreased growth and invasion of HNSCC cells, regardless of EGFR stimulation.50,51 HNSCC invasion is associated in part with the development of invadopodia, a phenomenon whereby cancer cells form plasma membrane-like protrusions that make contact with and facilitate degradation of the extracellular matrix and subsequent invasion invasion2.",HNSCC,plasma,1
PMC4214500A,"However, none of the other parameters of patient age, gender, tumor location, depth of invasion, lymph-node metastasis, lymphatic invasion, or pathological stage were found to be associated with positive Smac/DIABLO expression.",DIABLO,lymph,1
PMC3104081A,The effect of heat-inactivated human serum (56degC for 60 minutes) was also tested in the presence of effector PBL.,PBL,serum,1
PMC5410259A,"Briefly, trypsinized cells, prepared as a single cell suspension, were resuspended in 50 ml aliquots of 0.1% bovine serum albumin-Hanks' balanced salt solution (BSA-HBSS).",BSA,serum,1
PMC5410259A,"Briefly, trypsinized cells, prepared as a single cell suspension, were resuspended in 50 ml aliquots of 0.1% bovine serum albumin-Hanks' balanced salt solution (BSA-HBSS).",HBSS,serum,1
PMC3104081A,"To test for the possible inhibition of ADCC against ovarian cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3104081A,"To test for the possible inhibition of ADCC against ovarian cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3104081A,"To test for the possible inhibition of ADCC against ovarian cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3104081A,"To test for the possible inhibition of ADCC against ovarian cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3786374A,We further assessed whether serum TGFb1 levels of ThrbPV/PV mice were elevated to stimulate TGFBRII-SMAD signaling.,TGFb1,serum,1
PMC3786374A,We further assessed whether serum TGFb1 levels of ThrbPV/PV mice were elevated to stimulate TGFBRII-SMAD signaling.,SMAD,serum,1
PMC3786374A,We further assessed whether serum TGFb1 levels of ThrbPV/PV mice were elevated to stimulate TGFBRII-SMAD signaling.,TGFBRII,serum,1
PMC3104081A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all six ovarian cancer cell lines.",PLUS,blood,-1
PMC3104081A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all six ovarian cancer cell lines.",PBL,blood,-1
PMC3583404A,"WiDr, HepG2, and A549 cells were cultured in Dulbecco's minimum essential medium (D-MEM), which was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HCT-15 and",HCT-15,serum,1
PMC3583404A,"WiDr, HepG2, and A549 cells were cultured in Dulbecco's minimum essential medium (D-MEM), which was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HCT-15 and",HepG2,serum,1
PMC3583404A,"WiDr, HepG2, and A549 cells were cultured in Dulbecco's minimum essential medium (D-MEM), which was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HCT-15 and",MEM,serum,1
PMC3583404A,"WiDr, HepG2, and A549 cells were cultured in Dulbecco's minimum essential medium (D-MEM), which was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HCT-15 and",A549,serum,1
PMC3583404A,"WiDr, HepG2, and A549 cells were cultured in Dulbecco's minimum essential medium (D-MEM), which was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HCT-15 and",FBS,serum,1
PMC3786374A,"Indeed, Figure 3C shows that at 3-4 months of age, serum TGFb1 levels in ThrbPV/PV mice were significantly higher than those in WT mice (compare data group 2 with data group 1).",TGFb1,serum,1
PMC4687932A,"All cell lines were cultured in RPMI 1640 containing 10% (v/v) fetal calf serum and 1% (v/v) penicillin/streptomycin (all Gibco/Life Technologies, Darmstadt, Germany). SKBR3 and",RPMI,serum,1
PMC4687932A,"All cell lines were cultured in RPMI 1640 containing 10% (v/v) fetal calf serum and 1% (v/v) penicillin/streptomycin (all Gibco/Life Technologies, Darmstadt, Germany). SKBR3 and",SKBR3,serum,1
PMC4999623A,"In contrast, immunoselection for EpCAM+ cells from fetal livers results in predominantly hepatoblast population isolation with only a small percentage of hepatic stem cells.25,26 These isolated hepatic stem cells are capable of self-renewal and differentiate both in vitro and in vivo into hepatocytes and cholangiocytes, the epithelial cells of bile-duct.26,27The hepatoblast cells within the aforementioned fetal liver bud express AFP and are bipotent, capable of generating hepatocytes and cholangiocytes.28 These bipotent hepatoblasts have been isolated from human fetal liver (18-20 gestational age) by dual immuno-selection for EpCAM+/ICAM+ cells.29",AFP,bile,1
PMC4306156A,"Importantly, our data showed that administration of WCA and 5-FU effectively reduced serum CEA levels in the orthotopic transplant nude mouse model, which may be associated with the decreased rate of hepatic metastasis that we observed.",FU,serum,1
PMC4306156A,"Importantly, our data showed that administration of WCA and 5-FU effectively reduced serum CEA levels in the orthotopic transplant nude mouse model, which may be associated with the decreased rate of hepatic metastasis that we observed.",CEA,serum,1
PMC4306156A,"Importantly, our data showed that administration of WCA and 5-FU effectively reduced serum CEA levels in the orthotopic transplant nude mouse model, which may be associated with the decreased rate of hepatic metastasis that we observed.",WCA,serum,1
PMC3786374A,TGFb1 serum levels of ThrbPV/PV and WT mice were further increased at age 5-7 months.,TGFb1,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,IPTG,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,IPTG,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,SCC,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,SCC,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ECSA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ECSA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,PBS,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,PBS,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,EDTA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,EDTA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,FBS,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,FBS,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,PCR,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,PCR,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ECSA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ECSA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,cDNA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,cDNA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,SEREX,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,SEREX,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ELISA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,ELISA,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,GST,serum,1
PMC3135497A,EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl b-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.,GST,serum,1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC4966842A,"TF is present in sub-endothelial cells in the blood vessel wall and upon vascular damage proteins in the blood stream that, upon binding to TF, can initiate the blood coagulation cascade to achieve closure of the ruptured blood vessel.",TF,blood,-1
PMC3774116A,"Epithelial (EpCAM+Thy1), stromal (EpCAMThy1+) and myometrial (EpCAMThy1) cells were isolated from dissociated uterine cellular preparations after exclusion of endothelial (PECAM1), lymphoid (PTPRC) and red blood cells (Ter 119).",EpCAMThy1,blood,-1
PMC3774116A,"Epithelial (EpCAM+Thy1), stromal (EpCAMThy1+) and myometrial (EpCAMThy1) cells were isolated from dissociated uterine cellular preparations after exclusion of endothelial (PECAM1), lymphoid (PTPRC) and red blood cells (Ter 119).",PECAM1,blood,-1
PMC3774116A,"Epithelial (EpCAM+Thy1), stromal (EpCAMThy1+) and myometrial (EpCAMThy1) cells were isolated from dissociated uterine cellular preparations after exclusion of endothelial (PECAM1), lymphoid (PTPRC) and red blood cells (Ter 119).",PTPRC,blood,-1
PMC3774116A,"Epithelial (EpCAM+Thy1), stromal (EpCAMThy1+) and myometrial (EpCAMThy1) cells were isolated from dissociated uterine cellular preparations after exclusion of endothelial (PECAM1), lymphoid (PTPRC) and red blood cells (Ter 119).",EpCAMThy1,blood,-1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",N1,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",N1,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",N1,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",M1,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",M1,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",M1,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",CEA,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",CEA,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",CEA,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",AJCC,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",AJCC,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",AJCC,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",TNM,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",TNM,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",TNM,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",ICC,serum,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",ICC,lymph,1
PMC5328612A,"N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.42 Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages.43,44 Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).44A genomic biomarker profile can also help in differentiating patients with ICC.45-47 A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes.",ICC,serum,1
PMC2441949A,"A survival benefit from adjuvant 5-fluorouracil-based chemotherapy has been firmly established in these patients, and recent data have shown further efficacy through the inclusion of oxaliplatin into adjuvant treatment programmes (Chung and Saltz, 2007; Wolpin et al, 2007).At present, the standard procedure for determining the spread of metastatic disease to lymph nodes is pathological examination of ~20 resected lymph nodes stained with haematoxylin and eosin (HE).",HE,lymph,1
PMC2441949A,"A survival benefit from adjuvant 5-fluorouracil-based chemotherapy has been firmly established in these patients, and recent data have shown further efficacy through the inclusion of oxaliplatin into adjuvant treatment programmes (Chung and Saltz, 2007; Wolpin et al, 2007).At present, the standard procedure for determining the spread of metastatic disease to lymph nodes is pathological examination of ~20 resected lymph nodes stained with haematoxylin and eosin (HE).",HE,lymph,1
PMC4509052A,"Previous studies have identified that the genes for epidermal growth factor receptor (4), GA733 (5), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (6), colloid osmotic pressure of serum, and lung fibroblast growth factor receptor 1 (closely related to FGFR1) (7) are associated with tumor growth and development, apoptosis, metastasis, cell proliferation and aggressiveness.",GA733,serum,1
PMC4509052A,"Previous studies have identified that the genes for epidermal growth factor receptor (4), GA733 (5), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (6), colloid osmotic pressure of serum, and lung fibroblast growth factor receptor 1 (closely related to FGFR1) (7) are associated with tumor growth and development, apoptosis, metastasis, cell proliferation and aggressiveness.",FGFR1,serum,1
PMC4473102A,For this purpose we analyzed for the first time gene expression in paired peripheral blood cells (PBC) and synovial biopsies of 10 PsA patients.,PBC,blood,-1
PMC4621003A,"To elucidate the type of immunity induced by vaccination with GPI-HER-2-VLPs, a cell ELISA was conducted on sera from vaccinated mice using D2F2/E2 cells and HER-2-specific IgG subtypes were analyzed.",ELISA,sera,1
PMC4621003A,"To elucidate the type of immunity induced by vaccination with GPI-HER-2-VLPs, a cell ELISA was conducted on sera from vaccinated mice using D2F2/E2 cells and HER-2-specific IgG subtypes were analyzed.",GPI,sera,1
PMC3786374A,No additional increases in TGFb1 serum levels were detected in mice aged 10-12 months.,TGFb1,serum,1
PMC4695878A,Alexa Fluor 488 Goat Anti-Mouse IgG (Invitrogen A-11001) was diluted 1:200 in buffer (3% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.,A-11001,serum,1
PMC4695878A,Alexa Fluor 488 Goat Anti-Mouse IgG (Invitrogen A-11001) was diluted 1:200 in buffer (3% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.,NP-40,serum,1
PMC3906064A,"Tumor cell lines were spiked into NHD blood at 10, 50 or 100 cells per mL. EpCAM expressing cells were recovered from 2 mL samples using the CTC flow cell (Figure 1C).",CTC,blood,-1
PMC3906064A,"Tumor cell lines were spiked into NHD blood at 10, 50 or 100 cells per mL. EpCAM expressing cells were recovered from 2 mL samples using the CTC flow cell (Figure 1C).",NHD,blood,-1
PMC3128671A,"These data, therefore, demonstrate that although these tumor cells are extremely resistant to multiple clinically available chemotherapeutic agents, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2-specific antibody hRS7.To test the feasibility of hRS7-induced ADCC in the in vivo setting, ADCC experiments were performed in the presence of human serum as a source of high concentrations of irrelevant human IgG that could potentially block the ability of effector cells to interact with the antibody at the target site.",ADCC,serum,-1
PMC3128671A,"These data, therefore, demonstrate that although these tumor cells are extremely resistant to multiple clinically available chemotherapeutic agents, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2-specific antibody hRS7.To test the feasibility of hRS7-induced ADCC in the in vivo setting, ADCC experiments were performed in the presence of human serum as a source of high concentrations of irrelevant human IgG that could potentially block the ability of effector cells to interact with the antibody at the target site.",ADCC,serum,-1
PMC4062414A,"Plakophilins, such as PKP3/plakophilin (r = 0.71), and JUP/plakoglobin (r = 0.70), constitute the outer dense plaque that connects to the desmosomal cadherins and to the cytoskeletal linker protein DSP/desmoplakin (r = 0.62) on the cytoplasmic side of the plasma membrane (Figure 14).",DSP,plasma,1
PMC4062414A,"Plakophilins, such as PKP3/plakophilin (r = 0.71), and JUP/plakoglobin (r = 0.70), constitute the outer dense plaque that connects to the desmosomal cadherins and to the cytoskeletal linker protein DSP/desmoplakin (r = 0.62) on the cytoplasmic side of the plasma membrane (Figure 14).",JUP,plasma,1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",DC,CSF,1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",DC,blood,-1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",T,CSF,1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",T,blood,-1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",DC,CSF,1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",DC,blood,-1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",CSF,blood,-1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",GM,CSF,1
PMC4485845A,"GM-CSF plays a critical role in DC maturation and T-cell proliferation and activation, and increases DC-mediated responses to tumor cells.70 When used as an adjuvant, it might, however, increase MDSCs in the tumor micro-environment and in blood.",GM,blood,-1
PMC3786374A,"These data indicate that in addition to the elevated protein abundance of TGFBRII, increased serum TGFb1 levels also contributed to the activation of TGFBRII-SMAD signaling.",TGFBRII,serum,1
PMC3786374A,"These data indicate that in addition to the elevated protein abundance of TGFBRII, increased serum TGFb1 levels also contributed to the activation of TGFBRII-SMAD signaling.",TGFb1,serum,1
PMC3786374A,"These data indicate that in addition to the elevated protein abundance of TGFBRII, increased serum TGFb1 levels also contributed to the activation of TGFBRII-SMAD signaling.",SMAD,serum,1
PMC3786374A,"These data indicate that in addition to the elevated protein abundance of TGFBRII, increased serum TGFb1 levels also contributed to the activation of TGFBRII-SMAD signaling.",TGFBRII,serum,1
PMC3100619A,"Recipient mice were supplemented with T containing SILASTIC (Dow Corning Corp., Midland, MI) capsules (0.5 cm) that produced serum T levels of 12.7 ng/ml at 1 month.",MI,serum,1
PMC3100619A,"Recipient mice were supplemented with T containing SILASTIC (Dow Corning Corp., Midland, MI) capsules (0.5 cm) that produced serum T levels of 12.7 ng/ml at 1 month.",T,serum,1
PMC3100619A,"Recipient mice were supplemented with T containing SILASTIC (Dow Corning Corp., Midland, MI) capsules (0.5 cm) that produced serum T levels of 12.7 ng/ml at 1 month.",SILASTIC,serum,1
PMC3100619A,"Recipient mice were supplemented with T containing SILASTIC (Dow Corning Corp., Midland, MI) capsules (0.5 cm) that produced serum T levels of 12.7 ng/ml at 1 month.",T,serum,1
PMC4707334A,"Interaction of SDF-1a/CXCR4 is essential to initiate activation of oval cells, when hepatocyte proliferation is impaired, and maintain stem cell niches through the control of progenitor cell migration by possible recruitment of a second wave of bone marrow origin progenitor cells to the injured side of the liver [25, 29].The hepatic stellate cell represents the fraction of liver-resident cells with star-like morphology, located between liver sinusoidal endothelial cells and hepatocytes.",SDF-1a,bone marrow,-1
PMC4707334A,"Interaction of SDF-1a/CXCR4 is essential to initiate activation of oval cells, when hepatocyte proliferation is impaired, and maintain stem cell niches through the control of progenitor cell migration by possible recruitment of a second wave of bone marrow origin progenitor cells to the injured side of the liver [25, 29].The hepatic stellate cell represents the fraction of liver-resident cells with star-like morphology, located between liver sinusoidal endothelial cells and hepatocytes.",CXCR4,bone marrow,-1
PMC3478937A,"To investigate the contribution of Axl to AC uptake in response to TGF-b1 stimulation, we used M-CSF-dependent mouse BM-derived macrophages (BMDMs) genetically deficient for the TAM receptors.",AC,CSF,1
PMC3478937A,"To investigate the contribution of Axl to AC uptake in response to TGF-b1 stimulation, we used M-CSF-dependent mouse BM-derived macrophages (BMDMs) genetically deficient for the TAM receptors.",TAM,CSF,1
PMC3478937A,"To investigate the contribution of Axl to AC uptake in response to TGF-b1 stimulation, we used M-CSF-dependent mouse BM-derived macrophages (BMDMs) genetically deficient for the TAM receptors.",TGF,CSF,1
PMC4523269A,"By contrast, once the new hair cycle initiates, some bulge cells leave their niche and form an inverse proliferative gradient along the emerging outer root sheath (ORS).",ORS,hair,1
PMC3478937A,"(B and C) MoLCs were differentiated in the presence GM-CSF, IL-4, TGF-b1, and 5 ug/ml anti-Axl blocking Ab or isotype control for 5 d and subsequently activated with PAM3CSK4 for 20 h. A representative experiment out of four different donor experiments is shown.",GM,CSF,1
PMC3478937A,"(B and C) MoLCs were differentiated in the presence GM-CSF, IL-4, TGF-b1, and 5 ug/ml anti-Axl blocking Ab or isotype control for 5 d and subsequently activated with PAM3CSK4 for 20 h. A representative experiment out of four different donor experiments is shown.",IL-4,CSF,1
PMC3478937A,"(B and C) MoLCs were differentiated in the presence GM-CSF, IL-4, TGF-b1, and 5 ug/ml anti-Axl blocking Ab or isotype control for 5 d and subsequently activated with PAM3CSK4 for 20 h. A representative experiment out of four different donor experiments is shown.",PAM3CSK4,CSF,1
PMC3478937A,"(B and C) MoLCs were differentiated in the presence GM-CSF, IL-4, TGF-b1, and 5 ug/ml anti-Axl blocking Ab or isotype control for 5 d and subsequently activated with PAM3CSK4 for 20 h. A representative experiment out of four different donor experiments is shown.",TGF,CSF,1
PMC4188889A,"Bunger et al[2] reviewed about 43 serum biomarkers for PC divided into four main groups: carbohydrates (CA19-9, CA 50, CA 125, CA195, CA 72-4), carcinoembryonic antigens, other markers and the combination of different markers.",PC,serum,1
PMC4188889A,"Bunger et al[2] reviewed about 43 serum biomarkers for PC divided into four main groups: carbohydrates (CA19-9, CA 50, CA 125, CA195, CA 72-4), carcinoembryonic antigens, other markers and the combination of different markers.",CA195,serum,1
PMC4188889A,"Bunger et al[2] reviewed about 43 serum biomarkers for PC divided into four main groups: carbohydrates (CA19-9, CA 50, CA 125, CA195, CA 72-4), carcinoembryonic antigens, other markers and the combination of different markers.",CA19,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",rH2AX,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",EMD,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",rH2AX,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",San,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",PBS,serum,1
PMC4673178A,"After washing twice with 1% bovine serum albumin-PBS, cells were incubated with mouse anti-rH2AX-AF488 (EMD Millipore Corporation, Temecula, CA) for 45 minutes at 4degC. The signal intensity of rH2AX was measured by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).NCr female athymic nude (nu/nu) mice, 4-8 weeks old, were purchased from Taconic Farms (Germantown, NY).",AF488,serum,1
PMC3984178A,Balcerczak et al. used RT-qPCR to quantify cyclin D1 mRNA levels in the investigated colorectal cancers and he found that CCND1 expression was significantly related to lymph nodes and distant metastases.,qPCR,lymph,1
PMC3984178A,Balcerczak et al. used RT-qPCR to quantify cyclin D1 mRNA levels in the investigated colorectal cancers and he found that CCND1 expression was significantly related to lymph nodes and distant metastases.,CCND1,lymph,1
PMC3984178A,Balcerczak et al. used RT-qPCR to quantify cyclin D1 mRNA levels in the investigated colorectal cancers and he found that CCND1 expression was significantly related to lymph nodes and distant metastases.,mRNA,lymph,1
PMC3984178A,Balcerczak et al. used RT-qPCR to quantify cyclin D1 mRNA levels in the investigated colorectal cancers and he found that CCND1 expression was significantly related to lymph nodes and distant metastases.,D1,lymph,1
PMC3975176A,"Compared with mock-transfected controls, tumor volume and serum PSA levels are dramatically increased after castration in LNCaP-Hsp27 tumors, suggesting that increased Hsp27 levels can promote the development of CRPC.",PSA,serum,1
PMC3975176A,"Compared with mock-transfected controls, tumor volume and serum PSA levels are dramatically increased after castration in LNCaP-Hsp27 tumors, suggesting that increased Hsp27 levels can promote the development of CRPC.",CRPC,serum,1
PMC3975176A,"Compared with mock-transfected controls, tumor volume and serum PSA levels are dramatically increased after castration in LNCaP-Hsp27 tumors, suggesting that increased Hsp27 levels can promote the development of CRPC.",Hsp27,serum,1
PMC3975176A,"Compared with mock-transfected controls, tumor volume and serum PSA levels are dramatically increased after castration in LNCaP-Hsp27 tumors, suggesting that increased Hsp27 levels can promote the development of CRPC.",Hsp27,serum,1
PMC4707334A,"Presumably, among mesenchymal ""companion"" cells, pericytes (CD146+, CD90+, and CD140b+), normally localized around periportal blood vessels in human fetal and adult liver, contribute to clonogenic potential of EpCAM cells [26].",CD90,blood,-1
PMC4707334A,"Presumably, among mesenchymal ""companion"" cells, pericytes (CD146+, CD90+, and CD140b+), normally localized around periportal blood vessels in human fetal and adult liver, contribute to clonogenic potential of EpCAM cells [26].",CD146,blood,-1
PMC4999623A,"(a) Human iPSC-based model of hepatic and bile ductal development depicting the stages passed through during endodermal commitment, liver stem cell and hepatoblast-like liver progenitor formation, hepatocyte- and cholangiocyte- precursor formation and terminal differentiation into mature hepatocytes and cholangiocytes (biliary epithelial cells).",iPSC,bile,1
PMC4473102A,"PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) were used for blood collection and total RNA was extracted according to the protocol supplied by the manufacturer.",RNA,Blood,-1
PMC4473102A,"PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) were used for blood collection and total RNA was extracted according to the protocol supplied by the manufacturer.",RNA,blood,-1
PMC4473102A,"PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) were used for blood collection and total RNA was extracted according to the protocol supplied by the manufacturer.",RNA,Blood,-1
PMC4473102A,"PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) were used for blood collection and total RNA was extracted according to the protocol supplied by the manufacturer.",RNA,blood,-1
PMC3369609A,"Immunofluorescent microscopy and digital imaging of immunostained, cytocentrifuged cells demonstrated that IL-15R-a protein concentrated along the LC surface membrane (Figure 2B), similar to what we had observed with epidermal LC emigres cultured in GM-CSF.",IL-15R,CSF,1
PMC3369609A,"Immunofluorescent microscopy and digital imaging of immunostained, cytocentrifuged cells demonstrated that IL-15R-a protein concentrated along the LC surface membrane (Figure 2B), similar to what we had observed with epidermal LC emigres cultured in GM-CSF.",GM,CSF,1
PMC4882422A,4C) and the serum GPT levels (Fig.,GPT,serum,1
PMC5467782A,"To enrich the CD133+/CD326+ cells, A549 cells were resuspended in serum-free medium and grown as spheroids.",A549,serum,1
PMC5467782A,"To enrich the CD133+/CD326+ cells, A549 cells were resuspended in serum-free medium and grown as spheroids.",CD326,serum,1
PMC4473102A,"Indeed coactivity of IFN and Th17 pathways is typical of autoimmunity and has been described both in human diseases and in animal models [18-20].Moreover, using the same strategy, we could identify a novel biomarker, osteoactivin, that can be easily detected in PsA sera.",IFN,sera,1
PMC4473102A,"Indeed coactivity of IFN and Th17 pathways is typical of autoimmunity and has been described both in human diseases and in animal models [18-20].Moreover, using the same strategy, we could identify a novel biomarker, osteoactivin, that can be easily detected in PsA sera.",Th17,sera,1
PMC4882422A,Serum samples were collected at 6 h after the LPS injection (n = 4 each).,LPS,Serum,1
PMC4074497A,"The cells were washed three times with cold serum-free medium and treated with 0.5 mL trypsin-EDTA solution (0.25% trypsin, 0.02% EDTA in PBS buffer) for 10 minutes at 37degC. When the cells were detached, 0.5 mL complete medium was added to every dish and the cells were re-suspended.",EDTA,serum,-1
PMC4074497A,"The cells were washed three times with cold serum-free medium and treated with 0.5 mL trypsin-EDTA solution (0.25% trypsin, 0.02% EDTA in PBS buffer) for 10 minutes at 37degC. When the cells were detached, 0.5 mL complete medium was added to every dish and the cells were re-suspended.",EDTA,serum,-1
PMC4074497A,"The cells were washed three times with cold serum-free medium and treated with 0.5 mL trypsin-EDTA solution (0.25% trypsin, 0.02% EDTA in PBS buffer) for 10 minutes at 37degC. When the cells were detached, 0.5 mL complete medium was added to every dish and the cells were re-suspended.",PBS,serum,-1
PMC4370053A,"Human skin and other nonlymphoid tissues contain several subsets of DCs and macrophages[1, 2].In addition to LCs of stratified epidermis, the interstitial tissues containCD1c+ myeloid DCs and a minor population of CD141high myeloidDCs that mirror the CD1c+ and CD141+ blood DC populations [3].",DC,blood,-1
PMC4370053A,"Human skin and other nonlymphoid tissues contain several subsets of DCs and macrophages[1, 2].In addition to LCs of stratified epidermis, the interstitial tissues containCD1c+ myeloid DCs and a minor population of CD141high myeloidDCs that mirror the CD1c+ and CD141+ blood DC populations [3].",CD141,blood,-1
PMC3474961A,However the single most prominent factor likely leading to the observed increased incidence of PCa is the development of diagnostic screening for serum levels of prostate-specific antigen (PSA) [13].,PSA,serum,1
PMC5289527A,"The Transcriptome filter set gene-level prioritization by retaining differentially expressed genes between 131 paired acute and convalescent whole blood RNA samples (PAXgene).[29] Transcript levels were measured using the Illumina HumanRef-12 V4 BeadChip with 47,000 probes and quality control and analysis were as described.",V4,blood,-1
PMC5289527A,"The Transcriptome filter set gene-level prioritization by retaining differentially expressed genes between 131 paired acute and convalescent whole blood RNA samples (PAXgene).[29] Transcript levels were measured using the Illumina HumanRef-12 V4 BeadChip with 47,000 probes and quality control and analysis were as described.",HumanRef-12,blood,-1
PMC5289527A,"The Transcriptome filter set gene-level prioritization by retaining differentially expressed genes between 131 paired acute and convalescent whole blood RNA samples (PAXgene).[29] Transcript levels were measured using the Illumina HumanRef-12 V4 BeadChip with 47,000 probes and quality control and analysis were as described.",RNA,blood,-1
PMC3655979A,Serum concentrations of intact (E1)-l1 were measured using enzyme-linked immunosorbent assay (ELISA).,ELISA,Serum,1
PMC4777741A,"0.001.The migration of phosphorylated PKC to the plasma membrane is essential in order to initiate downstream signaling (Newton, 1995).",PKC,plasma,1
PMC3655979A,"MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) were coated overnight with goat anti-human F(ab')2 antibody and blocked with PBS containing 2% bovine serum albumin (BSA) for 1 h. Serum samples for pharmacokinetic study were serially diluted and added to the coated plates.",PBS,serum,1
PMC3655979A,"MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) were coated overnight with goat anti-human F(ab')2 antibody and blocked with PBS containing 2% bovine serum albumin (BSA) for 1 h. Serum samples for pharmacokinetic study were serially diluted and added to the coated plates.",PBS,Serum,1
PMC3655979A,"MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) were coated overnight with goat anti-human F(ab')2 antibody and blocked with PBS containing 2% bovine serum albumin (BSA) for 1 h. Serum samples for pharmacokinetic study were serially diluted and added to the coated plates.",BSA,serum,1
PMC3655979A,"MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) were coated overnight with goat anti-human F(ab')2 antibody and blocked with PBS containing 2% bovine serum albumin (BSA) for 1 h. Serum samples for pharmacokinetic study were serially diluted and added to the coated plates.",BSA,Serum,1
PMC4966842B,"The safety profile of the anti-collagen 4 ADC was examined and indicated that AST and ALT levels, plus white blood cell counts were acceptable.",ADC,blood,-1
PMC4966842B,"The safety profile of the anti-collagen 4 ADC was examined and indicated that AST and ALT levels, plus white blood cell counts were acceptable.",AST,blood,-1
PMC4966842B,"The safety profile of the anti-collagen 4 ADC was examined and indicated that AST and ALT levels, plus white blood cell counts were acceptable.",ALT,blood,-1
PMC4558321A,"Immunohistology showed a 2+ staining of her primary cancer; her plasma CEA was 781 ng/mL. Therapy was initiated at 8 mg/kg and 6 treatments later (12 weeks), the 3 target lesions had reduced from a sum of 7.9 cm to 5.0 cm (-37%; PR).",CEA,plasma,1
PMC4558321A,"Immunohistology showed a 2+ staining of her primary cancer; her plasma CEA was 781 ng/mL. Therapy was initiated at 8 mg/kg and 6 treatments later (12 weeks), the 3 target lesions had reduced from a sum of 7.9 cm to 5.0 cm (-37%; PR).",PR,plasma,1
PMC4673473A,"By IF analysis, we found that Foxa2+ endodermal precursor cells were present in adult murine bone marrow cells, and our in vitro protocol yielded efficient initial expansion of these cells.27 Day 6 endodermal cells also had the potential to differentiate into Pdx1+ pancreatic precursor cells in vitro (data not shown).",IF,bone marrow,1
PMC4673473A,"By IF analysis, we found that Foxa2+ endodermal precursor cells were present in adult murine bone marrow cells, and our in vitro protocol yielded efficient initial expansion of these cells.27 Day 6 endodermal cells also had the potential to differentiate into Pdx1+ pancreatic precursor cells in vitro (data not shown).",Foxa2,bone marrow,1
PMC4673473A,"By IF analysis, we found that Foxa2+ endodermal precursor cells were present in adult murine bone marrow cells, and our in vitro protocol yielded efficient initial expansion of these cells.27 Day 6 endodermal cells also had the potential to differentiate into Pdx1+ pancreatic precursor cells in vitro (data not shown).",Pdx1,bone marrow,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,IMMU-132,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,ELISA,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,hRS7,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,SN-38,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,T,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,TNBC,serum,1
PMC4558321A,Concentrations of IgG and sacituzumab govitecan (IMMU-132) by ELISA and SN-38 (Total and Free) in serum samples (patient 15).The top panel shows the concentrations of hRS7 IgG and sacituzumab govitecan as determined by ELISA in the peak (P) and trough (T) samples of a TNBC patient.,ELISA,serum,1
PMC4964535A,"Moreover, anti-Trop2 bispecific antibody was approved to effectively lead pre-targeted immunoPET and radioimmunotherapy of PCa in preclinical models, which significantly increased PCa related survival [83,84].CD117 (also known as c-Kit) is a receptor tyrosine kinase protein, and has been used as an important cell surface marker to identify hematopoietic progenitors in bone marrow [85,86,87].",Trop2,bone marrow,1
PMC3906064A,The elution efficiency of releasing captured cells from the flow cell was evaluated by spiking 4 normal healthy donor (NHD) blood samples with 30 MCF7 cells/mL and processing them using the LiquidBiopsy platform.,MCF7,blood,-1
PMC3906064A,The elution efficiency of releasing captured cells from the flow cell was evaluated by spiking 4 normal healthy donor (NHD) blood samples with 30 MCF7 cells/mL and processing them using the LiquidBiopsy platform.,NHD,blood,-1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",GFP,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",AR,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",CK18,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",WIT,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",AR,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",WIT,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",PSA,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",PSAP,serum,1
PMC5442765A,"By adopting and modifying the WIT medium that has previously been developed to culture human mammary luminal progenitors [13], we show that WIT, unlike PrEGM and some other culture systems (e.g., fibroblast feeder-based culture [41] and low Ca2+ serum-free defined medium [42]), can efficiently maintain and propagate the human prostatic luminal progenitors that possess enormous proliferative potential and sphere-forming capacities, express luminal genes (AR, PSA, and CK18) and have AR activity evidenced by PSAP-GFP reporter assay.",Ca2,serum,1
PMC4370053A,"Finally, freshly isolatedblood CD1c+ DCs contain langerin mRNA and up-regulate langerinsurface-antigen expression in response to serum or TGF-b within18 h. Together, these results indicate that CD1c+ myeloid DCs can be inducedto express langerin and that in vivo, a fraction of these cells is langerin+,possibly through the action of local environmental factors, such asTGF-b.",TGF,serum,1
PMC4370053A,"Finally, freshly isolatedblood CD1c+ DCs contain langerin mRNA and up-regulate langerinsurface-antigen expression in response to serum or TGF-b within18 h. Together, these results indicate that CD1c+ myeloid DCs can be inducedto express langerin and that in vivo, a fraction of these cells is langerin+,possibly through the action of local environmental factors, such asTGF-b.",mRNA,serum,1
PMC5538449A,"D and E, FACS of GFP+ day 5 precursors subcultured under p-LC-promoting (+/-TGF-b1; Fig 6, D) or p-moDC-promoting (Fig 6, E; GM-CSF plus IL-4) conditions at day 7 (n = 6).",GM,CSF,1
PMC5538449A,"D and E, FACS of GFP+ day 5 precursors subcultured under p-LC-promoting (+/-TGF-b1; Fig 6, D) or p-moDC-promoting (Fig 6, E; GM-CSF plus IL-4) conditions at day 7 (n = 6).",FACS,CSF,1
PMC5538449A,"D and E, FACS of GFP+ day 5 precursors subcultured under p-LC-promoting (+/-TGF-b1; Fig 6, D) or p-moDC-promoting (Fig 6, E; GM-CSF plus IL-4) conditions at day 7 (n = 6).",IL-4,CSF,1
PMC4546469A,"Briefly, LNCaP and PC3Trop-2- cells were serum starved for 18 h, then treated for 24 h with 20 mg/ml of exosomes obtained from PC3 cells.",PC3,serum,1
PMC3906064A,These tumor cell lines were then spiked into NHD blood at a concentration of 90 cells per mL. Target cells were recovered from 8 mL samples using the LiquidBiopsy platform.,NHD,blood,-1
PMC5193343A,Solely Borie et al. [8] studied the survival of Caucasian patients stage UICC I stratified according to lymph node involvement and demonstrated a tumor related five year survival of 92% in patients without lymph node involvement.,UICC,lymph,1
PMC5193343A,Solely Borie et al. [8] studied the survival of Caucasian patients stage UICC I stratified according to lymph node involvement and demonstrated a tumor related five year survival of 92% in patients without lymph node involvement.,UICC,lymph,1
PMC3369113A,"After three washes with serum-free RPMI/1% BSA, cells were counted and seeded on 96-well plates for 1 h at 37degC. Cells were later fixed with 3.7% paraformaldehyde (PFA) and stained with 0.1% crystal violet.",PFA,serum,1
PMC3369113A,"After three washes with serum-free RPMI/1% BSA, cells were counted and seeded on 96-well plates for 1 h at 37degC. Cells were later fixed with 3.7% paraformaldehyde (PFA) and stained with 0.1% crystal violet.",BSA,serum,1
PMC4964535A,"CD117 could be activated by its ligand, Stem Cell Factor (SCF), to promote bone marrow cell migration, tumor dissemination and potential bone metastasis [91,92,93,94].AR splice variants were found to promote EMT as well as induce the expression of stem cell signature genes [95].",EMT,bone marrow,1
PMC4964535A,"CD117 could be activated by its ligand, Stem Cell Factor (SCF), to promote bone marrow cell migration, tumor dissemination and potential bone metastasis [91,92,93,94].AR splice variants were found to promote EMT as well as induce the expression of stem cell signature genes [95].",CD117,bone marrow,1
PMC4964535A,"CD117 could be activated by its ligand, Stem Cell Factor (SCF), to promote bone marrow cell migration, tumor dissemination and potential bone metastasis [91,92,93,94].AR splice variants were found to promote EMT as well as induce the expression of stem cell signature genes [95].",SCF,bone marrow,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",ALP,bile,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",ALP,serum,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",DDC,bile,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",DDC,serum,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",T,bile,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",T,serum,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",TBA,bile,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",TBA,serum,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",ALT,bile,1
PMC4077671A,"(a) The serum levels of ALT, ALP, total bilirubin (T-Bil) and total bile acids (TBA) in mice fed with the DDC diet for14 days.",ALT,serum,1
PMC3135497A,"The levels of s-ECSA-2-Ab were divided into two groups: A serum level less than 0.31 was considered normal, as this was the mean + three standard deviations (SD) of s-ECSA-2-Ab level of healthy donors; abnormal or positive values were higher than 0.31.",SD,serum,1
PMC3135497A,"The levels of serum antibody in patients with esophageal SCC were significantly higher than those in healthy donors (0.145 +- 0.483 versus 0.050 +- 0.087, P = 0.0026) (Figure 3).",SCC,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",FBS,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",CAA,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",Trop2,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",GTG,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",CAA-3,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",GCT,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",CO2,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",DMEM,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",USA,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",RNA,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",GCT,serum,1
PMC4509052A,"The cells were maintained in Dulbeccos modified Eagles medium (DMEM; Beyotime Institute of Biotechnology, Beijing, China), supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 100 U/ml penicillin and 100 ug/ml streptomycin (Beyotime Institute of Biotechnology), in a humidified incubator with 5% CO2 at 37degC.Following the evaluation of the knockdown efficiencies of a number of small interfering RNA (siRNA) constructs, the following siRNA oligonucleotide (rAd5-siTrop2-siRNA) was selected to target the 21-bp interference sequence of the Trop2 gene: 5'-CTC CAA GTG TCT GCT GCT CAA-3'.",TCT,serum,1
PMC3135497A,ELISA assays were performed on sera from patients and healthy donors using a recombinant antigen protein to analyze the levels of s-ECSA-Abs quantitatively.,ECSA,sera,1
PMC3135497A,ELISA assays were performed on sera from patients and healthy donors using a recombinant antigen protein to analyze the levels of s-ECSA-Abs quantitatively.,ELISA,sera,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,PSA,serum,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,PSA,urine,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,TMPRSS2-ERG,serum,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,TMPRSS2-ERG,urine,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,T,serum,1
PMC4202120A,Detection of TMPRSS2-ERG (T/E) fusion in urine in combination with serum PSA was reported to be successful in risk stratification for PCa [319].,T,urine,1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",SHH,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",p21,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",BAX,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",AEG,lymph,1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",CDX2,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",BCL,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",HIF1A,lymph,1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",UICC,lymph,1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",TROP2,lymph,1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",TP53,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",Ki-67,lymph,-1
PMC5193343A,"Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16-18], p21 [19], TP53 [20]), apoptosis (BAX [21], BCL [22], Survivin [23-25]), cell adhesion (E-cadherin [26-28]), cell differentiation (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor 1a) [32] and mismatch repair deficiency [33].These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.",cadherin,lymph,-1
PMC4606475A,Wls knockout in macrophages was confirmed by qPCR for Wls in bone marrow-derived macrophages (Additional file 1: Figure S1A).,S1A,bone marrow,1
PMC4606475A,Wls knockout in macrophages was confirmed by qPCR for Wls in bone marrow-derived macrophages (Additional file 1: Figure S1A).,qPCR,bone marrow,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",EOC,lymph,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",EOC,ascites,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",FIGO,lymph,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",FIGO,ascites,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",TROP2,lymph,1
PMC4926055A,"Statistical analysis showed that TROP2 overexpression was significantly associated with EOC histological type, lymph node involvement and histological grade, but not with age, FIGO stage, the presence of ascites or omental metastases.",TROP2,ascites,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",Capan-1,serum,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",Capan-1,serum,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",SN-38,serum,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",SN-38,serum,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",IMMU-132,serum,1
PMC4673178A,"Determination of SN-38 and associated products in serum and Capan-1 tumors taken from animals given irinotecan or IMMU-132Animals were given irinotecan (773 mg) or IMMU-132 (1.0 mg) and then at 5 intervals, 3 animals from each group were euthanized with serum panel (A) and tumor panel (B) extracted for the products of interest.",IMMU-132,serum,1
PMC4596896A,"The IgG1v1-vc4 ADC had better in vivo tumor efficacy than the native IgG1-vcF4 ADC, which was attributed to increased serum exposure of the Fc mutated IgG1 ADC.",ADC,serum,1
PMC4596896A,"The IgG1v1-vc4 ADC had better in vivo tumor efficacy than the native IgG1-vcF4 ADC, which was attributed to increased serum exposure of the Fc mutated IgG1 ADC.",IgG1,serum,1
PMC4596896A,"The IgG1v1-vc4 ADC had better in vivo tumor efficacy than the native IgG1-vcF4 ADC, which was attributed to increased serum exposure of the Fc mutated IgG1 ADC.",ADC,serum,1
PMC4596896A,"The IgG1v1-vc4 ADC had better in vivo tumor efficacy than the native IgG1-vcF4 ADC, which was attributed to increased serum exposure of the Fc mutated IgG1 ADC.",ADC,serum,1
PMC4426451A,"Please see SI Appendix for cell preparation, fluorescence measurements, HPV-DNA detection, and clinical lymph node samples.",SI,lymph,1
PMC4426451A,"Please see SI Appendix for cell preparation, fluorescence measurements, HPV-DNA detection, and clinical lymph node samples.",HPV,lymph,1
PMC4426451A,"Please see SI Appendix for cell preparation, fluorescence measurements, HPV-DNA detection, and clinical lymph node samples.",DNA,lymph,1
PMC4807992A,"Since testosterone levels are similar in the three groups [51] and estrogen levels are higher in African-American men than in Caucasian men [53, 54], a direct correlation between serum estradiol levels and PC risk was hypothesized.",PC,serum,1
PMC5414739A,These results suggest that PRL (or lactogens in general) can stimulate hair follicle stem cells directly.,PRL,hair,-1
PMCA,MDCK cells were detached by trypsin and resuspended in serum-free medium at 5x103 cells/ml.,MDCK,serum,1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",LGR6,hair,1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",LGR6,hair,-1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",LRIG1,hair,1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",LRIG1,hair,-1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",IFE,hair,1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",IFE,hair,-1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",IFE,hair,1
PMC3049439A,"Intriguingly, the LGR6 and LRIG1 stem-cell populations located high in the hair follicle clearly generate IFE (Jensen et al, 2009; Snippert et al, 2010a), whereas uninjured IFE has been reported to self-maintain without the need for hair follicles (Levy et al, 2005; Ito et al, 2005; Clayton et al, 2007).",IFE,hair,-1
PMC5414739A,"Indeed, genetic manipulation of PRLR signaling leads to alteration of many functions that extend far beyond mammopoiesis and lactopoiesis, including, among others, female reproduction (28), bone turnover (29), pituitary homeostasis (30), glucose tolerance (31), maternal behavior (32), hair growth (33), and adipogenesis (34, 35).",PRLR,hair,-1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",EEC,serum,1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",EEC,serum,1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3233648A,"To evaluate the potential inhibition of ADCC against EEC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3233648A,"In some experiments, heat-inactivated human serum (56degC for 60 minutes) was added in the presence of effector PBL.",PBL,serum,1
PMC3233648A,"A standard 5-hours chromium (51Cr) release assay identical to those performed for ADCC assays was used, except that human serum in a dilution of 1:2 was added in place of the effector cells.",ADCC,serum,1
PMC4596896A,"Although the HAMA response has been reported to result in rapid systemic clearance of the antibody thus rendering the antibody or in this case ADC ineffective, high serum levels of the KS1/4 antibody were reported in patients treated with the higher doses of the KS1/4 antibody or ADCs.",ADC,serum,1
PMC4596896A,"Although the HAMA response has been reported to result in rapid systemic clearance of the antibody thus rendering the antibody or in this case ADC ineffective, high serum levels of the KS1/4 antibody were reported in patients treated with the higher doses of the KS1/4 antibody or ADCs.",KS1/4,serum,1
PMC4596896A,"Although the HAMA response has been reported to result in rapid systemic clearance of the antibody thus rendering the antibody or in this case ADC ineffective, high serum levels of the KS1/4 antibody were reported in patients treated with the higher doses of the KS1/4 antibody or ADCs.",HAMA,serum,1
PMC4596896A,"Although the HAMA response has been reported to result in rapid systemic clearance of the antibody thus rendering the antibody or in this case ADC ineffective, high serum levels of the KS1/4 antibody were reported in patients treated with the higher doses of the KS1/4 antibody or ADCs.",KS1/4,serum,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",MI,Serum,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",MI,plasma,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",PCR,Serum,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",PCR,plasma,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",EIA,Serum,1
PMC3774116A,"Serum plasma hormone levels were measured using estradiol and progesterone EIA kits (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com).Quantitative PCR was performed as described previously 17.",EIA,plasma,1
PMC5437520A,were able to link elevated serum levels of C - reactive protein (CRP) with increased circulating pro-inflammatory cytokines.,CRP,serum,1
PMC4275355A,"The binding of SHH to the receptor Ptch1 results in its repression and activation of Smo, which promotes the nuclear translocation of Gli transcription factors, consequently increasing the self-renewal capacity of some ASCs [10].BCC was thought to derive from the hair follicle due its cellular similarity to the hair follicle [78].",SHH,hair,-1
PMC4275355A,"The binding of SHH to the receptor Ptch1 results in its repression and activation of Smo, which promotes the nuclear translocation of Gli transcription factors, consequently increasing the self-renewal capacity of some ASCs [10].BCC was thought to derive from the hair follicle due its cellular similarity to the hair follicle [78].",SHH,hair,-1
PMC4275355A,"The binding of SHH to the receptor Ptch1 results in its repression and activation of Smo, which promotes the nuclear translocation of Gli transcription factors, consequently increasing the self-renewal capacity of some ASCs [10].BCC was thought to derive from the hair follicle due its cellular similarity to the hair follicle [78].",Ptch1,hair,-1
PMC4275355A,"The binding of SHH to the receptor Ptch1 results in its repression and activation of Smo, which promotes the nuclear translocation of Gli transcription factors, consequently increasing the self-renewal capacity of some ASCs [10].BCC was thought to derive from the hair follicle due its cellular similarity to the hair follicle [78].",Ptch1,hair,-1
PMC4146555A,"NSCLC is an angiogenesis-dependent tumor, and angiogenesis plays pivotal roles in progression and blood-borne metastases [41], [42].",NSCLC,blood,-1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TIMP-1,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TIMP-1,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TNM,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TNM,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",LSCC,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",LSCC,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TIMP-1,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with high TIMP-1 expression (p=0.001), TNM stage (p=0.004), tumor differentiation (p=0.023) and lymph node metastasis (p=0.001). Multivariate analysis with the Cox regression model suggested that high TIMP-1 protein level and lymph node metastasis may serve as two independent prognostic factors for overall survival (p=0.008 and p=0.029, respectively) (Table 2).",TIMP-1,lymph,1
PMC3740004A,"Alternatively, oncogenic signaling can also be specifically introduced into individual lineages by virus infection such as the RCAS/TVA system, and so on (Figure 1b (iii)).15A typical example is a study from Lapouge et al.,16 in which the authors showed that K-ras activation in hair follicle bulge stem cells leads to squamous skin carcinoma.",RCAS,hair,-1
PMC3740004A,"Alternatively, oncogenic signaling can also be specifically introduced into individual lineages by virus infection such as the RCAS/TVA system, and so on (Figure 1b (iii)).15A typical example is a study from Lapouge et al.,16 in which the authors showed that K-ras activation in hair follicle bulge stem cells leads to squamous skin carcinoma.",TVA,hair,-1
PMC3049439A,"By using the Lgr5 knock-in mouse, actual stemness has been shown for LGR5+ cells in the stomach, small intestine, colon and the hair follicle (Barker et al, 2007, 2010; Jaks et al, 2008).",Lgr5,hair,-1
PMC3049439A,"By using the Lgr5 knock-in mouse, actual stemness has been shown for LGR5+ cells in the stomach, small intestine, colon and the hair follicle (Barker et al, 2007, 2010; Jaks et al, 2008).",LGR5,hair,-1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",TAA,Serum,1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",ESO-1,Serum,1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",TROP2,Serum,1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",GLUT-1,Serum,1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",TRIM21,Serum,1
PMC5378227A,"Serum TAA levels are believed to increase even in very early stages of cancer.39We previously reported that several TAAs, including p53, tumor associated calcium signal transducer (TROP2), tripartite motif containing 21 (TRIM21), glucose transporter 1 (GLUT-1), myomegalin, and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are useful to identify gastrointestinal malignant diseases.6, 40, 41",p53,Serum,1
PMC4966842B,"The serum from AIPV-treated mice also displayed responses to many tumor antigens and antigen presentation on dendritic cells was critical for the success of AIPV therapy, as demonstrated in Batf3-/- mice.",AIPV,serum,1
PMC4966842B,"The serum from AIPV-treated mice also displayed responses to many tumor antigens and antigen presentation on dendritic cells was critical for the success of AIPV therapy, as demonstrated in Batf3-/- mice.",AIPV,serum,1
PMC4999623A,"In human embryonic liver, bulk of the hepatocytes express EpCAM; however in adult liver, hepatocytes do not express EpCAM,93 while the bile duct epithelium does.96 EpCAM is highly expressed in murine and human embryonic stem cells and is down-regulated during spontaneous differentiation (on LIF withdrawal or embryoid body differentiation).89,97",LIF,bile,1
PMC3885479A,Kaplan-Meier survival curves exhibited that LSCC patients with high TIMP-1 expression and positive lymph node metastasis showed the significantly poor survival time (Figure 3).View larger versionFigure 3.,LSCC,lymph,1
PMC3885479A,Kaplan-Meier survival curves exhibited that LSCC patients with high TIMP-1 expression and positive lymph node metastasis showed the significantly poor survival time (Figure 3).View larger versionFigure 3.,TIMP-1,lymph,1
PMC5328612A,"Moreover, the liver remnant should be adequate in size and function, with or without prior PVE.8,77,79,80 Extrahepatic disease, including lymph node metastases beyond the regional basin (N2), is a contraindication for curative-intent surgery.41 Multifocal ICC is considered unresectable by some experts.79-83 Nevertheless, other experts report favorable long-term outcomes in selected patients with typically two to three lesions, with a 5-year overall survival (OS) of 20%.84,85 A 2015 cure model confirms the possibility of cure, albeit at a chance of only 4%.78 Recent studies have reported favorable outcomes of portal vein reconstructions.86-88 However, tumor invasion of the main hepatic artery and bilateral hepatic artery involvement remain contraindications for resection in most Western centers.",OS,lymph,1
PMC5328612A,"Moreover, the liver remnant should be adequate in size and function, with or without prior PVE.8,77,79,80 Extrahepatic disease, including lymph node metastases beyond the regional basin (N2), is a contraindication for curative-intent surgery.41 Multifocal ICC is considered unresectable by some experts.79-83 Nevertheless, other experts report favorable long-term outcomes in selected patients with typically two to three lesions, with a 5-year overall survival (OS) of 20%.84,85 A 2015 cure model confirms the possibility of cure, albeit at a chance of only 4%.78 Recent studies have reported favorable outcomes of portal vein reconstructions.86-88 However, tumor invasion of the main hepatic artery and bilateral hepatic artery involvement remain contraindications for resection in most Western centers.",N2,lymph,1
PMC5328612A,"Moreover, the liver remnant should be adequate in size and function, with or without prior PVE.8,77,79,80 Extrahepatic disease, including lymph node metastases beyond the regional basin (N2), is a contraindication for curative-intent surgery.41 Multifocal ICC is considered unresectable by some experts.79-83 Nevertheless, other experts report favorable long-term outcomes in selected patients with typically two to three lesions, with a 5-year overall survival (OS) of 20%.84,85 A 2015 cure model confirms the possibility of cure, albeit at a chance of only 4%.78 Recent studies have reported favorable outcomes of portal vein reconstructions.86-88 However, tumor invasion of the main hepatic artery and bilateral hepatic artery involvement remain contraindications for resection in most Western centers.",ICC,lymph,1
PMC5376003A,"Moreover, the 44-mer protects primary rat hepatocytes against apoptosis induced by serum deprivation and TGF-b1, supporting its hepatocellular protective function [18].",mer,serum,1
PMC5376003A,"Moreover, the 44-mer protects primary rat hepatocytes against apoptosis induced by serum deprivation and TGF-b1, supporting its hepatocellular protective function [18].",TGF,serum,1
PMC3906064A,"(C) Efficiency of recovery of target cells using EpCAM based recovery: Incremental numbers of MCF7 (N = 34), HCC1419 (N = 27) or A549 (N = 65) cells were spiked into NHD blood and purified on the CTC flow cell.",A549,blood,-1
PMC3906064A,"(C) Efficiency of recovery of target cells using EpCAM based recovery: Incremental numbers of MCF7 (N = 34), HCC1419 (N = 27) or A549 (N = 65) cells were spiked into NHD blood and purified on the CTC flow cell.",NHD,blood,-1
PMC3906064A,"(C) Efficiency of recovery of target cells using EpCAM based recovery: Incremental numbers of MCF7 (N = 34), HCC1419 (N = 27) or A549 (N = 65) cells were spiked into NHD blood and purified on the CTC flow cell.",MCF7,blood,-1
PMC3906064A,"(C) Efficiency of recovery of target cells using EpCAM based recovery: Incremental numbers of MCF7 (N = 34), HCC1419 (N = 27) or A549 (N = 65) cells were spiked into NHD blood and purified on the CTC flow cell.",HCC1419,blood,-1
PMC3906064A,"(C) Efficiency of recovery of target cells using EpCAM based recovery: Incremental numbers of MCF7 (N = 34), HCC1419 (N = 27) or A549 (N = 65) cells were spiked into NHD blood and purified on the CTC flow cell.",CTC,blood,-1
PMC3476529A,"CD141hi DCs and blood CD141+ DCs produce very little IL-12 (Jongbloed et al., 2010; Poulin et al.,",CD141,blood,-1
PMC3476529A,"CD141hi DCs and blood CD141+ DCs produce very little IL-12 (Jongbloed et al., 2010; Poulin et al.,",IL-12,blood,-1
PMC3233648A,"These data, therefore, demonstrate that although these poorly-differentiated tumors are per se resistant to NK activity in the absence of tumor specific antibodies, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2 specific antibody hRS7.In vivo, ADCC activity is known to be dependent upon the availability of the effector cells to interact with the antibody at the target site in the presence of high concentrations of irrelevant human IgG. In this study, we show that ADCC against EEC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",Trop-2,serum,1
PMC3233648A,"These data, therefore, demonstrate that although these poorly-differentiated tumors are per se resistant to NK activity in the absence of tumor specific antibodies, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2 specific antibody hRS7.In vivo, ADCC activity is known to be dependent upon the availability of the effector cells to interact with the antibody at the target site in the presence of high concentrations of irrelevant human IgG. In this study, we show that ADCC against EEC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",ADCC,serum,1
PMC3233648A,"These data, therefore, demonstrate that although these poorly-differentiated tumors are per se resistant to NK activity in the absence of tumor specific antibodies, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2 specific antibody hRS7.In vivo, ADCC activity is known to be dependent upon the availability of the effector cells to interact with the antibody at the target site in the presence of high concentrations of irrelevant human IgG. In this study, we show that ADCC against EEC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",ADCC,serum,1
PMC3233648A,"These data, therefore, demonstrate that although these poorly-differentiated tumors are per se resistant to NK activity in the absence of tumor specific antibodies, they remain highly sensitive to lysis by NK cells when these are engaged by the Trop-2 specific antibody hRS7.In vivo, ADCC activity is known to be dependent upon the availability of the effector cells to interact with the antibody at the target site in the presence of high concentrations of irrelevant human IgG. In this study, we show that ADCC against EEC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",EEC,serum,1
PMC3092477A,"Following Institutional Review Board Approval, patients scheduled to undergo radical prostatectomy [robot-assisted laparoscopic radical prostatectomy (RALP) or open radical retropubic prostatectomy (RRP)] are consented for research participation to collect blood and prostate tissue.",RRP,blood,-1
PMC3092477A,"Following Institutional Review Board Approval, patients scheduled to undergo radical prostatectomy [robot-assisted laparoscopic radical prostatectomy (RALP) or open radical retropubic prostatectomy (RRP)] are consented for research participation to collect blood and prostate tissue.",RALP,blood,-1
PMC5193343A,"Furthermore, we found a high correlation between V1 and L1 status (p0.0001).The aim of this retrospective study was to identify prognostic histopathological and immunohistological markers for patients with AEG/S stage UICC I on top of the known main risk factor lymph node metastasis to identify potential high risk subgroups.",UICC,lymph,-1
PMC5193343A,"Furthermore, we found a high correlation between V1 and L1 status (p0.0001).The aim of this retrospective study was to identify prognostic histopathological and immunohistological markers for patients with AEG/S stage UICC I on top of the known main risk factor lymph node metastasis to identify potential high risk subgroups.",L1,lymph,-1
PMC5193343A,"Furthermore, we found a high correlation between V1 and L1 status (p0.0001).The aim of this retrospective study was to identify prognostic histopathological and immunohistological markers for patients with AEG/S stage UICC I on top of the known main risk factor lymph node metastasis to identify potential high risk subgroups.",V1,lymph,-1
PMC5193343A,"Furthermore, we found a high correlation between V1 and L1 status (p0.0001).The aim of this retrospective study was to identify prognostic histopathological and immunohistological markers for patients with AEG/S stage UICC I on top of the known main risk factor lymph node metastasis to identify potential high risk subgroups.",AEG,lymph,-1
PMC4586470A,"Of note, despite RNA serving as the major immunomodulatory molecule following PapMV administration, the use of RNA alone cannot replace rPVPs since it would be rapidly degraded following administration due to the abundance of host RNAses found within the blood or other bodily fluids.",RNA,blood,-1
PMC4586470A,"Of note, despite RNA serving as the major immunomodulatory molecule following PapMV administration, the use of RNA alone cannot replace rPVPs since it would be rapidly degraded following administration due to the abundance of host RNAses found within the blood or other bodily fluids.",RNA,blood,-1
PMC4188889A,"MTA2 was correlated with poor tumor differentiation, TNM stage and lymph node metastasis.",MTA2,lymph,1
PMC4188889A,"MTA2 was correlated with poor tumor differentiation, TNM stage and lymph node metastasis.",TNM,lymph,1
PMC4077671A,"Male mice were then killed and their sera and livers were collected after 2, 7 or 14 days of feeding the DDC diets.",DDC,sera,1
PMC4926055A,"Additionally, serous histological type, advanced FIGO stage, omental metastases and lymph node involvement were significantly associated with unfavourable OS and DFS, as shown in Table 2.See full tableTable 2.",FIGO,lymph,1
PMC4926055A,"Additionally, serous histological type, advanced FIGO stage, omental metastases and lymph node involvement were significantly associated with unfavourable OS and DFS, as shown in Table 2.See full tableTable 2.",DFS,lymph,1
PMC4926055A,"Additionally, serous histological type, advanced FIGO stage, omental metastases and lymph node involvement were significantly associated with unfavourable OS and DFS, as shown in Table 2.See full tableTable 2.",OS,lymph,1
PMC4773505A,WIT Medium is a serum-free defined medium originally optimized for the robust culture of human primary mammary epithelial cells without the need of feeder cells57.,WIT,serum,1
PMC4777741A,"MARCKS normally resides in the plasma membrane where it plays a crucial role in the regulation of actin cytoskeleton (Arbuzova et al.,",MARCKS,plasma,1
PMC4707334A,Isolated dermal mesenchymal progenitors expressed surface markers similar to bone marrow-derived MSC.,MSC,bone marrow,1
PMC3566310A,"Under this condition, increases in the level of the cholestatic markers TBIL and ALP were greatly reduced in FGF7 Tg mice compared with the control mice, with the severity of symptoms of jaundice being apparently reduced, which means that bile duct obstruction was alleviated (Fig.",TBIL,bile,1
PMC3566310A,"Under this condition, increases in the level of the cholestatic markers TBIL and ALP were greatly reduced in FGF7 Tg mice compared with the control mice, with the severity of symptoms of jaundice being apparently reduced, which means that bile duct obstruction was alleviated (Fig.",ALP,bile,1
PMC3566310A,"Under this condition, increases in the level of the cholestatic markers TBIL and ALP were greatly reduced in FGF7 Tg mice compared with the control mice, with the severity of symptoms of jaundice being apparently reduced, which means that bile duct obstruction was alleviated (Fig.",FGF7,bile,1
PMC4188889A,"Peripheral blood samples were collected from 25 patients diagnosed with PC and diabetes, 27 patients with PC without diabetes, 25 patients with diabetes mellitus  5 years, and 25 controls.",PC,blood,1
PMC4188889A,"Peripheral blood samples were collected from 25 patients diagnosed with PC and diabetes, 27 patients with PC without diabetes, 25 patients with diabetes mellitus  5 years, and 25 controls.",PC,blood,1
PMC3655979A,"To corroborate with the results of ELISA, the bioactivity of IFN-l1 in selective serum samples was also evaluated by ex vivo proliferation assay of ME-180 cells, using (E1)-l1 as a standard.",IFN,serum,1
PMC3655979A,"To corroborate with the results of ELISA, the bioactivity of IFN-l1 in selective serum samples was also evaluated by ex vivo proliferation assay of ME-180 cells, using (E1)-l1 as a standard.",ME-180,serum,1
PMC3655979A,"To corroborate with the results of ELISA, the bioactivity of IFN-l1 in selective serum samples was also evaluated by ex vivo proliferation assay of ME-180 cells, using (E1)-l1 as a standard.",ELISA,serum,1
PMC3800471A,"Studies have identified increased serum levels of IL6 in prostate cancer patients correlating to increased clinical stage, hormone refractory disease and metastasis (7,8).",IL6,serum,1
PMC4777741A,Therefore we examined whether MARCKS translocate from plasma membrane to cytosol in HMEECs in response to P. aeruginosa infection.,MARCKS,plasma,1
PMC5378227A,"Serum CEA and CA19-9 were also evaluated as previously described.35The cut-off value designating positive reactivity was defined as an optical density value greater than the mean + 3x SD of the normal controls from the test cohort.12, 17 The specificity of the assay was calculated as the percentage of the healthy controls from whom a negative result was obtained.",CA19,Serum,1
PMC5378227A,"Serum CEA and CA19-9 were also evaluated as previously described.35The cut-off value designating positive reactivity was defined as an optical density value greater than the mean + 3x SD of the normal controls from the test cohort.12, 17 The specificity of the assay was calculated as the percentage of the healthy controls from whom a negative result was obtained.",SD,Serum,1
PMC5378227A,"Serum CEA and CA19-9 were also evaluated as previously described.35The cut-off value designating positive reactivity was defined as an optical density value greater than the mean + 3x SD of the normal controls from the test cohort.12, 17 The specificity of the assay was calculated as the percentage of the healthy controls from whom a negative result was obtained.",CEA,Serum,1
PMC4188889A,The results were further validated by quantitative qRT-PCR for 101 blood samples.,qRT,blood,-1
PMC4188889A,The results were further validated by quantitative qRT-PCR for 101 blood samples.,PCR,blood,-1
PMC4275355A,"However, using an inducible Cre allele, driven by either a basal keratinocyte promoter (Keratin 14), a hair follicle TAC promoter (Shh), or a hair follicle stem cell promoter (Keratin 15) to drive expression of activated Smo, it was found that cells adjacent to the follicle but within the interfollicular epidermis were the CCOs (Table 1) [79].",TAC,hair,-1
PMC4275355A,"However, using an inducible Cre allele, driven by either a basal keratinocyte promoter (Keratin 14), a hair follicle TAC promoter (Shh), or a hair follicle stem cell promoter (Keratin 15) to drive expression of activated Smo, it was found that cells adjacent to the follicle but within the interfollicular epidermis were the CCOs (Table 1) [79].",TAC,hair,-1
PMC4621003A,Active immunotherapies include HER-2-expressing tumor cells that also secrete the cytokine GM-CSF (Kim et al.,GM,CSF,1
PMC4077671A,"Serum levels of alanine aminotransferase, alkaline phosphatase, total bilirubin, direct bilirubin, triglyceride, total cholesterol and total bile acids were measured using reagents and controls from Diagnostic Chemicals and the Cobas Mira plus CC analyzer (Roche Diagnostics).Liver tissue specimens were fixed in 10% formalin, processed, embedded in paraffin, sectioned and stained with hematoxylin-eosin (HE) or hematoxylin.",HE,Serum,1
PMC4077671A,"Serum levels of alanine aminotransferase, alkaline phosphatase, total bilirubin, direct bilirubin, triglyceride, total cholesterol and total bile acids were measured using reagents and controls from Diagnostic Chemicals and the Cobas Mira plus CC analyzer (Roche Diagnostics).Liver tissue specimens were fixed in 10% formalin, processed, embedded in paraffin, sectioned and stained with hematoxylin-eosin (HE) or hematoxylin.",HE,bile,1
PMC3049439A,"The same in vivo lineage-tracing strategy was used to document actual stemness for LGR6+ cells, which marks cells above the bulge region where hair follicle stem cells reside (Snippert et al, 2010a).",LGR6,hair,-1
PMC5385398A,"Primary PHCC tissues (n = 78), 12 of which had matched adjacent normal bile duct tissues, were obtained from PHCC patients who underwent curative surgery at the Department of General Surgery, The People's Hospital of Binzhou, China, between 2003 and 2010.",PHCC,bile,1
PMC5385398A,"Primary PHCC tissues (n = 78), 12 of which had matched adjacent normal bile duct tissues, were obtained from PHCC patients who underwent curative surgery at the Department of General Surgery, The People's Hospital of Binzhou, China, between 2003 and 2010.",PHCC,bile,1
PMC4186637A,"Tumor uptake of the 177Lu-labeled parental mAb hRS7 was much higher (62.0%+-11.0% ID/g), at the expense of higher blood levels (10.0%+-1.6% ID/g), even at 3 days after injection of the radiolabel.",hRS7,blood,-1
PMC4673178A,"Increased Trop-2 mRNA is a strong predictor of poor survival and lymph node metastasis in patients with invasive ductal breast cancers, and Kaplan-Meier survival curves show that breast cancer patients with high Trop-2 expression have a significantly shorter survival [21].",mRNA,lymph,1
PMC4673178A,"Increased Trop-2 mRNA is a strong predictor of poor survival and lymph node metastasis in patients with invasive ductal breast cancers, and Kaplan-Meier survival curves show that breast cancer patients with high Trop-2 expression have a significantly shorter survival [21].",Trop-2,lymph,1
PMC4673178A,"Increased Trop-2 mRNA is a strong predictor of poor survival and lymph node metastasis in patients with invasive ductal breast cancers, and Kaplan-Meier survival curves show that breast cancer patients with high Trop-2 expression have a significantly shorter survival [21].",Trop-2,lymph,1
PMC4186637A,"This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of the 177Lu-hRS7 as compared with TF12/177Lu-IMP288.",hRS7,blood,-1
PMC4186637A,"This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of the 177Lu-hRS7 as compared with TF12/177Lu-IMP288.",RIT,blood,-1
PMC4186637A,"This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of the 177Lu-hRS7 as compared with TF12/177Lu-IMP288.",IMP288,blood,-1
PMC4186637A,"This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of the 177Lu-hRS7 as compared with TF12/177Lu-IMP288.",hRS7,blood,-1
PMC4186637A,"This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of the 177Lu-hRS7 as compared with TF12/177Lu-IMP288.",IMP288,blood,-1
PMC3284520A,"Lymph node metastasis and/or adjacent organ involvement in stage II is said to have a recurrence of 20%-30% and stage III 50%-80% recurrence after surgery[3].Various factors have been proposed to play a crucial role in the recurrence of cancer including: number of nodes positive at surgery, pre operative and operative conditions, body mass index (BMI)/obesity, physical activity post surgery and chemotherapy, certain tumor markers and genetic factors, etc.",III,Lymph,-1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CRC,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CD97,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CD55,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CD166,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CD97,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",ALCAM,lymph,1
PMC3039945A,"CD55 acts as a cellular ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 staining throughout the tumour [226].Membranous expression of the cell adhesion molecule CD166 (ALCAM), a member of the immunoglobulin superfamily, has been correlated with significantly shorter survival time in CRC patients [227].",CD97,lymph,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",HER-2,blood,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",HER-2,CSF,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",GM,blood,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",GM,CSF,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",CSF,blood,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",HER-2,blood,1
PMC4621003A,"2014), patient derived peripheral blood mononuclear cells (PBMCs) activated with fusion proteins consisting of HER-2 and GM-CSF (Park et al. 2007; Peethambaram et al. 2009), ex vivo loaded dendritic cells transfected with adenoviruses encoding HER-2 along with immunostimulatory molecules (Chen et al. 2001",HER-2,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",SCF,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",SCF,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CD34,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CD34,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TGF,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TGF,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",FLT3L,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",FLT3L,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",GM,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",GM,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CSF,serum,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TNF,CSF,1
PMC3478937A,"(A) CD34+ cells were cultured for 3 d in serum-free medium containing an LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TNF,serum,1
PMC3789024A,"The associations between Trop-2 immunostaining and the clinicopathological parameters (gender, age, histologic grade, lymph node metastasis, TNM stage and ECOG-PS) were analyzed using kh2 and Fisher's exact tests.",TNM,lymph,1
PMC3789024A,"The associations between Trop-2 immunostaining and the clinicopathological parameters (gender, age, histologic grade, lymph node metastasis, TNM stage and ECOG-PS) were analyzed using kh2 and Fisher's exact tests.",Trop-2,lymph,1
PMC3789024A,"The associations between Trop-2 immunostaining and the clinicopathological parameters (gender, age, histologic grade, lymph node metastasis, TNM stage and ECOG-PS) were analyzed using kh2 and Fisher's exact tests.",ECOG,lymph,1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD49b,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",T,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",T,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD49f,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD49d,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD49a,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD8,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD27-CD45RA-,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",T,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",CD29,blood,-1
PMC3039945A,"In a comparison of patients with high T-cell infiltration, primary tumours from patients with metastases had significantly decreased densities of CD8+ T-cells and effector memory T-cells (CD27-CD45RA-) than patients without metastases [59].The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and CD49b [84].",T,blood,-1
PMC3039945A,"The conventional prognostic factors for patient survival are histologic tumour grade (differentiation) and tumour stage (TNM, tumors/nodes/metastases, stages I-IV) [1,2], which is based on depth of tumour invasion, involvement of regional lymph nodes and metastatic spread to other organs [3].",TNM,lymph,1
PMC3789024A,"However, Trop-2 overexpression was significantly correlated with the histological grade, lymph node metastasis and TNM stage (P= 0.01, 0.024 and 0.015, respectively; Table II).The median OS time of all patients was 15.197 months (95% CI, 13.688-16.706).",OS,lymph,1
PMC3789024A,"However, Trop-2 overexpression was significantly correlated with the histological grade, lymph node metastasis and TNM stage (P= 0.01, 0.024 and 0.015, respectively; Table II).The median OS time of all patients was 15.197 months (95% CI, 13.688-16.706).",CI,lymph,1
PMC3789024A,"However, Trop-2 overexpression was significantly correlated with the histological grade, lymph node metastasis and TNM stage (P= 0.01, 0.024 and 0.015, respectively; Table II).The median OS time of all patients was 15.197 months (95% CI, 13.688-16.706).",Trop-2,lymph,1
PMC3789024A,"However, Trop-2 overexpression was significantly correlated with the histological grade, lymph node metastasis and TNM stage (P= 0.01, 0.024 and 0.015, respectively; Table II).The median OS time of all patients was 15.197 months (95% CI, 13.688-16.706).",TNM,lymph,1
PMC3110956A,"2009) and mixed with the same volume of hepatic colony-forming medium (Dulbecco's modified Eagle medium/F-12, 10% fetal bovine serum, insulin-transferrin-selenium-X, 10 mmol/L nicotinamide, 10-7 mol/L dexamethasone, 2.5 mmol/L HEPES, penicillin/streptomycin/l-glutamine).",F-12,serum,1
PMC3110956A,"2009) and mixed with the same volume of hepatic colony-forming medium (Dulbecco's modified Eagle medium/F-12, 10% fetal bovine serum, insulin-transferrin-selenium-X, 10 mmol/L nicotinamide, 10-7 mol/L dexamethasone, 2.5 mmol/L HEPES, penicillin/streptomycin/l-glutamine).",X,serum,1
PMC3110956A,"2009) and mixed with the same volume of hepatic colony-forming medium (Dulbecco's modified Eagle medium/F-12, 10% fetal bovine serum, insulin-transferrin-selenium-X, 10 mmol/L nicotinamide, 10-7 mol/L dexamethasone, 2.5 mmol/L HEPES, penicillin/streptomycin/l-glutamine).",mol,serum,1
PMC3110956A,"2009) and mixed with the same volume of hepatic colony-forming medium (Dulbecco's modified Eagle medium/F-12, 10% fetal bovine serum, insulin-transferrin-selenium-X, 10 mmol/L nicotinamide, 10-7 mol/L dexamethasone, 2.5 mmol/L HEPES, penicillin/streptomycin/l-glutamine).",HEPES,serum,1
PMC3110956A,"After 30 min of incubation at 37degC, 1 mL of medium (Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, insulin-transferrin-selenium X, 20 ng/mL hepatocyte growth factor, 50 ng/mL TNFa) was added on top.",X,serum,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",HR,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",TNM,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",ECOG,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",Trop-2,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",HR,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",HR,lymph,1
PMC3789024A,"4-6].In the univariate survival tests of AdC that were performed using clinicopathological factors, the statistically significant parameters, other than Trop-2 expression (HR, 2.606; P= 0.004) were lymph node metastasis (HR, 2.258; P= 0.011), TNM stage (HR, 2.478; P= 0.005) and ECOG-PS (HR, 2.586; P=0.005).",HR,lymph,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",hTERT,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",hTERT,plasma,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",NLR,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",NLR,plasma,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",TIMP-1,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",TIMP-1,plasma,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",HMGA1,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",HMGA1,plasma,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",IL-6,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",IL-6,plasma,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",YKL-40,serum,1
PMC5480073A,"Systemic expression of, plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT, HMGA1; has clinical utility for predicting progression-free survival.",YKL-40,plasma,1
PMC3180064A,"In ESCC, tumors with reduced CDH1 expression invade deeper, have more lymph node metastasis, and have more lymphatic invasion than tumors with preserved CDH1 expression [154]",CDH1,lymph,1
PMC3180064A,"In ESCC, tumors with reduced CDH1 expression invade deeper, have more lymph node metastasis, and have more lymphatic invasion than tumors with preserved CDH1 expression [154]",CDH1,lymph,1
PMC3180064A,"In ESCC, tumors with reduced CDH1 expression invade deeper, have more lymph node metastasis, and have more lymphatic invasion than tumors with preserved CDH1 expression [154]",ESCC,lymph,1
PMC3284520A,"Various mechanisms like cyclooxigenase-2 expression reduction, a marker of anti-inflammatory response, physical activity induced decrease in IL-6, TNF-a, CRP, stimulation of toll-like receptor 4 that causes production of inflammatory cytokines and innate immunity activation were thought to be the mechanisms responsible[14].Numerous investigators have studied the role of histopathological features of tumors such as: number of lymph nodes, stage and grade of the primary tumor, adjacent organ involvement, the presence of inflammatory cells in the tumor, pathological type and gross pathological view of the tumor, in terms of causing recurrence.",IL-6,lymph,1
PMC3284520A,"Various mechanisms like cyclooxigenase-2 expression reduction, a marker of anti-inflammatory response, physical activity induced decrease in IL-6, TNF-a, CRP, stimulation of toll-like receptor 4 that causes production of inflammatory cytokines and innate immunity activation were thought to be the mechanisms responsible[14].Numerous investigators have studied the role of histopathological features of tumors such as: number of lymph nodes, stage and grade of the primary tumor, adjacent organ involvement, the presence of inflammatory cells in the tumor, pathological type and gross pathological view of the tumor, in terms of causing recurrence.",CRP,lymph,1
PMC3284520A,"Various mechanisms like cyclooxigenase-2 expression reduction, a marker of anti-inflammatory response, physical activity induced decrease in IL-6, TNF-a, CRP, stimulation of toll-like receptor 4 that causes production of inflammatory cytokines and innate immunity activation were thought to be the mechanisms responsible[14].Numerous investigators have studied the role of histopathological features of tumors such as: number of lymph nodes, stage and grade of the primary tumor, adjacent organ involvement, the presence of inflammatory cells in the tumor, pathological type and gross pathological view of the tumor, in terms of causing recurrence.",TNF,lymph,1
PMC5332937A,"However, the cancer often reappears, and is accompanied by rising levels of serum prostate-specific antigen (PSA) [8,9].",PSA,serum,1
PMC4485845A,"A variety of agents can be defined as adjuvants (e.g., water-in-oil emulsions, GM-CSF, toll-like receptor (TLR) agonists).Several water-in-oil emulsions were tested after Freund incomplete adjuvant (FIA) was abandoned.",GM,CSF,1
PMC4485845A,"A variety of agents can be defined as adjuvants (e.g., water-in-oil emulsions, GM-CSF, toll-like receptor (TLR) agonists).Several water-in-oil emulsions were tested after Freund incomplete adjuvant (FIA) was abandoned.",TLR,CSF,1
PMC4485845A,"A variety of agents can be defined as adjuvants (e.g., water-in-oil emulsions, GM-CSF, toll-like receptor (TLR) agonists).Several water-in-oil emulsions were tested after Freund incomplete adjuvant (FIA) was abandoned.",FIA,CSF,1
PMC4926055A,Lymph node involvement with an advanced FIGO stage and TROP2 overexpression were independently associated with poor DFS (Table 3).See full tableTable 3.,DFS,Lymph,1
PMC4926055A,Lymph node involvement with an advanced FIGO stage and TROP2 overexpression were independently associated with poor DFS (Table 3).See full tableTable 3.,TROP2,Lymph,1
PMC4926055A,Lymph node involvement with an advanced FIGO stage and TROP2 overexpression were independently associated with poor DFS (Table 3).See full tableTable 3.,FIGO,Lymph,1
PMC5385398A,"Accumulating evidence has indicated that the EMT mediates tumour progression including local invasion, dissemination from the primary tumour, intravasation into blood circulation, and metastasis.",EMT,blood,-1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",PROSTVAC,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",LFA-3,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",PSA,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",B7.1,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",GM,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",NKG2D,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",NKG2D,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",MICB,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",ICAM-1,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",TRICOM,CSF,1
PMC4202120B,"The membrane-restricted NKG2D ligand MICB.A2 could sustain NKG2D protective immunity and prevent spontaneous tumorigenesis, whereas the native NKG2D ligand MICB facilitates tumor progression through soluble ligand-mediated impairment of NK cell peripheral maintenance [342].PROSTVAC-V and PROSTVAC-F are vaccinia and fowlpox based virus vaccines expressing PSA and TRICOM (three immunostimulatory proteins B7.1, ICAM-1, and LFA-3), and with GM-CSF.",NKG2D,CSF,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",CVX,serum,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",CVX,serum,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",SCC-1,serum,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",SCC-1,serum,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",hRS7,serum,1
PMC3224189A,"In CVX-SCC-1, a significant increase in killing was seen in the presence of human serum which declined to baseline killing in the presence of heat-inactivated serum and hRS7 suggesting that this cell line is highly sensitive to complement in vitro.",hRS7,serum,1
PMC4650945A,YAP expression is high in the bile duct and expressed at lower levels in hepatocytes under normal conditions.,YAP,bile,1
PMC3605152A,We thus assessed TIM-3 expression on CD8 T cells of viremic HIV-1-infected patients and of patients under antiretroviral therapy with no detectable viral load in peripheral blood (virologically suppressed).,T,blood,-1
PMC3605152A,We thus assessed TIM-3 expression on CD8 T cells of viremic HIV-1-infected patients and of patients under antiretroviral therapy with no detectable viral load in peripheral blood (virologically suppressed).,CD8,blood,-1
PMC3605152A,We thus assessed TIM-3 expression on CD8 T cells of viremic HIV-1-infected patients and of patients under antiretroviral therapy with no detectable viral load in peripheral blood (virologically suppressed).,TIM-3,blood,-1
PMC5414739A,"In addition, a more recent study showed that PRL treatment of rat bone marrow MSCs cultured in differentiation medium induced the expression of various pancreatic endocrine-specific genes, including somatostatin and long PRLR (119).Thus, depending on culture conditions, PRL appears to induce proliferation or differentiation of MSCs.",PRL,bone marrow,1
PMC5414739A,"In addition, a more recent study showed that PRL treatment of rat bone marrow MSCs cultured in differentiation medium induced the expression of various pancreatic endocrine-specific genes, including somatostatin and long PRLR (119).Thus, depending on culture conditions, PRL appears to induce proliferation or differentiation of MSCs.",PRLR,bone marrow,1
PMC5414739A,"In addition, a more recent study showed that PRL treatment of rat bone marrow MSCs cultured in differentiation medium induced the expression of various pancreatic endocrine-specific genes, including somatostatin and long PRLR (119).Thus, depending on culture conditions, PRL appears to induce proliferation or differentiation of MSCs.",PRL,bone marrow,1
PMC5538449A,"A, KLF4 expression of CD14+ blood monocytes stimulated with indicated cytokines.",CD14,blood,-1
PMC5538449A,"A, KLF4 expression of CD14+ blood monocytes stimulated with indicated cytokines.",KLF4,blood,-1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",GM,CSF,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",GM,blood,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",GM,CSF,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",GM,blood,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",TAM,CSF,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",TAM,blood,1
PMC3478937A,"Human peripheral blood monocytes were differentiated for 5 d with the indicated cytokines and ligands (GM, GM-CSF; Delta, Delta-like-1) and were then analyzed for the expression of the TAM receptors and surface markers.",CSF,blood,1
PMC3476529A,"Representative and composite data from four blood and five skin donors are shown, mean +- SEM. *p  0.05, Mann-Whitney U test comparing skin CD141hi DCs with all other subsets.",SEM,blood,-1
PMC3476529A,"Right panel shows percent of DCs in S, G2, or M phase in blood and skin.",G2,blood,-1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",AC,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",AC,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",CSF,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",GM,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",GM,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",Tyro3,CSF,1
PMC3478937A,"However, Mer but not Tyro3 was found to be induced concomitant with macrophage differentiation in the presence of either M-CSF or GM-CSF, in keeping with the previous demonstration that Mer is crucial for AC uptake by macrophages (Fig",Tyro3,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",CD34,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",CD34,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",CSF,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",mRNA,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",mRNA,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",SCF,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",SCF,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",TNF,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",TNF,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",TGF,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",TGF,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",FLT3L,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",FLT3L,CSF,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",GM,serum,1
PMC5538449A,"Detailed descriptions of cytokines and reagents, sources for cells and skin tissue, isolation of immune cells for microarray studies, mRNA microarray and data analysis, retroviral vectors, confocal microscopy, and the chromatin immunoprecipitation assay are presented in the Methods section in this article's Online Repository at www.jacionline.org.TGF-b1 induces the generation of CD1a+CD207+ p-LCs at the expense of monocytes/macrophages when added to serum-free, cytokine-supplemented cultures (GM-CSF, SCF, FLT3L, and TNF-a) of CD34+ hematopoietic progenitor cells.8 We screened for TGF-b1-regulated transcription factors during p-LC commitment.",GM,CSF,1
PMC2951427A,"Stromal fragments were digested with collagenase, passed through a 100-mm nylon mesh, and cultured short term in BFS media (DMEM, 5% FBS, 5% Nu-serum, and 5 mg/mL insulin).Dissociated epithelial cells were lentivirally infected with centrifugation at a multiplicity of infection of 40. Dissociated epithelial and stromal cells were mixed and resuspended in rat-tail collagen (BD Biosciences; 354236) neutralized according to the manufacturer's instructions.",DMEM,serum,1
PMC2951427A,"Stromal fragments were digested with collagenase, passed through a 100-mm nylon mesh, and cultured short term in BFS media (DMEM, 5% FBS, 5% Nu-serum, and 5 mg/mL insulin).Dissociated epithelial cells were lentivirally infected with centrifugation at a multiplicity of infection of 40. Dissociated epithelial and stromal cells were mixed and resuspended in rat-tail collagen (BD Biosciences; 354236) neutralized according to the manufacturer's instructions.",BFS,serum,1
PMC2951427A,"Stromal fragments were digested with collagenase, passed through a 100-mm nylon mesh, and cultured short term in BFS media (DMEM, 5% FBS, 5% Nu-serum, and 5 mg/mL insulin).Dissociated epithelial cells were lentivirally infected with centrifugation at a multiplicity of infection of 40. Dissociated epithelial and stromal cells were mixed and resuspended in rat-tail collagen (BD Biosciences; 354236) neutralized according to the manufacturer's instructions.",FBS,serum,1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",DNA,blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",DNA,Blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",USA,blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",USA,Blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",EZNA,blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",EZNA,Blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",GA,blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",GA,Blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",DNA,blood,-1
PMC4317886A,"All the patients donated 5 mL blood before treatment for genomic DNA extraction using the EZNA Blood DNA Midi Kit (Omega Bio-Tek, Norcross, GA, USA) in the laboratory.",DNA,Blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD83,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD83,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CLA,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CLA,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD14,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD14,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",L1,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",L1,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD86,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD86,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CCR7,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CCR7,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD80,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD80,blood,-1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD141,Blood,1
PMC3476529A,"Potentially Develop from Blood CD141+ DCs(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and CD141hi DCs (red) compared to isotype (gray).",CD141,blood,-1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",IgG1,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",ADC,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",IgG1,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",ADC,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",DNA,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",ADC,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",IgG1,serum,1
PMC4596896A,"This provided only a partial explanation for the enhanced efficacy of the Fc mutated IgG1 ADC because the wild type IgG2-vcF4 ADC had comparable serum exposure as the Fc mutated IgG1 ADC yet it was not as efficacious as the mutated IgG1 ADC.The drugs used for ADCs inhibit cellular processes that are vital for cell proliferation and/or survival, such as tubulin polymerization or DNA replication (Table III).",III,serum,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",CXCL16,bone marrow,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",EMT,bone marrow,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",MSC,bone marrow,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",HIF-1,bone marrow,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",CXCR6,bone marrow,1
PMC4202120A,"Cancer associated fibroblasts develop an inflammatory signature characterized by activation of COX-2/NF-kB /HIF-1, which induces generation of reactive oxygen species and the EMT program in prostate cancer cells [298].Another example of the role that paracrine interactions play in EMT and metastasis of PCa involves tumor secreted cytokine CXCL16 and its receptor CXCR6 expressed on bone marrow derived mesenchymal stem cells (MSC).",EMT,bone marrow,1
PMC2695576A,"In LCD2 amyloid deposits in the cornea (Figure 46), but also in scleral, choroidal and adnexal blood vessels as well as in the lacrimal gland and perineurium of ciliary nerves.",LCD2,blood,-1
PMC2695576A,"Patients with MCD whose corneas fail to react with anti-KS antibodies also lack detectable corneal KS, while those with immunohistochemically detectable KS have normal levels of serum KS.View larger versionFigure 27.",KS,serum,1
PMC2695576A,"Patients with MCD whose corneas fail to react with anti-KS antibodies also lack detectable corneal KS, while those with immunohistochemically detectable KS have normal levels of serum KS.View larger versionFigure 27.",KS,serum,1
PMC2695576A,"Patients with MCD whose corneas fail to react with anti-KS antibodies also lack detectable corneal KS, while those with immunohistochemically detectable KS have normal levels of serum KS.View larger versionFigure 27.",KS,serum,1
PMC2695576A,"Patients with MCD whose corneas fail to react with anti-KS antibodies also lack detectable corneal KS, while those with immunohistochemically detectable KS have normal levels of serum KS.View larger versionFigure 27.",MCD,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",GFP,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",SHIP,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",ATP,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",CD44,serum,-1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",cDNA,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",CD166,serum,-1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",CD133,serum,-1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",ALDEFLUOR,serum,1
PMC4425227A,"Enrichment in stem-like cell subpopulations could be achieved by multiple approaches: by modifying cell culture conditions such as cultivating cells in low-calcium serum-free defined medium [4] or under hypoxia [5]; by using a combination of cell surface markers, such as CD133 [6], CD44 [7], CD166 [8,9], or TROP2 [10]; by developing functional assays on cytoprotective activity such as the side population assay based on the efflux of Hoechst 33342 fluorescent dye by the ATP-binding cassette transporter and the ALDEFLUOR assay based on activity of aldehyde dehydrogenases detoxifying enzyme activity [11-13]; or finally by using reporter vectors containing fluorescent protein driven by stemness gene promoters [14,15].In this study, we applied this latter approach using the green fluorescent protein (GFP) cDNA under the control of the promoter of s-SHIP.",TROP2,serum,-1
PMC3718634A,"All sera were aliquoted and stored at -80degC.Differences in cellular viability, proliferation, apoptosis, protein and RNA expression, and human serum IgG responses were assessed using the unpaired two-tailed student's t test.",RNA,sera,1
PMC3718634A,"All sera were aliquoted and stored at -80degC.Differences in cellular viability, proliferation, apoptosis, protein and RNA expression, and human serum IgG responses were assessed using the unpaired two-tailed student's t test.",RNA,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",MCD,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC2695576A,"Three immunophenotypes of MCD are recognized [51,53,56]: one has no detectable keratan sulfate (KS) in the serum or cornea (MCD type I) (Figures 27 and 28), another has normal amounts of KS in the serum and cornea (MCD type II) (Figure 29) and a third lacks detectable antigenic keratan sulfate in the serum, but has stainable KS in the keratocytes (MCD type IA).",KS,serum,1
PMC4882422A,"After cell attachment, the macrophages were serum-starved for 16 h followed by treatment with up to 10 ng/ml of LPS.",LPS,serum,1
PMC3478937A,We used CD34+ hematopoietic progenitor/stem cells from human umbilical cord blood to study Axl induction during DC subset differentiation.,CD34,blood,-1
PMC3478937A,We used CD34+ hematopoietic progenitor/stem cells from human umbilical cord blood to study Axl induction during DC subset differentiation.,DC,blood,-1
PMC3967411A,Serum-free conditioned medium from BPH1 was used as control for MMP2 and MMP9 (27).Animal studies were conducted in accordance with approved Institutional Animal Care and Use Committee protocols and the NIH Guide for the Care and Use of Laboratory Animals.,NIH,Serum,1
PMC3967411A,Serum-free conditioned medium from BPH1 was used as control for MMP2 and MMP9 (27).Animal studies were conducted in accordance with approved Institutional Animal Care and Use Committee protocols and the NIH Guide for the Care and Use of Laboratory Animals.,BPH1,Serum,1
PMC3967411A,Serum-free conditioned medium from BPH1 was used as control for MMP2 and MMP9 (27).Animal studies were conducted in accordance with approved Institutional Animal Care and Use Committee protocols and the NIH Guide for the Care and Use of Laboratory Animals.,MMP2,Serum,1
PMC3967411A,Serum-free conditioned medium from BPH1 was used as control for MMP2 and MMP9 (27).Animal studies were conducted in accordance with approved Institutional Animal Care and Use Committee protocols and the NIH Guide for the Care and Use of Laboratory Animals.,MMP9,Serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TGF,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TGF,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",FLT3L,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",FLT3L,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CD34,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CD34,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",GM,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",GM,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",CSF,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TNF,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",TNF,serum,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",SCF,CSF,1
PMC3478937A,"(B) CD34+ cells were cultured for 7 d in serum-free medium containing LC-promoting cytokine cocktail (GM-CSF, SCF, FLT3L, TNF, and TGF-b1).",SCF,serum,1
PMC3478937A,"GM-CSF/IL4-dependent DCs generated in vitro from CD34+ cells via a two-step culture system (Ratzinger et al., 2004) lacked TAM receptor expression in keeping with the observed absence of these receptors by moDCs (Figs.",CD34,CSF,1
PMC3478937A,"GM-CSF/IL4-dependent DCs generated in vitro from CD34+ cells via a two-step culture system (Ratzinger et al., 2004) lacked TAM receptor expression in keeping with the observed absence of these receptors by moDCs (Figs.",GM,CSF,1
PMC3478937A,"GM-CSF/IL4-dependent DCs generated in vitro from CD34+ cells via a two-step culture system (Ratzinger et al., 2004) lacked TAM receptor expression in keeping with the observed absence of these receptors by moDCs (Figs.",TAM,CSF,1
PMC3478937A,(A) CD34+ cells were cultured using a two-step DC-promoting culture system containing GM-CSF and IL-4 in the final step.,DC,CSF,1
PMC3478937A,(A) CD34+ cells were cultured using a two-step DC-promoting culture system containing GM-CSF and IL-4 in the final step.,IL-4,CSF,1
PMC3478937A,(A) CD34+ cells were cultured using a two-step DC-promoting culture system containing GM-CSF and IL-4 in the final step.,CD34,CSF,1
PMC3478937A,(A) CD34+ cells were cultured using a two-step DC-promoting culture system containing GM-CSF and IL-4 in the final step.,GM,CSF,1
PMC3128671A,"In this study, we show that ADCC against USPC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",ADCC,serum,1
PMC3128671A,"In this study, we show that ADCC against USPC cell lines was not significantly decreased by high concentrations (up to 50%) of human serum.",USPC,serum,1
PMC3434166A,NP460 cells were cultured in defined keratinocyte serum-free medium.,NP460,serum,1
PMC3434166A,"CNE2, SUNE1 and C666 were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.",SUNE1,serum,1
PMC3434166A,"CNE2, SUNE1 and C666 were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.",CNE2,serum,1
PMC3434166A,"CNE2, SUNE1 and C666 were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.",RPMI-1640,serum,1
PMC3434166A,"CNE2, SUNE1 and C666 were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.",C666,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",PTN,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",PTN,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",GAPDH,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",PC3,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",MAOA,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",GAPDH,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",RPMI,serum,1
PMC4157741A,"The sequences of primers used in this study were: GAPDH forward, 5'-CCTCAACGACCACTTTGTCA-3'; GAPDH reverse, 5'-TTACTCCTTGGAGGCCATGT-3'; MAOA forward, 5'-AAAGTGGAGCGGCTACATGG-3'; MAOA reverse, 5'-CAGAAACAGAGGGCAGGTTCC-3'; pleiotrophin (PTN) forward: 5'-GGGCAGCAATTTAAATGTTATGACTA-3'; PTN reverse: 5'-ACCCCCATTTTGCTGACTACATT-3'.The androgen responsive prostate cancer cell line, LNCaP and androgen insensitive prostate cancer cell line PC3 (both from the American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and 100 IU/ml penicillin (Invitrogen Corp, Carlsbad, CA).",MAOA,serum,1
PMC4370053A,"SortedCD1c+ myeloid DCs, but not other populations, also expressed langerinafter 18 h with serum-containing medium or with TGF-b (Fig.",TGF,serum,1
PMC4606116A,(b) Extended verification of ELISA of BST2 and TROP2 in another plasma sample set containing 120 CRC patients and 120 healthy controls.,BST2,plasma,1
PMC4606116A,(b) Extended verification of ELISA of BST2 and TROP2 in another plasma sample set containing 120 CRC patients and 120 healthy controls.,TROP2,plasma,1
PMC4606116A,(b) Extended verification of ELISA of BST2 and TROP2 in another plasma sample set containing 120 CRC patients and 120 healthy controls.,CRC,plasma,1
PMC4606116A,(b) Extended verification of ELISA of BST2 and TROP2 in another plasma sample set containing 120 CRC patients and 120 healthy controls.,ELISA,plasma,1
PMC5289527A,Transcript levels for IL6 in whole blood samples from KD subjects as a function of genotype for rs56245262 in TLR6.TLR6 rs56245262 risk allele (A) is shown in red.,IL6,blood,-1
PMC4673178A,"In irinotecan-treated animals, water homogenates of the tumor (1 part tumor + 10 parts water) or serum diluted 1:1 in water were extracted and analyzed by reversed-phase HPLC for irinotecan, SN-38, and SN-38 glucuronide (SN-38G).",HPLC,serum,1
PMC4673178A,"In irinotecan-treated animals, water homogenates of the tumor (1 part tumor + 10 parts water) or serum diluted 1:1 in water were extracted and analyzed by reversed-phase HPLC for irinotecan, SN-38, and SN-38 glucuronide (SN-38G).",SN-38,serum,1
PMC4673178A,"In irinotecan-treated animals, water homogenates of the tumor (1 part tumor + 10 parts water) or serum diluted 1:1 in water were extracted and analyzed by reversed-phase HPLC for irinotecan, SN-38, and SN-38 glucuronide (SN-38G).",SN-38,serum,1
PMC4673178A,"In irinotecan-treated animals, water homogenates of the tumor (1 part tumor + 10 parts water) or serum diluted 1:1 in water were extracted and analyzed by reversed-phase HPLC for irinotecan, SN-38, and SN-38 glucuronide (SN-38G).",SN-38,serum,1
PMC3786374A,"The serum concentrations of TGFb1 were determined, as described in Materials and methods, using sera obtained from WT and ThrbPV/PV mice at the indicated age.",TGFb1,sera,-1
PMC3786374A,"The serum concentrations of TGFb1 were determined, as described in Materials and methods, using sera obtained from WT and ThrbPV/PV mice at the indicated age.",TGFb1,serum,1
PMC3934101A,Lgr6 expression also marks hair follicle epidermal stem cells34.,Lgr6,hair,-1
PMC4448470A,"A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues.7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells.",TNM,lymph,1
PMC4448470A,"A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues.7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells.",H520,lymph,1
PMC4448470A,"A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues.7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells.",TRIM29,lymph,1
PMC4448470A,"A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues.7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells.",TRIM29,lymph,1
PMC4448470A,"A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues.7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells.",NCI,lymph,1
PMC5332937A,This is consistent with other reports showing that WNT3A signaling can preserve an undifferentiated phenotype in CD133+ human cord blood-derived cells [176] and it supports embryonic stem cell self-renewal [177].,CD133,blood,-1
PMC5332937A,This is consistent with other reports showing that WNT3A signaling can preserve an undifferentiated phenotype in CD133+ human cord blood-derived cells [176] and it supports embryonic stem cell self-renewal [177].,WNT3A,blood,-1
PMC4448470A,"Early in 2007, Kosaka et al. proved that increased TRIM29 expression was markedly associated with tumor invasion and lymph node metastasis in gastric cancer.11 Our results are consistent with previous research that has shown that TRIM29 expression can influence the extent of tumor invasion and lymph node metastasis in some cancers.",TRIM29,lymph,1
PMC4448470A,"Early in 2007, Kosaka et al. proved that increased TRIM29 expression was markedly associated with tumor invasion and lymph node metastasis in gastric cancer.11 Our results are consistent with previous research that has shown that TRIM29 expression can influence the extent of tumor invasion and lymph node metastasis in some cancers.",TRIM29,lymph,1
PMC4448470A,"Early in 2007, Kosaka et al. proved that increased TRIM29 expression was markedly associated with tumor invasion and lymph node metastasis in gastric cancer.11 Our results are consistent with previous research that has shown that TRIM29 expression can influence the extent of tumor invasion and lymph node metastasis in some cancers.",TRIM29,lymph,1
PMC4448470A,"Early in 2007, Kosaka et al. proved that increased TRIM29 expression was markedly associated with tumor invasion and lymph node metastasis in gastric cancer.11 Our results are consistent with previous research that has shown that TRIM29 expression can influence the extent of tumor invasion and lymph node metastasis in some cancers.",TRIM29,lymph,1
PMC4698345A,"Furthermore, the general feasibility of depleting tumor-associated PMNs is complicated by the fact that patients on chemotherapy routinely receive recombinant G-CSF to maintain blood neutrophil numbers.",CSF,blood,-1
PMC4370053A,"Induction of langerin in CD1c+ blood myeloid DCs.(A) Langerin induction on whole-cultured PBMC after 18 h (T18) of culture invitro, with or without TGF-b, compared with isotypecontrol.",PBMC,blood,1
PMC4370053A,"Induction of langerin in CD1c+ blood myeloid DCs.(A) Langerin induction on whole-cultured PBMC after 18 h (T18) of culture invitro, with or without TGF-b, compared with isotypecontrol.",T18,blood,1
PMC4370053A,"Induction of langerin in CD1c+ blood myeloid DCs.(A) Langerin induction on whole-cultured PBMC after 18 h (T18) of culture invitro, with or without TGF-b, compared with isotypecontrol.",Langerin,blood,1
PMC4370053A,"Induction of langerin in CD1c+ blood myeloid DCs.(A) Langerin induction on whole-cultured PBMC after 18 h (T18) of culture invitro, with or without TGF-b, compared with isotypecontrol.",TGF,blood,1
PMC4673178A,"Each sample (150 mL diluted serum or tissue homogenate that was not clarified by centrifugation prior to extraction) was first spiked with an internal standard (9 mL of 3.33 mg/mL of 10-hydroxycamptothecin), and then mixed with 150 mL of an extraction/protein-precipitation reagent (1:1:1 methanol, ethylene glycol and 1 M ZnSO4 in DI water) as described previously by Hirose et al. [53].",ZnSO4,serum,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,GM,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,GM,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,NCT01341652,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,NCT01341652,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PROSTVAC,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PROSTVAC,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PAP,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PAP,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,GM,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,GM,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PROST,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,PROST,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,CSF,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,VAC,CSF,1
PMC4202120B,Development of a humoral response to an viral antigen in PROSTVAC as reported to be a potential predictive marker for favorable response to PROST-VAC in patients [345].Phase II trial NCT01341652 examines PAP vaccine plus GM-CSF versus GM-CSF alone in non-metastatic PCa.,VAC,CSF,1
PMC4096804A,"Genomic DNA from MOC cells was extracted using DNeasy Blood  Tissue Kit (Qiagen) and was constructed into Illumina libraries according to the manufacturer's protocol (Illumina Inc, San Diego, CA).",MOC,Blood,-1
PMC4096804A,"Genomic DNA from MOC cells was extracted using DNeasy Blood  Tissue Kit (Qiagen) and was constructed into Illumina libraries according to the manufacturer's protocol (Illumina Inc, San Diego, CA).",San,Blood,-1
PMC4096804A,"Genomic DNA from MOC cells was extracted using DNeasy Blood  Tissue Kit (Qiagen) and was constructed into Illumina libraries according to the manufacturer's protocol (Illumina Inc, San Diego, CA).",DNA,Blood,-1
PMC5494437A,"With continued development, the cells move into a HSC niche of the adult bone marrow where the HSCs and pericytes evolve into a quiescent state.",HSC,bone marrow,1
PMC2976030A,The intensities of d013C0- and d413C0- labeled peptides from plasma before and after tumor induction were much higher than that from d413C4- labeled peptides from tumors.,d413C4-,plasma,1
PMC4803572A,"To further complicate the situation, non-epithelial cells (e.g. plasma cells) in the bone marrow may be CK positive [27].Based on what we have learned to date, we can no longer rely on the use of anti-EpCAM antibodies alone for the identification and isolation of PCa DTC from the bone marrow.",DTC,bone marrow,1
PMC4803572A,"To further complicate the situation, non-epithelial cells (e.g. plasma cells) in the bone marrow may be CK positive [27].Based on what we have learned to date, we can no longer rely on the use of anti-EpCAM antibodies alone for the identification and isolation of PCa DTC from the bone marrow.",DTC,plasma,1
PMC4803572A,"To further complicate the situation, non-epithelial cells (e.g. plasma cells) in the bone marrow may be CK positive [27].Based on what we have learned to date, we can no longer rely on the use of anti-EpCAM antibodies alone for the identification and isolation of PCa DTC from the bone marrow.",DTC,bone marrow,1
PMC4467439A,"Cholangiocarcinoma (CCA), the second most common primary hepatobiliary malignancy, is an epithelial cell malignancy originating from the bile ducts.",CCA,bile,1
PMC4370053A,(C) Expression of langerin mRNA byCD14+ monocytes (blue bars) and CD1c+ blood DCs (redbars) at 0 h and 18 h with TGF-b.,TGF,blood,-1
PMC4370053A,(C) Expression of langerin mRNA byCD14+ monocytes (blue bars) and CD1c+ blood DCs (redbars) at 0 h and 18 h with TGF-b.,mRNA,blood,-1
PMC2976030A,"Two of the tumor-associated proteins, Tenascin-C and Arylsulfatase B, were further detected and quantified in plasma from the same cancer-bearing mice using isotope labeling and 2D-LC-MALDI-MS/MS.",MALDI,plasma,1
PMC3906064A,"As demonstrated in Figure 4B the non target recovery is independent of target density and averages 55 cells/mL. The validation data predicts that only 6 CTC/mL need to be recovered to achieve a purity of 10% and less than 1 CTC/mL to achieve a purity better than 1%.To evaluate the importance of this partition efficiency, the ability to detect an EGFR mutation in the H1650 cell line recovered from whole blood was evaluated.",EGFR,blood,-1
PMC3906064A,"As demonstrated in Figure 4B the non target recovery is independent of target density and averages 55 cells/mL. The validation data predicts that only 6 CTC/mL need to be recovered to achieve a purity of 10% and less than 1 CTC/mL to achieve a purity better than 1%.To evaluate the importance of this partition efficiency, the ability to detect an EGFR mutation in the H1650 cell line recovered from whole blood was evaluated.",CTC,blood,-1
PMC3906064A,"As demonstrated in Figure 4B the non target recovery is independent of target density and averages 55 cells/mL. The validation data predicts that only 6 CTC/mL need to be recovered to achieve a purity of 10% and less than 1 CTC/mL to achieve a purity better than 1%.To evaluate the importance of this partition efficiency, the ability to detect an EGFR mutation in the H1650 cell line recovered from whole blood was evaluated.",H1650,blood,-1
PMC3906064A,"As demonstrated in Figure 4B the non target recovery is independent of target density and averages 55 cells/mL. The validation data predicts that only 6 CTC/mL need to be recovered to achieve a purity of 10% and less than 1 CTC/mL to achieve a purity better than 1%.To evaluate the importance of this partition efficiency, the ability to detect an EGFR mutation in the H1650 cell line recovered from whole blood was evaluated.",CTC,blood,-1
PMC2976030A,Identifying tissue-derived peptides in plasma from MALDI-TOF/TOF (ABI 4800) was performed using GPS Explorer software (version 3.6).,ABI,plasma,1
PMC2976030A,Identifying tissue-derived peptides in plasma from MALDI-TOF/TOF (ABI 4800) was performed using GPS Explorer software (version 3.6).,GPS,plasma,1
PMC2976030A,Identifying tissue-derived peptides in plasma from MALDI-TOF/TOF (ABI 4800) was performed using GPS Explorer software (version 3.6).,MALDI,plasma,1
PMC2976030A,Identifying tissue-derived peptides in plasma from MALDI-TOF/TOF (ABI 4800) was performed using GPS Explorer software (version 3.6).,TOF,plasma,1
PMC2976030A,Identifying tissue-derived peptides in plasma from MALDI-TOF/TOF (ABI 4800) was performed using GPS Explorer software (version 3.6).,TOF,plasma,1
PMC2976030A,"Finally, specific mass-spectrometry-based methods and affinity reagents can be developed for the specific and sensitive detection of identified tissue proteins in plasma 15, selective isolation of a specific proteins or peptides using affinity reagents16, or the recently developed targeted approach using multiple reaction monitoring (MRM) 17-19.The chemically induced two-stage mouse skin carcinogenesis model has been used for decades to study the genetic, molecular, and biologic basis of tumor development 20.",MRM,plasma,-1
PMC3418405A,"Accordingly, Foxo3a transcriptional targets TRAIL and FasL (26, 27), whose expression levels have been shown to be up-regulated by interferons in infected blood and tissues, are responsible for T cell and B cell death in HIV+ subjects (4, 84-88).",FasL,blood,-1
PMC3418405A,"Accordingly, Foxo3a transcriptional targets TRAIL and FasL (26, 27), whose expression levels have been shown to be up-regulated by interferons in infected blood and tissues, are responsible for T cell and B cell death in HIV+ subjects (4, 84-88).",TRAIL,blood,-1
PMC3418405A,"Accordingly, Foxo3a transcriptional targets TRAIL and FasL (26, 27), whose expression levels have been shown to be up-regulated by interferons in infected blood and tissues, are responsible for T cell and B cell death in HIV+ subjects (4, 84-88).",T,blood,-1
PMC2976030A,"In addition to the modifications for Met, Asp, and Cys that were used in LTQ MS/MS spectra analyses as described above, N-termini of peptides and Lys are modified by succinic anhydride (100 Da for d013C0, 104 Da for d413C0, and 108 Da for d413C4).The objective of this study was to use N-linked glycopeptide isolation, isotopic labeling, and LC- MS to identify skin cancer related extracellular proteins and determine if these proteins could be detected in plasma from tumor bearing mice.",LC-,plasma,1
PMC2976030A,"In addition to the modifications for Met, Asp, and Cys that were used in LTQ MS/MS spectra analyses as described above, N-termini of peptides and Lys are modified by succinic anhydride (100 Da for d013C0, 104 Da for d413C0, and 108 Da for d413C4).The objective of this study was to use N-linked glycopeptide isolation, isotopic labeling, and LC- MS to identify skin cancer related extracellular proteins and determine if these proteins could be detected in plasma from tumor bearing mice.",Met,plasma,1
PMC2976030A,"In addition to the modifications for Met, Asp, and Cys that were used in LTQ MS/MS spectra analyses as described above, N-termini of peptides and Lys are modified by succinic anhydride (100 Da for d013C0, 104 Da for d413C0, and 108 Da for d413C4).The objective of this study was to use N-linked glycopeptide isolation, isotopic labeling, and LC- MS to identify skin cancer related extracellular proteins and determine if these proteins could be detected in plasma from tumor bearing mice.",LTQ,plasma,1
PMC3369113A,"Negative control Abs were: purified non-immune mouse IgG (Pierce/Thermo Fisher Scientific) and purified normal goat IgG (Santa Cruz Biotechnology).LNCaP (ATCC) and C4-2B (UroCor, Inc.) cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) (Gemini Bioproducts), 1% non-essential aminoacids, 1 mM sodium pyruvate, 10 mM Hepes pH 7.3.",ATCC,serum,1
PMC3369113A,"Negative control Abs were: purified non-immune mouse IgG (Pierce/Thermo Fisher Scientific) and purified normal goat IgG (Santa Cruz Biotechnology).LNCaP (ATCC) and C4-2B (UroCor, Inc.) cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) (Gemini Bioproducts), 1% non-essential aminoacids, 1 mM sodium pyruvate, 10 mM Hepes pH 7.3.",C4,serum,1
PMC3369113A,"Negative control Abs were: purified non-immune mouse IgG (Pierce/Thermo Fisher Scientific) and purified normal goat IgG (Santa Cruz Biotechnology).LNCaP (ATCC) and C4-2B (UroCor, Inc.) cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) (Gemini Bioproducts), 1% non-essential aminoacids, 1 mM sodium pyruvate, 10 mM Hepes pH 7.3.",RPMI,serum,1
PMC3369113A,"Negative control Abs were: purified non-immune mouse IgG (Pierce/Thermo Fisher Scientific) and purified normal goat IgG (Santa Cruz Biotechnology).LNCaP (ATCC) and C4-2B (UroCor, Inc.) cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) (Gemini Bioproducts), 1% non-essential aminoacids, 1 mM sodium pyruvate, 10 mM Hepes pH 7.3.",FBS,serum,1
PMC3369113A,"FN - purified from whole blood as described in (Engvall and Ruoslahti, 1977) - and Poly-L-Lysine (PLL) (Sigma-Aldrich) were diluted in sterile phosphate buffer saline (PBS) for coating.",PBS,blood,1
PMC3369113A,"FN - purified from whole blood as described in (Engvall and Ruoslahti, 1977) - and Poly-L-Lysine (PLL) (Sigma-Aldrich) were diluted in sterile phosphate buffer saline (PBS) for coating.",PLL,blood,1
PMC3551651A,"Kaplan-Meier survival curves demonstrated that patients with high aB-crystallin expression, advanced pTNM stage of LSCC and lymph node metastasis had a significantly shorter survival time.",pTNM,lymph,1
PMC3551651A,"Kaplan-Meier survival curves demonstrated that patients with high aB-crystallin expression, advanced pTNM stage of LSCC and lymph node metastasis had a significantly shorter survival time.",LSCC,lymph,1
PMC3284520A,"As per this study, 130 colorectal cancer patients with recurrence diagnosed during 1999-2005 were followed for a period of 20 mo with physical examination, serum carcinoembryonic antigen levels, chest X-ray and abdominopelvic sonography done every 2 mo in the first year, every 3 mo the second year, every 4-6 mo for the next 2 years and annually thereafter until the completion of the study.",X,serum,1
PMC4558321A,"Serum samples from seven patients also were assayed for SN-38 content, both total (representing SN-38 bound to the IgG and free) and free SN-38 (i.e., unbound SN-38).",SN-38,Serum,1
PMC4558321A,"Serum samples from seven patients also were assayed for SN-38 content, both total (representing SN-38 bound to the IgG and free) and free SN-38 (i.e., unbound SN-38).",SN-38,Serum,1
PMC4558321A,"Serum samples from seven patients also were assayed for SN-38 content, both total (representing SN-38 bound to the IgG and free) and free SN-38 (i.e., unbound SN-38).",SN-38,Serum,1
PMC4558321A,"Serum samples from seven patients also were assayed for SN-38 content, both total (representing SN-38 bound to the IgG and free) and free SN-38 (i.e., unbound SN-38).",SN-38,Serum,1
PMC4251850A,"Human pancreatic ductal epithelial (HPDE) cells were kindly provided by M.S. Tsao (Toronto) and cultured in defined Keratinocyte-SFM (KFSM, Life technology), as described previously [39].The collection of ascites was done in the German university hospital, Knappschaftskrankenhaus Bochum, during patient therapy.",HPDE,ascites,1
PMC4251850A,"Human pancreatic ductal epithelial (HPDE) cells were kindly provided by M.S. Tsao (Toronto) and cultured in defined Keratinocyte-SFM (KFSM, Life technology), as described previously [39].The collection of ascites was done in the German university hospital, Knappschaftskrankenhaus Bochum, during patient therapy.",SFM,ascites,1
PMC4251850A,"Human pancreatic ductal epithelial (HPDE) cells were kindly provided by M.S. Tsao (Toronto) and cultured in defined Keratinocyte-SFM (KFSM, Life technology), as described previously [39].The collection of ascites was done in the German university hospital, Knappschaftskrankenhaus Bochum, during patient therapy.",KFSM,ascites,1
PMC5289527A,"For the intronic variant (rs56245262), only one gene (IL6) among 415 NFKB and/or AP1 targets showed a significant difference in acute whole blood transcript levels as a function of genotype (nominal p 0.001).",AP1,blood,-1
PMC5289527A,"For the intronic variant (rs56245262), only one gene (IL6) among 415 NFKB and/or AP1 targets showed a significant difference in acute whole blood transcript levels as a function of genotype (nominal p 0.001).",NFKB,blood,-1
PMC5289527A,"For the intronic variant (rs56245262), only one gene (IL6) among 415 NFKB and/or AP1 targets showed a significant difference in acute whole blood transcript levels as a function of genotype (nominal p 0.001).",IL6,blood,-1
PMC5000705A,"Another interesting marker gene for CTC-isolation and enumeration purposes could be cell-surface vimentin (CSV), which is only expressed on cancer cells and never found on the surface of healthy blood cells.",CSV,blood,-1
PMC5000705A,"Another interesting marker gene for CTC-isolation and enumeration purposes could be cell-surface vimentin (CSV), which is only expressed on cancer cells and never found on the surface of healthy blood cells.",CTC,blood,-1
PMC4450322A,"In the DDC model, b-galactosidase activity was found in some A6+ bile ducts, although most of A6+ OCs and cholangiocytes were not positive for the X-Gal staining (Figure 2, E and F).",A6,bile,1
PMC4450322A,"In the DDC model, b-galactosidase activity was found in some A6+ bile ducts, although most of A6+ OCs and cholangiocytes were not positive for the X-Gal staining (Figure 2, E and F).",A6,bile,1
PMC4450322A,"In the DDC model, b-galactosidase activity was found in some A6+ bile ducts, although most of A6+ OCs and cholangiocytes were not positive for the X-Gal staining (Figure 2, E and F).",X,bile,1
PMC4450322A,"In the DDC model, b-galactosidase activity was found in some A6+ bile ducts, although most of A6+ OCs and cholangiocytes were not positive for the X-Gal staining (Figure 2, E and F).",DDC,bile,1
PMC5376003A,"After CCl4 administration for 48 h, mice were anesthetized by an intraperitoneal injection of a mixture of zoletil (6 mg/kg) and xylazine (3 mg/kg), the abdominal cavity was opened, and blood was removed by cardiac puncture from each mouse.",CCl4,blood,-1
PMC3929731A,"Using a similar analytic approach, we herein developed an UHPLC-MS-MS method using labeled BPA and BPA-G standards that permits direct quantitation of free BPA and BPA-G in 25 mL of serum.",BPA,serum,1
PMC3929731A,"Using a similar analytic approach, we herein developed an UHPLC-MS-MS method using labeled BPA and BPA-G standards that permits direct quantitation of free BPA and BPA-G in 25 mL of serum.",BPA,serum,1
PMC3929731A,"Using a similar analytic approach, we herein developed an UHPLC-MS-MS method using labeled BPA and BPA-G standards that permits direct quantitation of free BPA and BPA-G in 25 mL of serum.",BPA,serum,1
PMC3929731A,"Using a similar analytic approach, we herein developed an UHPLC-MS-MS method using labeled BPA and BPA-G standards that permits direct quantitation of free BPA and BPA-G in 25 mL of serum.",UHPLC,serum,1
PMC3929731A,"Using a similar analytic approach, we herein developed an UHPLC-MS-MS method using labeled BPA and BPA-G standards that permits direct quantitation of free BPA and BPA-G in 25 mL of serum.",BPA,serum,1
PMC3418405A,"We will also present evidence showing that the deregulation of Foxo3a signaling during HIV infection occurs through two major mechanisms: one mediated by the viral proteins, and the second by the deregulated microenvironment within infected blood and tissues.",HIV,blood,-1
PMC3786374A,"Antibodies were TGFBRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).The serum levels of TGFb1 were determined using a TGF beta1 Mouse ELISA Kit (ab119557, Abcam, MA) according to the manufacturer's instructions.",Ki-67,serum,1
PMC3786374A,"Antibodies were TGFBRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).The serum levels of TGFb1 were determined using a TGF beta1 Mouse ELISA Kit (ab119557, Abcam, MA) according to the manufacturer's instructions.",TGFb1,serum,1
PMC3786374A,"Antibodies were TGFBRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).The serum levels of TGFb1 were determined using a TGF beta1 Mouse ELISA Kit (ab119557, Abcam, MA) according to the manufacturer's instructions.",ELISA,serum,1
PMC3786374A,"Antibodies were TGFBRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).The serum levels of TGFb1 were determined using a TGF beta1 Mouse ELISA Kit (ab119557, Abcam, MA) according to the manufacturer's instructions.",TGF,serum,1
PMC3786374A,"Antibodies were TGFBRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).The serum levels of TGFb1 were determined using a TGF beta1 Mouse ELISA Kit (ab119557, Abcam, MA) according to the manufacturer's instructions.",TGFBRII,serum,1
PMC3786374A,"Cells (4 x 104 cells/well) were seeded in a chambered coverglass (Thermo Scientific, NY, #155411) and were cultured in Coon's modified Ham's F-12 medium supplemented with 5% bovine serum containing 10 mg/ml insulin, 0.4ng/ml cortisol, 5 mg/ml transferrin, 10ng/ml glycyl-l-histidyl-l-lysine acetate, 10ng/ml somatostatin and 1 milliunit/ml thyroid-stimulating hormone (Sigma) for 24 h.",F-12,serum,1
PMC5045392A,"A transgenic mouse model (Tg 11.5kb-GFP) was generated using the 11.5kb s-SHIP promoter and we found that the s-SHIP promoter specifically expressed enhanced green fluorescent protein (GFP) in several potential stem cell populations in embryonic development, including the skin epidermis, hair follicles, mammary gland, and prostate [26].",SHIP,hair,-1
PMC5045392A,"A transgenic mouse model (Tg 11.5kb-GFP) was generated using the 11.5kb s-SHIP promoter and we found that the s-SHIP promoter specifically expressed enhanced green fluorescent protein (GFP) in several potential stem cell populations in embryonic development, including the skin epidermis, hair follicles, mammary gland, and prostate [26].",GFP,hair,-1
PMC5045392A,"A transgenic mouse model (Tg 11.5kb-GFP) was generated using the 11.5kb s-SHIP promoter and we found that the s-SHIP promoter specifically expressed enhanced green fluorescent protein (GFP) in several potential stem cell populations in embryonic development, including the skin epidermis, hair follicles, mammary gland, and prostate [26].",SHIP,hair,-1
PMC5045392A,"A transgenic mouse model (Tg 11.5kb-GFP) was generated using the 11.5kb s-SHIP promoter and we found that the s-SHIP promoter specifically expressed enhanced green fluorescent protein (GFP) in several potential stem cell populations in embryonic development, including the skin epidermis, hair follicles, mammary gland, and prostate [26].",GFP,hair,-1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",MEK1,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",PD98059,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",San,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",DMEM,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",MTS,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",EL-800,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",FBS,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",DMEM,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",FBS,serum,1
PMC2946292A,"Cells were cultured for 3 or 5 days, at which point 20 ml of 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI) was added to each well and incubated at 37degC for 1.5 h. Absorbance was recorded at 490 nm with an EL-800 universal microplate reader (Bio-Tek Instruments, Winooski, VT).For the proliferation assay in the presence of the MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA), serum starvation was released by the addition of DMEM containing 0.2% FBS and PD98059 (1 mM) for 4 h. After incubation cells were carefully washed twice and kept in DMEM with 0.2% FBS.",PD98059,serum,1
PMC4186637A,"Cells were obtained from ATCC (CRL 1435) and were grown in RPMI 1640 medium (GIBCO, Life Technologies Corporation), supplemented with 10% fetal calf serum (Life Technologies).",CRL,serum,1
PMC4186637A,"Cells were obtained from ATCC (CRL 1435) and were grown in RPMI 1640 medium (GIBCO, Life Technologies Corporation), supplemented with 10% fetal calf serum (Life Technologies).",RPMI,serum,1
PMC4186637A,"Cells were obtained from ATCC (CRL 1435) and were grown in RPMI 1640 medium (GIBCO, Life Technologies Corporation), supplemented with 10% fetal calf serum (Life Technologies).",ATCC,serum,1
PMC4186637A,"Cells were obtained from ATCC (CRL 1435) and were grown in RPMI 1640 medium (GIBCO, Life Technologies Corporation), supplemented with 10% fetal calf serum (Life Technologies).",GIBCO,serum,1
PMC3476529A,"CD141+ blood DCs show the highest enrichment with skin CD141hi DCs, followed by pDCs, then CD1c DCs of skin and blood.",CD141,blood,-1
PMC3476529A,"CD141+ blood DCs show the highest enrichment with skin CD141hi DCs, followed by pDCs, then CD1c DCs of skin and blood.",CD141,blood,-1
PMC4425227A,"RWPE-1 cells (a gift of Dr. B.S. Kundsen; Fred Hutchinson Cancer Research Center) were maintained in Keratinocyte Serum-Free Medium (KSFM Gibco; Life Technologies) supplemented with 5 ng/mL epidermal growth factor (EGF, PeproTech), bovine pituitary extract (Gibco; Life Technologies), and Zell Shield (Minerva Biolabs; Biovalley).",RWPE-1,Serum,1
PMC4425227A,"RWPE-1 cells (a gift of Dr. B.S. Kundsen; Fred Hutchinson Cancer Research Center) were maintained in Keratinocyte Serum-Free Medium (KSFM Gibco; Life Technologies) supplemented with 5 ng/mL epidermal growth factor (EGF, PeproTech), bovine pituitary extract (Gibco; Life Technologies), and Zell Shield (Minerva Biolabs; Biovalley).",KSFM,Serum,1
PMC4425227A,"RWPE-1 cells (a gift of Dr. B.S. Kundsen; Fred Hutchinson Cancer Research Center) were maintained in Keratinocyte Serum-Free Medium (KSFM Gibco; Life Technologies) supplemented with 5 ng/mL epidermal growth factor (EGF, PeproTech), bovine pituitary extract (Gibco; Life Technologies), and Zell Shield (Minerva Biolabs; Biovalley).",EGF,Serum,1
PMC3581970A,(B) Southern blotting analyses of CLL and benign hyperplasias (normal lymph node).,CLL,lymph,-1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CMAP,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CMAP,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CMAP,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",DC,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CD141,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CD141,blood,1
PMC3476529A,"A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141hi skin DCs with CD141+ blood DCs and CD1c+ DCs from blood with CD1c+ DCs from skin, suggesting the existence of two common DC subsets in blood and skin (Figure 7A).Connectivity map analysis (CMAP) was performed comparing the skin CD141hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures).",CD141,blood,1
PMC4485845A,"The main reported adverse reactions are transient local reactions, including local swelling and pain with or without fever.69GM-CSF is used as a local adjuvant for IMA-901, and is expressed within a fusion protein in the sipuleucel-T and AdGMCAIX-transduced autologous DC-based vaccines.",T,CSF,1
PMC4485845A,"The main reported adverse reactions are transient local reactions, including local swelling and pain with or without fever.69GM-CSF is used as a local adjuvant for IMA-901, and is expressed within a fusion protein in the sipuleucel-T and AdGMCAIX-transduced autologous DC-based vaccines.",DC,CSF,1
PMC4485845A,"The main reported adverse reactions are transient local reactions, including local swelling and pain with or without fever.69GM-CSF is used as a local adjuvant for IMA-901, and is expressed within a fusion protein in the sipuleucel-T and AdGMCAIX-transduced autologous DC-based vaccines.",IMA-901,CSF,1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",DC,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"Because skin CD141hi and blood CD141+ DCs and CD1c+ DCs from both skin and blood clustered with each other, we generated a pooled skin CD141hi or blood CD141+ DC signature and a pooled CD1c+ DC signature from the two tissues.",CD141,blood,-1
PMC3476529A,"We sorted tissue DC subsets, blood DCs, and monocytes from human samples and generated gene signatures for each subset by removing tissue-specific expression patterns as detailed in the Supplemental Experimental Procedures.",DC,blood,-1
PMC3476529A,CD14+ skin DCs and blood monocyte subsets both show inverse relationships with skin CD141hi DCs (Figure 7B).,CD14,blood,-1
PMC4156178A,"It has been previously shown that the cytoplasmic tail of TACSTD2 is essential for signaling, and phosphorylation of serine 303 regulated by protein kinase C can control the tumor growth stimulatory capacity of TACSTD2 (8,9).TACSTD2 overexpression has been reported in numerous human cancers, such as colorectal, ovarian, pancreatic, cervical, gastric, bile duct cancer and squamous cell carcinoma of the oral cavity, as compared with the corresponding normal tissue, and the expression level has been shown to correlate with the poor patient prognosis (10-16).",TACSTD2,bile,1
PMC4156178A,"It has been previously shown that the cytoplasmic tail of TACSTD2 is essential for signaling, and phosphorylation of serine 303 regulated by protein kinase C can control the tumor growth stimulatory capacity of TACSTD2 (8,9).TACSTD2 overexpression has been reported in numerous human cancers, such as colorectal, ovarian, pancreatic, cervical, gastric, bile duct cancer and squamous cell carcinoma of the oral cavity, as compared with the corresponding normal tissue, and the expression level has been shown to correlate with the poor patient prognosis (10-16).",TACSTD2,bile,1
PMC4650945A,"In favor of such theory, some reports point out the additive value of individual or combined trophic factors (TWEAK, SCF, GM-CSF) as direct modulators of liver repair in mice with acute hepatic injury (Meng et al.,",SCF,CSF,1
PMC4650945A,"In favor of such theory, some reports point out the additive value of individual or combined trophic factors (TWEAK, SCF, GM-CSF) as direct modulators of liver repair in mice with acute hepatic injury (Meng et al.,",GM,CSF,1
PMC4650945A,"In favor of such theory, some reports point out the additive value of individual or combined trophic factors (TWEAK, SCF, GM-CSF) as direct modulators of liver repair in mice with acute hepatic injury (Meng et al.,",TWEAK,CSF,1
PMC4251850A,The remaining cells were cultured in DMEM containing 10% foetal calf serum and supplements.,DMEM,serum,1
PMC4438912A,"The Hep2 human laryngeal carcinoma cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in RPMI-1640 (Gibco Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco Life Technologies) at 37degC in a humidified atmosphere containing 5% CO2.Hep2 cells in the logarithmic growth phase were harvested and sub-cultured into 6-well plates.",FBS,serum,1
PMC4438912A,"The Hep2 human laryngeal carcinoma cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in RPMI-1640 (Gibco Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco Life Technologies) at 37degC in a humidified atmosphere containing 5% CO2.Hep2 cells in the logarithmic growth phase were harvested and sub-cultured into 6-well plates.",Hep2,serum,1
PMC4438912A,"The Hep2 human laryngeal carcinoma cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in RPMI-1640 (Gibco Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco Life Technologies) at 37degC in a humidified atmosphere containing 5% CO2.Hep2 cells in the logarithmic growth phase were harvested and sub-cultured into 6-well plates.",USA,serum,1
PMC4438912A,"The Hep2 human laryngeal carcinoma cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in RPMI-1640 (Gibco Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco Life Technologies) at 37degC in a humidified atmosphere containing 5% CO2.Hep2 cells in the logarithmic growth phase were harvested and sub-cultured into 6-well plates.",RPMI-1640,serum,1
PMC4154955A,"Alternatively, it can be assumed that accumulation of bile juice in the DDC-model may promote cholangiocyte differentiation of LPCs, whereas severe damage on MHs in CDE-injured livers may induce their hepatocytic differentiation.",CDE,bile,1
PMC4154955A,"Alternatively, it can be assumed that accumulation of bile juice in the DDC-model may promote cholangiocyte differentiation of LPCs, whereas severe damage on MHs in CDE-injured livers may induce their hepatocytic differentiation.",DDC,bile,1
PMC4154955A,"In addition, biliary transcription factors are expressed in human hepatocytes in chronic biliary diseases.60 Dipeptidyl peptidase IV (DPPIV)--rats reconstituted with DPPIV+ hepatocytes, in which only donor-derived hepatocytes are DPPIV+, were exposed to DAPM followed by bile duct ligation (BDL).",DAPM,bile,1
PMC4154955A,"In addition, biliary transcription factors are expressed in human hepatocytes in chronic biliary diseases.60 Dipeptidyl peptidase IV (DPPIV)--rats reconstituted with DPPIV+ hepatocytes, in which only donor-derived hepatocytes are DPPIV+, were exposed to DAPM followed by bile duct ligation (BDL).",BDL,bile,1
PMC3718634A,The dotted line represents the cut-off or serum value of the mean plus 2 SD of controls for each protein.,SD,serum,-1
PMC3718634A,"Closed circles represent CRC patient sera, open circles represent control sera, and horizontal bars represent mean serum values.",CRC,sera,1
PMC3718634A,"Closed circles represent CRC patient sera, open circles represent control sera, and horizontal bars represent mean serum values.",CRC,sera,1
PMC3718634A,"Closed circles represent CRC patient sera, open circles represent control sera, and horizontal bars represent mean serum values.",CRC,serum,1
PMC4188889A,"Using eight serum features, Ca were differentiated from H (SN = 88%, SP = 93%), Ca from CP (SN = 88%, SP = 30%) and Ca from both H and CP combined (SN = 88%, SP = 66%).",CP,serum,1
PMC4188889A,"Using eight serum features, Ca were differentiated from H (SN = 88%, SP = 93%), Ca from CP (SN = 88%, SP = 30%) and Ca from both H and CP combined (SN = 88%, SP = 66%).",SN,serum,1
PMC4188889A,"Using eight serum features, Ca were differentiated from H (SN = 88%, SP = 93%), Ca from CP (SN = 88%, SP = 30%) and Ca from both H and CP combined (SN = 88%, SP = 66%).",SN,serum,1
PMC4188889A,"Using eight serum features, Ca were differentiated from H (SN = 88%, SP = 93%), Ca from CP (SN = 88%, SP = 30%) and Ca from both H and CP combined (SN = 88%, SP = 66%).",SN,serum,1
PMC4188889A,"Using eight serum features, Ca were differentiated from H (SN = 88%, SP = 93%), Ca from CP (SN = 88%, SP = 30%) and Ca from both H and CP combined (SN = 88%, SP = 66%).",CP,serum,1
PMC4483763A,"For example, mutations in NOTCH2 or JAG1, which encodes a Notch ligand, are associated with the paucity of bile ducts in Alagille syndrome (Li et al., 1997; McDaniell et al., 2006).",JAG1,bile,1
PMC4483763A,"For example, mutations in NOTCH2 or JAG1, which encodes a Notch ligand, are associated with the paucity of bile ducts in Alagille syndrome (Li et al., 1997; McDaniell et al., 2006).",NOTCH2,bile,1
PMC5042010A,This prospective clinical trial was funded with a NIH/NCI contract with the express purpose of expanding the definition of evaluable tumor cells in blood.,NCI,blood,-1
PMC5042010A,This prospective clinical trial was funded with a NIH/NCI contract with the express purpose of expanding the definition of evaluable tumor cells in blood.,NIH,blood,-1
PMC5494437A,"Cre recombinase (Cre-lox) mapping demonstrated that these NE cells are the source of neural stem cells (NSCs) since they can form both neurons and radial glial cells (RF) in the embryo[31].In the developing brain, RG cells form astrocytes but also form neurons.",NE,astrocytes,1
PMC5494437A,"Cre recombinase (Cre-lox) mapping demonstrated that these NE cells are the source of neural stem cells (NSCs) since they can form both neurons and radial glial cells (RF) in the embryo[31].In the developing brain, RG cells form astrocytes but also form neurons.",RG,astrocytes,1
PMC5538449A,"LCs efficiently stimulate regulatory T cells and are involved in mediating tolerance to epithelial and environmental antigens.6 Consistently, even in the absence of microbial or danger signals, LCs continuously migrate to T-cell areas of skin-draining lymph nodes.1LCs lack expression of monocyte/macrophage lineage-affiliated markers, including CD11b, CD36, lysozyme, CD209/DC-specific intercellular adhesion molecule-grabbing nonintegrin, and c-fms/monocyte colony-stimulating factor,7 as well as the early myeloid lineage marker myeloperoxidase.8",DC,lymph,1
PMC5538449A,"LCs efficiently stimulate regulatory T cells and are involved in mediating tolerance to epithelial and environmental antigens.6 Consistently, even in the absence of microbial or danger signals, LCs continuously migrate to T-cell areas of skin-draining lymph nodes.1LCs lack expression of monocyte/macrophage lineage-affiliated markers, including CD11b, CD36, lysozyme, CD209/DC-specific intercellular adhesion molecule-grabbing nonintegrin, and c-fms/monocyte colony-stimulating factor,7 as well as the early myeloid lineage marker myeloperoxidase.8",CD11b,lymph,1
PMC5538449A,"LCs efficiently stimulate regulatory T cells and are involved in mediating tolerance to epithelial and environmental antigens.6 Consistently, even in the absence of microbial or danger signals, LCs continuously migrate to T-cell areas of skin-draining lymph nodes.1LCs lack expression of monocyte/macrophage lineage-affiliated markers, including CD11b, CD36, lysozyme, CD209/DC-specific intercellular adhesion molecule-grabbing nonintegrin, and c-fms/monocyte colony-stimulating factor,7 as well as the early myeloid lineage marker myeloperoxidase.8",T,lymph,1
PMC5538449A,"LCs efficiently stimulate regulatory T cells and are involved in mediating tolerance to epithelial and environmental antigens.6 Consistently, even in the absence of microbial or danger signals, LCs continuously migrate to T-cell areas of skin-draining lymph nodes.1LCs lack expression of monocyte/macrophage lineage-affiliated markers, including CD11b, CD36, lysozyme, CD209/DC-specific intercellular adhesion molecule-grabbing nonintegrin, and c-fms/monocyte colony-stimulating factor,7 as well as the early myeloid lineage marker myeloperoxidase.8",T,lymph,1
PMC5538449A,"LCs efficiently stimulate regulatory T cells and are involved in mediating tolerance to epithelial and environmental antigens.6 Consistently, even in the absence of microbial or danger signals, LCs continuously migrate to T-cell areas of skin-draining lymph nodes.1LCs lack expression of monocyte/macrophage lineage-affiliated markers, including CD11b, CD36, lysozyme, CD209/DC-specific intercellular adhesion molecule-grabbing nonintegrin, and c-fms/monocyte colony-stimulating factor,7 as well as the early myeloid lineage marker myeloperoxidase.8",CD36,lymph,1
PMC5029744A,"All cell lines were cultured in DMEM-H (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), penicillin (100 U/mL) and streptomycin (100 lg/mL).",DMEM,serum,1
PMC5029744A,"All cell lines were cultured in DMEM-H (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), penicillin (100 U/mL) and streptomycin (100 lg/mL).",FBS,serum,1
PMC5029744A,"All cell lines were cultured in DMEM-H (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), penicillin (100 U/mL) and streptomycin (100 lg/mL).",USA,serum,1
PMC3551651A,"Univariate analysis showed that not only aB-crystallin expression, but also the pTNM stage, lymph node metastasis and tumor differentiation were correlated with life span of LSCC patients.",pTNM,lymph,1
PMC3551651A,"Univariate analysis showed that not only aB-crystallin expression, but also the pTNM stage, lymph node metastasis and tumor differentiation were correlated with life span of LSCC patients.",LSCC,lymph,1
PMC4202120B,"""Liquid"" biopsies or predictive gene signatures based on DNA and mRNA analyses of whole blood are being developed.",DNA,blood,-1
PMC4202120B,"""Liquid"" biopsies or predictive gene signatures based on DNA and mRNA analyses of whole blood are being developed.",mRNA,blood,-1
PMC3039945A,"Tumour budding at the invasive front promotes progression and dissemination of CRC cells into the vasculature and lymph nodes, while infiltrating immune cells, particularly cytotoxic T-cells, mount an immune response.",T,lymph,1
PMC3039945A,"Tumour budding at the invasive front promotes progression and dissemination of CRC cells into the vasculature and lymph nodes, while infiltrating immune cells, particularly cytotoxic T-cells, mount an immune response.",CRC,lymph,1
PMC2728569A,Genomic DNA was obtained from peripheral blood leukocytes according to standard procedures.,DNA,blood,-1
PMC5042010A,The blood samples had a minimum volume of 16mL minimum from two K2-EDTA tubes with minimal signs of hemolysis.,K2-EDTA,blood,-1
PMC3410424A,"Consistent with this prediction, overexpression of parathyroid hormone receptor, a PDZ1 ligand, reduces EBP50 turnover at the basal plasma membrane in rat osteosarcoma cells (Ardura et al., 2011).",PDZ1,plasma,1
PMC3410424A,"Consistent with this prediction, overexpression of parathyroid hormone receptor, a PDZ1 ligand, reduces EBP50 turnover at the basal plasma membrane in rat osteosarcoma cells (Ardura et al., 2011).",EBP50,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",ESRP2,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",NEC,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",NEC,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",ESRP1,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",RNA,plasma,1
PMC4062414A,"Also related to this process is the highly NEC-correlated CNN1A/ENaC (r = 0.83), which is involved in regulation of ion channels in the plasma membrane [90] (Figure 15).An efficient mechanism of switching between epithelial and mesenchymal phenotypes may be by way of alternative RNA splicing induced by the highly NEC-correlated genes ESRP1 and ESRP2 (r = 0.97 and 0.85, respectively).",CNN1A,plasma,1
PMC3906064A,DNA recovered from incremental numbers of H1650 tumor cells spiked into whole blood and processed on the LiquidBiopsy platform are indicated.,H1650,blood,-1
PMC3906064A,DNA recovered from incremental numbers of H1650 tumor cells spiked into whole blood and processed on the LiquidBiopsy platform are indicated.,DNA,blood,-1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",HER-2-VLP,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",HER-2-VLP,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-protein transferred-VLPs induces HER-2-specific antibody responses(A) Protein transferred GPI-HER-2-VLP vaccination induces HER-2-specific serum IgG. Mice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected from vaccinated mice on day 21.",GPI,serum,1
PMC4183706A,"The resulting protocol involves low-percentage Matrigel floating culture in the presence of epidermal growth factor, heat-inactivated charcoal-stripped fetal bovine serum (FBS), which lacks androgens, and supplementation with dihydrotestosterone (DHT) (see Methods).",DHT,serum,1
PMC4183706A,"The resulting protocol involves low-percentage Matrigel floating culture in the presence of epidermal growth factor, heat-inactivated charcoal-stripped fetal bovine serum (FBS), which lacks androgens, and supplementation with dihydrotestosterone (DHT) (see Methods).",FBS,serum,1
PMC2441949A,Real-time RT-PCR was performed on patients who did (n=18; right side of each matched data set; filled circles) and who did not have (n=18; left side of each matched data set; open circles) metastatic lymph nodes from CRC as described in Materials and Methods using primer pairs for the indicated genes.,PCR,lymph,1
PMC2441949A,Real-time RT-PCR was performed on patients who did (n=18; right side of each matched data set; filled circles) and who did not have (n=18; left side of each matched data set; open circles) metastatic lymph nodes from CRC as described in Materials and Methods using primer pairs for the indicated genes.,CRC,lymph,1
PMC2441949A,Real-time RT-PCR analysis of metastatic and benign lymph nodes from colon cancer patients.,PCR,lymph,1
PMC2441949A,Real-time PCR analyses of seven benign lymph nodes (left side of each matched data set; open triangles) and seven metastatic lymph nodes (right side of each matched data set; closed diamonds) were performed as described in Materials and Methods using primer pairs for the indicated genes.,PCR,lymph,1
PMC2441949A,Real-time PCR analyses of seven benign lymph nodes (left side of each matched data set; open triangles) and seven metastatic lymph nodes (right side of each matched data set; closed diamonds) were performed as described in Materials and Methods using primer pairs for the indicated genes.,PCR,lymph,1
PMC4889960A,"Jaesook et al. suggested that PTT may increase blood flow in tumors and reduce the hypoxic region, which sensitizes the tumor to radiotherapy [47], thus indicating that PTT is an excellent radiosensitizer.",PTT,blood,-1
PMC4889960A,"Jaesook et al. suggested that PTT may increase blood flow in tumors and reduce the hypoxic region, which sensitizes the tumor to radiotherapy [47], thus indicating that PTT is an excellent radiosensitizer.",PTT,blood,-1
PMC2441949A,"Note: The mean B2M Ct value of the metastatic lymph nodes was slightly lower (i.e. B2M gene expression was slightly higher) but not significantly different from that of benign tissue (17.8+-2.1 vs 20.2+-2.1, respectively).View larger versionFigure 2.",B2,lymph,1
PMC2441949A,"Note: The mean B2M Ct value of the metastatic lymph nodes was slightly lower (i.e. B2M gene expression was slightly higher) but not significantly different from that of benign tissue (17.8+-2.1 vs 20.2+-2.1, respectively).View larger versionFigure 2.",B2,lymph,1
PMC5467782A,"The human lung cancer cell line A549 was obtained from the American Type Culture Collection (ATCC) and was cultured in DMEM (Hyclone, USA) with 10% fetal bovine serum at 37degC, 5% CO2.",DMEM,serum,1
PMC5467782A,"The human lung cancer cell line A549 was obtained from the American Type Culture Collection (ATCC) and was cultured in DMEM (Hyclone, USA) with 10% fetal bovine serum at 37degC, 5% CO2.",A549,serum,1
PMC5467782A,"The human lung cancer cell line A549 was obtained from the American Type Culture Collection (ATCC) and was cultured in DMEM (Hyclone, USA) with 10% fetal bovine serum at 37degC, 5% CO2.",CO2,serum,1
PMC5467782A,"The human lung cancer cell line A549 was obtained from the American Type Culture Collection (ATCC) and was cultured in DMEM (Hyclone, USA) with 10% fetal bovine serum at 37degC, 5% CO2.",ATCC,serum,1
PMC5467782A,"The human lung cancer cell line A549 was obtained from the American Type Culture Collection (ATCC) and was cultured in DMEM (Hyclone, USA) with 10% fetal bovine serum at 37degC, 5% CO2.",USA,serum,1
PMC2441949A,DCt values were obtained by subtracting the mean Ct value of B2M (which is highly expressed in normal lymph node tissue) from the mean Ct value for each respective gene.,B2,lymph,1
PMC3551651A,"C: Overall survival rate in patients with lymph node metastasis (red line, LN metastasis = 1) was significantly lower than that in patients without lymph node metastasis (green line, LN metastasis = 0).Several state-of-the-art treatment strategies have been developed for LSCC, including molecular targeted therapy[18], gene therapy[19] and immunotherapy[20].",LSCC,lymph,-1
PMC3551651A,"C: Overall survival rate in patients with lymph node metastasis (red line, LN metastasis = 1) was significantly lower than that in patients without lymph node metastasis (green line, LN metastasis = 0).Several state-of-the-art treatment strategies have been developed for LSCC, including molecular targeted therapy[18], gene therapy[19] and immunotherapy[20].",LSCC,lymph,-1
PMC4410184A,"Histological analyses have shown them in the vicinity of bile ducts6,31; thus, it has been suggested that LPC derive from the biliary compartment and participate in the generation of new cholangiocytes and hepatocytes.",LPC,bile,1
PMC4631976A,"HIF-1 activation has been implicated in maintaining epithelial barrier protection in models of intestinal ischemia/reperfusion, experimental colitis with inflammatory hypoxia, and in mouse ileal loops after exposure to bacterial toxins[41,42,46-48].Cyclooxygenase (COX)-2, a catalyzing enzyme for PGE2 production, is involved in increased vascular permeability and blood flow during inflammation and wound healing.",HIF-1,blood,-1
PMC4631976A,"HIF-1 activation has been implicated in maintaining epithelial barrier protection in models of intestinal ischemia/reperfusion, experimental colitis with inflammatory hypoxia, and in mouse ileal loops after exposure to bacterial toxins[41,42,46-48].Cyclooxygenase (COX)-2, a catalyzing enzyme for PGE2 production, is involved in increased vascular permeability and blood flow during inflammation and wound healing.",PGE2,blood,-1
PMC5437009A,"The results showed that increased CKAP2 expression was significantly correlated with age, FIGO stage, lymph node metastasis, recurrence and tumor size, but not other clinical characteristics (Table 1).",FIGO,lymph,1
PMC5437009A,"The results showed that increased CKAP2 expression was significantly correlated with age, FIGO stage, lymph node metastasis, recurrence and tumor size, but not other clinical characteristics (Table 1).",CKAP2,lymph,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",ELISA,serum,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",Trop-2,serum,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",NCI,serum,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",RECIST,serum,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",CTCAE,serum,1
PMC4558321A,"Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.",Trop-2,serum,1
PMC4361250A,As castration-resistant prostate cancer (CRPC) continues to be dependent on AR signaling which is active despite low serum levels of androgen (Chen et al.,AR,serum,1
PMC4361250A,As castration-resistant prostate cancer (CRPC) continues to be dependent on AR signaling which is active despite low serum levels of androgen (Chen et al.,CRPC,serum,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S1,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",Trop-2,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S1,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S7,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S4,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S1,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",CI,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S5,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",CCI,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",Trop-2,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",S6,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",Trop-2,lymph,1
PMC4019539A,"The absolute frequencies of the first adverse events during follow-up were analyzed according to lymph node status (Table S4 in File S1), expression of immature intracellular Trop-2 (Table S5 in File S1), mature intracellular Trop-2 (Table S6 in File S1), and membrane Trop-2 (Table S7 in File S1).The unadjusted estimates of death CI and of relapse CCI according to different levels of membrane and intracellular Trop-2 are shown in Figures 4 and 5.",Trop-2,lymph,1
PMC5480073A,"Likewise, in a study by Samaras et al[16], IL-6 secretion levels in peripheral blood mononuclear cells of glioma patients were found to be significantly higher compared to controls indicating a role of inflammation in tumor proliferation.",IL-6,blood,-1
PMC2441949A,The gene with the second highest prognostic accuracy was GPX2 (Table 4); low expression of this gene was also associated with lymph node metastases.,GPX2,lymph,1
PMC5447959A,"Yu et al. examined microRNAs from 50 SCLC patients and 30 healthy controls, and suggested that miR-92a-2 level in plasma could be a potential and non-invasive method for the diagnosis of SCLC [46].",SCLC,plasma,1
PMC5447959A,"Yu et al. examined microRNAs from 50 SCLC patients and 30 healthy controls, and suggested that miR-92a-2 level in plasma could be a potential and non-invasive method for the diagnosis of SCLC [46].",SCLC,plasma,1
PMC3561800A,"Preliminary experiments confirmed that the ELF1 mAb reacts selectively with recombinant human b4 in transfected LNCaP cells (Figure 1C) and that it specifically stains basal cells in normal prostatic glands and endothelial cells in blood vessels (Figure 1D, left, microvessel indicated by asterisk), as anticipated from the known pattern of expression of b4 in the normal human prostate (37).",1D,blood,1
PMC3561800A,"Preliminary experiments confirmed that the ELF1 mAb reacts selectively with recombinant human b4 in transfected LNCaP cells (Figure 1C) and that it specifically stains basal cells in normal prostatic glands and endothelial cells in blood vessels (Figure 1D, left, microvessel indicated by asterisk), as anticipated from the known pattern of expression of b4 in the normal human prostate (37).",ELF1,blood,1
PMC4253434A,Cells grown in serum-free media for two hours show decreased ErbB3 activity by immunoblot analysis (lanes 1 vs. 2 and 5 vs. 6) that is increased after two hour exposure to conditioned media (C.M.) from Trop2 knockdown cells (shown in lanes 4 and 8) but not by conditioned media from shLacZ control knockdown cells (shown in lanes 3 and 7).,Trop2,serum,1
PMC4253434A,Cells grown in serum-free media for two hours show decreased ErbB3 activity by immunoblot analysis (lanes 1 vs. 2 and 5 vs. 6) that is increased after two hour exposure to conditioned media (C.M.) from Trop2 knockdown cells (shown in lanes 4 and 8) but not by conditioned media from shLacZ control knockdown cells (shown in lanes 3 and 7).,ErbB3,serum,1
PMC4673178A,SN-38G's secretion into the bile and subsequent deconjugation by beta-glucuronidase produced by the intestinal flora is strongly implicated in the enterohepatic recirculation of SN-38 and the delayed severe diarrhea observed with irinotecan [52].,SN-38,bile,1
PMC4673178A,SN-38G's secretion into the bile and subsequent deconjugation by beta-glucuronidase produced by the intestinal flora is strongly implicated in the enterohepatic recirculation of SN-38 and the delayed severe diarrhea observed with irinotecan [52].,SN-38,bile,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",FIGO,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",FIGO,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",FIGO,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",DFS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",DFS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",DFS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",OS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",OS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",OS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",EEC,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",EEC,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",EEC,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",PFS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",PFS,lymph,1
PMC3534488A,"The sites of recurrence were either local (pelvic lymph nodes, vaginal cupola), or distant (para-aortic lymph nodes, lung, brain, bone).As expected, known EEC clinical prognostic factors, such as FIGO stage and lymph node involvement, showed a statistically significant association with OS, PFS and DFS in univariate analysis (all p0.01, Table 2).",PFS,lymph,1
PMC3110957A,"After another wash, cells were resuspended in DMEM + 5% rat serum (Serotec) and held for 10 min on ice to block the secondary antibody.",DMEM,serum,-1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",FBS,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",MIC1,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",APC,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",DPBS,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",FBS,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",MIC1,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",DMEM,serum,1
PMC3110957A,"Dissociated cells were resuspended at 1 x 106 cells per milliliter in DMEM + 2% FBS prior to the addition of MIC1-1C3 hybridoma supernatant at a 1:20 dilution, or a 1:200 dilution of purified MIC1-1C3 antibody (Novus Biologicals) and incubation for 30 min at 4degC. After a wash with cold DPBS, cells were resuspended in DMEM + 2% FBS containing a 1:200 dilution of APC-conjugated goat anti-rat secondary antibody adsorbed against mouse serum proteins (Jackson Immunoresearch).",DMEM,serum,1
PMC3110957A,Primary labeling used hybridoma supernatants diluted 1:20 in DPBS for 30 min and secondary labeling with 1:200 dilutions of DyLight488- or Cy3-conjugated anti-rat Ig preadsorbed against mouse serum proteins (Jackson ImmunoResearch) for 20 min.,DPBS,serum,1
PMC5000705A,"In colorectal cancer, Plastin3 (PLS3) was identified as a marker for EMT-CTCs, helping to detect CTCs as this marker is not expressed in healthy blood cells.",Plastin3,blood,-1
PMC5000705A,"In colorectal cancer, Plastin3 (PLS3) was identified as a marker for EMT-CTCs, helping to detect CTCs as this marker is not expressed in healthy blood cells.",PLS3,blood,-1
PMC5000705A,"In colorectal cancer, Plastin3 (PLS3) was identified as a marker for EMT-CTCs, helping to detect CTCs as this marker is not expressed in healthy blood cells.",EMT,blood,-1
PMC3250983A,"The mice were weighed weekly for 96 days, and blood samples were taken from the inner border of the eye at 0, 14, 28, 40, 55, and 90 days after 131I-labeled B-B4 mAb injection.",B4,blood,-1
PMC4606116A,"Briefly, plasma samples were prepared by collecting blood in EDTA tubes (10 mL from each subject) and left at room temperature (for a maximum of 30 min) until centrifugation.",EDTA,blood,1
PMC4606116A,"Briefly, plasma samples were prepared by collecting blood in EDTA tubes (10 mL from each subject) and left at room temperature (for a maximum of 30 min) until centrifugation.",EDTA,plasma,1
PMC4698345A,"Csf3r-/- mice have systemically low PMN numbers (Liu et al., 1996), and 4-week-old PRPL-Csf3r-/- mice accordingly exhibited a profound (80%) reduction in uterine and blood PMNs (Figures 2A and S2A) when compared to PRPL mice.",PRPL,blood,-1
PMC4698345A,"Csf3r-/- mice have systemically low PMN numbers (Liu et al., 1996), and 4-week-old PRPL-Csf3r-/- mice accordingly exhibited a profound (80%) reduction in uterine and blood PMNs (Figures 2A and S2A) when compared to PRPL mice.",PMN,blood,-1
PMC4698345A,"Csf3r-/- mice have systemically low PMN numbers (Liu et al., 1996), and 4-week-old PRPL-Csf3r-/- mice accordingly exhibited a profound (80%) reduction in uterine and blood PMNs (Figures 2A and S2A) when compared to PRPL mice.",S2A,blood,-1
PMC4698345A,"Csf3r-/- mice have systemically low PMN numbers (Liu et al., 1996), and 4-week-old PRPL-Csf3r-/- mice accordingly exhibited a profound (80%) reduction in uterine and blood PMNs (Figures 2A and S2A) when compared to PRPL mice.",PRPL,blood,-1
PMC3929731A,"The lower limits of quantitation for BPA and BPA-G were 0.5 and 0.2 ng/mL, respectively, and the lower limits of detection (LOD) for BPA and BPA-G in mouse serum were 0.2 and 0.1 ng/mL, respectively.",BPA,serum,1
PMC3929731A,"The lower limits of quantitation for BPA and BPA-G were 0.5 and 0.2 ng/mL, respectively, and the lower limits of detection (LOD) for BPA and BPA-G in mouse serum were 0.2 and 0.1 ng/mL, respectively.",BPA,serum,1
PMC3929731A,"The lower limits of quantitation for BPA and BPA-G were 0.5 and 0.2 ng/mL, respectively, and the lower limits of detection (LOD) for BPA and BPA-G in mouse serum were 0.2 and 0.1 ng/mL, respectively.",LOD,serum,1
PMC3929731A,"The lower limits of quantitation for BPA and BPA-G were 0.5 and 0.2 ng/mL, respectively, and the lower limits of detection (LOD) for BPA and BPA-G in mouse serum were 0.2 and 0.1 ng/mL, respectively.",BPA,serum,1
PMC3929731A,"The lower limits of quantitation for BPA and BPA-G were 0.5 and 0.2 ng/mL, respectively, and the lower limits of detection (LOD) for BPA and BPA-G in mouse serum were 0.2 and 0.1 ng/mL, respectively.",BPA,serum,1
PMC5109830A,"A 24-wells plate (Greiner Bio-one, Germany) was prepared with 0.02% sodium azide and serum/probe in a ratio of 1:1 and PBS as control and incubated at 37 degC under 5% CO2.",PBS,serum,1
PMC5109830A,"A 24-wells plate (Greiner Bio-one, Germany) was prepared with 0.02% sodium azide and serum/probe in a ratio of 1:1 and PBS as control and incubated at 37 degC under 5% CO2.",CO2,serum,1
PMC4687932A,"Blood samples from 25 breast cancer patients (Table 1) were analyzed by CellSearch for EpCAMpos CTCs: 11 out of 29 blood samples from 25 patients were negative for CTCs (8x) or CTC count could not be determined (3x); three samples had 1 CTC and 15 samples harbored at least 3 CTCs (mean: 20, median: 3; range 0-206 CTCs) (Fig 5A; Table 1).",CTC,Blood,1
PMC4687932A,"Blood samples from 25 breast cancer patients (Table 1) were analyzed by CellSearch for EpCAMpos CTCs: 11 out of 29 blood samples from 25 patients were negative for CTCs (8x) or CTC count could not be determined (3x); three samples had 1 CTC and 15 samples harbored at least 3 CTCs (mean: 20, median: 3; range 0-206 CTCs) (Fig 5A; Table 1).",CTC,blood,1
PMC4687932A,"Blood samples from 25 breast cancer patients (Table 1) were analyzed by CellSearch for EpCAMpos CTCs: 11 out of 29 blood samples from 25 patients were negative for CTCs (8x) or CTC count could not be determined (3x); three samples had 1 CTC and 15 samples harbored at least 3 CTCs (mean: 20, median: 3; range 0-206 CTCs) (Fig 5A; Table 1).",CTC,Blood,1
PMC4687932A,"Blood samples from 25 breast cancer patients (Table 1) were analyzed by CellSearch for EpCAMpos CTCs: 11 out of 29 blood samples from 25 patients were negative for CTCs (8x) or CTC count could not be determined (3x); three samples had 1 CTC and 15 samples harbored at least 3 CTCs (mean: 20, median: 3; range 0-206 CTCs) (Fig 5A; Table 1).",CTC,blood,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRLR,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRLR,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRLR,hair,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRLR,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRLR,hair,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,-1
PMC5414739A,"In humans, hair loss has been documented in hyperprolactinemic women, although discriminating the actual role of PRLR signaling from that of other skin/hair regulator(s) (eg, estrogens) remains debated (146).Recently, a mechanism supporting PRL actions on mouse hair growth regulation was elucidated by showing that hair follicle stem cells responded to PRL stimulation with increased quiescence, resulting in a delay in their activation and thus stalling hair growth (147).",PRL,hair,1
PMC4708083A,"The hypothesis that HPCs can originate from bone marrow is further supported by the fact that HPCs and hematopoietic stem cells express the same markers, such as Thy1 (Petersen, Goff, Greenberger,  Michalopoulos, 1998), CD34 (Omori et al., 1997), and Kit (Fujio, Evarts, Hu, Marsden,  Thorgeirsson, 1994).",CD34,bone marrow,1
PMC4708083A,"The hypothesis that HPCs can originate from bone marrow is further supported by the fact that HPCs and hematopoietic stem cells express the same markers, such as Thy1 (Petersen, Goff, Greenberger,  Michalopoulos, 1998), CD34 (Omori et al., 1997), and Kit (Fujio, Evarts, Hu, Marsden,  Thorgeirsson, 1994).",Thy1,bone marrow,1
PMC3566310A,"(blood cell, excluding T-cell) fractions were isolated from the livers of DDC-treated mice.",DDC,blood,-1
PMC3566310A,"(blood cell, excluding T-cell) fractions were isolated from the livers of DDC-treated mice.",T,blood,-1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",S3,serum,1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",DMEM,serum,1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",FBS,serum,1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",SILAC,serum,1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",A431,serum,1
PMC3959865A,"The MTS assay for cell viability at 48 hours (Figure S3) was conducted as directed by the manufacturer (Promega, Madison, WI).The A431 human epithelial carcinoma cells were grown in DMEM media (Invitrogen) containing 1% of dialyzed fetal bovine serum (FBS, Invitrogen) with 13C - lysine (Invitrogen) substituted for lysine for seven passages (1:2) according the previously published SILAC protocol (23).",MTS,serum,1
PMC3959865A,To confirm this we preformed cell viability assays on A431 cells and did not observe differences in cell growth rate or gefitinib IC50 upon dosing between 1-10% serum.,A431,serum,1
PMC3959865A,To confirm this we preformed cell viability assays on A431 cells and did not observe differences in cell growth rate or gefitinib IC50 upon dosing between 1-10% serum.,IC50,serum,1
PMC4621003A,(B) Minimum or no serum IgG was detected against D2F2 cells showing HER-2-specific antibody reactivity against D2F2/E2.,D2F2,serum,-1
PMC3266428A,Fat mass at 15 years of age was positively correlated with DNA methylation in cord blood (Table 3).,DNA,blood,-1
PMC3973208A,"HaCaT cells (CLS, Eppelheim, Germany) and SiHa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen), supplemented with L-glutamine, 10% fetal bovine serum and penicillin/streptomycin.Tacstd2",DMEM,serum,1
PMC3973208A,"HaCaT cells (CLS, Eppelheim, Germany) and SiHa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen), supplemented with L-glutamine, 10% fetal bovine serum and penicillin/streptomycin.Tacstd2",CLS,serum,1
PMC3973208A,"HaCaT cells (CLS, Eppelheim, Germany) and SiHa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen), supplemented with L-glutamine, 10% fetal bovine serum and penicillin/streptomycin.Tacstd2",USA,serum,1
PMC3973208A,"HaCaT cells (CLS, Eppelheim, Germany) and SiHa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen), supplemented with L-glutamine, 10% fetal bovine serum and penicillin/streptomycin.Tacstd2",ATCC,serum,1
PMC3973208A,"HaCaT cells (CLS, Eppelheim, Germany) and SiHa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen), supplemented with L-glutamine, 10% fetal bovine serum and penicillin/streptomycin.Tacstd2",Tacstd2,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",pAKT,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",pAKT,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",AR,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",AR,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K14,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K14,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",MMS-162P,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",MMS-162P,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",Troma-1,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",Troma-1,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",GFP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",GFP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",GFP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",GFP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",SC-816,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",SC-816,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",LL002,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",LL002,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K5,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K5,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",JL8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",JL8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",HRP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",HRP,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",Ki67,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",Ki67,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",P63,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",P63,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",K8,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",NCL,serum,1
PMC3918789A,"Cooled slides were incubated with 5% normal goat serum (Vector Labs) and with primary antibodies diluted in the 5% normal goat serum overnight at 4 degC. Primary antibodies used were rabbit anti-K5 (PRB-160P; Covance), mouse anti-K8 (MMS-162P; Covance), rat anti-K8 (Troma-1; Developmental Studies Hybridoma Bank), mouse anti-P63 (4A4; Santa Cruz Biotechnology), rabbit anti-AR (SC-816; Santa Cruz Biotechnology), mouse anti-smooth muscle actin (Sigma-Aldrich), rabbit anti-vimentin (5741; Cell Signaling Technology), rabbit anti-Ki67 (NCL-Ki67-P; Novocastra), mouse anti-K14 (LL002; Biogenex), mouse anti-GFP (JL8; Clontech), chicken anti-GFP (ab13970; Abcam), rabbit anti-synaptophysin (18-0130; Invitrogen), rabbit anti-cleaved caspase 3 (9661; Cell Signaling Technology), and rabbit anti-pAKT (3787; Cell Signaling Technology) Biotinylated secondary antibodies and streptavidin-conjugated HRP (Vector Laboratories) were used for chromatic visualization.",NCL,serum,1
PMC4596896A,"Solid tumors have leaky blood vessels and chaotic blood flow, which can result in heterogeneous distribution of the antibody within the tumor thus rendering portions of the tumor inaccessible to the antibody or ADC (36-38).",ADC,blood,-1
PMC4596896A,"Solid tumors have leaky blood vessels and chaotic blood flow, which can result in heterogeneous distribution of the antibody within the tumor thus rendering portions of the tumor inaccessible to the antibody or ADC (36-38).",ADC,blood,-1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",INTREPID,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",AES,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",COOH,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",TEM,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",IRIS,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",ICP,plasma,1
PMC4437992A,"The diameter and morphology of the particles were viewed by transmission electron microscopy (TEM) (JEM-100CX, Japan), and the concentration was tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) (IRIS INTREPID II XSP).Bifunctional SH-PEG-COOH was used as a linker to conjugate antibodies to HGNs, which is in a lyophilized form stored in an argon environment.",PEG,plasma,1
PMC3269833A,"D), E), F) Flow cytometry analysis of TACSTD2 expression in MCF10A, MCF7 and primary rat astrocytes (Black lines).",TACSTD2,astrocytes,1
PMC3269833A,"D), E), F) Flow cytometry analysis of TACSTD2 expression in MCF10A, MCF7 and primary rat astrocytes (Black lines).",MCF7,astrocytes,1
PMC3128671A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ, USA).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 6 USPC cell lines.",PLUS,blood,-1
PMC3128671A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ, USA).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 6 USPC cell lines.",PBL,blood,-1
PMC3128671A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ, USA).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 6 USPC cell lines.",USPC,blood,-1
PMC5494437A,"There are many molecular similarities between the fetal and adult HSC stem cells that were analyzed by DNA analysis using bioinformatics and hybridization techniques that outlines the complete molecular phenotype of the HSC[16].Many primitive HSCs are quiescent or reserved, used for homeostasis or in response to injury while others are active cycling stem cells that replenish the rapid turnover of blood cells.",HSC,blood,-1
PMC5494437A,"There are many molecular similarities between the fetal and adult HSC stem cells that were analyzed by DNA analysis using bioinformatics and hybridization techniques that outlines the complete molecular phenotype of the HSC[16].Many primitive HSCs are quiescent or reserved, used for homeostasis or in response to injury while others are active cycling stem cells that replenish the rapid turnover of blood cells.",DNA,blood,-1
PMC2722670A,"Protein identification was performed using Mascot search (Matrix Science, http://www.matrixscience.com/).A total of approximately 2 x 107 pfu from the T.Tn cDNA library were screened using serum samples derived from 21 patients with esophageal SCC.",cDNA,serum,1
PMC2722670A,"Protein identification was performed using Mascot search (Matrix Science, http://www.matrixscience.com/).A total of approximately 2 x 107 pfu from the T.Tn cDNA library were screened using serum samples derived from 21 patients with esophageal SCC.",SCC,serum,1
PMC2605882A,"A related observation is that serum CA125 levels are elevated in 80% of patients with advanced stage epithelial ovarian carcinoma but are increased in only 60% of patients with early stage disease [27,28].",CA125,serum,1
PMC2722670A,The final concentration of the purified serum was 1:1.83.Extracts of MKRN1-transfected ras-NIH3T3 cells were immunoprecipitated with anti-ubiquitin antibody (Santa Cruz) followed by SDS-polyacrylamide gel electrophoresis as described previously [30].,NIH3T3,serum,1
PMC2722670A,The final concentration of the purified serum was 1:1.83.Extracts of MKRN1-transfected ras-NIH3T3 cells were immunoprecipitated with anti-ubiquitin antibody (Santa Cruz) followed by SDS-polyacrylamide gel electrophoresis as described previously [30].,SDS,serum,1
PMC3039945A,"As an alternative to the use of viable cells for analysis with the DotScan CRC antibody microarray, tumour cell-derived membrane fragments, microvesicles or microparticles could be used, as demonstrated with plasma-derived microparticles from patients with cardiovascular disease [268].",CRC,plasma,1
PMC5513028A,"Cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM, Life Technology, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY) in a humidified cell culture incubator at 37 degC and 5% CO2 .",DMEM,serum,1
PMC5513028A,"Cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM, Life Technology, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY) in a humidified cell culture incubator at 37 degC and 5% CO2 .",CO2,serum,1
PMC5513028A,"Cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM, Life Technology, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY) in a humidified cell culture incubator at 37 degC and 5% CO2 .",FBS,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",FBS,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",GIBCO,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",CO2,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",GIBCO,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",CNE-1,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",USA,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",RPMI,serum,1
PMC4637632A,"CNE-1, nasopharyngeal carcinoma cells were purchased from Shanghai Aiyan Biotechnology Co., Ltd. and maintained at 37degC, 5% CO2 in RPMI 1640 complete medium (GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA).",USA,serum,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",DTPA,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",SD,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",DTPA,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",INCA,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",INCA,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",SD,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",INCA,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",X,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",SD,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",X,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",SD,blood,1
PMC4074497A,"Despite the high uptake in the spleen of non-predosed mice, 111In-DTPA-INCA-X accumulated well in tumors, with a tumor-to-blood ratio around 30 by 96 hours post-injection (Table 3).Interestingly, mice pre-administered with cold DTPA-INCA-X displayed significantly higher accumulation of activity in the tumors (P = 0.03) increasing from 8 %IA/g (SD 3) to 13 %IA/g (SD 1) (Table 1 and Figure 5A), and significantly reduced activity in the spleen (P = 0.002) from 101 %IA/g (SD 18) to 12 %IA/g (SD 2) (Table 1 and Figure 5B) at 48 hours post-injection of 111In-DTPA-INCA-X.",DTPA,blood,1
PMC4673473A,(a) Serum alanine aminotransferase levels were determined 2 days after the final treatment with CCl4 (n=8 mice) or vehicle (n=6 mice).,CCl4,Serum,1
PMC4718644A,"Additionally, it has been demonstrated that TLR4-mutant mice critically attenuated fibrosis in the bile duct ligation (BDL) model and antibiotic treatment suppresses liver fibrosis [12].",BDL,bile,1
PMC4202120B,Phase III trial NCT01322490 for PROSTVAC-V/F with GM-CSF is in progress.,PROSTVAC,CSF,1
PMC4202120B,Phase III trial NCT01322490 for PROSTVAC-V/F with GM-CSF is in progress.,NCT01322490,CSF,1
PMC4202120B,Phase III trial NCT01322490 for PROSTVAC-V/F with GM-CSF is in progress.,GM,CSF,1
PMC4202120B,Phase III trial NCT01322490 for PROSTVAC-V/F with GM-CSF is in progress.,III,CSF,1
PMC5328612A,"31(9):1188-1195.43Abbreviations: CEA, carcino-embryonic antigen; LN, lymph node; PI, periductal invasion.",CEA,lymph,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",GBM,serum,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",GBM,blood,-1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",PFS,serum,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",PFS,blood,-1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",hTERT,serum,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",hTERT,blood,-1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",S2,serum,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",S2,blood,-1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",GBM,serum,1
PMC5480073A,"Our results indicate that increased expression of hTERT in tissue and serum corresponds with GBM status, but are lower in the presented case than the threshold value of this maker in tissue and blood of reference GBM group (Supplementary Table S2) and thus may have contributed to the extended PFS seen in this case.",GBM,blood,-1
PMC4202120A,A combination urine test for ERG and PCA3 (a noncoding R,ERG,urine,1
PMC4202120A,A combination urine test for ERG and PCA3 (a noncoding R,PCA3,urine,1
PMC4631976A,"Moreover, XIAP-associated factor 1 (XAF1) negatively regulates the anti-apoptotic function of XIAP[5,9,10].Necrosis is traditionally known as an uncontrolled form of cell death, characterized by morphological features of mitochondrial swelling, cytoplasmic vacuolation, cytosol density loss, and plasma membrane rupture.",XAF1,plasma,1
PMC4631976A,"Moreover, XIAP-associated factor 1 (XAF1) negatively regulates the anti-apoptotic function of XIAP[5,9,10].Necrosis is traditionally known as an uncontrolled form of cell death, characterized by morphological features of mitochondrial swelling, cytoplasmic vacuolation, cytosol density loss, and plasma membrane rupture.",XIAP,plasma,1
PMC5348388A,"This was replaced with serum-free medium containing 100 ng/mL SDF-1, while medium with both 10% FBS and 100 ng/mL SDF-1 wad added to the lower chamber.",SDF-1,serum,1
PMC5348388A,"This was replaced with serum-free medium containing 100 ng/mL SDF-1, while medium with both 10% FBS and 100 ng/mL SDF-1 wad added to the lower chamber.",SDF-1,serum,1
PMC5348388A,"This was replaced with serum-free medium containing 100 ng/mL SDF-1, while medium with both 10% FBS and 100 ng/mL SDF-1 wad added to the lower chamber.",FBS,serum,1
PMC4690245A,"Signals were visualized with ECL and detected using LAS 4000 Imaging system (Fijifilm, Tokyo, Japan).Cells were seeded in serum-free medium in the upper wells of transwell chambers with a 8-mm pore polycarbonate membrane (#3422; Corning Life Sciences, Tewksbury, MA, USA).",USA,serum,1
PMC4690245A,"Signals were visualized with ECL and detected using LAS 4000 Imaging system (Fijifilm, Tokyo, Japan).Cells were seeded in serum-free medium in the upper wells of transwell chambers with a 8-mm pore polycarbonate membrane (#3422; Corning Life Sciences, Tewksbury, MA, USA).",LAS,serum,1
PMC4690245A,"Signals were visualized with ECL and detected using LAS 4000 Imaging system (Fijifilm, Tokyo, Japan).Cells were seeded in serum-free medium in the upper wells of transwell chambers with a 8-mm pore polycarbonate membrane (#3422; Corning Life Sciences, Tewksbury, MA, USA).",ECL,serum,1
PMC4011766A,"Indeed, increasing miR-125b levels in serum are correlated to more malignant NSCLC stages as well as poor survival [44].",NSCLC,serum,-1
PMC3785439A,"Non-specific binding was blocked with normal goat serum for 30 min at 37degC, then the sections were incubated with anti-TROP2 (Santa Cruz, USA, 1:500 dilution) or anti-Ki-67 monoclonal antibody (Dako, lostrup, Denmark, 1:100 dilution) overnight at 4degC. After washing with PBS, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated anti-mouse secondary antibody (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China) at 37degC for 30 min.",PBS,serum,1
PMC3785439A,"Non-specific binding was blocked with normal goat serum for 30 min at 37degC, then the sections were incubated with anti-TROP2 (Santa Cruz, USA, 1:500 dilution) or anti-Ki-67 monoclonal antibody (Dako, lostrup, Denmark, 1:100 dilution) overnight at 4degC. After washing with PBS, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated anti-mouse secondary antibody (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China) at 37degC for 30 min.",USA,serum,1
PMC3785439A,"Non-specific binding was blocked with normal goat serum for 30 min at 37degC, then the sections were incubated with anti-TROP2 (Santa Cruz, USA, 1:500 dilution) or anti-Ki-67 monoclonal antibody (Dako, lostrup, Denmark, 1:100 dilution) overnight at 4degC. After washing with PBS, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated anti-mouse secondary antibody (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China) at 37degC for 30 min.",Ki-67,serum,1
PMC3785439A,"Non-specific binding was blocked with normal goat serum for 30 min at 37degC, then the sections were incubated with anti-TROP2 (Santa Cruz, USA, 1:500 dilution) or anti-Ki-67 monoclonal antibody (Dako, lostrup, Denmark, 1:100 dilution) overnight at 4degC. After washing with PBS, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated anti-mouse secondary antibody (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China) at 37degC for 30 min.",TROP2,serum,1
PMC3039945A,"Tumour budding is a term used to describe the appearance of foci of de-differentiated cancer cells at the invasive tumour front of differentiated adenocarcinomas, i.e., epithelial-to-mesenchymal transition (EMT) [131-133], and is frequently linked to high-grade tumours, lymph node positivity, vascular and lymphatic invasion and local and distant metastases [134].Decreased membranous EpCAM staining throughout the tumour rather than just at the invasive margin also correlates with increased risk of local recurrence, but is not indicative of distant recurrence [120].",EMT,lymph,1
PMC3959865A,Analysis of panel proteins from serum of animals bearing gefitinib-sensitive and gefitinib-resistant tumorsSera were collected from naive mice and mice implanted with A431 cells and A431-ZDR tumors and analyzed by immunoblot for the 16 proteins in our panel.,A431-ZDR,serum,1
PMC3959865A,Analysis of panel proteins from serum of animals bearing gefitinib-sensitive and gefitinib-resistant tumorsSera were collected from naive mice and mice implanted with A431 cells and A431-ZDR tumors and analyzed by immunoblot for the 16 proteins in our panel.,A431,serum,1
PMC4074497A,Organ-to-blood ratios in nude mice bearing PC-3 tumorsSee full tableTable 3.,PC-3,blood,-1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,IL-6,serum,1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,IL-6,Plasma,1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,ELISA,serum,1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,ELISA,Plasma,1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,YKL-40,serum,1
PMC4188889A,Plasma YKL-40 and IL-6 were determined by ELISA and serum CA 19.9 by chemiluminescent immunoassay.,YKL-40,Plasma,1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,saliva,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,saliva,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC3266428A,"Pyrosequencing success rates in cohort 1 were 97 and 94% for DNA that was extracted from blood and saliva, respectively and, in cohort 2, 94% for DNA extracted from cord blood and 97% from year 7 blood.",DNA,blood,-1
PMC4673473A,"(a) Murine Lin- bone marrow cells were treated with normal adult mouse serum (MS) for 6 days in basal culture medium and subsequently cultured with LCM, recombinant HGF and anti-transforming growth factor b (anti-TGFb) antibody for an additional 9 days.",LCM,bone marrow,1
PMC4673473A,"(a) Murine Lin- bone marrow cells were treated with normal adult mouse serum (MS) for 6 days in basal culture medium and subsequently cultured with LCM, recombinant HGF and anti-transforming growth factor b (anti-TGFb) antibody for an additional 9 days.",LCM,serum,1
PMC4673473A,"(a) Murine Lin- bone marrow cells were treated with normal adult mouse serum (MS) for 6 days in basal culture medium and subsequently cultured with LCM, recombinant HGF and anti-transforming growth factor b (anti-TGFb) antibody for an additional 9 days.",HGF,bone marrow,1
PMC4673473A,"(a) Murine Lin- bone marrow cells were treated with normal adult mouse serum (MS) for 6 days in basal culture medium and subsequently cultured with LCM, recombinant HGF and anti-transforming growth factor b (anti-TGFb) antibody for an additional 9 days.",HGF,serum,1
PMC4074497A,"Low to marginal uptake values were noted in the kidney (4 %IA/g (SD 1)), liver (4 %IA/g (SD 1)), lungs (3.47 %IA/g (SD 0.41)) and blood pool (1.87 %IA/g (SD 0.44)) (Figure 3C).",SD,blood,-1
PMC4074497A,"Low to marginal uptake values were noted in the kidney (4 %IA/g (SD 1)), liver (4 %IA/g (SD 1)), lungs (3.47 %IA/g (SD 0.41)) and blood pool (1.87 %IA/g (SD 0.44)) (Figure 3C).",SD,blood,-1
PMC4074497A,"Low to marginal uptake values were noted in the kidney (4 %IA/g (SD 1)), liver (4 %IA/g (SD 1)), lungs (3.47 %IA/g (SD 0.41)) and blood pool (1.87 %IA/g (SD 0.44)) (Figure 3C).",SD,blood,-1
PMC4074497A,"Low to marginal uptake values were noted in the kidney (4 %IA/g (SD 1)), liver (4 %IA/g (SD 1)), lungs (3.47 %IA/g (SD 0.41)) and blood pool (1.87 %IA/g (SD 0.44)) (Figure 3C).",SD,blood,-1
PMC5538449A,"Moreover, moDCs possess a much higher capacity to synthesize proinflammatory cytokines.14,15 The transcriptional mechanism underlying monocyte/macrophage/moDC versus peripheral blood CD14+ monocyte-derived Langerhans cell (moLC) differentiation remains elusive.",CD14,blood,-1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",USA,serum,1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",USA,serum,1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",THP-1,serum,1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",RPM,serum,1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",CO2,serum,1
PMC4718644A,"Briefly, THP-1 cells were cultured in RPM 1640 medium (Lonza, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, NY, USA) and 2 mmol/L L-glutamine, maintained at 37degC in a humidified 5% CO2 incubator.",FBS,serum,1
PMC4790095A,"GO functional analysis for downregulated RAG co-expression modules (purple and dark red) revealed enrichment for various categories related to plasma membrane, ion/gated channel, ion binding, and synapse/cell junction (Table S3).",S3,plasma,1
PMC4790095A,"GO functional analysis for downregulated RAG co-expression modules (purple and dark red) revealed enrichment for various categories related to plasma membrane, ion/gated channel, ion binding, and synapse/cell junction (Table S3).",RAG,plasma,1
PMC4790095A,"GO functional analysis for downregulated RAG co-expression modules (purple and dark red) revealed enrichment for various categories related to plasma membrane, ion/gated channel, ion binding, and synapse/cell junction (Table S3).",GO,plasma,1
PMC3718634A,"The serum responses in CRC patients to KRT23 were higher than serum responses in controls (mean 1.42 +- 0.2 ug/ml vs. 0.54 +- 0.1 ug/ml, p=0.0007) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to KRT23 were higher than serum responses in controls (mean 1.42 +- 0.2 ug/ml vs. 0.54 +- 0.1 ug/ml, p=0.0007) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to KRT23 were higher than serum responses in controls (mean 1.42 +- 0.2 ug/ml vs. 0.54 +- 0.1 ug/ml, p=0.0007) (Fig.",KRT23,serum,1
PMC3718634A,"The serum responses in CRC patients to KRT23 were higher than serum responses in controls (mean 1.42 +- 0.2 ug/ml vs. 0.54 +- 0.1 ug/ml, p=0.0007) (Fig.",KRT23,serum,1
PMC4483763A,"Efforts have been made to generate extra-corporeal bioartificial liver (BAL) devices that increase hepatocyte survival and blood detoxification, although these have had relatively limited clinical success.",BAL,blood,-1
PMC5447959A,"They demonstrated that five plasma microRNAs (miR-20a, miR-145, miR-21, miR-223, and miR-221) could be used as promising biomarkers for the early screening of NSCLC [73].",NSCLC,plasma,-1
PMC5494437A,"In the fetal/adult bone marrow, the HSC niche is associated with trabecular bone closely linked to adherent osteoblasts.",HSC,bone marrow,1
PMC3906064A,"For H1650 cells, the range of 9-300 cells/mL has an R2 of 0.980 and an average recovery of 70% (Figure 4D).To determine if the drop in percent recovery observed for both cell lines at high concentrations was due to either saturation of recovery sites on the flow cell or insufficient capture antibody, NHD blood was spiked with 1x106 HCC1419 breast cancer tumor cells and recovered in the CTC flow cell.",R2,blood,-1
PMC3906064A,"For H1650 cells, the range of 9-300 cells/mL has an R2 of 0.980 and an average recovery of 70% (Figure 4D).To determine if the drop in percent recovery observed for both cell lines at high concentrations was due to either saturation of recovery sites on the flow cell or insufficient capture antibody, NHD blood was spiked with 1x106 HCC1419 breast cancer tumor cells and recovered in the CTC flow cell.",HCC1419,blood,-1
PMC3906064A,"For H1650 cells, the range of 9-300 cells/mL has an R2 of 0.980 and an average recovery of 70% (Figure 4D).To determine if the drop in percent recovery observed for both cell lines at high concentrations was due to either saturation of recovery sites on the flow cell or insufficient capture antibody, NHD blood was spiked with 1x106 HCC1419 breast cancer tumor cells and recovered in the CTC flow cell.",CTC,blood,-1
PMC3906064A,"For H1650 cells, the range of 9-300 cells/mL has an R2 of 0.980 and an average recovery of 70% (Figure 4D).To determine if the drop in percent recovery observed for both cell lines at high concentrations was due to either saturation of recovery sites on the flow cell or insufficient capture antibody, NHD blood was spiked with 1x106 HCC1419 breast cancer tumor cells and recovered in the CTC flow cell.",H1650,blood,-1
PMC3906064A,"For H1650 cells, the range of 9-300 cells/mL has an R2 of 0.980 and an average recovery of 70% (Figure 4D).To determine if the drop in percent recovery observed for both cell lines at high concentrations was due to either saturation of recovery sites on the flow cell or insufficient capture antibody, NHD blood was spiked with 1x106 HCC1419 breast cancer tumor cells and recovered in the CTC flow cell.",NHD,blood,-1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",BQ062,plasma,1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",T,plasma,1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",CEA,plasma,1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",ELISA,plasma,1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",CEA,plasma,1
PMC4606116A,"The CEA concentrations in plasma samples were measured using a commercial ELISA kit of CEA (Carcinoembryonic Antigen ELISA, BQ Kits Cat#: BQ062T).",ELISA,plasma,1
PMC4685746A,"The role of notch signaling and the local production of GM-CSF, TGFb, TSLP and BMP7 have not been tested in in vivo models.",TSLP,CSF,1
PMC4685746A,"The role of notch signaling and the local production of GM-CSF, TGFb, TSLP and BMP7 have not been tested in in vivo models.",GM,CSF,1
PMC4685746A,"The role of notch signaling and the local production of GM-CSF, TGFb, TSLP and BMP7 have not been tested in in vivo models.",BMP7,CSF,1
PMC2441949A,"Of the 14 cancer-associated genes used in the current study, none proved to be prognostic for lymph node metastases at an AUC value 0.80.",AUC,lymph,1
PMC4483763A,"In the perinatal period in mice and at ~30 weeks of gestation in humans, some of these pockets form bile ducts composed of mature cholangiocytes that maintain CK19 expression.",CK19,bile,1
PMC2441949A,"accuracy of B2M for prognosis of lymph node metastases was 0.83+-0.04, a value that is sufficiently high to warrant further investigation into this biomarker.",B2,lymph,1
PMC4467439A,Seven fresh paired CCA and adjacent normal bile duct tissues were obtained from CCA patients undergoing curative surgical resection of the primary tumor from March to October 2013 at Qilu Hospital of Shandong University.,CCA,bile,-1
PMC4467439A,Seven fresh paired CCA and adjacent normal bile duct tissues were obtained from CCA patients undergoing curative surgical resection of the primary tumor from March to October 2013 at Qilu Hospital of Shandong University.,CCA,bile,-1
PMC5480073A,"The plasma level of YKL-40 in this case was 71.47 ng/mL and TIMP1 plasma level corresponded to 80 ng/mL, values, which were within the range of the control group.",TIMP1,plasma,-1
PMC5480073A,"The plasma level of YKL-40 in this case was 71.47 ng/mL and TIMP1 plasma level corresponded to 80 ng/mL, values, which were within the range of the control group.",TIMP1,plasma,-1
PMC5480073A,"The plasma level of YKL-40 in this case was 71.47 ng/mL and TIMP1 plasma level corresponded to 80 ng/mL, values, which were within the range of the control group.",YKL-40,plasma,-1
PMC5480073A,"The plasma level of YKL-40 in this case was 71.47 ng/mL and TIMP1 plasma level corresponded to 80 ng/mL, values, which were within the range of the control group.",YKL-40,plasma,-1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",GM,CSF,1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",HLA,CSF,1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",IMA-901,CSF,1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",IMPRINT,CSF,1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",mRCC,CSF,1
PMC4485845A,"Ongoing clinical trials of therapeutic vaccines in renal cell carcinomaIn the IMPRINT phase III trial, 340 mRCC patients with HLA-A*02 haplotype were randomized to a combination of first-line sunitinib and IMA-901 (with single dose cyclophosphamide and GM-CSF as adjuvant) or sunitinib alone.",III,CSF,1
PMC4698345A,"To determine whether PMNs affected PRPL tumorigenesis, we generated PRPL-Csf3r-/- mice deficient in the receptor for the PMN growth and survival factor G-CSF.",PRPL,CSF,1
PMC4698345A,"To determine whether PMNs affected PRPL tumorigenesis, we generated PRPL-Csf3r-/- mice deficient in the receptor for the PMN growth and survival factor G-CSF.",PMN,CSF,1
PMC4698345A,"To determine whether PMNs affected PRPL tumorigenesis, we generated PRPL-Csf3r-/- mice deficient in the receptor for the PMN growth and survival factor G-CSF.",PRPL,CSF,1
PMC4292049A,"In conjunction, the stability of the TCO tag could be improved by removal of the PEG linker between the TCO and the lysine residue on the Ab, increasing the steric hindrance on the TCO thus hampering interaction with serum protein-bound copper.",TCO,serum,1
PMC4292049A,"In conjunction, the stability of the TCO tag could be improved by removal of the PEG linker between the TCO and the lysine residue on the Ab, increasing the steric hindrance on the TCO thus hampering interaction with serum protein-bound copper.",TCO,serum,1
PMC4292049A,"In conjunction, the stability of the TCO tag could be improved by removal of the PEG linker between the TCO and the lysine residue on the Ab, increasing the steric hindrance on the TCO thus hampering interaction with serum protein-bound copper.",TCO,serum,1
PMC4292049A,"In conjunction, the stability of the TCO tag could be improved by removal of the PEG linker between the TCO and the lysine residue on the Ab, increasing the steric hindrance on the TCO thus hampering interaction with serum protein-bound copper.",PEG,serum,1
PMC4214500A,"In gastric carcinomas, none of the parameters of patient age, gender, tumor location, depth of invasion, lymph-node metastasis, lymphatic invasion, vascular invasion or pathological stage were found to be associated with the positive expression of Smac/DIABLO.",DIABLO,lymph,1
PMC5494437A,Alternate HSC niches in the bone marrow are in perivascular sites proximal to the endothelium[6].,HSC,bone marrow,1
PMC3369609A,"Peripheral blood or marrow of patients with acute leukemia provided primary blasts as targets for colorimetric cytolytic assays, after semiquantitative PCR (Eppendorf) confirmed WT1 expression using published sequences.28,33By adding 5 x 10351Cr-labeled target cells directly to replicate microwells after only 7 days of stimulation by WT1 mRNA-electroporated LCs or moDCs, total cytolytic activity generated per primary culture condition could be compared based on 51Cr release into the supernatants collected after 4 to 6 hours.9 Percent specific lysis was calculated in standard fashion.",mRNA,blood,1
PMC3369609A,"Peripheral blood or marrow of patients with acute leukemia provided primary blasts as targets for colorimetric cytolytic assays, after semiquantitative PCR (Eppendorf) confirmed WT1 expression using published sequences.28,33By adding 5 x 10351Cr-labeled target cells directly to replicate microwells after only 7 days of stimulation by WT1 mRNA-electroporated LCs or moDCs, total cytolytic activity generated per primary culture condition could be compared based on 51Cr release into the supernatants collected after 4 to 6 hours.9 Percent specific lysis was calculated in standard fashion.",WT1,blood,1
PMC3369609A,"Peripheral blood or marrow of patients with acute leukemia provided primary blasts as targets for colorimetric cytolytic assays, after semiquantitative PCR (Eppendorf) confirmed WT1 expression using published sequences.28,33By adding 5 x 10351Cr-labeled target cells directly to replicate microwells after only 7 days of stimulation by WT1 mRNA-electroporated LCs or moDCs, total cytolytic activity generated per primary culture condition could be compared based on 51Cr release into the supernatants collected after 4 to 6 hours.9 Percent specific lysis was calculated in standard fashion.",WT1,blood,1
PMC3369609A,"Peripheral blood or marrow of patients with acute leukemia provided primary blasts as targets for colorimetric cytolytic assays, after semiquantitative PCR (Eppendorf) confirmed WT1 expression using published sequences.28,33By adding 5 x 10351Cr-labeled target cells directly to replicate microwells after only 7 days of stimulation by WT1 mRNA-electroporated LCs or moDCs, total cytolytic activity generated per primary culture condition could be compared based on 51Cr release into the supernatants collected after 4 to 6 hours.9 Percent specific lysis was calculated in standard fashion.",PCR,blood,1
PMC4467439A,We found that the expression of FBXW7 was lower in both CCA cell lines and tumor tissues compared with normal intrahepatic bile duct epithelial cells and tumor adjacent tissues respectively.,CCA,bile,1
PMC4467439A,We found that the expression of FBXW7 was lower in both CCA cell lines and tumor tissues compared with normal intrahepatic bile duct epithelial cells and tumor adjacent tissues respectively.,FBXW7,bile,1
PMC4292049A,The increased reactivity (up to k2 = 2.7 x 105 M-1s-1 in PBS (61) and improved stability of the IEDDA between a tetrazine and TCO-tagged antibody resulted in an improved tumor-to-blood ratio (61).,PBS,blood,-1
PMC4292049A,The increased reactivity (up to k2 = 2.7 x 105 M-1s-1 in PBS (61) and improved stability of the IEDDA between a tetrazine and TCO-tagged antibody resulted in an improved tumor-to-blood ratio (61).,TCO,blood,-1
PMC4292049A,The increased reactivity (up to k2 = 2.7 x 105 M-1s-1 in PBS (61) and improved stability of the IEDDA between a tetrazine and TCO-tagged antibody resulted in an improved tumor-to-blood ratio (61).,IEDDA,blood,-1
PMC3233648A,"Analysis was conducted with a FACScan using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ).A standard five-hours chromium(51Cr)-release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 3 EEC cell lines.",PBL,blood,-1
PMC3233648A,"Analysis was conducted with a FACScan using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ).A standard five-hours chromium(51Cr)-release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 3 EEC cell lines.",PLUS,blood,-1
PMC3233648A,"Analysis was conducted with a FACScan using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ).A standard five-hours chromium(51Cr)-release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all 3 EEC cell lines.",EEC,blood,-1
PMC4637775A,"Expression of MAGT1 and AKAP13 in HepG2 cells was highest 24 h after PMA induction, but decreased with prolonged incubation of 48 h. Reduction of protein expression at 48 h may be due to cell arrest induced by starvation under serum-depleted conditions [61,62].",PMA,serum,1
PMC4637775A,"Expression of MAGT1 and AKAP13 in HepG2 cells was highest 24 h after PMA induction, but decreased with prolonged incubation of 48 h. Reduction of protein expression at 48 h may be due to cell arrest induced by starvation under serum-depleted conditions [61,62].",AKAP13,serum,1
PMC4637775A,"Expression of MAGT1 and AKAP13 in HepG2 cells was highest 24 h after PMA induction, but decreased with prolonged incubation of 48 h. Reduction of protein expression at 48 h may be due to cell arrest induced by starvation under serum-depleted conditions [61,62].",MAGT1,serum,1
PMC4637775A,"Expression of MAGT1 and AKAP13 in HepG2 cells was highest 24 h after PMA induction, but decreased with prolonged incubation of 48 h. Reduction of protein expression at 48 h may be due to cell arrest induced by starvation under serum-depleted conditions [61,62].",HepG2,serum,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",IFN,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",T,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",CD8,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",CMV,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",IFN,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",R9,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",HCV,blood,1
PMC4586470A,"IFN-g production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8+ T cells (i.e., IFN-g production).",HCV,blood,1
PMC4292049A,"At 3 h p.i., the 111In-IMP241 tumor uptake was 19.1 +- 8.7% ID/g and the blood levels were only 0.25 +- 0.08% ID/g corresponding with a tumor-to-blood ratio of 83 +- 44% ID/g.",IMP241,blood,-1
PMC4292049A,"At 3 h p.i., the 111In-IMP241 tumor uptake was 19.1 +- 8.7% ID/g and the blood levels were only 0.25 +- 0.08% ID/g corresponding with a tumor-to-blood ratio of 83 +- 44% ID/g.",IMP241,blood,-1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",USA,serum,1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",C33A,serum,1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",CO2,serum,1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",USA,serum,1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",USA,serum,1
PMC3785439A,"The classification was as follows: -, (10%, restricted to the parabasal cell layers); +, (10% to 30%, restricted to the lower third of the epithelium); ++, (30 to 70%, reaching the upper third of the epithelium); +++, (70% or more of the epithelial cells including full thickness express ion of Ki-67).Four human cervical cancer cell lines CaSki, Siha, HeLa and C33A cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco-modified Eagle medium (DMEM; Gibco Inc., Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen) in a humidified incubator at 37degC and 5% CO2 atmosphere.",DMEM,serum,1
PMC3126726A,"Results indicated that KIAA0247 ubiquitously expresses in gastrointestinal tissues and in peripheral blood leukocytes (PBL), with highest expression in PBL and lowest expression in the small intestine (Figure 1).View larger versionFigure 1.",PBL,blood,-1
PMC3126726A,"Results indicated that KIAA0247 ubiquitously expresses in gastrointestinal tissues and in peripheral blood leukocytes (PBL), with highest expression in PBL and lowest expression in the small intestine (Figure 1).View larger versionFigure 1.",PBL,blood,-1
PMC3126726A,"Results indicated that KIAA0247 ubiquitously expresses in gastrointestinal tissues and in peripheral blood leukocytes (PBL), with highest expression in PBL and lowest expression in the small intestine (Figure 1).View larger versionFigure 1.",KIAA0247,blood,-1
PMC4854811A,"Selection of epithelial cells may be performed both mechanically and by plating onto plastic or collagen gel in selective medium formulations (specifically relatively low serum, the presence of EGF, insulin, and cholera toxin as well as the use of bovine pituitary extract - see Table 8).",EGF,serum,1
PMC4606116A,"After washing, the plates were blocked by the addition of 200 mL per well of 1% BSA (Sigma)/PBS and incubated overnight at 4degC. After washing with PBS, 50 mL of plasma sample diluted 1 : 10 in blocking buffer was added and incubated at room temperature for 1 hour.",PBS,plasma,1
PMC4606116A,"After washing, the plates were blocked by the addition of 200 mL per well of 1% BSA (Sigma)/PBS and incubated overnight at 4degC. After washing with PBS, 50 mL of plasma sample diluted 1 : 10 in blocking buffer was added and incubated at room temperature for 1 hour.",BSA,plasma,1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",DC,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",DC,CSF,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",DC,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",CSF,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",CSF,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",GM,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",GM,CSF,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",GM,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",TGF,blood,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",TGF,CSF,-1
PMC5538449A,"Interestingly, human CD1c+ blood DCs differentiate into LCs without exogenous Notch ligand (ie, GM-CSF plus either TGF-b1 or BMP7).51 Whether Notch signaling is activated during CD1c+ blood DC-derived LC differentiation remains to be analyzed.",TGF,blood,-1
PMC4370053A,"Langerin has not been detected on tissue DCs of the skin and lung by previous studies[7, 10],although langerin+ DCs were reported in human colon [11], and there is reference to trace levels of langerin expressionin human blood [28, 29].",Langerin,blood,-1
PMC3785439A,"Siha and CaSki cells were cultured on glass slides in a 6-well plate and incubated for 24 h. Cells were fixed with 4% paraformaldehyde and blocked with normal goat's serum for 30 min at 37degC. After thorough washing with Tris-buffered saline (TBS), the cells were incubated with primary anti-TROP2 monoclonal antibody (Santa Cruz, USA, 1:500 dilution) overnight at 4degC and stained with FITC conjugated anti-mouse IgG (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China, 1:200 dilution) for 30 min.",USA,serum,1
PMC3785439A,"Siha and CaSki cells were cultured on glass slides in a 6-well plate and incubated for 24 h. Cells were fixed with 4% paraformaldehyde and blocked with normal goat's serum for 30 min at 37degC. After thorough washing with Tris-buffered saline (TBS), the cells were incubated with primary anti-TROP2 monoclonal antibody (Santa Cruz, USA, 1:500 dilution) overnight at 4degC and stained with FITC conjugated anti-mouse IgG (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China, 1:200 dilution) for 30 min.",TBS,serum,1
PMC3785439A,"Siha and CaSki cells were cultured on glass slides in a 6-well plate and incubated for 24 h. Cells were fixed with 4% paraformaldehyde and blocked with normal goat's serum for 30 min at 37degC. After thorough washing with Tris-buffered saline (TBS), the cells were incubated with primary anti-TROP2 monoclonal antibody (Santa Cruz, USA, 1:500 dilution) overnight at 4degC and stained with FITC conjugated anti-mouse IgG (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China, 1:200 dilution) for 30 min.",FITC,serum,1
PMC3785439A,"Siha and CaSki cells were cultured on glass slides in a 6-well plate and incubated for 24 h. Cells were fixed with 4% paraformaldehyde and blocked with normal goat's serum for 30 min at 37degC. After thorough washing with Tris-buffered saline (TBS), the cells were incubated with primary anti-TROP2 monoclonal antibody (Santa Cruz, USA, 1:500 dilution) overnight at 4degC and stained with FITC conjugated anti-mouse IgG (Beijing Zhong Shan Biotech Co. Ltd, BeiJing, China, 1:200 dilution) for 30 min.",TROP2,serum,1
PMC5380941A,"Co-localization (Supplementary Figure S3) was calculated using bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 3 (for 3-color co-localization).LCs were incubated in serum-free IMDM for 30 min, incubated with 50 ug mL-1 anti-langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 min on ice to ensure binding.",mL-1,serum,1
PMC5380941A,"Co-localization (Supplementary Figure S3) was calculated using bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 3 (for 3-color co-localization).LCs were incubated in serum-free IMDM for 30 min, incubated with 50 ug mL-1 anti-langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 min on ice to ensure binding.",R3,serum,1
PMC5380941A,"Co-localization (Supplementary Figure S3) was calculated using bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 3 (for 3-color co-localization).LCs were incubated in serum-free IMDM for 30 min, incubated with 50 ug mL-1 anti-langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 min on ice to ensure binding.",Dectin-1,serum,1
PMC5380941A,"Co-localization (Supplementary Figure S3) was calculated using bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 3 (for 3-color co-localization).LCs were incubated in serum-free IMDM for 30 min, incubated with 50 ug mL-1 anti-langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 min on ice to ensure binding.",IMDM,serum,1
PMC5380941A,"Co-localization (Supplementary Figure S3) was calculated using bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 3 (for 3-color co-localization).LCs were incubated in serum-free IMDM for 30 min, incubated with 50 ug mL-1 anti-langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 min on ice to ensure binding.",S3,serum,1
PMC4251850A,"(The ascites derived cell line A818-4 also expressing some amount of EPCAM was disregarded for this approach, because it is not mutated in p53 and smad4 and because these cells can not easily be produced in very large numbers.)",p53,ascites,1
PMC4251850A,"(The ascites derived cell line A818-4 also expressing some amount of EPCAM was disregarded for this approach, because it is not mutated in p53 and smad4 and because these cells can not easily be produced in very large numbers.)",A818,ascites,1
PMC4251850A,"(The ascites derived cell line A818-4 also expressing some amount of EPCAM was disregarded for this approach, because it is not mutated in p53 and smad4 and because these cells can not easily be produced in very large numbers.)",EPCAM,ascites,1
PMC5480073A,"This can be distinctly linked to recurrence, as evident from IF based quantitative analysis and levels of expression of this protein in patient's serum (Tables 1 and 2).",IF,serum,1
PMC3418405A,"During chronic HIV infection, lymphoid and mucosal tissues, and peripheral blood undergo substantial anatomical and microenvironmental alterations.",HIV,blood,-1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",B27,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",USA,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",USA,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",A549,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",TGF,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",CD326,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",USA,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",bFGF,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",EGF,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",CD326,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",A549,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",BSA,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",CD326,serum,1
PMC5467782A,"The induced CD133+/CD326+ subpopulation cells were suspended in serum-free medium supplemented with 0.4% BSA (Sigma, USA), insulin (5 ng/ml, Sigma), bFGF (10 ng/ml, PeproTech, USA), EGF (20 ng/ml, PeproTech), and B27 (20 ng/ml, Invitrogen, USA) at a density of 103 cells/3 ml in ultralow attachment plates (Corning, USA).To induce the EMT process, adherent A549 cells and CD133+/CD326+ spheroids were treated with 5 ng/ml TGF-b1 (Sigma) for 72 h. Adherent A549 cells and suspended CD133+/CD326+ cells were transfected with agomiR-181b-5p and antagomiR-181b-5p, which were purchased from RiboBio Co. Ltd. (China).",EMT,serum,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,CSF,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,blood,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,CSF,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,blood,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",S2D,CSF,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",S2D,blood,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",CSF,blood,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",S2,CSF,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",S2,blood,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,CSF,1
PMC4698345A,"Furthermore, antibody-mediated G-CSF neutralization in PRPL mice recapitulated the reduction in blood and uterine PMNs, tumor size increase, and morphological alterations observed in 4-week-old PRPL-Csf3r-/- mice (Figures S2D-S2G), indicating that the PRPL-Csf3r-/- phenotype was not due to a developmental defect in Csf3r-/- mice.",PRPL,blood,1
PMC4292049A,"However, the tumor-to-blood ratio still remained low due to the relative high amount of free-circulating CC49-TCO.",CC49-TCO,blood,-1
PMC4558321A,"Concentrations of the IgG and sacituzumab govitecan in the 30-min serum over multiple doses by ELISA (panel A) were similar over time, adjusting lower when the dose was reduced.",ELISA,serum,1
PMC5183739A,"The THP-1 cells were acquired from the cell bank of Shanghai Institute of Biochemistry and Biology (Chinese Academy of Sciences, Shanghai, China). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA).",THP-1,serum,1
PMC5183739A,"The THP-1 cells were acquired from the cell bank of Shanghai Institute of Biochemistry and Biology (Chinese Academy of Sciences, Shanghai, China). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA).",RPMI-1640,serum,1
PMC5183739A,"The THP-1 cells were acquired from the cell bank of Shanghai Institute of Biochemistry and Biology (Chinese Academy of Sciences, Shanghai, China). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA).",USA,serum,1
PMC5183739A,"The THP-1 cells were acquired from the cell bank of Shanghai Institute of Biochemistry and Biology (Chinese Academy of Sciences, Shanghai, China). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA).",FBS,serum,1
PMC5183739A,"The purified cells were differentiated in complete RPMI-1640 supplied with M-CSF (10 ng/ml) (BD Biosciences, CA, USA) for 6 days.",USA,CSF,1
PMC5183739A,"The purified cells were differentiated in complete RPMI-1640 supplied with M-CSF (10 ng/ml) (BD Biosciences, CA, USA) for 6 days.",RPMI-1640,CSF,1
PMC4485845A,A fusion gene construct of GM-CSF and CAIX is transduced by a replication deficient adenovirus into autologous DC.,CAIX,CSF,1
PMC4485845A,A fusion gene construct of GM-CSF and CAIX is transduced by a replication deficient adenovirus into autologous DC.,GM,CSF,1
PMC4485845A,A fusion gene construct of GM-CSF and CAIX is transduced by a replication deficient adenovirus into autologous DC.,DC,CSF,1
PMC4485845A,"However, it is unclear whether they affect VEGF-dependent DC maturation or Treg proliferation.82 In a prospective study of 28 mRCC patients receiving first-line sunitinib, the number of Tregs (defined as CD3+CD4+CD25(hi) Foxp3+) in blood and tumor fell after each sunitinib cycle.",mRCC,blood,-1
PMC4485845A,"However, it is unclear whether they affect VEGF-dependent DC maturation or Treg proliferation.82 In a prospective study of 28 mRCC patients receiving first-line sunitinib, the number of Tregs (defined as CD3+CD4+CD25(hi) Foxp3+) in blood and tumor fell after each sunitinib cycle.",VEGF,blood,-1
PMC4485845A,"However, it is unclear whether they affect VEGF-dependent DC maturation or Treg proliferation.82 In a prospective study of 28 mRCC patients receiving first-line sunitinib, the number of Tregs (defined as CD3+CD4+CD25(hi) Foxp3+) in blood and tumor fell after each sunitinib cycle.",DC,blood,-1
PMC4485845A,"However, it is unclear whether they affect VEGF-dependent DC maturation or Treg proliferation.82 In a prospective study of 28 mRCC patients receiving first-line sunitinib, the number of Tregs (defined as CD3+CD4+CD25(hi) Foxp3+) in blood and tumor fell after each sunitinib cycle.",Foxp3,blood,-1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",CO2,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",DMEM,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",EGF,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",LIF,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",F-12,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",USA,serum,1
PMC5505023A,"The cells were maintained in DMEM/F-12 containing 1% penicillin/streptomycin, 10 mg/ml insulin (Sigma-Aldrich), 10% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor (EGF; Peprotech, Inc., Rocky Hill, NJ, USA), 10 ng/ml leukemia inhibitory factor (LIF; Sigma-Aldrich) and 2 mM L-glutamine at 37degC with 5% CO2.",FBS,serum,1
PMC4586470A,"When PapMV was administered jointly with bone marrow-derived DCs presenting OVA, cellular immune responses towards OVA were enhanced, leading to better protection against a Listeria monocytogenes-OVA challenge in mice [79].",OVA,bone marrow,1
PMC4586470A,"When PapMV was administered jointly with bone marrow-derived DCs presenting OVA, cellular immune responses towards OVA were enhanced, leading to better protection against a Listeria monocytogenes-OVA challenge in mice [79].",OVA,bone marrow,1
PMC4586470A,"When PapMV was administered jointly with bone marrow-derived DCs presenting OVA, cellular immune responses towards OVA were enhanced, leading to better protection against a Listeria monocytogenes-OVA challenge in mice [79].",OVA,bone marrow,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",hTERT,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",hTERT,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",NLR,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",NLR,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",TIMP-1,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",TIMP-1,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",GBM,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",GBM,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",IL-6,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",IL-6,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",YKL-40,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",YKL-40,plasma,1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",HMGA1,serum,-1
PMC5480073A,"The current investigation thus provides experimental data-based evidence of the clinical utility of circulating plasma YKL-40, TIMP-1, IL-6 and NLR and serum hTERT and HMGA1 for monitoring primary GBM patients.",HMGA1,plasma,1
PMC3786374A,(C) Comparison of serum levels of TGFb1 in ThrbPV/PV and WT mice.,TGFb1,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",RPMI,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",RPMI,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",RPMI,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",RPMI,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",CO2,serum,1
PMC3224774A,"Enzymatically dissociated cells were then washed twice in RPMI 1640 with 10% fetal bovine serum and maintained in RPMI supplemented with 10% fetal bovine serum, 200 mg/ml of penicillin and 200 mg/ml of streptomycin at 37degC, 5% CO2 in 75 cm2 tissue culture flasks or Petri dishes (Corning).",CO2,serum,1
PMC5378227A,"In addition, serum tumor markers, such as CEA, CA19-9, and CA72-4 also have limited sensitivity and specificity for gastric cancer screening.4",CA19,serum,1
PMC5378227A,"In addition, serum tumor markers, such as CEA, CA19-9, and CA72-4 also have limited sensitivity and specificity for gastric cancer screening.4",CA72,serum,1
PMC5378227A,"In addition, serum tumor markers, such as CEA, CA19-9, and CA72-4 also have limited sensitivity and specificity for gastric cancer screening.4",CEA,serum,1
PMC4558321A,"Total SN-38 concentration in the 30-min serum sample of patient 15 was 3,930 ng/mL after the first dose in cycle 1 (C1D1), but when sacituzumab govitecan treatment was reduced to 9.0 mg/kg for the second dose of the first cycle (C1D2), the level decreased to 2,947 ng/mL (Figure 3, panel B).",SN-38,serum,1
PMC4558321A,"Total SN-38 concentration in the 30-min serum sample of patient 15 was 3,930 ng/mL after the first dose in cycle 1 (C1D1), but when sacituzumab govitecan treatment was reduced to 9.0 mg/kg for the second dose of the first cycle (C1D2), the level decreased to 2,947 ng/mL (Figure 3, panel B).",C1D1,serum,1
PMC4558321A,"Total SN-38 concentration in the 30-min serum sample of patient 15 was 3,930 ng/mL after the first dose in cycle 1 (C1D1), but when sacituzumab govitecan treatment was reduced to 9.0 mg/kg for the second dose of the first cycle (C1D2), the level decreased to 2,947 ng/mL (Figure 3, panel B).",C1D2,serum,1
PMC4202120B,This treatment consists of autologous peripheral blood mononuclear cells (PBMCs) enriched for a CD54+ DCs (dendritic cells).,CD54,blood,-1
PMC4485845A,Its expression in ccRCC is ubiquitous because of the mutational loss of VHL that is invariable in ccRCC ( 95%) but rare in normal cells.62 It is used to activate a specific immune response whereas GM-CSF is used to boost antitumor immunity.,GM,CSF,-1
PMC4485845A,Its expression in ccRCC is ubiquitous because of the mutational loss of VHL that is invariable in ccRCC ( 95%) but rare in normal cells.62 It is used to activate a specific immune response whereas GM-CSF is used to boost antitumor immunity.,VHL,CSF,-1
PMC4306156A,"The principal elements comprising WCA are invigorating spleen herbs, whereas heat-clearing and detoxicating herbs, hard lump-resolving herbs and blood stasis removing herbs are adjuvant components.",WCA,blood,-1
PMC3843273A,"None of the other parameters (patient age, tumor location, depth of invasion, lymph-node metastasis, lymphatic invasion, vascular invasion, or pathological stage) was associated with positive survivin expression.",survivin,lymph,1
PMC3135497A,"A total of 3 x 106 clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical.",NCBI,sera,1
PMC3135497A,"A total of 3 x 106 clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical.",SCC,sera,1
PMC3135497A,"A total of 3 x 106 clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical.",DNA,sera,1
PMC3135497A,"A total of 3 x 106 clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical.",cDNA,sera,1
PMC3135497A,"A total of 3 x 106 clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical.",DNA,sera,1
PMC5302940A,"After removing the red blood cells, cell suspension was filtered through a 40-mm cell strainer and collected in WIT media (01-0009-500, Stemgent, San Diego, CA).",WIT,blood,1
PMC5302940A,"After removing the red blood cells, cell suspension was filtered through a 40-mm cell strainer and collected in WIT media (01-0009-500, Stemgent, San Diego, CA).",San,blood,1
PMC5378227A,"Although serum p53 antibodies have been detected even in the early stages of tumors, the positive rate for stage I tumors is 10%.8, 9, 10 To overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies against a panel of TAAs.11, 12, 13, 14, 15, 16, 17, 18, 19, 20The panel of six antigens selected in this study includes a well-recognized TAA, p53, which is mutated in a large number of cancers.",p53,serum,1
PMC5378227A,"Although serum p53 antibodies have been detected even in the early stages of tumors, the positive rate for stage I tumors is 10%.8, 9, 10 To overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies against a panel of TAAs.11, 12, 13, 14, 15, 16, 17, 18, 19, 20The panel of six antigens selected in this study includes a well-recognized TAA, p53, which is mutated in a large number of cancers.",p53,serum,1
PMC5378227A,"Although serum p53 antibodies have been detected even in the early stages of tumors, the positive rate for stage I tumors is 10%.8, 9, 10 To overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies against a panel of TAAs.11, 12, 13, 14, 15, 16, 17, 18, 19, 20The panel of six antigens selected in this study includes a well-recognized TAA, p53, which is mutated in a large number of cancers.",TAA,serum,1
PMC4577600A,"The ability of TGF-b1 to directly accelerate wound healing has been shown in rat incisional wounds.2728 Exogenous application of TGF-b1 to skin wounds also enhanced epithelial regeneration in vivo.2930 Upon injury to skin, TGF-b1 are released by both mesenchymal cells (e.g., blood platelets, endothelial cells, and activated, infiltrating macrophages) and epithelial cells, especially in the epithelial cells next to the site of injury,3132 which suggest that epithelia play a central role, not only as a key cell type in repair, but also as the source of growth factors during wound healing.",TGF,blood,-1
PMC4577600A,"The ability of TGF-b1 to directly accelerate wound healing has been shown in rat incisional wounds.2728 Exogenous application of TGF-b1 to skin wounds also enhanced epithelial regeneration in vivo.2930 Upon injury to skin, TGF-b1 are released by both mesenchymal cells (e.g., blood platelets, endothelial cells, and activated, infiltrating macrophages) and epithelial cells, especially in the epithelial cells next to the site of injury,3132 which suggest that epithelia play a central role, not only as a key cell type in repair, but also as the source of growth factors during wound healing.",TGF,blood,-1
PMC4577600A,"The ability of TGF-b1 to directly accelerate wound healing has been shown in rat incisional wounds.2728 Exogenous application of TGF-b1 to skin wounds also enhanced epithelial regeneration in vivo.2930 Upon injury to skin, TGF-b1 are released by both mesenchymal cells (e.g., blood platelets, endothelial cells, and activated, infiltrating macrophages) and epithelial cells, especially in the epithelial cells next to the site of injury,3132 which suggest that epithelia play a central role, not only as a key cell type in repair, but also as the source of growth factors during wound healing.",TGF,blood,-1
PMC5467782A,"Peripheral blood samples were obtained from NSCLC patients prior to treatment at the Xinqiao Hospital of the Third Military Medical University between 2014 and 2015 and were stored at -80degC. This project was approved by the ethics committee of the Xinqiao Hospital of the Third Military Medical University, and informed consent was obtained from all the patients.",NSCLC,blood,-1
PMC4505024A,"FGF signaling has also been implicated in a variety of tissue stem cell activities, including neural stem cells (23), bone marrow mesenchymal stem cells (24), and hematopoietic stem cells (25).",FGF,bone marrow,1
PMC3250983A,"Immuno-PET images recapitulated the results of biodistribution at all times, with a clear tumor imaging at day 1 together with an intense activity in the heart and blood vessels.",PET,blood,-1
PMC4448470A,"Lai et al. discovered that both TRIM29 mRNA and protein expression in esophageal squamous-cell carcinoma (ESCC) tissues were significantly correlated with tumor differentiation, stage, and lymph node metastasis.26 Jiang et al.",ESCC,lymph,1
PMC4448470A,"Lai et al. discovered that both TRIM29 mRNA and protein expression in esophageal squamous-cell carcinoma (ESCC) tissues were significantly correlated with tumor differentiation, stage, and lymph node metastasis.26 Jiang et al.",mRNA,lymph,1
PMC4448470A,"Lai et al. discovered that both TRIM29 mRNA and protein expression in esophageal squamous-cell carcinoma (ESCC) tissues were significantly correlated with tumor differentiation, stage, and lymph node metastasis.26 Jiang et al.",TRIM29,lymph,1
PMC3528570A,"Moreover, cancer cells can influence their microenvironment by recruiting bone marrow-derived inflammatory cells and inducing profound changes in the extracellular matrix (ECM), which fuels tumor survival, growth, invasion, and metastasis (7).Reciprocal communication between cancer cells and their microenvironment is evident during tumor evolution; however, the mechanisms for the phenotypic and molecular changes in CAFs remain uncertain.",ECM,bone marrow,1
PMC3126726A,"Previous studies have identified that many molecules have altered expression in the feces of CRC patients [14,15]; some of these novel candidate genes with unknown function.",CRC,feces,1
PMC4448470A,"reported that the expression of TRIM29 was significantly associated with the depth of tumor invasion, lymph node metastasis, and distant metastasis in colorectal cancer.25",TRIM29,lymph,1
PMC3959865A,Sera from mice implanted with either A431 or A431-ZDR tumors were collected and immunoblots were performed.,A431-ZDR,Sera,1
PMC3959865A,Sera from mice implanted with either A431 or A431-ZDR tumors were collected and immunoblots were performed.,A431,Sera,1
PMC3785439A,"Cells (1x105 cells) transfected with TROP2 siRNA or pcDNA3.1-TROP2 were suspended in 200 ul serum-free 1640 medium and cultured in the upper transwell chamber for 24 h at 37degC, the lower chamber was filled with 600 uL of 1640 medium supplemented with 10% FBS.",TROP2,serum,1
PMC3785439A,"Cells (1x105 cells) transfected with TROP2 siRNA or pcDNA3.1-TROP2 were suspended in 200 ul serum-free 1640 medium and cultured in the upper transwell chamber for 24 h at 37degC, the lower chamber was filled with 600 uL of 1640 medium supplemented with 10% FBS.",FBS,serum,1
PMC3785439A,"Cells (1x105 cells) transfected with TROP2 siRNA or pcDNA3.1-TROP2 were suspended in 200 ul serum-free 1640 medium and cultured in the upper transwell chamber for 24 h at 37degC, the lower chamber was filled with 600 uL of 1640 medium supplemented with 10% FBS.",TROP2,serum,1
PMC5042010A,Whole blood was collected in purple top (K2EDTA) tubes and stabilized using LiquidBiopsy (Cynvenio Biosystems) fixative.,K2EDTA,blood,-1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF4,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF4,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",PU.1,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",PU.1,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF8,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF8,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF8,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",IRF8,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",Id2,bone marrow,1
PMC4685746A,"A systematic study of the role of IRF8, IRF4, PU.1 and Id2 in LC development shows concordant results with human IRF8 mutation [29].Following human bone marrow transplantation, rapid replenishment of LCs by bone marrow-derived cells is reported, even after non-myeloablative conditioning in the absence of overt graft versus host disease [30-32], although one recent study does not concur with these results [33].",Id2,bone marrow,1
PMC4270176A,"The rigidity of the ECM compresses blood vessels leading to reduced perfusion, which is proposed to impede the delivery of drugs to neoplastic cells and contribute to drug resistance (82).",ECM,blood,-1
PMC4292049A,"Corresponding mouse dosimetry experiments suggested that at MTD for bone marrow (dose-limiting organ for both approaches), this should allow for an eightfold higher tumor dose than is possible with non-pretargeted RIT.",RIT,bone marrow,1
PMC4292049A,"Corresponding mouse dosimetry experiments suggested that at MTD for bone marrow (dose-limiting organ for both approaches), this should allow for an eightfold higher tumor dose than is possible with non-pretargeted RIT.",MTD,bone marrow,1
PMC4188889A,Patients with high expression levels of MTA2 showed lower OS.Diagnostic biomarkers from genomics-based studies (Table 4) are identified both from tissue and serum samples.,MTA2,serum,-1
PMC4146555A,"The follow-up evaluation of patients consisted of physical examination, blood tests, computed tomography, ultrasound examination, chest X-ray and fiberoptic bronchoscopy if necessary.",X,blood,-1
PMC2774463A,Genomic DNA was extracted from peripheral blood by standard procedures [11].,DNA,blood,-1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",A549,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",RPMI,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",H1975,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",FBS,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",USA,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",SPCA-1,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",BEAS2B,serum,1
PMC4146555A,"The BEAS2B, A549, SPCA-1 and H1975 cells were cultured in Roswell's Park Memorial Institute (RPMI) 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA).",USA,serum,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PRPL,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PMN,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PMA,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",BMT,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",ROS,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PMN,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PMN,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",S4D,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PRPL,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PMN,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",PRPL,bone marrow,1
PMC4698345A,"These findings could not be easily ascribed to a change in uterine PMN tissue density (Figure 4D) nor to a PMN developmental defect, as PRPL-Myd88-/- PMNs remained capable of producing ROS in response to PMA (Figure 4B) and expressed the developmental markers myeloperoxidase and MMP-9 (Figures S4D and S4E).To more directly assess the role of MyD88-dependent PMN activation in PRPL tumorigenesis, we employed a bone marrow transfer (BMT) protocol to reconstitute the PMN compartment of PRPL-Csf3r-/- neonates with either wild-type (WT) or Myd88-/- cells.",MMP-9,bone marrow,1
PMC4483763A,"KCs originate from fetal yolk sac precursors and self-renew dependent on GM-CSF and M-CSF (Schulz et al., 2012; Yona et al., 2013)",CSF,CSF,1
PMC4483763A,"KCs originate from fetal yolk sac precursors and self-renew dependent on GM-CSF and M-CSF (Schulz et al., 2012; Yona et al., 2013)",GM,CSF,1
PMC4483763A,"KCs originate from fetal yolk sac precursors and self-renew dependent on GM-CSF and M-CSF (Schulz et al., 2012; Yona et al., 2013)",GM,CSF,1
PMC3929731A,"Murine hosts were given daily oral exposure to BPA for 2 weeks after renal grafting, and serum samples collected 20 to 30 minutes after feeding were used to quantitate the biologically relevant, internal BPA levels.",BPA,serum,1
PMC3929731A,"Murine hosts were given daily oral exposure to BPA for 2 weeks after renal grafting, and serum samples collected 20 to 30 minutes after feeding were used to quantitate the biologically relevant, internal BPA levels.",BPA,serum,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",TCHO,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",TCHO,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",ALB,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",ALB,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",DBIL,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",DBIL,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",LDH,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",LDH,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",TBIL,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",TBIL,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",AST,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",AST,blood,-1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",ALT,plasma,1
PMC4023823A,"The plasma was analyzed using Fuji Dri-Chem 7000 (Fujifilm Corp., Tokyo, Japan) to detect alanine transferase (ALT), aspartate transferase (AST), lactate dehydrogenase (LDH), total cholesterol (TCHO), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), uric acid (UA), and blood urea nitrogen (BUN).The tissues were homogenized in 9 volumes of 0.25 M sucrose, and the 10% homogenate was filtered through a 100-mm-pore-size membrane.",ALT,blood,-1
PMC4146555A,"HUVECs were cultured in endothelial cell growth medium M199 supplemented with 15% FBS, 1 mg/ml low serum growth supplements and 2 mM glutamine.",FBS,serum,1
PMC4146555A,"HUVECs were cultured in endothelial cell growth medium M199 supplemented with 15% FBS, 1 mg/ml low serum growth supplements and 2 mM glutamine.",M199,serum,1
PMC4777741A,"Upon activation by PKC, MARCKs migrates from plasma membrane to the cytosol.",PKC,plasma,1
PMC4966842C,"BNAbs are thought to be a key component of a protective HIV vaccine, however, only 15-30% of long-term infected patients develop broadly neutralizing serum responses and known bNAbs show multiple unusual genetic features (e.g., high mutation rates, up to ~30% (nt), very long HCDR3s, up to 39aa), calling for novel immunization strategies.",HIV,serum,1
PMC3680444A,"Cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum.",RPMI,serum,1
PMC3680444A,"Cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum.",USA,serum,1
PMC4146555A,"siRNA2 5'-UUAACAUGCCGGUUAUCCAGGCUCU-3'; control siRNA 5'-UUCUCCGAAGGUGUCACGUTT -3'.The RBP2-siRNA1 H1975 cells, RBP2-siRNA2 H1975 cells and control-siRNA H1975 cells were cultured under serum-free conditions in RPMI 1640 medium for 24 h, respectively.",H1975,serum,1
PMC4146555A,"siRNA2 5'-UUAACAUGCCGGUUAUCCAGGCUCU-3'; control siRNA 5'-UUCUCCGAAGGUGUCACGUTT -3'.The RBP2-siRNA1 H1975 cells, RBP2-siRNA2 H1975 cells and control-siRNA H1975 cells were cultured under serum-free conditions in RPMI 1640 medium for 24 h, respectively.",H1975,serum,1
PMC4146555A,"siRNA2 5'-UUAACAUGCCGGUUAUCCAGGCUCU-3'; control siRNA 5'-UUCUCCGAAGGUGUCACGUTT -3'.The RBP2-siRNA1 H1975 cells, RBP2-siRNA2 H1975 cells and control-siRNA H1975 cells were cultured under serum-free conditions in RPMI 1640 medium for 24 h, respectively.",RPMI,serum,1
PMC4146555A,"siRNA2 5'-UUAACAUGCCGGUUAUCCAGGCUCU-3'; control siRNA 5'-UUCUCCGAAGGUGUCACGUTT -3'.The RBP2-siRNA1 H1975 cells, RBP2-siRNA2 H1975 cells and control-siRNA H1975 cells were cultured under serum-free conditions in RPMI 1640 medium for 24 h, respectively.",H1975,serum,1
PMC3224189A,The effect of heat-inactivated human serum (56degC for 60 minutes) was also tested in the presence of effector PBL.,PBL,serum,1
PMC4815333A,"Transglutaminase (EC 2.3.2.13, protein-glutamine g-glutamyltransferase, TGase) is a member of the enzyme family which catalyzes cross linking between the g-carboxyamide groups of glutamine residues and a variety of primary amines, including the amino group of lysine.1, 2 TGases can be found throughout all groups of organisms including prokaryotes, eukaryotes,1 and plants.3 TGases in animals (aTGase), for example, human blood coagulation factor XIII, TG2, and guinea pig liver TGase, are multi-domain proteins and depend on calcium for regulation of enzyme function.4, 5 Microbial transglutaminases (mTGase), on the other hand, like the enzyme first discovered in S. mobarensis,6 have only one single domain and do not depend on calcium for activity.7 aTGases and mTGases utilize a catalytic triad comprised of Cys, His, and Asp residues, although, relative to the aTGase active site cysteine, in mTGase, the positions of His and Asp appear to be reversed.8, 9, 10S. mobarensis mTGases evolved from proteases and the protein fold surrounding the catalytic triad shows similarities to the aTGases suggesting that both enzymes are related by convergent evolution.",XIII,blood,-1
PMC4815333A,"Transglutaminase (EC 2.3.2.13, protein-glutamine g-glutamyltransferase, TGase) is a member of the enzyme family which catalyzes cross linking between the g-carboxyamide groups of glutamine residues and a variety of primary amines, including the amino group of lysine.1, 2 TGases can be found throughout all groups of organisms including prokaryotes, eukaryotes,1 and plants.3 TGases in animals (aTGase), for example, human blood coagulation factor XIII, TG2, and guinea pig liver TGase, are multi-domain proteins and depend on calcium for regulation of enzyme function.4, 5 Microbial transglutaminases (mTGase), on the other hand, like the enzyme first discovered in S. mobarensis,6 have only one single domain and do not depend on calcium for activity.7 aTGases and mTGases utilize a catalytic triad comprised of Cys, His, and Asp residues, although, relative to the aTGase active site cysteine, in mTGase, the positions of His and Asp appear to be reversed.8, 9, 10S. mobarensis mTGases evolved from proteases and the protein fold surrounding the catalytic triad shows similarities to the aTGases suggesting that both enzymes are related by convergent evolution.",TG2,blood,-1
PMC3816821A,"In contrast, no significant association was discovered between SHIP2 expression and other clinical parameters, such as gender, age, tumor diameter, hepatitis B virus infection, portal vein invasion, lymph node metastasis and TNM stage (Table 1).See full tableTable 1.",TNM,lymph,1
PMC3816821A,"In contrast, no significant association was discovered between SHIP2 expression and other clinical parameters, such as gender, age, tumor diameter, hepatitis B virus infection, portal vein invasion, lymph node metastasis and TNM stage (Table 1).See full tableTable 1.",SHIP2,lymph,1
PMC3092477A,"Add 50 ml Fetal Bovine Serum (FBS), Glutamine to a final concentration of 4 mM, Penicillin-G/Streptomycin solution (Penicillin: final concentration of 100 units ml-1, Streptomycin: final concentration of 100 mg ml-1), to 440 ml DMEM media.",DMEM,Serum,1
PMC3092477A,"Add 50 ml Fetal Bovine Serum (FBS), Glutamine to a final concentration of 4 mM, Penicillin-G/Streptomycin solution (Penicillin: final concentration of 100 units ml-1, Streptomycin: final concentration of 100 mg ml-1), to 440 ml DMEM media.",FBS,Serum,1
PMC3548755A,"Glioma is the most common primary malignant central nervous system (CNS) tumor in adults and arises from neuroepithelial cells, mostly astrocytes or oligodendrocytes.",CNS,astrocytes,1
PMC4370053A,"In patients receiving HSCT, LCs remain predominantly recipient in origin for thefirst 28 d post-transplant, whereas donor-derived cells replace the blood andinterstitial DC compartments [9, 25].",DC,blood,-1
PMC4370053A,"In patients receiving HSCT, LCs remain predominantly recipient in origin for thefirst 28 d post-transplant, whereas donor-derived cells replace the blood andinterstitial DC compartments [9, 25].",HSCT,blood,-1
PMC4426451A,"Compared with fluorescent detection, the bead-based D3 assay benefited from simpler optics (i.e., no filter sets) and stronger light signal (bright field).Extending the clinical utility of D3 to other malignancies, we conducted a pilot study to detect lymphoma cells in fine-needle aspirates (FNA) of lymph nodes in patients with lymphadenopathy.",D3,lymph,1
PMC4426451A,"Compared with fluorescent detection, the bead-based D3 assay benefited from simpler optics (i.e., no filter sets) and stronger light signal (bright field).Extending the clinical utility of D3 to other malignancies, we conducted a pilot study to detect lymphoma cells in fine-needle aspirates (FNA) of lymph nodes in patients with lymphadenopathy.",D3,lymph,1
PMC4426451A,"Compared with fluorescent detection, the bead-based D3 assay benefited from simpler optics (i.e., no filter sets) and stronger light signal (bright field).Extending the clinical utility of D3 to other malignancies, we conducted a pilot study to detect lymphoma cells in fine-needle aspirates (FNA) of lymph nodes in patients with lymphadenopathy.",FNA,lymph,1
PMC3548755A,The levels of serum autoantibodies to SH3GL1 were significantly higher in patients with low-grade gliomas than in healthy donors by ELISA.,SH3GL1,serum,1
PMC3548755A,The levels of serum autoantibodies to SH3GL1 were significantly higher in patients with low-grade gliomas than in healthy donors by ELISA.,ELISA,serum,1
PMC4370053A,"None was detectable on freshly isolated cells, butlangerin was induced at a low level in serum-containing medium and byTGF-b after 18 h of culture of unfractionated PBMC.",PBMC,serum,1
PMC4023823A,"The protein concentration was determined using a bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, Rockford, IL), with bovine serum albumin as the standard.",BCA,serum,1
PMC3816821A,"In addition, certain HCC clinical prognostic factors, such as differentiation (p = 0.005), lymph node metastasis (p = 0.040), and advanced TNM stage classification (p = 0.014), also showed a statistically significant correlation with the decreased five-year survival rate based on Cox regression univariate analysis (Table 2).",TNM,lymph,1
PMC3816821A,"In addition, certain HCC clinical prognostic factors, such as differentiation (p = 0.005), lymph node metastasis (p = 0.040), and advanced TNM stage classification (p = 0.014), also showed a statistically significant correlation with the decreased five-year survival rate based on Cox regression univariate analysis (Table 2).",HCC,lymph,1
PMC3566310A,We also performed serum biochemical tests using the mice fed DDC for 10 wk.,DDC,serum,1
PMC3566310A,"Gross pathological and histopathological examinations of the mice that survived at 11 wk of injury confirmed that liver failure with severe leakage of bile into the liver vasculature is the most plausible cause of death in Fgf7 knockout mice, while no fatal abnormality was recognized in any organs/tissues other than the liver (data not shown).",Fgf7,bile,1
PMC3906064A,The Exon 19 deletion could be detected when as few as 9 cells/mL were spiked into NHD blood with a decreasing [?],NHD,blood,-1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",DDC,Serum,1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",ALT,Serum,1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",ALP,Serum,1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",AST,Serum,1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",Fgf7,Serum,1
PMC3566310A,"(G) Serum TBIL, ALP, AST, and ALT levels were measured in control and Fgf7 knockout mice fed a normal (wild type, n = 3; knockout, n = 3) or DDC-containing (wild type, n = 6; knockout, n = 3) diet for 10 wk.",TBIL,Serum,1
PMC3566310A,These results indicate that the lack of FGF7 exacerbates damages in both hepatocytes and bile ducts and that the LPC response directly correlates with liver function and survival of an organism upon toxic insult.,FGF7,bile,1
PMC3566310A,These results indicate that the lack of FGF7 exacerbates damages in both hepatocytes and bile ducts and that the LPC response directly correlates with liver function and survival of an organism upon toxic insult.,LPC,bile,1
PMC4882422A,"By neutralization with anti-oxidant agent N-acetyl-l-cysteine, the serum GPT levels were decreased in the PtenDhep mice stimulated with LPS (Fig. 10E).",GPT,serum,1
PMC4882422A,"By neutralization with anti-oxidant agent N-acetyl-l-cysteine, the serum GPT levels were decreased in the PtenDhep mice stimulated with LPS (Fig. 10E).",LPS,serum,1
PMC3474961A,"Nevertheless, biochemical recurrence (BCR), defined by increased serum PSA levels following prostatectomy or radiation therapy for clinically localized PCa, has been shown to predict metastatic progression (MP) and prostate cancer-specific mortality (PCSM) by a median of 8 years and 13 years, respectively [16, 17].",BCR,serum,1
PMC3474961A,"Nevertheless, biochemical recurrence (BCR), defined by increased serum PSA levels following prostatectomy or radiation therapy for clinically localized PCa, has been shown to predict metastatic progression (MP) and prostate cancer-specific mortality (PCSM) by a median of 8 years and 13 years, respectively [16, 17].",PSA,serum,1
PMC3474961A,"Nevertheless, biochemical recurrence (BCR), defined by increased serum PSA levels following prostatectomy or radiation therapy for clinically localized PCa, has been shown to predict metastatic progression (MP) and prostate cancer-specific mortality (PCSM) by a median of 8 years and 13 years, respectively [16, 17].",PCSM,serum,1
PMC3929731A,Tail vein blood was collected from host mice 20 to 30 minutes after feeding on exposure day 7 for quantitation of internal BPA levels.,BPA,blood,1
PMC2156208A,"1997), and TGN to plasma membrane (PM) transport (Hirschberg et al. 1998",PM,plasma,1
PMC2156208A,"1997), and TGN to plasma membrane (PM) transport (Hirschberg et al. 1998",TGN,plasma,1
PMC3018888A,"A proteomics end point analysis in a phase II trial of imatinib identified a statistically significant trend between pretreatment p-Kit levels in both microdissected tumor and stroma with gastrointestinal toxicity, between tumor EGFR and PDGFR with grade of fatigue, and EGFR and p-AKT levels with ascites and edema (P = 0.01).",EGFR,ascites,1
PMC3018888A,"A proteomics end point analysis in a phase II trial of imatinib identified a statistically significant trend between pretreatment p-Kit levels in both microdissected tumor and stroma with gastrointestinal toxicity, between tumor EGFR and PDGFR with grade of fatigue, and EGFR and p-AKT levels with ascites and edema (P = 0.01).",AKT,ascites,1
PMC3018888A,"A proteomics end point analysis in a phase II trial of imatinib identified a statistically significant trend between pretreatment p-Kit levels in both microdissected tumor and stroma with gastrointestinal toxicity, between tumor EGFR and PDGFR with grade of fatigue, and EGFR and p-AKT levels with ascites and edema (P = 0.01).",PDGFR,ascites,1
PMC3018888A,"A proteomics end point analysis in a phase II trial of imatinib identified a statistically significant trend between pretreatment p-Kit levels in both microdissected tumor and stroma with gastrointestinal toxicity, between tumor EGFR and PDGFR with grade of fatigue, and EGFR and p-AKT levels with ascites and edema (P = 0.01).",EGFR,ascites,1
PMC3378878A,"HEK293 cells and MEFs were maintained in Dulbecco's modified Eagle's Medium (DMEM) (Gibco) supplemented with 10% heat-inactivated fetal bovine serum, 4 mM l-glutamine (Gibco), 1 mM sodium pyruvate (Gibco) and 50 mM b-mercaptoethanol (Gibco).",DMEM,serum,1
PMC3378878A,"HEK293 cells and MEFs were maintained in Dulbecco's modified Eagle's Medium (DMEM) (Gibco) supplemented with 10% heat-inactivated fetal bovine serum, 4 mM l-glutamine (Gibco), 1 mM sodium pyruvate (Gibco) and 50 mM b-mercaptoethanol (Gibco).",HEK293,serum,1
PMC3378878A,"Splenocytes from 8- to 12-weeks-old wild-type and Nfat5-/- mice (46) were isolated by density gradient sedimentation with Lymphoprep (Axis-Shield PoC AS) and stimulated with 2.5 ug/ml concanavalin A (Sigma-Aldrich) plus 25 ng/ml of IL-2 (Chiron) during 24 h in culture medium containing DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 50 uM b-mercaptoethanol, penicillin-streptomycin and non-essential amino acids (Gibco) and then cultured under isotonic or hypertonic conditions as indicated in the figure legend.",IL-2,serum,1
PMC3378878A,"Splenocytes from 8- to 12-weeks-old wild-type and Nfat5-/- mice (46) were isolated by density gradient sedimentation with Lymphoprep (Axis-Shield PoC AS) and stimulated with 2.5 ug/ml concanavalin A (Sigma-Aldrich) plus 25 ng/ml of IL-2 (Chiron) during 24 h in culture medium containing DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 50 uM b-mercaptoethanol, penicillin-streptomycin and non-essential amino acids (Gibco) and then cultured under isotonic or hypertonic conditions as indicated in the figure legend.",AS,serum,1
PMC3378878A,"Splenocytes from 8- to 12-weeks-old wild-type and Nfat5-/- mice (46) were isolated by density gradient sedimentation with Lymphoprep (Axis-Shield PoC AS) and stimulated with 2.5 ug/ml concanavalin A (Sigma-Aldrich) plus 25 ng/ml of IL-2 (Chiron) during 24 h in culture medium containing DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 50 uM b-mercaptoethanol, penicillin-streptomycin and non-essential amino acids (Gibco) and then cultured under isotonic or hypertonic conditions as indicated in the figure legend.",DMEM,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,PCR,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,PCR,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,cDNA,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,MKRN1,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,SEREX,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,SCC,serum,1
PMC2722670A,s-MKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC.IPTG: isopropyl b-D-thiogalactoside; ORF: open reading frame; RT-PCR: reverse transcription-PCR; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-MKRN1-Abs: serum anti-MKRN1 antibodies.,ORF,serum,1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",HCC1419,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",SK,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",ATCC,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",H1650,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",MCF7,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",Mel-28,blood,-1
PMC3906064A,"For cell culture spiked experiments, fixed MCF7, HCC1419, H1650, BT20 or SK-Mel-28 cells (ATCC, Manassas, VA) were added to the control blood.",BT20,blood,-1
PMC3411798A,We focused on those genes that fell in the gene ontology category of 'plasma membrane' and identified CD166/ALCAM as one of only two common castration-enriched cell surface molecules (Table S1).,ALCAM,plasma,1
PMC3411798A,We focused on those genes that fell in the gene ontology category of 'plasma membrane' and identified CD166/ALCAM as one of only two common castration-enriched cell surface molecules (Table S1).,S1,plasma,1
PMC3789024A,"However, Trop-2 expression in AdC was correlated with the histological grade, lymph node metastasis and TNM stage.",Trop-2,lymph,1
PMC3789024A,"However, Trop-2 expression in AdC was correlated with the histological grade, lymph node metastasis and TNM stage.",TNM,lymph,1
PMC3566310A,(blood cell) fractions were isolated from the livers of mice fed DDC.,DDC,blood,-1
PMC3906064A,less than 20% and a % CV less than 25% over the range of 9-300 spiked cells/mL in NHD blood.,NHD,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",EDTA,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",EDTA,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",EDTA,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",PBS,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",PBS,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",PBS,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",FBS,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",FBS,blood,-1
PMC3906064A,"After fixation the blood was brought to a volume of 50 mL with wash buffer (1x PBS, 10% FBS and 0.02M EDTA) and spun down at 500x g for 15 min at 4degC. The blood was washed and resuspended to the original blood volume with wash buffer.",FBS,blood,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",LGR5,hair,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",LGR5,hair,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",IFE,hair,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",IFE,hair,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",LGR6,hair,-1
PMC3049439A,"LGR5 stem cells generate progeny that repopulate the hair follicle (blue), whereas LGR6 stem cells predominantly generate progeny for sebaceous gland and IFE (blue) and, to a lesser extent, hair follicle (light blue).",LGR6,hair,-1
PMC3049439A,LGR6 indicate different stem-cell populations along hair follicles.,LGR6,hair,-1
PMC3135497A,"The serum antibody levels against HCA-81/97 were significantly higher in patients with esophageal SCC than in healthy donors (Figure 5, Table 3).",SCC,serum,1
PMC3754468A,"The serum-dependent TRAMP-C1 cell line was used as internal control, together with a wild-type or, for TAg, a TRAMP postnatal prostate.",TRAMP,serum,1
PMC3754468A,"The serum-dependent TRAMP-C1 cell line was used as internal control, together with a wild-type or, for TAg, a TRAMP postnatal prostate.",TRAMP,serum,1
PMC3754468A,"The serum-dependent TRAMP-C1 cell line was used as internal control, together with a wild-type or, for TAg, a TRAMP postnatal prostate.",C1,serum,1
PMC4606116A,"As a blood biomarker of CRC, the specificity and sensitivity of CEA are around 70~80% [12, 43].",CRC,blood,-1
PMC4606116A,"As a blood biomarker of CRC, the specificity and sensitivity of CEA are around 70~80% [12, 43].",CEA,blood,-1
PMC3110956A,"We reported previously that, while Foxl1-expressing cells are undetectable in the healthy liver, Foxl1 expression is dramatically induced in the liver after bile duct ligation or in mice fed a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-containing diet.",Foxl1,bile,1
PMC3440735A,"Carcinoembryonic antigen (CEA) is a well-known tumor marker and has been used to detect small amounts of adenocarcinoma cells in the blood, peritoneal wash or other body fluids (8-12).",CEA,blood,-1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",NH2-ARPPLLGSEEPLCPASR,sera,1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",NH2-ARPPLLGSEEPLCPASR,serum,1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",SCC,sera,1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",SCC,serum,1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",COOH,sera,1
PMC3135497A,"The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs.",COOH,serum,1
PMC3490134A,"KO mouse prostates were able to involute and regenerate similarly to WT prostates in response to fluctuating serum testosterone levels, suggesting that RBP-J mediated Notch signaling is not essential for the regenerative capacity of prostate epithelia (Fig.",KO,serum,1
PMC3490134A,"KO mouse prostates were able to involute and regenerate similarly to WT prostates in response to fluctuating serum testosterone levels, suggesting that RBP-J mediated Notch signaling is not essential for the regenerative capacity of prostate epithelia (Fig.",RBP,serum,1
PMC3440735A,Detection of circulating tumor cells at the mRNA level [reverse transcription-polymerase chain reaction (RT-PCR)] in blood samples of patients with cancer could serve as a unique and easy diagnostic tool to predict cancer recurrence and to monitor treatment effectiveness (5-7).,PCR,blood,-1
PMC3440735A,Detection of circulating tumor cells at the mRNA level [reverse transcription-polymerase chain reaction (RT-PCR)] in blood samples of patients with cancer could serve as a unique and easy diagnostic tool to predict cancer recurrence and to monitor treatment effectiveness (5-7).,mRNA,blood,-1
PMC2757864A,"(35) as a CT antigen by serological screening of recombinant expression libraries of human cancer with human serum (SEREX), providing validation for our approach to defining putative cell surface CT antigens.",SEREX,serum,1
PMC2757864A,"(35) as a CT antigen by serological screening of recombinant expression libraries of human cancer with human serum (SEREX), providing validation for our approach to defining putative cell surface CT antigens.",CT,serum,1
PMC2757864A,"(35) as a CT antigen by serological screening of recombinant expression libraries of human cancer with human serum (SEREX), providing validation for our approach to defining putative cell surface CT antigens.",CT,serum,1
PMC3934101A,"Lgr5 has been identified as a stem cell marker in the small intestine30, stomach 31 and hair follicles32.",Lgr5,hair,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",CD14,blood,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",CMAP,blood,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",DC,blood,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",CD141,blood,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",DC,blood,-1
PMC3476529A,"Enrichment scores for human skin CD141hi DCs with all other human monocyte and DC subsets were significant at p  0.0001.(C) CMAP enrichment scores for human (1) CD141 lineage, (2) CD1c lineage, (3) skin CD14+ DCs, and (4) blood CD14+ monocytes against mouse monocyte and DC subsets.",CD14,blood,-1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",RAN,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",RAN,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",NPC,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",NPC,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",TRIM29,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",TRIM29,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",SQSTM1,lymph,1
PMC5085135A,"We observed that RAN and TRIM29 expression level were closely correlated with lymph node (P = 0.000; P = 0.000) and distant metastasis (P = 0.002; P = 0.000), and clinical stage (P = 0.036; P = 0.041); SQSTM1 expression level was closely correlated with lymph node metastasis (P = 0.002), but not correlated with distant metastasis (P = 0.073) and clinical stage (P = 0.733) in NPC patients.",SQSTM1,lymph,1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",FACS,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD16,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD141,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",DC,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,bone marrow,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,blood,-1
PMC3476529A,"Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCsMicroarray expression profiles were obtained from FACS-purified monocyte and DC subsets from human blood and skin and mouse bone marrow, blood, spleen, liver, and lung.(A) Cluster dendrogram of human DC and monocyte subsets after removal of tissue-specific genes demonstrating the relationships between blood CD141+ DCs and skin CD141hi DCs (red), blood and skin CD1c+ DCs (green), CD14+ monocytes and DCs (blue), blood CD16+ monocytes (light blue), and pDCs (brown).",CD14,blood,-1
PMC3906064A,This antibody ferrofluid solution was incubated for 30 minutes on ice and then washed twice with CMEM before transferring into the blood sample.,CMEM,blood,-1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",LPS,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",IFN,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",TNF,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",CD14,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",pIC,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",CXCL10,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",LPS,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",GM,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",IFN,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",TNF,CSF,1
PMC3476529A,"CD141hi DCs Synthesize CXCL10 and TNF-a but Not IL-12(A) IL-12p70 and IL-23p19 production from unstimulated (-), LPS (LPS)-, poly(I:C) (pIC)-, a cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and pIC (c)-, and cocktail with the addition of GM-CSF (c + GM-CSF)-stimulated CD141hi DCs, CD1c+ DCs, CD14+ DCs, and LCs with mo-DCs as control.",GM,CSF,1
PMC3548755A,"In the C6 glioma model, the serum levels of autoantibody to SH3GL1 significantly increased in the rats at 2-week after tumor inoculation compared with those at 3-day after the inoculation (p = 0.0028) (Figure7B).",C6,serum,1
PMC3548755A,"In the C6 glioma model, the serum levels of autoantibody to SH3GL1 significantly increased in the rats at 2-week after tumor inoculation compared with those at 3-day after the inoculation (p = 0.0028) (Figure7B).",SH3GL1,serum,1
PMC3284520A,"However, the prognostic potential of number of lymph nodes involved at presentation might vary with the stage of CRC at initial presentation, as the Basingstoke Predictive Index is applied for patients with liver metastasis, leaving the possibility that the number of lymph nodes involved at initial presentation might not have a similar prognostic value for patients with stage I, II and III of the disease.",CRC,lymph,-1
PMC3284520A,"However, the prognostic potential of number of lymph nodes involved at presentation might vary with the stage of CRC at initial presentation, as the Basingstoke Predictive Index is applied for patients with liver metastasis, leaving the possibility that the number of lymph nodes involved at initial presentation might not have a similar prognostic value for patients with stage I, II and III of the disease.",CRC,lymph,-1
PMC3284520A,"However, the prognostic potential of number of lymph nodes involved at presentation might vary with the stage of CRC at initial presentation, as the Basingstoke Predictive Index is applied for patients with liver metastasis, leaving the possibility that the number of lymph nodes involved at initial presentation might not have a similar prognostic value for patients with stage I, II and III of the disease.",III,lymph,-1
PMC3284520A,"However, the prognostic potential of number of lymph nodes involved at presentation might vary with the stage of CRC at initial presentation, as the Basingstoke Predictive Index is applied for patients with liver metastasis, leaving the possibility that the number of lymph nodes involved at initial presentation might not have a similar prognostic value for patients with stage I, II and III of the disease.",III,lymph,-1
PMC4259449A,"Third, dormant DTC do not express any known biomarker that is detectable via non-invasive or minimally invasive techniques such as urine collection or peripheral blood draw.",DTC,blood,-1
PMC4259449A,"Third, dormant DTC do not express any known biomarker that is detectable via non-invasive or minimally invasive techniques such as urine collection or peripheral blood draw.",DTC,urine,1
PMC4685746A,"A microscopic dissection of this process showed that CCL2 and CCL20 (CCR2 and CCR6 ligands, respectively) are expressed by discrete portions of the hair follicle that function as portals for monocyte recruitment [51].",CCR2,hair,-1
PMC4685746A,"A microscopic dissection of this process showed that CCL2 and CCL20 (CCR2 and CCR6 ligands, respectively) are expressed by discrete portions of the hair follicle that function as portals for monocyte recruitment [51].",CCL2,hair,-1
PMC4685746A,"A microscopic dissection of this process showed that CCL2 and CCL20 (CCR2 and CCR6 ligands, respectively) are expressed by discrete portions of the hair follicle that function as portals for monocyte recruitment [51].",CCR6,hair,-1
PMC4685746A,"A microscopic dissection of this process showed that CCL2 and CCL20 (CCR2 and CCR6 ligands, respectively) are expressed by discrete portions of the hair follicle that function as portals for monocyte recruitment [51].",CCL20,hair,-1
PMC3475800A,"Confocal microscopy revealed that the ICD is found on the membrane in 100% of the cells and within the nucleus in 15% of the cells, while Trop2 ECD can be detected only on the plasma membrane and in the cytoplasm (Fig.",ICD,plasma,1
PMC3475800A,"Confocal microscopy revealed that the ICD is found on the membrane in 100% of the cells and within the nucleus in 15% of the cells, while Trop2 ECD can be detected only on the plasma membrane and in the cytoplasm (Fig.",Trop2,plasma,1
PMC3475800A,"Confocal microscopy revealed that the ICD is found on the membrane in 100% of the cells and within the nucleus in 15% of the cells, while Trop2 ECD can be detected only on the plasma membrane and in the cytoplasm (Fig.",ECD,plasma,1
PMC3224774A,"Analysis was conducted with FACScan, using Cell Quest software (Becton Dickinson, Franklin Lakes, NJ).A standard 5-hour chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-PaqueTM PLUS (GE Healthcare, Uppsala, Sweden) separated peripheral blood lymphocytes (PBLs) obtained from several healthy donors against each cell line.",PLUS,blood,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,serum,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,breast milk,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,blood,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,urine,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,serum,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,breast milk,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,blood,-1
PMC4519179A,"Consequently, BPA and its metabolite BPA-glucuronide are detectable in the urine of most adults and children [16, 17], serum of pregnant women and newborns [18, 19], breast milk [20], amniotic fluid [21], cord blood [22, 23] and fetal livers [24].",BPA,urine,-1
PMC3605152A,"For analysis of TIM-3 and PD-1 expression on T cells of HIV-1-infected and healthy donors, whole blood samples were stained with TIM-3-PE, PD-1-PE or a PE-labelled isotype control (all from Biolegend).",PD-1-PE,blood,-1
PMC3605152A,"For analysis of TIM-3 and PD-1 expression on T cells of HIV-1-infected and healthy donors, whole blood samples were stained with TIM-3-PE, PD-1-PE or a PE-labelled isotype control (all from Biolegend).",TIM-3,blood,-1
PMC3605152A,"For analysis of TIM-3 and PD-1 expression on T cells of HIV-1-infected and healthy donors, whole blood samples were stained with TIM-3-PE, PD-1-PE or a PE-labelled isotype control (all from Biolegend).",PD-1,blood,-1
PMC3605152A,"For analysis of TIM-3 and PD-1 expression on T cells of HIV-1-infected and healthy donors, whole blood samples were stained with TIM-3-PE, PD-1-PE or a PE-labelled isotype control (all from Biolegend).",TIM-3-PE,blood,-1
PMC3605152A,"For analysis of TIM-3 and PD-1 expression on T cells of HIV-1-infected and healthy donors, whole blood samples were stained with TIM-3-PE, PD-1-PE or a PE-labelled isotype control (all from Biolegend).",T,blood,-1
PMC4519179A,"Although BPA is rapidly metabolized to glucuronidated BPA (BPA-G) which lacks bioactivity and is excreted within 6-24 hour, free BPA has been detected in human sera at 0.2 to 1.0 ng/ml levels [22, 25].",BPA,sera,-1
PMC4519179A,"Although BPA is rapidly metabolized to glucuronidated BPA (BPA-G) which lacks bioactivity and is excreted within 6-24 hour, free BPA has been detected in human sera at 0.2 to 1.0 ng/ml levels [22, 25].",BPA,sera,-1
PMC4519179A,"Although BPA is rapidly metabolized to glucuronidated BPA (BPA-G) which lacks bioactivity and is excreted within 6-24 hour, free BPA has been detected in human sera at 0.2 to 1.0 ng/ml levels [22, 25].",BPA,sera,-1
PMC4519179A,"Although BPA is rapidly metabolized to glucuronidated BPA (BPA-G) which lacks bioactivity and is excreted within 6-24 hour, free BPA has been detected in human sera at 0.2 to 1.0 ng/ml levels [22, 25].",BPA,sera,-1
PMC4673473A,"Previous protocols for hepatocyte differentiation from bone marrow cells unanimously used hepatocyte-conditioned medium or HGF from the beginning, which prevented expansion or evaluation of the putative endodermal precursor cells.9, 10 Transfer of bone marrow cells into mice cannot be used to trace cellular differentiation.6, 8",HGF,bone marrow,-1
PMC4673473A,"Previous protocols for hepatocyte differentiation from bone marrow cells unanimously used hepatocyte-conditioned medium or HGF from the beginning, which prevented expansion or evaluation of the putative endodermal precursor cells.9, 10 Transfer of bone marrow cells into mice cannot be used to trace cellular differentiation.6, 8",HGF,bone marrow,-1
PMC3369609A,"For the generation of moDCs, tissue culture plastic adherent CD14+ monocytes were cultured in complete RPMI-1% NHS with GM-CSF and IL-4 for 5 to 6 days.",CD14,CSF,1
PMC3369609A,"For the generation of moDCs, tissue culture plastic adherent CD14+ monocytes were cultured in complete RPMI-1% NHS with GM-CSF and IL-4 for 5 to 6 days.",IL-4,CSF,1
PMC3369609A,"For the generation of moDCs, tissue culture plastic adherent CD14+ monocytes were cultured in complete RPMI-1% NHS with GM-CSF and IL-4 for 5 to 6 days.",NHS,CSF,1
PMC3369609A,"For the generation of moDCs, tissue culture plastic adherent CD14+ monocytes were cultured in complete RPMI-1% NHS with GM-CSF and IL-4 for 5 to 6 days.",GM,CSF,1
PMC3369609A,"Complete RPMI 1640 included 10mM HEPES, 1% penicillin/streptomycin (Media Lab, Memorial Sloan-Kettering Cancer Center [MSKCC]), 50mM 2-mercaptoethanol (Invitrogen), 1% l-glutamine (Invitrogen), and 1% or 10% volume/volume heat-inactivated, pooled normal human serum (NHS; Atlanta Biologicals).",NHS,serum,1
PMC3369609A,"Complete RPMI 1640 included 10mM HEPES, 1% penicillin/streptomycin (Media Lab, Memorial Sloan-Kettering Cancer Center [MSKCC]), 50mM 2-mercaptoethanol (Invitrogen), 1% l-glutamine (Invitrogen), and 1% or 10% volume/volume heat-inactivated, pooled normal human serum (NHS; Atlanta Biologicals).",MSKCC,serum,1
PMC3369609A,"Complete RPMI 1640 included 10mM HEPES, 1% penicillin/streptomycin (Media Lab, Memorial Sloan-Kettering Cancer Center [MSKCC]), 50mM 2-mercaptoethanol (Invitrogen), 1% l-glutamine (Invitrogen), and 1% or 10% volume/volume heat-inactivated, pooled normal human serum (NHS; Atlanta Biologicals).",RPMI,serum,1
PMC3369609A,"Complete RPMI 1640 included 10mM HEPES, 1% penicillin/streptomycin (Media Lab, Memorial Sloan-Kettering Cancer Center [MSKCC]), 50mM 2-mercaptoethanol (Invitrogen), 1% l-glutamine (Invitrogen), and 1% or 10% volume/volume heat-inactivated, pooled normal human serum (NHS; Atlanta Biologicals).",HEPES,serum,1
PMC4646304A,"MCF10A cells were cultured in Dulbecco's modified Eagle's media (DMEM)/F-12(1:1) (Life Technologies) with 5% horse serum, 10 mg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 mg/ml hydrocortisone, and penicillin/streptomycin (Invitrogen).",EGF,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",CSF,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",VIVO,CSF,-1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",VIVO,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",TNF,CSF,-1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",TNF,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",CD34,CSF,-1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",CD34,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",GM,CSF,-1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",GM,serum,1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",X,CSF,-1
PMC3369609A,"Media, media supplements, cytokines, and commercial sources were exactly as published9 (see erratum for correct FLT-3-ligand dose22).In brief, however, CD34+ HPCs were cultured in serum-free X-VIVO 15, supplemented with GM-CSF and TNF-a, to which c-kit-ligand and FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day culture.",X,serum,1
PMC3369609A,G-CSF-elicited CD34+ HPCs from healthy donors undergoing leukopheresis for allogeneic hematopoietic stem cell transplantation were used to generate LCs and DDC-IDCs.,CD34,CSF,1
PMC3369609A,G-CSF-elicited CD34+ HPCs from healthy donors undergoing leukopheresis for allogeneic hematopoietic stem cell transplantation were used to generate LCs and DDC-IDCs.,DDC,CSF,1
PMC3369609A,"Epidermal sheets and cells were never exposed to xenogeneic serum (eg, FCS).",FCS,serum,-1
PMC3369609A,"GM-CSF 1000 IU/mL was added or not to maintain LC viability21 after either method to obtain epidermal sheets, but no other cytokines were added for maturation or activation.",GM,CSF,1
PMC4646304A,"MDA-MB-231 human breast cancer cell lines were obtained from the ATCC and cultured in DMEM with 10% fetal bovine serum (FBS), 2 mm glutamine, and penicillin/streptomycin (Invitrogen) as described (31, 32).",MB-231,serum,1
PMC4646304A,"MDA-MB-231 human breast cancer cell lines were obtained from the ATCC and cultured in DMEM with 10% fetal bovine serum (FBS), 2 mm glutamine, and penicillin/streptomycin (Invitrogen) as described (31, 32).",FBS,serum,1
PMC4646304A,"MDA-MB-231 human breast cancer cell lines were obtained from the ATCC and cultured in DMEM with 10% fetal bovine serum (FBS), 2 mm glutamine, and penicillin/streptomycin (Invitrogen) as described (31, 32).",DMEM,serum,1
PMC4646304A,"MDA-MB-231 human breast cancer cell lines were obtained from the ATCC and cultured in DMEM with 10% fetal bovine serum (FBS), 2 mm glutamine, and penicillin/streptomycin (Invitrogen) as described (31, 32).",ATCC,serum,1
PMC4646304A,"MDA-MB-231 human breast cancer cell lines were obtained from the ATCC and cultured in DMEM with 10% fetal bovine serum (FBS), 2 mm glutamine, and penicillin/streptomycin (Invitrogen) as described (31, 32).",MDA,serum,1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",NOTA,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",TAT,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",rGO,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",TAT,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",TRC105,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",TAT,blood,-1
PMC4863686A,"In vivo, in vitro, and ex vivo studies confirmed the specificity of (64)Cu-NOTA-rGO-TRC105 for tumor vascular CD105.243 Lalwani et al244 reported that oxidized single- and multi-walled GO nanoribbons exhibit approximately five- to tenfold signal enhancement for photoacoustic tomography in comparison to blood at the wavelength of 755 nm, and ~10%-28% signal enhancement for thermoacoustic tomography (TAT) in comparison to deionized water at 3 GHz. Oxidized graphene nanoribbons show promise as multimodal photoacoustic tomography and TAT contrast agents, and oxidized graphene NPs are suitable contrast agents for TAT.",GO,blood,-1
PMC4370053A,(B) Langerin induction on sorted monocytes and blood DCs after 18h of culture in serum containing medium and TGF-b.*P  0.05; **P 0.01.,TGF,serum,1
PMC4370053A,(B) Langerin induction on sorted monocytes and blood DCs after 18h of culture in serum containing medium and TGF-b.*P  0.05; **P 0.01.,TGF,blood,-1
PMC4370053A,(B) Langerin induction on sorted monocytes and blood DCs after 18h of culture in serum containing medium and TGF-b.*P  0.05; **P 0.01.,Langerin,serum,1
PMC4370053A,(B) Langerin induction on sorted monocytes and blood DCs after 18h of culture in serum containing medium and TGF-b.*P  0.05; **P 0.01.,Langerin,blood,-1
PMC3039945A,"The over-expression of claudin-1 and -4 occurs not only in the plasma membrane, but also in the cytoplasm [176], and its function in CRC is not yet defined.",CRC,plasma,1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",Alix,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",ARRDC1,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",MVB,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",MVB,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",Paca44,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",Paca44,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",TSG101,plasma,-1
PMC4251850A,"Syntenin, Alix and ESCRT proteins are involved in the formation and release of EVs from the MVB [30].The affinity pure vesicles derived from the pancreatic cancer cells as presented in this work have the attributes of both, of plasma membrane origin (ectosomes) and of MVB origin (exosomes).The ectosomal proteins ARRDC1 and tetraspanin TSG101 are present in affinity pure vesicle preparations from Paca44 cells, and the EVs from Paca44 seem to be a mixture of both vesicle types.",ESCRT,plasma,-1
PMC4366163A,GFP-tagged PLLP co-localizes with Ocln and Cldn4 at the TJ and along the basolateral plasma membrane in MDCK II cells (Fig.,Cldn4,plasma,1
PMC4366163A,GFP-tagged PLLP co-localizes with Ocln and Cldn4 at the TJ and along the basolateral plasma membrane in MDCK II cells (Fig.,PLLP,plasma,1
PMC4366163A,GFP-tagged PLLP co-localizes with Ocln and Cldn4 at the TJ and along the basolateral plasma membrane in MDCK II cells (Fig.,GFP,plasma,1
PMC4366163A,GFP-tagged PLLP co-localizes with Ocln and Cldn4 at the TJ and along the basolateral plasma membrane in MDCK II cells (Fig.,MDCK,plasma,1
PMC4473102A,"For the analysis of IL-17-positive CD4+T cells in PBMCs and of IL-17 and IL-23 synovial fluid levels, the significance of the differences between patients and controls was determined using the unpaired Student's t-test.",IL-17,synovial fluid,1
PMC4473102A,"For the analysis of IL-17-positive CD4+T cells in PBMCs and of IL-17 and IL-23 synovial fluid levels, the significance of the differences between patients and controls was determined using the unpaired Student's t-test.",IL-23,synovial fluid,1
PMC4202120B,"NA associated with PCa) by PCR, and PSA serum levels, was reported to have a superior diagnostic value compared to either marker alone [320], in particular in the active surveillance group of patients [321].",PCR,serum,1
PMC4202120B,"NA associated with PCa) by PCR, and PSA serum levels, was reported to have a superior diagnostic value compared to either marker alone [320], in particular in the active surveillance group of patients [321].",PSA,serum,1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,NSCLC,lymph,1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,NSCLC,blood,-1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,NSCLC,lymph,1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,NSCLC,blood,-1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,ALDH,lymph,1
PMC3844723A,Recently it has also reported that selected markers including EpCAM have been found to be present at high levels in the primary tumors while the level of expression was found to be low or non-detectable in normal lymph nodes or peripheral blood of NSCLC patients [34].Our results also confirm an elevated level of activity of the ALDH in seven out of eight NSCLC cell lines where 75% of squamous cell carcinoma and all the large cells are positive for the enzyme.,ALDH,blood,1
PMC3551651A,"Furthermore, pTNM stage (P = 0.027) and lymph node metastasis (P = 0.015) were identified as independent predictive factors for poor outcome of LSCC.",LSCC,lymph,1
PMC3551651A,"Furthermore, pTNM stage (P = 0.027) and lymph node metastasis (P = 0.015) were identified as independent predictive factors for poor outcome of LSCC.",pTNM,lymph,1
PMC2722670A,"On the other hand, Hirotsune et al. have reported that a putative pseudogene-induced destabilization of MKRN1 led to defects of differentiation such as polycystic kidneys and bone deformity [32].The presence of serum MKRN1 antibodies (s-MKRN1-Abs) in cancer patients was examined by Western blotting (Figure 1).",MKRN1,serum,1
PMC2722670A,"On the other hand, Hirotsune et al. have reported that a putative pseudogene-induced destabilization of MKRN1 led to defects of differentiation such as polycystic kidneys and bone deformity [32].The presence of serum MKRN1 antibodies (s-MKRN1-Abs) in cancer patients was examined by Western blotting (Figure 1).",MKRN1,serum,1
PMC5355237A,"Several recent studies have described similar functions of antibody drugs in cancer therapy [40, 41].The JAK/STAT pathway is crucial in signaling by cytokine receptors, blood formation and the immune response [42].",JAK,blood,-1
PMC5355237A,"Several recent studies have described similar functions of antibody drugs in cancer therapy [40, 41].The JAK/STAT pathway is crucial in signaling by cytokine receptors, blood formation and the immune response [42].",STAT,blood,-1
PMC3551651A,"Correlation of aB-crystallin expression with clinicopathological characteristics of LSCCUnivariate analysis showed that the life span of LSCC patients was correlated with aB-crystallin expression (P = 0.010), pTNM stage (P  0.001), lymph node metastasis (P  0.001) and tumor differentiation (P = 0.022). Multivariate analysis with the Cox regression model indicated that aB-crystallin protein level may serve as an independent prognostic factor for overall survival (P = 0.013) (Table 2).",pTNM,lymph,1
PMC3551651A,"Correlation of aB-crystallin expression with clinicopathological characteristics of LSCCUnivariate analysis showed that the life span of LSCC patients was correlated with aB-crystallin expression (P = 0.010), pTNM stage (P  0.001), lymph node metastasis (P  0.001) and tumor differentiation (P = 0.022). Multivariate analysis with the Cox regression model indicated that aB-crystallin protein level may serve as an independent prognostic factor for overall survival (P = 0.013) (Table 2).",LSCC,lymph,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",RM1,serum,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",TRAMP,serum,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",NE,serum,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",PCSC,serum,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",C2,serum,1
PMC3754468A,"Unsupervised clustering revealed that the gene expression profile of T-NE PCSCs was very different from that of the other stage-specific PCSC lines and of serum-dependent mouse prostate cancer cell lines, such as TRAMP-C1/C2 and RM1 cells (Fig.",T,serum,1
PMC4621003A,ELISA of serum from vaccinated mice collected 7 days after boost was performed by plating 100 ml of 1 mg/ml VLP in triplicate in 96-well flat bottom ELISA plates overnight at 4degC.,VLP,serum,1
PMC4621003A,ELISA of serum from vaccinated mice collected 7 days after boost was performed by plating 100 ml of 1 mg/ml VLP in triplicate in 96-well flat bottom ELISA plates overnight at 4degC.,ELISA,serum,1
PMC4621003A,ELISA of serum from vaccinated mice collected 7 days after boost was performed by plating 100 ml of 1 mg/ml VLP in triplicate in 96-well flat bottom ELISA plates overnight at 4degC.,ELISA,serum,1
PMC4202120A,"Ideally, it should perform better than the current histopathological/clinical grading (Gleason score in combination with tumor size, lymph node involvement, metastases, and PSA levels).",PSA,lymph,1
PMC4999623A,"In adult (human and rat) liver, the immature biliary cells present in the reactive bile ductules express NCAM.120,135,136 These ductules occur in various liver diseases and contribute to an atypical ductular reaction,137,138 which is modulated by NCAM.139 In humans, NCAM may have a role in intrahepatic duct development since its patchy expression is observed in the duplicated ductal plates and merging bile ducts from gestational 16th to 40th week.",NCAM,bile,1
PMC4999623A,"In adult (human and rat) liver, the immature biliary cells present in the reactive bile ductules express NCAM.120,135,136 These ductules occur in various liver diseases and contribute to an atypical ductular reaction,137,138 which is modulated by NCAM.139 In humans, NCAM may have a role in intrahepatic duct development since its patchy expression is observed in the duplicated ductal plates and merging bile ducts from gestational 16th to 40th week.",NCAM,bile,1
PMC4165776A,Testing MCF7 Cell Capture and Release from Artificial Blood.,MCF7,Blood,-1
PMC5480073A,"Establishing optimal cut off for threshold values of this blood-based marker panel with enhanced sensitivity and specificity (Supplementary Table S2, Supplementary Figure S1) indicated that these markers were significantly associated with median survival (Supplementary Table S3, Supplementary Figure S2) in GBM.",S2,blood,1
PMC5480073A,"Establishing optimal cut off for threshold values of this blood-based marker panel with enhanced sensitivity and specificity (Supplementary Table S2, Supplementary Figure S1) indicated that these markers were significantly associated with median survival (Supplementary Table S3, Supplementary Figure S2) in GBM.",S2,blood,1
PMC5480073A,"Establishing optimal cut off for threshold values of this blood-based marker panel with enhanced sensitivity and specificity (Supplementary Table S2, Supplementary Figure S1) indicated that these markers were significantly associated with median survival (Supplementary Table S3, Supplementary Figure S2) in GBM.",S1,blood,1
PMC5480073A,"Establishing optimal cut off for threshold values of this blood-based marker panel with enhanced sensitivity and specificity (Supplementary Table S2, Supplementary Figure S1) indicated that these markers were significantly associated with median survival (Supplementary Table S3, Supplementary Figure S2) in GBM.",S3,blood,1
PMC5480073A,"Establishing optimal cut off for threshold values of this blood-based marker panel with enhanced sensitivity and specificity (Supplementary Table S2, Supplementary Figure S1) indicated that these markers were significantly associated with median survival (Supplementary Table S3, Supplementary Figure S2) in GBM.",GBM,blood,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,B1,astrocytes,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,B1,astrocytes,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,SVZ,astrocytes,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,SVZ,astrocytes,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,SGZ,astrocytes,1
PMC5494437A,The two neurogenic niches of neural stem cells harbor B1 astrocytes in the SVZ and radial astrocytes in the SGZ.,SGZ,astrocytes,1
PMC4275355A,"Since it is pathologically defined by the presence of squamous cells, or terminally differentiated cells from the interfollicular epidermis, and not from the hair follicle, it was assumed that SCC arose from differentiated cells of the interfollicular epidermis, and not from the ASC population nor from hair follicles.",ASC,hair,-1
PMC4275355A,"Since it is pathologically defined by the presence of squamous cells, or terminally differentiated cells from the interfollicular epidermis, and not from the hair follicle, it was assumed that SCC arose from differentiated cells of the interfollicular epidermis, and not from the ASC population nor from hair follicles.",ASC,hair,-1
PMC4275355A,"Since it is pathologically defined by the presence of squamous cells, or terminally differentiated cells from the interfollicular epidermis, and not from the hair follicle, it was assumed that SCC arose from differentiated cells of the interfollicular epidermis, and not from the ASC population nor from hair follicles.",SCC,hair,-1
PMC4275355A,"Since it is pathologically defined by the presence of squamous cells, or terminally differentiated cells from the interfollicular epidermis, and not from the hair follicle, it was assumed that SCC arose from differentiated cells of the interfollicular epidermis, and not from the ASC population nor from hair follicles.",SCC,hair,-1
PMC5414739A,"Next, we discuss tissues for which available data are either less recent (bone marrow), more limited (hair follicle), or only concern the pathological context (colon cancer).Together with estrogens and progesterone, PRL is one of the main regulators of mammary gland differentiation during pregnancy (25, 59).",PRL,hair,-1
PMC5414739A,"Next, we discuss tissues for which available data are either less recent (bone marrow), more limited (hair follicle), or only concern the pathological context (colon cancer).Together with estrogens and progesterone, PRL is one of the main regulators of mammary gland differentiation during pregnancy (25, 59).",PRL,bone marrow,1
PMC4606116A,Plasma samples were collected from 152 CRC patients before surgery and 152 controls without CRC between 2010 and 2013 according to the protocol as described previously [21].,CRC,Plasma,1
PMC4606116A,Plasma samples were collected from 152 CRC patients before surgery and 152 controls without CRC between 2010 and 2013 according to the protocol as described previously [21].,CRC,Plasma,1
PMC3090697A,"In contrast to RFP expression in the skin of adult mice, many cells in the hair follicles of newborn mice express RFP (data not shown), thus accounting for the observed strong red fluorescence of perinatal skin.",RFP,hair,-1
PMC3090697A,"In contrast to RFP expression in the skin of adult mice, many cells in the hair follicles of newborn mice express RFP (data not shown), thus accounting for the observed strong red fluorescence of perinatal skin.",RFP,hair,-1
PMC4165776A,"Blood samples were collected from healthy volunteers in EDTA-Vacutainer tubes, where white blood cells (WBCs) were counted immediately after collection using a hemocytometer.",EDTA,Blood,-1
PMC4165776A,"Blood samples were collected from healthy volunteers in EDTA-Vacutainer tubes, where white blood cells (WBCs) were counted immediately after collection using a hemocytometer.",EDTA,blood,-1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,-1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",CD34,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",CD34,hair,-1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",CD34,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",CD34,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,-1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC4275355A,"By contrast, experimental evidence implicated cells of the hair follicle in SCC initiation [65-67]: the rate of tumor formation was affected by depilation, or hair removal [68]; and deletion of a hair follicle stem cell specific gene (CD34) affected tumor initiation [69].Therefore, the question remained, does oncogenic mutation in ASCs or TACs of the hair follicle result in SCC?",SCC,hair,1
PMC2976030A,"The peptides containing d413C0 and d413C4 pairs indicated the tumor-derived peptides detected in plasma from tumor-bearing mice, and they were selected for MS/MS analysis for peptide identifications.",d413C4,plasma,1
PMC2976030A,"Glycopeptides from plasma samples taken from mice before and after development of skin tumors and tumor tissues were labeled with d013C0, d413C0, and d413C4 succinic anhydride respectively.",d413C4,plasma,1
PMC4202120B,"According to several studies, the mere enumeration of CTCs in blood samples is prognostic and could be predictive of response to therapies in CRPC [329-332].",CRPC,blood,-1
PMC4621003A,"We found that protein transfer of HER-2 did not alter the antigenicity of viral proteins expressed on the VLPs, as GPI-HER-2-VLPs still induced VLP-specific serum IgG responses similar to unmodified VLPs (Figure 3C).For protein transfer to incorporate antigens onto the surface of lipid bilayers, only a GPI-anchor attached to the antigen is needed (Selvaraj et al.",VLP,serum,1
PMC4621003A,"We found that protein transfer of HER-2 did not alter the antigenicity of viral proteins expressed on the VLPs, as GPI-HER-2-VLPs still induced VLP-specific serum IgG responses similar to unmodified VLPs (Figure 3C).For protein transfer to incorporate antigens onto the surface of lipid bilayers, only a GPI-anchor attached to the antigen is needed (Selvaraj et al.",HER-2,serum,1
PMC4621003A,"We found that protein transfer of HER-2 did not alter the antigenicity of viral proteins expressed on the VLPs, as GPI-HER-2-VLPs still induced VLP-specific serum IgG responses similar to unmodified VLPs (Figure 3C).For protein transfer to incorporate antigens onto the surface of lipid bilayers, only a GPI-anchor attached to the antigen is needed (Selvaraj et al.",GPI,serum,1
PMC4621003A,"We found that protein transfer of HER-2 did not alter the antigenicity of viral proteins expressed on the VLPs, as GPI-HER-2-VLPs still induced VLP-specific serum IgG responses similar to unmodified VLPs (Figure 3C).For protein transfer to incorporate antigens onto the surface of lipid bilayers, only a GPI-anchor attached to the antigen is needed (Selvaraj et al.",GPI,serum,1
PMC5378227A,"We found that the sensitivity of the panel did not differ between tumors that differed in any of the features that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), TNM stage (I or =II), or pathological type (such as tubular adenocarcinoma, signet ring cell carcinoma, and papillary adenocarcinoma).",T1,lymph,1
PMC5378227A,"We found that the sensitivity of the panel did not differ between tumors that differed in any of the features that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), TNM stage (I or =II), or pathological type (such as tubular adenocarcinoma, signet ring cell carcinoma, and papillary adenocarcinoma).",TNM,lymph,1
PMC5378227A,"We found that the sensitivity of the panel did not differ between tumors that differed in any of the features that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), TNM stage (I or =II), or pathological type (such as tubular adenocarcinoma, signet ring cell carcinoma, and papillary adenocarcinoma).",T2,lymph,1
PMC3100619A,"A rising E2:T ratio in aging men (50), association of polymorphisms in estrogen metabolizing genes and urine hydroxy-estrone ratios with higher prostate cancer risk (51, 52), progressive increases in aromatase expression in primary prostate cancers to metastatic prostate cancers (53), and marked alterations in ER expression with cancer progression (3, 5) support the hypothesis that estrogens are involved in the etiology and progression of this disease.",aromatase,urine,1
PMC3100619A,"A rising E2:T ratio in aging men (50), association of polymorphisms in estrogen metabolizing genes and urine hydroxy-estrone ratios with higher prostate cancer risk (51, 52), progressive increases in aromatase expression in primary prostate cancers to metastatic prostate cancers (53), and marked alterations in ER expression with cancer progression (3, 5) support the hypothesis that estrogens are involved in the etiology and progression of this disease.",ER,urine,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",MRI,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",PDT,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",Her2,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",GO,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",Ling247,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",PTT,lymph,1
PMC4863686A,"GO has been coupled with anti-Her2 antibody, which is used for the treatment of breast cancer, and radiolabeled with [In111]-benzyl-diethylene-triaminepenta-acetic acid via p-p stacking for targeted and functional imaging.245 A magnetic graphene complex was used to identify metastatic pancreatic cells in the lymph nodes and also used for direct guided PTT against cancer cells.246 Gollavelli and Ling247 used magnetic graphene as a potential theranostic nanocarrier for MRI and fluorescence dual-modality imaging and for PDT and PTT.",PTT,lymph,1
PMC4011766A,demonstrated that miR-125b levels are elevated in serum of NSCLC patients by 10-fold [44].,NSCLC,serum,1
PMC4467439A,Reduced FBXW7 protein level was also found in six of seven primary CCA tumors relative to adjacent nontumorous bile duct (Fig. 1B; Supplementary Fig.,FBXW7,bile,1
PMC4467439A,Reduced FBXW7 protein level was also found in six of seven primary CCA tumors relative to adjacent nontumorous bile duct (Fig. 1B; Supplementary Fig.,CCA,bile,1
PMC4366163A,"GFP-RNtre co-localizes with both Ocln and Cldn4 at the lateral plasma membrane and TJ (Fig. 6B, S2 Fig.",Cldn4,plasma,1
PMC4366163A,"GFP-RNtre co-localizes with both Ocln and Cldn4 at the lateral plasma membrane and TJ (Fig. 6B, S2 Fig.",S2,plasma,1
PMC4366163A,"GFP-RNtre co-localizes with both Ocln and Cldn4 at the lateral plasma membrane and TJ (Fig. 6B, S2 Fig.",GFP,plasma,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",ECD,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",RFP,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",TRAMP,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",V188,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",C2,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",V188K,Serum,1
PMC3475800A,"(E) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control), mTrop2-Myc tag (mTrop2), or V188K-Myc tag (V188K) was precipitated, followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD.",ICD,Serum,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",ANIT,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",ANIT,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",ANIT,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",ANIT,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",ANIT,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",FAH,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",FAH,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",FAH,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",FAH,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",FAH,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",DDC,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",DDC,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",DDC,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",DDC,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",DDC,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",GFP,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",GFP,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",GFP,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",GFP,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",GFP,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CCl4,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CCl4,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CCl4,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CCl4,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CCl4,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CDE,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CDE,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CDE,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CDE,bone marrow,1
PMC4708083A,"However, hepatocytes positive for FAH derived from transplanted bone marrow cells were shown subsequently to be the result of cell fusion rather than actual differentiation of bone marrow cells into HPCs or hepatocytes (Wang et al., 2003).To address this discrepancy, two independent research groups transplanted GFP-expressing bone marrow cells or lacZ-transgenic bone marrow cells, respectively, and demonstrated that bone marrow cells played a negligible role in liver regeneration when recipient mice were subjected to CCl4, ANIT, DDC, or CDE diet-mediated liver injury (Rountree, Wang, et al.",CDE,bone marrow,1
PMC4997669A,"HPV16 immortalized human keratinocytes, HeLa, SiHa and CaSki Gal-7 positive and control cells as well as 293 T cells were maintained under standard conditions in Dulbecco's modified Eagle medium supplemented with 10 % Fetal Calf Serum and 1 % penicillin/streptomycin (P/S).",HPV16,Serum,1
PMC4997669A,"HPV16 immortalized human keratinocytes, HeLa, SiHa and CaSki Gal-7 positive and control cells as well as 293 T cells were maintained under standard conditions in Dulbecco's modified Eagle medium supplemented with 10 % Fetal Calf Serum and 1 % penicillin/streptomycin (P/S).",Gal-7,Serum,1
PMC4997669A,"HPV16 immortalized human keratinocytes, HeLa, SiHa and CaSki Gal-7 positive and control cells as well as 293 T cells were maintained under standard conditions in Dulbecco's modified Eagle medium supplemented with 10 % Fetal Calf Serum and 1 % penicillin/streptomycin (P/S).",T,Serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",SEREX,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",ECSA,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",ECSA,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",ECSA,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",SCC,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",mRNA,serum,1
PMC3135497A,"In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn.",SEREX,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",SLC2A1,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",TROP2,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",p53,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",SCC,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",SEREX,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",TRIM21,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",SURF1,serum,1
PMC3135497A,"The presence of serum p53 antibodies has been associated with poor prognosis [15].In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25].",SEREX,serum,1
PMC3135497A,This analytical method developed by Sahin et al. is called SEREX (serological identification of antigens by recombinant cDNA expression cloning) [10]; it involves immunoscreening with autologous or allogeneic sera of expressed cDNA libraries prepared from tumor specimens.,cDNA,sera,1
PMC3135497A,This analytical method developed by Sahin et al. is called SEREX (serological identification of antigens by recombinant cDNA expression cloning) [10]; it involves immunoscreening with autologous or allogeneic sera of expressed cDNA libraries prepared from tumor specimens.,cDNA,sera,1
PMC3135497A,This analytical method developed by Sahin et al. is called SEREX (serological identification of antigens by recombinant cDNA expression cloning) [10]; it involves immunoscreening with autologous or allogeneic sera of expressed cDNA libraries prepared from tumor specimens.,SEREX,sera,1
PMC4023823A,The preliminary blood biochemistry analyses revealed that the UA level in plasma at P15 was three times higher in Pten::Keap1-Alb mice than in control mice but that the BUN score was elevated only mildly (data not shown).,BUN,blood,1
PMC4023823A,The preliminary blood biochemistry analyses revealed that the UA level in plasma at P15 was three times higher in Pten::Keap1-Alb mice than in control mice but that the BUN score was elevated only mildly (data not shown).,BUN,plasma,1
PMC4023823A,The preliminary blood biochemistry analyses revealed that the UA level in plasma at P15 was three times higher in Pten::Keap1-Alb mice than in control mice but that the BUN score was elevated only mildly (data not shown).,P15,blood,1
PMC4023823A,The preliminary blood biochemistry analyses revealed that the UA level in plasma at P15 was three times higher in Pten::Keap1-Alb mice than in control mice but that the BUN score was elevated only mildly (data not shown).,P15,plasma,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",C18,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",HPLC,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",H2O,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",BSA,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",IMP288,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",IMP288,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",TFA,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",hRS7,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",ITLC,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",C18,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",hRS7,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",RCP,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",ITLC,serum,1
PMC4186637A,"injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in phosphate-buffered saline (PBS).DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed essentially as described previously.6,8,13 The radiochemical purity (RCP) of the labeled IMP288 and hRS7 preparations was determined using instant thin-layer chromatography (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 as described previously.12 ITLC using silicagel strips (Biodex) was performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate, pH 6.0; Merck).For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 mm, 4.6x250 mm2; Agilent Technologies) was eluted with a mixture of 97% of a 0.1% trifluoroacetic acid in H2O solution (TFA; Sigma-Aldrich) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences) with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/min.",TFA,serum,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",OMMT,plasma,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",OMMT,plasma,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",ADCC,plasma,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",ADCC,plasma,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",UMMT,plasma,1
PMC3224774A,"To evaluate the potential inhibition of ADCC against UMMT and OMMT cell lines by physiologic human plasma concentrations of g-globulin, human plasma was added in the presence or absence of effector PBLs in a 1:2 ratio.",UMMT,plasma,1
PMC5289527A,"Although IL6 levels in the serum are high in acute KD, this may represent synthesis of IL6 by hepatocytes as part of the acute phase response rather than synthesis by circulating immune cells as eQTL are often tissue-specific [35].",IL6,serum,-1
PMC5289527A,"Although IL6 levels in the serum are high in acute KD, this may represent synthesis of IL6 by hepatocytes as part of the acute phase response rather than synthesis by circulating immune cells as eQTL are often tissue-specific [35].",IL6,serum,-1
PMC5289527A,"Although IL6 levels in the serum are high in acute KD, this may represent synthesis of IL6 by hepatocytes as part of the acute phase response rather than synthesis by circulating immune cells as eQTL are often tissue-specific [35].",eQTL,serum,-1
PMC2976030A,One was that the intensity of d413C4- labeled peptides (with 8 mass unit shift for each amino group from peptides derived from cancer tissues) was much greater than d413C0-labeled peptide (with 4 mass unit shift for each amino group from peptides derived from plasma of cancer-bearing mice) and intensity of d013C0-labeled peptide (with 0 mass unit shift for each amino group from peptides derived from plasma before carcinogen induction) was lower than that of peptides from plasma of cancer-bearing mice.,d413C4-,plasma,1
PMC2976030A,One was that the intensity of d413C4- labeled peptides (with 8 mass unit shift for each amino group from peptides derived from cancer tissues) was much greater than d413C0-labeled peptide (with 4 mass unit shift for each amino group from peptides derived from plasma of cancer-bearing mice) and intensity of d013C0-labeled peptide (with 0 mass unit shift for each amino group from peptides derived from plasma before carcinogen induction) was lower than that of peptides from plasma of cancer-bearing mice.,d413C4-,plasma,1
PMC2976030A,One was that the intensity of d413C4- labeled peptides (with 8 mass unit shift for each amino group from peptides derived from cancer tissues) was much greater than d413C0-labeled peptide (with 4 mass unit shift for each amino group from peptides derived from plasma of cancer-bearing mice) and intensity of d013C0-labeled peptide (with 0 mass unit shift for each amino group from peptides derived from plasma before carcinogen induction) was lower than that of peptides from plasma of cancer-bearing mice.,d413C4-,plasma,1
PMC5378227A,"Moreover, autoantibodies against HSP70 have been identified in esophageal squamous cell carcinoma.27 Both purified HCC-22-5 and HCC-22-5 fusion proteins have an immune response to serum antibodies of HCC.",HCC-22,serum,1
PMC5378227A,"Moreover, autoantibodies against HSP70 have been identified in esophageal squamous cell carcinoma.27 Both purified HCC-22-5 and HCC-22-5 fusion proteins have an immune response to serum antibodies of HCC.",HCC-22,serum,1
PMC5378227A,"Moreover, autoantibodies against HSP70 have been identified in esophageal squamous cell carcinoma.27 Both purified HCC-22-5 and HCC-22-5 fusion proteins have an immune response to serum antibodies of HCC.",HSP70,serum,1
PMC5378227A,"Moreover, autoantibodies against HSP70 have been identified in esophageal squamous cell carcinoma.27 Both purified HCC-22-5 and HCC-22-5 fusion proteins have an immune response to serum antibodies of HCC.",HCC,serum,1
PMC3754468A,(A): Unsupervised clustering of PCSC lines and serum-grown prostate cancer cell lines.,PCSC,serum,1
PMC4202120A,A striking example of the selection for AR mutations was shown in a study that sequenced AR in bone marrow metastases of CRPC developed after therapy with flutamide.,AR,bone marrow,1
PMC4202120A,A striking example of the selection for AR mutations was shown in a study that sequenced AR in bone marrow metastases of CRPC developed after therapy with flutamide.,CRPC,bone marrow,1
PMC4202120A,A striking example of the selection for AR mutations was shown in a study that sequenced AR in bone marrow metastases of CRPC developed after therapy with flutamide.,AR,bone marrow,1
PMC4202120A,"F876L mutation was identified independently in cell lines selected for resistance to enzalutamide or ARN-509 in two other studies [92, 93], and F876L mutation was identified in plasma DNA of progressing patients [92].",ARN-509,plasma,-1
PMC4202120A,"F876L mutation was identified independently in cell lines selected for resistance to enzalutamide or ARN-509 in two other studies [92, 93], and F876L mutation was identified in plasma DNA of progressing patients [92].",DNA,plasma,-1
PMC4202120A,"F876L mutation was identified independently in cell lines selected for resistance to enzalutamide or ARN-509 in two other studies [92, 93], and F876L mutation was identified in plasma DNA of progressing patients [92].",F876L,plasma,-1
PMC4202120A,"F876L mutation was identified independently in cell lines selected for resistance to enzalutamide or ARN-509 in two other studies [92, 93], and F876L mutation was identified in plasma DNA of progressing patients [92].",F876L,plasma,-1
PMC4146555A,"A total of 102 patients (71 men and 31 women, mean age 62+-3.56 years) with stage I NSCLC who underwent complete tumor resection (lobectomy or pneumonectomy) with regional lymph node dissection between January 2006 and December 2008 at the department of Thoracic Surgery, Qilu Hospital, were included in the study.",NSCLC,lymph,1
PMC4371775A,"Bentivegna and colleagues (43) have shown that urothelial CSCs that can be cultured as urospheres in serum-free conditions and in the presence of growth factors express high levels of CD133, and low levels of cytokeratins-5 and -8.",CD133,serum,1
PMC5378227A,. They also participate in cellular antioxidant defense by inducing cell proliferation and protecting cells from undergoing apoptosis.30 KM-HN-1 was identified in the serum of a patient with squamous cell carcinoma of the head and neck by means of serologic identification of antigens by recombinant expression cloning and a testis cDNA expression library.,HN-1,serum,1
PMC5378227A,. They also participate in cellular antioxidant defense by inducing cell proliferation and protecting cells from undergoing apoptosis.30 KM-HN-1 was identified in the serum of a patient with squamous cell carcinoma of the head and neck by means of serologic identification of antigens by recombinant expression cloning and a testis cDNA expression library.,cDNA,serum,1
PMC3885472A,"Most prostate cell line is adherent in vitro, such as PC3, DU145, 22Rv1 and LNCaP, and certain amount of fetal bovine serum is essential for the cells proliferation.",DU145,serum,1
PMC3885472A,"Most prostate cell line is adherent in vitro, such as PC3, DU145, 22Rv1 and LNCaP, and certain amount of fetal bovine serum is essential for the cells proliferation.",PC3,serum,1
PMC4621003A,"Unincorporated GPI-HER-2 was washed out by centrifugation at 2000 rpm for 5 min using PBS, 5 mM EDTA, and 1% cosmic calf serum.",GPI,serum,1
PMC4621003A,"Unincorporated GPI-HER-2 was washed out by centrifugation at 2000 rpm for 5 min using PBS, 5 mM EDTA, and 1% cosmic calf serum.",HER-2,serum,1
PMC4621003A,"Unincorporated GPI-HER-2 was washed out by centrifugation at 2000 rpm for 5 min using PBS, 5 mM EDTA, and 1% cosmic calf serum.",EDTA,serum,1
PMC4621003A,"Unincorporated GPI-HER-2 was washed out by centrifugation at 2000 rpm for 5 min using PBS, 5 mM EDTA, and 1% cosmic calf serum.",PBS,serum,1
PMC4558321A,"S2.Concentrations of sacituzumab govitecan and IgG in the 30-min serum sample are provided in Supplementary Table S1, which show a general trend for the values to increase as the dose increased.",S1,serum,1
PMC2946292A,(a) Panc02-mTrop2 and control cells were serum starved for 24 h followed by the addition of media containing either 0% or 5% FBS.,FBS,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",NCI,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",H520,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",H520,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",TRIM29,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",NCI,serum,1
PMC4448470A,"Downregulation of tripartite motif (TRIM)29 inhibits invasion of NCI-H520 cells. (a) NCI-H520, siCONTROL and TRIM29 small interfering ribonucleic acid (siRNA) cells were seeded in the upper chamber in medium supplemented with five percent fetal bovine serum (FBS.",FBS,serum,1
PMC4188889A,Baseline levels of IGFs/IGF binding proteins were analyzed in serum or plasma while mutations and gene expression were analyzed in archival samples.,IGF,plasma,1
PMC4188889A,Baseline levels of IGFs/IGF binding proteins were analyzed in serum or plasma while mutations and gene expression were analyzed in archival samples.,IGF,serum,1
PMC2946292A,"After 24 h of serum starvation, cells were released by the addition of 2% FBS for 4 h (Panc02 and 4T1 cells) or 8 h (MC38 cells).",Panc02,serum,1
PMC2946292A,"After 24 h of serum starvation, cells were released by the addition of 2% FBS for 4 h (Panc02 and 4T1 cells) or 8 h (MC38 cells).",MC38,serum,1
PMC2946292A,"After 24 h of serum starvation, cells were released by the addition of 2% FBS for 4 h (Panc02 and 4T1 cells) or 8 h (MC38 cells).",FBS,serum,1
PMC5042010A,"Despite those limitations, because of their detection in a peripheral blood sample, circulating tumor cells provide an attractive source of genetic material for longitudinal monitoring in view of the minimal invasiveness of a blood draw and their potential to reflect the molecular profile of the metastatic cell population [8, 16-17].Circulating cell-free DNA was identified in 1948 in the plasma and derives from both normal and diseased tissue [18].",DNA,blood,-1
PMC5042010A,"Despite those limitations, because of their detection in a peripheral blood sample, circulating tumor cells provide an attractive source of genetic material for longitudinal monitoring in view of the minimal invasiveness of a blood draw and their potential to reflect the molecular profile of the metastatic cell population [8, 16-17].Circulating cell-free DNA was identified in 1948 in the plasma and derives from both normal and diseased tissue [18].",DNA,plasma,-1
PMC5042010A,"Despite those limitations, because of their detection in a peripheral blood sample, circulating tumor cells provide an attractive source of genetic material for longitudinal monitoring in view of the minimal invasiveness of a blood draw and their potential to reflect the molecular profile of the metastatic cell population [8, 16-17].Circulating cell-free DNA was identified in 1948 in the plasma and derives from both normal and diseased tissue [18].",DNA,blood,-1
PMC2946292A,"However, expression of mTrop2 resulted in a further increase in the rate of migration when compared to the parental and GFP control cell lines at both 0% and 5% serum concentrations (P  0.0001) (Fig.",GFP,serum,1
PMC2855629A,Blocking solution was PBS supplemented with 50% normal horse serum and 1% BSA.,BSA,serum,1
PMC2855629A,Blocking solution was PBS supplemented with 50% normal horse serum and 1% BSA.,PBS,serum,1
PMC4718644A,"Briefly, THP-1 transformed macrophages were treated with serum-free medium containing different concentration of hTLR4-Fab01 and incubated for 2 h. Anthrax chimeric Fab antibody was used as negative control [25].",THP-1,serum,1
PMC5045392A,"Prostate tissue was collected from mice, minced into small fragment, digested with 200 U/ml collagenase IA-S (Sigma; C5894) in Dulbecco's modified Eagles medium (DME, Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone, South Logan, UT) (DME-10% FBS) at 37degC for 60 min with gentle agitation.",FBS,serum,1
PMC5045392A,"Prostate tissue was collected from mice, minced into small fragment, digested with 200 U/ml collagenase IA-S (Sigma; C5894) in Dulbecco's modified Eagles medium (DME, Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone, South Logan, UT) (DME-10% FBS) at 37degC for 60 min with gentle agitation.",FBS,serum,1
PMC5045392A,"Prostate tissue was collected from mice, minced into small fragment, digested with 200 U/ml collagenase IA-S (Sigma; C5894) in Dulbecco's modified Eagles medium (DME, Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone, South Logan, UT) (DME-10% FBS) at 37degC for 60 min with gentle agitation.",DME,serum,1
PMC5045392A,"Prostate tissue was collected from mice, minced into small fragment, digested with 200 U/ml collagenase IA-S (Sigma; C5894) in Dulbecco's modified Eagles medium (DME, Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone, South Logan, UT) (DME-10% FBS) at 37degC for 60 min with gentle agitation.",C5894,serum,1
PMC3134227A,"Neonatal rats were briefly exposed to 17b-estradiol or the environmental estrogen bisphenol A (BPA) at serum concentration levels similar to those measured in humans - considered the first hit - followed by a second exposure to estradiol in adulthood to mimic increased estrogen levels observed in aging men [33,61].",BPA,serum,-1
PMC4011766A,"A second study confirmed the correlation of miR-125b serum levels and poor survival rates as well as poor response to cis-platin chemotherapy, suggesting that serum levels of miR-125b might be a useful prognostic and therapeutic marker for NSCLC [48].",NSCLC,serum,-1
PMC4011766A,"A second study confirmed the correlation of miR-125b serum levels and poor survival rates as well as poor response to cis-platin chemotherapy, suggesting that serum levels of miR-125b might be a useful prognostic and therapeutic marker for NSCLC [48].",NSCLC,serum,-1
PMC5378227A,"After two washes with PBS, the proteins were blocked with 200 mL PBS containing 1% BSA and 5% sucrose at room temperature for 3 h. All human serum samples were diluted (1:100) in PBS containing 0.15% Tween 20, 1% casein, and 0.2 mg/mL E. coli extract.",PBS,serum,1
PMC5378227A,"After two washes with PBS, the proteins were blocked with 200 mL PBS containing 1% BSA and 5% sucrose at room temperature for 3 h. All human serum samples were diluted (1:100) in PBS containing 0.15% Tween 20, 1% casein, and 0.2 mg/mL E. coli extract.",PBS,serum,1
PMC5378227A,"After two washes with PBS, the proteins were blocked with 200 mL PBS containing 1% BSA and 5% sucrose at room temperature for 3 h. All human serum samples were diluted (1:100) in PBS containing 0.15% Tween 20, 1% casein, and 0.2 mg/mL E. coli extract.",BSA,serum,1
PMC5378227A,"After two washes with PBS, the proteins were blocked with 200 mL PBS containing 1% BSA and 5% sucrose at room temperature for 3 h. All human serum samples were diluted (1:100) in PBS containing 0.15% Tween 20, 1% casein, and 0.2 mg/mL E. coli extract.",PBS,serum,1
PMC5442765A,(A): Comparison of cumulative PDs of human prostate bulk epithelial cells cultured in serum-free PrEGM versus WIT medium.,WIT,serum,1
PMC5086635A,"These antibodies have been used to treat blood cancers including T cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma [5,6,7,8,9,10].",T,blood,-1
PMC3110957A,"Finally, once all three NPC fractions were collected and combined, these were resuspended in 35% Percoll (GE Healthcare) and centrifuged at 900g for 10 min to exclude debris (which reduces the efficiency of FACS sorting).Mouse liver cryosections (5 mm) were prepared using a Reichert 2800 Frigocut (Reichert Scientific Instruments) and fixed in acetone for 10 min at -20degC. Nonspecific labeling was blocked by incubation in 2% goat serum (Hyclone) for 10 min.",FACS,serum,1
PMC3110957A,"Finally, once all three NPC fractions were collected and combined, these were resuspended in 35% Percoll (GE Healthcare) and centrifuged at 900g for 10 min to exclude debris (which reduces the efficiency of FACS sorting).Mouse liver cryosections (5 mm) were prepared using a Reichert 2800 Frigocut (Reichert Scientific Instruments) and fixed in acetone for 10 min at -20degC. Nonspecific labeling was blocked by incubation in 2% goat serum (Hyclone) for 10 min.",NPC,serum,1
PMC3476529A,"These data are consistent with the possibility that blood CD141+ DCs are the precursors of immature CD141hi DCs, before acquiring CD1a, CD1c, activation antigens, and CCR7.",CD141,blood,-1
PMC3476529A,"These data are consistent with the possibility that blood CD141+ DCs are the precursors of immature CD141hi DCs, before acquiring CD1a, CD1c, activation antigens, and CCR7.",CCR7,blood,-1
PMC3476529A,"Although these do not express CLA and cannot be blood CD141+ DCs per se, they have a similar immature phenotype (Figure 3C).",CLA,blood,-1
PMC3476529A,"Although these do not express CLA and cannot be blood CD141+ DCs per se, they have a similar immature phenotype (Figure 3C).",CD141,blood,-1
PMC5378227A,"Then, 100 mL diluted serum was added to each TAA- or PBS-coated well and incubated at room temperature at 20 g for 60 min.",PBS,serum,1
PMC5378227A,"Then, 100 mL diluted serum was added to each TAA- or PBS-coated well and incubated at room temperature at 20 g for 60 min.",TAA-,serum,1
PMC3476529A,"Blood, and to a lesser extent lung and liver, also contain CD16+ monocytes or equivalent cells.",CD16,Blood,-1
PMC3476529A,This is at least consistent with a precursor-progeny relationship between blood CD141+ DCs and skin CD141hi DCs.,CD141,blood,-1
PMC4889960A,"Then, inductively coupled plasma mass spectrometry (ICP-MS) was employed to measure the amount of Au using the following formula: M (the weight of Au measured by ICP-MS)/[M (the weight of the cells) + M (the uptake of GNCs)].The cytotoxicity of the GNCs when applied to 4T1 cells was evaluated using a CCK-8 assay.",ICP,plasma,1
PMC4889960A,"Then, inductively coupled plasma mass spectrometry (ICP-MS) was employed to measure the amount of Au using the following formula: M (the weight of Au measured by ICP-MS)/[M (the weight of the cells) + M (the uptake of GNCs)].The cytotoxicity of the GNCs when applied to 4T1 cells was evaluated using a CCK-8 assay.",CCK-8,plasma,1
PMC4889960A,"Then, inductively coupled plasma mass spectrometry (ICP-MS) was employed to measure the amount of Au using the following formula: M (the weight of Au measured by ICP-MS)/[M (the weight of the cells) + M (the uptake of GNCs)].The cytotoxicity of the GNCs when applied to 4T1 cells was evaluated using a CCK-8 assay.",ICP,plasma,1
PMC3478937A,"Even though the TAM receptors are responsible for maintaining long-term self-tolerance, the molecular mechanisms underlying their normal homeostatic expression remain elusive (Lu and Lemke, 2001).As the mechanisms governing LC differentiation and maturation in response to TGF-b1 signaling remain for the most part unclear, we made use of a defined serum-free human in vitro LC differentiation model to identify key effector molecules.",TAM,serum,-1
PMC3478937A,"Even though the TAM receptors are responsible for maintaining long-term self-tolerance, the molecular mechanisms underlying their normal homeostatic expression remain elusive (Lu and Lemke, 2001).As the mechanisms governing LC differentiation and maturation in response to TGF-b1 signaling remain for the most part unclear, we made use of a defined serum-free human in vitro LC differentiation model to identify key effector molecules.",TGF,serum,-1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",Delta-1,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",Delta-1,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",Delta-1,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",Delta-1,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",TGF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",TGF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",TGF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",TGF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",CSF,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",IL-4,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",IL-4,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",IL-4,CSF,1
PMC3478937A,"Conversely, neither monocyte-derived DCs (moDCs; GM-CSF, IL-4 or GM-CSF, Delta-1; generated in the absence of TGF-b1) nor monocyte-derived macrophages (M-CSF or GM-CSF) expressed Axl at detectable levels (Fig. 1 B, histograms and bar diagram).",IL-4,CSF,1
PMC3478937A,"Conversely, in vitro-generated monocyte-derived CD207+ LCs (in response to GM-CSF, Delta-1, and TGF-b1) strongly expressed Axl (Fig.",CD207,CSF,1
PMC3478937A,"Conversely, in vitro-generated monocyte-derived CD207+ LCs (in response to GM-CSF, Delta-1, and TGF-b1) strongly expressed Axl (Fig.",TGF,CSF,1
PMC3478937A,"Conversely, in vitro-generated monocyte-derived CD207+ LCs (in response to GM-CSF, Delta-1, and TGF-b1) strongly expressed Axl (Fig.",GM,CSF,1
PMC3478937A,"Conversely, in vitro-generated monocyte-derived CD207+ LCs (in response to GM-CSF, Delta-1, and TGF-b1) strongly expressed Axl (Fig.",Delta-1,CSF,1
PMC4858267A,The cells were cultured as routine in an incubator supplied with 5% CO2 and in a DMEM supplemented with 10% fetal bovine serum.,CO2,serum,1
PMC4858267A,The cells were cultured as routine in an incubator supplied with 5% CO2 and in a DMEM supplemented with 10% fetal bovine serum.,DMEM,serum,1
PMC3478937A,"Similarly, Axl was detectable on LCs generated in the presence of GM-CSF, IL-4, and TGF-b1 (Fig. 1 B, histograms and bar diagram).",IL-4,CSF,1
PMC3478937A,"Similarly, Axl was detectable on LCs generated in the presence of GM-CSF, IL-4, and TGF-b1 (Fig. 1 B, histograms and bar diagram).",TGF,CSF,1
PMC3478937A,"Similarly, Axl was detectable on LCs generated in the presence of GM-CSF, IL-4, and TGF-b1 (Fig. 1 B, histograms and bar diagram).",GM,CSF,1
PMC3840448A,Serum REG4 has been extensively studied in epidemiologic studies and seems to be an excellent diagnostics marker [6].,REG4,Serum,1
PMC3655712A,Six-to-eight week-old male SCID mice were anesthetized with 100 mg/kg ketamine and 20 mg/kg xylazine and successively inoculated in the left cardiac ventricle with PC3-MM2 cell transfectants (2.5x105 cells in a volume of 100 uL of serum-free DMEM).,DMEM,serum,1
PMC3655712A,Six-to-eight week-old male SCID mice were anesthetized with 100 mg/kg ketamine and 20 mg/kg xylazine and successively inoculated in the left cardiac ventricle with PC3-MM2 cell transfectants (2.5x105 cells in a volume of 100 uL of serum-free DMEM).,SCID,serum,1
PMC3655712A,Six-to-eight week-old male SCID mice were anesthetized with 100 mg/kg ketamine and 20 mg/kg xylazine and successively inoculated in the left cardiac ventricle with PC3-MM2 cell transfectants (2.5x105 cells in a volume of 100 uL of serum-free DMEM).,PC3-MM2,serum,1
PMC3269833A,"In contrast, the expression of the TACSTD2 protein in primary rat astrocytes shows a unimodal expression under the same test conditions.",TACSTD2,astrocytes,1
PMC3269833A,"Furthermore stimulation of astrocytes by FI leads to a non-significant change in the protein level and with the cells predominantly remaining in the OFF steady-states (Figure 7-F).The activation of TACSTD2 has been suggested to transduce calcium signal, likely by mediating calcium release from intracellular stores [48].",TACSTD2,astrocytes,1
PMC3269833A,"Furthermore stimulation of astrocytes by FI leads to a non-significant change in the protein level and with the cells predominantly remaining in the OFF steady-states (Figure 7-F).The activation of TACSTD2 has been suggested to transduce calcium signal, likely by mediating calcium release from intracellular stores [48].",FI,astrocytes,1
PMC3269833A,"Furthermore stimulation of astrocytes by FI leads to a non-significant change in the protein level and with the cells predominantly remaining in the OFF steady-states (Figure 7-F).The activation of TACSTD2 has been suggested to transduce calcium signal, likely by mediating calcium release from intracellular stores [48].",OFF,astrocytes,1
PMC4803572A,"Additionally, in BCa, bone marrow stroma has been purported to promote tumor dormancy by reducing CXCL12 and cell cycling in cancer cells (Fig. 1) [46,47].",CXCL12,bone marrow,-1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",ALP,bile,1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",ALP,serum,1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",DDC,bile,1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",DDC,serum,1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",ALT,bile,1
PMC4077671A,"The increased serum levels of ALT, ALP, bilirubin and bile acids suggested that the Car+/+/C3He mice, but not Car-/-/C3He mice developed liver injury and cholestasis after feeding the DDC diet (Figure 3a).",ALT,serum,1
PMC4096804A,(D) Hoxb7 and Bmp4 expression in MOC2 (LN-lymph node metastatic) and MOC2-10 (LN/lung metastatic).View larger versionFigure 3.,Hoxb7,lymph,1
PMC4096804A,(D) Hoxb7 and Bmp4 expression in MOC2 (LN-lymph node metastatic) and MOC2-10 (LN/lung metastatic).View larger versionFigure 3.,MOC2,lymph,1
PMC4096804A,(D) Hoxb7 and Bmp4 expression in MOC2 (LN-lymph node metastatic) and MOC2-10 (LN/lung metastatic).View larger versionFigure 3.,Bmp4,lymph,1
PMC4096804A,(D) Hoxb7 and Bmp4 expression in MOC2 (LN-lymph node metastatic) and MOC2-10 (LN/lung metastatic).View larger versionFigure 3.,MOC2,lymph,1
PMC3266428A,Total RNA was extracted using PAXgene Blood RNA System kits (Qiagen).,RNA,Blood,-1
PMC3266428A,Total RNA was extracted using PAXgene Blood RNA System kits (Qiagen).,RNA,Blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,saliva,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,Blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,saliva,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,Blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,saliva,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,Blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,saliva,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,blood,-1
PMC3266428A,"QIAamp DNA Blood Midi kits (Qiagen, West Sussex, U.K.) and Oragene DNA Purifier kits (DNA Genotek) were used for DNA extraction from blood and saliva samples, respectively.",DNA,Blood,-1
PMC5538449A,"Furthermore, RUNX3 was expressed by moLCs but by neither moDCs nor macrophages generated from peripheral blood monocytes (Fig 6, B, and see also Fig 2, A).Ectopic expression of RUNX3 in CD34+ cells promoted the generation of day 5 p-LC precursors (CD1a+ cells) at the expense of monocyte precursors (CD14+CD1a- cells; Fig 6, C).",CD34,blood,1
PMC5538449A,"Furthermore, RUNX3 was expressed by moLCs but by neither moDCs nor macrophages generated from peripheral blood monocytes (Fig 6, B, and see also Fig 2, A).Ectopic expression of RUNX3 in CD34+ cells promoted the generation of day 5 p-LC precursors (CD1a+ cells) at the expense of monocyte precursors (CD14+CD1a- cells; Fig 6, C).",RUNX3,blood,1
PMC5538449A,"Furthermore, RUNX3 was expressed by moLCs but by neither moDCs nor macrophages generated from peripheral blood monocytes (Fig 6, B, and see also Fig 2, A).Ectopic expression of RUNX3 in CD34+ cells promoted the generation of day 5 p-LC precursors (CD1a+ cells) at the expense of monocyte precursors (CD14+CD1a- cells; Fig 6, C).",RUNX3,blood,1
PMC3326009A,FACS analysis of total prostate epithelial cells using fluorescent antibodies to detect Epcam and CD44 expression demonstrate clear separation of (Epcam+) epithelial cells from (Epcam-) stromal/blood cells (Figure 1B).,FACS,blood,-1
PMC3326009A,FACS analysis of total prostate epithelial cells using fluorescent antibodies to detect Epcam and CD44 expression demonstrate clear separation of (Epcam+) epithelial cells from (Epcam-) stromal/blood cells (Figure 1B).,CD44,blood,-1
PMC4096804A,"Independent validation of OCAMP-B and development of a clinical assay for stratification of OSCCs (A) An independent UPENN dataset is classified with high accuracy (21/22 tumors) by OCAMP-B weighted voting (WV output) with respect to lymph node metastatic status (Path= known pathologic status), (B) Schematic illustrating the selection of 42 OCAMP genes and SVM processing on training set samples to identify the best discriminating genes.",OCAMP,lymph,-1
PMC4096804A,"Independent validation of OCAMP-B and development of a clinical assay for stratification of OSCCs (A) An independent UPENN dataset is classified with high accuracy (21/22 tumors) by OCAMP-B weighted voting (WV output) with respect to lymph node metastatic status (Path= known pathologic status), (B) Schematic illustrating the selection of 42 OCAMP genes and SVM processing on training set samples to identify the best discriminating genes.",OCAMP,lymph,-1
PMC4096804A,"Independent validation of OCAMP-B and development of a clinical assay for stratification of OSCCs (A) An independent UPENN dataset is classified with high accuracy (21/22 tumors) by OCAMP-B weighted voting (WV output) with respect to lymph node metastatic status (Path= known pathologic status), (B) Schematic illustrating the selection of 42 OCAMP genes and SVM processing on training set samples to identify the best discriminating genes.",OCAMP,lymph,-1
PMC4096804A,"Independent validation of OCAMP-B and development of a clinical assay for stratification of OSCCs (A) An independent UPENN dataset is classified with high accuracy (21/22 tumors) by OCAMP-B weighted voting (WV output) with respect to lymph node metastatic status (Path= known pathologic status), (B) Schematic illustrating the selection of 42 OCAMP genes and SVM processing on training set samples to identify the best discriminating genes.",SVM,lymph,-1
PMC4096804A,"Independent validation of OCAMP-B and development of a clinical assay for stratification of OSCCs (A) An independent UPENN dataset is classified with high accuracy (21/22 tumors) by OCAMP-B weighted voting (WV output) with respect to lymph node metastatic status (Path= known pathologic status), (B) Schematic illustrating the selection of 42 OCAMP genes and SVM processing on training set samples to identify the best discriminating genes.",UPENN,lymph,-1
PMC4673473A,"Thus, MSCs-derived from bone marrow and other tissues were focused upon and many studies used MSCs as starting materials for hepatocyte differentiation.28, 29 Under our culture conditions, the differentiating cells did not assume MSC characteristics in vitro and featured endodermal epithelial-like phenotypes early in culture with normal untreated MS, which ruled out the possibility that hepatocyte cell differentiation in our study occurred through MSCs.",MSC,bone marrow,1
PMC4863686A,"The ratio of albumin and globulin, the urea levels in the blood, and all hematology markers were also unchanged.27,33,176 Singh et al182 found that GO could induce extensive pulmonary thromboembolism in mice.",GO,blood,1
PMC4096804A,"Of the aggressive lines, MOC2-7 and MOC2-10 were derived from the MOC2 line, but the MOC2-10 line was included in the current analysis because it uniquely displayed lung in addition to lymph node metastasis.",MOC2,lymph,1
PMC4096804A,"Of the aggressive lines, MOC2-7 and MOC2-10 were derived from the MOC2 line, but the MOC2-10 line was included in the current analysis because it uniquely displayed lung in addition to lymph node metastasis.",MOC2,lymph,1
PMC4096804A,"Of the aggressive lines, MOC2-7 and MOC2-10 were derived from the MOC2 line, but the MOC2-10 line was included in the current analysis because it uniquely displayed lung in addition to lymph node metastasis.",MOC2,lymph,1
PMC4096804A,"Of the aggressive lines, MOC2-7 and MOC2-10 were derived from the MOC2 line, but the MOC2-10 line was included in the current analysis because it uniquely displayed lung in addition to lymph node metastasis.",MOC2,lymph,1
PMC4863686A,"The evidence from blood biochemistry and histological examinations showed that the NPs mainly accumulated in the lung, liver, and spleen, and caused acute liver injury and chronic inflammation in the accumulated organs.183 Zhang et al184 demonstrated the behavior of mice after short- and long-term administration of rGO.",rGO,blood,1
PMC2941705A,"The Wt and LRAT-/- embryonic stem (ES) cell lines were maintained as monolayer cultures in the embryonic stem cell culture medium (ESCM) (Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM glutamine, 1x penicillin/streptomycin [Invitrogen, cat# 10378-016], 1x non-essential amino acids [Invitrogen, cat# 11140-019], 1 mM sodium pyruvate [Invitrogen, cat# 11360-070], 0.1 mM b-mercaptoethanol and leukemia inhibitory factor (LIF) (103 units/ml; ESGRO, Invitrogen).",ESCM,serum,1
PMC2941705A,"The Wt and LRAT-/- embryonic stem (ES) cell lines were maintained as monolayer cultures in the embryonic stem cell culture medium (ESCM) (Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM glutamine, 1x penicillin/streptomycin [Invitrogen, cat# 10378-016], 1x non-essential amino acids [Invitrogen, cat# 11140-019], 1 mM sodium pyruvate [Invitrogen, cat# 11360-070], 0.1 mM b-mercaptoethanol and leukemia inhibitory factor (LIF) (103 units/ml; ESGRO, Invitrogen).",LIF,serum,1
PMC2941705A,"The Wt and LRAT-/- embryonic stem (ES) cell lines were maintained as monolayer cultures in the embryonic stem cell culture medium (ESCM) (Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM glutamine, 1x penicillin/streptomycin [Invitrogen, cat# 10378-016], 1x non-essential amino acids [Invitrogen, cat# 11140-019], 1 mM sodium pyruvate [Invitrogen, cat# 11360-070], 0.1 mM b-mercaptoethanol and leukemia inhibitory factor (LIF) (103 units/ml; ESGRO, Invitrogen).",ESGRO,serum,1
PMC5042010A,"Critically, with the exception of HCC-1395 which demonstrated no significant capture with either reagent set, 90 tumor cells/mL could be enriched to an average purity of between 29% and 67% from whole blood (see bottom graph).",HCC-1395,blood,-1
PMC3885472A,"Primary prostatic cancer cells grew well in keratinocyte serum-free medium with epidermal growth factor (EGF) and bovine pituitary extract (BPE), supplemented with leukemia inhibitory factor (LIF), stem cell factor (SCF) and cholera toxin.",SCF,serum,1
PMC3885472A,"Primary prostatic cancer cells grew well in keratinocyte serum-free medium with epidermal growth factor (EGF) and bovine pituitary extract (BPE), supplemented with leukemia inhibitory factor (LIF), stem cell factor (SCF) and cholera toxin.",EGF,serum,1
PMC3885472A,"Primary prostatic cancer cells grew well in keratinocyte serum-free medium with epidermal growth factor (EGF) and bovine pituitary extract (BPE), supplemented with leukemia inhibitory factor (LIF), stem cell factor (SCF) and cholera toxin.",LIF,serum,1
PMC3885472A,"Primary prostatic cancer cells grew well in keratinocyte serum-free medium with epidermal growth factor (EGF) and bovine pituitary extract (BPE), supplemented with leukemia inhibitory factor (LIF), stem cell factor (SCF) and cholera toxin.",BPE,serum,1
PMC5494437A,"It is often expressed with the lineage antigen (Lin-) in combination with CD38+, CD45, CD90, CD133 along with Tie (angiopoietin-receptor ) and c-kit (tyrosine kinase KIT)[19].A compendium of phenotypes in the HSC lineage through successive levels of differentiation to the ten terminal differentiated blood cells has been described for both murine animals and the human.",HSC,blood,-1
PMC5494437A,"It is often expressed with the lineage antigen (Lin-) in combination with CD38+, CD45, CD90, CD133 along with Tie (angiopoietin-receptor ) and c-kit (tyrosine kinase KIT)[19].A compendium of phenotypes in the HSC lineage through successive levels of differentiation to the ten terminal differentiated blood cells has been described for both murine animals and the human.",CD45,blood,-1
PMC5494437A,"It is often expressed with the lineage antigen (Lin-) in combination with CD38+, CD45, CD90, CD133 along with Tie (angiopoietin-receptor ) and c-kit (tyrosine kinase KIT)[19].A compendium of phenotypes in the HSC lineage through successive levels of differentiation to the ten terminal differentiated blood cells has been described for both murine animals and the human.",CD133,blood,-1
PMC5494437A,"It is often expressed with the lineage antigen (Lin-) in combination with CD38+, CD45, CD90, CD133 along with Tie (angiopoietin-receptor ) and c-kit (tyrosine kinase KIT)[19].A compendium of phenotypes in the HSC lineage through successive levels of differentiation to the ten terminal differentiated blood cells has been described for both murine animals and the human.",CD38,blood,-1
PMC5494437A,"It is often expressed with the lineage antigen (Lin-) in combination with CD38+, CD45, CD90, CD133 along with Tie (angiopoietin-receptor ) and c-kit (tyrosine kinase KIT)[19].A compendium of phenotypes in the HSC lineage through successive levels of differentiation to the ten terminal differentiated blood cells has been described for both murine animals and the human.",CD90,blood,-1
PMC4292049A,"In addition, Rossin et al. reported that the TCO can be deactivated through isomerization to the unreactive cis-cyclooctene (CCO) isomer via copper-containing proteins (e.g., transcuprein, mouse serum albumin, ceruloplasmin) (61).",TCO,serum,1
PMC4292049A,"In addition, Rossin et al. reported that the TCO can be deactivated through isomerization to the unreactive cis-cyclooctene (CCO) isomer via copper-containing proteins (e.g., transcuprein, mouse serum albumin, ceruloplasmin) (61).",CCO,serum,1
PMC3476529A,"In addition to plasmacytoid DCs (pDCs), human blood harbors two subsets of CD11c+ myeloid DCs: a major CD1c+ (BDCA-1) population and a discrete CD141+ (thrombomodulin or BDCA-3) subset (Dzionek et al., 2000; MacDonald et al., 2002; Ziegler-Heitbrock et al., 2010).",BDCA-3,blood,1
PMC3476529A,"In addition to plasmacytoid DCs (pDCs), human blood harbors two subsets of CD11c+ myeloid DCs: a major CD1c+ (BDCA-1) population and a discrete CD141+ (thrombomodulin or BDCA-3) subset (Dzionek et al., 2000; MacDonald et al., 2002; Ziegler-Heitbrock et al., 2010).",BDCA-1,blood,1
PMC3476529A,"In addition to plasmacytoid DCs (pDCs), human blood harbors two subsets of CD11c+ myeloid DCs: a major CD1c+ (BDCA-1) population and a discrete CD141+ (thrombomodulin or BDCA-3) subset (Dzionek et al., 2000; MacDonald et al., 2002; Ziegler-Heitbrock et al., 2010).",CD141,blood,1
PMC2634835A,"Incorporation of novel serum biomarkers such as cross linked C telopeptides (CTX), a validated marker of bone resorption and a surrogate for osteoclastic activity, might provide early information as to whether the distant metastatic endpoint is being met.",CTX,serum,-1
PMC2943378A,CAUTION All experiments involving live rodents must conform to national and institutional regulations.^ CRITICAL This serum was found to be optimal for the support of UGSM growth.!CAUTION Handle with care.^ CRITICAL Some other clones are more diluted and the staining will not look the same.^CRITICAL STEP,CRITICAL,serum,-1
PMC2943378A,CAUTION All experiments involving live rodents must conform to national and institutional regulations.^ CRITICAL This serum was found to be optimal for the support of UGSM growth.!CAUTION Handle with care.^ CRITICAL Some other clones are more diluted and the staining will not look the same.^CRITICAL STEP,CAUTION,serum,-1
PMC2943378A,CAUTION All experiments involving live rodents must conform to national and institutional regulations.^ CRITICAL This serum was found to be optimal for the support of UGSM growth.!CAUTION Handle with care.^ CRITICAL Some other clones are more diluted and the staining will not look the same.^CRITICAL STEP,CRITICAL,serum,-1
PMC2943378A,CAUTION All experiments involving live rodents must conform to national and institutional regulations.^ CRITICAL This serum was found to be optimal for the support of UGSM growth.!CAUTION Handle with care.^ CRITICAL Some other clones are more diluted and the staining will not look the same.^CRITICAL STEP,STEP,serum,1
PMC2943378A,CAUTION All experiments involving live rodents must conform to national and institutional regulations.^ CRITICAL This serum was found to be optimal for the support of UGSM growth.!CAUTION Handle with care.^ CRITICAL Some other clones are more diluted and the staining will not look the same.^CRITICAL STEP,UGSM,serum,-1
PMC4251850A,"Exosomes, smaller than 120 nm, in restricted view are produced by inward budding of the endosomal membrane, accumulate as intraluminal vesicles, and are secreted by the fusion of multivesicular bodies (MVB) with the plasma membrane.",MVB,plasma,1
PMC4505916A,"Prior to analysis at 2 weeks, mice were bled, and serum was injected into naive, uninfected R26YFP mice whose livers were assessed after 1 week (Recipient).",R26YFP,serum,1
PMC5215363A,"Fifteen melanoma cell lines derived from melanoma metastases were also analyzed; early passage cultures were used, and clonal sub-selection was not performed.38 Cell lines were cultured with RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (Cellgro), 0.01% L-glutamine Pen-Strep solution (Gemini Bio-Products), 0.001% Ciprofloxacin (10 mg/mL) and 0.01% Fungizone Amphotericin B (Gibco), and detached with 0.2% Trypsin-EDTA (Gemini Bio-Products).Gene expression assays performed on metastatic melanoma and ovarian carcinoma tumor specimens.",RPMI,serum,1
PMC5215363A,"Fifteen melanoma cell lines derived from melanoma metastases were also analyzed; early passage cultures were used, and clonal sub-selection was not performed.38 Cell lines were cultured with RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (Cellgro), 0.01% L-glutamine Pen-Strep solution (Gemini Bio-Products), 0.001% Ciprofloxacin (10 mg/mL) and 0.01% Fungizone Amphotericin B (Gibco), and detached with 0.2% Trypsin-EDTA (Gemini Bio-Products).Gene expression assays performed on metastatic melanoma and ovarian carcinoma tumor specimens.",EDTA,serum,1
PMC2695576A,"Although most patients with FECD lack a positive family history, blood relatives sometimes manifest corneal guttae.",FECD,blood,-1
PMC4863686A,"Lower concentration of GO has no significant effect on cellular uptake, morphology, viability, mortality, and membrane integrity.162 Hu et al163 reported that the effect of GO was largely attenuated by incubation with 10% fetal bovine serum; the reason was found to be that GO has extremely high protein adsorption ability.",GO,serum,-1
PMC4863686A,"Lower concentration of GO has no significant effect on cellular uptake, morphology, viability, mortality, and membrane integrity.162 Hu et al163 reported that the effect of GO was largely attenuated by incubation with 10% fetal bovine serum; the reason was found to be that GO has extremely high protein adsorption ability.",GO,serum,-1
PMC4863686A,"Lower concentration of GO has no significant effect on cellular uptake, morphology, viability, mortality, and membrane integrity.162 Hu et al163 reported that the effect of GO was largely attenuated by incubation with 10% fetal bovine serum; the reason was found to be that GO has extremely high protein adsorption ability.",GO,serum,1
PMC2946292A,"Cells were serum-starved for 24 h followed by the addition of media containing 2% serum and collected after 4 or 8 h. Cells were harvested and processed using the CycleTEST PLUS DNA reagent kit (Becton Dickinson, Franklin Lakes, NJ) following the manufacturer's instructions.",PLUS,serum,1
PMC2946292A,"Cells were serum-starved for 24 h followed by the addition of media containing 2% serum and collected after 4 or 8 h. Cells were harvested and processed using the CycleTEST PLUS DNA reagent kit (Becton Dickinson, Franklin Lakes, NJ) following the manufacturer's instructions.",PLUS,serum,1
PMC2946292A,"Cells were serum-starved for 24 h followed by the addition of media containing 2% serum and collected after 4 or 8 h. Cells were harvested and processed using the CycleTEST PLUS DNA reagent kit (Becton Dickinson, Franklin Lakes, NJ) following the manufacturer's instructions.",DNA,serum,1
PMC2946292A,"Cells were serum-starved for 24 h followed by the addition of media containing 2% serum and collected after 4 or 8 h. Cells were harvested and processed using the CycleTEST PLUS DNA reagent kit (Becton Dickinson, Franklin Lakes, NJ) following the manufacturer's instructions.",DNA,serum,1
PMC4889960A,"In the current study, we kept the temperature within the range of 40-43 degC; in this range, PTT can reduce tumor hypoxia by increasing blood perfusion [66].",PTT,blood,-1
PMC2976030A,"Useful biomarkers for cancer detection in blood are those proteins released specifically from cancer tissues (overexpression of cancer proteins), indicators of a specific response of the system to cancer cells, or leaking of organ restricted proteins to blood due to structural changes in the microenvironment surrounding cancer cells (leaking of normal proteins such as PSA) 7.",PSA,blood,1
PMC2976030A,"Useful biomarkers for cancer detection in blood are those proteins released specifically from cancer tissues (overexpression of cancer proteins), indicators of a specific response of the system to cancer cells, or leaking of organ restricted proteins to blood due to structural changes in the microenvironment surrounding cancer cells (leaking of normal proteins such as PSA) 7.",PSA,blood,1
PMC4465473A,"High serum CEA level (=15 ng/ml) was observed in 14 cases, whereas low serum CEA level (15 ng/ml) was displayed in 71 cases.",CEA,serum,1
PMC4465473A,"High serum CEA level (=15 ng/ml) was observed in 14 cases, whereas low serum CEA level (15 ng/ml) was displayed in 71 cases.",CEA,serum,1
PMC4465473A,"High serum CEA level (=15 ng/ml) was observed in 14 cases, whereas low serum CEA level (15 ng/ml) was displayed in 71 cases.",CEA,serum,1
PMC4465473A,"High serum CEA level (=15 ng/ml) was observed in 14 cases, whereas low serum CEA level (15 ng/ml) was displayed in 71 cases.",CEA,serum,1
PMC3655979A,"After a single dose (2.4 nmol) of subcutaneous administration, the mean serum concentration of intact (E1)-l1 reached a high level by 6 h and fell below the limit of ELISA detection by 48 h (Figure 6A).",ELISA,serum,1
PMC3655979A,"When the concentrations of (E1)-l1 in the serum sample were also measured by its inhibitory activity on ME-180 cells using the MTS assay, the results were largely consistent (Figure 6B).View larger versionFigure 6.",MTS,serum,1
PMC3655979A,"When the concentrations of (E1)-l1 in the serum sample were also measured by its inhibitory activity on ME-180 cells using the MTS assay, the results were largely consistent (Figure 6B).View larger versionFigure 6.",ME-180,serum,1
PMC2946292A,"The next day, cells were serum-starved for 24 h followed by the addition of 0.2% FBS.",FBS,serum,1
PMC4469888A,"A single prostate cell suspension isolated as above was cultured in growth medium (DMEM supplemented with 10% serum, 1% antibiotics, and 1% HEPES) for 6 h (37degC/5% CO2) to attach stromal cells.",HEPES,serum,1
PMC4469888A,"A single prostate cell suspension isolated as above was cultured in growth medium (DMEM supplemented with 10% serum, 1% antibiotics, and 1% HEPES) for 6 h (37degC/5% CO2) to attach stromal cells.",CO2,serum,1
PMC4469888A,"A single prostate cell suspension isolated as above was cultured in growth medium (DMEM supplemented with 10% serum, 1% antibiotics, and 1% HEPES) for 6 h (37degC/5% CO2) to attach stromal cells.",DMEM,serum,1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",BST2,plasma,-1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",BST2,blood,-1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",BST2,plasma,-1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",BST2,blood,-1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",CRC,plasma,-1
PMC4606116A,"Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present.",CRC,blood,-1
PMC3551651A,Nonspecific binding was blocked by incubation with 5% goat serum in TBS for 30 min.,TBS,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3929731A,"Because adult host mice have greater BPA-metabolizing capacity than the fetus (36), preliminary studies were conducted using 50 to 500 mg BPA/kg body weight (BW) to identify oral doses that produce internal free BPA levels comparable to levels found in human umbilical cord, fetal serum, and neonatal serum.",BPA,serum,1
PMC3250983A,"Consequently, in this MDA-MB-468 tumor model, the tumor/blood ratio is almost 1:1, as compared to 2:1 in other models.",MB-468,blood,-1
PMC3250983A,"Consequently, in this MDA-MB-468 tumor model, the tumor/blood ratio is almost 1:1, as compared to 2:1 in other models.",MDA,blood,-1
PMC3551651A,"Related clinical data were collected, including gender, age, tobacco and alcohol consumption, tumor differentiation, pTNM stage, lymph node metastasis, and 5-year follow-up survival.",pTNM,lymph,1
PMC2855629A,"Blocking was performed by incubation in PBS supplemented with 5% normal goat serum and 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) at room temperature (RT) for 30 minutes.",BSA,serum,1
PMC2855629A,"Blocking was performed by incubation in PBS supplemented with 5% normal goat serum and 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) at room temperature (RT) for 30 minutes.",BSA,serum,1
PMC2855629A,"Blocking was performed by incubation in PBS supplemented with 5% normal goat serum and 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) at room temperature (RT) for 30 minutes.",PBS,serum,1
PMC2855629A,"Blocking was performed by incubation in PBS supplemented with 5% normal goat serum and 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) at room temperature (RT) for 30 minutes.",PBS,serum,1
PMC4606116A,Receiver operating characteristic (ROC) analysis was performed for plasma BST2 and CEA in discriminating CRC patients from controls.,CRC,plasma,1
PMC4606116A,Receiver operating characteristic (ROC) analysis was performed for plasma BST2 and CEA in discriminating CRC patients from controls.,BST2,plasma,1
PMC4606116A,Receiver operating characteristic (ROC) analysis was performed for plasma BST2 and CEA in discriminating CRC patients from controls.,ROC,plasma,1
PMC4606116A,Receiver operating characteristic (ROC) analysis was performed for plasma BST2 and CEA in discriminating CRC patients from controls.,CEA,plasma,1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",HLA,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD14,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD90,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD34,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD31,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD45,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD73,serum,-1
PMC4707334A,"Adherent skin-origin MSCs are growing in the presence of serum, express markers specific for mesenchymal stem cell lineages CD73, CD90, and CD105, are negative for hematopoietic merkers including CD34, CD45, CD14, CD31, and HLA-DR, and are negative for nestin and positive for fibronectin, vimentin, and collagen type I.",CD105,serum,-1
PMC4707334A,"Moreover, serum-free expanded floating spheres represent skin-derived precursors with limited mesodermal but higher neurogenic differentiation potential comparable to neural crest stem cells [45].Diversity of human MSC of dermis origin was also confirmed in studies on mesenchymal progenitors isolated from foreskin samples [48].",MSC,serum,1
PMC2976030A,"In an attempt to identify the proteins derived from cancerous tissue that are most likely to be present in blood, we employed our recently developed glycoproteomic analysis method using solid-phase extraction of N-linked glycopeptides (SPEG) 8-10.",SPEG,blood,-1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",Trop2,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",GC,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",GC,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",AREG,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",GC,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",TNM,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",AREG,lymph,1
PMC5430091A,"Trop2 and AREG expression in gastric tissues.+: represents high expression, -: represents Low or no expressionThis study was also collected the data of GC patients' clinicopathologic characteristics and examined the relationship between Trop2 and AREG protein expression and clinicopathologic parameter in GC patients (Table 2).The result indicated that T+A+ expression in GC was significantly associated with TNM stage (kh2 = 50.345, P  0.001), tumor size(kh2 = 40.349, P  0.001), lymph node metastases (kh2 = 26.481, P  0.001), and distant metastases(kh2 = 8.387, P = 0.039).",Trop2,lymph,1
PMC4716673A,Sections were then blocked at room temperature for 1 h with 1.5 % normal donkey serum diluted in PBS containing 5 % bovine serum albumin and incubated overnight at 4 degC with primary antibody diluted 1:20 in PBS.,PBS,serum,1
PMC4716673A,Sections were then blocked at room temperature for 1 h with 1.5 % normal donkey serum diluted in PBS containing 5 % bovine serum albumin and incubated overnight at 4 degC with primary antibody diluted 1:20 in PBS.,PBS,serum,1
PMC4716673A,Sections were then blocked at room temperature for 1 h with 1.5 % normal donkey serum diluted in PBS containing 5 % bovine serum albumin and incubated overnight at 4 degC with primary antibody diluted 1:20 in PBS.,PBS,serum,1
PMC4716673A,Sections were then blocked at room temperature for 1 h with 1.5 % normal donkey serum diluted in PBS containing 5 % bovine serum albumin and incubated overnight at 4 degC with primary antibody diluted 1:20 in PBS.,PBS,serum,1
PMC4673473A,"Moreover, similar to pluripotent stem cell differentiation protocols, we successfully reiterated the various normal-like sequential developmental stages, which guarantee more physiologically relevant cells.5Clinical studies have reported that mobilization of bone-marrow-derived CD34+ cells into alcoholic liver cirrhosis patients led to clinical and biochemical improvement.31, 32 Human transplant recipient studies have reported that hepatocytes have been derived from donor bone marrow cells.33, 34 Endodermal stem cell lines from human embryonic stem cells were characterized and could expand endodermal stem cells 1016-fold relatively easily.35 These reports suggest that equivalent endodermal precursor populations exist in human bone marrow, allowing for efficient in vitro expansion capacity.",CD34,bone marrow,1
PMC4673473A,"Moreover, similar to pluripotent stem cell differentiation protocols, we successfully reiterated the various normal-like sequential developmental stages, which guarantee more physiologically relevant cells.5Clinical studies have reported that mobilization of bone-marrow-derived CD34+ cells into alcoholic liver cirrhosis patients led to clinical and biochemical improvement.31, 32 Human transplant recipient studies have reported that hepatocytes have been derived from donor bone marrow cells.33, 34 Endodermal stem cell lines from human embryonic stem cells were characterized and could expand endodermal stem cells 1016-fold relatively easily.35 These reports suggest that equivalent endodermal precursor populations exist in human bone marrow, allowing for efficient in vitro expansion capacity.",CD34,bone marrow,1
PMC2855629A,Blocking solution was PBS supplemented with 5% normal rabbit serum and 1% BSA.,BSA,serum,1
PMC2855629A,Blocking solution was PBS supplemented with 5% normal rabbit serum and 1% BSA.,PBS,serum,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",ECM,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",DDC,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",CDE,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",ECM,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",CDE,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",OPN,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",YFP,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",CDE,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",DDC,bile,1
PMC4154955A,"On the other hand, when bile ducts and the canal of Hering were labeled using OPN-CreERT2:ROSA-YFP mice, YFP+ cells forming ductular structures differentiated into MHs in mice fed with CDE-diet but not in chronic CCl4-injured and DDC-injured livers.30 The authors suggested a possibility that the fate of LPCs in DDC and CDE models attribute to differential association with the ECM layer; LPCs are completely surrounded by ECM layers in DDC-injured livers but not in CDE-injured ones.",DDC,bile,1
PMC5190113A,Media for all cell lines was supplemented with 10% Fetal Bovine Serum (FBS) (Invitrogen 10100-147).,FBS,Serum,1
PMC4505916A,"Such BECs, in both rodent and human studies, are characterized as single or small groups of cells positive for the BEC marker, cytokeratin-19 (KRT19), and located within the hepatic lobule separated from the larger bile ducts (Crawford et al.",BEC,bile,1
PMC4505916A,"Such BECs, in both rodent and human studies, are characterized as single or small groups of cells positive for the BEC marker, cytokeratin-19 (KRT19), and located within the hepatic lobule separated from the larger bile ducts (Crawford et al.",KRT19,bile,1
PMC3215704A,"DU145 was maintained at 37degC/5% CO2 in RPMI 1640 containing 5% fetal calf serum (FCS) and penicillin/streptomycin (P/S) (Lonza, Verviers, Belgium).",FCS,serum,1
PMC3215704A,"DU145 was maintained at 37degC/5% CO2 in RPMI 1640 containing 5% fetal calf serum (FCS) and penicillin/streptomycin (P/S) (Lonza, Verviers, Belgium).",DU145,serum,1
PMC3215704A,"DU145 was maintained at 37degC/5% CO2 in RPMI 1640 containing 5% fetal calf serum (FCS) and penicillin/streptomycin (P/S) (Lonza, Verviers, Belgium).",RPMI,serum,1
PMC3215704A,"DU145 was maintained at 37degC/5% CO2 in RPMI 1640 containing 5% fetal calf serum (FCS) and penicillin/streptomycin (P/S) (Lonza, Verviers, Belgium).",CO2,serum,1
PMC5344228A,"Additionally, skin explant experiments demonstrated that Met activation induces dDC and LC emigration from skin [27,28].These findings were supported using a conditional Met deficient mouse model where activated skin resident DCs failed to migrate towards the skin-draining lymph nodes despite an activated phenotype [28].",Met,lymph,-1
PMC5344228A,"Additionally, skin explant experiments demonstrated that Met activation induces dDC and LC emigration from skin [27,28].These findings were supported using a conditional Met deficient mouse model where activated skin resident DCs failed to migrate towards the skin-draining lymph nodes despite an activated phenotype [28].",Met,lymph,-1
PMC5344228A,"Additionally, skin explant experiments demonstrated that Met activation induces dDC and LC emigration from skin [27,28].These findings were supported using a conditional Met deficient mouse model where activated skin resident DCs failed to migrate towards the skin-draining lymph nodes despite an activated phenotype [28].",dDC,lymph,-1
PMC4344740A,"We screened 8 x 106 cDNA clones using plasma from ten patients with ischemic stroke caused by severe carotid stenosis (90%) and isolated 6 reactive clones (Figure 1A, Table 2).",cDNA,plasma,1
PMC3754468A,"37degC. Following the removal of small undigested tissue fragments and differential centrifugation, the single-cell suspension was seeded in serum-free DMEM/F12 medium containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) [37].",EGF,serum,1
PMC3754468A,"37degC. Following the removal of small undigested tissue fragments and differential centrifugation, the single-cell suspension was seeded in serum-free DMEM/F12 medium containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) [37].",DMEM,serum,1
PMC3754468A,"37degC. Following the removal of small undigested tissue fragments and differential centrifugation, the single-cell suspension was seeded in serum-free DMEM/F12 medium containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) [37].",F12,serum,1
PMC3754468A,"37degC. Following the removal of small undigested tissue fragments and differential centrifugation, the single-cell suspension was seeded in serum-free DMEM/F12 medium containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) [37].",FGF2,serum,1
PMC4637632A,77.6% patients had lymph node metastasis at the diagnosis and 67% patients had locally advanced disease with stage III and IV.,III,lymph,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",HCT116,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",HCT116,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",USA,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",USA,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",DMEM,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",DMEM,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",USA,serum,1
PMC3039653A,"HCT116 cell line was cultured in McCoy's 5A medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, all other cell lines were cultured in DMEM medium (Invitrogen, USA) supplemented with 10% fetal bovine serum.",USA,serum,1
PMC3754468A,"PCSC differentiation was induced by culture in serum-free mitogen-free medium supplemented with 10-8 M dihydrotestosterone for 7-10 days in Matrigel (BD Biosciences, San Diego, CA, http://www.bdbiosciences.com)-coated flasks.",PCSC,serum,1
PMC3754468A,"PCSC differentiation was induced by culture in serum-free mitogen-free medium supplemented with 10-8 M dihydrotestosterone for 7-10 days in Matrigel (BD Biosciences, San Diego, CA, http://www.bdbiosciences.com)-coated flasks.",San,serum,1
PMC3126726A,"Each fecal sample run also included human reference cDNA (Clontech, Mountain View, CA) as a standard to estimate the relative expression levels in feces.",cDNA,feces,1
PMC3754468A,"Cells were then resuspended in blocking solution (phosphate-buffered saline [PBS] supplemented with 5 mg/ml bovine serum albumin and 2 mM EDTA, pH 8) and kept on ice for 20 minutes.",EDTA,serum,1
PMC3754468A,"Cells were then resuspended in blocking solution (phosphate-buffered saline [PBS] supplemented with 5 mg/ml bovine serum albumin and 2 mM EDTA, pH 8) and kept on ice for 20 minutes.",PBS,serum,1
PMC5042010A,Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donorsPaired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample.,DNA,blood,-1
PMC5042010A,Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donorsPaired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample.,DNA,blood,-1
PMC5042010A,Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donorsPaired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample.,SF,blood,-1
PMC5042010A,Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donorsPaired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample.,SNV,blood,-1
PMC5042010A,Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donorsPaired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample.,DNA,blood,-1
PMC5385398A,The present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts and is obviously correlated with a poor prognosis of PHCC patients.,CUL4A,bile,1
PMC5385398A,The present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts and is obviously correlated with a poor prognosis of PHCC patients.,PHCC,bile,1
PMC5385398A,The present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts and is obviously correlated with a poor prognosis of PHCC patients.,PHCC,bile,1
PMC4558321A,"In addition, Trop-2 was not found in the sera of 12 patients with diverse metastatic cancers, further suggesting that a serum assay would not be useful for patient selection.",Trop-2,serum,1
PMC4558321A,"In addition, Trop-2 was not found in the sera of 12 patients with diverse metastatic cancers, further suggesting that a serum assay would not be useful for patient selection.",Trop-2,sera,1
PMC4558321A,"Although the largest number of patients enrolled in this trial had advanced pancreatic ductal cancer (N = 7; median time to progression 2.9 months; range, 1.0 to 4.0 months), there were encouraging reductions in target lesions and CA19-9 serum concentrations to suggest activity because of the advanced disease in these patients (15).",CA19,serum,1
PMC4803572A,"Prostate cancer (PCa) disseminated tumor cells (DTC) have been detected in patient bone marrow prior to radical prostatectomy (RP) [1,2].",DTC,bone marrow,1
PMC3008507A,"All cell lines were cultured in the recommended media containing 10% fetal bovine serum (FBS), and cell line cross-contamination was excluded by short tandem repeat profiling.3 Total RNA was isolated using TRIzol (Invitrogen, Gaithersburg, MD), and purified using the RNeasy Mini kit (Qiagen, Germantown, MD).",FBS,serum,1
PMC3008507A,"All cell lines were cultured in the recommended media containing 10% fetal bovine serum (FBS), and cell line cross-contamination was excluded by short tandem repeat profiling.3 Total RNA was isolated using TRIzol (Invitrogen, Gaithersburg, MD), and purified using the RNeasy Mini kit (Qiagen, Germantown, MD).",RNA,serum,1
PMC4366163A,"Tet-off MDCK II cells (BD Biosciences) were cultured under standard conditions in DMEM (4.5 g/liter glucose), 10% fetal bovine serum, and penicillin/streptomycin. Transfections with BL-Ocln, Ocln-BL and BL-Cldn4 encoding plasmids were performed by Nucleofection (Lonza, Allendale, NJ).",DMEM,serum,1
PMC4366163A,"Tet-off MDCK II cells (BD Biosciences) were cultured under standard conditions in DMEM (4.5 g/liter glucose), 10% fetal bovine serum, and penicillin/streptomycin. Transfections with BL-Ocln, Ocln-BL and BL-Cldn4 encoding plasmids were performed by Nucleofection (Lonza, Allendale, NJ).",Cldn4,serum,1
PMC4366163A,"Tet-off MDCK II cells (BD Biosciences) were cultured under standard conditions in DMEM (4.5 g/liter glucose), 10% fetal bovine serum, and penicillin/streptomycin. Transfections with BL-Ocln, Ocln-BL and BL-Cldn4 encoding plasmids were performed by Nucleofection (Lonza, Allendale, NJ).",MDCK,serum,1
PMC4631976A,"Moreover, both EGFR and its downstream Akt and ERK pathways are known to be involved in preventing apoptosis in stem-like cell populations in serum-deprived colorectal cancer cells[113].",ERK,serum,1
PMC4631976A,"Moreover, both EGFR and its downstream Akt and ERK pathways are known to be involved in preventing apoptosis in stem-like cell populations in serum-deprived colorectal cancer cells[113].",EGFR,serum,1
PMC3039945A,"Primary CRC tumours without early signs of metastatic invasion such as vascular emboli (i.e., infiltration of cancer tissue into blood vessels) presented with significant increases in T-cell sub-populations from early memory (CD45RO+CCR7- CD28+CD27+) to effector memory CD8+ T-cells (CD45RO+CCR7-CD28+CD27-).",T,blood,-1
PMC3039945A,"Primary CRC tumours without early signs of metastatic invasion such as vascular emboli (i.e., infiltration of cancer tissue into blood vessels) presented with significant increases in T-cell sub-populations from early memory (CD45RO+CCR7- CD28+CD27+) to effector memory CD8+ T-cells (CD45RO+CCR7-CD28+CD27-).",CD8,blood,-1
PMC3039945A,"Primary CRC tumours without early signs of metastatic invasion such as vascular emboli (i.e., infiltration of cancer tissue into blood vessels) presented with significant increases in T-cell sub-populations from early memory (CD45RO+CCR7- CD28+CD27+) to effector memory CD8+ T-cells (CD45RO+CCR7-CD28+CD27-).",T,blood,-1
PMC3039945A,"Primary CRC tumours without early signs of metastatic invasion such as vascular emboli (i.e., infiltration of cancer tissue into blood vessels) presented with significant increases in T-cell sub-populations from early memory (CD45RO+CCR7- CD28+CD27+) to effector memory CD8+ T-cells (CD45RO+CCR7-CD28+CD27-).",CRC,blood,-1
PMC3800471A,"For cytokine treatment assays, cells were serum starved in DMEM supplemented with 0.2% FBS and 2 mM L-glutamine for 6-18 hours and treated with cytokines for indicated times.",FBS,serum,1
PMC3800471A,"For cytokine treatment assays, cells were serum starved in DMEM supplemented with 0.2% FBS and 2 mM L-glutamine for 6-18 hours and treated with cytokines for indicated times.",DMEM,serum,1
PMC5378227A,"Serum samples from patients and healthy controls were analyzed by ELISA, as previously described.6 Briefly, purified recombinant proteins were coated onto 96-well microtiter plates (Maxisorp; Nunc, Rochester, NY, USA).",ELISA,Serum,1
PMC5378227A,"Serum samples from patients and healthy controls were analyzed by ELISA, as previously described.6 Briefly, purified recombinant proteins were coated onto 96-well microtiter plates (Maxisorp; Nunc, Rochester, NY, USA).",USA,Serum,1
PMC3785439A,The serum-stimulated matrigel invasion assay showed that the number of Siha and CaSki cells that passed through the polycarbonat emembrane in the TROP2 siRNA transfection group was significantly less than that in the negative control group (p0.05; Figure 6A).,TROP2,serum,1
PMC4673473A,"Bone marrow is the largest reservoir of multipotent stem cells, particularly of the two major stem cell populations, HSCs and mesenchymal stem cells (MSCs);3, 17 however, it remains unclear which bone marrow stem cell population is most effective in the regeneration of injured liver tissues.16 A pioneering study suggested that HSCs (c-KithiThyloLin-Sca1+) could give rise to hepatocytes and rescue FAH-/- mice,6 although subsequent studies had questioned these findings.5",Sca1,bone marrow,1
PMC4673473A,"Bone marrow is the largest reservoir of multipotent stem cells, particularly of the two major stem cell populations, HSCs and mesenchymal stem cells (MSCs);3, 17 however, it remains unclear which bone marrow stem cell population is most effective in the regeneration of injured liver tissues.16 A pioneering study suggested that HSCs (c-KithiThyloLin-Sca1+) could give rise to hepatocytes and rescue FAH-/- mice,6 although subsequent studies had questioned these findings.5",Sca1,Bone marrow,1
PMC3440735A,"We prepared peripheral blood mononuclear cells (PBMCs) using Ficoll (Amersham Biosciences, Buckinghamshire, UK) and extracted total RNA using TRIzol (Invitrogen, Inc., Carlsbad, CA, USA) according to the manufacturer's instructions.",RNA,blood,1
PMC3440735A,"We prepared peripheral blood mononuclear cells (PBMCs) using Ficoll (Amersham Biosciences, Buckinghamshire, UK) and extracted total RNA using TRIzol (Invitrogen, Inc., Carlsbad, CA, USA) according to the manufacturer's instructions.",USA,blood,1
PMC4370053A,(B) Analysis of LCs and dermal DCs in 2 patients with failureof bone marrow-derived DC hematopoiesis as a result of GATA-2mutation.,DC,bone marrow,1
PMC5505023A,"Moreover, immunofluorescence staining revealed that the expression of FHPC markers (CD133 and EpCAM) was downregulated in these bile duct structures (Fig.",FHPC,bile,1
PMC5505023A,"Moreover, immunofluorescence staining revealed that the expression of FHPC markers (CD133 and EpCAM) was downregulated in these bile duct structures (Fig.",CD133,bile,1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DIII,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DIII,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DIV,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DIV,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DAPI,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,DAPI,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,CTC,blood,-1
PMC4687932A,Number of EpCAM-enriched CTCs and potential CTCs/double positive events (CKpos/CD45pos) within the EpCAM-depleted fractions in blood of breast cancer patients.(A) CTC count determined by EpCAM-enrichment and subsequent CK/DAPI stain in 29 blood samples of 25 patients (DIII and DIV).,CTC,blood,-1
PMC4958526A,"Langerhans cells (LC) are resident epidermal dendritic cells (DC) that migrate to skin-draining lymph nodes (LN) during the steady state and in response to inflammatory stimuli (Schuler and Steinman, 1985) (Jakob et al., 2001)",DC,lymph,1
PMC5344228A,"Met expression was found on bone marrow (BM)-derived DCs and dermal DCs (dDCs) and Langerhans cells (LCs; the epidermal contingent of DCs), which play a pivotal role in skin immunity [27,28].",Met,bone marrow,-1
PMC3866276A,"To date, reproducibility of our previously published results has been demonstrated in two independent publications indicating that the hESC-based model express bona fide human tumor blood vessels and enhance tumor engraftment rate by primary human ovarian CSC-like [37], and that the hESC-based model enable the implantation and growth of childhood neuroectodermal tumors biopsies as it provides an embryonic niche well suited for in vivo studies of neuroblastoma [64].",hESC,blood,1
PMC3866276A,"To date, reproducibility of our previously published results has been demonstrated in two independent publications indicating that the hESC-based model express bona fide human tumor blood vessels and enhance tumor engraftment rate by primary human ovarian CSC-like [37], and that the hESC-based model enable the implantation and growth of childhood neuroectodermal tumors biopsies as it provides an embryonic niche well suited for in vivo studies of neuroblastoma [64].",CSC,blood,1
PMC3866276A,"To date, reproducibility of our previously published results has been demonstrated in two independent publications indicating that the hESC-based model express bona fide human tumor blood vessels and enhance tumor engraftment rate by primary human ovarian CSC-like [37], and that the hESC-based model enable the implantation and growth of childhood neuroectodermal tumors biopsies as it provides an embryonic niche well suited for in vivo studies of neuroblastoma [64].",hESC,blood,1
PMC3548755A,Changes in the serum autoantibody level to SH3GL1 in a rat brain tumor model using C6 rat glioblastoma cells which were confirmed to express SH3GL1 protein.,SH3GL1,serum,-1
PMC3548755A,Changes in the serum autoantibody level to SH3GL1 in a rat brain tumor model using C6 rat glioblastoma cells which were confirmed to express SH3GL1 protein.,SH3GL1,serum,-1
PMC3548755A,Changes in the serum autoantibody level to SH3GL1 in a rat brain tumor model using C6 rat glioblastoma cells which were confirmed to express SH3GL1 protein.,C6,serum,-1
PMC5410259A,Cells of non-malignant and malignant regions of a prostatectomy specimen were grown in keratinocyte serum-free medium (K-SFM) and then transferred to CR conditions to generate immortalized cultures as previously described [8].,SFM,serum,1
PMC5410259A,Cells of non-malignant and malignant regions of a prostatectomy specimen were grown in keratinocyte serum-free medium (K-SFM) and then transferred to CR conditions to generate immortalized cultures as previously described [8].,CR,serum,1
PMC3548755A,"However, the levels of serum autoantibodies to SH3GL1 in the patients with high-grade glioma were not increased in our study, while the levels in the patients with low-grade glioma were increased.",SH3GL1,serum,1
PMC3799850A,"As EVT approach maternal blood vessels, they are exposed to increasingly higher O2 tensions (~14% O2), causing a gradual shift from proliferation to invasion [5].",EVT,blood,-1
PMC3799850A,"As EVT approach maternal blood vessels, they are exposed to increasingly higher O2 tensions (~14% O2), causing a gradual shift from proliferation to invasion [5].",O2,blood,-1
PMC3799850A,"As EVT approach maternal blood vessels, they are exposed to increasingly higher O2 tensions (~14% O2), causing a gradual shift from proliferation to invasion [5].",O2,blood,-1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",LNCAP,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",PHG0311,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",N2,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",B27,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",EGF,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",FBS,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",FBS,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",PBS,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",DMEM,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",FGF,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",TROP2,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",PHG0026,serum,1
PMC5190113A,"The usual androgen concentration within FBS (0.1-1 nM Di Hydro Testosterone) is sufficient to efficiently maintain androgen-sensitive cells such as LNCAP and 22RV1 [36].For spheroid culture, cells were grown in serum-free DMEM/F-12 medium (Invitrogen 10565) supplemented with 1% N2 (Invitrogen 17502-048), 2% B27 (Invitrogen 17504-044), 20 ng/mL human epidermal growth factor (EGF Invitrogen PHG0311), 20ng/mL human fibroblast growth factor-basic (FGF-b Invitrogen PHG0026) and 100 units of Penicillin-Streptomycin (Invitrogen) in ultra-low attachment plates (Costar).Cells were stained with Mouse anti-human TROP2 antibody (BD Bioscience 551317, 1/200) in antibody staining buffer (0.9% (w/v), sodium azide and 2% FBS in PBS) for 1 hour.",F-12,serum,1
PMC3680444A,"A recent report described a correlation of ATDC mRNA expression with poor histological grade, large tumor size, extent of tumor invasion, and lymph node metastasis in gastric cancer [15].",mRNA,lymph,1
PMC3680444A,"A recent report described a correlation of ATDC mRNA expression with poor histological grade, large tumor size, extent of tumor invasion, and lymph node metastasis in gastric cancer [15].",ATDC,lymph,1
PMC5344228A,Met-signaling was found to play a role in monocyte-macrophage development [23] and in regulating B cell homing to the lymph nodes [24].,Met,lymph,-1
PMC4803572A,"To keep or push PCa DTC towards a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTC at the epigenetic or miRNA level.",DTC,bone marrow,1
PMC4803572A,"To keep or push PCa DTC towards a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTC at the epigenetic or miRNA level.",p38,bone marrow,1
PMC4803572A,"To keep or push PCa DTC towards a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTC at the epigenetic or miRNA level.",BMP7,bone marrow,1
PMC4803572A,"To keep or push PCa DTC towards a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTC at the epigenetic or miRNA level.",MEK,bone marrow,1
PMC4803572A,"To keep or push PCa DTC towards a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTC at the epigenetic or miRNA level.",DTC,bone marrow,1
PMC4889960A,(v/v) fetal bovine serum at 37 degC with 5 % CO2.,CO2,serum,1
PMC5344228A,Upon activation DCs/Langerhans cells (LCs) migrate via lymphatics to draining lymph nodes to present antigens to naive T cells.,T,lymph,-1
PMC4292049A,"A decrease in tumor mass, serum thyrocalcitonin, and CEA levels was observed in six of the patients receiving the MTD.",CEA,serum,1
PMC4292049A,"A decrease in tumor mass, serum thyrocalcitonin, and CEA levels was observed in six of the patients receiving the MTD.",MTD,serum,1
PMC3743266A,"Slides were blocked in 10% normal goat serum (NGS) (Vector Labs), and incubated with primary antibodies diluted in 10% NGS overnight at 4 degC. Secondary antibodies were obtained from Vectastain ABC kits (Vector Labs) and diluted 1:250.",NGS,serum,1
PMC3743266A,"Slides were blocked in 10% normal goat serum (NGS) (Vector Labs), and incubated with primary antibodies diluted in 10% NGS overnight at 4 degC. Secondary antibodies were obtained from Vectastain ABC kits (Vector Labs) and diluted 1:250.",NGS,serum,1
PMC3743266A,"Slides were blocked in 10% normal goat serum (NGS) (Vector Labs), and incubated with primary antibodies diluted in 10% NGS overnight at 4 degC. Secondary antibodies were obtained from Vectastain ABC kits (Vector Labs) and diluted 1:250.",ABC,serum,1
PMC5480073A,Interleukin 6 (IL-6) is an interleukin that is characterized as a regulator of immune and inflammatory responses and capable of crossing the blood-brain barrier.,IL-6,blood,-1
PMC5143353A,PHGDHhigh was correlated with TNM stage and lymph node invasion and also conferred a significant survival disadvantage over PHGDHlow.,TNM,lymph,1
PMC3476529A,"CD141hi DCs were more difficult to isolate than CD141+ blood DCs, owing to the upregulation of CD141 on a number of other cells including CD14+ DCs and a proportion of CD1c+ DCs.",CD14,blood,-1
PMC3476529A,"CD141hi DCs were more difficult to isolate than CD141+ blood DCs, owing to the upregulation of CD141 on a number of other cells including CD14+ DCs and a proportion of CD1c+ DCs.",CD141,blood,-1
PMC3476529A,"CD141hi DCs were more difficult to isolate than CD141+ blood DCs, owing to the upregulation of CD141 on a number of other cells including CD14+ DCs and a proportion of CD1c+ DCs.",CD141,blood,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",BST2,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",CRC,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",AUC,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",CEA,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",CRC,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",BST2,plasma,-1
PMC4606116A,"We also showed the significant elevation of plasma BST2 levels in CRC patients compared to normal controls and showed that BST2 may increase AUC after combining CEA for CRC detection, especially for stage 1-2 CRC detection (Figure 4).",CRC,plasma,-1
PMC3476529A,"Comparison of this cell with the major population of CD1c+ DCs, CD14+ DCs, and blood DCs allowed us to align mouse and human DC subsets across species.",DC,blood,-1
PMC3476529A,"Comparison of this cell with the major population of CD1c+ DCs, CD14+ DCs, and blood DCs allowed us to align mouse and human DC subsets across species.",CD14,blood,-1
PMC4074497A,"In animals pre-administered DTPA-INCA-X, there was a shift of activity from the spleen to the blood pool and tumor (Figure 3B and 3C), indicating a block of a dominating off target effect.",DTPA,blood,-1
PMC4074497A,"In animals pre-administered DTPA-INCA-X, there was a shift of activity from the spleen to the blood pool and tumor (Figure 3B and 3C), indicating a block of a dominating off target effect.",X,blood,-1
PMC4074497A,"In animals pre-administered DTPA-INCA-X, there was a shift of activity from the spleen to the blood pool and tumor (Figure 3B and 3C), indicating a block of a dominating off target effect.",INCA,blood,-1
PMC3548755A,"To verify the generality of low-grade glioma-specific increase in serum antibodies to SH3GL1, an independent validation test was carried out using other serum set.",SH3GL1,serum,1
PMC3548755A,"To verify the generality of low-grade glioma-specific increase in serum antibodies to SH3GL1, an independent validation test was carried out using other serum set.",SH3GL1,serum,1
PMC3548755A,Kaplan-Meier analysis for the overall survival of the patients with low-grade gliomas according to the serum level of anti-SH3GL1 autoantibody.,SH3GL1,serum,1
PMC3548755A,The patients with higher serum level of anti-SH3GL1 autoantibody survived significantly longer than those with lower levels (p = 0.0124) (Figure3).View larger versionFigure 3.,SH3GL1,serum,1
PMC3548755A,Overall survival of the patients with low-grade gliomas according to the serum level of anti-SH3GL1 autoantibody was analyzed by Kaplan-Meier analysis.,SH3GL1,serum,1
PMC3224189A,hRS7-mediated ADCC was not significantly decreased in the presence of human serum in our experiments.,ADCC,serum,1
PMC3548755A,Comparison of serum antibody levels among deletion mutants of SH3GL1.,SH3GL1,serum,-1
PMC4467439A,All cell lines were cultured in DMEM medium or RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin.,DMEM,serum,1
PMC4467439A,All cell lines were cultured in DMEM medium or RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin.,RPMI,serum,1
PMC3548755A,"These results were suitable for that of overlap peptide array, and approximately the 15 amino acids in the C-terminal of SH3GL1 are indispensable as the epitope recognized by serum antibodies in the patient with low-grade glioma.",SH3GL1,serum,1
PMC4606116A,"However, unlike CEA, plasma BST2 levels did not correlate with the disease progression of CRC in the sample set used in this study (Supplemental Figure 1).",BST2,plasma,1
PMC4606116A,"However, unlike CEA, plasma BST2 levels did not correlate with the disease progression of CRC in the sample set used in this study (Supplemental Figure 1).",CRC,plasma,1
PMC4606116A,"However, unlike CEA, plasma BST2 levels did not correlate with the disease progression of CRC in the sample set used in this study (Supplemental Figure 1).",CEA,plasma,1
PMC4366198A,"The primary objective of this study is to characterize the cytotoxity of GNPs in lung cancer cells when GCLC was knocked down by siRNA.A549 cells (Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences, cat number: TCHu150) were maintained in RPMI-1640 medium containing 4.5g/L glucose, 2mM L-glutamine, 1mM sodium pyruvate, 10% heat inactivated fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin.",GCLC,serum,1
PMC4366198A,"The primary objective of this study is to characterize the cytotoxity of GNPs in lung cancer cells when GCLC was knocked down by siRNA.A549 cells (Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences, cat number: TCHu150) were maintained in RPMI-1640 medium containing 4.5g/L glucose, 2mM L-glutamine, 1mM sodium pyruvate, 10% heat inactivated fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin.",TCHu150,serum,1
PMC4366198A,"The primary objective of this study is to characterize the cytotoxity of GNPs in lung cancer cells when GCLC was knocked down by siRNA.A549 cells (Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences, cat number: TCHu150) were maintained in RPMI-1640 medium containing 4.5g/L glucose, 2mM L-glutamine, 1mM sodium pyruvate, 10% heat inactivated fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin.",RPMI-1640,serum,1
PMC4366198A,"The primary objective of this study is to characterize the cytotoxity of GNPs in lung cancer cells when GCLC was knocked down by siRNA.A549 cells (Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences, cat number: TCHu150) were maintained in RPMI-1640 medium containing 4.5g/L glucose, 2mM L-glutamine, 1mM sodium pyruvate, 10% heat inactivated fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin.",FBS,serum,1
PMC3474961A,"A; normal prostate tissue with intact basement membrane, and organized luminal and neuroendocrine (NE) cells,B; PCa progression is signified by disorganized expansion of luminal and NE cells, angiogenesis, and increased invasiveness of PCa cells, C;chemokine rich milieu of the bone marrow combined with adhesion molecules expressed within HSC niche play an important role in recruitingDTCs, D; extravasation of PCa into bone microenvironment, and bone metastasis.",NE,bone marrow,1
PMC3474961A,"A; normal prostate tissue with intact basement membrane, and organized luminal and neuroendocrine (NE) cells,B; PCa progression is signified by disorganized expansion of luminal and NE cells, angiogenesis, and increased invasiveness of PCa cells, C;chemokine rich milieu of the bone marrow combined with adhesion molecules expressed within HSC niche play an important role in recruitingDTCs, D; extravasation of PCa into bone microenvironment, and bone metastasis.",HSC,bone marrow,1
PMC3474961A,"A; normal prostate tissue with intact basement membrane, and organized luminal and neuroendocrine (NE) cells,B; PCa progression is signified by disorganized expansion of luminal and NE cells, angiogenesis, and increased invasiveness of PCa cells, C;chemokine rich milieu of the bone marrow combined with adhesion molecules expressed within HSC niche play an important role in recruitingDTCs, D; extravasation of PCa into bone microenvironment, and bone metastasis.",NE,bone marrow,1
PMC5494437A,"Other astrocyte-like neural stem cells, originally derived from embryonic RG cells also have glial cell properties[34].",RG,astrocyte,1
PMC4690245A,"Significantly positive associations were identified between MTA1 expression and tumor diameter (p = 0.04), lymph node metastasis (p  0.01), clinical stage (p  0.01), but negative correlation was found with smoking status (p = 0.01).",MTA1,lymph,1
PMC4650945A,"Indeed, FGF7 expression was induced concomitantly with a HSPC response in the liver of mouse models (such DDC, CBDL), as well as in the serum of patients with acute liver failure corroborating earlier data (Dezso et al.",FGF7,serum,1
PMC4650945A,"Indeed, FGF7 expression was induced concomitantly with a HSPC response in the liver of mouse models (such DDC, CBDL), as well as in the serum of patients with acute liver failure corroborating earlier data (Dezso et al.",HSPC,serum,1
PMC4650945A,"Indeed, FGF7 expression was induced concomitantly with a HSPC response in the liver of mouse models (such DDC, CBDL), as well as in the serum of patients with acute liver failure corroborating earlier data (Dezso et al.",DDC,serum,1
PMC4650945A,"Indeed, FGF7 expression was induced concomitantly with a HSPC response in the liver of mouse models (such DDC, CBDL), as well as in the serum of patients with acute liver failure corroborating earlier data (Dezso et al.",CBDL,serum,1
PMC4165776A,"(a) Optical microscopic images depicting the specific capture and subsequent electric field-mediated release of MCF7 cells spiked into artificial blood. EpCAM-positive MCF7 cells (black arrow) were captured on the center of the microchannel, whereas non-specifically trapped WBCs primarily formed large cell agglomerates or clumps against the wall of the microfluidic device.",MCF7,blood,1
PMC4165776A,"(a) Optical microscopic images depicting the specific capture and subsequent electric field-mediated release of MCF7 cells spiked into artificial blood. EpCAM-positive MCF7 cells (black arrow) were captured on the center of the microchannel, whereas non-specifically trapped WBCs primarily formed large cell agglomerates or clumps against the wall of the microfluidic device.",MCF7,blood,1
PMC5410259A,"The cells were grown in Keratinocyte serum-free medium (K-SFM) supplemented with bovine pituitary extract and recombinant epidermal growth factor (Life Technologies, Inc., Gaithersburg, MD).Cells were seeded on a feeder layer of lethally irradiated (30 Gy) J2 fibroblasts in F medium.",J2,serum,1
PMC5410259A,"The cells were grown in Keratinocyte serum-free medium (K-SFM) supplemented with bovine pituitary extract and recombinant epidermal growth factor (Life Technologies, Inc., Gaithersburg, MD).Cells were seeded on a feeder layer of lethally irradiated (30 Gy) J2 fibroblasts in F medium.",SFM,serum,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",SCC,lymph,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",ECOG,lymph,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",NSCLC,lymph,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",TNM,lymph,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",Trop-2,lymph,1
PMC3789024A,"Trop-2 expression was higher in the advanced NSCLC tissues than in the tumor-adjacent normal tissues (P=0.000), and higher in the SCC cases [67.6% (25/37)] than in the AdC cases [42.0% (21/50); P=0.018]Trop-2 overexpression in SCC did not differ significantly with regard to patient gender, age, lymph node metastasis, TNM stage or ECOG-PS.",SCC,lymph,1
PMC4370053A,"Addition of TNF-a or GM-CSF, cytokinesthat are known to derive langerin+ DCs, did not further augment theexpression of langerin, and langerin induction was not observed on the small numberof CD141+ DCs present in these experiments (not shown).",GM,CSF,-1
PMC4370053A,"Addition of TNF-a or GM-CSF, cytokinesthat are known to derive langerin+ DCs, did not further augment theexpression of langerin, and langerin induction was not observed on the small numberof CD141+ DCs present in these experiments (not shown).",CD141,CSF,-1
PMC4370053A,"Addition of TNF-a or GM-CSF, cytokinesthat are known to derive langerin+ DCs, did not further augment theexpression of langerin, and langerin induction was not observed on the small numberof CD141+ DCs present in these experiments (not shown).",TNF,CSF,-1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",Trop-2,serum,1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",Trop-2,serum,1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",ADCC,serum,1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",ADCC,serum,1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",hRS7,serum,1
PMC3224189A,"After addition of diluted human serum, no significant decrease in killing was noted compared to incubation without serum, suggesting that irrelevant IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing cells.",hRS7,serum,1
PMC3840448A,Takayama et al. reported serum REG4 for pancreatic diagnosis.,REG4,serum,1
PMC3840448A,Stable isotope-labeled proteome (SILAP) standard with extensive multidimensional separation in combination with tandem MS-MS has been used for separating serum samples from pancreatic cancer patients [6].,SILAP,serum,1
PMC4437992A,The surface plasma resonance (SPR) peak for HGNs was approximately at 733 nm based on the UV-vis extinction spectrum as shown in Fig.,SPR,plasma,1
PMC3840448A,"Technologies such as Liquid ESI-MS analyses of sera, used in identifying biomarkers, hold promise for future pancreatic cancer blood tests.",ESI,sera,1
PMC3840448A,"Technologies such as Liquid ESI-MS analyses of sera, used in identifying biomarkers, hold promise for future pancreatic cancer blood tests.",ESI,blood,-1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",T,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",T,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",TNM,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",TNM,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",T,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",T,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",TNM,lymph,1
PMC3342122A,"Univariate analysis of EpCAM overexpression in relation to sex, age at diagnosis, tumor differentiation, pathologic T stage, lymph node metastasis, TNM stage, and smoking status revealed that in AdC, EpCAM overexpression was significantly associated with sex, tumor differentiation, pathologic T stage, lymph node metastatis, and TNM stage.",TNM,lymph,1
PMC3749571A,"All data were normalised to the housekeeping gene GAPDH.Human prostate benign cell line BPH-1 in addition to human prostate cancer cell lines LNCaP and VCaP (American Type Culture Collection (ATCC), Manassas, VA, USA) were maintained in RPMI 1640 medium (Sigma, Gillingham, UK) containing 10% fetal calf serum (Sigma) and 2 mM L-glutamine (Sigma), referred to as complete medium.",ATCC,serum,1
PMC3749571A,"All data were normalised to the housekeeping gene GAPDH.Human prostate benign cell line BPH-1 in addition to human prostate cancer cell lines LNCaP and VCaP (American Type Culture Collection (ATCC), Manassas, VA, USA) were maintained in RPMI 1640 medium (Sigma, Gillingham, UK) containing 10% fetal calf serum (Sigma) and 2 mM L-glutamine (Sigma), referred to as complete medium.",BPH-1,serum,1
PMC3749571A,"All data were normalised to the housekeeping gene GAPDH.Human prostate benign cell line BPH-1 in addition to human prostate cancer cell lines LNCaP and VCaP (American Type Culture Collection (ATCC), Manassas, VA, USA) were maintained in RPMI 1640 medium (Sigma, Gillingham, UK) containing 10% fetal calf serum (Sigma) and 2 mM L-glutamine (Sigma), referred to as complete medium.",RPMI,serum,1
PMC3749571A,"All data were normalised to the housekeeping gene GAPDH.Human prostate benign cell line BPH-1 in addition to human prostate cancer cell lines LNCaP and VCaP (American Type Culture Collection (ATCC), Manassas, VA, USA) were maintained in RPMI 1640 medium (Sigma, Gillingham, UK) containing 10% fetal calf serum (Sigma) and 2 mM L-glutamine (Sigma), referred to as complete medium.",USA,serum,1
PMC5414739A,"In vivo studies using human lymphoid cells (isolated from peripheral blood and transplanted into SCID mice, which are deficient in T and B cells), showed that PRL injection favored successful engraftment and/or proliferation of these cells in the recipient mice (132, 133).",PRL,blood,-1
PMC5414739A,"In vivo studies using human lymphoid cells (isolated from peripheral blood and transplanted into SCID mice, which are deficient in T and B cells), showed that PRL injection favored successful engraftment and/or proliferation of these cells in the recipient mice (132, 133).",SCID,blood,-1
PMC5414739A,"In vivo studies using human lymphoid cells (isolated from peripheral blood and transplanted into SCID mice, which are deficient in T and B cells), showed that PRL injection favored successful engraftment and/or proliferation of these cells in the recipient mice (132, 133).",T,blood,-1
PMC4425227A,"From this Ship1 gene, a second protein (~104 kDa) is encoded but lacking the amino-terminal SH2 domain compared with the SHIP1 protein, it is expressed in embryonic stem cells and bone marrow cells enriched for the stem cell population [16,17].",Ship1,bone marrow,1
PMC4425227A,"From this Ship1 gene, a second protein (~104 kDa) is encoded but lacking the amino-terminal SH2 domain compared with the SHIP1 protein, it is expressed in embryonic stem cells and bone marrow cells enriched for the stem cell population [16,17].",SH2,bone marrow,1
PMC4425227A,"From this Ship1 gene, a second protein (~104 kDa) is encoded but lacking the amino-terminal SH2 domain compared with the SHIP1 protein, it is expressed in embryonic stem cells and bone marrow cells enriched for the stem cell population [16,17].",SHIP1,bone marrow,1
PMC3749571A,"The isogenic androgen-independent cell line LNCaP-AI, used to mimic castration resistant prostate cancer (CRPC; Halkidou et al, 2003), was maintained in steroid-depleted media; RPMI 1640 medium (Sigma) containing 10% heat-inactivated dextran charcoal-treated fetal calf serum (Hyclone, Fisher Scientific, Loughborough, UK) and 2 mM L-glutamine (Sigma).Cells were seeded in six-well plates before being transfected with either non-silencing small-interfering RNA (siRNA) or equivalent concentration UGT1A siRNA (sequences are listed in Supplementary Information) using Lipofectamine RNAiMAX (Invitrogen).",CRPC,serum,1
PMC3749571A,"The isogenic androgen-independent cell line LNCaP-AI, used to mimic castration resistant prostate cancer (CRPC; Halkidou et al, 2003), was maintained in steroid-depleted media; RPMI 1640 medium (Sigma) containing 10% heat-inactivated dextran charcoal-treated fetal calf serum (Hyclone, Fisher Scientific, Loughborough, UK) and 2 mM L-glutamine (Sigma).Cells were seeded in six-well plates before being transfected with either non-silencing small-interfering RNA (siRNA) or equivalent concentration UGT1A siRNA (sequences are listed in Supplementary Information) using Lipofectamine RNAiMAX (Invitrogen).",UGT1A,serum,1
PMC3749571A,"The isogenic androgen-independent cell line LNCaP-AI, used to mimic castration resistant prostate cancer (CRPC; Halkidou et al, 2003), was maintained in steroid-depleted media; RPMI 1640 medium (Sigma) containing 10% heat-inactivated dextran charcoal-treated fetal calf serum (Hyclone, Fisher Scientific, Loughborough, UK) and 2 mM L-glutamine (Sigma).Cells were seeded in six-well plates before being transfected with either non-silencing small-interfering RNA (siRNA) or equivalent concentration UGT1A siRNA (sequences are listed in Supplementary Information) using Lipofectamine RNAiMAX (Invitrogen).",RPMI,serum,1
PMC3749571A,"The isogenic androgen-independent cell line LNCaP-AI, used to mimic castration resistant prostate cancer (CRPC; Halkidou et al, 2003), was maintained in steroid-depleted media; RPMI 1640 medium (Sigma) containing 10% heat-inactivated dextran charcoal-treated fetal calf serum (Hyclone, Fisher Scientific, Loughborough, UK) and 2 mM L-glutamine (Sigma).Cells were seeded in six-well plates before being transfected with either non-silencing small-interfering RNA (siRNA) or equivalent concentration UGT1A siRNA (sequences are listed in Supplementary Information) using Lipofectamine RNAiMAX (Invitrogen).",RNA,serum,1
PMC4695878A,"Furthermore, the overproduction of MUC1 in ovarian cancer leads to the increased circulating serum MUC1 levels detectable by standardized ELISA tests [15].",ELISA,serum,-1
PMC4695878A,"Furthermore, the overproduction of MUC1 in ovarian cancer leads to the increased circulating serum MUC1 levels detectable by standardized ELISA tests [15].",MUC1,serum,-1
PMC4695878A,"Furthermore, the overproduction of MUC1 in ovarian cancer leads to the increased circulating serum MUC1 levels detectable by standardized ELISA tests [15].",MUC1,serum,-1
PMC4637775A,"At the present time, serum alpha-fetoprotein (AFP) levels greater than 400 ng/ml and ultrasonography performed every 6 to 12 months are the gold-standard techniques most commonly used for HCC detection.",HCC,serum,1
PMC4637775A,"At the present time, serum alpha-fetoprotein (AFP) levels greater than 400 ng/ml and ultrasonography performed every 6 to 12 months are the gold-standard techniques most commonly used for HCC detection.",AFP,serum,1
PMC1247656A,"This approach revealed that E2 targets predominantly genes involved in protein metabolism, cell cycle, cell proliferation, DNA replication, RNA metabolism, mRNA transcription, and blood vessel development [Supplemental Data, Table 2 (http://ehp.niehs.nih.gov/txg/members/2004/7345/supplemental.pdf)].",mRNA,blood,-1
PMC1247656A,"This approach revealed that E2 targets predominantly genes involved in protein metabolism, cell cycle, cell proliferation, DNA replication, RNA metabolism, mRNA transcription, and blood vessel development [Supplemental Data, Table 2 (http://ehp.niehs.nih.gov/txg/members/2004/7345/supplemental.pdf)].",DNA,blood,-1
PMC1247656A,"This approach revealed that E2 targets predominantly genes involved in protein metabolism, cell cycle, cell proliferation, DNA replication, RNA metabolism, mRNA transcription, and blood vessel development [Supplemental Data, Table 2 (http://ehp.niehs.nih.gov/txg/members/2004/7345/supplemental.pdf)].",E2,blood,-1
PMC1247656A,"This approach revealed that E2 targets predominantly genes involved in protein metabolism, cell cycle, cell proliferation, DNA replication, RNA metabolism, mRNA transcription, and blood vessel development [Supplemental Data, Table 2 (http://ehp.niehs.nih.gov/txg/members/2004/7345/supplemental.pdf)].",RNA,blood,-1
PMC4606116A,Several previous studies regarding the identification of proteins in exosomes derived from a variety of cell/tissue types provided important clue about the potential mechanism for shedding of BST2 into blood circulation.,BST2,blood,-1
PMC3224189A,"To test for the possible inhibition of ADCC against cervical cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3224189A,"To test for the possible inhibition of ADCC against cervical cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3224189A,"To test for the possible inhibition of ADCC against cervical cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3224189A,"To test for the possible inhibition of ADCC against cervical cancer cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC4108928A,"TMA sections were incubated with a primary polyclonal rabbit anti-ROR1 antibody (1:200, Abcam, England) in TBS containing 1% bovine serum albumin for 1 hour.",ROR1,serum,1
PMC4108928A,"TMA sections were incubated with a primary polyclonal rabbit anti-ROR1 antibody (1:200, Abcam, England) in TBS containing 1% bovine serum albumin for 1 hour.",TBS,serum,1
PMC4108928A,"TMA sections were incubated with a primary polyclonal rabbit anti-ROR1 antibody (1:200, Abcam, England) in TBS containing 1% bovine serum albumin for 1 hour.",TMA,serum,1
PMC4606116A,(a) Plasma samples from 32 CRC patients and 32 healthy controls were used in this study.,CRC,Plasma,1
PMC3100619A,"Subcutaneous pellets of 25 mg of T and 2.5 mg of E2 produced serum steroid levels of 25.4 +- 2.1 ng/ml T and 675 +- 43 pg/ml E2, which is 5- to 9-fold higher than levels measured in untreated male mice as well as human males.",E2,serum,1
PMC3100619A,"Subcutaneous pellets of 25 mg of T and 2.5 mg of E2 produced serum steroid levels of 25.4 +- 2.1 ng/ml T and 675 +- 43 pg/ml E2, which is 5- to 9-fold higher than levels measured in untreated male mice as well as human males.",E2,serum,1
PMC3100619A,"Subcutaneous pellets of 25 mg of T and 2.5 mg of E2 produced serum steroid levels of 25.4 +- 2.1 ng/ml T and 675 +- 43 pg/ml E2, which is 5- to 9-fold higher than levels measured in untreated male mice as well as human males.",T,serum,1
PMC3100619A,"Subcutaneous pellets of 25 mg of T and 2.5 mg of E2 produced serum steroid levels of 25.4 +- 2.1 ng/ml T and 675 +- 43 pg/ml E2, which is 5- to 9-fold higher than levels measured in untreated male mice as well as human males.",T,serum,1
PMC5414739A,This was further confirmed in experiments of bone marrow reconstitution after irradiation where PRL-injected mice showed an increase in granulocyte/macrophage colony-forming unit and erythroid burst forming unit progenitor populations in the bone marrow and the spleen (133).,PRL,bone marrow,1
PMC5414739A,This was further confirmed in experiments of bone marrow reconstitution after irradiation where PRL-injected mice showed an increase in granulocyte/macrophage colony-forming unit and erythroid burst forming unit progenitor populations in the bone marrow and the spleen (133).,PRL,bone marrow,1
PMC5437009A,"The increased CKAP2 expression was significantly correlated with age, FIGO stage, lymph node metastasis, recurrence and tumor size.",FIGO,lymph,1
PMC5437009A,"The increased CKAP2 expression was significantly correlated with age, FIGO stage, lymph node metastasis, recurrence and tumor size.",CKAP2,lymph,1
PMC4606116A,"Using mass spectrometry-based proteomics approach, BST2 has been repeatedly detected in the exosomal fractions purified from B cells [54], ovarian cancer cells [55], thymic tissues [56], and urine [57].",BST2,urine,-1
PMC3885472A,(2) Differentiation inducing by fetal bovine serum (FBS).,FBS,serum,1
PMC4074497A,PC-3 cells were incubated for one hour with individual antibodies at a concentration of 10 ug/mL in PBS containing 0.5% w/v bovine serum albumin.,PC-3,serum,1
PMC4074497A,PC-3 cells were incubated for one hour with individual antibodies at a concentration of 10 ug/mL in PBS containing 0.5% w/v bovine serum albumin.,PBS,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",F12,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",H9,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",hESC,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",H1,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",MEF,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",hESC,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",DMEM,serum,1
PMC3799850A,"Briefly, the hESC were cultured on irradiated mouse embryonic fibroblast (MEF) cells in 80% DMEM/F12 supplemented with 20% KnockOut serum replacement, 1 mM l-glutamine/0.1 mM 2-mercaptoethanol/1% nonessential amino acids (Life Technologies) and 4 ng/ml FGF2 (in house). H1 or H9 hESC were dispersed by using 1 mg/mL of collagenase Type IV (Life Technologies).",FGF2,serum,1
PMC4074497A,"The cells were incubated for three hours at 4degC on ice with 4 ug/dish of 111In-labeled INCA-X. Thereafter, the incubation medium was discarded and the cells were washed three times using ice-cold serum-free medium.",INCA,serum,1
PMC4425227A,We showed that cells with higher s-SHIP expression (RW-GFP cells) were able to form more spheres compared with the parental RWPE-1 cells when cultivated in defined PrEGM serum-free medium and onto ultra-low attachment plates (Fig.,RWPE-1,serum,1
PMC4425227A,We showed that cells with higher s-SHIP expression (RW-GFP cells) were able to form more spheres compared with the parental RWPE-1 cells when cultivated in defined PrEGM serum-free medium and onto ultra-low attachment plates (Fig.,GFP,serum,1
PMC4425227A,We showed that cells with higher s-SHIP expression (RW-GFP cells) were able to form more spheres compared with the parental RWPE-1 cells when cultivated in defined PrEGM serum-free medium and onto ultra-low attachment plates (Fig.,SHIP,serum,1
PMC5467782A,(D) Confocal microscopy of A549 spheroids in serum-free medium stained in situ with anti-CD133 antibody and anti-CD326 antibody; cell nuclei were counterstained with DAPI.,DAPI,serum,1
PMC5467782A,(D) Confocal microscopy of A549 spheroids in serum-free medium stained in situ with anti-CD133 antibody and anti-CD326 antibody; cell nuclei were counterstained with DAPI.,A549,serum,1
PMC5467782A,(D) Confocal microscopy of A549 spheroids in serum-free medium stained in situ with anti-CD133 antibody and anti-CD326 antibody; cell nuclei were counterstained with DAPI.,CD326,serum,1
PMC5467782A,(D) Confocal microscopy of A549 spheroids in serum-free medium stained in situ with anti-CD133 antibody and anti-CD326 antibody; cell nuclei were counterstained with DAPI.,CD133,serum,1
PMC5363540A,"Additionally, the proportion of patients with ""high"" AREG expression was associated with disease progression, including TNM stage (p  0.001), invasion (p  0.001), lymph node metastasis (p  0.001), distant metastasis (p = 0.001), histological type (p = 0.006), and there was a trend of a correlation with de-differentiation (p = 0.042).",AREG,lymph,1
PMC5363540A,"Additionally, the proportion of patients with ""high"" AREG expression was associated with disease progression, including TNM stage (p  0.001), invasion (p  0.001), lymph node metastasis (p  0.001), distant metastasis (p = 0.001), histological type (p = 0.006), and there was a trend of a correlation with de-differentiation (p = 0.042).",TNM,lymph,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",EPB41L3,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",EPB41L3,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",EPB41L3,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",EPB41L3,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",NCALD,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",NCALD,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",NCALD,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",NCALD,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",MTSS1,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",MTSS1,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",MTSS1,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",MTSS1,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",LTBP1,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",LTBP1,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",LTBP1,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",LTBP1,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",CACNA2D2,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",CACNA2D2,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",CACNA2D2,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",CACNA2D2,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",FOSB,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",FOSB,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",FOSB,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",FOSB,blood,-1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",GADD45A,sputum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",GADD45A,serum,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",GADD45A,plasma,1
PMC5447959A,"They identified asbestos-related microRNA (Overexpression of miR-148b, miR-374a, miR-24-1*, let-7d, let-7e, miR-199b-5p, miR-331-3p, and miR-96; Underexpression of miR-939, miR-671-5p, miR-605, miR-1224-5p, and miR-202) (Table 1) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, and EPB41L3) [34].Importantly, microRNAs are present in stable form not only in tissues but also in body fluids (e.g., blood, plasma, serum, or sputum).",GADD45A,blood,-1
PMC4253434A,"We observed that after two hours of serum starvation, levels of ErbB3 activity were reduced by over one-half in shLacZ control cells (Figure 4A).",ErbB3,serum,1
PMC3224189A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all five cervical cancer cell lines.",PLUS,blood,-1
PMC3224189A,"Analysis was conducted with a FACScan, using Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ).A standard five-hours chromium (51Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Paque(tm) PLUS (GE Healthcare) separated peripheral blood lymphocytes (PBL) obtained from several healthy donors against all five cervical cancer cell lines.",PBL,blood,-1
PMC4972371A,Levels of sCD40L have been shown to be significantly higher in PDAC versus non-cancerous groups and elevated serum sCD40L levels also correlate with PDAC unresectability (p = 0.011).16Patients undergoing resection with elevated s100a2 levels did not gain a survival benefit when compared to patients with s100a2 negative tumours (19.4months vs 8.8months p  0.0001).,PDAC,serum,1
PMC4972371A,Levels of sCD40L have been shown to be significantly higher in PDAC versus non-cancerous groups and elevated serum sCD40L levels also correlate with PDAC unresectability (p = 0.011).16Patients undergoing resection with elevated s100a2 levels did not gain a survival benefit when compared to patients with s100a2 negative tumours (19.4months vs 8.8months p  0.0001).,PDAC,serum,1
PMC4175977A,"This association included high PSA levels, Gleason score, clinical stage, and lymph node metastasis.",PSA,lymph,1
PMC5018629A,NAI increased with recurrence; highest value being at 4th resection when tumor grade progressed (Table 1).Value of NLR was calculated from pre-surgery full blood count using Leishman stain.,NLR,blood,-1
PMC5018629A,NAI increased with recurrence; highest value being at 4th resection when tumor grade progressed (Table 1).Value of NLR was calculated from pre-surgery full blood count using Leishman stain.,NAI,blood,-1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",F12,serum,1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",FBS,serum,1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",F12,serum,1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",DMEM,serum,1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",CO2,serum,1
PMC5357254A,"After washing again with PBS, the resultant cells were finally suspended and cultured in plastic culture dishes with Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 degC in a 5% CO2 atmosphere incubator.",PBS,serum,1
PMC5467782A,Quantitative real-time PCR detection of the expression of miR-181b-5p in peripheral blood between normal person and patients with NSCLC.,PCR,blood,-1
PMC5467782A,Quantitative real-time PCR detection of the expression of miR-181b-5p in peripheral blood between normal person and patients with NSCLC.,NSCLC,blood,-1
PMC5494437A,"Furthermore, the RG cells produce separate intermediate progenitor cells that generate either neurons or astrocytes during embryonic development and in the adult[33,34].In the neonatal stage, RG cells continue to produce neurons and oligodendrocytes via intermediate progenitor cells.",RG,astrocytes,1
PMC5494437A,"Furthermore, the RG cells produce separate intermediate progenitor cells that generate either neurons or astrocytes during embryonic development and in the adult[33,34].In the neonatal stage, RG cells continue to produce neurons and oligodendrocytes via intermediate progenitor cells.",RG,astrocytes,1
PMC5494437A,"A sub-population of RG cells, known as B cells, convert into astrocytes in the (SVZ).",RG,astrocytes,1
PMC5494437A,"A sub-population of RG cells, known as B cells, convert into astrocytes in the (SVZ).",SVZ,astrocytes,1
PMC3929731A,"Together, these results document the fact that levels of bioactive BPA in the present study are similar to levels found in human umbilical cord blood and newborns in the general population (22).View larger versionFigure 4.",BPA,blood,-1
PMC4483763A,"The homeobox gene Prox1 also modulates hepatoblast differentiation; when it is deleted from bipotent hepatoblasts, ectopic bile ducts develop at the expense of liver parenchyma, while in periportal areas the progenitors generate excessive cholangiocytes and biliary hyperplasia (Seth et al.",Prox1,bile,1
PMC4621003A,"Notably, cross-presentation of VLP-expressing proteins is considered to activate both CD4+ helper T-cells and cytotoxic T lymphocytes (CTLs), and incubation of VLPs with splenocytes was shown to induce IgG2a producing plasma cell differentiation (Zhang et al.",VLP,plasma,1
PMC4621003A,"Notably, cross-presentation of VLP-expressing proteins is considered to activate both CD4+ helper T-cells and cytotoxic T lymphocytes (CTLs), and incubation of VLPs with splenocytes was shown to induce IgG2a producing plasma cell differentiation (Zhang et al.",T,plasma,1
PMC4621003A,"Notably, cross-presentation of VLP-expressing proteins is considered to activate both CD4+ helper T-cells and cytotoxic T lymphocytes (CTLs), and incubation of VLPs with splenocytes was shown to induce IgG2a producing plasma cell differentiation (Zhang et al.",T,plasma,1
PMC4621003A,"Notably, cross-presentation of VLP-expressing proteins is considered to activate both CD4+ helper T-cells and cytotoxic T lymphocytes (CTLs), and incubation of VLPs with splenocytes was shown to induce IgG2a producing plasma cell differentiation (Zhang et al.",CD4,plasma,1
PMC5086635A,"Additionally, the sera from five patients that were treated with the original version of SS1P were characterized for their ability to bind the new mutated version.",SS1P,sera,-1
PMC4253434A,Trop2 Loss Activates ErbB3 Through NRG1A. Serum-free conditioned media from Trop2 knockdown cells stimulates ErbB3 activity in SCC1 cells.,ErbB3,Serum,1
PMC4253434A,Trop2 Loss Activates ErbB3 Through NRG1A. Serum-free conditioned media from Trop2 knockdown cells stimulates ErbB3 activity in SCC1 cells.,Trop2,Serum,1
PMC4253434A,Trop2 Loss Activates ErbB3 Through NRG1A. Serum-free conditioned media from Trop2 knockdown cells stimulates ErbB3 activity in SCC1 cells.,ErbB3,Serum,1
PMC4253434A,Trop2 Loss Activates ErbB3 Through NRG1A. Serum-free conditioned media from Trop2 knockdown cells stimulates ErbB3 activity in SCC1 cells.,SCC1,Serum,1
PMC4253434A,Trop2 Loss Activates ErbB3 Through NRG1A. Serum-free conditioned media from Trop2 knockdown cells stimulates ErbB3 activity in SCC1 cells.,Trop2,Serum,1
PMC4606116A,The plasma level of BST2 may be a potential novel CRC biomarker.,BST2,plasma,1
PMC4606116A,The plasma level of BST2 may be a potential novel CRC biomarker.,CRC,plasma,1
PMC4558321A,"Samples were separated and sera frozen for determination of total IgG and sacituzumab govitecan concentrations, as well as anti-hRS7 and anti-SN-38 antibodies, by ELISA.",SN-38,sera,1
PMC4558321A,"Samples were separated and sera frozen for determination of total IgG and sacituzumab govitecan concentrations, as well as anti-hRS7 and anti-SN-38 antibodies, by ELISA.",ELISA,sera,1
PMC4558321A,"Samples were separated and sera frozen for determination of total IgG and sacituzumab govitecan concentrations, as well as anti-hRS7 and anti-SN-38 antibodies, by ELISA.",hRS7,sera,1
PMC4473102A,"TNF level is increased both in the synovium and in the synovial fluid of PSA patients [149].Besides these wellknown effects on inflammation and on bone resorption by inducing osteoclastogenesis and osteoclast recruitment, TNF is also able to induce the expression of the glycoprotein dickkopf-1 (DKK-1), the Wnt-signaling antagonist that suppresses the bone-formation process and the production of the osteoclastogenesis inhibitor, osteoprotegerin [92].However several phase-3 studies showed that TNF inhibitors significantly ameliorated radiographic progression of the disease, but failed to control new bone formation [92].",DKK-1,synovial fluid,1
PMC4473102A,"TNF level is increased both in the synovium and in the synovial fluid of PSA patients [149].Besides these wellknown effects on inflammation and on bone resorption by inducing osteoclastogenesis and osteoclast recruitment, TNF is also able to induce the expression of the glycoprotein dickkopf-1 (DKK-1), the Wnt-signaling antagonist that suppresses the bone-formation process and the production of the osteoclastogenesis inhibitor, osteoprotegerin [92].However several phase-3 studies showed that TNF inhibitors significantly ameliorated radiographic progression of the disease, but failed to control new bone formation [92].",TNF,synovial fluid,1
PMC4473102A,"TNF level is increased both in the synovium and in the synovial fluid of PSA patients [149].Besides these wellknown effects on inflammation and on bone resorption by inducing osteoclastogenesis and osteoclast recruitment, TNF is also able to induce the expression of the glycoprotein dickkopf-1 (DKK-1), the Wnt-signaling antagonist that suppresses the bone-formation process and the production of the osteoclastogenesis inhibitor, osteoprotegerin [92].However several phase-3 studies showed that TNF inhibitors significantly ameliorated radiographic progression of the disease, but failed to control new bone formation [92].",PSA,synovial fluid,1
PMC4473102A,"TNF level is increased both in the synovium and in the synovial fluid of PSA patients [149].Besides these wellknown effects on inflammation and on bone resorption by inducing osteoclastogenesis and osteoclast recruitment, TNF is also able to induce the expression of the glycoprotein dickkopf-1 (DKK-1), the Wnt-signaling antagonist that suppresses the bone-formation process and the production of the osteoclastogenesis inhibitor, osteoprotegerin [92].However several phase-3 studies showed that TNF inhibitors significantly ameliorated radiographic progression of the disease, but failed to control new bone formation [92].",TNF,synovial fluid,1
PMC4473102A,"TNF level is increased both in the synovium and in the synovial fluid of PSA patients [149].Besides these wellknown effects on inflammation and on bone resorption by inducing osteoclastogenesis and osteoclast recruitment, TNF is also able to induce the expression of the glycoprotein dickkopf-1 (DKK-1), the Wnt-signaling antagonist that suppresses the bone-formation process and the production of the osteoclastogenesis inhibitor, osteoprotegerin [92].However several phase-3 studies showed that TNF inhibitors significantly ameliorated radiographic progression of the disease, but failed to control new bone formation [92].",TNF,synovial fluid,1
PMC3929731A,BPA and BPA-G quantitation in mouse serum 20 to 30 minutes after oral exposure.,BPA,serum,1
PMC3929731A,BPA and BPA-G quantitation in mouse serum 20 to 30 minutes after oral exposure.,BPA,serum,1
PMC5086635A,"Interestingly, all of the sera showed a decreased ability to bind the mutated version of SS1P, indicating that the B cell epitopes had been effectively silenced [90].",SS1P,sera,1
PMC4473102A,"It has been suggested that continued suppression of inflammation via anti-TNF agents may accelerate new bone formation and ankylosis [92] possibly through upregulation of DKK-1.As expected, a large number of modulated genes encode for proinflammatory transcripts and the highest levels of induction were observed for FN1 (F.C. 405) followed by OLR1 (F.C. 83) and CXCL13 (F.C. 79).Fibronectin is a component of the cartilage matrix but is also locally produced in the synovial fluid where its level positively correlates with joint destruction [150].",OLR1,synovial fluid,1
PMC4473102A,"It has been suggested that continued suppression of inflammation via anti-TNF agents may accelerate new bone formation and ankylosis [92] possibly through upregulation of DKK-1.As expected, a large number of modulated genes encode for proinflammatory transcripts and the highest levels of induction were observed for FN1 (F.C. 405) followed by OLR1 (F.C. 83) and CXCL13 (F.C. 79).Fibronectin is a component of the cartilage matrix but is also locally produced in the synovial fluid where its level positively correlates with joint destruction [150].",FN1,synovial fluid,1
PMC4473102A,"It has been suggested that continued suppression of inflammation via anti-TNF agents may accelerate new bone formation and ankylosis [92] possibly through upregulation of DKK-1.As expected, a large number of modulated genes encode for proinflammatory transcripts and the highest levels of induction were observed for FN1 (F.C. 405) followed by OLR1 (F.C. 83) and CXCL13 (F.C. 79).Fibronectin is a component of the cartilage matrix but is also locally produced in the synovial fluid where its level positively correlates with joint destruction [150].",CXCL13,synovial fluid,1
PMC4473102A,"It has been suggested that continued suppression of inflammation via anti-TNF agents may accelerate new bone formation and ankylosis [92] possibly through upregulation of DKK-1.As expected, a large number of modulated genes encode for proinflammatory transcripts and the highest levels of induction were observed for FN1 (F.C. 405) followed by OLR1 (F.C. 83) and CXCL13 (F.C. 79).Fibronectin is a component of the cartilage matrix but is also locally produced in the synovial fluid where its level positively correlates with joint destruction [150].",TNF,synovial fluid,1
PMC5289527A,"Shey et al stimulated whole blood from 70 healthy Africans with the diacylated lipopeptides, FSL-1 and PAM2 (TLR6/2 ligands), and found reduced IL6 levels in cells from subjects homozygous for the C allele of rs3821985 compared to G homozygotes [39].",FSL-1,blood,-1
PMC5289527A,"Shey et al stimulated whole blood from 70 healthy Africans with the diacylated lipopeptides, FSL-1 and PAM2 (TLR6/2 ligands), and found reduced IL6 levels in cells from subjects homozygous for the C allele of rs3821985 compared to G homozygotes [39].",PAM2,blood,-1
PMC5289527A,"Shey et al stimulated whole blood from 70 healthy Africans with the diacylated lipopeptides, FSL-1 and PAM2 (TLR6/2 ligands), and found reduced IL6 levels in cells from subjects homozygous for the C allele of rs3821985 compared to G homozygotes [39].",IL6,blood,-1
PMC5029744A,"The data of DoX release test implies that this Trop2Fab-DOX does not release drug in human plasma under neutral pH environment, but allows DOX to be released from the antibody vector after pH change.",DOX,plasma,-1
PMC5029744A,"The data of DoX release test implies that this Trop2Fab-DOX does not release drug in human plasma under neutral pH environment, but allows DOX to be released from the antibody vector after pH change.",DOX,plasma,-1
PMC2570520A,"Univariate analysis showed TROP2 overexpression to be significantly correlated with histologic grading (P=0.01) and the presence of lymph node metastases (P=0.04), but not with sex, age, T stage, presence of distant metastasis, or involvement of the resection margin (Table 2).",T,lymph,1
PMC2570520A,"Univariate analysis showed TROP2 overexpression to be significantly correlated with histologic grading (P=0.01) and the presence of lymph node metastases (P=0.04), but not with sex, age, T stage, presence of distant metastasis, or involvement of the resection margin (Table 2).",TROP2,lymph,1
PMC5414739A,"Hematopoietic CD34+ progenitors isolated from umbilical cord blood responded to PRL stimulation by activating the STAT5 pathway, supporting a direct effect (136).",CD34,blood,-1
PMC5414739A,"Hematopoietic CD34+ progenitors isolated from umbilical cord blood responded to PRL stimulation by activating the STAT5 pathway, supporting a direct effect (136).",STAT5,blood,-1
PMC5414739A,"Hematopoietic CD34+ progenitors isolated from umbilical cord blood responded to PRL stimulation by activating the STAT5 pathway, supporting a direct effect (136).",PRL,blood,-1
PMC4893788A,"show that low-calcium, serum-free media can select for CD133+ /ABCG2+ /a2b1Hi /p63",p63,serum,1
PMC4893788A,"show that low-calcium, serum-free media can select for CD133+ /ABCG2+ /a2b1Hi /p63",CD133,serum,1
PMC4893788A,"show that low-calcium, serum-free media can select for CD133+ /ABCG2+ /a2b1Hi /p63",ABCG2,serum,1
PMC4437474A,"The Wnt-regulated gene Lgr5 has been shown to serve as a stem cell marker in several adult tissues, including the ovary, mammary gland, intestinal tract, and hair follicle (Barker et al., 2007; Jaks et al., 2008; Ng et al., 2014; Plaks et al., 2013",Lgr5,hair,-1
PMC4606116A,ELISA for four candidate proteins in plasma samples from CRC patients and healthy controls.,ELISA,plasma,1
PMC4606116A,ELISA for four candidate proteins in plasma samples from CRC patients and healthy controls.,CRC,plasma,1
PMC4366163A,PLLP has been localized both to apical and basolateral plasma membranes in epithelial cells in a variety of tissues [85].,PLLP,plasma,-1
PMC4410184A,1A). Immunostaining analysis showed Cre expression restricted to the bile duct cells and colocalized with YFP expression (Supporting Fig.,YFP,bile,-1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC4863686A,"Among various cell lines, HeLa cells exhibited greater toxicity compared to the other cell lines.165 However, purified GO showed no significant cytotoxicity in epithelial lung carcinoma cells up to 100 mg/mL, and no inflammation or granuloma formation (up to 50 mg/animal dose exposure) in vivo.166 Lammel et al167 showed that GO has a dose-dependent toxic effect through plasma membrane damage, that is, loss of plasma membrane structural integrity, which was associated with a strong physical interaction of GO with the phospholipid bilayer.",GO,plasma,1
PMC3476529A,"We considered the possibility that inflammatory cytokine production might be required for cross-presentation by these cells, but the addition of exogenous TNF-a, IFN-a, and GM-CSF failed to confer cross-presenting capacity.",GM,CSF,-1
PMC3476529A,"We considered the possibility that inflammatory cytokine production might be required for cross-presentation by these cells, but the addition of exogenous TNF-a, IFN-a, and GM-CSF failed to confer cross-presenting capacity.",IFN,CSF,-1
PMC3476529A,"We considered the possibility that inflammatory cytokine production might be required for cross-presentation by these cells, but the addition of exogenous TNF-a, IFN-a, and GM-CSF failed to confer cross-presenting capacity.",TNF,CSF,-1
PMC3476529A,"CD141hi DCs in skin also express CCR7, migrate spontaneously, and are detectable as a distinct population within the migratory fraction of DCs in skin-draining lymph nodes.",CCR7,lymph,-1
PMC3434166A,"Vessels were counted by a blinded observer using standard criteria [52].RBMS3 and vector-transfected SUNE1 cells were grown on gelatin-coated cover slips, fixed with 4% paraformaldehyde, permeabilized in PBS, which contain 0.1% Triton-X 100, and blocked with 1% bovine serum albumin.",X,serum,1
PMC3434166A,"Vessels were counted by a blinded observer using standard criteria [52].RBMS3 and vector-transfected SUNE1 cells were grown on gelatin-coated cover slips, fixed with 4% paraformaldehyde, permeabilized in PBS, which contain 0.1% Triton-X 100, and blocked with 1% bovine serum albumin.",PBS,serum,1
PMC3434166A,"Vessels were counted by a blinded observer using standard criteria [52].RBMS3 and vector-transfected SUNE1 cells were grown on gelatin-coated cover slips, fixed with 4% paraformaldehyde, permeabilized in PBS, which contain 0.1% Triton-X 100, and blocked with 1% bovine serum albumin.",SUNE1,serum,1
PMC4253434A,"After Trop2 depletion in SCC1 cells, we isolated the plasma membrane fraction of cellular proteins by cell-surface biotinylation followed by streptavidin immunoprecipitation, and immunoblotted for NRG1.",SCC1,plasma,1
PMC4253434A,"After Trop2 depletion in SCC1 cells, we isolated the plasma membrane fraction of cellular proteins by cell-surface biotinylation followed by streptavidin immunoprecipitation, and immunoblotted for NRG1.",NRG1,plasma,1
PMC4253434A,"After Trop2 depletion in SCC1 cells, we isolated the plasma membrane fraction of cellular proteins by cell-surface biotinylation followed by streptavidin immunoprecipitation, and immunoblotted for NRG1.",Trop2,plasma,1
PMC4637775A,"Glypican-3 (GPC-3), an oncofetal protein and heparan sulfate proteoglycan, is anchored to the plasma membrane through glycosylphosphatidylinositol [12] and has been reported to be up-regulated in HCC [13].",GPC-3,plasma,-1
PMC4637775A,"Glypican-3 (GPC-3), an oncofetal protein and heparan sulfate proteoglycan, is anchored to the plasma membrane through glycosylphosphatidylinositol [12] and has been reported to be up-regulated in HCC [13].",Glypican-3,plasma,-1
PMC4637775A,"Glypican-3 (GPC-3), an oncofetal protein and heparan sulfate proteoglycan, is anchored to the plasma membrane through glycosylphosphatidylinositol [12] and has been reported to be up-regulated in HCC [13].",HCC,plasma,-1
PMC3476529A,"Skin CD141hi DCs are proliferating and include a subset of immature cells related to but distinct from blood CD141+ DCs, suggesting that they are potentially derived from CD141+ blood DCs.",CD141,blood,-1
PMC3476529A,"Skin CD141hi DCs are proliferating and include a subset of immature cells related to but distinct from blood CD141+ DCs, suggesting that they are potentially derived from CD141+ blood DCs.",CD141,blood,-1
PMC3476529A,"Skin CD141hi DCs are proliferating and include a subset of immature cells related to but distinct from blood CD141+ DCs, suggesting that they are potentially derived from CD141+ blood DCs.",CD141,blood,-1
PMC3476529A,"Skin CD141hi DCs are proliferating and include a subset of immature cells related to but distinct from blood CD141+ DCs, suggesting that they are potentially derived from CD141+ blood DCs.",CD141,blood,-1
PMC5467782A,(A) Quantitative real-time PCR measured the expression levels of miR-181b-5p in peripheral blood between normal person and patients with NSCLC (*p0.05).,PCR,blood,-1
PMC5467782A,(A) Quantitative real-time PCR measured the expression levels of miR-181b-5p in peripheral blood between normal person and patients with NSCLC (*p0.05).,NSCLC,blood,-1
PMC3434166A,"Briefly, paraffin-embedded sections were deparaffinized, blocked with goat serum, followed by incubation with mouse anti- RBMS3 (1:100) or anti-CD34 (1:100) overnight at 4degC. After incubation with horseradish peroxidase linked secondary antibody for 30 min, the sections were counterstained with Mayer's hematoxylin.",CD34,serum,1
PMC3434166A,"Briefly, paraffin-embedded sections were deparaffinized, blocked with goat serum, followed by incubation with mouse anti- RBMS3 (1:100) or anti-CD34 (1:100) overnight at 4degC. After incubation with horseradish peroxidase linked secondary antibody for 30 min, the sections were counterstained with Mayer's hematoxylin.",RBMS3,serum,1
PMC4966842A,Flow cytometry analyses demonstrated that TF on plasma membrane is able to internalize without an antibody or a ligand being present.,TF,plasma,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",SUNE1,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",SUNE1,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RBMS3,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RBMS3,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RBMS3,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RBMS3,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RPMI,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",RPMI,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",NP460,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",NP460,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",FBS,serum,1
PMC3434166A,"RBMS3 and vector-transfected SUNE1 cells (1x106) were cultured in RPMI medium containing 10% fetal bovine serum (FBS), while si-RBMS3 and si-scramble transfected NP460 cells were cultured in defined keratinocyte serum-free medium.",FBS,serum,1
PMC3476529A,"A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs.",LPS,CSF,1
PMC3476529A,"A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs.",GM,CSF,1
PMC3476529A,"A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs.",TNF,CSF,1
PMC3476529A,"A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs.",CD40,CSF,1
PMC3476529A,"A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs.",IFN,CSF,1
PMC4473102A,"Noteworthy a type I interferon signature is present also in DEGs from PBC of patients with PsA, indicating that indeed peripheral blood cells reflects, although at lower level, the gene modulation present in the synovium.",PBC,blood,-1
PMC3476529A,This analysis suggests by an unbiased means that CD141hi skin DCs have a transcriptional profile that links them to murine CD103+ tissue DCs and that both form a conserved DC lineage that includes CD141+ blood DCs in humans and CD8+ lymphoid DCs in mice.,DC,blood,-1
PMC3476529A,This analysis suggests by an unbiased means that CD141hi skin DCs have a transcriptional profile that links them to murine CD103+ tissue DCs and that both form a conserved DC lineage that includes CD141+ blood DCs in humans and CD8+ lymphoid DCs in mice.,CD103,blood,-1
PMC3476529A,This analysis suggests by an unbiased means that CD141hi skin DCs have a transcriptional profile that links them to murine CD103+ tissue DCs and that both form a conserved DC lineage that includes CD141+ blood DCs in humans and CD8+ lymphoid DCs in mice.,CD8,blood,-1
PMC3476529A,This analysis suggests by an unbiased means that CD141hi skin DCs have a transcriptional profile that links them to murine CD103+ tissue DCs and that both form a conserved DC lineage that includes CD141+ blood DCs in humans and CD8+ lymphoid DCs in mice.,CD141,blood,-1
PMC3781731A,"Extensive or chronic liver damage, or prolonged intoxication and viral infection results in hepatocyte senescence, when mature hepatocyte proliferation is exhausted and suppressed.28,29 In this case, liver regeneration is carried out by a heterogeneous population of progenitor cells, located within (or immediately adjacent to) the canal of Hering, which become activated and proliferate to replace the impaired hepatic parenchyma.4 These cells were first described by E Faber in 1956 as ""small oval cells with scant lightly basophilic cytoplasm and pale blue-staining nuclei"" with a high nuclear/cytoplasmic ratio and an ovoid nucleus, and were called ""oval cells"".6Oval cells represent a bipotential precursor population, which can simultaneously co-express epithelial markers typical for cholangiocytes (CK-7, CK-19, and OV-6) and hepatocytes (alpha-fetoprotein and albumin), suggesting the close relationship of oval cells to differentiated liver parenchymal cells.30,31 Experiments tracing the transfer of 3H in thymidine-labeled oval cells confirm that these cells behave like bipotential progenitor cells and are able to differentiate into hepatocytes and cholangiocytes.30-34 Once activated and proliferating, it is proposed oval cells give rise to duct-like structures that arise from the periportal regions and spread into the liver acinus; several days after activation these ductlike structures change appearance, and transform into clusters of small basophilic hepatocytes and mature bile ducts.",CK-7,bile,1
PMC3781731A,"Extensive or chronic liver damage, or prolonged intoxication and viral infection results in hepatocyte senescence, when mature hepatocyte proliferation is exhausted and suppressed.28,29 In this case, liver regeneration is carried out by a heterogeneous population of progenitor cells, located within (or immediately adjacent to) the canal of Hering, which become activated and proliferate to replace the impaired hepatic parenchyma.4 These cells were first described by E Faber in 1956 as ""small oval cells with scant lightly basophilic cytoplasm and pale blue-staining nuclei"" with a high nuclear/cytoplasmic ratio and an ovoid nucleus, and were called ""oval cells"".6Oval cells represent a bipotential precursor population, which can simultaneously co-express epithelial markers typical for cholangiocytes (CK-7, CK-19, and OV-6) and hepatocytes (alpha-fetoprotein and albumin), suggesting the close relationship of oval cells to differentiated liver parenchymal cells.30,31 Experiments tracing the transfer of 3H in thymidine-labeled oval cells confirm that these cells behave like bipotential progenitor cells and are able to differentiate into hepatocytes and cholangiocytes.30-34 Once activated and proliferating, it is proposed oval cells give rise to duct-like structures that arise from the periportal regions and spread into the liver acinus; several days after activation these ductlike structures change appearance, and transform into clusters of small basophilic hepatocytes and mature bile ducts.",OV-6,bile,1
PMC3781731A,"Extensive or chronic liver damage, or prolonged intoxication and viral infection results in hepatocyte senescence, when mature hepatocyte proliferation is exhausted and suppressed.28,29 In this case, liver regeneration is carried out by a heterogeneous population of progenitor cells, located within (or immediately adjacent to) the canal of Hering, which become activated and proliferate to replace the impaired hepatic parenchyma.4 These cells were first described by E Faber in 1956 as ""small oval cells with scant lightly basophilic cytoplasm and pale blue-staining nuclei"" with a high nuclear/cytoplasmic ratio and an ovoid nucleus, and were called ""oval cells"".6Oval cells represent a bipotential precursor population, which can simultaneously co-express epithelial markers typical for cholangiocytes (CK-7, CK-19, and OV-6) and hepatocytes (alpha-fetoprotein and albumin), suggesting the close relationship of oval cells to differentiated liver parenchymal cells.30,31 Experiments tracing the transfer of 3H in thymidine-labeled oval cells confirm that these cells behave like bipotential progenitor cells and are able to differentiate into hepatocytes and cholangiocytes.30-34 Once activated and proliferating, it is proposed oval cells give rise to duct-like structures that arise from the periportal regions and spread into the liver acinus; several days after activation these ductlike structures change appearance, and transform into clusters of small basophilic hepatocytes and mature bile ducts.",CK-19,bile,1
PMC4366163A,"GFP-tagged Leucine-rich repeat transmembrane protein FLRT2 (FLRT2), a protein involved in cell adhesion and or receptor signaling, was localized diffusely in the cytoplasm as well as co-localized with Ocln and Cldn4 along the basolateral plasma membrane and the apical TJ (Fig.",Cldn4,plasma,1
PMC4366163A,"GFP-tagged Leucine-rich repeat transmembrane protein FLRT2 (FLRT2), a protein involved in cell adhesion and or receptor signaling, was localized diffusely in the cytoplasm as well as co-localized with Ocln and Cldn4 along the basolateral plasma membrane and the apical TJ (Fig.",GFP,plasma,1
PMC4366163A,"GFP-tagged Leucine-rich repeat transmembrane protein FLRT2 (FLRT2), a protein involved in cell adhesion and or receptor signaling, was localized diffusely in the cytoplasm as well as co-localized with Ocln and Cldn4 along the basolateral plasma membrane and the apical TJ (Fig.",FLRT2,plasma,1
PMC4366163A,"GFP-tagged Leucine-rich repeat transmembrane protein FLRT2 (FLRT2), a protein involved in cell adhesion and or receptor signaling, was localized diffusely in the cytoplasm as well as co-localized with Ocln and Cldn4 along the basolateral plasma membrane and the apical TJ (Fig.",FLRT2,plasma,1
PMC4889960A,"Because of the enhanced permeability and retention (EPR) effect [8, 16] and receptor-mediated endocytosis (RME), nanoparticles conjugated to specific antibodies can easily permeate leaky tumor blood vessels and selectively target cancer cells [17, 18].",RME,blood,-1
PMC4889960A,"Because of the enhanced permeability and retention (EPR) effect [8, 16] and receptor-mediated endocytosis (RME), nanoparticles conjugated to specific antibodies can easily permeate leaky tumor blood vessels and selectively target cancer cells [17, 18].",EPR,blood,-1
PMC4108928A,"High ROR1 expression was associated with FIGO stage (p = 0.019), tumor grade (p = 0.027) and positive lymph node metastasis (p = 0.015).",FIGO,lymph,1
PMC4108928A,"High ROR1 expression was associated with FIGO stage (p = 0.019), tumor grade (p = 0.027) and positive lymph node metastasis (p = 0.015).",ROR1,lymph,1
PMC4074497A,"The mice were imaged 48 hours post-injection of 111In-DTPA-INCA-X. Tumors are circled in yellow, white arrow points to spleen and red arrows indicate activity in red bone marrow.",DTPA,bone marrow,1
PMC4074497A,"The mice were imaged 48 hours post-injection of 111In-DTPA-INCA-X. Tumors are circled in yellow, white arrow points to spleen and red arrows indicate activity in red bone marrow.",INCA,bone marrow,1
PMC3446379A,"It has also been shown [13] that use of dextran coated charcoal-stripped (DCC) serum in tamoxifen treatment may introduce, in addition to adaptive changes of the cells in response to tamoxifen, effects of long term estrogen deprivation (LTED), thus complicating the interpretation of molecular signals of resistance development for tamoxifen.",LTED,serum,1
PMC3446379A,"It has also been shown [13] that use of dextran coated charcoal-stripped (DCC) serum in tamoxifen treatment may introduce, in addition to adaptive changes of the cells in response to tamoxifen, effects of long term estrogen deprivation (LTED), thus complicating the interpretation of molecular signals of resistance development for tamoxifen.",DCC,serum,1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",DTPA,blood,-1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",DTPA,blood,-1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",INCA,blood,-1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",INCA,blood,-1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",X,blood,-1
PMC4074497A,"The image of predose group 1 animal, which was pre-administered cold DTPA-INCA-X 24 hours prior to administering 111In-DTPA-INCA-X, showed increased localization to the tumor (Figure 6C, circled in yellow); however, there was background activity from circulating antibody in highly vascularized organs and blood.",X,blood,-1
PMC4108928A,"In contrast, no significant correlation was discovered between ROR1 expression and other clinical parameters, such as age, tumor diameter, histological type, serum CA-125 level, ascites condition and relapse status.",CA-125,serum,1
PMC4108928A,"In contrast, no significant correlation was discovered between ROR1 expression and other clinical parameters, such as age, tumor diameter, histological type, serum CA-125 level, ascites condition and relapse status.",CA-125,ascites,1
PMC4108928A,"In contrast, no significant correlation was discovered between ROR1 expression and other clinical parameters, such as age, tumor diameter, histological type, serum CA-125 level, ascites condition and relapse status.",ROR1,serum,1
PMC4108928A,"In contrast, no significant correlation was discovered between ROR1 expression and other clinical parameters, such as age, tumor diameter, histological type, serum CA-125 level, ascites condition and relapse status.",ROR1,ascites,1
PMC4467439A,B. The expression of FBXW7 in 7 paired samples of CCA tissues versus adjacent normal bile duct tissues was measured by Western blotting.,CCA,bile,1
PMC4467439A,B. The expression of FBXW7 in 7 paired samples of CCA tissues versus adjacent normal bile duct tissues was measured by Western blotting.,FBXW7,bile,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",ROR1,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",ROR1,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",ROR1,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",ROR1,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",FIGO,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",FIGO,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",FIGO,lymph,1
PMC4108928A,"According to univariate analysis, the disease-free survival of the ovarian cancer patients was correlated with ROR1 expression (p = 0.005), FIGO stage (p = 0.001), and lymph node metastasis (p = 0.001), whereas the overall survival was correlated with ROR1 expression (p = 0.001), FIGO stage (p = 0.001), tumor grade (p = 0.009), and lymph node metastasis (p = 0.001) in overall survival (Tables 2 and 3).",FIGO,lymph,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",PBL,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",ADCC,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",EEC,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",HI,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",hRS7,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",hRS7,serum,1
PMC3233648A,"Incubation with physiological concentrations of IgG (i.e., heat-inactivated (HI) serum diluted 1:2) to PBL in the presence of hRS7 did not significantly reduce the degree of ADCC achieved in the presence of hRS7 against EEC-ARK-1 (p= 0.773).See full tableTable 2.",ARK-1,serum,1
PMC4188889A,"Regarding diagnostic biomarkers (Table 2), the most recent studies are based on the determination of protein panels in serum or plasma, exploiting ELISA or proximity ligation assay (PLA) for their determination.",PLA,plasma,1
PMC4188889A,"Regarding diagnostic biomarkers (Table 2), the most recent studies are based on the determination of protein panels in serum or plasma, exploiting ELISA or proximity ligation assay (PLA) for their determination.",PLA,serum,1
PMC4188889A,"Regarding diagnostic biomarkers (Table 2), the most recent studies are based on the determination of protein panels in serum or plasma, exploiting ELISA or proximity ligation assay (PLA) for their determination.",ELISA,plasma,1
PMC4188889A,"Regarding diagnostic biomarkers (Table 2), the most recent studies are based on the determination of protein panels in serum or plasma, exploiting ELISA or proximity ligation assay (PLA) for their determination.",ELISA,serum,1
PMC3233648A,The tumor cell line was treated with serum (with or without heat inactivation) in the presence or absence of the effector cells and hRS7 in a standard 5-hours 51Cr-release assays.,hRS7,serum,1
PMC4707334A,"If the above criteria are not completed, the term ""mesenchymal stem cells"" should be used for bone marrow-derived adherent cells or other MSC-like cells of different origin.",MSC,bone marrow,1
PMC5414739A,Several early reports indicated that PRL was a potent hair growth modulator and that annual changes in hair growth of several species were modulated by seasonal PRL (142-145).,PRL,hair,1
PMC5414739A,Several early reports indicated that PRL was a potent hair growth modulator and that annual changes in hair growth of several species were modulated by seasonal PRL (142-145).,PRL,hair,-1
PMC5414739A,Several early reports indicated that PRL was a potent hair growth modulator and that annual changes in hair growth of several species were modulated by seasonal PRL (142-145).,PRL,hair,1
PMC5414739A,Several early reports indicated that PRL was a potent hair growth modulator and that annual changes in hair growth of several species were modulated by seasonal PRL (142-145).,PRL,hair,1
PMC4188889A,"In the first study, Chang et al[51] applied PLA to the identification of plasma levels of 21 biomarkers in 52 locally advanced PDAC cases and 43 age-matched controls.",PDAC,plasma,1
PMC4188889A,"In the first study, Chang et al[51] applied PLA to the identification of plasma levels of 21 biomarkers in 52 locally advanced PDAC cases and 43 age-matched controls.",PLA,plasma,1
PMC4188889A,Phosphoglycerate kinase-1 and histone H4 were noted to elicit a significant differential humoral response in cancer sera.,H4,sera,1
PMC3233648A,Representative cytotoxicity experiments adding human serum (diluted 1:2) to hRS7 against EEC-ARK-1 cell line.,hRS7,serum,1
PMC3233648A,Representative cytotoxicity experiments adding human serum (diluted 1:2) to hRS7 against EEC-ARK-1 cell line.,EEC,serum,-1
PMC3233648A,Representative cytotoxicity experiments adding human serum (diluted 1:2) to hRS7 against EEC-ARK-1 cell line.,ARK-1,serum,-1
PMC4803572A,"With the relative ease of acquisition of DTC from the bone marrow and the recent advance in technology to molecularly characterize DTC at a single cell level, investigation of DTC by liquid biopsy before the detection of overt metastasis will be attractive to assess individual prognosis and stratify patients at risk to systemic adjuvant anti-cancer therapies [63].",DTC,bone marrow,-1
PMC4803572A,"With the relative ease of acquisition of DTC from the bone marrow and the recent advance in technology to molecularly characterize DTC at a single cell level, investigation of DTC by liquid biopsy before the detection of overt metastasis will be attractive to assess individual prognosis and stratify patients at risk to systemic adjuvant anti-cancer therapies [63].",DTC,bone marrow,-1
PMC4803572A,"With the relative ease of acquisition of DTC from the bone marrow and the recent advance in technology to molecularly characterize DTC at a single cell level, investigation of DTC by liquid biopsy before the detection of overt metastasis will be attractive to assess individual prognosis and stratify patients at risk to systemic adjuvant anti-cancer therapies [63].",DTC,bone marrow,-1
PMC4154955A,"Although we have not examined such NPC-EpCAM+ cells and BT-EpCAM+ cells are identical to small and large cholangiocytes, our results support the idea that cholangiocytes are a heterogeneous cell population in terms of proliferation and differentiation potential.34Extrahepatic bile ducts (EHBDs) are composed of hepatic, cystic, pancreatic, and common ducts.",NPC,bile,1
PMC4154955A,"Although we have not examined such NPC-EpCAM+ cells and BT-EpCAM+ cells are identical to small and large cholangiocytes, our results support the idea that cholangiocytes are a heterogeneous cell population in terms of proliferation and differentiation potential.34Extrahepatic bile ducts (EHBDs) are composed of hepatic, cystic, pancreatic, and common ducts.",BT,bile,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC2695576A,"Most patients with MCD do not have detectable keratan sulfate in the serum (MCD types I and IA), but in some have normal antigenic keratan sulfate levels in the serum (MCD type II) [50-53].",MCD,serum,1
PMC5312042A,"Abbreviations: BD, bile duct; HPF, high-power field; WT, wild type.",HPF,bile,1
PMC3743266A,"We tested this luminal origin leading-edge signature (LOLES) with two different datasets from Memorial Sloan-Kettering Cancer Center (MSKCC)22, 30, in which patients are characterized by their biochemical recurrence (BCR) free survival time, representing the duration between prostatectomy and subsequent detection of rising serum prostate-specific antigen (PSA) levels.",LOLES,serum,1
PMC3743266A,"We tested this luminal origin leading-edge signature (LOLES) with two different datasets from Memorial Sloan-Kettering Cancer Center (MSKCC)22, 30, in which patients are characterized by their biochemical recurrence (BCR) free survival time, representing the duration between prostatectomy and subsequent detection of rising serum prostate-specific antigen (PSA) levels.",BCR,serum,1
PMC3743266A,"We tested this luminal origin leading-edge signature (LOLES) with two different datasets from Memorial Sloan-Kettering Cancer Center (MSKCC)22, 30, in which patients are characterized by their biochemical recurrence (BCR) free survival time, representing the duration between prostatectomy and subsequent detection of rising serum prostate-specific antigen (PSA) levels.",PSA,serum,1
PMC4673473A,"When the blocks adhered to the bottom of the dishes, 1.5 ml basic medium was added containing Iscove's Modified Dulbecco's Medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 1 x minimum essential medium (MEM) nonessential amino acids (Gibco Life Technologies), 1 mM L-glutamine (Gibco Life Technologies), 1 x antibiotic-antimycotic (Gibco Life Technologies) and 10 mM 2-mercaptoethanol (Sigma-Aldrich) and the tissues incubated at 37 degC in a 5% CO2 incubator for 48 h. Supernatants were collected and treated with RNase (10 mg ml-1, Intron Biotechnology, Gyeonggi-do, Korea) and DNase (40 mg ml-1, Roche, Indianapolis, IN, USA) at 37 degC for 1 h, and passed through a 0.2 mm filter.",USA,serum,1
PMC4673473A,"When the blocks adhered to the bottom of the dishes, 1.5 ml basic medium was added containing Iscove's Modified Dulbecco's Medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 1 x minimum essential medium (MEM) nonessential amino acids (Gibco Life Technologies), 1 mM L-glutamine (Gibco Life Technologies), 1 x antibiotic-antimycotic (Gibco Life Technologies) and 10 mM 2-mercaptoethanol (Sigma-Aldrich) and the tissues incubated at 37 degC in a 5% CO2 incubator for 48 h. Supernatants were collected and treated with RNase (10 mg ml-1, Intron Biotechnology, Gyeonggi-do, Korea) and DNase (40 mg ml-1, Roche, Indianapolis, IN, USA) at 37 degC for 1 h, and passed through a 0.2 mm filter.",MEM,serum,1
PMC4673473A,"When the blocks adhered to the bottom of the dishes, 1.5 ml basic medium was added containing Iscove's Modified Dulbecco's Medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 1 x minimum essential medium (MEM) nonessential amino acids (Gibco Life Technologies), 1 mM L-glutamine (Gibco Life Technologies), 1 x antibiotic-antimycotic (Gibco Life Technologies) and 10 mM 2-mercaptoethanol (Sigma-Aldrich) and the tissues incubated at 37 degC in a 5% CO2 incubator for 48 h. Supernatants were collected and treated with RNase (10 mg ml-1, Intron Biotechnology, Gyeonggi-do, Korea) and DNase (40 mg ml-1, Roche, Indianapolis, IN, USA) at 37 degC for 1 h, and passed through a 0.2 mm filter.",IN,serum,1
PMC4673473A,"When the blocks adhered to the bottom of the dishes, 1.5 ml basic medium was added containing Iscove's Modified Dulbecco's Medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 1 x minimum essential medium (MEM) nonessential amino acids (Gibco Life Technologies), 1 mM L-glutamine (Gibco Life Technologies), 1 x antibiotic-antimycotic (Gibco Life Technologies) and 10 mM 2-mercaptoethanol (Sigma-Aldrich) and the tissues incubated at 37 degC in a 5% CO2 incubator for 48 h. Supernatants were collected and treated with RNase (10 mg ml-1, Intron Biotechnology, Gyeonggi-do, Korea) and DNase (40 mg ml-1, Roche, Indianapolis, IN, USA) at 37 degC for 1 h, and passed through a 0.2 mm filter.",USA,serum,1
PMC4673473A,"When the blocks adhered to the bottom of the dishes, 1.5 ml basic medium was added containing Iscove's Modified Dulbecco's Medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 1 x minimum essential medium (MEM) nonessential amino acids (Gibco Life Technologies), 1 mM L-glutamine (Gibco Life Technologies), 1 x antibiotic-antimycotic (Gibco Life Technologies) and 10 mM 2-mercaptoethanol (Sigma-Aldrich) and the tissues incubated at 37 degC in a 5% CO2 incubator for 48 h. Supernatants were collected and treated with RNase (10 mg ml-1, Intron Biotechnology, Gyeonggi-do, Korea) and DNase (40 mg ml-1, Roche, Indianapolis, IN, USA) at 37 degC for 1 h, and passed through a 0.2 mm filter.",CO2,serum,1
PMC5467782A,We found that the levels of miR-181b-5p were increased in peripheral blood of NSCLC patients and specifically in patients with stage II/III/IV disease.,NSCLC,blood,-1
PMC5467782A,We found that the levels of miR-181b-5p were increased in peripheral blood of NSCLC patients and specifically in patients with stage II/III/IV disease.,III,blood,-1
PMC2928967A,"In addition, at least a recognizable amount of the CLDN1 and 7 proteins were distributed to the plasma membrane, as was found with the CLDN4 protein.",CLDN4,plasma,1
PMC2928967A,"In addition, at least a recognizable amount of the CLDN1 and 7 proteins were distributed to the plasma membrane, as was found with the CLDN4 protein.",CLDN1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",TACSTD2,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",TACSTD2,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",OCLN,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",OCLN,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",HCE,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",HCE,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",TJP1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",TJP1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",T-15,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",T-15,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",CLDN1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",CLDN1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",CLDN1,plasma,1
PMC2928967A,"In addition, the subcellular localization appeared to be changed from plasma membrane to cytoplasm in CLDN1, 4, and 7, and OCLN, and from plasma membrane to nucleus in the TJP1 protein (Figure 3, D and E).We next investigated whether the reduced expression and/or altered subcellular localization of the CLDN1, 4, and 7 proteins caused by the knockdown of the TACSTD2 gene in the HCE-T-15 cells has any effects on the epithelial barrier function.",CLDN1,plasma,1
PMC4366163A,"Given the overlapping distribution with ZO-1 as well as expression on the lateral cell membrane, we would expect proteins biotinylated by the fusion proteins to include TJ proteins also identified by ZO-1 as well as novel relevant lateral plasma membrane proteins and trafficking proteins.",ZO-1,plasma,1
PMC4366163A,"Given the overlapping distribution with ZO-1 as well as expression on the lateral cell membrane, we would expect proteins biotinylated by the fusion proteins to include TJ proteins also identified by ZO-1 as well as novel relevant lateral plasma membrane proteins and trafficking proteins.",ZO-1,plasma,1
PMC4958526A,Enhanced humoral and cellular immune responses to topically applied antigen in LC EpCAM cKO mice(a) Serum Ova-specific IgG and IgE were quantified by ELISA 2 wk after topical immunization with Ova.,ELISA,Serum,1
PMC4958526A,Enhanced humoral and cellular immune responses to topically applied antigen in LC EpCAM cKO mice(a) Serum Ova-specific IgG and IgE were quantified by ELISA 2 wk after topical immunization with Ova.,cKO,Serum,1
PMC2928967A,These results indicate that the association between the TACSTD2 and the CLDN proteins mainly occurred at the plasma membrane.,CLDN,plasma,1
PMC2928967A,These results indicate that the association between the TACSTD2 and the CLDN proteins mainly occurred at the plasma membrane.,TACSTD2,plasma,1
PMC2928967A,"In the PLA experiment plus immunolabeling using a fluorescence-labeled antibody against desmoplakin or golgin, most of the PLA signals fall onto the plasma membrane, but only a trace amount in cytoplasm (Figure 2C).",PLA,plasma,1
PMC2928967A,"In the PLA experiment plus immunolabeling using a fluorescence-labeled antibody against desmoplakin or golgin, most of the PLA signals fall onto the plasma membrane, but only a trace amount in cytoplasm (Figure 2C).",PLA,plasma,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",AST,Serum,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",FGF7,Serum,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",TBIL,Serum,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",ALT,Serum,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",DDC,Serum,1
PMC3566310A,"(B) Serum TBIL, ALP, AST, and ALT levels were measured in control and FGF7 Tg mice fed a normal (control, n = 3; Tg, n = 3) or DDC-containing (control, n = 9; Tg, n = 7) diet.",ALP,Serum,1
PMC4188889A,The studies based on serum and tissue biomarkers determined by non-omics techniques usually exploit monovariate and multivariate Cox regression to evaluate the effect played by different factors on time to progression (TTP) and overall survival (OS).,TTP,serum,1
PMC4188889A,The studies based on serum and tissue biomarkers determined by non-omics techniques usually exploit monovariate and multivariate Cox regression to evaluate the effect played by different factors on time to progression (TTP) and overall survival (OS).,OS,serum,1
PMC4425227A,"Human androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer epithelial cells were obtained from American Type Culture Collection (ATCC), and were maintained in RPMI 1640 Medium (Gibco; Life Technologies) supplemented with 10% fetal bovine serum (FBS, Gibco; Life Technologies) and Zell Shield.",RPMI,serum,1
PMC4425227A,"Human androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer epithelial cells were obtained from American Type Culture Collection (ATCC), and were maintained in RPMI 1640 Medium (Gibco; Life Technologies) supplemented with 10% fetal bovine serum (FBS, Gibco; Life Technologies) and Zell Shield.",PC-3,serum,1
PMC4425227A,"Human androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer epithelial cells were obtained from American Type Culture Collection (ATCC), and were maintained in RPMI 1640 Medium (Gibco; Life Technologies) supplemented with 10% fetal bovine serum (FBS, Gibco; Life Technologies) and Zell Shield.",DU145,serum,1
PMC4425227A,"Human androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer epithelial cells were obtained from American Type Culture Collection (ATCC), and were maintained in RPMI 1640 Medium (Gibco; Life Technologies) supplemented with 10% fetal bovine serum (FBS, Gibco; Life Technologies) and Zell Shield.",ATCC,serum,1
PMC4425227A,"Human androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer epithelial cells were obtained from American Type Culture Collection (ATCC), and were maintained in RPMI 1640 Medium (Gibco; Life Technologies) supplemented with 10% fetal bovine serum (FBS, Gibco; Life Technologies) and Zell Shield.",FBS,serum,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",TNBC,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",OS,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",pCR,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",CD8,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",T,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",PFS,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",TNBC,lymph,1
PMC5502951A,"Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.119,120Recent studies have revealed that a higher level of TILs (50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.121-124However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.125",Ki-67,lymph,1
PMC3845885A,"Treatment was comprised of a total of 8 injections of IMA901 at days 1, 2, 3, 8, 15, 22, 36 and 64, with GM-CSF prior to delivery.",IMA901,CSF,1
PMC3845885A,"Treatment was comprised of a total of 8 injections of IMA901 at days 1, 2, 3, 8, 15, 22, 36 and 64, with GM-CSF prior to delivery.",GM,CSF,1
PMC3959865A,Serum from 5 mice was pooled and depleted using two MARS-3 columns (Agilent) connected in tandem with HPLC.,MARS-3,Serum,1
PMC3959865A,Serum from 5 mice was pooled and depleted using two MARS-3 columns (Agilent) connected in tandem with HPLC.,HPLC,Serum,1
PMC3249013A,"Further, TCDD increased tumor-free survival in transgenic TRAMP mice that spontaneously develop prostate cancer while AhR activation decreased lymph node metastasis suggesting that TCDDs may protect against prostate cancer in adulthood (Vezina et al., 2009).",TRAMP,lymph,1
PMC3249013A,"Further, TCDD increased tumor-free survival in transgenic TRAMP mice that spontaneously develop prostate cancer while AhR activation decreased lymph node metastasis suggesting that TCDDs may protect against prostate cancer in adulthood (Vezina et al., 2009).",TCDD,lymph,1
PMC5328612A,"Risk factors for survival after resection were age, number of tumors, tumor diameter, cirrhosis, lymph node metastases, and macrovascular invasion.129 The Chinese nomogram had superior discrimination at external validation.43,44Other prognostic models were developed for conditional survival, accounting for the years that a patient had already survived after surgery.84,130,131 Conditional survival was found to be the most important prognostic factor, when predicting future survival time.84,130,131 OS in this study decreased over time to 16% at 8 years, while the 3-year conditional survival at 5 years, that is, the chance of surviving to year 8 after having survived to year 5, was 65%.84Personalized treatments for ICC patients could improve the overall outcomes, mainly by withholding treatments from patients who are unlikely to benefit from surgery or chemotherapy.",OS,lymph,1
PMC5328612A,"Risk factors for survival after resection were age, number of tumors, tumor diameter, cirrhosis, lymph node metastases, and macrovascular invasion.129 The Chinese nomogram had superior discrimination at external validation.43,44Other prognostic models were developed for conditional survival, accounting for the years that a patient had already survived after surgery.84,130,131 Conditional survival was found to be the most important prognostic factor, when predicting future survival time.84,130,131 OS in this study decreased over time to 16% at 8 years, while the 3-year conditional survival at 5 years, that is, the chance of surviving to year 8 after having survived to year 5, was 65%.84Personalized treatments for ICC patients could improve the overall outcomes, mainly by withholding treatments from patients who are unlikely to benefit from surgery or chemotherapy.",ICC,lymph,1
PMC4966842B,"Although both Teff and Treg cell populations expand in the lymph nodes of mice by treating with anti-CTLA-4 antibodies, specific elimination of Tregs within the tumor is promoted.",CTLA-4,lymph,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",X-100,serum,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",GFP,serum,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",PBS,serum,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",A11122,serum,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",BSA,serum,1
PMC4327780A,"For immunostaining, tissue sections were rinsed in PBS twice, then blocked in 10% goat serum in PBS containing 2% BSA and 0.25% Triton X-100 for 1 h, and incubated with the following primary antibodies diluted in blocking solution overnight at 4degC in a humidified chamber: rabbit anti-GFP (Invitrogen A11122, 1:500), chicken anti-vimentin (Millipore, 1:600).",PBS,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",hRS7,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",hRS7,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",hRS7,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",PBL,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",PBL,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",PBL,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",ARK-2,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",ARK-2,serum,1
PMC3104081A,"However, in one clear cell carcinoma cell line (CC-ARK-2), the addition of serum led to a significant increase in killing (p=0.02), while the addition of heat-inactivated serum with hRS7 and PBL to this cell line resulted in a decrease of killing compared to the killing in the presence of serum (Figure 3, bottom panel).",ARK-2,serum,1
PMC3104081A,"In the former study, Trop-2 protein expression was significantly associated with tumor histology, along with the presence of ascites and lymph node involvement, suggesting a relationship between biological aggressiveness and Trop-2 overexpression in ovarian cancer.",Trop-2,lymph,1
PMC3104081A,"In the former study, Trop-2 protein expression was significantly associated with tumor histology, along with the presence of ascites and lymph node involvement, suggesting a relationship between biological aggressiveness and Trop-2 overexpression in ovarian cancer.",Trop-2,ascites,1
PMC3104081A,"In the former study, Trop-2 protein expression was significantly associated with tumor histology, along with the presence of ascites and lymph node involvement, suggesting a relationship between biological aggressiveness and Trop-2 overexpression in ovarian cancer.",Trop-2,lymph,1
PMC3104081A,"In the former study, Trop-2 protein expression was significantly associated with tumor histology, along with the presence of ascites and lymph node involvement, suggesting a relationship between biological aggressiveness and Trop-2 overexpression in ovarian cancer.",Trop-2,ascites,1
PMC5538449A,"Stimulation of monocytes with GM-CSF only in the presence of Delta-1 caused repression of KLF4 (Fig 2, A).",KLF4,CSF,1
PMC5538449A,"Stimulation of monocytes with GM-CSF only in the presence of Delta-1 caused repression of KLF4 (Fig 2, A).",Delta-1,CSF,1
PMC5538449A,"Stimulation of monocytes with GM-CSF only in the presence of Delta-1 caused repression of KLF4 (Fig 2, A).",GM,CSF,1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",NT5E,plasma,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",NT5E,urine,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",NT5E,saliva,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",NT5E,ascites,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",CD73,plasma,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",CD73,urine,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",CD73,saliva,-1
PMC4251850A,"The role of NT5E/CD73 was recently summarized as a suppressor of anti cancer immune responses during carcinogenesis [43].EVs isolated from various body fluids, including plasma, malignant ascites, urine, amniotic fluid and saliva by different methods, were used for diagnosis [6], but the origin of the EVs is often not clear.",CD73,ascites,-1
PMC5494437A,"Three similar domains of radial astrocytes (RA) are located within the dentate gyrus, DI, a subgranular zone adjacent to blood vessels, DII, a granular zone where RAs interact with their progeny and DIII, an inner molecular zone that exposes RA cell extensions to neuronal networks.",DIII,astrocytes,-1
PMC5494437A,"Three similar domains of radial astrocytes (RA) are located within the dentate gyrus, DI, a subgranular zone adjacent to blood vessels, DII, a granular zone where RAs interact with their progeny and DIII, an inner molecular zone that exposes RA cell extensions to neuronal networks.",DIII,blood,-1
PMC5494437A,"Three similar domains of radial astrocytes (RA) are located within the dentate gyrus, DI, a subgranular zone adjacent to blood vessels, DII, a granular zone where RAs interact with their progeny and DIII, an inner molecular zone that exposes RA cell extensions to neuronal networks.",DII,astrocytes,-1
PMC5494437A,"Three similar domains of radial astrocytes (RA) are located within the dentate gyrus, DI, a subgranular zone adjacent to blood vessels, DII, a granular zone where RAs interact with their progeny and DIII, an inner molecular zone that exposes RA cell extensions to neuronal networks.",DII,blood,-1
PMC3128671A,"USPC has a tendency toward early invasion of the lymphatic and vascular spaces and lymph nodes and to microscopically involve other intraperitoneal structures, despite minimal or no invasion present within the uterus.",USPC,lymph,1
PMC4448470A,Cells were harvested in 200 ml of serum free RPMI-1640 medium and added to the upper compartment of the chamber.,RPMI-1640,serum,1
PMC5467782A,(B) Quantitative real-time PCR measured the expression levels of miR-181b-5p in different stages of NSCLC in peripheral blood.,NSCLC,blood,-1
PMC5467782A,(B) Quantitative real-time PCR measured the expression levels of miR-181b-5p in different stages of NSCLC in peripheral blood.,PCR,blood,-1
PMC3781731A,"Thus, rat oval cells express OV6, bile duct epithelium markers (CK-19) and hepatocyte markers (albumin, a-fetoprotein [AFP]) and resemble hepatoblasts.2 The detailed characterization of oval cells in the rat has been done by Yovchev and colleagues7 (Figure 2).",AFP,bile,1
PMC3781731A,"Thus, rat oval cells express OV6, bile duct epithelium markers (CK-19) and hepatocyte markers (albumin, a-fetoprotein [AFP]) and resemble hepatoblasts.2 The detailed characterization of oval cells in the rat has been done by Yovchev and colleagues7 (Figure 2).",OV6,bile,1
PMC3781731A,"Thus, rat oval cells express OV6, bile duct epithelium markers (CK-19) and hepatocyte markers (albumin, a-fetoprotein [AFP]) and resemble hepatoblasts.2 The detailed characterization of oval cells in the rat has been done by Yovchev and colleagues7 (Figure 2).",CK-19,bile,1
PMC4275355A,"Using strategies employing Smo activation, Ptch1 inactivation, or Gli1 overexpression in the hair follicle stem cell population, it was shown that injury can enable HFSCs to act as CCOs for BCC [124,126].",BCC,hair,-1
PMC4275355A,"Using strategies employing Smo activation, Ptch1 inactivation, or Gli1 overexpression in the hair follicle stem cell population, it was shown that injury can enable HFSCs to act as CCOs for BCC [124,126].",Gli1,hair,-1
PMC4275355A,"Using strategies employing Smo activation, Ptch1 inactivation, or Gli1 overexpression in the hair follicle stem cell population, it was shown that injury can enable HFSCs to act as CCOs for BCC [124,126].",Ptch1,hair,-1
PMC3885479A,"The original clinical data were obtained from hospital medical records, including patient gender and age, tobacco use, alcohol consumption, tumor differentiation, TNM stage, lymph node metastasis, and overall survival.",TNM,lymph,1
PMC4606116A,"Under the same assay condition, however, plasma TROP2 levels did not maintain significant difference between CRC patients and controls (53.37 +- 12.27 ng/mL versus 57.11 +- 15.02 ng/mL; p = 0.31, independent t-test; Figure 1(b), right panel).",TROP2,plasma,1
PMC4606116A,"Under the same assay condition, however, plasma TROP2 levels did not maintain significant difference between CRC patients and controls (53.37 +- 12.27 ng/mL versus 57.11 +- 15.02 ng/mL; p = 0.31, independent t-test; Figure 1(b), right panel).",CRC,plasma,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",HPLC,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",HPLC,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4558321A,"The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that 96% of the SN-38 in the serum in these peak samples was bound to IgG. Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 +- 0.91% of the total SN-38 in these samples.",SN-38,serum,1
PMC4596896A,"Although the linkers can be processed by the enzymes or environment of the lysosome, some linkers such as maleimide linkers, can transfer the cytotoxic drug to free sulfhydryls such as the cysteine on human serum albumin (HSA) or glutathione via a retro-michael reaction (54,55).",HSA,serum,1
PMC4756367A,"Then, the cells were stimulated with EGF (20 ng/mL, Sigma, Shanghai, China) under serum starvation conditions for 15 min at 37 degC, 5% CO2.",EGF,serum,1
PMC4756367A,"Then, the cells were stimulated with EGF (20 ng/mL, Sigma, Shanghai, China) under serum starvation conditions for 15 min at 37 degC, 5% CO2.",CO2,serum,1
PMC3342122A,"There was no statistical significance between TROP2 overexpression and sex, age at diagnosis, pathologic T stage, lymph node metastasis, TNM stage, and smoking status (Table 1).",TROP2,lymph,1
PMC3342122A,"There was no statistical significance between TROP2 overexpression and sex, age at diagnosis, pathologic T stage, lymph node metastasis, TNM stage, and smoking status (Table 1).",T,lymph,1
PMC3342122A,"There was no statistical significance between TROP2 overexpression and sex, age at diagnosis, pathologic T stage, lymph node metastasis, TNM stage, and smoking status (Table 1).",TNM,lymph,1
PMC4966842B,"A mutant anti-CTLA4 hIgG1 antibody that had enhanced ADCC activity prevented accumulation of Tregs in the lymph node and enhanced elimination of Tregs within tumors, leading to an increase Teff/Treg ratio.",ADCC,lymph,1
PMC4966842B,"A mutant anti-CTLA4 hIgG1 antibody that had enhanced ADCC activity prevented accumulation of Tregs in the lymph node and enhanced elimination of Tregs within tumors, leading to an increase Teff/Treg ratio.",CTLA4,lymph,1
PMC2946292A,were maintained in keratinocyte serum-free (KSF) medium supplemented with bovine pituitary extract and epidermal growth factor (Gibco) [47].The following antibodies and dilutions were used: anti-p44/42 MAPK (Thr202/Tyr204) 1:1000 (Cell,MAPK,serum,1
PMC2946292A,were maintained in keratinocyte serum-free (KSF) medium supplemented with bovine pituitary extract and epidermal growth factor (Gibco) [47].The following antibodies and dilutions were used: anti-p44/42 MAPK (Thr202/Tyr204) 1:1000 (Cell,KSF,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",FGF10,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",RD,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",hES,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",activin,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",MN,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",H9,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",RD,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",H1,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",RD,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",WNT10B,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",RPMI,serum,1
PMC4519179A,"To differentiate hES cells into DE, H9 or H1 cells were plated on plastic cover slips or 24-well Nunclon delta surface culture dishes (Nunc) and treated for 3 consecutive days with: 100 ng/ml activin A (RD systems, Minneapolis, MN) in RPMI 1640 media (Gibco), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 100 U/ml penicillin--100 ml/ml streptomycin (Invitrogen) and daily increasing concentrations of 0, 0.2 and 2% defined fetal bovine serum (Hyclone, Rockford, IL) as previously described [37].Endoderm differentiated cells were driven into a prostatic fate by culture in 500 ng/ml human FGF10 (RD systems) and 500 ng/ml human WNT10B (RD systems) for 4 days in RPMI 1640 containing 2 mM L-glutamine and 100 U/ml penicillin--100 ml/ml streptomycin.",RPMI,serum,1
PMC4188889A,"Studies based on serum and tissue biomarkers through non-omics techniquesIn the second study, Haas et al[42] pooled pre-treatment data on CA 19-9, carcinoembryonic antigen (CEA), C-reactive protein (CRP), lactate dehydrogenase (LDH) and bilirubin from two multicenter randomized phase II trials and prospective patient data.",CRP,serum,1
PMC4188889A,"Studies based on serum and tissue biomarkers through non-omics techniquesIn the second study, Haas et al[42] pooled pre-treatment data on CA 19-9, carcinoembryonic antigen (CEA), C-reactive protein (CRP), lactate dehydrogenase (LDH) and bilirubin from two multicenter randomized phase II trials and prospective patient data.",LDH,serum,1
PMC4188889A,"Studies based on serum and tissue biomarkers through non-omics techniquesIn the second study, Haas et al[42] pooled pre-treatment data on CA 19-9, carcinoembryonic antigen (CEA), C-reactive protein (CRP), lactate dehydrogenase (LDH) and bilirubin from two multicenter randomized phase II trials and prospective patient data.",CEA,serum,1
PMC3800471A,Loading control is ERK1/2.B4-5) Secretion and activity of the IL6 and OSM cytokines was confirmed by treating serum-starved 3T3 cells with conditioned media from infected UGSM.,UGSM,serum,1
PMC3800471A,Loading control is ERK1/2.B4-5) Secretion and activity of the IL6 and OSM cytokines was confirmed by treating serum-starved 3T3 cells with conditioned media from infected UGSM.,OSM,serum,1
PMC3800471A,Loading control is ERK1/2.B4-5) Secretion and activity of the IL6 and OSM cytokines was confirmed by treating serum-starved 3T3 cells with conditioned media from infected UGSM.,IL6,serum,1
PMC5193343A,"Although PMC phenotype (see Fig 2A and 2B) is not part of the classification systems currently in use (WHO, Ming, Lauren), it seems to represent an atypical form of gastric cancer which should be studied further, considered as a separate entity, and included in histopathological classification systems [46].According to our data, all other parameters analyzed, like Lauren and Ming classification, tumor size, grading, lymph vessel invasion, and signet ring cell type, did not show a prognostic relevance.",WHO,lymph,1
PMC5193343A,"Although PMC phenotype (see Fig 2A and 2B) is not part of the classification systems currently in use (WHO, Ming, Lauren), it seems to represent an atypical form of gastric cancer which should be studied further, considered as a separate entity, and included in histopathological classification systems [46].According to our data, all other parameters analyzed, like Lauren and Ming classification, tumor size, grading, lymph vessel invasion, and signet ring cell type, did not show a prognostic relevance.",PMC,lymph,1
PMC4154955A,"Hepatoblasts around the portal vein are committed to cholangiocytes by activation of Notch and TGFb signals and form ductal plates, the primitive structure of bile ducts.19-22 Those ""immature"" cholangiocytes readily express cholangiocyte markers including Sry box containing gene 9 (Sox9), osteopontin (OPN), and EpCAM.23 When cholangiocytes in the ductal plate were labeled around E15 in Sox9-CreERT2 knock-in mice by peritoneal injection of tamoxifen to the pregnant mouse, they differentiated to ductular cholangiocytes, the canal of Hering, and periportal hepatocytes.24 This result indicates that cholangiocytes that form the ductal plate succeed to bidirectional differentiation potential from hepatoblasts.",E15,bile,1
PMC4154955A,"Hepatoblasts around the portal vein are committed to cholangiocytes by activation of Notch and TGFb signals and form ductal plates, the primitive structure of bile ducts.19-22 Those ""immature"" cholangiocytes readily express cholangiocyte markers including Sry box containing gene 9 (Sox9), osteopontin (OPN), and EpCAM.23 When cholangiocytes in the ductal plate were labeled around E15 in Sox9-CreERT2 knock-in mice by peritoneal injection of tamoxifen to the pregnant mouse, they differentiated to ductular cholangiocytes, the canal of Hering, and periportal hepatocytes.24 This result indicates that cholangiocytes that form the ductal plate succeed to bidirectional differentiation potential from hepatoblasts.",OPN,bile,1
PMC4154955A,"Hepatoblasts around the portal vein are committed to cholangiocytes by activation of Notch and TGFb signals and form ductal plates, the primitive structure of bile ducts.19-22 Those ""immature"" cholangiocytes readily express cholangiocyte markers including Sry box containing gene 9 (Sox9), osteopontin (OPN), and EpCAM.23 When cholangiocytes in the ductal plate were labeled around E15 in Sox9-CreERT2 knock-in mice by peritoneal injection of tamoxifen to the pregnant mouse, they differentiated to ductular cholangiocytes, the canal of Hering, and periportal hepatocytes.24 This result indicates that cholangiocytes that form the ductal plate succeed to bidirectional differentiation potential from hepatoblasts.",Sox9,bile,1
PMC3326512A,Note residual EpCAM expression in hair follicles in WT and KO mice.,KO,hair,-1
PMC4188889A,The lymph node (LN) ratio and dCK protein expression were significant predictors of DFS and OS in univariate analysis.,dCK,lymph,1
PMC4188889A,The lymph node (LN) ratio and dCK protein expression were significant predictors of DFS and OS in univariate analysis.,OS,lymph,1
PMC4188889A,The lymph node (LN) ratio and dCK protein expression were significant predictors of DFS and OS in univariate analysis.,DFS,lymph,1
PMC4777741A,The activated PKC translocates to the plasma membrane to initiate downstream signaling transduction events.,PKC,plasma,-1
PMC5193343A,"As other authors found grading, lymph vessel invasion and tumor size as prognostic in early tumor stages mainly with lymph node involvement [10-14], employing a more detailed analysis (N0 versus N+) of the tumor, might explain these differences.",N0,lymph,1
PMC5193343A,"As other authors found grading, lymph vessel invasion and tumor size as prognostic in early tumor stages mainly with lymph node involvement [10-14], employing a more detailed analysis (N0 versus N+) of the tumor, might explain these differences.",N0,lymph,1
PMC3410494A,"Mounting evidence indicates that TLR-9 expression is not confined to cells of the immune system, as TLR-9 expression has been detected in astrocytes, mesenchymal cells and in various normal epithelial and cancer cells, including breast, brain, lung and gastric cancer cells (17,19,34-38).Against this background, we aimed to analyze whether MMP-13 expression is also regulated by TLR-9 in CRC.",CRC,astrocytes,1
PMC3410494A,"Mounting evidence indicates that TLR-9 expression is not confined to cells of the immune system, as TLR-9 expression has been detected in astrocytes, mesenchymal cells and in various normal epithelial and cancer cells, including breast, brain, lung and gastric cancer cells (17,19,34-38).Against this background, we aimed to analyze whether MMP-13 expression is also regulated by TLR-9 in CRC.",TLR-9,astrocytes,1
PMC3410494A,"Mounting evidence indicates that TLR-9 expression is not confined to cells of the immune system, as TLR-9 expression has been detected in astrocytes, mesenchymal cells and in various normal epithelial and cancer cells, including breast, brain, lung and gastric cancer cells (17,19,34-38).Against this background, we aimed to analyze whether MMP-13 expression is also regulated by TLR-9 in CRC.",TLR-9,astrocytes,1
PMC3410494A,"Mounting evidence indicates that TLR-9 expression is not confined to cells of the immune system, as TLR-9 expression has been detected in astrocytes, mesenchymal cells and in various normal epithelial and cancer cells, including breast, brain, lung and gastric cancer cells (17,19,34-38).Against this background, we aimed to analyze whether MMP-13 expression is also regulated by TLR-9 in CRC.",MMP-13,astrocytes,1
PMC3410494A,"Mounting evidence indicates that TLR-9 expression is not confined to cells of the immune system, as TLR-9 expression has been detected in astrocytes, mesenchymal cells and in various normal epithelial and cancer cells, including breast, brain, lung and gastric cancer cells (17,19,34-38).Against this background, we aimed to analyze whether MMP-13 expression is also regulated by TLR-9 in CRC.",TLR-9,astrocytes,1
PMC4165776A,"The blood samples were prepared by spiking 10 uL RPMI media containing MCF7 cells at concentrations ranging from 3, 5, 10, 20, 50, and 100 cells into 1 mL of lysed blood.",MCF7,blood,-1
PMC4165776A,"The blood samples were prepared by spiking 10 uL RPMI media containing MCF7 cells at concentrations ranging from 3, 5, 10, 20, 50, and 100 cells into 1 mL of lysed blood.",MCF7,blood,-1
PMC4165776A,"The blood samples were prepared by spiking 10 uL RPMI media containing MCF7 cells at concentrations ranging from 3, 5, 10, 20, 50, and 100 cells into 1 mL of lysed blood.",RPMI,blood,-1
PMC4165776A,"The blood samples were prepared by spiking 10 uL RPMI media containing MCF7 cells at concentrations ranging from 3, 5, 10, 20, 50, and 100 cells into 1 mL of lysed blood.",RPMI,blood,-1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",TNM,lymph,1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",ASCO,lymph,1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",CRC,lymph,1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",EGTM-2007,lymph,1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",T4,lymph,1
PMC3791955A,"These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells.12 There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over-or, even worse, under-treatment of patients.11,13-18In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology's Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart, The European Group on Tumor Markers (EGTM-2007), have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers.19-21 Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use.",TEMP-2006,lymph,1
PMC5492016A,"Peng et al. constructed a serum ncRNA panel (miR-1254, miR-485-5p, miR-574-5p, and lncRNA MALAT1), and tested whether the ncRNA panel could distinguish NSCLC patient samples from controls.",MALAT1,serum,-1
PMC5492016A,"Peng et al. constructed a serum ncRNA panel (miR-1254, miR-485-5p, miR-574-5p, and lncRNA MALAT1), and tested whether the ncRNA panel could distinguish NSCLC patient samples from controls.",NSCLC,serum,-1
PMC3583531A,"Tissues were washed with a solution containing 25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2.7 mM KCl, and 0.1% Tween-20 (TBSTw) and non-specific binding sites were blocked for 1 hr in TBSTw containing 1% Blocking Reagent (Roche Diagnostics), 5% normal goat sera, and 1% bovine serum albumin fraction 5 (RGBTw).",Tween-20,sera,1
PMC3583531A,"Tissues were washed with a solution containing 25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2.7 mM KCl, and 0.1% Tween-20 (TBSTw) and non-specific binding sites were blocked for 1 hr in TBSTw containing 1% Blocking Reagent (Roche Diagnostics), 5% normal goat sera, and 1% bovine serum albumin fraction 5 (RGBTw).",Tween-20,serum,1
PMC5494437A,"In the post-natal rodent brain the radial glia-astrocyte stem cell sequence yields neurons, ependymal cells and astrocytes in two niches of the adult brain One region is located in the brain wall adjacent to the lateral ventricles of the forebrain, the sub-ventricular zone (V-SVZ), that ultimately generates olfactory bulb interneurons.",SVZ,astrocytes,1
PMC5494437A,"In the post-natal rodent brain the radial glia-astrocyte stem cell sequence yields neurons, ependymal cells and astrocytes in two niches of the adult brain One region is located in the brain wall adjacent to the lateral ventricles of the forebrain, the sub-ventricular zone (V-SVZ), that ultimately generates olfactory bulb interneurons.",SVZ,astrocyte,1
PMC4165776A,"In addition, MCF7 cells were labeled with DiO green fluorescent dye prior to addition to the blood samples.",MCF7,blood,-1
PMC4096804A,Each published OSCC dataset was formatted for GSEA and classified by regional lymph node involvement or stage.,GSEA,lymph,1
PMC4096804A,Each published OSCC dataset was formatted for GSEA and classified by regional lymph node involvement or stage.,OSCC,lymph,1
PMC3566310A,"Human FGF7 concentration in serum was quantitatively determined in duplicate by FGF7-specific enzyme-linked immunosorbent assay (ELISA; RD systems, Inc.) according to the manufacturer's instructions.",FGF7,serum,1
PMC3566310A,"Human FGF7 concentration in serum was quantitatively determined in duplicate by FGF7-specific enzyme-linked immunosorbent assay (ELISA; RD systems, Inc.) according to the manufacturer's instructions.",RD,serum,1
PMC3566310A,"Human FGF7 concentration in serum was quantitatively determined in duplicate by FGF7-specific enzyme-linked immunosorbent assay (ELISA; RD systems, Inc.) according to the manufacturer's instructions.",ELISA,serum,1
PMC3566310A,HSCE1 cells were maintained in type I collagen-coated dishes using a medium supplemented with fetal bovine serum and 10 ng/mL each recombinant human EGF and HGF.,HSCE1,serum,1
PMC3566310A,HSCE1 cells were maintained in type I collagen-coated dishes using a medium supplemented with fetal bovine serum and 10 ng/mL each recombinant human EGF and HGF.,HGF,serum,1
PMC3566310A,HSCE1 cells were maintained in type I collagen-coated dishes using a medium supplemented with fetal bovine serum and 10 ng/mL each recombinant human EGF and HGF.,EGF,serum,1
PMC4803572A,"However, many patients remain clinically disease-free for years until an increase in serum prostate-specific antigen (PSA) or overt metastases are detected.",PSA,serum,1
PMC3566310A,The proliferative response of HSCE1 cells was examined in the absence of the serum by a colorimetric assay using WST-1 cell proliferation reagent (Roche) according to the manufacturer's directions.,HSCE1,serum,1
PMC3566310A,The proliferative response of HSCE1 cells was examined in the absence of the serum by a colorimetric assay using WST-1 cell proliferation reagent (Roche) according to the manufacturer's directions.,WST-1,serum,1
PMC3906064A,Control antibody threshold is indicated by the red line (B) Recovery and purity of target cells using magnetophoretic capture from NHD blood: 90 cells/mL were spiked into NHD blood and purified on the LiquidBiopsy platform.,NHD,blood,-1
PMC3906064A,Control antibody threshold is indicated by the red line (B) Recovery and purity of target cells using magnetophoretic capture from NHD blood: 90 cells/mL were spiked into NHD blood and purified on the LiquidBiopsy platform.,NHD,blood,-1
PMC3906064A,Control antibody threshold is indicated by the red line (B) Recovery and purity of target cells using magnetophoretic capture from NHD blood: 90 cells/mL were spiked into NHD blood and purified on the LiquidBiopsy platform.,NHD,blood,-1
PMC3906064A,Control antibody threshold is indicated by the red line (B) Recovery and purity of target cells using magnetophoretic capture from NHD blood: 90 cells/mL were spiked into NHD blood and purified on the LiquidBiopsy platform.,NHD,blood,-1
PMC4777741A,"Briefly, HMEECs were cultured in a 1:1 mixture of Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ, USA) and DulbeccoaEUR(tm)s Modified Eagle Medium (Cellgro, Manassas, VA, USA) supplemented with bronchial epithelial growth medium (BEGM) Singlequots (Lonza, Allendale, NJ, USA) and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC4777741A,"Briefly, HMEECs were cultured in a 1:1 mixture of Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ, USA) and DulbeccoaEUR(tm)s Modified Eagle Medium (Cellgro, Manassas, VA, USA) supplemented with bronchial epithelial growth medium (BEGM) Singlequots (Lonza, Allendale, NJ, USA) and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC4777741A,"Briefly, HMEECs were cultured in a 1:1 mixture of Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ, USA) and DulbeccoaEUR(tm)s Modified Eagle Medium (Cellgro, Manassas, VA, USA) supplemented with bronchial epithelial growth medium (BEGM) Singlequots (Lonza, Allendale, NJ, USA) and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA).",BEGM,serum,1
PMC4777741A,"Briefly, HMEECs were cultured in a 1:1 mixture of Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ, USA) and DulbeccoaEUR(tm)s Modified Eagle Medium (Cellgro, Manassas, VA, USA) supplemented with bronchial epithelial growth medium (BEGM) Singlequots (Lonza, Allendale, NJ, USA) and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC4777741A,"Briefly, HMEECs were cultured in a 1:1 mixture of Bronchial Epithelial Cell Basal Medium (Lonza, Allendale, NJ, USA) and DulbeccoaEUR(tm)s Modified Eagle Medium (Cellgro, Manassas, VA, USA) supplemented with bronchial epithelial growth medium (BEGM) Singlequots (Lonza, Allendale, NJ, USA) and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC4015355A,"Viable cells were measured using MTS substrate Cell Titer96(r) AQueous One Solution (Promega, Madison, WI).Buffy coats from healthy donors were purchased from the Blood Center of New Jersey, with approval by the New England Institutional Review Board.",MTS,Blood,-1
PMC3474961A,"Apart from 99mTc-MDP, an increased level of serum alkaline phosphatase, which is a marker for osteoblastic proliferation, has also been associated with PCa metastasis [29].",MDP,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",UGM,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",DMEM,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",FBS,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",FBS,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",DMEM,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",E18,serum,1
PMC4437474A,"Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37degC. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin.",UGM,serum,1
PMC4188889A,Paulo et al[67] also evaluated the endoscopic pancreatic function test (ePFT) as a method able to safely obtain pancreatic fluid for MS analysis from patients during upper endoscopy and reproducibly identify pancreas-specific proteins.,ePFT,pancreatic fluid,-1
PMC4188889A,The ePFT-collected pancreatic fluid from 3 individuals without evidence of chronic pancreatitis was analyzed by SDS-PAGE and GeLC-MS/MS.,ePFT,pancreatic fluid,1
PMC4188889A,The ePFT-collected pancreatic fluid from 3 individuals without evidence of chronic pancreatitis was analyzed by SDS-PAGE and GeLC-MS/MS.,PAGE,pancreatic fluid,1
PMC4188889A,The ePFT-collected pancreatic fluid from 3 individuals without evidence of chronic pancreatitis was analyzed by SDS-PAGE and GeLC-MS/MS.,SDS,pancreatic fluid,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",F12,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",F12,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",BSA,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",BSA,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",bFGF,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",bFGF,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",DMEM,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",DMEM,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",EGF,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",EGF,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",N2,serum,1
PMC3885472A,"By culturing cells in ultra-low attachment dishes, serum-free DMEM/F12 medium, supplemented with EGF, basic fibroblast growth factor (bFGF), bovine serum albumin (BSA), insulin and with/without N2 nutrition were used to enrich PrCSC.",N2,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",BSA,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",N2,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",DMEM,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",EGF,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",F12,serum,1
PMC3885472A,"According to the prostasphere morphology and the prostasphere number, the optimized suspension medium is serum-free DMEM/F12 medium supplemented with EGF, bFGF, BSA, insulin and N2 nutrition in ultra-low attachment dishes.",bFGF,serum,1
PMC3756971A,"As deduced from cleavage assays performed at different pH values, cleavage of mEpCAM at the plasma membrane (pH 7) appears far less efficient than in acidified intracellular organelles (pH4).",pH4,plasma,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",F12,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",VWR,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",SAFC,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",DMEM,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",B27,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",PA,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",F12,serum,1
PMC3844723A,"Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) was obtained from SAFC Biosciences (Lenexa, KS), B27 serum-free supplements and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA), sodium bicarbonate and sodium pyruvate were obtained from VWR (West Chester, PA), basic fibroblast growth factor was purchased from Millipore Inc. (Billerica, MA).",KS,serum,1
PMC3938934A,"(iii-v) Specific inhibition of lipoxygenases-12e and -15 with ethyl 3,4-dihydroxybenzylidenecyanoacetate (DHBLCA) resulted in a dose-dependent decrease in ABSC proliferation with a decrease in sphere diameter, nuclei per sphere, and reduced Ki67 expression (P0.0001 and P0.001 respectively).We hypothesized that during airway injury when glucose levels are low due to an interruption of blood supply or inflammation, progenitor cells would require an alternative energy source to proliferate rapidly and repair the airway.",DHBLCA,blood,-1
PMC3938934A,"(iii-v) Specific inhibition of lipoxygenases-12e and -15 with ethyl 3,4-dihydroxybenzylidenecyanoacetate (DHBLCA) resulted in a dose-dependent decrease in ABSC proliferation with a decrease in sphere diameter, nuclei per sphere, and reduced Ki67 expression (P0.0001 and P0.001 respectively).We hypothesized that during airway injury when glucose levels are low due to an interruption of blood supply or inflammation, progenitor cells would require an alternative energy source to proliferate rapidly and repair the airway.",ABSC,blood,-1
PMC3938934A,"(iii-v) Specific inhibition of lipoxygenases-12e and -15 with ethyl 3,4-dihydroxybenzylidenecyanoacetate (DHBLCA) resulted in a dose-dependent decrease in ABSC proliferation with a decrease in sphere diameter, nuclei per sphere, and reduced Ki67 expression (P0.0001 and P0.001 respectively).We hypothesized that during airway injury when glucose levels are low due to an interruption of blood supply or inflammation, progenitor cells would require an alternative energy source to proliferate rapidly and repair the airway.",Ki67,blood,-1
PMC5430091A,"The results also indicated that high Trop2 and AREG protein coexpression was associated with TNM stage, lymph node metastases and distant metastases.",AREG,lymph,1
PMC5430091A,"The results also indicated that high Trop2 and AREG protein coexpression was associated with TNM stage, lymph node metastases and distant metastases.",TNM,lymph,1
PMC5430091A,"The results also indicated that high Trop2 and AREG protein coexpression was associated with TNM stage, lymph node metastases and distant metastases.",Trop2,lymph,1
PMC4074497A,"The tissue and tumor uptake was decay-corrected and calculated as the mean percentage of injected activity per gram of tissue (%IA/g), tumor-to-organ (T/O) and organ-to-blood (O/Bl) ratios and as the standard deviation (SD) of the mean values.",SD,blood,-1
PMC4074497A,"The tissue and tumor uptake was decay-corrected and calculated as the mean percentage of injected activity per gram of tissue (%IA/g), tumor-to-organ (T/O) and organ-to-blood (O/Bl) ratios and as the standard deviation (SD) of the mean values.",T,blood,-1
PMC4685746A,"In humans, CD14+ monocytes can be induced to express langerin in response to GM-CSF, IL-4 and TGFb [54, 55].",CD14,CSF,1
PMC4685746A,"In humans, CD14+ monocytes can be induced to express langerin in response to GM-CSF, IL-4 and TGFb [54, 55].",GM,CSF,1
PMC4685746A,"In humans, CD14+ monocytes can be induced to express langerin in response to GM-CSF, IL-4 and TGFb [54, 55].",IL-4,CSF,1
PMC4074497A,"Error bars represent mean +- standard error. ****: P0.0001.The 111In-DTPA-INCA-X antibody biodistribution in the major organs, blood and tumors of mice bearing subcutaneous PC-3 tumors was ascertained from the %IA/g values (Table 1 and Figure 3A).",DTPA,blood,1
PMC4074497A,"Error bars represent mean +- standard error. ****: P0.0001.The 111In-DTPA-INCA-X antibody biodistribution in the major organs, blood and tumors of mice bearing subcutaneous PC-3 tumors was ascertained from the %IA/g values (Table 1 and Figure 3A).",X,blood,1
PMC4074497A,"Error bars represent mean +- standard error. ****: P0.0001.The 111In-DTPA-INCA-X antibody biodistribution in the major organs, blood and tumors of mice bearing subcutaneous PC-3 tumors was ascertained from the %IA/g values (Table 1 and Figure 3A).",INCA,blood,1
PMC4074497A,"Error bars represent mean +- standard error. ****: P0.0001.The 111In-DTPA-INCA-X antibody biodistribution in the major organs, blood and tumors of mice bearing subcutaneous PC-3 tumors was ascertained from the %IA/g values (Table 1 and Figure 3A).",PC-3,blood,1
PMC3135497A,The development of serum autoantibodies against the conserved sequence of the ECSA family suggests that the conserved domain in some members of the ECSA family was translated into proteins.,ECSA,serum,1
PMC3135497A,The development of serum autoantibodies against the conserved sequence of the ECSA family suggests that the conserved domain in some members of the ECSA family was translated into proteins.,ECSA,serum,1
PMC4777741A,"Therefore, we examined whether phosphorylated PKC in response to P. aeruginosa infection translocate to the plasma membrane of HMEECs.",PKC,plasma,1
PMC3250983A,"Despite the low tumor/blood ratio, this assay demonstrated that targeting low CD138-expressing triple-negative breast cancer cells with 131I-labeled B-B4 mAb affords a very encouraging tumor response with only transient toxicity.",B4,blood,1
PMC5193343A,"Over all stages of gastric cancer Ki-67 is associated with metastasis and disease progression in gastric cancer and is especially associated with lymph node involvement in early diseases [47,48].Also TP53 mutation is known to be associated with reduced survival [15,49,50] and the mutation of TP53 plays a crucial role in the progression from intestinal metaplasia to gastric cancer [49,51].",TP53,lymph,1
PMC5193343A,"Over all stages of gastric cancer Ki-67 is associated with metastasis and disease progression in gastric cancer and is especially associated with lymph node involvement in early diseases [47,48].Also TP53 mutation is known to be associated with reduced survival [15,49,50] and the mutation of TP53 plays a crucial role in the progression from intestinal metaplasia to gastric cancer [49,51].",TP53,lymph,1
PMC5193343A,"Over all stages of gastric cancer Ki-67 is associated with metastasis and disease progression in gastric cancer and is especially associated with lymph node involvement in early diseases [47,48].Also TP53 mutation is known to be associated with reduced survival [15,49,50] and the mutation of TP53 plays a crucial role in the progression from intestinal metaplasia to gastric cancer [49,51].",Ki-67,lymph,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",mGM,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3478937A,"Differentiation media was supplemented with 100 ng/ml mM-CSF (for BMDMs), 20 ng/ml mGM-CSF (for BMDCs), or 20 ng/ml mGM-CSF + 20 ng/ml mM-CSF (for BM-derived LCs).",CSF,CSF,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",NaHCO3,serum,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",GIBCO,serum,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",FBS,serum,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",RPMI,serum,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",GIBCO,serum,1
PMC3443948A,"The cells were grown in RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg, MD) or Dulbecco's modified Eagle's medium (GIBCO-Life Technologies), supplemented with 1.5 g/L of NaHCO3, and 10% foetal bovine serum (FBS; GIBCO-Life Technologies).",GIBCO,serum,1
PMC4469888A,Single prostate cell suspension was washed with stain wash buffer (PBS supplemented with 1% serum and 1% antibiotics) twice.,PBS,serum,1
PMC2939361A,"Patients are also diagnosed by the status of their primary tumors, from organ-confined to fully invasive (T1-4), with or without lymph node involvement (N0 or 1), and the presence and degree of distant metastases (M0 and 1a-c) (Ohori et al.",N0,lymph,1
PMC2939361A,"Patients are also diagnosed by the status of their primary tumors, from organ-confined to fully invasive (T1-4), with or without lymph node involvement (N0 or 1), and the presence and degree of distant metastases (M0 and 1a-c) (Ohori et al.",M0,lymph,1
PMC2939361A,"Patients are also diagnosed by the status of their primary tumors, from organ-confined to fully invasive (T1-4), with or without lymph node involvement (N0 or 1), and the presence and degree of distant metastases (M0 and 1a-c) (Ohori et al.",T1,lymph,1
PMC3418405A,"Perhaps validation of the role of Foxo3a pathway in the immune response is best illustrated in a rare subset ( 0.3%) of chronic HIV-infected subjects, the elite controllers (ECs), that are able to fully control viral replication (plasma loads  50 copies/ml) and maintain high CD4 cell counts ( 500 cells/ml) for many years without HAART (89).",HAART,plasma,1
PMC3418405A,"Perhaps validation of the role of Foxo3a pathway in the immune response is best illustrated in a rare subset ( 0.3%) of chronic HIV-infected subjects, the elite controllers (ECs), that are able to fully control viral replication (plasma loads  50 copies/ml) and maintain high CD4 cell counts ( 500 cells/ml) for many years without HAART (89).",HIV,plasma,1
PMC3418405A,"Perhaps validation of the role of Foxo3a pathway in the immune response is best illustrated in a rare subset ( 0.3%) of chronic HIV-infected subjects, the elite controllers (ECs), that are able to fully control viral replication (plasma loads  50 copies/ml) and maintain high CD4 cell counts ( 500 cells/ml) for many years without HAART (89).",CD4,plasma,1
PMC3548755A,"Sera diluted at 1:100 in PBS with 10% FBS were added to the wells and incubated for 1 h. The wells were exposed to 1:2 000-diluted horseradish peroxidase-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).",PBS,Sera,1
PMC3548755A,"Sera diluted at 1:100 in PBS with 10% FBS were added to the wells and incubated for 1 h. The wells were exposed to 1:2 000-diluted horseradish peroxidase-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).",FBS,Sera,1
PMC3548755A,"Sera diluted at 1:100 in PBS with 10% FBS were added to the wells and incubated for 1 h. The wells were exposed to 1:2 000-diluted horseradish peroxidase-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).",PA,Sera,1
PMC3548755A,"After washing and blocking, the membranes were exposed in 1:2000-diluted serum for 1 h. The membranes were treated with 1:5000-diluted alkalinephosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",PA,serum,1
PMC5042010A,"This has driven the development of various ""liquid biopsy"" technologies that seek to address the need for monitoring tools that use the specific readout of DNA based biomarkers to monitor changes in tumor profile [4].The earliest version of a liquid biopsy was built on careful enumeration of a small number of cells that could be found in the blood of patients with epithelial cancers [5, 6].",DNA,blood,-1
PMC2939361A,"PSA is a kallikrein-related serine protease that is produced in normal prostate secretions, but is released into the blood as a consequence of disruption of normal prostate architecture (Lilja et al.",PSA,blood,-1
PMC2757864A,"To evaluate whether our dataset reliably represents the collection of cell surface proteins, a GO analysis was performed to evaluate whether it was enriched with GO categories clearly associated with plasma membrane.",GO,plasma,1
PMC2757864A,"To evaluate whether our dataset reliably represents the collection of cell surface proteins, a GO analysis was performed to evaluate whether it was enriched with GO categories clearly associated with plasma membrane.",GO,plasma,1
PMC4637775A,"However, diagnosis of small HCC (= 3 cm in diameter) by detection of serum AFP levels and ultrasound is far from perfect [4,5].",AFP,serum,-1
PMC4637775A,"However, diagnosis of small HCC (= 3 cm in diameter) by detection of serum AFP levels and ultrasound is far from perfect [4,5].",HCC,serum,-1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",HepG2,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",USA,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",DMEM,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",USA,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",NaHCO3,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",HepG2,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",MTT,serum,1
PMC4637775A,"Human hepatoma cells (HepG2 cell line, kindly gifted by Dr. Jetsumon Prachumsri, Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Thailand) were grown in HyClone(tm) Dulbecco's modified Eagle's medium (DMEM; GE Healthcare, Logan, UT, USA), supplemented with 10% (vol/vol) fetal bovine serum (Biowest, Nuaille, France), 1 x penicillin/streptomycin (Biowest), and 0.37% (wt/vol) NaHCO3 at 37degC in a humidified atmosphere of 95% air and 5% CO2.The cytotoxic effects of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) on HepG2 cells were determined by measurement of cell proliferation using the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay as previously described with some modifications [17].",PMA,serum,1
PMC4292049A,"Three hours p.i., the blood level of 125I-CC49-TCO was lowest after the double dose of clearing agent (0.19 +- 0.04%ID/g), followed by the single dose (1.16 +- 0.43%ID/g) and highest in the group without clearing agent injection (8.47 +- 4.12%ID/g).",CC49-TCO,blood,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",CD34,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",CD34,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",SCF,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",SCF,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",CSF,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",GM,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",GM,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",DC,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",DC,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",CD14,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",CD14,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",TNF,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",TNF,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",Flt3,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",Flt3,serum,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",TGF,CSF,1
PMC3478937A,"In brief, CD34+ cells (5 x 104 to 105/ml per well) were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) supplemented with 100 ng/ml GM-CSF, 20 ng/ml SCF, 50 ng/ml Flt3, 2.5 ng/ml TNF, and 1 ng/ml TGF-b1 for 7 d. Cultures were supplemented with 2.5 mM GlutaMAX (Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. CD14+ moDC and moLC cultures were described previously (Geissmann et al., 1998; Hoshino et al., 2005).",TGF,serum,1
PMC3092219A,"For example, Whitaker et al. recently showed that nuclear b-catenin was commonly seen in benign prostatic tissue yet was often lost in prostatic carcinoma.54 In another study, although the relation between b-catenin levels and MYC was not examined, Fiorentino et al. found that cytoplasmic b-catenin (after subtracting plasma membrane staining) was elevated in some prostate cancers, indicating that this may be equivalent to nuclear staining in terms of biological significance.55",MYC,plasma,1
PMC4673473A,"In addition, Fr25Lin- marrow-homing cells had differentiated into multiple cell types, including hepatocytes following in vivo transfer8 and these cells differentiated into hepatocyte-like cells in vitro within 7 days.9 We questioned the initial phenotypes of bone marrow cells that could differentiate into hepatocytes in our system in terms of KLS markers.",KLS,bone marrow,1
PMC4773505A,"Characterization of the end point cultures revealed strong staining of astrocyte marker GFAP and neuronal marker TH, and relatively weak staining of mature neuronal markers MAP2, NeuN and b-tubulin III (Fig. 5h).",TH,astrocyte,1
PMC4773505A,"Characterization of the end point cultures revealed strong staining of astrocyte marker GFAP and neuronal marker TH, and relatively weak staining of mature neuronal markers MAP2, NeuN and b-tubulin III (Fig. 5h).",NeuN,astrocyte,1
PMC4773505A,"Characterization of the end point cultures revealed strong staining of astrocyte marker GFAP and neuronal marker TH, and relatively weak staining of mature neuronal markers MAP2, NeuN and b-tubulin III (Fig. 5h).",GFAP,astrocyte,1
PMC4773505A,"Characterization of the end point cultures revealed strong staining of astrocyte marker GFAP and neuronal marker TH, and relatively weak staining of mature neuronal markers MAP2, NeuN and b-tubulin III (Fig. 5h).",MAP2,astrocyte,1
PMC4773505A,"Characterization of the end point cultures revealed strong staining of astrocyte marker GFAP and neuronal marker TH, and relatively weak staining of mature neuronal markers MAP2, NeuN and b-tubulin III (Fig. 5h).",III,astrocyte,1
PMC5513028A,"Cells (2 x 104) in serum-free medium were plated into the upper chamber of 8 mm pore boyden chambers coated with or without Matrigel (BD Biosystems, San Jose, CA).",San,serum,1
PMC5494437A,CD44 is involved in adhesion of cells to the ECM by hyaluron and is a receptor for the cytokine osteopontin (Opn) in the bone marrow.,CD44,bone marrow,1
PMC5494437A,CD44 is involved in adhesion of cells to the ECM by hyaluron and is a receptor for the cytokine osteopontin (Opn) in the bone marrow.,ECM,bone marrow,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",San,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",San,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",MMS-162P,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",MMS-162P,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K14,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K14,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K5,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K5,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K8,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",K8,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",LL002,serum,1
PMC4816225A,"Slides were incubated with 5% normal goat serum (Vector Labs, Burlingame, CA) and with primary antibodies diluted in 2.5% normal goat serum overnight at 4degC. Primary antibodies used in this study were mouse anti-K14 (LL002, Biogenex, San Ramon, CA), rabbit anti-K5 (#PRB-160P, Covance, Berkeley, CA), mouse anti-K8 (#MMS-162P, Covance), rat",LL002,serum,1
PMC3680444A,"Only one report described increased ATDC mRNA expression in association with high histological grade, large tumor size, extent of tumor invasion and lymph node metastasis in gastric cancer [15].",ATDC,lymph,1
PMC3680444A,"Only one report described increased ATDC mRNA expression in association with high histological grade, large tumor size, extent of tumor invasion and lymph node metastasis in gastric cancer [15].",mRNA,lymph,1
PMC3326009A,"Cells were counted with a hemocytometer and resuspended in RPMI supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin (Mediatech Inc.), and Methyltrienolone R1881 (Sigma) for culture in vitro.",FBS,serum,1
PMC3326009A,"Cells were counted with a hemocytometer and resuspended in RPMI supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin (Mediatech Inc.), and Methyltrienolone R1881 (Sigma) for culture in vitro.",RPMI,serum,1
PMC3326009A,"Cells were counted with a hemocytometer and resuspended in RPMI supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin (Mediatech Inc.), and Methyltrienolone R1881 (Sigma) for culture in vitro.",R1881,serum,1
PMC3039945A,"It has been suggested that a comparison of the pro- and anti-tumour factors at the invasive front could contribute to development of a prognostic score for patients with CRC [133], with proteomic analysis providing new prognostic markers for CRC.An alternative proteomic approach is the analysis of patient blood plasma or other biological fluids for CRC biomarkers [271], which include cancer-associated soluble factors, as well as tumour-derived microvesicles [272-275].",CRC,plasma,1
PMC3039945A,"It has been suggested that a comparison of the pro- and anti-tumour factors at the invasive front could contribute to development of a prognostic score for patients with CRC [133], with proteomic analysis providing new prognostic markers for CRC.An alternative proteomic approach is the analysis of patient blood plasma or other biological fluids for CRC biomarkers [271], which include cancer-associated soluble factors, as well as tumour-derived microvesicles [272-275].",CRC,blood,-1
PMC3039945A,"It has been suggested that a comparison of the pro- and anti-tumour factors at the invasive front could contribute to development of a prognostic score for patients with CRC [133], with proteomic analysis providing new prognostic markers for CRC.An alternative proteomic approach is the analysis of patient blood plasma or other biological fluids for CRC biomarkers [271], which include cancer-associated soluble factors, as well as tumour-derived microvesicles [272-275].",CRC,plasma,1
PMC3039945A,"It has been suggested that a comparison of the pro- and anti-tumour factors at the invasive front could contribute to development of a prognostic score for patients with CRC [133], with proteomic analysis providing new prognostic markers for CRC.An alternative proteomic approach is the analysis of patient blood plasma or other biological fluids for CRC biomarkers [271], which include cancer-associated soluble factors, as well as tumour-derived microvesicles [272-275].",CRC,blood,-1
PMC2946292A,This low requirement for serum might be indicative that Trop2 transduces a survival signal in a growth-factor independent manner.,Trop2,serum,-1
PMC3566310A,(H) Serum FGF7 levels in human samples.,FGF7,Serum,1
PMC4882422A,5A). Transplanting Tlr4-/- BM cells resulted in lower serum GPT levels (Fig.,GPT,serum,1
PMC2939361B,"More generally, the investigation of potential urine biomarkers has led to the identification of PCA3 (prostate cancer antigen 3), a promising marker for predicting disease outcome (Ploussard and de la Taille 2010).However, to date, few if any biomarkers are now being used that can predict disease outcome more effectively than Gleason score alone.",PCA3,urine,1
PMC5348388A,"SW480 and SW620 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin.",SW620,serum,1
PMC5348388A,"SW480 and SW620 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin.",DMEM,serum,1
PMC5348388A,"SW480 and SW620 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin.",SW480,serum,1
PMC5348388A,"SW480 and SW620 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin.",FBS,serum,1
PMC3929731A,"The highly sensitive UHPLC-MS-MS system allowed direct quantitation of both free BPA and BPA-G in 25 mL of sera, thus permitting measurement in individual mice from tail vein sampling (Figure 4A).",BPA,sera,1
PMC3929731A,"The highly sensitive UHPLC-MS-MS system allowed direct quantitation of both free BPA and BPA-G in 25 mL of sera, thus permitting measurement in individual mice from tail vein sampling (Figure 4A).",UHPLC,sera,1
PMC3929731A,"The highly sensitive UHPLC-MS-MS system allowed direct quantitation of both free BPA and BPA-G in 25 mL of sera, thus permitting measurement in individual mice from tail vein sampling (Figure 4A).",BPA,sera,1
PMC3476529A,"Although cross-presenting capacity is also found in lymph node (LN)-resident DCs and may augment antigen presentation by migratory DCs (Shortman and Heath, 2010), the latter are obligatory for efficient T cell priming (Allenspach et al.",T,lymph,1
PMC3266428A,"There was weak evidence for a positive correlation between normalized TACSTD2 expression levels and fat mass (Spearman r = 0.44, P = 0.061) but not for other indices of body composition (Supplementary Table 2).Whole blood samples, taken at ~11 years of age, were available for DNA methylation analysis from 94 children born preterm (cohort 1-methylation).",TACSTD2,blood,-1
PMC3266428A,"There was weak evidence for a positive correlation between normalized TACSTD2 expression levels and fat mass (Spearman r = 0.44, P = 0.061) but not for other indices of body composition (Supplementary Table 2).Whole blood samples, taken at ~11 years of age, were available for DNA methylation analysis from 94 children born preterm (cohort 1-methylation).",DNA,blood,-1
PMC3266428A,"Mean methylation levels derived from blood samples in cohort 1 were higher than but correlated with those estimated using DNA from available saliva samples (n = 68, Spearman r = 0.71, P = 1.12e-11) (Supplementary Table 4).",DNA,blood,1
PMC3266428A,"Mean methylation levels derived from blood samples in cohort 1 were higher than but correlated with those estimated using DNA from available saliva samples (n = 68, Spearman r = 0.71, P = 1.12e-11) (Supplementary Table 4).",DNA,saliva,1
PMC3266428A,"Strong correlations in percentage methylation were demonstrated across the seven CpG sites investigated in three sources of DNA (average Spearman r: cohort 1-methylation 0.95, P = 1.05e-39; cohort 2-cord blood 0.97, P = 4.17e-71; cohort 2-age 7 blood 0.95, P = 3.24e-61) (Supplementary Table 3).",DNA,blood,-1
PMC3266428A,"Strong correlations in percentage methylation were demonstrated across the seven CpG sites investigated in three sources of DNA (average Spearman r: cohort 1-methylation 0.95, P = 1.05e-39; cohort 2-cord blood 0.97, P = 4.17e-71; cohort 2-age 7 blood 0.95, P = 3.24e-61) (Supplementary Table 3).",DNA,blood,-1
PMC5494437A,"They consist of sequential cell stages, Type B1 astrocytes (radial astrocytes), that develop Type C transit amplifying cells (intermediate progenitors) which divide to form Type A granule cells (neuroblasts), precursors of differentiated neurons[29,40-43].",B1,astrocytes,1
PMC5494437A,"They consist of sequential cell stages, Type B1 astrocytes (radial astrocytes), that develop Type C transit amplifying cells (intermediate progenitors) which divide to form Type A granule cells (neuroblasts), precursors of differentiated neurons[29,40-43].",B1,astrocytes,1
PMC5467782A,We found that the levels of miR-181b-5p in peripheral blood were increased in NSCLC patients (Fig.,NSCLC,blood,-1
PMC4366163A,"For example, b1-integrin-mediated adhesion of brain endothelial cells to the surrounding ECM is critical for stabilizing claudin-5 at blood brain barrier (BBB) TJ, and to maintain BBB integrity [70].",ECM,blood,-1
PMC4366163A,"For example, b1-integrin-mediated adhesion of brain endothelial cells to the surrounding ECM is critical for stabilizing claudin-5 at blood brain barrier (BBB) TJ, and to maintain BBB integrity [70].",BBB,blood,-1
PMC4366163A,"For example, b1-integrin-mediated adhesion of brain endothelial cells to the surrounding ECM is critical for stabilizing claudin-5 at blood brain barrier (BBB) TJ, and to maintain BBB integrity [70].",BBB,blood,-1
PMC4708083A,"Rountree, Barsky, et al., 2007), choline-deficient, ethionine-supplemented diet (CDE) (Espanol-Suner et al., 2012; Knight  Yeoh, 2005; Tirnitz-Parker, Tonkin, Knight, Olynyk,  Yeoh, 2007), methionine choline-deficient diet supplemented with ethionine (MCDE) (Huch et al., 2013), bile duct ligation (BDL) (Chu et al., 2011;",MCDE,bile,1
PMC4708083A,"Rountree, Barsky, et al., 2007), choline-deficient, ethionine-supplemented diet (CDE) (Espanol-Suner et al., 2012; Knight  Yeoh, 2005; Tirnitz-Parker, Tonkin, Knight, Olynyk,  Yeoh, 2007), methionine choline-deficient diet supplemented with ethionine (MCDE) (Huch et al., 2013), bile duct ligation (BDL) (Chu et al., 2011;",CDE,bile,1
PMC4708083A,"Rountree, Barsky, et al., 2007), choline-deficient, ethionine-supplemented diet (CDE) (Espanol-Suner et al., 2012; Knight  Yeoh, 2005; Tirnitz-Parker, Tonkin, Knight, Olynyk,  Yeoh, 2007), methionine choline-deficient diet supplemented with ethionine (MCDE) (Huch et al., 2013), bile duct ligation (BDL) (Chu et al., 2011;",BDL,bile,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD90,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",MSC,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD166,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD14,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD73,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD105,lavage fluids,1
PMC5357254A,"In consistent with our data, a recent study shows that the peritoneal mesenchymal cells isolated from human peritoneal lavage fluid display some MSC surface markers (positive: CD90, CD73, CD105, CD166; negative: CD14 and CD45) [41], suggesting that the MSCs we identified in PD effluents may also come from the peritoneal lavage fluids.",CD45,lavage fluids,1
PMC4803572A,"Later on, DTC were detected using antibodies against pan-CK/EpCAM on bone marrow aspirates by immunocytochemistry [13].",DTC,bone marrow,1
PMC4270176A,"One of the original versions of this, cytometry time-of-flight (CyTOF) MS, combined inductively coupled plasma with TOF MS and has now been optimized for the real-time detection of multiple biomarkers in single-cells present in suspension (126).",TOF,plasma,1
PMC4370053A,"In humans, however,the DC1 subset of CD141high XCR1+ myeloid DCs is langerin negative[3].In human progenitor cells and monocytes, langerin is induced by a wide range ofcytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7[8, 21-24].",TNF,CSF,1
PMC4370053A,"In humans, however,the DC1 subset of CD141high XCR1+ myeloid DCs is langerin negative[3].In human progenitor cells and monocytes, langerin is induced by a wide range ofcytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7[8, 21-24].",XCR1,CSF,1
PMC4370053A,"In humans, however,the DC1 subset of CD141high XCR1+ myeloid DCs is langerin negative[3].In human progenitor cells and monocytes, langerin is induced by a wide range ofcytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7[8, 21-24].",TGF,CSF,1
PMC4370053A,"In humans, however,the DC1 subset of CD141high XCR1+ myeloid DCs is langerin negative[3].In human progenitor cells and monocytes, langerin is induced by a wide range ofcytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7[8, 21-24].",GM,CSF,1
PMC4370053A,"In humans, however,the DC1 subset of CD141high XCR1+ myeloid DCs is langerin negative[3].In human progenitor cells and monocytes, langerin is induced by a wide range ofcytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7[8, 21-24].",DC1,CSF,1
PMC4251850A,The carcinoma cell lines were then washed three times with DMEM and incubated in a serum-free medium with supplements for 16 hours.,DMEM,serum,1
PMC3963546A,"In the non-tumoural surrounding tissue, TACSTD2, VASP and laminin were found to be mainly expressed by the HPCs and the smaller bile ducts, whereas, the larger bile ducts showed a variable, focal positivity for these proteins.",VASP,bile,1
PMC3963546A,"In the non-tumoural surrounding tissue, TACSTD2, VASP and laminin were found to be mainly expressed by the HPCs and the smaller bile ducts, whereas, the larger bile ducts showed a variable, focal positivity for these proteins.",VASP,bile,1
PMC3963546A,"In the non-tumoural surrounding tissue, TACSTD2, VASP and laminin were found to be mainly expressed by the HPCs and the smaller bile ducts, whereas, the larger bile ducts showed a variable, focal positivity for these proteins.",TACSTD2,bile,1
PMC3963546A,"In the non-tumoural surrounding tissue, TACSTD2, VASP and laminin were found to be mainly expressed by the HPCs and the smaller bile ducts, whereas, the larger bile ducts showed a variable, focal positivity for these proteins.",TACSTD2,bile,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",ZEB2,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",NOTCH1,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",SNAI1,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",ZEB1,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",EMT,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",ETV5,blood,1
PMC5000705A,"An analysis of CTCs from blood samples of high risk endometrial adenocarcinoma patients (grade 3, stage IB-IV) showed a high plasticity in the expression of EMT markers like ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and ZEB2.",TGFB1,blood,1
PMC5505023A,(G-I) Immunocytochemistry analysis of the expression of epithelial cell adhesion molecule (EpCAM) and CD133 in bile duct structures.,CD133,bile,1
PMC3474961A,"PCa is in fact most commonly diagnosed through screening, which may be performed through digital rectal examination (DRE), and/or blood tests for prostate-specific antigen (PSA).",DRE,blood,-1
PMC3474961A,"PCa is in fact most commonly diagnosed through screening, which may be performed through digital rectal examination (DRE), and/or blood tests for prostate-specific antigen (PSA).",PSA,blood,-1
PMC3474961A,"In this context, the number PCa diagnosis has increased significantly concurrently with the development of the PSA serum immunoassay in 1980 [13, 27].",PSA,serum,1
PMC5494437A,"Moving inward into the ventricular wall, domain II (DII), B1 astrocyte cells form transit amplifying ""C"" cells that divide to form A cells (neuroblasts).",B1,astrocyte,1
PMC5494437A,"Moving inward into the ventricular wall, domain II (DII), B1 astrocyte cells form transit amplifying ""C"" cells that divide to form A cells (neuroblasts).",DII,astrocyte,1
PMC3474961A,Limitations of DRE include limited sensitivity and reduced number of detections as compared to PSA blood test.,DRE,blood,-1
PMC3474961A,Limitations of DRE include limited sensitivity and reduced number of detections as compared to PSA blood test.,PSA,blood,-1
PMC3476529A,"Work with humanized mice has also described the development of CD141+ DCs similar to blood CD141+ DCs in the spleen but not in nonlymphoid organs (Poulin et al., 2010).",CD141,blood,-1
PMC3476529A,"Work with humanized mice has also described the development of CD141+ DCs similar to blood CD141+ DCs in the spleen but not in nonlymphoid organs (Poulin et al., 2010).",CD141,blood,-1
PMC3474961A,Thus the chemokine rich milieu of the bone marrow combined with adhesion molecules expressed within the HSC niche are believed to be crucial in recruiting DTCs promoting PCa metastasis in the bone Fig.,HSC,bone marrow,-1
PMC4096804A,"As knowledge of lymph node metastatic status of OSCC is critical in clinical decision making, including whether to suggest neck surgery for early stage cancers, we next asked whether the mouse signature could be translated into a diagnostic test as described for ocular melanoma (Fig.",OSCC,lymph,-1
PMC5000705A,The measurement of DCLK1 levels in serum samples and of its expression in CTCs could hence be an important marker for tumor malignancy [88] and EMT.,EMT,serum,1
PMC5000705A,The measurement of DCLK1 levels in serum samples and of its expression in CTCs could hence be an important marker for tumor malignancy [88] and EMT.,DCLK1,serum,1
PMC5494437A,"In the third innermost zone (DIII), B1 cells are in communication with blood vessels via extended cell processes [40,43].",B1,blood,-1
PMC5494437A,"In the third innermost zone (DIII), B1 cells are in communication with blood vessels via extended cell processes [40,43].",DIII,blood,-1
PMC3364558A,These efforts identified a NOTA structure with favorable binding properties to hold Al18F complexes stably in serum and in vivo.,NOTA,serum,1
PMC4637775A,"Although standard diagnostic surveillance techniques, such as serum AFP and ultrasonography, are commonly available with affordable cost misdiagnosis associated with poor prognostic markers has been a problem for several decades [24,25].",AFP,serum,1
PMC4690245A,"After that, the slides were immersed in 3 % H2O2 to inactivate endogenous peroxidase and blocked with goat serum for 30 min.",H2O2,serum,1
PMC2722670A,"SEREX analysis has also led to the isolation of several antigens with known cancer relatedness, including a mutated version of the p53 tumor suppressor protein, while the presence of antibodies to p53 in serum was associated with poor prognosis in esophageal cancer [11-13].",p53,serum,1
PMC2722670A,"SEREX analysis has also led to the isolation of several antigens with known cancer relatedness, including a mutated version of the p53 tumor suppressor protein, while the presence of antibodies to p53 in serum was associated with poor prognosis in esophageal cancer [11-13].",SEREX,serum,1
PMC2722670A,"SEREX analysis has also led to the isolation of several antigens with known cancer relatedness, including a mutated version of the p53 tumor suppressor protein, while the presence of antibodies to p53 in serum was associated with poor prognosis in esophageal cancer [11-13].",p53,serum,1
PMC4096804A,"Although NGS confirmed MOC and human OSCC conservation, analysis of mutations specific to indolent or aggressive lines and lymph node versus lung metastatic lines was inconclusive likely due in part to the limited numbers of samples (Tables S7 and S9).",MOC,lymph,1
PMC4096804A,"Although NGS confirmed MOC and human OSCC conservation, analysis of mutations specific to indolent or aggressive lines and lymph node versus lung metastatic lines was inconclusive likely due in part to the limited numbers of samples (Tables S7 and S9).",S9,lymph,1
PMC4096804A,"Although NGS confirmed MOC and human OSCC conservation, analysis of mutations specific to indolent or aggressive lines and lymph node versus lung metastatic lines was inconclusive likely due in part to the limited numbers of samples (Tables S7 and S9).",S7,lymph,1
PMC4096804A,"Although NGS confirmed MOC and human OSCC conservation, analysis of mutations specific to indolent or aggressive lines and lymph node versus lung metastatic lines was inconclusive likely due in part to the limited numbers of samples (Tables S7 and S9).",NGS,lymph,1
PMC4096804A,"Although NGS confirmed MOC and human OSCC conservation, analysis of mutations specific to indolent or aggressive lines and lymph node versus lung metastatic lines was inconclusive likely due in part to the limited numbers of samples (Tables S7 and S9).",OSCC,lymph,1
PMC5086635A,The deletion of domain II from the SS1P immunotoxins reduced the already short serum half-life from nineteen minutes to only thirteen minutes [90].,SS1P,serum,-1
PMC4096804A,"We next approached this question by comparing our mouse sequencing data to mutations unique to lymph node metastasis negative (N0, 62 patients) versus positive (N+, 84 patients) OSCC samples from TCGA.",TCGA,lymph,1
PMC4096804A,"We next approached this question by comparing our mouse sequencing data to mutations unique to lymph node metastasis negative (N0, 62 patients) versus positive (N+, 84 patients) OSCC samples from TCGA.",OSCC,lymph,1
PMC4096804A,"We next approached this question by comparing our mouse sequencing data to mutations unique to lymph node metastasis negative (N0, 62 patients) versus positive (N+, 84 patients) OSCC samples from TCGA.",N0,lymph,1
PMC4306156A,"Recent reports have shown that measurement of serum CEA levels, in combination with CA199 and CA125, can serve as an important predictor of hepatic metastasis of colorectal cancer[36].",CA199,serum,1
PMC4306156A,"Recent reports have shown that measurement of serum CEA levels, in combination with CA199 and CA125, can serve as an important predictor of hepatic metastasis of colorectal cancer[36].",CA125,serum,1
PMC4306156A,"Recent reports have shown that measurement of serum CEA levels, in combination with CA199 and CA125, can serve as an important predictor of hepatic metastasis of colorectal cancer[36].",CEA,serum,1
PMC4306156A,"Moreover, serum CEA levels in combination with imaging techniques may accurately predict tumor recurrence following radical surgery of colorectal hepatic metastases[38].",CEA,serum,1
PMC3393688A,"Red blood cells were lysed using RBC lysis buffer (Sigma-Aldrich, Castle Hill, NSW, Australia) and single cells were then re-suspended in DMEM with 10% FCS.",DMEM,blood,1
PMC3393688A,"Red blood cells were lysed using RBC lysis buffer (Sigma-Aldrich, Castle Hill, NSW, Australia) and single cells were then re-suspended in DMEM with 10% FCS.",NSW,blood,1
PMC3393688A,"Red blood cells were lysed using RBC lysis buffer (Sigma-Aldrich, Castle Hill, NSW, Australia) and single cells were then re-suspended in DMEM with 10% FCS.",FCS,blood,1
PMC3393688A,"Red blood cells were lysed using RBC lysis buffer (Sigma-Aldrich, Castle Hill, NSW, Australia) and single cells were then re-suspended in DMEM with 10% FCS.",RBC,blood,1
PMC5410259A,"We found that culturing CRs in DMEM without serum for 3 days led to differentiation of normal GUMC-29 cells, while supporting a ""fibroblast""-like or mesenchymal morphologic phenotype of GUMC-30 (Figure 8A).",DMEM,serum,-1
PMC5410259A,"We found that culturing CRs in DMEM without serum for 3 days led to differentiation of normal GUMC-29 cells, while supporting a ""fibroblast""-like or mesenchymal morphologic phenotype of GUMC-30 (Figure 8A).",GUMC-29,serum,-1
PMC5410259A,"We found that culturing CRs in DMEM without serum for 3 days led to differentiation of normal GUMC-29 cells, while supporting a ""fibroblast""-like or mesenchymal morphologic phenotype of GUMC-30 (Figure 8A).",GUMC-30,serum,-1
PMC4275355A,"Together, these data suggest not only that SCC can arise from the hair follicle, but that the cells with the greatest developmental capacity, in this case ASCs, can serve as CCOs.",SCC,hair,1
PMC3393688A,"Cell suspensions were passed through 18 and 21 gauge syringes and 40 um cell strainers and then incubated with Red Blood Cell Lysis Buffer (Sigma-Aldrich, Castle Hill, NSW, Australia).",NSW,Blood,-1
PMC3393688A,"Benign regions of prostate tissue were dissected by a Urological Pathologist and primary epithelial cell cultures were established in Keratinocyte Serum-Free Medium supplemented with 50 ng/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF; Gibco, Invitrogen, Blackburn, VIC, Australia) and antibiotics (100 IU/ml penicillin and 10 ug/ml streptomycin; Invitrogen, Blackburn, VIC, Australia) at 37degC in a humidified atmosphere of 5% CO2.The spheroid assay was performed using previously reported methods with minor modifications [15], [16].",VIC,Serum,1
PMC3393688A,"Benign regions of prostate tissue were dissected by a Urological Pathologist and primary epithelial cell cultures were established in Keratinocyte Serum-Free Medium supplemented with 50 ng/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF; Gibco, Invitrogen, Blackburn, VIC, Australia) and antibiotics (100 IU/ml penicillin and 10 ug/ml streptomycin; Invitrogen, Blackburn, VIC, Australia) at 37degC in a humidified atmosphere of 5% CO2.The spheroid assay was performed using previously reported methods with minor modifications [15], [16].",VIC,Serum,1
PMC3393688A,"Benign regions of prostate tissue were dissected by a Urological Pathologist and primary epithelial cell cultures were established in Keratinocyte Serum-Free Medium supplemented with 50 ng/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF; Gibco, Invitrogen, Blackburn, VIC, Australia) and antibiotics (100 IU/ml penicillin and 10 ug/ml streptomycin; Invitrogen, Blackburn, VIC, Australia) at 37degC in a humidified atmosphere of 5% CO2.The spheroid assay was performed using previously reported methods with minor modifications [15], [16].",EGF,Serum,1
PMC3393688A,"Benign regions of prostate tissue were dissected by a Urological Pathologist and primary epithelial cell cultures were established in Keratinocyte Serum-Free Medium supplemented with 50 ng/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF; Gibco, Invitrogen, Blackburn, VIC, Australia) and antibiotics (100 IU/ml penicillin and 10 ug/ml streptomycin; Invitrogen, Blackburn, VIC, Australia) at 37degC in a humidified atmosphere of 5% CO2.The spheroid assay was performed using previously reported methods with minor modifications [15], [16].",BPE,Serum,1
PMC4637775A,"Next, 100 ml of HepG2 cells (1 x 106 cells/ml) was applied to the upper chamber and PMA was added at a final concentration of 100, 200, and 500 nM. The lower chamber was filled with 650 ml of DMEM supplemented with 1% fetal bovine serum.",PMA,serum,1
PMC4637775A,"Next, 100 ml of HepG2 cells (1 x 106 cells/ml) was applied to the upper chamber and PMA was added at a final concentration of 100, 200, and 500 nM. The lower chamber was filled with 650 ml of DMEM supplemented with 1% fetal bovine serum.",DMEM,serum,1
PMC4637775A,"Next, 100 ml of HepG2 cells (1 x 106 cells/ml) was applied to the upper chamber and PMA was added at a final concentration of 100, 200, and 500 nM. The lower chamber was filled with 650 ml of DMEM supplemented with 1% fetal bovine serum.",HepG2,serum,1
PMC3655712A,This suggests that Trop-2 forms a complex with a5b1 during trafficking from/to plasma membrane and facilitates localization of a5b1 at the leading edges preventing accumulation in focal adhesions.,Trop-2,plasma,1
PMC5045392A,The only GFP-expressing cells observed in prostate tissue throughout the prostate development and in the adult were those associated to blood vessels surrounding the epithelium.,GFP,blood,-1
PMC3816821A,"Univariate analysis indicated that in addition to SHIP2 expression, tumor differentiation, lymph node metastasis, and TNM stage were also correlated with the life span of HCC patients.",TNM,lymph,1
PMC3816821A,"Univariate analysis indicated that in addition to SHIP2 expression, tumor differentiation, lymph node metastasis, and TNM stage were also correlated with the life span of HCC patients.",SHIP2,lymph,1
PMC3816821A,"Univariate analysis indicated that in addition to SHIP2 expression, tumor differentiation, lymph node metastasis, and TNM stage were also correlated with the life span of HCC patients.",HCC,lymph,1
PMC5494437A,"Many soluble factors (TGFs, IGFs, PDGFs, BMPs, Wnt, SHH) and retinoic acid are found in the cerebral spinal fluid (CSF) that can affect cell proliferation, neurogenesis and oligodendrogenesis [40,42,43].",SHH,CSF,1
PMC3470557A,"[B] Orthogonal sectioning following three-dimensional reconstruction of 150 slices (red lines marked by hollow and solid arrowheads indicate the x-z planes shown below, or to the right of the confocal image, respectively) indicate CD133 expression only along the apical border of the plasma cell membrane [21].",CD133,plasma,1
PMC4631976A,"The overexpression of IGF1 receptors in human colon cancer cells was found to confer resistance to serum-deprivation induced apoptosis, which was associated with increased activation of Akt and an upregulation of Bcl-XL[122].",IGF1,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",IL-2,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",IL-2,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",hRS7,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",hRS7,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",PBL,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",PBL,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",PBL,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",PBL,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",hRS7,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",hRS7,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",ADCC,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",ADCC,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",ADCC,serum,1
PMC3104081A,"While the stimulation of PBL with IL-2 leads to a significantly higher ADCC in the presence of hRS7, it did not significantly increase tumor killing in the absence of hRS7 or in the presence of rituximab (Figure 3, top panel).In order to evaluate the effect of complement on hRS7-mediated ADCC as well as its potential inhibition by physiological IgG serum concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to the ovarian cancer cell lines during standard 5-hours 51Cr-release assays in the presence of PBL.",ADCC,serum,1
PMC4292049A,. tagged the anti-EGFR antibody cetuximab with trans-cyclooctene succinimidyl carbonate and combined with a fluorescent tetrazine probe was able to target A549 cancer cells in serum at 37degC (60).,EGFR,serum,1
PMC4292049A,. tagged the anti-EGFR antibody cetuximab with trans-cyclooctene succinimidyl carbonate and combined with a fluorescent tetrazine probe was able to target A549 cancer cells in serum at 37degC (60).,A549,serum,1
PMC4854811A,"Typically fresh tissue is unavailable in most centers until after 11am, so an overnight digest that includes a controlled freezing step in high serum and DMSO allowing delayed analysis by flow cytometry is a reasonable compromise.",DMSO,serum,1
PMC4306156A,HPLC fingerprinting of hesperidin (A) and Weichang'an (B); HCT-116 cells were treated with different concentrations of Weichang'an (C) and different concentrations of Weichang'an-containing serum (D) in vitro.,HPLC,serum,1
PMC4306156A,HPLC fingerprinting of hesperidin (A) and Weichang'an (B); HCT-116 cells were treated with different concentrations of Weichang'an (C) and different concentrations of Weichang'an-containing serum (D) in vitro.,HCT-116,serum,1
PMC3548755A,"Three representative higher immune-reactive sera of the patients with low-grade glioma, two of the normal volunteers and PBS without serum as background control, were applied in the peptide array (Figure5B-C).",PBS,sera,1
PMC3548755A,"Three representative higher immune-reactive sera of the patients with low-grade glioma, two of the normal volunteers and PBS without serum as background control, were applied in the peptide array (Figure5B-C).",PBS,serum,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",HCC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC5328612A,"The mass is usually confined to the bile duct wall.26,31,32 Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening.33 This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC.34,35 The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.26,36ICC and HCC may occur simultaneously in the same patient or even in the same lesion.37,38 Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC.37 Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation.38,39",ICC,bile,1
PMC3981717A,"Continuous variables including age, tumor size and serum AFP concentration were transformed into categorical variables in all regression analyses.",AFP,serum,-1
PMC3039945A,"However, there is little evidence for correlation between CD29 levels and patient outcome, possibly because up-regulation of CD29 has also been correlated with lymph node metastasis and depth of invasion in CRC [106].",CD29,lymph,1
PMC3039945A,"However, there is little evidence for correlation between CD29 levels and patient outcome, possibly because up-regulation of CD29 has also been correlated with lymph node metastasis and depth of invasion in CRC [106].",CRC,lymph,1
PMC3039945A,"However, there is little evidence for correlation between CD29 levels and patient outcome, possibly because up-regulation of CD29 has also been correlated with lymph node metastasis and depth of invasion in CRC [106].",CD29,lymph,1
PMC3135497A,"Recent studies have shown that serum autoantibodies such as p53 and AFP are useful tumor markers [13-15,27].",AFP,serum,1
PMC3135497A,"Recent studies have shown that serum autoantibodies such as p53 and AFP are useful tumor markers [13-15,27].",p53,serum,1
PMC4306156A,"The human colon cancer cell line HCT-116 was treated with 0, 3%, 6% and 9% WCA decoction filtrate or with 5%, 10% and 20% of serum extracted from rats that received WCA by OG (2 mL/d for 1 wk).",WCA,serum,-1
PMC4306156A,"The human colon cancer cell line HCT-116 was treated with 0, 3%, 6% and 9% WCA decoction filtrate or with 5%, 10% and 20% of serum extracted from rats that received WCA by OG (2 mL/d for 1 wk).",HCT-116,serum,-1
PMC4306156A,"The human colon cancer cell line HCT-116 was treated with 0, 3%, 6% and 9% WCA decoction filtrate or with 5%, 10% and 20% of serum extracted from rats that received WCA by OG (2 mL/d for 1 wk).",WCA,serum,-1
PMC3476529A,Microarray profiles were obtained from six blood and four skin donors.(B) CMAP enrichment scores for skin CD141hi DCs against all human skin and blood monocyte and DC subsets.,CMAP,blood,-1
PMC3476529A,Microarray profiles were obtained from six blood and four skin donors.(B) CMAP enrichment scores for skin CD141hi DCs against all human skin and blood monocyte and DC subsets.,CMAP,blood,-1
PMC3476529A,Microarray profiles were obtained from six blood and four skin donors.(B) CMAP enrichment scores for skin CD141hi DCs against all human skin and blood monocyte and DC subsets.,DC,blood,-1
PMC3476529A,Microarray profiles were obtained from six blood and four skin donors.(B) CMAP enrichment scores for skin CD141hi DCs against all human skin and blood monocyte and DC subsets.,DC,blood,-1
PMC3494970A,Middle and lower panels: canals of Hering are also identified by CEACAM staining which marks the bile canaliculi at the apical pole of hepatocytes.,CEACAM,bile,-1
PMC4673178A,Serum was taken at 5 intervals from 0.5 to 168 h and assayed by ELISA for hRS7 IgG.,hRS7,Serum,1
PMC4673178A,Serum was taken at 5 intervals from 0.5 to 168 h and assayed by ELISA for hRS7 IgG.,ELISA,Serum,1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",TSLP,CSF,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",TSLP,blood,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",CSF,blood,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",GM,CSF,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",GM,blood,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",BMP7,CSF,-1
PMC4685746A,"In addition two recent papers highlight the potential of CD1c+ blood DCs to acquire high levels of langerin and CD1a, forming LC-like cells in vitro in response to TSLP and TGFb [56] or GM-CSF and BMP7 [57].",BMP7,blood,-1
PMC2939361A,"However, the availability of a highly accessible blood test for prostate-specific antigen (PSA) has revolutionized the diagnosis of prostate cancer over the past three decades.",PSA,blood,1
PMC3049439A,"Once these cells were isolated from adult mice and transplanted, they gave rise to all three of the main structures of the skin: all cell lineages of the hair follicle, sebaceous gland and interfollicular epidermis (IFE; Morris et al, 2004).",IFE,hair,1
PMC5045392A,(C) Representative photograph (n  10) showing the typical morphology of blood vessels in Tg 11.5kb-GFP mice with GFP+-vascular smooth muscle cells (a).,GFP,blood,-1
PMC4685746A,"Axl ligand Gas 6 is abundant in the suprabasal epidermis and Axl expression maintains TLR hyporesponsiveness, contributing to the stability of the LC network [48].Inflammation of the epidermis results in increased turnover and trafficking of LCs to draining lymph nodes [49].",TLR,lymph,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",PRDX6,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",PRDX6,sera,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",PRDX6,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",PRDX6,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431-ZDR,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431-ZDR,sera,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431-ZDR,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431-ZDR,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431,sera,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431,serum,1
PMC3959865A,"In addition, we were able to differentiate sera from sensitive and resistant mice as the serum concentrations of EpCAM and PRDX6 were significantly higher in the A431-ZDR serum than in A431 serum (Fig.",A431,serum,1
PMC3548755A,"All of three sera of patients showed the fine specific reaction in two consecutive blots, spot 177 and 178, indicating the C-terminal-end of SH3GL1, comparing with the sera from normal volunteers.",SH3GL1,sera,1
PMC3548755A,"All of three sera of patients showed the fine specific reaction in two consecutive blots, spot 177 and 178, indicating the C-terminal-end of SH3GL1, comparing with the sera from normal volunteers.",SH3GL1,sera,1
PMC3967411A,"D, Parental, shb5 or shb6 PC3-1 cells were serum starved for 24 hr and cell lysates were analyzed by SDS-PAGE and probed with an Ab to b5 or 2A1 Ab to b6.",SDS,serum,1
PMC3967411A,"D, Parental, shb5 or shb6 PC3-1 cells were serum starved for 24 hr and cell lysates were analyzed by SDS-PAGE and probed with an Ab to b5 or 2A1 Ab to b6.",PAGE,serum,1
PMC3967411A,"D, Parental, shb5 or shb6 PC3-1 cells were serum starved for 24 hr and cell lysates were analyzed by SDS-PAGE and probed with an Ab to b5 or 2A1 Ab to b6.",PC3,serum,1
PMC3110957A,"As expected, the expression of genes associated with bile duct, stellate, or progenitor cells were associated with the CD45-/11b-/31- NPC population rather than hepatocytes, whether isolated from untreated (Fig.",NPC,bile,1
PMC4707334A,"In many studies, topography of MSCs in the BM environment is introduced as the cell lining the outer surfaces of blood vessels and perivascular cells and these cells express CD146 antigen [8, 16, 17].",CD146,blood,-1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",GM,CSF,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",GM,blood,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",RPMI,CSF,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",RPMI,blood,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",CSF,blood,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",IL-4,CSF,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",IL-4,blood,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",CD14,CSF,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",CD14,blood,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",FCS,CSF,1
PMC5538449A,"Clusters were purified by means of 1 g of sedimentation, as previously described.23 For generating moDCs, purified CD14+ blood monocytes were cultured in RPMI medium supplemented with GM-CSF (100 ng/mL) and IL-4 (25 ng/mL) in the presence of 10% FCS for 7 days.",FCS,blood,1
PMC4202120B,"Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes.",BPX-201,lymph,1
PMC4473102A,"Graphical representation of the distributions of osteopontin (A) and osteoactivin (B) serum levels in: 60 psoriatic arthritis (PsA) patients, 60 rheumatoid arthritis (RA) patients, 60 ankylosing spondylitis (AS) patients and in 60 normal subjects (NS).",NS,serum,1
PMC4473102A,"Graphical representation of the distributions of osteopontin (A) and osteoactivin (B) serum levels in: 60 psoriatic arthritis (PsA) patients, 60 rheumatoid arthritis (RA) patients, 60 ankylosing spondylitis (AS) patients and in 60 normal subjects (NS).",AS,serum,1
PMC5467782A,"In this study, we investigated whether TGF-b1 can induce EMT in both CSCs and non-CSCs during the initial stage of tumor metastasis in NSCLC.For this purpose, we sorted a CD133+/CD326+ cell subpop-ulation from A549 cells cultured in serum-free medium.",A549,serum,1
PMC5467782A,"In this study, we investigated whether TGF-b1 can induce EMT in both CSCs and non-CSCs during the initial stage of tumor metastasis in NSCLC.For this purpose, we sorted a CD133+/CD326+ cell subpop-ulation from A549 cells cultured in serum-free medium.",TGF,serum,1
PMC5467782A,"In this study, we investigated whether TGF-b1 can induce EMT in both CSCs and non-CSCs during the initial stage of tumor metastasis in NSCLC.For this purpose, we sorted a CD133+/CD326+ cell subpop-ulation from A549 cells cultured in serum-free medium.",EMT,serum,1
PMC5467782A,"In this study, we investigated whether TGF-b1 can induce EMT in both CSCs and non-CSCs during the initial stage of tumor metastasis in NSCLC.For this purpose, we sorted a CD133+/CD326+ cell subpop-ulation from A549 cells cultured in serum-free medium.",CD326,serum,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",GC,ascites,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",AREG,ascites,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",AREG,ascites,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",CXCR4,ascites,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",GC,ascites,1
PMC5363540A,"High concentrations of AREG in malignant ascites of GC patients also have been found to play an important role in the development of peritoneal carcinomatosis via interactions with CXCL12/CXCR4, suggesting that the AREG/CXCL12/CXCR4 axis could be a potential therapeutic target for peritoneal carcinomatosis of GC [31].",CXCR4,ascites,1
PMC4011766A,"In brain blood vessels of glioma patients, MAZ protein expression is also elevated, leading to enhanced VEGF signaling that supposedly shuts down miR-125b expression in a feedback loop [18], suggesting that miR-125b acts as a tumor suppressor.",MAZ,blood,-1
PMC4011766A,"In brain blood vessels of glioma patients, MAZ protein expression is also elevated, leading to enhanced VEGF signaling that supposedly shuts down miR-125b expression in a feedback loop [18], suggesting that miR-125b acts as a tumor suppressor.",VEGF,blood,-1
PMC3326009A,"In previous studies of prostate S/P cells, Trop2, which has an almost identical pattern of expression as Epcam (Trop1) within prostate epithelial cells, was utilized to separate prostate epithelial from stromal and blood cells [1].",Trop2,blood,-1
PMC3326009A,"In previous studies of prostate S/P cells, Trop2, which has an almost identical pattern of expression as Epcam (Trop1) within prostate epithelial cells, was utilized to separate prostate epithelial from stromal and blood cells [1].",Trop1,blood,-1
PMC4118235A,"Subsequently, pleural sections were blocked for 1 hr at 37degC in PBS blocking buffer (10% normal goat serum) to inhibit non-specific antibody binding.",PBS,serum,1
PMC4473102A,"Serum levels of osteoactivin/GPNMB [29] were detected using a commercially available ELISA kit (Biorbyt Ltd, Cambridge, UK).",ELISA,Serum,1
PMC4473102A,"Serum levels of osteoactivin/GPNMB [29] were detected using a commercially available ELISA kit (Biorbyt Ltd, Cambridge, UK).",GPNMB,Serum,1
PMC4344740A,"The blotted proteins were probed with an autologous plasma by which the protein was identified or with goat anti-GST polyclonal antibody (Rockland, Gilbertsville, PA).",GST,plasma,1
PMC4344740A,"The blotted proteins were probed with an autologous plasma by which the protein was identified or with goat anti-GST polyclonal antibody (Rockland, Gilbertsville, PA).",PA,plasma,1
PMC4673473A,Serum alanine aminotransferase levels were decreased in the hepatocyte-like cell transfer group 2 days after final treatment with CCl4 compared to the vehicle-treated controls (Figure 5a).,CCl4,Serum,1
PMC4306156A,"There was no significant difference in serum CEA levels among the CON (43.040 +- 11.273 mg/L), WCA (34.282 +- 14.731 mg/L), and 5-FU (35.462 +- 11.022 mg/L) groups (P = 0.122).",CEA,serum,1
PMC4306156A,"There was no significant difference in serum CEA levels among the CON (43.040 +- 11.273 mg/L), WCA (34.282 +- 14.731 mg/L), and 5-FU (35.462 +- 11.022 mg/L) groups (P = 0.122).",FU,serum,1
PMC4306156A,"There was no significant difference in serum CEA levels among the CON (43.040 +- 11.273 mg/L), WCA (34.282 +- 14.731 mg/L), and 5-FU (35.462 +- 11.022 mg/L) groups (P = 0.122).",CON,serum,1
PMC4306156A,"There was no significant difference in serum CEA levels among the CON (43.040 +- 11.273 mg/L), WCA (34.282 +- 14.731 mg/L), and 5-FU (35.462 +- 11.022 mg/L) groups (P = 0.122).",WCA,serum,1
PMC5363540A,AREG is the shedding ectodomain of a 252 amino acid transmembrane precursor (pre-AREG) that is secreted into the blood or cellular microenvironment [8].,AREG,blood,-1
PMC5363540A,AREG is the shedding ectodomain of a 252 amino acid transmembrane precursor (pre-AREG) that is secreted into the blood or cellular microenvironment [8].,AREG,blood,-1
PMC3934101A,"Red blood cells in prostate primary cell suspensions were lysed in 2ml RBC lysis buffer (eBioscience, San Diego, CA) at room temperature for 5 minutes.",San,blood,-1
PMC3934101A,"Red blood cells in prostate primary cell suspensions were lysed in 2ml RBC lysis buffer (eBioscience, San Diego, CA) at room temperature for 5 minutes.",RBC,blood,-1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",HLA,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",NaN3,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",BSA,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",PBS,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",CD14,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",CD83,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",MoP9,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",L203,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",HLA,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",CD86,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",FITC,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",HI149,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",FITC,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",APC,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",CD70,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",Ki-24,serum,1
PMC5380941A,"Cells were washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% NaN3 and incubated for 30 min at 4 degC in the presence of the appropriate dilutions of fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 (FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 (PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), HLA-ABC (FITC, clone W6/32, ImmunoTools, Friesoythe, Germany) CD83 (PE, clone HB15e, Beckman Coulter Immunoteck, Bubenec, Czeck Republic), or the corresponding isotype-matched control mAbs (Becton Dickinson).",ABC,serum,1
PMC3581970A,"Using these assays, we investigated 103 cases of CLL, as well as 5 benign lymph node hyperplasias and purified lymphocyte subpopulations, germinal center B cells, naive B cells, memory B cells, and T cells purified from hyperplastic tonsils.",CLL,lymph,-1
PMC3581970A,"Using these assays, we investigated 103 cases of CLL, as well as 5 benign lymph node hyperplasias and purified lymphocyte subpopulations, germinal center B cells, naive B cells, memory B cells, and T cells purified from hyperplastic tonsils.",T,lymph,-1
PMC4712003A,"In cells incubated with levels of DHT (10 nM) equivalent to those present in the serum, the cells not only maintained the expression of PTGS1, but also formed spheroid acini (Fig.",PTGS1,serum,-1
PMC4712003A,"In cells incubated with levels of DHT (10 nM) equivalent to those present in the serum, the cells not only maintained the expression of PTGS1, but also formed spheroid acini (Fig.",DHT,serum,-1
PMC5085135A,"We found and confirmed that TRIM29 expression increased in NPC cells and tissues with high metastatic potentials, and high TRIM29 expression were correlated with lymph node and distant metastasis of PCR.",NPC,lymph,1
PMC5085135A,"We found and confirmed that TRIM29 expression increased in NPC cells and tissues with high metastatic potentials, and high TRIM29 expression were correlated with lymph node and distant metastasis of PCR.",TRIM29,lymph,1
PMC5085135A,"We found and confirmed that TRIM29 expression increased in NPC cells and tissues with high metastatic potentials, and high TRIM29 expression were correlated with lymph node and distant metastasis of PCR.",TRIM29,lymph,1
PMC5085135A,"We found and confirmed that TRIM29 expression increased in NPC cells and tissues with high metastatic potentials, and high TRIM29 expression were correlated with lymph node and distant metastasis of PCR.",PCR,lymph,1
PMC5414739A,"Even more striking, PRL was shown to regulate human hair growth but its ultimate effects were shown to be opposite depending on the gender and/or the location of the hair follicle within the body (45).",PRL,hair,-1
PMC5414739A,"Even more striking, PRL was shown to regulate human hair growth but its ultimate effects were shown to be opposite depending on the gender and/or the location of the hair follicle within the body (45).",PRL,hair,-1
PMC4685746A,"First, the puzzling report of CD1a+ 'LC precursors' in human blood [59] is reconciled by the knowledge that the antibody clone used to detect CD1a in this study is actually specific for CD1c, thus correctly identifying the CD1c+ DC as a potential LC precursor [60].",DC,blood,-1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",PCR,serum,1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",FU,serum,1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",mRNA,serum,1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",CEA,serum,1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",WCA,serum,1
PMC4306156A,"However, serum CEA levels in the WCA + 5-FU group (31.263 +- 7.421 mg/L) were significantly lower than that in the CON group (P = 0.023).To begin to investigate the molecular mechanisms underlying metastasis in our model, we measured mRNA expression of b-catenin, a Wnt pathway regulator of cell-cell adhesion, by real-time RT-PCR.",CON,serum,1
PMC3566310A,"Finally, serum FGF7 levels were found to be increased in human patients with liver diseases such as fulminant hepatic failure and acute hepatitis (Fig.",FGF7,serum,1
PMC4606116A,These 109 proteins represent a valuable reservoir for further verification study to find novel blood markers for CRC.,CRC,blood,-1
PMC3476529A,", we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail (Figure 5 and data not shown).",CD40,CSF,1
PMC3476529A,", we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail (Figure 5 and data not shown).",LPS,CSF,1
PMC3476529A,", we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail (Figure 5 and data not shown).",CL075,CSF,1
PMC3476529A,", we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail (Figure 5 and data not shown).",TLR8,CSF,1
PMC3476529A,", we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail (Figure 5 and data not shown).",GM,CSF,1
PMC2800362A,"For tissue recombination and renal grafting, prostate tissues (corresponding to the combined anterior, dorsolateral, and ventral lobes) were dissected and minced to small clumps, followed by enzymatic dissociation with 0.2% collagenase I (Invitrogen) in DMEM media with 10% fetal bovine serum for 90 min.",DMEM,serum,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",LPS,blood,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",TNF,blood,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",TLR3,blood,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",IFN,blood,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",CD141,blood,1
PMC3476529A,"In blood, only CD141+ DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).",IFN,blood,1
PMC4606116A,We integrated these 109 proteins with the Human Protein Atlas (HPA) [23] and Human Plasma Proteome Project (HPPP) [24] datasets and then applied stringent literature search to narrow down candidate list.,HPA,Plasma,1
PMC4606116A,We integrated these 109 proteins with the Human Protein Atlas (HPA) [23] and Human Plasma Proteome Project (HPPP) [24] datasets and then applied stringent literature search to narrow down candidate list.,HPPP,Plasma,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",FBS,blood,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",FACS,blood,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",PBS,blood,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",NaN3,blood,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",FACS,blood,1
PMC3912035A,"Following removal of the secondary antibody, blots were washed, and the specific bands were detected by chemiluminescence enhanced chemiluminescence kit (Santa Cruz).Trop-2 surface expressionwas analyzed by flow cytometry as Zhang et al. described previously.33 Briefly, lung cancer cells were harvested and washed with FACS buffer (PBS with 5% FBS buffer and 0.1% NaN3) for twice and then incubated with PE-anti human Trop-2 or isotype control antibodies for 30 min at 4 degC. Cells were then washed with FACS buffer and analyzed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson).Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep density gradient centrifugation (Accurate Chemical) from healthy human donors.",Trop-2,blood,1
PMC5312042A,"Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts, which ultimately progresses to biliary cirrhosis.1 Patients with PSC are at high risk of developing cholangiocarcinoma (10-year cumulative risk of 7%-9%).",PSC,bile,-1
PMC5312042A,"Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts, which ultimately progresses to biliary cirrhosis.1 Patients with PSC are at high risk of developing cholangiocarcinoma (10-year cumulative risk of 7%-9%).",PSC,bile,-1
PMC4251850A,"Additionally, we found this protein in the ascites of CRC patients.",CRC,ascites,1
PMC5042010A,COSMIC identified SNV from matched tumor samples derived from blood or biopsyThe ctcDNA and ccfDNA samples were analyzed using a case-control model with a limit of detection of 1%.,COSMIC,blood,-1
PMC5042010A,COSMIC identified SNV from matched tumor samples derived from blood or biopsyThe ctcDNA and ccfDNA samples were analyzed using a case-control model with a limit of detection of 1%.,SNV,blood,-1
PMC4621003A,"ELISA was performed using 1:10,000 diluted serum collected 1 week post boost from groups of vaccinated mice (n = 15).View larger versionFigure 4.",ELISA,serum,1
PMC4165776A,Bovine serum albumin (BSA) was obtained from Bovogen Biologicals Pty.,BSA,serum,1
PMC4183706A,"In this regard, we note that our culture conditions are distinct from conditions employed in other organoid studies16, 22, 23, 57 that utilize defined media containing EGF, the BMP inhibitor Noggin, and the canonical Wnt pathway activator R-spondin, in contrast with our serum-containing media.",BMP,serum,1
PMC4183706A,"In this regard, we note that our culture conditions are distinct from conditions employed in other organoid studies16, 22, 23, 57 that utilize defined media containing EGF, the BMP inhibitor Noggin, and the canonical Wnt pathway activator R-spondin, in contrast with our serum-containing media.",EGF,serum,1
PMC4673473A,"Thus, the initial in vitro culture with MS resulted in extensive proliferation and endodermal differentiation of bone marrow cells, and culture with LCM and HGF induced hepatocyte precursor and hepatocyte-like cell differentiation and reduced their in vitro proliferative capacity.",LCM,bone marrow,1
PMC4673473A,"Thus, the initial in vitro culture with MS resulted in extensive proliferation and endodermal differentiation of bone marrow cells, and culture with LCM and HGF induced hepatocyte precursor and hepatocyte-like cell differentiation and reduced their in vitro proliferative capacity.",HGF,bone marrow,1
PMC3929731A,"B, Levels of free BPA and BPA-G by direct quantitation in sera of individual mice treated with vehicle, 100 or 250 mg BPA/kg BW.",BPA,sera,1
PMC3929731A,"B, Levels of free BPA and BPA-G by direct quantitation in sera of individual mice treated with vehicle, 100 or 250 mg BPA/kg BW.",BPA,sera,1
PMC3929731A,"B, Levels of free BPA and BPA-G by direct quantitation in sera of individual mice treated with vehicle, 100 or 250 mg BPA/kg BW.",BPA,sera,1
PMC5042010A,COSMIC identified SNV from matched tumor samples derived from blood or biopsyAlterations are counted in all clinical samples.,COSMIC,blood,-1
PMC5042010A,COSMIC identified SNV from matched tumor samples derived from blood or biopsyAlterations are counted in all clinical samples.,SNV,blood,-1
PMC4882422A,"Furthermore, macrophage depletion ameliorated histological improvement of steatohepatitis, including liver fibrosis examined on Sirius red staining, and lowered the serum GPT and the gene expression levels of profibrogenic factors (Fig. 9A).",GPT,serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,HER-2,Serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,RPMI,Serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,GPI,Serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,CHO,Serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,K1,Serum,1
PMC4621003A,CHO-K1 cell transfectants expressing either full-length transmembrane HER-2 or GPI-HER-2 were maintained in RPMI 1640 and 10% Cosmic Calf Serum (Invitrogen) containing 10 mg/ml Blasticidin (Invitrogen).,HER-2,Serum,1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",PRL,blood,-1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",PRL,bone marrow,1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",MSC,blood,-1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",MSC,bone marrow,1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",MSC,blood,-1
PMC5414739A,"The authors concluded that the observed actions of PRL probably were produced on a more restricted population of hippocampal precursor cells rather than on NSCs (114), in agreement with the report by Mak and Weiss (113).MSCs were isolated initially from the bone marrow, but later, it was demonstrated that MSC or MSC-like cells also were present in other tissues, such as adipose tissue, umbilical cord blood, or even muscle (115).",MSC,bone marrow,1
PMC4596896A,"Several examples of site specifically conjugated ADCs, using antibodies containing engineered cysteines or the non-natural amino acid, p-acetyl phenyalanine (pAF), have reported improved in vitro and in vivo serum stability, improved pharmacokinetic properties, comparable anti-tumor efficacy and improved toxicology profiles as compared to the conventional ADCs (55,66,67).",pAF,serum,1
PMC4596896A,"Cytotoxic drugs conjugated to pAF via an oxime bond are reported to have improved serum stability when compared to cytotoxic drugs conjugated to thiols via maleimide (10,55).One cysteine engineered site specifically conjugated ADC, SGN-CD33A, is currently in phase I clinical development.",CD33A,serum,-1
PMC4596896A,"Cytotoxic drugs conjugated to pAF via an oxime bond are reported to have improved serum stability when compared to cytotoxic drugs conjugated to thiols via maleimide (10,55).One cysteine engineered site specifically conjugated ADC, SGN-CD33A, is currently in phase I clinical development.",pAF,serum,-1
PMC4596896A,"Cytotoxic drugs conjugated to pAF via an oxime bond are reported to have improved serum stability when compared to cytotoxic drugs conjugated to thiols via maleimide (10,55).One cysteine engineered site specifically conjugated ADC, SGN-CD33A, is currently in phase I clinical development.",ADC,serum,-1
PMC4596896A,"Cytotoxic drugs conjugated to pAF via an oxime bond are reported to have improved serum stability when compared to cytotoxic drugs conjugated to thiols via maleimide (10,55).One cysteine engineered site specifically conjugated ADC, SGN-CD33A, is currently in phase I clinical development.",SGN,serum,-1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,Olfm4,plasma,1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,Olfm4,blood,-1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,OLFM4,plasma,1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,OLFM4,blood,-1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,mRNA,plasma,1
PMC5057043A,OLFM4 protein exists in the granules of mature neutrophils while its mRNA expression shuts down.20 It is possible that Olfm4 has its role in colon stromal myeloid cells or as a secreted protein in blood plasma.,mRNA,blood,-1
PMC3250983A,The level of 125I-labeled B-B4 mAb in the blood reflected the serum stability of radiolabeled B-B4 mAb.,B4,blood,-1
PMC3250983A,The level of 125I-labeled B-B4 mAb in the blood reflected the serum stability of radiolabeled B-B4 mAb.,B4,serum,1
PMC3250983A,The level of 125I-labeled B-B4 mAb in the blood reflected the serum stability of radiolabeled B-B4 mAb.,B4,blood,-1
PMC3250983A,The level of 125I-labeled B-B4 mAb in the blood reflected the serum stability of radiolabeled B-B4 mAb.,B4,serum,1
PMC4306156A,"Medium containing 0, 3%, 6% and 9% WCA decoction or 5%, 10% and 20% of serum extracted from rats that received WCA by oral gavage (OG) (2 mL/d for 1 wk) was added to each well (100 mL/well).",WCA,serum,1
PMC4306156A,"Medium containing 0, 3%, 6% and 9% WCA decoction or 5%, 10% and 20% of serum extracted from rats that received WCA by oral gavage (OG) (2 mL/d for 1 wk) was added to each well (100 mL/well).",WCA,serum,1
PMC4661894A,The first evidence confirming the hypothesis of the existence of cancer stem cells derives from the 1990s and is based on the study of blood diseases such as acute myeloid leukemia (AML) [8].,AML,blood,-1
PMC4156178A,Serological identification of TACSTD2 in patients with esophageal squamous cell carcinoma suggested that the TACSTD2 antigen may be a valuable serum tumor marker (20).,TACSTD2,serum,1
PMC4156178A,Serological identification of TACSTD2 in patients with esophageal squamous cell carcinoma suggested that the TACSTD2 antigen may be a valuable serum tumor marker (20).,TACSTD2,serum,1
PMC3548755A,C6 glioma cells and 9 L gliosarcoma cells were originally obtained from ATCC and maintained in Dulbecco's modified Eagle medium (D-MEM) supplemented with 10% fetal calf serum in a humidified atmosphere of 5% CO2.,ATCC,serum,1
PMC3548755A,C6 glioma cells and 9 L gliosarcoma cells were originally obtained from ATCC and maintained in Dulbecco's modified Eagle medium (D-MEM) supplemented with 10% fetal calf serum in a humidified atmosphere of 5% CO2.,MEM,serum,1
PMC3548755A,C6 glioma cells and 9 L gliosarcoma cells were originally obtained from ATCC and maintained in Dulbecco's modified Eagle medium (D-MEM) supplemented with 10% fetal calf serum in a humidified atmosphere of 5% CO2.,C6,serum,1
PMC3548755A,C6 glioma cells and 9 L gliosarcoma cells were originally obtained from ATCC and maintained in Dulbecco's modified Eagle medium (D-MEM) supplemented with 10% fetal calf serum in a humidified atmosphere of 5% CO2.,CO2,serum,1
PMC4473102A,"In addition, as observed in bone fracture in animal models, OA is able to accelerate bone repair [175].We have found that osteopontin is elevated also in the sera of subjects with RA and AS, whereas high levels of osteoactivin are present only in the sera of PsA patients.",AS,sera,1
PMC4473102A,"In addition, as observed in bone fracture in animal models, OA is able to accelerate bone repair [175].We have found that osteopontin is elevated also in the sera of subjects with RA and AS, whereas high levels of osteoactivin are present only in the sera of PsA patients.",AS,sera,-1
PMC4251850A,b) Ascites derived from PDAC and CRC (colorectal carcinoma) patients and the conditioned medium (CM) of primary cancer cells (isolated from ascites) were used to prepare the EV samples.,PDAC,Ascites,1
PMC4251850A,b) Ascites derived from PDAC and CRC (colorectal carcinoma) patients and the conditioned medium (CM) of primary cancer cells (isolated from ascites) were used to prepare the EV samples.,PDAC,ascites,1
PMC4251850A,b) Ascites derived from PDAC and CRC (colorectal carcinoma) patients and the conditioned medium (CM) of primary cancer cells (isolated from ascites) were used to prepare the EV samples.,CRC,Ascites,1
PMC4251850A,b) Ascites derived from PDAC and CRC (colorectal carcinoma) patients and the conditioned medium (CM) of primary cancer cells (isolated from ascites) were used to prepare the EV samples.,CRC,ascites,1
PMC4606116A,"Our present study showed that BST2 levels were significantly elevated in both CRC tissues and plasma specimens, implicating the potential of BST2 as a novel CRC biomarker.",CRC,plasma,1
PMC4606116A,"Our present study showed that BST2 levels were significantly elevated in both CRC tissues and plasma specimens, implicating the potential of BST2 as a novel CRC biomarker.",BST2,plasma,1
PMC4606116A,"Our present study showed that BST2 levels were significantly elevated in both CRC tissues and plasma specimens, implicating the potential of BST2 as a novel CRC biomarker.",CRC,plasma,1
PMC4606116A,"Our present study showed that BST2 levels were significantly elevated in both CRC tissues and plasma specimens, implicating the potential of BST2 as a novel CRC biomarker.",BST2,plasma,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",KLF4-IRES,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",IL-4,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",RUNX3,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",CD11b,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",GM,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",E2,CSF,1
PMC5538449A,"Furthermore, RUNX3 reduced percentages of CD11b+CD209+CD1a+ p-moDCs generated in the presence of GM-CSF plus IL-4 in favor of CD11b-CD209-CD1a+CD207+ p-LCs (Fig 6, E, and see Fig E2, B).CD34+ cells were transduced with KLF4-IRES-GFP or empty control vector and induced to differentiate into p-LCs or monocytes (schematically shown in Fig 2, C).",GFP,CSF,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",GST,serum,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",GST,serum,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",RPA2,serum,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",RPA2,serum,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",GST,serum,1
PMC4344740A,"After normalization by the standards, the levels of serum antibody were calculated by subtracting the absorbance of serum against GST from that against GST-tagged antigens as described previously [11].Three epitope sites in RPA2 protein were predicted using the program ProPred (http://www.imtech.res.in/raghava/propred/).",GST,serum,1
PMC4687932A,"However, the fact that the number of dual-positive events is also remarkably high within the blood of healthy donors [84], and oddly, that a high proportion of those events could be assigned to patient samples with corresponding low EpCAMpos CTC numbers, underscores the demand for further investigations with respect to their clinical significance.",CTC,blood,-1
PMC5225197A,The serum concentration of LJM716 was measured using a validated ELISA.,LJM716,serum,1
PMC5225197A,The serum concentration of LJM716 was measured using a validated ELISA.,ELISA,serum,1
PMC3249013A,"Significant levels of BPA have been found in the urine of 93% of US individuals (Calafat et al., 2008) with highest levels found in infants and children (Calafat et al.",BPA,urine,1
PMC4711826A,Note that not only most hepatocytes but also most cholangiocytes in mutant liver showed Mob1a deletion. (D) Quantitation of total bilirubin concentrations in the serum of control and LMob1DKO mice at P14.,P14,serum,1
PMC4483763A,"The non-canonical Wnt pathway is also implicated in biliary development, as disruption in the Wnt/planar cell polarity (PCP) pathway impairs bile duct formation (Cui et al.,",PCP,bile,1
PMC3476529A,"CD1c+ DCs showed lower expression of FLT3 and CLEC9A and intermediate levels of M-CSFR and CX3CR1, compared with CD141hi DCs (Figure 2D).The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations (Figure 2E) and scanning electron microscopy (SEM) (Figure 2F).",CX3CR1,blood,-1
PMC3476529A,"CD1c+ DCs showed lower expression of FLT3 and CLEC9A and intermediate levels of M-CSFR and CX3CR1, compared with CD141hi DCs (Figure 2D).The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations (Figure 2E) and scanning electron microscopy (SEM) (Figure 2F).",FLT3,blood,-1
PMC3476529A,"CD1c+ DCs showed lower expression of FLT3 and CLEC9A and intermediate levels of M-CSFR and CX3CR1, compared with CD141hi DCs (Figure 2D).The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations (Figure 2E) and scanning electron microscopy (SEM) (Figure 2F).",CSFR,blood,-1
PMC3476529A,"CD1c+ DCs showed lower expression of FLT3 and CLEC9A and intermediate levels of M-CSFR and CX3CR1, compared with CD141hi DCs (Figure 2D).The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations (Figure 2E) and scanning electron microscopy (SEM) (Figure 2F).",CLEC9A,blood,-1
PMC3476529A,"CD1c+ DCs showed lower expression of FLT3 and CLEC9A and intermediate levels of M-CSFR and CX3CR1, compared with CD141hi DCs (Figure 2D).The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations (Figure 2E) and scanning electron microscopy (SEM) (Figure 2F).",SEM,blood,1
PMC3476529A,"All tissue DCs, especially CD141hi DCs, expressed an activated phenotype compared with the blood (Figures 3A and 3B) and acquired high levels of CCR7 while downregulating the skin-homing molecule cutaneous lymphocyte antigen (CLA, also known as P-selectin glycoprotein ligand; PSGL-1) (Figures 3A and 3B).Careful analysis of skin CD141hi DCs shows two distinct populations of cells with differential expression of CD1a and CD1c (Figure 3C).",CCR7,blood,-1
PMC3476529A,"All tissue DCs, especially CD141hi DCs, expressed an activated phenotype compared with the blood (Figures 3A and 3B) and acquired high levels of CCR7 while downregulating the skin-homing molecule cutaneous lymphocyte antigen (CLA, also known as P-selectin glycoprotein ligand; PSGL-1) (Figures 3A and 3B).Careful analysis of skin CD141hi DCs shows two distinct populations of cells with differential expression of CD1a and CD1c (Figure 3C).",CLA,blood,-1
PMC3476529A,"All tissue DCs, especially CD141hi DCs, expressed an activated phenotype compared with the blood (Figures 3A and 3B) and acquired high levels of CCR7 while downregulating the skin-homing molecule cutaneous lymphocyte antigen (CLA, also known as P-selectin glycoprotein ligand; PSGL-1) (Figures 3A and 3B).Careful analysis of skin CD141hi DCs shows two distinct populations of cells with differential expression of CD1a and CD1c (Figure 3C).",PSGL-1,blood,-1
PMC4143989A,"Maturation and upregulation of co- stimulatory molecules CD80, CD86, and CD40 following antigen uptake and processing within APCs promotes their migration to lymph nodes where they can activate T cells.",CD86,lymph,1
PMC4143989A,"Maturation and upregulation of co- stimulatory molecules CD80, CD86, and CD40 following antigen uptake and processing within APCs promotes their migration to lymph nodes where they can activate T cells.",CD40,lymph,1
PMC4143989A,"Maturation and upregulation of co- stimulatory molecules CD80, CD86, and CD40 following antigen uptake and processing within APCs promotes their migration to lymph nodes where they can activate T cells.",CD80,lymph,1
PMC4143989A,"Maturation and upregulation of co- stimulatory molecules CD80, CD86, and CD40 following antigen uptake and processing within APCs promotes their migration to lymph nodes where they can activate T cells.",T,lymph,1
PMC2441949A,"To determine whether expression levels of molecular markers might correlate with lymph node metastases, RNA was isolated from FFPE primary tumour sections as described in Materials and Methods and analysed for the expression of the 14 cancer-associated genes listed in Table 1.",FFPE,lymph,1
PMC2441949A,"To determine whether expression levels of molecular markers might correlate with lymph node metastases, RNA was isolated from FFPE primary tumour sections as described in Materials and Methods and analysed for the expression of the 14 cancer-associated genes listed in Table 1.",RNA,lymph,1
PMC2441949A,"For ordinal variables (e.g. T-stage, pathologic stage), we also used t-test to compare mean levels across lymph node and expression categories due to concern over sparseness.",T,lymph,1
PMC2441949A,We conclude from this experiment that the set of 14 genes is highly overexpressed in metastatic CRC and hypothesise that one or more genes in this set may be prognostic for lymph node metastases.,CRC,lymph,1
PMC3476529A,Comparison of skin CD141hi DCs with blood CD141+ DCs suggested a potential developmental relationship between the blood and skin.,CD141,blood,-1
PMC3476529A,Comparison of skin CD141hi DCs with blood CD141+ DCs suggested a potential developmental relationship between the blood and skin.,CD141,blood,-1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,D1,lymph,1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,D1,lymph,1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,AEG,lymph,1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,AEG,lymph,1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,D2,lymph,1
PMC5193343A,A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)See full tableTable 1.,D2,lymph,1
PMC4687932A,Nonspecific binding to the AL substrate itself (pure spotting buffer) as well as to an isotype control (mouse) or bovine serum albumin could not be observed at any time on single marker arrays (S1 Fig).,S1,serum,-1
PMC3548755A,"To identify glioma-associated antigens, a total of 5 x 106 cDNA clones were screened using sera from 48 patients with glioma and 57 reacting clones were isolated from 19 of 48 sera. DNA sequence analysis and",DNA,sera,-1
PMC3548755A,"To identify glioma-associated antigens, a total of 5 x 106 cDNA clones were screened using sera from 48 patients with glioma and 57 reacting clones were isolated from 19 of 48 sera. DNA sequence analysis and",DNA,sera,1
PMC3548755A,"To identify glioma-associated antigens, a total of 5 x 106 cDNA clones were screened using sera from 48 patients with glioma and 57 reacting clones were isolated from 19 of 48 sera. DNA sequence analysis and",cDNA,sera,-1
PMC3548755A,"To identify glioma-associated antigens, a total of 5 x 106 cDNA clones were screened using sera from 48 patients with glioma and 57 reacting clones were isolated from 19 of 48 sera. DNA sequence analysis and",cDNA,sera,1
PMC4329473A,"Since the symmetry between fetal development and adult regeneration has been described and with the knowledge that the ductular reaction is invariably accompanied by inflammatory cells recruited from the bone marrow, the re-expression of EpCAM on HSPC descendants in adult liver might also reflect a particular relationship between the two cellular compartments.",HSPC,bone marrow,1
PMC4329473A,"(7) has demonstrated that the exogenous application of mature bone marrow-derived macrophages is sufficient to induce HSPC proliferation in the absence of any underlying disease pathology, once again, reiterating that inflammation and epithelial repair are intrinsically linked.",HSPC,bone marrow,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",USPC,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-6,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-6,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-2,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-2,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-2,serum,1
PMC3128671A,"As representatively demonstrated in Figure 5 for USPC ARK-2, in two primary cell lines (i.e., USPC ARK-2 and USPC ARK-6), no significant decrease in killing after incubation with serum compared to incubation without serum was noted.",ARK-2,serum,1
PMC3476529A,CD3+ T cells were isolated from whole blood to 95% purity with Rosette-Sep isolation kit (StemCell Technologies).,T,blood,-1
PMC3476529A,CD3+ T cells were isolated from whole blood to 95% purity with Rosette-Sep isolation kit (StemCell Technologies).,CD3,blood,-1
PMC5225197A,"PK parameters (maximum observed serum concentration after drug administration [Cmax], time to Cmax [Tmax], area under the curve [AUC], etc.) were determined by a non-compartmental method with a lower limit of quantification of 150 ng/mL. Serum immunogenicity was assessed using an anti-LJM716 antibody test.",AUC,serum,1
PMC5225197A,"PK parameters (maximum observed serum concentration after drug administration [Cmax], time to Cmax [Tmax], area under the curve [AUC], etc.) were determined by a non-compartmental method with a lower limit of quantification of 150 ng/mL. Serum immunogenicity was assessed using an anti-LJM716 antibody test.",AUC,Serum,1
PMC5225197A,"PK parameters (maximum observed serum concentration after drug administration [Cmax], time to Cmax [Tmax], area under the curve [AUC], etc.) were determined by a non-compartmental method with a lower limit of quantification of 150 ng/mL. Serum immunogenicity was assessed using an anti-LJM716 antibody test.",LJM716,serum,1
PMC5225197A,"PK parameters (maximum observed serum concentration after drug administration [Cmax], time to Cmax [Tmax], area under the curve [AUC], etc.) were determined by a non-compartmental method with a lower limit of quantification of 150 ng/mL. Serum immunogenicity was assessed using an anti-LJM716 antibody test.",LJM716,Serum,1
PMC3548755A,The serum used for SEREX screening was excluded.,SEREX,serum,1
PMC5059479A,"Sections were incubated in citrate buffer (pH 6) and 3% H2O2, followed by blocking with 10% normal goat serum (Vector Labs), incubated with primary antibodies diluted in 10% normal goat serum.",H2O2,serum,1
PMC5059479A,"Sections were incubated in citrate buffer (pH 6) and 3% H2O2, followed by blocking with 10% normal goat serum (Vector Labs), incubated with primary antibodies diluted in 10% normal goat serum.",H2O2,serum,1
PMC3548755A,"First screening test (A) and the individual validation test (B), revealed the significant higher levels of autologous antibody against SH3GL1 in low-grade glioma patients, than healthy donors (P = 0.045 and 0.0189).Using a recombinant antigen protein, ELISA was performed on sera from 32 patients with high-grade glioma, 40 with low-grade glioma and 56 healthy volunteers, which were collected between 1998 and 2005 in Chiba University Hospital.",SH3GL1,sera,1
PMC3548755A,"First screening test (A) and the individual validation test (B), revealed the significant higher levels of autologous antibody against SH3GL1 in low-grade glioma patients, than healthy donors (P = 0.045 and 0.0189).Using a recombinant antigen protein, ELISA was performed on sera from 32 patients with high-grade glioma, 40 with low-grade glioma and 56 healthy volunteers, which were collected between 1998 and 2005 in Chiba University Hospital.",ELISA,sera,1
PMC3548755A,The increasing levels of antibodies to SH3GL1 in sera of the patients with low-grade glioma.,SH3GL1,sera,1
PMC4519179A,"Furthermore, recent findings in murine adipocytes [63], neural cells [64], mammary gland [65] spermatogonia [66] and human umbilical cord blood showed an increase in the stem cell pool following exposure to BPA [67] and/or other EDCs including diethylhexylphthalate, tributyltin, and BPA diglycidyl ether [63].",BPA,blood,-1
PMC4519179A,"Furthermore, recent findings in murine adipocytes [63], neural cells [64], mammary gland [65] spermatogonia [66] and human umbilical cord blood showed an increase in the stem cell pool following exposure to BPA [67] and/or other EDCs including diethylhexylphthalate, tributyltin, and BPA diglycidyl ether [63].",BPA,blood,-1
PMC3128671A,"A standard 5-hours chromium (51Cr) release assay identical to those performed for ADCC assays was used, except that human serum in a dilution of 1:2 was added in place of the effector cells.",ADCC,serum,1
PMC5289527A,"Both TLR6 and MEF2A were differentially expressed in acute and convalescent whole blood RNA samples, with the highest expression levels in the acute phase of KD (Fig 2a and 2b).See full tableTable 1.",TLR6,blood,-1
PMC5289527A,"Both TLR6 and MEF2A were differentially expressed in acute and convalescent whole blood RNA samples, with the highest expression levels in the acute phase of KD (Fig 2a and 2b).See full tableTable 1.",MEF2A,blood,-1
PMC5289527A,"Both TLR6 and MEF2A were differentially expressed in acute and convalescent whole blood RNA samples, with the highest expression levels in the acute phase of KD (Fig 2a and 2b).See full tableTable 1.",RNA,blood,-1
PMC3269833A,"The cells were treated with 10 mM forskolin and 100 mM IBMX (FI) for 1 day (Red lines) and the two modes of TACSTD2 in MCF10A, MCF7, and primary astrocyte cell population are pointed out by the blue arrows.",IBMX,astrocyte,1
PMC3269833A,"The cells were treated with 10 mM forskolin and 100 mM IBMX (FI) for 1 day (Red lines) and the two modes of TACSTD2 in MCF10A, MCF7, and primary astrocyte cell population are pointed out by the blue arrows.",FI,astrocyte,1
PMC3269833A,"The cells were treated with 10 mM forskolin and 100 mM IBMX (FI) for 1 day (Red lines) and the two modes of TACSTD2 in MCF10A, MCF7, and primary astrocyte cell population are pointed out by the blue arrows.",MCF7,astrocyte,1
PMC3269833A,"The cells were treated with 10 mM forskolin and 100 mM IBMX (FI) for 1 day (Red lines) and the two modes of TACSTD2 in MCF10A, MCF7, and primary astrocyte cell population are pointed out by the blue arrows.",TACSTD2,astrocyte,1
PMC3840448A,(PRSS2) pre-proprotein and pancreatic lipase related protein-1 (PLRP1) from pancreatic juice of pancreatic cancer patients [24].,PLRP1,pancreatic juice,1
PMC3840448A,(PRSS2) pre-proprotein and pancreatic lipase related protein-1 (PLRP1) from pancreatic juice of pancreatic cancer patients [24].,PRSS2,pancreatic juice,1
PMC3128671A,"In some experiments, heat-inactivated human serum (56degC for 60 minutes) was added in the presence of effector PBL.",PBL,serum,1
PMC5492016A,"Unlike mRNA, microRNAs exist in tissues and body fluids, such as blood and sputum.",mRNA,sputum,-1
PMC5492016A,"Unlike mRNA, microRNAs exist in tissues and body fluids, such as blood and sputum.",mRNA,blood,-1
PMC3224189A,"The p-value between MFI seen in high Trop-2 expressing cell lines versus the low expressing cell line was 0.001.All five cervical cancer cell lines were tested for their sensitivity to NK cell activity, by exposure to peripheral blood lymphocytes (PBL) collected from several healthy donors.",Trop-2,blood,-1
PMC3224189A,"The p-value between MFI seen in high Trop-2 expressing cell lines versus the low expressing cell line was 0.001.All five cervical cancer cell lines were tested for their sensitivity to NK cell activity, by exposure to peripheral blood lymphocytes (PBL) collected from several healthy donors.",PBL,blood,-1
PMC3224189A,"The p-value between MFI seen in high Trop-2 expressing cell lines versus the low expressing cell line was 0.001.All five cervical cancer cell lines were tested for their sensitivity to NK cell activity, by exposure to peripheral blood lymphocytes (PBL) collected from several healthy donors.",MFI,blood,-1
PMC2797899A,"A similar pattern was observed in prostate cancer metastases to lymph nodes and bones, altogether supporting the idea that TRAP-1 cytoprotection is exploited at all stages of prostate cancer.",TRAP-1,lymph,1
PMC4062414A,"The EPN3 N-terminal domain binds PtdIns(3,4) P2, which is enriched at endocytic sites of the plasma membrane; this interaction induces a conformational change in EPN3 that promotes membrane curvature, which promotes the formation of clathrin-coated pits and endocytosis.",EPN3,plasma,1
PMC4062414A,"The EPN3 N-terminal domain binds PtdIns(3,4) P2, which is enriched at endocytic sites of the plasma membrane; this interaction induces a conformational change in EPN3 that promotes membrane curvature, which promotes the formation of clathrin-coated pits and endocytosis.",P2,plasma,1
PMC4062414A,"The EPN3 N-terminal domain binds PtdIns(3,4) P2, which is enriched at endocytic sites of the plasma membrane; this interaction induces a conformational change in EPN3 that promotes membrane curvature, which promotes the formation of clathrin-coated pits and endocytosis.",EPN3,plasma,1
PMC4673473A,Our simple and effective initial protocol of expanding immature bone marrow cells revealed that Foxa2+ endodermal precursor cells exist in Sca1+ subpopulations of Lin- cells.,Sca1,bone marrow,-1
PMC4673473A,Our simple and effective initial protocol of expanding immature bone marrow cells revealed that Foxa2+ endodermal precursor cells exist in Sca1+ subpopulations of Lin- cells.,Foxa2,bone marrow,-1
PMC2797899A,"In clinical samples, TRAP-1 staining was uniformly present in grade 3 cancers, more heterogeneous in higher-grade tumors, and again uniformly strong in metastases to lymph nodes and bone.",TRAP-1,lymph,1
PMC4062414A,"ADAP1 also regulates cargo transport between plasma membrane and vesicles, and regulates cortical actin cytoskeleton for several processes, including focal adhesions [83].Motor function for vesicle transport is provided by MYO5B (r = 0.79) and MYO5C (r = 0.73).",MYO5B,plasma,1
PMC4062414A,"ADAP1 also regulates cargo transport between plasma membrane and vesicles, and regulates cortical actin cytoskeleton for several processes, including focal adhesions [83].Motor function for vesicle transport is provided by MYO5B (r = 0.79) and MYO5C (r = 0.73).",ADAP1,plasma,1
PMC4062414A,"ADAP1 also regulates cargo transport between plasma membrane and vesicles, and regulates cortical actin cytoskeleton for several processes, including focal adhesions [83].Motor function for vesicle transport is provided by MYO5B (r = 0.79) and MYO5C (r = 0.73).",MYO5C,plasma,1
PMC4803572A,These two biological sources of error prompt us to urge the field to use a more robust cocktail of antibodies to identify and capture DTC which have lost EpCAM expression and to identify those rare EpCAM-positive bone marrow progenitor cells as non DTC.,DTC,bone marrow,-1
PMC4803572A,These two biological sources of error prompt us to urge the field to use a more robust cocktail of antibodies to identify and capture DTC which have lost EpCAM expression and to identify those rare EpCAM-positive bone marrow progenitor cells as non DTC.,DTC,bone marrow,-1
PMC5125324A,"In addition, SSEA-4 expression was detected in human adult mesenchymal stem cells within the bone marrow 28.Our results demonstrate that up to 80% of expanded murine Sca-1+/CD49f+/Trop2high basal PESCs express SSEA-1.",SSEA-4,bone marrow,1
PMC5125324A,"In addition, SSEA-4 expression was detected in human adult mesenchymal stem cells within the bone marrow 28.Our results demonstrate that up to 80% of expanded murine Sca-1+/CD49f+/Trop2high basal PESCs express SSEA-1.",SSEA-1,bone marrow,1
PMC5385398A,"In conclusion, the present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts, and it is obviously correlated with the poor prognosis of PHCC patients.",PHCC,bile,1
PMC5385398A,"In conclusion, the present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts, and it is obviously correlated with the poor prognosis of PHCC patients.",CUL4A,bile,1
PMC5385398A,"In conclusion, the present study indicates that CUL4A is overexpressed in PHCC tumour tissues than in normal intrahepatic bile ducts, and it is obviously correlated with the poor prognosis of PHCC patients.",PHCC,bile,1
PMC4863686A,"A number of studies have also reported GO reduction using various biomolecules, such as ascorbic acid,135 amino acids,98 glucose,136,137 bovine serum albumin,138 melatonin,139 humanin,140 enhanced green fluorescent protein,111 and resveratrol, a phenolic compound derived from grapes.113 In particular, use of recombinant proteins for the synthesis of graphene or NPs would save energy and time in downstream processing, and compared to bacterial reduction, this method does not pose the danger of introducing endotoxins.141,142",GO,serum,1
PMC3561800A,"Finally, the tumor cells within a large fraction of metastatic lesions (14 out of 36 lymph node, 3 out of 4 soft tissue, 2 out of 4 lung, and 6 out of 31 bone metastases) exhibited high levels of b4 at the cell surface (Figure 1D, right panels).To validate these results, we tested a second mAb to b4, 439-9B, which has been used to stain paraffin-embedded sections of breast cancer cases (38).",1D,lymph,-1
PMC4202120B,These are primed in vitro with the recombinant fusion protein consisting of prostatic acid phosphatase (PAP) and GM-CSF.,GM,CSF,1
PMC4202120B,These are primed in vitro with the recombinant fusion protein consisting of prostatic acid phosphatase (PAP) and GM-CSF.,PAP,CSF,1
PMC3224774A,"In this study, we show that ADCC against carcinosarcomas was not significantly inhibited by high concentrations (up to 50%) of human plasma.",ADCC,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,ARK-2,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,hRS7,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,ADCC,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,hRS7,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,OMMT,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,PBL,plasma,1
PMC3224774A,Addition of untreated plasma (diluted 1:2) to PBL in the presence of hRS7 significantly increased the ADCC achieved in the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).,PBL,plasma,1
PMC5447959A,"Nadal et al. examined 70 NSCLC patients and 22 controls for serum microRNAs and identified a four-microRNA signature (miR-193b, miR-301, miR-141, and miR-200b) that could differentiate NSCLC patients from non-cancer individuals.",NSCLC,serum,1
PMC5447959A,"Nadal et al. examined 70 NSCLC patients and 22 controls for serum microRNAs and identified a four-microRNA signature (miR-193b, miR-301, miR-141, and miR-200b) that could differentiate NSCLC patients from non-cancer individuals.",NSCLC,serum,1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",hRS7,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",OMMT,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",PBL,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",ARK-2,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",PBL,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",Trop-2,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",ADCC,plasma,-1
PMC3224774A,"Addition of physiological concentrations of IgG (i.e. heat-inactivated plasma diluted 1:2) to PBL in the presence of hRS7 did not significantly alter the degree of ADCC achieved against OMMT-ARK-2 in the presence of hRS7 and PBL (P = 0.95).In this study, we have investigated Trop-2 expression and localization by immunohistochemistry in uterine and ovarian carcinosarcomas and compared these findings to normal endometrium and ovarian control tissues.",hRS7,plasma,-1
PMC4473102A,Moreover the levels of IL-17 and IL-23 in synovial fluid were higher than in control synovial fluids further confirming the findings of the gene array analysis.,IL-23,synovial fluid,1
PMC4473102A,Moreover the levels of IL-17 and IL-23 in synovial fluid were higher than in control synovial fluids further confirming the findings of the gene array analysis.,IL-17,synovial fluid,1
PMC3840448A,Few investigators have combined SILAP with iso-electrofocusing (to concentrate proteins by immune-affinity) and 2D LC MS-MS in order to increase specificity of serum biomarkers.,SILAP,serum,1
PMC5143353A,"Clinical information was retrieved from the archives at the hospital, including patient sex, age, smoking status, tumor size, tumor differentiation, histological type, tumor status (T), lymph node metastasis (N), distant metastasis (M), and TNM stage.",T,lymph,1
PMC5143353A,"Clinical information was retrieved from the archives at the hospital, including patient sex, age, smoking status, tumor size, tumor differentiation, histological type, tumor status (T), lymph node metastasis (N), distant metastasis (M), and TNM stage.",TNM,lymph,1
PMC3364558A,"The bone marrow of mice had exceptionally high uptake of 18F-FDG, along with the expected uptake in the heart wall and brain, and diffuse uptake in the abdomen.",FDG,bone marrow,1
PMC4803572A,"To understand the biology behind the DTC and its relation to tumor dormancy, we [6,30] and others [15] recently profiled single DTC in the bone marrow of PCa patients at different stages of disease progression.",DTC,bone marrow,1
PMC4803572A,"To understand the biology behind the DTC and its relation to tumor dormancy, we [6,30] and others [15] recently profiled single DTC in the bone marrow of PCa patients at different stages of disease progression.",DTC,bone marrow,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",HPC,bile,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",HPC,bile,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",HCC,bile,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",HCC,bile,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",K19,bile,1
PMC3963546A,"Left panel shows a representative example of a K19-positive HCC, middle panel a K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).In view of the strong association between K19 expression and microvascular invasion, and the high expression of invasion-related genes, we evaluated the invasive potential of K19-positive HCC cells in vitro.",HCC,bile,1
PMC3135497A,"When the cut-off value was defined as the average + 3 SD, 22% of patients with esophageal SCC were positive for the serum anti-HCA-81/97 antibody but none of the healthy donors were positive (Table 3).",SD,serum,1
PMC3135497A,"When the cut-off value was defined as the average + 3 SD, 22% of patients with esophageal SCC were positive for the serum anti-HCA-81/97 antibody but none of the healthy donors were positive (Table 3).",SCC,serum,1
PMC4606116A,"Until now, there is still no single CRC biomarker comparable to CEA.The present study applying secretome-based strategy has successfully verified BST2 as a potential CRC plasma biomarker for the first time.",BST2,plasma,1
PMC4606116A,"Until now, there is still no single CRC biomarker comparable to CEA.The present study applying secretome-based strategy has successfully verified BST2 as a potential CRC plasma biomarker for the first time.",CRC,plasma,1
PMC4606116A,"Until now, there is still no single CRC biomarker comparable to CEA.The present study applying secretome-based strategy has successfully verified BST2 as a potential CRC plasma biomarker for the first time.",CRC,plasma,1
PMC4251850A,"Additionally, the expression of NT5E/CD73 is upregulated in pancreatic cancer on transcriptional level [25].We tested for this protein in the EV samples of other pancreatic cancer cells and in the ascites fluid of patients.",NT5E,ascites,1
PMC4251850A,"Additionally, the expression of NT5E/CD73 is upregulated in pancreatic cancer on transcriptional level [25].We tested for this protein in the EV samples of other pancreatic cancer cells and in the ascites fluid of patients.",CD73,ascites,1
PMC4251850A,NT5E/CD73 could also be detected in small amounts of EVs from the ascites of PDAC patients (Figure 8b).,NT5E,ascites,1
PMC4251850A,NT5E/CD73 could also be detected in small amounts of EVs from the ascites of PDAC patients (Figure 8b).,CD73,ascites,1
PMC4251850A,NT5E/CD73 could also be detected in small amounts of EVs from the ascites of PDAC patients (Figure 8b).,PDAC,ascites,1
PMC4683719A,"A non-invasive assay system has been developed based on the detection of TMPRSS2-ERG fusion transcripts in urine samples from patients, which in combination with the detection of urine PCA3 improved the performance of the multivariate Prostate Cancer Prevention Trial risk calculator in predicting cancer on biopsy [143].",TMPRSS2-ERG,urine,1
PMC4683719A,"A non-invasive assay system has been developed based on the detection of TMPRSS2-ERG fusion transcripts in urine samples from patients, which in combination with the detection of urine PCA3 improved the performance of the multivariate Prostate Cancer Prevention Trial risk calculator in predicting cancer on biopsy [143].",TMPRSS2-ERG,urine,1
PMC4683719A,"A non-invasive assay system has been developed based on the detection of TMPRSS2-ERG fusion transcripts in urine samples from patients, which in combination with the detection of urine PCA3 improved the performance of the multivariate Prostate Cancer Prevention Trial risk calculator in predicting cancer on biopsy [143].",PCA3,urine,1
PMC4683719A,"A non-invasive assay system has been developed based on the detection of TMPRSS2-ERG fusion transcripts in urine samples from patients, which in combination with the detection of urine PCA3 improved the performance of the multivariate Prostate Cancer Prevention Trial risk calculator in predicting cancer on biopsy [143].",PCA3,urine,1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",FACS,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",CD14,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",Delta-1,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",KLF4,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",mRNA,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",CD11b,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",dDC,blood,-1
PMC5538449A,"Gene profiling of FACS-sorted cell subsets confirmed that both dDC subsets, monocytes, and keratinocytes express KLF4 mRNA at high levels, whereas it is virtually undetectable in LCs (Fig 3, D).Notch activation in response to Delta-1 represses KLF4, as well as the monocyte lineage markers CD14 and CD11b, in blood monocytes.",KLF4,blood,-1
PMC3136110A,"The Venereal Disease Research Laboratory (VDRL) test, for example, is a very common blood test for syphilis that detects nonspecific antibody in human serum that reacts with beef cardiolipin.(21) Such a large incidence of antibody cross-reactivity is clearly worrisome, as the aberrant binding events that have been reported most likely just scratch the surface of the problem.",VDRL,blood,1
PMC3136110A,"The Venereal Disease Research Laboratory (VDRL) test, for example, is a very common blood test for syphilis that detects nonspecific antibody in human serum that reacts with beef cardiolipin.(21) Such a large incidence of antibody cross-reactivity is clearly worrisome, as the aberrant binding events that have been reported most likely just scratch the surface of the problem.",VDRL,serum,1
PMC5414739A,The delayed hair growth cycle observed in PRLR knockout mice suggested that regulation of epidermal maintenance and regeneration was one of the intrinsic physiological functions of PRL (33).,PRL,hair,1
PMC5414739A,The delayed hair growth cycle observed in PRLR knockout mice suggested that regulation of epidermal maintenance and regeneration was one of the intrinsic physiological functions of PRL (33).,PRLR,hair,1
PMC4606475A,Livers were perfused with 10 ml of PBS via the portal vein in situ prior to tissue harvest to minimise blood contamination.,PBS,blood,-1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",HCT116,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",HCT116,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",SW48,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",SW48,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",FET,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",FET,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",RKO,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",RKO,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",SW480,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",SW480,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",MSI,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",MSI,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",CIN,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",CIN,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",CIMP,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",CIMP,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",AAC,serum,1
PMC3718634A,"All data is expressed as mean +- standard deviation of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200.",AAC,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",ADC,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",DM1,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",DLT,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",ADC,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",DLT,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",DM4,serum,1
PMC4596896A,"The DLT for the huC242-SPP-DM1 ADC was elevated hepatic transaminase and the DLT for the huC242-SPDB-DM4 ADC was ocular toxicity, which was only observed in patients with low serum levels of CanAg (56).",SPP,serum,1
PMC2946292A,We showed that mTrop2 expression in the murine pancreatic cancer line (Panc02) led to an increased number of cells entering S phase which resulted in increased cell growth at low serum concentrations.,Panc02,serum,1
PMC4863686A,"For in vivo imaging, GO-PEG NPs were intravenously injected into mice via the tail vein, and their flow, distribution, and clearance from blood vessels were observed by utilizing a deep-penetrating two-photon imaging technique.241 Gollavelli and Ling242 linked a polyacrylic acid bridge with fluorescein O-methacrylate to yield multifunctional graphene (MFG) with water dispersibility via a green synthetic approach.",GO,blood,1
PMC4863686A,"For in vivo imaging, GO-PEG NPs were intravenously injected into mice via the tail vein, and their flow, distribution, and clearance from blood vessels were observed by utilizing a deep-penetrating two-photon imaging technique.241 Gollavelli and Ling242 linked a polyacrylic acid bridge with fluorescein O-methacrylate to yield multifunctional graphene (MFG) with water dispersibility via a green synthetic approach.",MFG,blood,1
PMC4863686A,"For in vivo imaging, GO-PEG NPs were intravenously injected into mice via the tail vein, and their flow, distribution, and clearance from blood vessels were observed by utilizing a deep-penetrating two-photon imaging technique.241 Gollavelli and Ling242 linked a polyacrylic acid bridge with fluorescein O-methacrylate to yield multifunctional graphene (MFG) with water dispersibility via a green synthetic approach.",Ling242,blood,1
PMC4863686A,"For in vivo imaging, GO-PEG NPs were intravenously injected into mice via the tail vein, and their flow, distribution, and clearance from blood vessels were observed by utilizing a deep-penetrating two-photon imaging technique.241 Gollavelli and Ling242 linked a polyacrylic acid bridge with fluorescein O-methacrylate to yield multifunctional graphene (MFG) with water dispersibility via a green synthetic approach.",PEG,blood,1
PMC2928967A,"First, the TACSTD2 protein acts as an anchor protein for the proper localization of the CLDN proteins at the plasma membrane.",CLDN,plasma,1
PMC2928967A,"First, the TACSTD2 protein acts as an anchor protein for the proper localization of the CLDN proteins at the plasma membrane.",TACSTD2,plasma,1
PMC3856845A,"Several metastatic CRPC patients that we evaluated contained similar anatomic sites of involvement including tumors in the liver, lung, dura, and distant lymph nodes.",CRPC,lymph,1
PMC3250983A,The expression of CD138 on primary breast tumors and in the corresponding invaded lymph node has been evaluated.,CD138,lymph,1
PMC3266428A,Anthropometric data taken at ~9 and ~15 years of age along with DNA extracted from cord blood buffy coats and whole blood samples collected at ~7 years of age (21) were provided for use in this study.,DNA,blood,-1
PMC3266428A,Anthropometric data taken at ~9 and ~15 years of age along with DNA extracted from cord blood buffy coats and whole blood samples collected at ~7 years of age (21) were provided for use in this study.,DNA,blood,-1
PMC4438912A,"Following solidification at 4degC, the mixture was hydrated with serum-free RPMI 1640 medium for 30 min at 37degC to provoke its reor-ganization into a basement membrane-like structure over the microporous membrane.",RPMI,serum,1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",MMP12,blood,-1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",PCR,blood,-1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",REG3A,blood,-1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",TSPAN8,blood,-1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",MMP7,blood,-1
PMC3440735A,"In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR.",EPCAM,blood,-1
PMC5328612A,"Typically, a very large mass has developed in the periphery of the liver with few clinical symptoms.19 Most patients present with nonspecific symptoms, such as pain in the right upper abdominal quadrant, weight loss, and high serum ALP levels.",ALP,serum,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",SHIP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",GFP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",GFP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",Alexa594,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",GFP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",SHIP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",GFP,blood,1
PMC5045392A,"s-SHIP/GFP-expressing cells are a subset of neonatal basal prostate cells(A) s-SHIP/GFP-expressing cells localized into the basal region of the prostate epithelium in the differentiating ducts of Tg11.5kb-GFP mice; representative photographs (n  10) of frozen sections of P8 prostate tissues from Tg 11.5kb-GFP mice stained with phalloidin-Alexa594 for polymerized actin (red) to show the glandular architecture (a,b); arrows indicate GFP+ cells located in close contact with the basement membrane and the arrowhead indicates a blood vessel.",P8,blood,1
PMC4270176A,"Another technology, reverse-phase protein array (RPPA), has been used for the quantitative analysis of proteins in their phosphorylated or unphosphorylated forms in arrays of cell lysates, plasma, or serum samples.",RPPA,serum,1
PMC4270176A,"Another technology, reverse-phase protein array (RPPA), has been used for the quantitative analysis of proteins in their phosphorylated or unphosphorylated forms in arrays of cell lysates, plasma, or serum samples.",RPPA,plasma,1
PMC4966842B,"The next product presented by Dr. Stumpp was MP0250, a multipathway DARPin that inhibits both VEGF and hepatocyte growth factor (HGF) combined to 2 human serum albumin (HAS) binding modules.",MP0250,serum,1
PMC4966842B,"The next product presented by Dr. Stumpp was MP0250, a multipathway DARPin that inhibits both VEGF and hepatocyte growth factor (HGF) combined to 2 human serum albumin (HAS) binding modules.",VEGF,serum,1
PMC4966842B,"The next product presented by Dr. Stumpp was MP0250, a multipathway DARPin that inhibits both VEGF and hepatocyte growth factor (HGF) combined to 2 human serum albumin (HAS) binding modules.",HGF,serum,1
PMC4966842B,"The next product presented by Dr. Stumpp was MP0250, a multipathway DARPin that inhibits both VEGF and hepatocyte growth factor (HGF) combined to 2 human serum albumin (HAS) binding modules.",HAS,serum,1
PMC4803572A,PCa DTC isolated from the bone marrow of NED patients for 7-18 years post-RP displayed higher expression of the dormancy-associated markers including NR2F1 and TGFB2 than those from patients with biochemical recurrence or bone metastasis (Fig. 1) [30].,NR2F1,bone marrow,1
PMC4803572A,PCa DTC isolated from the bone marrow of NED patients for 7-18 years post-RP displayed higher expression of the dormancy-associated markers including NR2F1 and TGFB2 than those from patients with biochemical recurrence or bone metastasis (Fig. 1) [30].,DTC,bone marrow,1
PMC4803572A,PCa DTC isolated from the bone marrow of NED patients for 7-18 years post-RP displayed higher expression of the dormancy-associated markers including NR2F1 and TGFB2 than those from patients with biochemical recurrence or bone metastasis (Fig. 1) [30].,NED,bone marrow,1
PMC4803572A,PCa DTC isolated from the bone marrow of NED patients for 7-18 years post-RP displayed higher expression of the dormancy-associated markers including NR2F1 and TGFB2 than those from patients with biochemical recurrence or bone metastasis (Fig. 1) [30].,TGFB2,bone marrow,1
PMC4606475A,a Serum ALT levels in water- and 12-week TAA-treated control and LysM-Wls mice.,ALT,Serum,1
PMC4606475A,a Serum ALT levels in water- and 12-week TAA-treated control and LysM-Wls mice.,TAA,Serum,1
PMC3110957A,"Substantial CK19 and cystic fibrosis transmembrane protein (CFTR) expression was detected in both the M+133+26- and M+26+ populations, indicating a bile duct identity for both.",CFTR,bile,1
PMC3110957A,"Substantial CK19 and cystic fibrosis transmembrane protein (CFTR) expression was detected in both the M+133+26- and M+26+ populations, indicating a bile duct identity for both.",CK19,bile,1
PMC4019539A,"The monoclonal anti-Trop-2 (m)Abs 162-46.2 (ATCC, HB-187) [18], 2EF and T16 [11] were purified from mouse ascites using protein-A Sepharose, as described previously [19].",HB-187,ascites,1
PMC4019539A,"The monoclonal anti-Trop-2 (m)Abs 162-46.2 (ATCC, HB-187) [18], 2EF and T16 [11] were purified from mouse ascites using protein-A Sepharose, as described previously [19].",T16,ascites,1
PMC4019539A,"The monoclonal anti-Trop-2 (m)Abs 162-46.2 (ATCC, HB-187) [18], 2EF and T16 [11] were purified from mouse ascites using protein-A Sepharose, as described previously [19].",ATCC,ascites,1
PMC4019539A,"The monoclonal anti-Trop-2 (m)Abs 162-46.2 (ATCC, HB-187) [18], 2EF and T16 [11] were purified from mouse ascites using protein-A Sepharose, as described previously [19].",Trop-2,ascites,1
PMC4685746A,"They were first described by Paul Langerhans as neurons [2] but the advent of monoclonal antibodies revealed expression of MHC class II and macrophage antigens [3, 4] and a potential bone marrow origin [5].",MHC,bone marrow,-1
PMC4329473A,CAM-mediated adhesion may indirectly promote receptor/ligand signaling by bringing the plasma membranes of opposing cells together and forcing interaction between a ligand on one cell and its receptor on the other cell.,CAM,plasma,1
PMC5385398A,"Validation with IHC also determined that an increased CUL4A IHC score could be found in primary PHCC tumours relative to adjacent non-tumoural intrahepatic bile ducts (4.04 +- 2.45 vs 1.47 +- 0.96, P = 0.001) (Figure 1C).",PHCC,bile,1
PMC5385398A,"Validation with IHC also determined that an increased CUL4A IHC score could be found in primary PHCC tumours relative to adjacent non-tumoural intrahepatic bile ducts (4.04 +- 2.45 vs 1.47 +- 0.96, P = 0.001) (Figure 1C).",IHC,bile,1
PMC5385398A,"Validation with IHC also determined that an increased CUL4A IHC score could be found in primary PHCC tumours relative to adjacent non-tumoural intrahepatic bile ducts (4.04 +- 2.45 vs 1.47 +- 0.96, P = 0.001) (Figure 1C).",CUL4A,bile,1
PMC5385398A,"Validation with IHC also determined that an increased CUL4A IHC score could be found in primary PHCC tumours relative to adjacent non-tumoural intrahepatic bile ducts (4.04 +- 2.45 vs 1.47 +- 0.96, P = 0.001) (Figure 1C).",IHC,bile,1
PMC4469888A,"Mouse prostates were washed with PBS and cut into ~1-mm3 segments in collagenase (1% collagenase in DMEM supplied with 5% serum, 1% antibiotics, and 1% HEPES).",DMEM,serum,1
PMC4469888A,"Mouse prostates were washed with PBS and cut into ~1-mm3 segments in collagenase (1% collagenase in DMEM supplied with 5% serum, 1% antibiotics, and 1% HEPES).",PBS,serum,1
PMC4469888A,"Mouse prostates were washed with PBS and cut into ~1-mm3 segments in collagenase (1% collagenase in DMEM supplied with 5% serum, 1% antibiotics, and 1% HEPES).",HEPES,serum,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",MSKCC,blood,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",MSKCC,blood,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",HAI,blood,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",HAI,blood,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",ICC,blood,1
PMC5328612A,"Best supportive care is recommended for patients with a poor performance status or a life expectancy of less than 6 months.111-114Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging.115-117 Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC).",ICC,blood,1
PMC4777741A,Activated PKC localizes in the plasma membrane.,PKC,plasma,1
PMC4997669A,"The expression of Gal-1 is functionally linked to histopathological grading in cervical cancer patients, namely by affecting the rate of proliferation, lymph node metastasis and tumor invasion [2].",Gal-1,lymph,-1
PMC4972371A,"It is hypothesized that PDAC biomarkers, which are readily available in blood or tissue, will come to play a central role in optimizing patient selection for resection by predicting outcomes based on tumour biology.",PDAC,blood,-1
PMC4882422A,"Serum GPT levels, the gene expression of proinflammatory cytokines, and the numbers of positive cells are shown in the right panel.",GPT,Serum,1
PMC3754468A,"In fact, the TRAMP model has been validated as an accurate model to test chemical agents for prostate cancer prevention [17] as well as to identify therapeutically relevant targets and markers, such as Sox9, b4 integrin, and KLF6 [18-20], and to isolate circulating prostate tumor cells [21].To date, more than 200 serum-dependent human PC cell lines have been generated for in vitro and in vivo studies [22, 23].",Sox9,serum,1
PMC3754468A,"In fact, the TRAMP model has been validated as an accurate model to test chemical agents for prostate cancer prevention [17] as well as to identify therapeutically relevant targets and markers, such as Sox9, b4 integrin, and KLF6 [18-20], and to isolate circulating prostate tumor cells [21].To date, more than 200 serum-dependent human PC cell lines have been generated for in vitro and in vivo studies [22, 23].",PC,serum,1
PMC3754468A,"In fact, the TRAMP model has been validated as an accurate model to test chemical agents for prostate cancer prevention [17] as well as to identify therapeutically relevant targets and markers, such as Sox9, b4 integrin, and KLF6 [18-20], and to isolate circulating prostate tumor cells [21].To date, more than 200 serum-dependent human PC cell lines have been generated for in vitro and in vivo studies [22, 23].",KLF6,serum,1
PMC3754468A,"In fact, the TRAMP model has been validated as an accurate model to test chemical agents for prostate cancer prevention [17] as well as to identify therapeutically relevant targets and markers, such as Sox9, b4 integrin, and KLF6 [18-20], and to isolate circulating prostate tumor cells [21].To date, more than 200 serum-dependent human PC cell lines have been generated for in vitro and in vivo studies [22, 23].",TRAMP,serum,-1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",DP,lymph,1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",HLA,lymph,1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",MHC,lymph,1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",HLA,lymph,1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",FasL,lymph,1
PMC3039945A,"Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor prognosis in CRC [209].The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, -DP).",CRC,lymph,1
PMC5437009A,Serum-free DMEM with 5 x 104 cells/well was filled in the upper wells of the chambers and DMEM with 10% FBS was added to the lower wells of the chambers.,DMEM,Serum,1
PMC5437009A,Serum-free DMEM with 5 x 104 cells/well was filled in the upper wells of the chambers and DMEM with 10% FBS was added to the lower wells of the chambers.,DMEM,Serum,1
PMC5437009A,Serum-free DMEM with 5 x 104 cells/well was filled in the upper wells of the chambers and DMEM with 10% FBS was added to the lower wells of the chambers.,FBS,Serum,1
PMC2774741A,"The first algorithm in the selection of highly expressed genes involved elimination of genes from NSCLC cell lines that were expressed in normal lymph nodes [n=11,326; 50.8% of total (22,283)].",NSCLC,lymph,1
PMC5447959A,"Using a large prospective early detection trial (the COSMOS study) for lung cancer by low-dose computed tomography, Bianchi et al. investigated serum microRNAs and identified a 34-microRNA signature that could identify patients with early-stage NSCLC in a population of asymptomatic high-risk individuals with 80% accuracy [74].",COSMOS,serum,1
PMC5447959A,"Using a large prospective early detection trial (the COSMOS study) for lung cancer by low-dose computed tomography, Bianchi et al. investigated serum microRNAs and identified a 34-microRNA signature that could identify patients with early-stage NSCLC in a population of asymptomatic high-risk individuals with 80% accuracy [74].",NSCLC,serum,-1
PMC4882422A,"Consequently, LPS challenge in the PtenDhep mice primed with P. acnes resulted in further elevation of the serum IL-6, TNFa, and GPT levels compared with that seen in the control Ptenfl/fl mice (Fig.",GPT,serum,1
PMC4882422A,"Consequently, LPS challenge in the PtenDhep mice primed with P. acnes resulted in further elevation of the serum IL-6, TNFa, and GPT levels compared with that seen in the control Ptenfl/fl mice (Fig.",IL-6,serum,1
PMC4882422A,"Consequently, LPS challenge in the PtenDhep mice primed with P. acnes resulted in further elevation of the serum IL-6, TNFa, and GPT levels compared with that seen in the control Ptenfl/fl mice (Fig.",LPS,serum,1
PMC4803572A,"In a head and neck squamous carcinoma model TGF-b2 signaling in the bone marrow has been shown to activate p38 MAPK, inducing a high p38/ERK signaling ratio and consequently dormancy (Fig. 1) [44].",ERK,bone marrow,1
PMC4803572A,"In a head and neck squamous carcinoma model TGF-b2 signaling in the bone marrow has been shown to activate p38 MAPK, inducing a high p38/ERK signaling ratio and consequently dormancy (Fig. 1) [44].",p38,bone marrow,1
PMC4803572A,"In a head and neck squamous carcinoma model TGF-b2 signaling in the bone marrow has been shown to activate p38 MAPK, inducing a high p38/ERK signaling ratio and consequently dormancy (Fig. 1) [44].",MAPK,bone marrow,1
PMC4803572A,"In a head and neck squamous carcinoma model TGF-b2 signaling in the bone marrow has been shown to activate p38 MAPK, inducing a high p38/ERK signaling ratio and consequently dormancy (Fig. 1) [44].",TGF,bone marrow,1
PMC4882422A,"The serum IL-6, TNFa, and GPT levels are presented as the indicated time points.",IL-6,serum,1
PMC4882422A,"The serum IL-6, TNFa, and GPT levels are presented as the indicated time points.",GPT,serum,1
PMC3981717A,"We then conducted the stratified analysis based on age, serum AFP, tumor size, number of tumor lesions, PVTT status, BCLC stage and number of TACE treatment.",TACE,serum,1
PMC3981717A,"We then conducted the stratified analysis based on age, serum AFP, tumor size, number of tumor lesions, PVTT status, BCLC stage and number of TACE treatment.",PVTT,serum,1
PMC3981717A,"We then conducted the stratified analysis based on age, serum AFP, tumor size, number of tumor lesions, PVTT status, BCLC stage and number of TACE treatment.",BCLC,serum,1
PMC3981717A,"We then conducted the stratified analysis based on age, serum AFP, tumor size, number of tumor lesions, PVTT status, BCLC stage and number of TACE treatment.",AFP,serum,1
PMC4673473A,These results indicated that murine Lin- bone marrow cells differentiated into albumin-expressing hepatocyte-like cells in sequential in vitro culture with normal MS and LCM.,LCM,bone marrow,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",PBS,sera,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",H2O2,sera,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",PBS,sera,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",FBS,sera,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",T,sera,1
PMC3135497A,"The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty ml of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 ml of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2.",PBS,sera,1
PMC4096804A,Accurate lymph node classification of 12/13 FFPE or 17/18 fresh tumors was achieved (Fig.,FFPE,lymph,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",PBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",FBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",PBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",FBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",PBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",PBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",T,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",PBS,serum,1
PMC3135497A,"Plates were blocked with 150 ml of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 ml of purified biotinylated synthetic peptides (10 mg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 ml of serum diluted 1/100 in PBS-FBS were added to each well.",T,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,Tween-20,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,T,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,PBS,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,FBS,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,PBS,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,PBS,serum,1
PMC3135497A,The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS).,PBS,serum,1
PMC3785439A,"There are several high risk factors are thought to be closely associated with unfavorable clinical outcome, including advanced International Federation of Obstetrics and Gynecology (FIGO) stage, large tumor size, lymph node metastasis, deep cervical stromal invasion and lymphovascular space invasion.",FIGO,lymph,1
PMC3918789A,"Intraurethral instillation of PBS may cause reflux of urine into the prostate, leading to chemical or physical trauma (39).",PBS,urine,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",C1,serum,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",DMEM,serum,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",TRAMP,serum,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",TRAMP,serum,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",C2,serum,1
PMC3754468A,"TRAMP-C1 and TRAMP-C2 cells [9] and RM1 cells [24] (kindly provided by Dr. Mariana P. Monteiro, Universita di Oporto, Porto, Portugal), were cultured in Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium, http://www.cambrex.com) supplemented with 10% fetal bovine serum (Invitrogen, Milan, Italy, http://www.invitrogen.com), 150 U/ml streptomycin, and 200 U/ml penicillin (Cambrex).",RM1,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",TACSTD2,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",H7000,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",HCE,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",PBS,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",T,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",X-100,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",EDTA,serum,1
PMC2928967A,"The sections were incubated with 20% bovine serum albumin-PBS at room temperature for 20 minutes, incubated overnight with a primary antibody (goat polyclonal anti-TACSTD2) at 4degC, washed in PBS, incubated with secondary antibody (Rabbit anti-goat IgG (H+L) Gold 10 nm; British BioCell International, Cardiff, UK) at room temperature for 2 hours, and then examined ultramicroscopically by use of an electron microscope (H7000; Hitachi, Tokyo, Japan).The HCE-T cells were lysed in a buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L EDTA, and a protease inhibitor mixture (Complete Mini; Roche Diagnostics).",PBS,serum,1
PMC4483763A,"In line with this, loss of Prox1 in the hepatoblast causes an expansion of biliary cells at the expense of hepatocytes (Seth et al., 2014), whereas Hnf1b knockout causes ductopenia and bile duct dysplasia (Coffinier et al., 2002).",Prox1,bile,1
PMC5344228A,DC precursors originating from hematopoietic stem cells (HSC) in bone marrow (BM) migrate towards peripheral tissues such as the skin.,HSC,bone marrow,1
PMC5344228A,DC precursors originating from hematopoietic stem cells (HSC) in bone marrow (BM) migrate towards peripheral tissues such as the skin.,DC,bone marrow,1
PMC3566310A,(C) Serum levels of human FGF7 protein after 3 wk of Dox administration were determined by ELISA.,FGF7,Serum,1
PMC3566310A,(C) Serum levels of human FGF7 protein after 3 wk of Dox administration were determined by ELISA.,ELISA,Serum,1
PMC4606116A,We further examined the relationship between plasma BST2 levels and different clinicopathologic characteristics of these 120 CRC patients.,BST2,plasma,1
PMC4606116A,We further examined the relationship between plasma BST2 levels and different clinicopathologic characteristics of these 120 CRC patients.,CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",BST2,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4606116A,"Although plasma BST2 levels did not significantly differ in CRC patients at different stages (Supplemental Figure 1), higher plasma BST2 levels were observed in older patients (2.61 +- 1.34 versus 2.03 +- 1.63; p = 0.03), mucinous carcinoma (4.63 +- 0.45 versus 2.28 +- 1.48; p = 0.05), and CRC patients with hypoalbuminemia (4.14 +- 2.46 versus 2.12 +- 1.14; p  0.01) (Supplemental Table 3).Since we have observed the significant elevation of BST2 plasma levels in CRC patients, we then turned to examine the expression levels of BST2 in CRC tissue specimens by immunohistochemistry.",CRC,plasma,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",R26YFP,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",R26YFP,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",R26YFP,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",AAV8,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",AAV8,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",AAV8,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",YFP,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",YFP,serum,1
PMC4505916A,"To this end, we performed a serum transfer experiment in which we assessed the infective activity of the virus by isolating serum from mice given AAV8 2 or 30 weeks previously and injecting it into Cre-naive R26YFP mice. Livers of these serum-recipient mice were assessed 1 or 6 weeks later, and no YFP signal was detected (Figure 4; data not shown).",YFP,serum,1
PMC3981717A,"In the multivariate analyses, the association between single SNP and OS was estimated as hazard ratios (HRs) with adjusting for age, gender, HBsAg status, serum AFP, tumor size, BCLC stage and TACE treatment number where appropriate.",OS,serum,1
PMC3981717A,"In the multivariate analyses, the association between single SNP and OS was estimated as hazard ratios (HRs) with adjusting for age, gender, HBsAg status, serum AFP, tumor size, BCLC stage and TACE treatment number where appropriate.",SNP,serum,1
PMC3981717A,"In the multivariate analyses, the association between single SNP and OS was estimated as hazard ratios (HRs) with adjusting for age, gender, HBsAg status, serum AFP, tumor size, BCLC stage and TACE treatment number where appropriate.",TACE,serum,1
PMC3981717A,"In the multivariate analyses, the association between single SNP and OS was estimated as hazard ratios (HRs) with adjusting for age, gender, HBsAg status, serum AFP, tumor size, BCLC stage and TACE treatment number where appropriate.",BCLC,serum,1
PMC3981717A,"In the multivariate analyses, the association between single SNP and OS was estimated as hazard ratios (HRs) with adjusting for age, gender, HBsAg status, serum AFP, tumor size, BCLC stage and TACE treatment number where appropriate.",AFP,serum,1
PMC3548755A,"To confirm the changes in the serum anti-SH3GL1 autoantibody level, we used rat glioma models with C6 and 9 L cells which expressed its messenger RNA (data not shown).",C6,serum,1
PMC3548755A,"To confirm the changes in the serum anti-SH3GL1 autoantibody level, we used rat glioma models with C6 and 9 L cells which expressed its messenger RNA (data not shown).",RNA,serum,1
PMC3548755A,"To confirm the changes in the serum anti-SH3GL1 autoantibody level, we used rat glioma models with C6 and 9 L cells which expressed its messenger RNA (data not shown).",SH3GL1,serum,1
PMC4505916A,"New Hepatocytes Are Not Labeled on AAV Serum Transfusion(A) Schematic showing the timing of infection, serum transfer, and analysis of injected R26YFP mice; each red ""x"" indicates a sampling point.",AAV,serum,1
PMC4505916A,"New Hepatocytes Are Not Labeled on AAV Serum Transfusion(A) Schematic showing the timing of infection, serum transfer, and analysis of injected R26YFP mice; each red ""x"" indicates a sampling point.",AAV,Serum,1
PMC4505916A,"New Hepatocytes Are Not Labeled on AAV Serum Transfusion(A) Schematic showing the timing of infection, serum transfer, and analysis of injected R26YFP mice; each red ""x"" indicates a sampling point.",R26YFP,serum,1
PMC4505916A,"New Hepatocytes Are Not Labeled on AAV Serum Transfusion(A) Schematic showing the timing of infection, serum transfer, and analysis of injected R26YFP mice; each red ""x"" indicates a sampling point.",R26YFP,Serum,1
PMC5378227A,"I. Surprisingly, the efficacy of the panel for detecting gastric cancer was not affected by any of the clinical features of the tumors that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), or TNM stage (I or =II).",T2,lymph,1
PMC5378227A,"I. Surprisingly, the efficacy of the panel for detecting gastric cancer was not affected by any of the clinical features of the tumors that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), or TNM stage (I or =II).",TNM,lymph,1
PMC5378227A,"I. Surprisingly, the efficacy of the panel for detecting gastric cancer was not affected by any of the clinical features of the tumors that we assessed in this study: depth of tumor invasion (T1 or =T2), lymph node metastasis (+ or -), distant metastasis (+ or -), peritoneal dissemination (+ or -), or TNM stage (I or =II).",T1,lymph,1
PMC4306156A,"Samples were centrifuged at 1000 g for 10 min, and the supernatant was collected and stored at -20 degC. Serum CEA levels were determined using a CEA ELISA kit (Bio-Swamp, Wuhan, China) according to the manufacturer's instructions.",CEA,Serum,1
PMC4306156A,"Samples were centrifuged at 1000 g for 10 min, and the supernatant was collected and stored at -20 degC. Serum CEA levels were determined using a CEA ELISA kit (Bio-Swamp, Wuhan, China) according to the manufacturer's instructions.",CEA,Serum,1
PMC4306156A,"Samples were centrifuged at 1000 g for 10 min, and the supernatant was collected and stored at -20 degC. Serum CEA levels were determined using a CEA ELISA kit (Bio-Swamp, Wuhan, China) according to the manufacturer's instructions.",ELISA,Serum,1
PMC4606116A,We performed ROC analysis to evaluate the efficacy of plasma BST2 and CEA levels for discriminating CRC patients (n = 120) and controls (n = 120).,CRC,plasma,1
PMC4606116A,We performed ROC analysis to evaluate the efficacy of plasma BST2 and CEA levels for discriminating CRC patients (n = 120) and controls (n = 120).,ROC,plasma,1
PMC4606116A,We performed ROC analysis to evaluate the efficacy of plasma BST2 and CEA levels for discriminating CRC patients (n = 120) and controls (n = 120).,BST2,plasma,1
PMC4606116A,We performed ROC analysis to evaluate the efficacy of plasma BST2 and CEA levels for discriminating CRC patients (n = 120) and controls (n = 120).,CEA,plasma,1
PMC3494970A,"This was in contrast with the observations of Furuyama and coworkers12.Thus, we concluded that SOX9+ ductal plate cells give rise to cholangiocytes lining the bile ducts including the most proximal biliary structures, as well as to periportal hepatocytes.",SOX9,bile,1
PMC3929731A,"Each unknown serum sample (25 mL) or calibration standard (25 mL) was mixed with 100 mL of acetonitrile containing the surrogate standards 5 ng/mL [d6]-BPA and 5 ng/mL [13C12]-BPA-G. The mixture was vortexed for 1 minute, centrifuged for 15 minutes at 13 000 x g at 4degC, and the supernatant was removed and evaporated to dryness.",BPA,serum,-1
PMC3929731A,"Each unknown serum sample (25 mL) or calibration standard (25 mL) was mixed with 100 mL of acetonitrile containing the surrogate standards 5 ng/mL [d6]-BPA and 5 ng/mL [13C12]-BPA-G. The mixture was vortexed for 1 minute, centrifuged for 15 minutes at 13 000 x g at 4degC, and the supernatant was removed and evaporated to dryness.",BPA,serum,-1
PMC4483763A,"Finally, the hepatoblast is a bipotential progenitor for both cholangiocytes (bile duct cells; HNF6+, SOX9+, HNF1b+) and hepatocytes (PROX1+, HNF4a+).",SOX9,bile,1
PMC4483763A,"Finally, the hepatoblast is a bipotential progenitor for both cholangiocytes (bile duct cells; HNF6+, SOX9+, HNF1b+) and hepatocytes (PROX1+, HNF4a+).",PROX1,bile,1
PMC4483763A,"Finally, the hepatoblast is a bipotential progenitor for both cholangiocytes (bile duct cells; HNF6+, SOX9+, HNF1b+) and hepatocytes (PROX1+, HNF4a+).",HNF6,bile,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",PCR,astrocytes,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",MB-231,astrocytes,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",MCF7,astrocytes,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",TACSTD2,astrocytes,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",mRNA,astrocytes,1
PMC3269833A,"B) The TACSTD2 mRNA levels in human mammary epithelial cell line, MCF10A, in breast cancer cell lines, MCF7 and MDA-MB-231, and in primary rat astrocytes were measured by quantitative real-time PCR (n = 3). **: p  0.01, ***: p  0.001.",MDA,astrocytes,1
PMC4558321A,"Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).Analysis of the serum samples 30 min after the end of infusion showed 96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed.",SD,serum,1
PMC4558321A,"Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).Analysis of the serum samples 30 min after the end of infusion showed 96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed.",CRC,serum,1
PMC4558321A,"Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).Analysis of the serum samples 30 min after the end of infusion showed 96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed.",TNBC,serum,1
PMC4558321A,"Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).Analysis of the serum samples 30 min after the end of infusion showed 96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed.",HRPC,serum,1
PMC4558321A,"Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).Analysis of the serum samples 30 min after the end of infusion showed 96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed.",SN-38,serum,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",MC3T3-E1,bone marrow,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",MSC,bone marrow,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",L929,bone marrow,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",GO,bone marrow,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",GO,bone marrow,1
PMC4863686A,"Due to their mechanical properties, they are suitable for the structural reinforcement of biocompatible films, hydrogels, and other scaffolding materials frequently used in tissue engineering.31MSCs are multipotent progenitor cells derived from adult bone marrow, and have shown promising applications in tissue repair and cell therapies.252,253 The differentiation of MSCs is controlled by several factors including the microenvironment via material mechanics,254 substrate topography,255 soluble growth factors,256 and osteogenic inducers, such as dexamethasone and beta-glycerolphosphate.191 Graphene-reinforced chitosan films showed enhanced mechanical and biocompatibility properties in murine fibrosarcoma L929 cell culture.189 GO-reinforced chitosan scaffolds significantly improved cellular adhesion, proliferation, differentiation, and calcium and phosphate deposition of MC3T3-E1 cells, a mouse preosteoblast cell line.197 Lee et al191 explored the possibility of using graphene and GO as substrates for MSC adhesion, proliferation, and differentiation, and found that graphene and GO accelerated stem cell growth and differentiation through molecular interactions.",GO,bone marrow,1
PMC3474961A,"Intra-tumor and serum androgen levels (testosterone and DHT) in recurrent PCa appear to be sufficient to activate AR, and suggested that the PCa microenvironment may be capable of intracrine androgen biosynthesis [73].",AR,serum,-1
PMC3474961A,"Intra-tumor and serum androgen levels (testosterone and DHT) in recurrent PCa appear to be sufficient to activate AR, and suggested that the PCa microenvironment may be capable of intracrine androgen biosynthesis [73].",DHT,serum,-1
PMC4275355A,"Additionally, a recent finding suggested that both interfollicular and hair follicle stem cells could give rise to BCC using a variety of lineage drivers (K15, Lgr5, K5, and K14) and a different oncogenic allele [81].",BCC,hair,-1
PMC4275355A,"Additionally, a recent finding suggested that both interfollicular and hair follicle stem cells could give rise to BCC using a variety of lineage drivers (K15, Lgr5, K5, and K14) and a different oncogenic allele [81].",K14,hair,-1
PMC4275355A,"Additionally, a recent finding suggested that both interfollicular and hair follicle stem cells could give rise to BCC using a variety of lineage drivers (K15, Lgr5, K5, and K14) and a different oncogenic allele [81].",Lgr5,hair,-1
PMC4275355A,"Additionally, a recent finding suggested that both interfollicular and hair follicle stem cells could give rise to BCC using a variety of lineage drivers (K15, Lgr5, K5, and K14) and a different oncogenic allele [81].",K5,hair,-1
PMC4275355A,"Additionally, a recent finding suggested that both interfollicular and hair follicle stem cells could give rise to BCC using a variety of lineage drivers (K15, Lgr5, K5, and K14) and a different oncogenic allele [81].",K15,hair,-1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",TLR8,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",RD,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",CL075,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",TNF,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",RD,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",GM,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",LPS,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",RD,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",LPS,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",RD,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",IFN,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",IFN,CSF,1
PMC3476529A,"Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ""cocktail"" containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (RD), 50 ng/ml TNF-a (RD), 3,000 IU/ml IFN-a (RD), and 25 ng/ml IL-1b (RD) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis.",BEI,CSF,1
PMC3655979A,"ME-180, TE-11, and A375 were grown in RPMI 1640 media (Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Thermo Scientific HyClone, Logan, UT).",TE-11,serum,1
PMC3655979A,"ME-180, TE-11, and A375 were grown in RPMI 1640 media (Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Thermo Scientific HyClone, Logan, UT).",ME-180,serum,1
PMC3655979A,"ME-180, TE-11, and A375 were grown in RPMI 1640 media (Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Thermo Scientific HyClone, Logan, UT).",RPMI,serum,1
PMC3655979A,"ME-180, TE-11, and A375 were grown in RPMI 1640 media (Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Thermo Scientific HyClone, Logan, UT).",A375,serum,1
PMC3655979A,"ME-180, TE-11, and A375 were grown in RPMI 1640 media (Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Thermo Scientific HyClone, Logan, UT).",FBS,serum,1
PMC3476529A,Viability was 90% by DAPI exclusion (Sigma).Peripheral blood mononuclear cells were isolated by density centrifugation (Ficoll-Paque; GE Healthcare).,DAPI,blood,-1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",SV40,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",SV40,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",F12,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",F12,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",T,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",T,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",T,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",T,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",HCE,serum,1
PMC2928967A,"SV40 immortalized human corneal epithelial (HCE-T) cells14 were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium/F12 containing 200 U/ml penicillin and streptomycin, 10% fetal bovine serum (Mediatech, Herndon, VA), 0.1 mg/ml cholera toxin (List Biological Laboratories, Campbell, CA), 5 mg/ml insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/ml human epidermal growth factor (Invitrogen).15 HeLa cells and 293T cells were subcultured every 4 days and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.",HCE,serum,1
PMC3476529A,Monocyte-derived DCs (mo-DCs) were generated from magnetically isolated CD14+ monocytes (Miltenyi Biotec) cultured for 6 days with 50 ng/ml rGM-CSF and IL-4 (RD).Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with FlowJo (Treestar).,IL-4,CSF,1
PMC3476529A,Monocyte-derived DCs (mo-DCs) were generated from magnetically isolated CD14+ monocytes (Miltenyi Biotec) cultured for 6 days with 50 ng/ml rGM-CSF and IL-4 (RD).Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with FlowJo (Treestar).,rGM,CSF,1
PMC3476529A,Monocyte-derived DCs (mo-DCs) were generated from magnetically isolated CD14+ monocytes (Miltenyi Biotec) cultured for 6 days with 50 ng/ml rGM-CSF and IL-4 (RD).Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with FlowJo (Treestar).,CD14,CSF,1
PMC3476529A,Monocyte-derived DCs (mo-DCs) were generated from magnetically isolated CD14+ monocytes (Miltenyi Biotec) cultured for 6 days with 50 ng/ml rGM-CSF and IL-4 (RD).Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with FlowJo (Treestar).,BDLSRII,CSF,1
PMC4062414A,These sodium channels are removed from the plasma membrane in endosomes formed with the participation of clathrin and EPN3 (r = 0.83) and may be recycled.,EPN3,plasma,1
PMC3981717A,"Since the significant association result between SNPs and cancer outcomes was observed in HCC patients with PVTT, we further examined whether the genotypes of these SNPs have effect on the formation of PVTT by logistic regression analysis with adjustment for age, gender, HBsAg, serum AFP, tumor size and number of tumor.",PVTT,serum,1
PMC3981717A,"Since the significant association result between SNPs and cancer outcomes was observed in HCC patients with PVTT, we further examined whether the genotypes of these SNPs have effect on the formation of PVTT by logistic regression analysis with adjustment for age, gender, HBsAg, serum AFP, tumor size and number of tumor.",PVTT,serum,1
PMC3981717A,"Since the significant association result between SNPs and cancer outcomes was observed in HCC patients with PVTT, we further examined whether the genotypes of these SNPs have effect on the formation of PVTT by logistic regression analysis with adjustment for age, gender, HBsAg, serum AFP, tumor size and number of tumor.",AFP,serum,1
PMC3981717A,"Since the significant association result between SNPs and cancer outcomes was observed in HCC patients with PVTT, we further examined whether the genotypes of these SNPs have effect on the formation of PVTT by logistic regression analysis with adjustment for age, gender, HBsAg, serum AFP, tumor size and number of tumor.",HCC,serum,1
PMC4966842B,This immunotherapy seeks to provide an adaptive-centric (lymph node targeting vaccine and anti-PD-1 checkpoint blockade) and innate-centric (anti-tumor antibody and Fc/IL-2) method for cancer treatment.,PD-1,lymph,1
PMC4966842B,This immunotherapy seeks to provide an adaptive-centric (lymph node targeting vaccine and anti-PD-1 checkpoint blockade) and innate-centric (anti-tumor antibody and Fc/IL-2) method for cancer treatment.,IL-2,lymph,1
PMC4558321A,"Comparison of SN-38 delivery in tumor-bearing animals given sacituzumab govitecan and irinotecan has indicated the SN-38 bound to the IgG is not glucuronidated, whereas in animals given irinotecan, 50% of the total SN-38 in the serum is glucuronidated (17).",SN-38,serum,1
PMC4558321A,"Comparison of SN-38 delivery in tumor-bearing animals given sacituzumab govitecan and irinotecan has indicated the SN-38 bound to the IgG is not glucuronidated, whereas in animals given irinotecan, 50% of the total SN-38 in the serum is glucuronidated (17).",SN-38,serum,1
PMC4558321A,"Comparison of SN-38 delivery in tumor-bearing animals given sacituzumab govitecan and irinotecan has indicated the SN-38 bound to the IgG is not glucuronidated, whereas in animals given irinotecan, 50% of the total SN-38 in the serum is glucuronidated (17).",SN-38,serum,1
PMC4711826A,"To induce hepatocyte differentiation, imMob1DKOLP cells (500 cells per 20 mL) were cultured for 2 d using the hanging drop method, followed by culture for an additional 9 d in multiwell plates that were coated with Matrigel (BD Bioscience) and filled with serum-free Williams' Medium E containing 1 uM dexamethasone and 10 ng/mL OncostatinM (RD).",RD,serum,1
PMC4606116A,"Taken together, these observations suggest that the exosome-based secretion pathway may represent one of the potential mechanisms for shedding of BST2 into blood circulation from CRC tumor cells.",BST2,blood,-1
PMC4606116A,"Taken together, these observations suggest that the exosome-based secretion pathway may represent one of the potential mechanisms for shedding of BST2 into blood circulation from CRC tumor cells.",CRC,blood,-1
PMC5386687A,The ARCaP cell pair was cultured in T-media (Invitrogen) supplemented with 5% heat-inactivated fetal bovine serum (FBS from Gibco 10437-028) and 1% penicillin/streptomycin (Pen/Strep from Hyclone SV30010).,SV30010,serum,1
PMC5386687A,The ARCaP cell pair was cultured in T-media (Invitrogen) supplemented with 5% heat-inactivated fetal bovine serum (FBS from Gibco 10437-028) and 1% penicillin/streptomycin (Pen/Strep from Hyclone SV30010).,T,serum,1
PMC5386687A,The ARCaP cell pair was cultured in T-media (Invitrogen) supplemented with 5% heat-inactivated fetal bovine serum (FBS from Gibco 10437-028) and 1% penicillin/streptomycin (Pen/Strep from Hyclone SV30010).,FBS,serum,1
PMC4509052A,"Following incubation for 48 h, 3x104 cells were transferred onto the top of the Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) in serum-free DMEM, while DMEM containing 10% FBS was added to the lower chamber.",DMEM,serum,1
PMC4509052A,"Following incubation for 48 h, 3x104 cells were transferred onto the top of the Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) in serum-free DMEM, while DMEM containing 10% FBS was added to the lower chamber.",USA,serum,1
PMC4509052A,"Following incubation for 48 h, 3x104 cells were transferred onto the top of the Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) in serum-free DMEM, while DMEM containing 10% FBS was added to the lower chamber.",DMEM,serum,1
PMC4509052A,"Following incubation for 48 h, 3x104 cells were transferred onto the top of the Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) in serum-free DMEM, while DMEM containing 10% FBS was added to the lower chamber.",San,serum,1
PMC4509052A,"Following incubation for 48 h, 3x104 cells were transferred onto the top of the Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) in serum-free DMEM, while DMEM containing 10% FBS was added to the lower chamber.",FBS,serum,1
PMC3866276A,"Furthermore, it was recently demonstrated that the hESC-based model express bona fide human tumor blood vessels and enhance tumor engraftment rate by primary human ovarian cancer stem-like cells (CSC) [37].",hESC,blood,-1
PMC3866276A,"Furthermore, it was recently demonstrated that the hESC-based model express bona fide human tumor blood vessels and enhance tumor engraftment rate by primary human ovarian cancer stem-like cells (CSC) [37].",CSC,blood,-1
PMC4175977A,"However, USP9Y-TTTY15 expression level changes from normal to cancer samples was not correlated with Gleason score (p=0.781), clinical (TNM) stage (p=0.856), or lymph node metastasis (p=0.799).",TNM,lymph,1
PMC4175977A,"However, USP9Y-TTTY15 expression level changes from normal to cancer samples was not correlated with Gleason score (p=0.781), clinical (TNM) stage (p=0.856), or lymph node metastasis (p=0.799).",TTTY15,lymph,1
PMC4175977A,"However, USP9Y-TTTY15 expression level changes from normal to cancer samples was not correlated with Gleason score (p=0.781), clinical (TNM) stage (p=0.856), or lymph node metastasis (p=0.799).",USP9Y,lymph,1
PMC3566310A,enzyme-linked immunosorbent assay (ELISA) for human FGF7 was performed on serum samples harvested from healthy controls (n = 6) and patients with fulminant (n = 6) or acute (n = 43) hepatitis.,ELISA,serum,1
PMC3566310A,enzyme-linked immunosorbent assay (ELISA) for human FGF7 was performed on serum samples harvested from healthy controls (n = 6) and patients with fulminant (n = 6) or acute (n = 43) hepatitis.,FGF7,serum,1
PMC5363540A,"In addition, using the tet-off system to manually control the expression of 11 amino acids of AREG protein at the C-terminus and thereby promote the translocation of pro-AREG from the plasma membrane to the nucleus, it was found that nuclear pro-AREG increased the resistance of cells to anti-cancer drugs [13].",AREG,plasma,1
PMC5363540A,"In addition, using the tet-off system to manually control the expression of 11 amino acids of AREG protein at the C-terminus and thereby promote the translocation of pro-AREG from the plasma membrane to the nucleus, it was found that nuclear pro-AREG increased the resistance of cells to anti-cancer drugs [13].",AREG,plasma,1
PMC5363540A,"In addition, using the tet-off system to manually control the expression of 11 amino acids of AREG protein at the C-terminus and thereby promote the translocation of pro-AREG from the plasma membrane to the nucleus, it was found that nuclear pro-AREG increased the resistance of cells to anti-cancer drugs [13].",AREG,plasma,1
PMC4175977A,"Furthermore, we frequently detected ten times higher SLC45A-ELK4 expression in prostate cancer than in normal samples in cases with higher baseline PSA (=20 ng/ml; p=0.031), Gleason score (p=0.032), TNM stage (p=0.012), and with lymph node metastasis (p=0.013), indicating that a dramatic increase of SLC45A3-ELK4 expression is associated with the progression of prostate cancer to an advanced disease status (Table 3).See full tableTable 3.",ELK4,lymph,1
PMC4175977A,"Furthermore, we frequently detected ten times higher SLC45A-ELK4 expression in prostate cancer than in normal samples in cases with higher baseline PSA (=20 ng/ml; p=0.031), Gleason score (p=0.032), TNM stage (p=0.012), and with lymph node metastasis (p=0.013), indicating that a dramatic increase of SLC45A3-ELK4 expression is associated with the progression of prostate cancer to an advanced disease status (Table 3).See full tableTable 3.",SLC45A3-ELK4,lymph,1
PMC4175977A,"Furthermore, we frequently detected ten times higher SLC45A-ELK4 expression in prostate cancer than in normal samples in cases with higher baseline PSA (=20 ng/ml; p=0.031), Gleason score (p=0.032), TNM stage (p=0.012), and with lymph node metastasis (p=0.013), indicating that a dramatic increase of SLC45A3-ELK4 expression is associated with the progression of prostate cancer to an advanced disease status (Table 3).See full tableTable 3.",SLC45A,lymph,1
PMC4175977A,"Furthermore, we frequently detected ten times higher SLC45A-ELK4 expression in prostate cancer than in normal samples in cases with higher baseline PSA (=20 ng/ml; p=0.031), Gleason score (p=0.032), TNM stage (p=0.012), and with lymph node metastasis (p=0.013), indicating that a dramatic increase of SLC45A3-ELK4 expression is associated with the progression of prostate cancer to an advanced disease status (Table 3).See full tableTable 3.",TNM,lymph,1
PMC4175977A,"Furthermore, we frequently detected ten times higher SLC45A-ELK4 expression in prostate cancer than in normal samples in cases with higher baseline PSA (=20 ng/ml; p=0.031), Gleason score (p=0.032), TNM stage (p=0.012), and with lymph node metastasis (p=0.013), indicating that a dramatic increase of SLC45A3-ELK4 expression is associated with the progression of prostate cancer to an advanced disease status (Table 3).See full tableTable 3.",PSA,lymph,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",FBS,serum,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",DMEM,serum,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",DMEM,serum,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",FBS,serum,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",DMEM,serum,1
PMC2946292A,"These cells were a kind gift from Dr. Sabry el-Naggar (Medical University of South Carolina) and were maintained in DMEM supplemented with 5% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells were a kind gift from Dr. Paul Ling and Dr. Adrian Lee (Baylor College of Medicine) and were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (complete DMEM).",NIH3T3,serum,1
PMC4673473A,"Thus, LCM and HGF treatment during the second phase of in vitro culture efficiently induced hepatocyte differentiation of initially expanded immature bone marrow cells.",LCM,bone marrow,1
PMC4673473A,"Thus, LCM and HGF treatment during the second phase of in vitro culture efficiently induced hepatocyte differentiation of initially expanded immature bone marrow cells.",HGF,bone marrow,1
PMC4448470A,"Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories Inc, Logan, UT, USA) in a humidified 5% CO2 atmosphere.",CO2,serum,1
PMC4448470A,"Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories Inc, Logan, UT, USA) in a humidified 5% CO2 atmosphere.",USA,serum,1
PMC4448470A,"Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories Inc, Logan, UT, USA) in a humidified 5% CO2 atmosphere.",RPMI,serum,1
PMC4448470A,"Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories Inc, Logan, UT, USA) in a humidified 5% CO2 atmosphere.",USA,serum,1
PMC5042010A,"In addition, a median background of 172 CD45+ events from a 7.5mL blood sample will allow detection of as few as 3-4 heterozygous events from a blood sample using a test that can detect mutations with a 1% frequency; a performance already approaching a single cell detection event.",CD45,blood,1
PMC5042010A,"In addition, a median background of 172 CD45+ events from a 7.5mL blood sample will allow detection of as few as 3-4 heterozygous events from a blood sample using a test that can detect mutations with a 1% frequency; a performance already approaching a single cell detection event.",CD45,blood,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",CH1,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",Tech,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",MCF-7,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",VL,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",DNA,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",VH,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",DMEM,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",CO2,serum,1
PMC4756367A,"MCF-7 were maintained at 37 degC in a 5% CO2 humidified atmosphere with DMEM medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin35.The DNA sequences of the entire light chain genes (VL and CL) and heavy chain genes (VH and CH1) of cetuximab were obtained from United States patent US 7, 060, 80836 and generated using synthetic oligonucleotides (Genewiz Tech Co., LTD; Suzhou, China).",LTD,serum,1
PMC4690245A,"These cells were cultured in RPMI1640 medium supplemented with 10 % fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml).",RPMI1640,serum,1
PMC4690245A,"These cells were cultured in RPMI1640 medium supplemented with 10 % fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml).",FBS,serum,1
PMC4108928A,"Besides, high ROR1 expression in ovarian cancer was correlated with certain clinical pathologic parameters, including FIGO stage, tumor grade and positive lymph node metastasis.",ROR1,lymph,1
PMC4108928A,"Besides, high ROR1 expression in ovarian cancer was correlated with certain clinical pathologic parameters, including FIGO stage, tumor grade and positive lymph node metastasis.",FIGO,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",TRAP-1,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",TRAP-1,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",PIN,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",TRAP-1,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",TRAP-1,lymph,1
PMC2797899A,"Gleason grade 5 cancers were also uniformly positive for TRAP-1 expression with heterogeneous staining intensity that varied from weak (Figure 1F) to strong (Figure 1G) in different tumor cell populations within the various samples (Table 1).In all strongly positive cases of PIN or prostate cancer, TRAP-1 staining appeared as discrete punctate granules dispersed throughout the cytoplasm of tumor cells (see inset panel E), potentially consistent with the subcellular localization of TRAP-1 to mitochondria.14 A control, nonbinding IgG gave no staining of normal or tumor glands, by immunohistochemistry (not shown).Unlike the heterogeneous pattern of TRAP-1 staining in localized high-grade cancers (Table 1), immunohistochemical analysis of metastatic prostate cancer revealed uniformly intense expression of TRAP-1 in the tumor cell population within lymph nodes (Figure 2, A and B), and bones (Figure 2, D-F).",TRAP-1,lymph,1
PMC2797899A,"In contrast, non neoplastic constituents of lymph nodes and bones were unstained for TRAP-1 (Figure 2, D-F), and a nonbinding IgG did not stain metastatic cancer cells in either location (Figure 2C and not shown).We next looked at the expression of TRAP-1 in genetic mouse models of prostate cancer.",TRAP-1,lymph,1
PMC2797899A,"In contrast, non neoplastic constituents of lymph nodes and bones were unstained for TRAP-1 (Figure 2, D-F), and a nonbinding IgG did not stain metastatic cancer cells in either location (Figure 2C and not shown).We next looked at the expression of TRAP-1 in genetic mouse models of prostate cancer.",TRAP-1,lymph,1
PMC5410259A,"To further validate this approach, GFP-labeled GUMC-30 cells were mixed with normal HFKs in equal amounts and were first grown in DMEM without serum for 7 days.",DMEM,serum,1
PMC5410259A,"To further validate this approach, GFP-labeled GUMC-30 cells were mixed with normal HFKs in equal amounts and were first grown in DMEM without serum for 7 days.",GFP,serum,1
PMC5410259A,"To further validate this approach, GFP-labeled GUMC-30 cells were mixed with normal HFKs in equal amounts and were first grown in DMEM without serum for 7 days.",GUMC-30,serum,1
PMC4270176A,"The ECM also has a key role in disease progression in pancreatic cancer, where the abundance of ECM induces an abnormal configuration of blood and lymphatic vessels.",ECM,blood,-1
PMC4270176A,"The ECM also has a key role in disease progression in pancreatic cancer, where the abundance of ECM induces an abnormal configuration of blood and lymphatic vessels.",ECM,blood,-1
PMC3845885A,"IMA901, given with GM-CSF, is delivered over a total of 4 months with a series of 10 consecutive vaccinations.",GM,CSF,1
PMC3845885A,"IMA901, given with GM-CSF, is delivered over a total of 4 months with a series of 10 consecutive vaccinations.",IMA901,CSF,1
PMC4344740A,"Based on the notion that antigens other than Hsps are implicated in stroke, we screened a human microvascular endothelial cell cDNA library using plasma from a stroke patient.",cDNA,plasma,1
PMC4673178A,"An examination of the pharmacokinetic behavior of the fully substituted conjugate was performed in non-tumor-bearing mice given 0.2 mg of IMMU-132, with comparison to unconjugated hRS7 IgG, as well as the reduced and then capped IgG with N-ethylmaleimide to evaluate whether breaking the interchain disulfides destabilizes the IgG in serum [37].",IMMU-132,serum,-1
PMC4673178A,"An examination of the pharmacokinetic behavior of the fully substituted conjugate was performed in non-tumor-bearing mice given 0.2 mg of IMMU-132, with comparison to unconjugated hRS7 IgG, as well as the reduced and then capped IgG with N-ethylmaleimide to evaluate whether breaking the interchain disulfides destabilizes the IgG in serum [37].",hRS7,serum,-1
PMC3364558A,"The 99mTc-anti-CEA Fab' showed only a minor blush in the tumor at 1 h, with most of the activity residing in the blood, liver and kidneys, with some elimination in the urinary bladder.",CEA,blood,-1
PMC4687932A,"Consequently, highly sensitive and specific methods for detection, isolation and molecular characterization in the background of supernumerary blood cell components (1 CTC per 106-107 peripheral mononuclear blood cells) are needed [8-11].",CTC,blood,-1
PMC4687932A,"Consequently, highly sensitive and specific methods for detection, isolation and molecular characterization in the background of supernumerary blood cell components (1 CTC per 106-107 peripheral mononuclear blood cells) are needed [8-11].",CTC,blood,-1
PMC3364558A,"18F-FDG has extensive uptake in the bone marrow (BM) of mice, as well as in the brain (Br) and heart wall (H).View larger versionFigure 5.",FDG,bone marrow,1
PMC4685746A,"The development of LCs and microglia is critically dependent upon the local production of IL-34 acting through the M-CSF receptor [14, 15].In the brain, microglia arise exclusively from yolk sac macrophages, as demonstrated by Ginhoux and colleagues using a Runx1 inducible fate-mapping system [16].",IL-34,CSF,1
PMC4685746A,"The development of LCs and microglia is critically dependent upon the local production of IL-34 acting through the M-CSF receptor [14, 15].In the brain, microglia arise exclusively from yolk sac macrophages, as demonstrated by Ginhoux and colleagues using a Runx1 inducible fate-mapping system [16].",Runx1,CSF,1
PMC2976030A,The whole blood was placed in a K3EDTA coated 1.5ml microcentrifuge tube and centrifuged at 4degC for 5 minutes at 3000rpm.,K3EDTA,blood,-1
PMC4687932A,"Within the presented study, we aimed to improve CTC enrichment/blood testing in an EpCAM-independent manner providing the opportunity to target multiple epithelial- and/or cancer-related antigens expressed on CTCs simultaneously.",CTC,blood,1
PMC3266428A,Two recent studies have reported associations between methylation in DNA extracted from cord blood (15) and umbilical cord tissue (16) and prepubertal adiposity in children.,DNA,blood,-1
PMC3180064A,"Regional recurrence after surgical resection is also a contributing factor as is seen more commonly in NSCLC SCC than other histologic subtypes because SCC is able to spread by extending through periobronchial tubes which allow them to directly invade mediastinal lymph nodes and other mediastinal structures [26, 30].",NSCLC,lymph,1
PMC3180064A,"Regional recurrence after surgical resection is also a contributing factor as is seen more commonly in NSCLC SCC than other histologic subtypes because SCC is able to spread by extending through periobronchial tubes which allow them to directly invade mediastinal lymph nodes and other mediastinal structures [26, 30].",SCC,lymph,1
PMC3180064A,"Regional recurrence after surgical resection is also a contributing factor as is seen more commonly in NSCLC SCC than other histologic subtypes because SCC is able to spread by extending through periobronchial tubes which allow them to directly invade mediastinal lymph nodes and other mediastinal structures [26, 30].",SCC,lymph,1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,Blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,saliva,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",EDTA,Blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",EDTA,saliva,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",EDTA,blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,Blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,saliva,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,Blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,saliva,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",RNA,blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,Blood,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,saliva,-1
PMC3266428A,"Whole blood (EDTA-Vacutainer and PAXgene Blood RNA tube; BD, Franklin Lakes, NJ) and saliva (Oragene*DNA; DNA Genotek, Kanata, Canada) samples were collected at age ~11 years for DNA and RNA analysis.",DNA,blood,-1
PMC3446379A,2.5 x 104 MCF-7 or MCF-7-TamR cells were seeded on the upper chamber of a transwell system where the lower wells contained media with 5% serum.,MCF-7,serum,1
PMC5376003A,"Slides were blocked with 10% goat serum for 60 min and then incubated with primary antibody against panCK and EpCAM (1:100 dilution) at room temperature (RT) for 2 h. The slides were subsequently incubated with the FITC-donkey anti-rabbit IgG and Alexa Fluor(r) 647 Goat anti-mouse IgG (1:500 dilution; BioLegend, San Diego, CA) for 20 min and then counterstaining with Hoechst 33258 for 6 min, and viewed with Zeiss epifluorescence microscope.",San,serum,1
PMC5376003A,"Slides were blocked with 10% goat serum for 60 min and then incubated with primary antibody against panCK and EpCAM (1:100 dilution) at room temperature (RT) for 2 h. The slides were subsequently incubated with the FITC-donkey anti-rabbit IgG and Alexa Fluor(r) 647 Goat anti-mouse IgG (1:500 dilution; BioLegend, San Diego, CA) for 20 min and then counterstaining with Hoechst 33258 for 6 min, and viewed with Zeiss epifluorescence microscope.",FITC,serum,1
PMC5003214A,"Previously, epithelial cells were obtained from endobronchial biopsies and cultured in serum-free bronchial epithelial growth medium (BEGM) for multiple passages (3).",BEGM,serum,1
PMC5430091A,"AREG is located at chromosome 4q13.3 and shedding ECD of original a 252 amino acid transmembrane precursor (pre-AREG), then secret into blood or other cell surrounding microenvironment through autocrine and paracrine.",AREG,blood,-1
PMC5430091A,"AREG is located at chromosome 4q13.3 and shedding ECD of original a 252 amino acid transmembrane precursor (pre-AREG), then secret into blood or other cell surrounding microenvironment through autocrine and paracrine.",AREG,blood,-1
PMC5430091A,"AREG is located at chromosome 4q13.3 and shedding ECD of original a 252 amino acid transmembrane precursor (pre-AREG), then secret into blood or other cell surrounding microenvironment through autocrine and paracrine.",ECD,blood,-1
PMC3906064A,"Following the loading of the blood, the device was washed with PBS and the top buffer turned off.",PBS,blood,-1
PMC3906064A,"Blood was drawn into 10 mL K2EDTA vacutainers (BD, Franklin Lakes, NJ) then fixed with the LiquidBiopsy fixative (Cynvenio Biosystems, Westlake Village, CA) within 4 hours of collection.",K2EDTA,Blood,-1
PMC4803572A,Our recent study reported detection of DTC in the bone marrow of PCa patients who have no evidence of disease (NED) for up to 18 years after surgery [6].,DTC,bone marrow,1
PMC4803572A,Our recent study reported detection of DTC in the bone marrow of PCa patients who have no evidence of disease (NED) for up to 18 years after surgery [6].,NED,bone marrow,1
PMC5376003A,"Cells were fixed with 4% paraformaldehyde and then treated at 4degC with methanol for 2 min, and blocked with 1% goat serum and 5% BSA for 1 h. Cells were stained with antibodies to EpCAM, desmin, HNF-3b or albumin (1:100 dilution) at RT for 2 h. The slides were subsequently incubated with the FITC-donkey anti-rabbit IgG (1:500 dilution) for 20 min and then counterstaining with Hoechst 33258 for 6 min.",BSA,serum,1
PMC5376003A,"Cells were fixed with 4% paraformaldehyde and then treated at 4degC with methanol for 2 min, and blocked with 1% goat serum and 5% BSA for 1 h. Cells were stained with antibodies to EpCAM, desmin, HNF-3b or albumin (1:100 dilution) at RT for 2 h. The slides were subsequently incubated with the FITC-donkey anti-rabbit IgG (1:500 dilution) for 20 min and then counterstaining with Hoechst 33258 for 6 min.",FITC,serum,1
PMC3938934A,"It has been proposed that cellular injury to the airway results in prolonged activation of PLA2, resulting in hydrolysis of plasma membrane phospholipids and release of AA [40].",PLA2,plasma,1
PMC2441949A,"To investigate whether these genes were overexpressed in metastatic CRC, we selected 14 genes and measured their level of expression in lymph nodes obtained from CRC patients who were positive (n=7) and negative (n=7) for metastatic disease by HE staining.",CRC,lymph,1
PMC2441949A,"To investigate whether these genes were overexpressed in metastatic CRC, we selected 14 genes and measured their level of expression in lymph nodes obtained from CRC patients who were positive (n=7) and negative (n=7) for metastatic disease by HE staining.",HE,lymph,1
PMC2441949A,"To investigate whether these genes were overexpressed in metastatic CRC, we selected 14 genes and measured their level of expression in lymph nodes obtained from CRC patients who were positive (n=7) and negative (n=7) for metastatic disease by HE staining.",CRC,lymph,1
PMC3269833A,"MCF10A cells were cultured in DMEM/F12(1:1) with 5% horse serum, 10 ug/ml insulin, 20 ng/ml EGF, 100 ng/ml choleratoxin, 0.5 ug/ml hydrocortisone and pen/strep.",DMEM,serum,1
PMC3269833A,"MCF10A cells were cultured in DMEM/F12(1:1) with 5% horse serum, 10 ug/ml insulin, 20 ng/ml EGF, 100 ng/ml choleratoxin, 0.5 ug/ml hydrocortisone and pen/strep.",EGF,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",MCF7,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",PA,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",FBS,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",BRL,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",USA,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",MDA,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",DMEM,serum,1
PMC3269833A,"MCF7 and MDA-MB-231 were cultured in Dulbecco's modified Eagles's media (DMEM, Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine and penicillin/streptomycin.",MB-231,serum,1
PMC3269833A,Primary astrocytes were maintained in DMEM/F12 (1:1) plus 10% FBS and pen/strep.,FBS,astrocytes,1
PMC3269833A,Primary astrocytes were maintained in DMEM/F12 (1:1) plus 10% FBS and pen/strep.,DMEM,astrocytes,1
PMC3269833A,Primary astrocytes were maintained in DMEM/F12 (1:1) plus 10% FBS and pen/strep.,F12,astrocytes,1
PMC4253434A,B. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media or whole cell lysates (W.C.L.) taken from Trop2 knockdown or LacZ control cells.,NRG1,serum,1
PMC4253434A,B. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media or whole cell lysates (W.C.L.) taken from Trop2 knockdown or LacZ control cells.,Trop2,serum,1
PMC3906064A,Sorting was achieved by first identifying the population of CK-/CD45+ mononuclear white blood cells (WBC).,WBC,blood,-1
PMC3418405A,"Phosphorylation of Foxo3a by several kinases including AKT, IKKa/b, ERK and serum glucose kinase (SGK) results in its exclusion from the nucleus and inhibition of its transcriptional activity (23, 26, 35, 36).",SGK,serum,1
PMC3418405A,"Phosphorylation of Foxo3a by several kinases including AKT, IKKa/b, ERK and serum glucose kinase (SGK) results in its exclusion from the nucleus and inhibition of its transcriptional activity (23, 26, 35, 36).",AKT,serum,1
PMC3418405A,"Phosphorylation of Foxo3a by several kinases including AKT, IKKa/b, ERK and serum glucose kinase (SGK) results in its exclusion from the nucleus and inhibition of its transcriptional activity (23, 26, 35, 36).",ERK,serum,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",NEC,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",NEC,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",MYO5B,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",MYO5B,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",MYO5C,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",MYO5C,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",RAB25,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",RAB25,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",AP1M2,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",AP1M2,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",GRHL2,plasma,1
PMC4062414A,"(See text for further description of the model).In summary, several of the epithelial-specific genes, identified by their selective expression in the NEC cell lines, are implicated in endocytosis, vesicle transport and cell polarity, including EPN3/epsin-3 (r = 0.83), RAB25 (r = 0.94), GRHL2 (r = 0.89), ADAP1/CENTA1 (r = 0.82), MYO5B (r = 0.79), MYO5C (r = 0.73), AP1M2 (r = 0.75), and PLEKHG6/MyoGEF (r = 0.85).Ca(2+) signaling is involved in coordinating the transport of cargo-containing vesicles from endoplasmic reticulum to Golgi to plasma membrane [91]; this process may be involved in transport of cargo to specific regions of plasma membrane to maintain epithelial cell polarity.",GRHL2,plasma,1
PMC4259449A,"The DTC isolated from one patient were of poor quality, the other patient had no DTC observed in the bone marrow sample.",DTC,bone marrow,1
PMC4259449A,"The DTC isolated from one patient were of poor quality, the other patient had no DTC observed in the bone marrow sample.",DTC,bone marrow,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CD34,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CD34,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CD34,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-4,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-4,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-4,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",RPMI,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",RPMI,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",RPMI,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FLT3L,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TGF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TGF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TGF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CSF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CSF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",SCF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-6,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-6,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",IL-6,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",CSF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",DC,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",DC,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",DC,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FMS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FMS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FMS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",FCS,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",GM,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC5538449A,"In brief, sorted CD34+ cells were cultured in CellGro DC (CellGenix, Freiburg, Germany) medium supplemented with 10% FCS, 100 ng/mL GM-CSF, 20 ng/mL stem cell factor (SCF), 50 ng/mL FMS-like tyrosine kinase 3 ligand (FLT3L), and 2.5 ng/mL TNF-a for 5 days before subculturing in RPMI (Sigma, St Louis, Mo; 110% FCS) under lineage-specific cytokine conditions (100 ng/mL monocyte colony-stimulating factor, 50 ng/mL FLT3L, 20 ng/mL SCF, 2.5 ng/mL TNF-a, and 2 ng/mL IL-6 for monocytes; 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 25 ng/mL IL-4 for p-moDCs; and 100 ng/mL GM-CSF, 2.5 ng/mL TNF-a, and 1 ng/mL TGF-b1 for p-LCs).",TNF,CSF,1
PMC4015355A,"The toxicity of (Rap)2-E1-(Rap)2 to hematological cells was assessed on human peripheral blood mononuclear cells (PBMC) obtained from two healthy donors, following treatment with (Rap)2-E1-(Rap)2 at 0.1, 1, and 10 nM for 18 h. Treatment with (Rap)2-E1-(Rap)2 had nearly the same amount of apoptotic and dead cells as the untreated control (Additional file 5: Figure S4), indicating that (Rap)2-E1-(Rap)2 is not toxic to PBMC at concentrations up to 10 nM.Among the four groups (20, 40, 60 or 80 mg) tested, only those mice that received the four injections of (Rap)2-22*-(Rap)2 at 20 mg survived without acute toxicity or death.",PBMC,blood,-1
PMC4015355A,"The toxicity of (Rap)2-E1-(Rap)2 to hematological cells was assessed on human peripheral blood mononuclear cells (PBMC) obtained from two healthy donors, following treatment with (Rap)2-E1-(Rap)2 at 0.1, 1, and 10 nM for 18 h. Treatment with (Rap)2-E1-(Rap)2 had nearly the same amount of apoptotic and dead cells as the untreated control (Additional file 5: Figure S4), indicating that (Rap)2-E1-(Rap)2 is not toxic to PBMC at concentrations up to 10 nM.Among the four groups (20, 40, 60 or 80 mg) tested, only those mice that received the four injections of (Rap)2-22*-(Rap)2 at 20 mg survived without acute toxicity or death.",S4,blood,-1
PMC4015355A,"The toxicity of (Rap)2-E1-(Rap)2 to hematological cells was assessed on human peripheral blood mononuclear cells (PBMC) obtained from two healthy donors, following treatment with (Rap)2-E1-(Rap)2 at 0.1, 1, and 10 nM for 18 h. Treatment with (Rap)2-E1-(Rap)2 had nearly the same amount of apoptotic and dead cells as the untreated control (Additional file 5: Figure S4), indicating that (Rap)2-E1-(Rap)2 is not toxic to PBMC at concentrations up to 10 nM.Among the four groups (20, 40, 60 or 80 mg) tested, only those mice that received the four injections of (Rap)2-22*-(Rap)2 at 20 mg survived without acute toxicity or death.",PBMC,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",T,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",T,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",T,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",T,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",TAA,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",CD4,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",TAA,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",III,blood,-1
PMC4485845A,"Evidence for immunosurveillance, which relies on T-cell response to tumor-associated antigens (TAA),16 comes from rare cases of spontaneous complete responses observed in the placebo arm of a phase III trial.18 The blood and tumor microenvironment of these cases harbored TAA-specific T-cells; the tumors were highly infiltrated by TAA-specific effector memory CD8 T-cells and CD4 T-cells.",CD8,blood,-1
PMC4673178A,"Since this initial work, we showed that a highly stable linkage of SN-38 was significantly less effective than the CL2A linker that has a more intermediate stability in serum [35].Another current tenet of ADC design is to use an ultra-cytotoxic drug to compensate for low levels of antibody accretion in tumors, typically 0.003 to 0.08% of the injected dose per gram [36].",ADC,serum,1
PMC4673178A,"Since this initial work, we showed that a highly stable linkage of SN-38 was significantly less effective than the CL2A linker that has a more intermediate stability in serum [35].Another current tenet of ADC design is to use an ultra-cytotoxic drug to compensate for low levels of antibody accretion in tumors, typically 0.003 to 0.08% of the injected dose per gram [36].",CL2A,serum,1
PMC4673178A,"Since this initial work, we showed that a highly stable linkage of SN-38 was significantly less effective than the CL2A linker that has a more intermediate stability in serum [35].Another current tenet of ADC design is to use an ultra-cytotoxic drug to compensate for low levels of antibody accretion in tumors, typically 0.003 to 0.08% of the injected dose per gram [36].",SN-38,serum,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",FCS,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",FCS,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",GM,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",GM,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",CSF,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",TGF,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",TGF,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",CD14,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",CD14,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",Delta-1,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",Delta-1,blood,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",RPMI,CSF,1
PMC5538449A,"For generating moLCs, purified CD14+ blood monocytes were cultured in 24-well plates low/2 int hi coated with Delta-1, as previously described,24 in the presence of GM-CSF (100 ng/mL) and TGF-b1 (10 ng/mL) for 5 to 6 days (RPMI medium and 10% FCS).",RPMI,blood,1
PMC3049439A,". Long-term healing of full-thickness wounds requires cells from above the hair follicle bulge, in particular LGR6+ cells, which can heal wounds efficiently by generating permanent residents for all three skin lineages (Ito et al, 2007; Levy et al, 2007; Snippert et al, 2010a).Similar discrepancies were observed in the testes, in which normal spermatogenesis is maintained by a small subset of undifferentiated NANOS2+ spermatogonia cells that self-renew.",NANOS2,hair,-1
PMC3049439A,". Long-term healing of full-thickness wounds requires cells from above the hair follicle bulge, in particular LGR6+ cells, which can heal wounds efficiently by generating permanent residents for all three skin lineages (Ito et al, 2007; Levy et al, 2007; Snippert et al, 2010a).Similar discrepancies were observed in the testes, in which normal spermatogenesis is maintained by a small subset of undifferentiated NANOS2+ spermatogonia cells that self-renew.",LGR6,hair,-1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",TCHO,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",AST,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",P15,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",DBIL,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",LDH,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",ALB,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",TBIL,Serum,1
PMC4023823A,"(B) Serum biochemical test, measuring markers for liver injury (ALT, AST, and LDH), TCHO, DBIL/TBIL ratio, and ALB at P15 (n = 8 to 27).",ALT,Serum,1
PMC3049439A,"LGR6+ cells predominantly give rise to sebaceous glands and IFE, whereas LGR6 hair-follicle potential diminishes with age (Jensen et al, 2009; Snippert et al, 2010a).",LGR6,hair,1
PMC3049439A,"LGR6+ cells predominantly give rise to sebaceous glands and IFE, whereas LGR6 hair-follicle potential diminishes with age (Jensen et al, 2009; Snippert et al, 2010a).",LGR6,hair,1
PMC3049439A,"LGR6+ cells predominantly give rise to sebaceous glands and IFE, whereas LGR6 hair-follicle potential diminishes with age (Jensen et al, 2009; Snippert et al, 2010a).",IFE,hair,1
PMC3049439A,"These counterintuitive results were confirmed when neighbouring cell populations of the hair follicle bulge were isolated using LRIG1, LGR5 or LGR6 expression.",LRIG1,hair,-1
PMC3049439A,"These counterintuitive results were confirmed when neighbouring cell populations of the hair follicle bulge were isolated using LRIG1, LGR5 or LGR6 expression.",LGR6,hair,-1
PMC3049439A,"These counterintuitive results were confirmed when neighbouring cell populations of the hair follicle bulge were isolated using LRIG1, LGR5 or LGR6 expression.",LGR5,hair,-1
PMC3049439A,"Under normal homeostasis, LGR5+ cells exclusively give rise to hair follicles (Jaks et al, 2008). LRIG1 and",LGR5,hair,-1
PMC3049439A,"Under normal homeostasis, LGR5+ cells exclusively give rise to hair follicles (Jaks et al, 2008). LRIG1 and",LRIG1,hair,-1
PMC3049439A,"However, when the same bulge cells were observed in normal homeostasis, the majority generated hair follicles and only occasionally sebaceous gland or IFE (Morris et al, 2004).",IFE,hair,-1
PMC4023823A,"Total cholesterol (TCHO) levels and the direct bilirubin/total bilirubin (DBIL/TBIL) ratio were both increased in Pten::Keap1-Alb mice, suggesting the presence of bile congestion in the livers of the Pten::Keap1-Alb mice.",DBIL,bile,1
PMC4023823A,"Total cholesterol (TCHO) levels and the direct bilirubin/total bilirubin (DBIL/TBIL) ratio were both increased in Pten::Keap1-Alb mice, suggesting the presence of bile congestion in the livers of the Pten::Keap1-Alb mice.",TBIL,bile,1
PMC4023823A,"Total cholesterol (TCHO) levels and the direct bilirubin/total bilirubin (DBIL/TBIL) ratio were both increased in Pten::Keap1-Alb mice, suggesting the presence of bile congestion in the livers of the Pten::Keap1-Alb mice.",TCHO,bile,1
PMC4023823A,"We also examined albumin (ALB) as a marker of liver function and observed that the level of this protein was maintained within a normal range in the plasma of Pten::Keap1-Alb mice, although the plasma ALB level was slightly reduced in Keap1-Alb single-knockout mice.",ALB,plasma,1
PMC4023823A,"We also examined albumin (ALB) as a marker of liver function and observed that the level of this protein was maintained within a normal range in the plasma of Pten::Keap1-Alb mice, although the plasma ALB level was slightly reduced in Keap1-Alb single-knockout mice.",ALB,plasma,1
PMC4023823A,"We also examined albumin (ALB) as a marker of liver function and observed that the level of this protein was maintained within a normal range in the plasma of Pten::Keap1-Alb mice, although the plasma ALB level was slightly reduced in Keap1-Alb single-knockout mice.",ALB,plasma,1
PMC4023823A,"We also examined albumin (ALB) as a marker of liver function and observed that the level of this protein was maintained within a normal range in the plasma of Pten::Keap1-Alb mice, although the plasma ALB level was slightly reduced in Keap1-Alb single-knockout mice.",ALB,plasma,1
PMC3655979A,(B) Specific bioactivity of serum samples in the ex vivo assay of ME-180 cell growth.,ME-180,serum,1
PMC4426451A,"In this light, the work presented here has catalyzed two larger clinical trials focused, respectively, on cervical cancer (including HPV testing) and lymphoma detection (FNAs of enlarged lymph nodes).",HPV,lymph,1
PMC3786374A,"After 24 h, cells were wounded with a p200 tip and washed with 1x PBS, and then media was replaced with culture media supplemented with 2% bovine serum with or without TGFb1 (10ng/ml).",TGFb1,serum,1
PMC3786374A,"After 24 h, cells were wounded with a p200 tip and washed with 1x PBS, and then media was replaced with culture media supplemented with 2% bovine serum with or without TGFb1 (10ng/ml).",PBS,serum,1
PMC3786374A,"After 24 h, cells were wounded with a p200 tip and washed with 1x PBS, and then media was replaced with culture media supplemented with 2% bovine serum with or without TGFb1 (10ng/ml).",p200,serum,1
PMC4371775A,Consistent with this CD49f/ITGA6 has been reported to be overexpressed in bladder cancer and is associated with poorer survival (42).CD133 (AC133 or prominin 1) is a plasma membrane protein expressed in embryonic epithelial structures and also found in various adult epithelial cells and hematopoietic/progenitor cells.,AC133,plasma,1
PMC4371775A,Consistent with this CD49f/ITGA6 has been reported to be overexpressed in bladder cancer and is associated with poorer survival (42).CD133 (AC133 or prominin 1) is a plasma membrane protein expressed in embryonic epithelial structures and also found in various adult epithelial cells and hematopoietic/progenitor cells.,CD49f,plasma,1
PMC4371775A,Consistent with this CD49f/ITGA6 has been reported to be overexpressed in bladder cancer and is associated with poorer survival (42).CD133 (AC133 or prominin 1) is a plasma membrane protein expressed in embryonic epithelial structures and also found in various adult epithelial cells and hematopoietic/progenitor cells.,ITGA6,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",NGFR,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",BST2,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",CRC,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",ELISA,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",TSPAN6,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",BST2,plasma,1
PMC4606116A,"In the present study, we extended prior work and examined the plasma levels of four targets (TROP2, TSPAN6, NGFR, and BST2) by ELISA of a small sample set of CRC patients and controls and further selected BST2 for detailed analysis.",TROP2,plasma,1
PMC3378878A,"17-0780-01) that had been pre-adsorbed with 57 ug/ml salmon sperm DNA (Roche, cat. 11 467 140 001) and 0.1 ug/ul of bovine serum albumin (BSA) (New England Biolabs) by rocking for 1 h at",BSA,serum,1
PMC3378878A,"17-0780-01) that had been pre-adsorbed with 57 ug/ml salmon sperm DNA (Roche, cat. 11 467 140 001) and 0.1 ug/ul of bovine serum albumin (BSA) (New England Biolabs) by rocking for 1 h at",DNA,serum,1
PMC5414739A,This has opened new hopes for using MSCs for regenerative medicine purposes (116).Human bone marrow-derived pluripotent MSCs displayed increased proliferation when incubated with PRL during a 48-hour starvation period in monolayer culture (117).,PRL,bone marrow,1
PMC4966842A,The effects of ABT-122 on these chemokine receptors were assessed using blood samples from volunteers.,ABT-122,blood,-1
PMC3774116A,"Hematopoietic and endothelial cells were excluded using the lineage depletion markers protein tyrosine phosphatase receptor C (PTPRC, lymphoid), platelet/endothelial cell adhesion marker 1 (PECAM1, endothelial) and Ter119 (red blood cells)17.",PECAM1,blood,-1
PMC3774116A,"Hematopoietic and endothelial cells were excluded using the lineage depletion markers protein tyrosine phosphatase receptor C (PTPRC, lymphoid), platelet/endothelial cell adhesion marker 1 (PECAM1, endothelial) and Ter119 (red blood cells)17.",PTPRC,blood,-1
PMC3774116A,"Hematopoietic and endothelial cells were excluded using the lineage depletion markers protein tyrosine phosphatase receptor C (PTPRC, lymphoid), platelet/endothelial cell adhesion marker 1 (PECAM1, endothelial) and Ter119 (red blood cells)17.",Ter119,blood,-1
PMC5414739A,"In organ-cultured hair follicles from human females, PRL stimulated the expression of CK-15 and CK-19, which are acknowledged stem cell-associated markers (152).",PRL,hair,-1
PMC5414739A,"In organ-cultured hair follicles from human females, PRL stimulated the expression of CK-15 and CK-19, which are acknowledged stem cell-associated markers (152).",CK-15,hair,-1
PMC5414739A,"In organ-cultured hair follicles from human females, PRL stimulated the expression of CK-15 and CK-19, which are acknowledged stem cell-associated markers (152).",CK-19,hair,-1
PMC5109830A,"The stability of 323/A3-800CW in human serum was evaluated using HPLC (Biosep-SEC-s2000, Phenomenex, USA).",323/A3,serum,1
PMC5109830A,"The stability of 323/A3-800CW in human serum was evaluated using HPLC (Biosep-SEC-s2000, Phenomenex, USA).",USA,serum,1
PMC5109830A,"The stability of 323/A3-800CW in human serum was evaluated using HPLC (Biosep-SEC-s2000, Phenomenex, USA).",HPLC,serum,1
PMC5109830A,"The stability of 323/A3-800CW in human serum was evaluated using HPLC (Biosep-SEC-s2000, Phenomenex, USA).",SEC,serum,1
PMC4621003A,"Mice vaccinated with unmodified VLPs or GPI-HER-2-modified-VLPs displayed a similar serum antibody response against viral proteins present on VLPs (Figure 3C), suggesting that protein transfer does not affect the antigenicity of intrinsic VLP proteins.",VLP,serum,1
PMC4621003A,"Mice vaccinated with unmodified VLPs or GPI-HER-2-modified-VLPs displayed a similar serum antibody response against viral proteins present on VLPs (Figure 3C), suggesting that protein transfer does not affect the antigenicity of intrinsic VLP proteins.",GPI,serum,1
PMC3786374A,"Although the TGFb1 serum level of ThrbPV/PV mice was not significantly different from that of WT mice at age 5-7 months (data groups 3 and 4), the TGFb1 serum level of ThrbPV/PV mice tended to be higher (data group 3 versus 4).",TGFb1,serum,1
PMC3786374A,"Although the TGFb1 serum level of ThrbPV/PV mice was not significantly different from that of WT mice at age 5-7 months (data groups 3 and 4), the TGFb1 serum level of ThrbPV/PV mice tended to be higher (data group 3 versus 4).",TGFb1,serum,1
PMC3786374A,"Although the TGFb1 serum level of ThrbPV/PV mice was not significantly different from that of WT mice at age 5-7 months (data groups 3 and 4), the TGFb1 serum level of ThrbPV/PV mice tended to be higher (data group 3 versus 4).",TGFb1,serum,1
PMC3786374A,"Although the TGFb1 serum level of ThrbPV/PV mice was not significantly different from that of WT mice at age 5-7 months (data groups 3 and 4), the TGFb1 serum level of ThrbPV/PV mice tended to be higher (data group 3 versus 4).",TGFb1,serum,1
PMC3885479A,"This result is consistent with that in previous studies, in which a TIMP-1 protein expression is found in malignant tumors [19,30].TIMP-1 overexpression (such as in serum, plasma, and tissue) is also associated with the poor prognosis of various cancers, including esophageal cancer [24], breast cancer [27], prostate cancer [31], lung cancer [25], glioblastoma [14], and myeloma [15].",TIMP-1,plasma,-1
PMC3885479A,"This result is consistent with that in previous studies, in which a TIMP-1 protein expression is found in malignant tumors [19,30].TIMP-1 overexpression (such as in serum, plasma, and tissue) is also associated with the poor prognosis of various cancers, including esophageal cancer [24], breast cancer [27], prostate cancer [31], lung cancer [25], glioblastoma [14], and myeloma [15].",TIMP-1,serum,-1
PMC4344740A,"We used a commercially available human microvascular endothelial cell cDNA library (Uni-ZAP XR Premade Library, Stratagene, La Jolla, CA) to screen for clones that were immunoreactive against plasma from patients with severe carotid stenosis.",cDNA,plasma,1
PMC4344740A,"We used a commercially available human microvascular endothelial cell cDNA library (Uni-ZAP XR Premade Library, Stratagene, La Jolla, CA) to screen for clones that were immunoreactive against plasma from patients with severe carotid stenosis.",La,plasma,1
PMC4344740A,"We used a commercially available human microvascular endothelial cell cDNA library (Uni-ZAP XR Premade Library, Stratagene, La Jolla, CA) to screen for clones that were immunoreactive against plasma from patients with severe carotid stenosis.",ZAP,plasma,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",TGF,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",TGF,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",GM,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",GM,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",CSF,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",GM,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",GM,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",KLF4,CSF,1
PMC5538449A,"In fact, KLF4 expression levels were increased in GM-CSF plus TGF-b1-supplemented cultures compared with those in cells stimulated with GM-CSF only.",KLF4,CSF,1
PMC3566310A,"In this injury/recovery setting, the overall level of Fgf7 expression strongly correlated with that of the LPC response as well as the progression of liver damage as measured by serum markers.",Fgf7,serum,1
PMC3566310A,"In this injury/recovery setting, the overall level of Fgf7 expression strongly correlated with that of the LPC response as well as the progression of liver damage as measured by serum markers.",LPC,serum,1
PMC3548755A,These results show that the serum levels of autoantibody to SH3GL1 increased at the early stage of the animal models and turned to decrease at the late stage according to the increase of tumor volume as the time proceeded.,SH3GL1,serum,1
PMC3478937A,"In brief 106/ml monocytes were seeded in 24-well tissue culture plates in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% FCS, 100 ng/ml GM-CSF, and 25 ng/ml IL-4 for moDC generation.",RPMI,CSF,1
PMC3478937A,"In brief 106/ml monocytes were seeded in 24-well tissue culture plates in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% FCS, 100 ng/ml GM-CSF, and 25 ng/ml IL-4 for moDC generation.",GM,CSF,1
PMC3478937A,"In brief 106/ml monocytes were seeded in 24-well tissue culture plates in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% FCS, 100 ng/ml GM-CSF, and 25 ng/ml IL-4 for moDC generation.",FCS,CSF,1
PMC3478937A,"In brief 106/ml monocytes were seeded in 24-well tissue culture plates in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% FCS, 100 ng/ml GM-CSF, and 25 ng/ml IL-4 for moDC generation.",IL-4,CSF,1
PMC4366163A,"This finding could possibly mean that the regulation of these transmembrane proteins is more dependent upon efficient turnover than ZO-1, e.g. that they are being delivered, removed and recycled to the plasma membrane (or degraded in lysosomes) at higher rates.",ZO-1,plasma,1
PMC3478937A,"CD14+ monocytes were isolated from peripheral blood of healthy donors as described previously (Taschner et al., 2007).",CD14,blood,-1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",FBS,serum,1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",EGF,serum,1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",DMEM,serum,1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",cAMP,serum,1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",HAM,serum,1
PMC4712003A,"Trypsin activity was stopped by the addition of DMEM/HAM F12 medium containing antibiotics, L-glutamine (2 mM), insulin (10 mg/ml), transferrin (10 mg/ml), hydrocortisone (80 ng/ml), epidermal growth factor [EGF; 10 ng/ml]), cAMP (10 ng/ml) and fetal bovine serum (FBS; 5%; Fraction V; Sigma-Aldrich).",F12,serum,1
PMC3478937A,", 2006).CD34+ cord blood cells were cultured serum free for 2-3 d under progenitor expansion conditions (Flt3L, SCF, and TPO, each at 50 ng/ml) before subculturing with lineage-specific cytokines.",TPO,serum,1
PMC3478937A,", 2006).CD34+ cord blood cells were cultured serum free for 2-3 d under progenitor expansion conditions (Flt3L, SCF, and TPO, each at 50 ng/ml) before subculturing with lineage-specific cytokines.",TPO,blood,1
PMC3478937A,", 2006).CD34+ cord blood cells were cultured serum free for 2-3 d under progenitor expansion conditions (Flt3L, SCF, and TPO, each at 50 ng/ml) before subculturing with lineage-specific cytokines.",SCF,serum,1
PMC3478937A,", 2006).CD34+ cord blood cells were cultured serum free for 2-3 d under progenitor expansion conditions (Flt3L, SCF, and TPO, each at 50 ng/ml) before subculturing with lineage-specific cytokines.",SCF,blood,1
PMC3250983A,"A higher level of 125I-labeled B-B4 mAb was observed in the more vascularized organs such as the heart and lungs, in keeping with their higher blood content.",B4,blood,-1
PMC3104081A,Representative cytotoxicity experiments adding human serum to hRS7 against CC-ARK-1 (middle panel) and CC-ARK-2 (bottom panel).,hRS7,serum,1
PMC3104081A,Representative cytotoxicity experiments adding human serum to hRS7 against CC-ARK-1 (middle panel) and CC-ARK-2 (bottom panel).,ARK-1,serum,1
PMC3104081A,Representative cytotoxicity experiments adding human serum to hRS7 against CC-ARK-1 (middle panel) and CC-ARK-2 (bottom panel).,ARK-2,serum,1
PMC3104081A,"Addition of physiological concentrations of IgG (i.e., heat-inactivated serum diluted 1:2) to PBL in the presence of hRS7 did not significantly decrease the degree of ADCC.",ADCC,serum,1
PMC3104081A,"Addition of physiological concentrations of IgG (i.e., heat-inactivated serum diluted 1:2) to PBL in the presence of hRS7 did not significantly decrease the degree of ADCC.",hRS7,serum,1
PMC3104081A,"Addition of physiological concentrations of IgG (i.e., heat-inactivated serum diluted 1:2) to PBL in the presence of hRS7 did not significantly decrease the degree of ADCC.",PBL,serum,1
PMC3478937A,"MoLCs were generated either by adding 10 ng/ml TGF-b1 during MoDC cultures or in the presence of 100 ng/ml GM-CSF, Delta1 (coated plates as described above), and 10 ng/ml TGF-b1.",Delta1,CSF,1
PMC3478937A,"MoLCs were generated either by adding 10 ng/ml TGF-b1 during MoDC cultures or in the presence of 100 ng/ml GM-CSF, Delta1 (coated plates as described above), and 10 ng/ml TGF-b1.",GM,CSF,1
PMC3478937A,"MoLCs were generated either by adding 10 ng/ml TGF-b1 during MoDC cultures or in the presence of 100 ng/ml GM-CSF, Delta1 (coated plates as described above), and 10 ng/ml TGF-b1.",TGF,CSF,1
PMC3478937A,"MoLCs were generated either by adding 10 ng/ml TGF-b1 during MoDC cultures or in the presence of 100 ng/ml GM-CSF, Delta1 (coated plates as described above), and 10 ng/ml TGF-b1.",TGF,CSF,1
PMC5363540A,"After proteolytic cleavage, the shedding ectodomain of pro-AREG is secreted into the blood and other body fluids as a soluble growth factor [8].",AREG,blood,-1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",NOTCH,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",NOTCH,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",SALL4,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",SALL4,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",ESC,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",ESC,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",EGF,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",EGF,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",iPSC,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",iPSC,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",SOX9,bile,1
PMC4999623A,"In humans, around the 8th gestational week, hepatocytes near the portal mesenchyme form the ductal plate, a ring of cells from which cholangiocytes develop.47 NOTCH pathway is one of the most important pathways driving biliary commitment, by inducing SOX9 expression, which controls bile duct morphogenesis and is thus considered to be the earliest and most-specific marker of biliary cells in the developing liver.47 SALL4 also plays a key role in biliary commitment of hepatoblasts, by inhibiting their differentiation toward hepatocytes and instead driving cholangiocyte fate.48 Hepatoblast-like progenitor cells derived from human induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), and HepaRG cells have been differentiated into cholangiocytes by employing different combinations of epidermal growth factor (EGF), interleukin-6, growth hormone (which regulates the insulin-like growth factor pathway),49 and sodium taurocholate hydrate.50-52 Others and we have recently demonstrated that these cholangiocytes can develop into functional cysts and biliary ducts in 3D culture conditions.50,53,54 Recent advances have demonstrated the in vivo ability of these human hepatic progenitor cells derived from primary,40,41,55,56 cell line42 or hepatic stem cell57 sources to engraft into animal model livers and differentiate into cholangiocytes that are usually located near or in bile ducts.",SOX9,bile,1
PMC3104081A,The addition of untreated serum to PBL in the presence of hRS7 significantly increased hRS7-mediated ADCC in CC-ARK-2 (bottom panel) suggesting a peculiar sensitivity of this cell line to complement-dependent cytotoxicity.,hRS7,serum,1
PMC3104081A,The addition of untreated serum to PBL in the presence of hRS7 significantly increased hRS7-mediated ADCC in CC-ARK-2 (bottom panel) suggesting a peculiar sensitivity of this cell line to complement-dependent cytotoxicity.,PBL,serum,1
PMC3104081A,The addition of untreated serum to PBL in the presence of hRS7 significantly increased hRS7-mediated ADCC in CC-ARK-2 (bottom panel) suggesting a peculiar sensitivity of this cell line to complement-dependent cytotoxicity.,ARK-2,serum,1
PMC3104081A,The addition of untreated serum to PBL in the presence of hRS7 significantly increased hRS7-mediated ADCC in CC-ARK-2 (bottom panel) suggesting a peculiar sensitivity of this cell line to complement-dependent cytotoxicity.,ADCC,serum,1
PMC4370053A,"TGF-b is able to up-regulate expressionby CD1c+ blood DCs, suggesting that langerin expression in tissues may beinduced by epithelial or autocrine TGF-b [30-32].",TGF,blood,-1
PMC4370053A,"TGF-b is able to up-regulate expressionby CD1c+ blood DCs, suggesting that langerin expression in tissues may beinduced by epithelial or autocrine TGF-b [30-32].",TGF,blood,-1
PMC3478937A,Macrophages were generated either with 100 ng/ml GM-CSF or 100 ng/ml M-CSF for 5 d.,GM,CSF,1
PMC3478937A,Macrophages were generated either with 100 ng/ml GM-CSF or 100 ng/ml M-CSF for 5 d.,GM,CSF,1
PMC3478937A,Macrophages were generated either with 100 ng/ml GM-CSF or 100 ng/ml M-CSF for 5 d.,CSF,CSF,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",EPCAM,blood,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",MMP12,blood,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",TSPAN8,blood,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",MMP7,blood,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",PCR,blood,1
PMC3440735A,"Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 a (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20), ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR.",REG3A,blood,1
PMC3438563A,"RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA).",FBS,serum,1
PMC3438563A,"RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA).",USA,serum,1
PMC3438563A,"RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA).",RPMI-1640,serum,1
PMC3438563A,"RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA).",BRL,serum,1
PMC3478937A,Jurkat T cells were labeled with PKH26 dye according to the commercial protocol (Sigma-Aldrich) and seeded overnight in serum-free RPMI medium.,PKH26,serum,1
PMC3478937A,Jurkat T cells were labeled with PKH26 dye according to the commercial protocol (Sigma-Aldrich) and seeded overnight in serum-free RPMI medium.,T,serum,1
PMC3478937A,Jurkat T cells were labeled with PKH26 dye according to the commercial protocol (Sigma-Aldrich) and seeded overnight in serum-free RPMI medium.,RPMI,serum,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with TNM stage, tumor differentiation, lymph node metastasis, and high TIMP-1 expression.",TIMP-1,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with TNM stage, tumor differentiation, lymph node metastasis, and high TIMP-1 expression.",TNM,lymph,1
PMC3885479A,"Univariate analysis showed that the life span of LSCC patients was correlated with TNM stage, tumor differentiation, lymph node metastasis, and high TIMP-1 expression.",LSCC,lymph,1
PMC4695878A,Coverslips were then incubated with blocking buffer (10% horse serum/PBS/0.1% NP-40) for one hour.,NP-40,serum,1
PMC3364558A,"With the anti-HSG/HSG system, we found that that as long as the concentration of the bsMAb in the blood was =10-fold lower than the concentration of the hapten-peptide the instant it was injected (assuming instantaneous distribution in the vascular volume), 95% would be cleared within 1 h 81.As the concentration of the bsMAb increases relative to the hapten-peptide, the hapten-peptide's clearance slows, but it still clears much faster than most directly-radiolabeled antibody fragments.",HSG,blood,1
PMC3364558A,"With the anti-HSG/HSG system, we found that that as long as the concentration of the bsMAb in the blood was =10-fold lower than the concentration of the hapten-peptide the instant it was injected (assuming instantaneous distribution in the vascular volume), 95% would be cleared within 1 h 81.As the concentration of the bsMAb increases relative to the hapten-peptide, the hapten-peptide's clearance slows, but it still clears much faster than most directly-radiolabeled antibody fragments.",HSG,blood,1
PMC3364558A,"The principles of AES often focus on the divalent hapten for enhanced retention in the tumor, but the principle also relates to how the bsMAb and hapten-peptide interact in the serum.",AES,serum,1
PMC3885479A,"Moreover, multivariate analysis revealed a prognostic value for TIMP-1 overexpression, indicating that the strong expression of TIMP-1 and positive lymph node metastasis correspond to the poor prognosis of patients with LSCC.",LSCC,lymph,1
PMC3885479A,"Moreover, multivariate analysis revealed a prognostic value for TIMP-1 overexpression, indicating that the strong expression of TIMP-1 and positive lymph node metastasis correspond to the poor prognosis of patients with LSCC.",TIMP-1,lymph,1
PMC3885479A,"Moreover, multivariate analysis revealed a prognostic value for TIMP-1 overexpression, indicating that the strong expression of TIMP-1 and positive lymph node metastasis correspond to the poor prognosis of patients with LSCC.",TIMP-1,lymph,1
PMC4695878A,"Anti-FLAG antibody (SIGMA F1804) was diluted 1:10,000 in buffer (5% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.",SIGMA,serum,1
PMC4695878A,"Anti-FLAG antibody (SIGMA F1804) was diluted 1:10,000 in buffer (5% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.",FLAG,serum,1
PMC4695878A,"Anti-FLAG antibody (SIGMA F1804) was diluted 1:10,000 in buffer (5% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.",NP-40,serum,1
PMC4695878A,"Anti-FLAG antibody (SIGMA F1804) was diluted 1:10,000 in buffer (5% horse serum/PBS/0.1% NP-40) and added to coverslips for one hour.",F1804,serum,1
PMC3364558A,"AES dictates that the divalent hapten structure encourages retention in the tumor, where the concentration of the bsMAb is higher than in the blood or in the tissues.",AES,blood,-1
PMC2722670A,"This was developed by Sahin et al. to establish a new method called SEREX (serological identification of antigens by recombinant cDNA expression cloning), which involves the immunoscreening of cDNA libraries prepared from tumor specimens with autologous or allogeneic sera [8].",cDNA,sera,1
PMC2722670A,"This was developed by Sahin et al. to establish a new method called SEREX (serological identification of antigens by recombinant cDNA expression cloning), which involves the immunoscreening of cDNA libraries prepared from tumor specimens with autologous or allogeneic sera [8].",SEREX,sera,1
PMC2722670A,"This was developed by Sahin et al. to establish a new method called SEREX (serological identification of antigens by recombinant cDNA expression cloning), which involves the immunoscreening of cDNA libraries prepared from tumor specimens with autologous or allogeneic sera [8].",cDNA,sera,-1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,Trop2,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,Trop2,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,NRG1,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,SCC1,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,NRG1,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,cDNA,serum,1
PMC4253434A,Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression.,Trop2,serum,1
PMC4165776A,"As a proof-of-concept study, MCF7 cells were spiked into 1 mL of whole blood (containing approximately 2.5 x 106 WBCs/mL) at concentrations ranging from approximately 3 to 100 cells/mL and introduced into anti-EpCAM-coated biotin/Ppy-microfluidics at a flow rate of 1.2 mL/h.",MCF7,blood,1
PMC5505023A,"The cells were harvested and washed twice with PBS, followed by staining in washing buffer (PBS containing 0.05% rat serum) at room temperature for 30 min.",PBS,serum,1
PMC5505023A,"The cells were harvested and washed twice with PBS, followed by staining in washing buffer (PBS containing 0.05% rat serum) at room temperature for 30 min.",PBS,serum,1
PMC3885479A,The Kaplan-Meier curve also indicated that the patients with LSCC exhibiting low or no TIMP-1 expression and who were negative for lymph node metastasis demonstrated a favorable overall survival.,TIMP-1,lymph,1
PMC3885479A,The Kaplan-Meier curve also indicated that the patients with LSCC exhibiting low or no TIMP-1 expression and who were negative for lymph node metastasis demonstrated a favorable overall survival.,LSCC,lymph,1
PMC3039945A,"Lectin glycoarrays have been used to profile plasma for CRC biomarkers, with the identification of significant glycosylation changes associated with tumour progression [277-281].In summary, the search continues for a reliable method of predicting metastatic spread and patient outcome after surgical resection of primary CRC.",CRC,plasma,1
PMC3039945A,"Lectin glycoarrays have been used to profile plasma for CRC biomarkers, with the identification of significant glycosylation changes associated with tumour progression [277-281].In summary, the search continues for a reliable method of predicting metastatic spread and patient outcome after surgical resection of primary CRC.",CRC,plasma,1
PMC4275355A,"This quiescent state may help explain why sun-exposed skin does not continually generate new tumors or papillomas despite the presence of Ras mutations, as regulation of these pathways serves to maintain the appropriate activation state of this stem cell population (inhibitory: Bmp and Fgf18; stimulatory: Wnt and Tgfb) [37,113-118].These results also suggest that the regulatory mechanisms that affect the hair cycle could, as a result, affect tumor initiation [47,108,110,118,119].",Fgf18,hair,-1
PMC4259449A,"Until further evidence is available to suggest that the predominantly EpCAM 2+ cells with a low prostate epithelial score and a high erythroid-progenitor-like score are associated with PCa, we determined that based on the extensive cellular plasticity present in these cells that they should be removed from our analysis. Of note, it is unlikely that these erythroid progenitor-like cells are present in the blood contaminating the analysis of CTC as erythropoiesis usually occurs in the BM, however the possibility should not be ruled out, e.g. extrameduallary erythropoiesis can occur in myelofibrosis [27].DTC from most patients (except one patient) unsurprisingly were heterogeneous between and within patient samples at the transcriptional level, regardless of disease type (i.e. NED or ADV) [28, 29].",NED,blood,-1
PMC4259449A,"Until further evidence is available to suggest that the predominantly EpCAM 2+ cells with a low prostate epithelial score and a high erythroid-progenitor-like score are associated with PCa, we determined that based on the extensive cellular plasticity present in these cells that they should be removed from our analysis. Of note, it is unlikely that these erythroid progenitor-like cells are present in the blood contaminating the analysis of CTC as erythropoiesis usually occurs in the BM, however the possibility should not be ruled out, e.g. extrameduallary erythropoiesis can occur in myelofibrosis [27].DTC from most patients (except one patient) unsurprisingly were heterogeneous between and within patient samples at the transcriptional level, regardless of disease type (i.e. NED or ADV) [28, 29].",ADV,blood,-1
PMC4259449A,"Until further evidence is available to suggest that the predominantly EpCAM 2+ cells with a low prostate epithelial score and a high erythroid-progenitor-like score are associated with PCa, we determined that based on the extensive cellular plasticity present in these cells that they should be removed from our analysis. Of note, it is unlikely that these erythroid progenitor-like cells are present in the blood contaminating the analysis of CTC as erythropoiesis usually occurs in the BM, however the possibility should not be ruled out, e.g. extrameduallary erythropoiesis can occur in myelofibrosis [27].DTC from most patients (except one patient) unsurprisingly were heterogeneous between and within patient samples at the transcriptional level, regardless of disease type (i.e. NED or ADV) [28, 29].",CTC,blood,-1
PMC4606116A,"Taken together, these results indicate that BST2 represents a potential, novel plasma biomarker for CRC, especially when used together with CEA.CRC is an important public health issue and a socioeconomic problem in Taiwan.",BST2,plasma,1
PMC4606116A,"Taken together, these results indicate that BST2 represents a potential, novel plasma biomarker for CRC, especially when used together with CEA.CRC is an important public health issue and a socioeconomic problem in Taiwan.",CRC,plasma,1
PMC5467782A,"Cells (2x105) were suspended in 200 ul serum-free DMEM/F12 medium and seeded into the Transwell inserts coated with Matrigel (BD Biosciences, USA).",USA,serum,1
PMC5467782A,"Cells (2x105) were suspended in 200 ul serum-free DMEM/F12 medium and seeded into the Transwell inserts coated with Matrigel (BD Biosciences, USA).",DMEM,serum,1
PMC5467782A,"Cells (2x105) were suspended in 200 ul serum-free DMEM/F12 medium and seeded into the Transwell inserts coated with Matrigel (BD Biosciences, USA).",F12,serum,1
PMC2695576A,"The latter seems more likely because blood relatives of individuals with PPCD may have CHED1 [138,139].",CHED1,blood,-1
PMC2695576A,"The latter seems more likely because blood relatives of individuals with PPCD may have CHED1 [138,139].",PPCD,blood,-1
PMC3918789A,"As reported here, we established this mouse model for prostatitis using a uropathogenic E. coli strain CP9 that was isolated from the blood of a patient with pyelonephrititis (35).",CP9,blood,-1
PMC5348388A,"Clinical information retrieved include gender, age, primary tumor location, primary tumor differentiation, primary tumor stage, preoperative CEA level, lymph node metastasis, extrahepatic metastasis; as well as the distribution, number, largest diameter, differentiation and resection margin of liver metastases.",CEA,lymph,1
PMC4154955A,"When bile ducts and the canal of Hering were labeled with YFP or LacZ in Sox9-CreERT2:ROSA mice, LacZ-labeled hepatocytes appeared near the portal vein and expanded along the portal to centrilobular axis, which strongly supported ""streaming model.""27",YFP,bile,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",USA,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",mL-1,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",IMDM,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",USA,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",mL-1,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",mL-1,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",FCS,serum,1
PMC5380941A,"The slices were incubated in dispase II (1 mg mL-1, Roche Diagnostics, Basil, Switzerland) in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA), 50 U mL-1 penicillin (Lonza, Basil, Switzerland), 50 mg mL-1 streptomycin (Lonza), and 10 mg mL-1 gentamicin (Lonza) overnight at 4 degC, followed by mechanical separation of the dermis and the epidermis using tweezers.",mL-1,serum,1
PMC4707334A,"Cardiac progenitor cells expressing Sca-1+CD31+ and lacking the blood cell lineage markers c-kit, FLT-1, CD45, and CD34 negative were identified in adult murine myocardium [60].",CD45,blood,-1
PMC4707334A,"Cardiac progenitor cells expressing Sca-1+CD31+ and lacking the blood cell lineage markers c-kit, FLT-1, CD45, and CD34 negative were identified in adult murine myocardium [60].",FLT-1,blood,-1
PMC4707334A,"Cardiac progenitor cells expressing Sca-1+CD31+ and lacking the blood cell lineage markers c-kit, FLT-1, CD45, and CD34 negative were identified in adult murine myocardium [60].",CD34,blood,-1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",MRI,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",MRI,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",MRI,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",p53,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ROS1,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ROS1,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ROS1,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",HCC,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",HCC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",HCC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",KRAS,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",CT,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",CT,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",CT,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",ICC,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",IL-6,serum,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",IL-6,bile,1
PMC5328612A,"Other risk factors for ICC are congenital malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking.13 In East Asia, hepatic parasite infections, in particular Opisthorchis viverrini and Clonorchis sinensis, are significant risk factors.15,16 The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.1,12ICC mostly develops as a well-differentiated adenocarcinoma.17,18 Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene.19 A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC.20-22 Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.23,24Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern.25,26 The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver.27,28 On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated.26 Mass-forming ICC typically has a diameter of 5-10 cm at the time of diagnosis.29,30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types.26 On imaging, it is a 1-2 cm mass within the bile duct with proximal ductal dilatation.",IL-6,bile,1
PMC3494970A,"Expression of CEACAM, which stains the bile canaliculi at the apical pole of hepatocytes, further confirmed the identification of the canals of Hering.",CEACAM,bile,1
PMC5378268A,"Notably, the spheroid cultivation of CSCs from the circulating blood of breast and lung cancer patients has attracted attention as a novel technology to isolate and expand circulating tumor cells in vitro.78, 79, 80 In conjunction with emerging liquid biology research, the isolation and expansion of CSC-related cells through sphere formation may be a powerful technology to investigate the original tumors without highly invasive clinical procedures.",CSC,blood,1
PMC3266428A,"For cohort 1, all individuals with adequate blood-extracted DNA samples and postnatal growth data (n = 94) were included in the analysis and, where available, methylation was also quantified in DNA extracted from saliva samples (n = 68) for comparison.",DNA,blood,-1
PMC3266428A,"For cohort 1, all individuals with adequate blood-extracted DNA samples and postnatal growth data (n = 94) were included in the analysis and, where available, methylation was also quantified in DNA extracted from saliva samples (n = 68) for comparison.",DNA,saliva,-1
PMC3266428A,"For cohort 1, all individuals with adequate blood-extracted DNA samples and postnatal growth data (n = 94) were included in the analysis and, where available, methylation was also quantified in DNA extracted from saliva samples (n = 68) for comparison.",DNA,blood,-1
PMC3266428A,"For cohort 1, all individuals with adequate blood-extracted DNA samples and postnatal growth data (n = 94) were included in the analysis and, where available, methylation was also quantified in DNA extracted from saliva samples (n = 68) for comparison.",DNA,saliva,-1
PMC4803572A,Bone marrow aspirates were analyzed initially for PSA mRNA expression [9-11] but this approach relies on the cells being PSA-positive.,PSA,Bone marrow,1
PMC4803572A,Bone marrow aspirates were analyzed initially for PSA mRNA expression [9-11] but this approach relies on the cells being PSA-positive.,PSA,Bone marrow,1
PMC4803572A,Bone marrow aspirates were analyzed initially for PSA mRNA expression [9-11] but this approach relies on the cells being PSA-positive.,mRNA,Bone marrow,1
PMC5385398A,"Cells (5 x 104) were suspended in 200 mL of serum-free medium and plated in the upper chamber, whereas 600 mL of medium with 10% FBS was added to the lower well.",FBS,serum,1
PMC4275355A,"Whether the dependence on hair cycle status is specific for Ras-induced tumors remains unclear because a wide variety of genetic hits have been implicated in SCC and head and neck SCC [57,58].",SCC,hair,1
PMC4275355A,"Whether the dependence on hair cycle status is specific for Ras-induced tumors remains unclear because a wide variety of genetic hits have been implicated in SCC and head and neck SCC [57,58].",SCC,hair,1
PMC5328612A,"Currently, a phase II trial is recruiting patients for HAI chemotherapy in the adjuvant setting (NCT01312857).Other hepatic artery-based treatments for locally advanced ICC include transarterial chemoembolization (TACE) and radio-embolization with yttrium-90 (Y-90).115 TACE affects the blood flow to the tumor in addition to locally releasing cytotoxic agents.",ICC,blood,-1
PMC5328612A,"Currently, a phase II trial is recruiting patients for HAI chemotherapy in the adjuvant setting (NCT01312857).Other hepatic artery-based treatments for locally advanced ICC include transarterial chemoembolization (TACE) and radio-embolization with yttrium-90 (Y-90).115 TACE affects the blood flow to the tumor in addition to locally releasing cytotoxic agents.",TACE,blood,-1
PMC5328612A,"Currently, a phase II trial is recruiting patients for HAI chemotherapy in the adjuvant setting (NCT01312857).Other hepatic artery-based treatments for locally advanced ICC include transarterial chemoembolization (TACE) and radio-embolization with yttrium-90 (Y-90).115 TACE affects the blood flow to the tumor in addition to locally releasing cytotoxic agents.",HAI,blood,-1
PMC5328612A,"Currently, a phase II trial is recruiting patients for HAI chemotherapy in the adjuvant setting (NCT01312857).Other hepatic artery-based treatments for locally advanced ICC include transarterial chemoembolization (TACE) and radio-embolization with yttrium-90 (Y-90).115 TACE affects the blood flow to the tumor in addition to locally releasing cytotoxic agents.",TACE,blood,-1
PMC3266428A,Comparisons between DNA methylation in cord blood and later life may indicate whether observed differences in methylation detected in childhood result from poor postnatal growth (or other environmental factors) or preexist in the infant.,DNA,blood,1
PMC3266428A,"Furthermore, analysis of TACSTD2 methylation in paired cord blood and whole blood DNA taken 7 years later showed little variation (1.3%).",TACSTD2,blood,-1
PMC3266428A,"Furthermore, analysis of TACSTD2 methylation in paired cord blood and whole blood DNA taken 7 years later showed little variation (1.3%).",TACSTD2,blood,-1
PMC3266428A,"Furthermore, analysis of TACSTD2 methylation in paired cord blood and whole blood DNA taken 7 years later showed little variation (1.3%).",DNA,blood,-1
PMC3266428A,"Furthermore, analysis of TACSTD2 methylation in paired cord blood and whole blood DNA taken 7 years later showed little variation (1.3%).",DNA,blood,-1
PMC3266428A,"The availability of both cord and age 7 blood samples in cohort 2, along with longitudinal body composition data, enabled further exploration of the causal pathways among postnatal growth, DNA methylation, and later adiposity.",DNA,blood,-1
PMC4344740A,Three synthetic peptides corresponding to the predicted epitope sites of RPA2 were used as antigens to examine the serum antibody levels.,RPA2,serum,-1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",T,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",T,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CEA,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CEA,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",TNM,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",TNM,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CEA,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CEA,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CRC,serum,1
PMC4465473A,"Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).",CRC,serum,1
PMC4966842A,It was suggested that MMAE in serum is partly responsible for the demonstrated toxicity profile.,MMAE,serum,1
PMC3509129A,E-cadherin/b-catenin complexes continuously recyle between the plasma membrane and perinuclear endocytic internal compartments [31].,cadherin,plasma,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",PA,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",PA,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",Tween-20,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",Tween-20,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",TBS,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-diluted serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-diluted alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).",T,serum,1
PMC3135497A,"Of the SCC patients, 57 underwent R0 resection with extended lymph node dissection and 89 received definitive chemo-radiation therapy.",R0,lymph,1
PMC3135497A,"Of the SCC patients, 57 underwent R0 resection with extended lymph node dissection and 89 received definitive chemo-radiation therapy.",SCC,lymph,1
PMC3816821A,"Related important clinical information (including gender, age, tumor size, serum level of a-fetoprotein (AFP), and other) was collected from each patient's medical records, which included a five-year follow-up period after surgery.",AFP,serum,1
PMC3864278A,"In mouse models of skin cancer, hair follicle bulge stem cells can serve as target cells for transformation (8) and CD34+ cells resembling their normal bulge stem cell counterpart are capable of propagating the disease as a cancer stem cell population (9).",CD34,hair,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",ECSA,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",SCC,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",SCC,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",SEREX,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",ECSA-1,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",ECSA,Serum,1
PMC3135497A,"We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC.",ECSA,Serum,1
PMC5000705A,In a microfluidics-based PCR system expression profiles from 84 EMT-related genes were analyzed in blood samples of prostate cancer patients.,EMT,blood,-1
PMC5000705A,In a microfluidics-based PCR system expression profiles from 84 EMT-related genes were analyzed in blood samples of prostate cancer patients.,PCR,blood,-1
PMC2946292A,MTS assay was performed after breaking serum starvation.,MTS,serum,1
PMC2946292A,(b) Panc02-mTrop2 and control cells were seeded in 96-well plates (1 x 103 cells/well) and serum-starved for 24 h before changing to growth medium containing 0.2% FBS.,FBS,serum,1
PMC5485361A,One study examining DTCs measured the percentage a6 integrin or a2 integrin expressing cells in the white blood cells extracted from the bone marrow.,a2,bone marrow,-1
PMC5485361A,One study examining DTCs measured the percentage a6 integrin or a2 integrin expressing cells in the white blood cells extracted from the bone marrow.,a2,blood,-1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",H2O2,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",H2O2,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",H2O2,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC-22,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC-22,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC-22,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC,sera,1
PMC5378227A,"Anti-HCC-22-5 antibody is not found in sera of patients with gastroenterological disease or lung cancer or in sera of healthy individuals, but it is found in sera of patients with HCC as well as those with other liver diseases.28 Peroxiredoxin (Prx) VI is a member of the Prx gene family.29 Peroxiredoxins are ubiquitous enzymes, such as antioxidant enzymes, that control intracellular levels of H2O2 by catalyzing its reduction to water.",HCC,sera,1
PMC3981717A,"Traditional clinicopathological parameters such as tumor morphology, histopathological features, concentration of serum alpha fetoprotein (AFP) and tumor stage offer limited information for prognosis prediction and fail to guide the therapeutic schedule for individual patient.",AFP,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",CI,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",BCLC,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",HCC,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",OS,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",AFP,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",CI,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",CI,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",HR,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",CI,serum,1
PMC3981717A,"Furthermore, in multivariate Cox regression analysis, significantly increased death risk was still observed in patients with high level of serum AFP (HR, 1.35; 95% CI, 1.08-1.70; P = 0.010), in patients with large size of tumor (HR,1.95; 95% CI 1.46-2.61, P0.0001), in patients with existence of PVTT(HR, 1.82; 95% CI 1.42-2.33, P0.0001) and in patients with high BCLC stage (HR, 1.54; 95% CI 1.20-1.98, P = 0.001).No significant association between either of the two SNPs and the OS of HCC patients was observed in univariate and multivariate Cox regression analysis (Table 2).",HR,serum,1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",CDK4,blood,-1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",MgCl2,blood,-1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",MDM2,blood,-1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",ALB,blood,-1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",ALB,blood,-1
PMC4203330A,"For the amplification of ALB, MgCl2 was added to a final concentration of 400 nM. The gene copy numbers were calculated from standard curves constructed by amplification of normal blood DNA of the target genes MDM2 and CDK4 and the reference gene ALB.",DNA,blood,-1
PMC4673178A,"However, when placed in serum and held at 37degC, SN-38 is released from the conjugate with a half-life of ~1 day (Fig 1C).This represents a marked departure from the two recently reported ADCs utilizing ultratoxic drugs, where their linkers maintain a relatively high degree of stability in serum [33, 34].",SN-38,serum,1
PMC4673178A,"However, when placed in serum and held at 37degC, SN-38 is released from the conjugate with a half-life of ~1 day (Fig 1C).This represents a marked departure from the two recently reported ADCs utilizing ultratoxic drugs, where their linkers maintain a relatively high degree of stability in serum [33, 34].",SN-38,serum,1
PMC4292049A,"However, the tumor-to-blood (T/B) and the tumor-to-liver (T/L) ratios were significantly improved in the pretargeting approach: 7.8 vs. 4.2 and 2.8 vs. 0.8, respectively (29).Besides using a pretargeting approach to detect tumor lesions, the pretargeting approach was also tested to treat tumor lesions.",T,blood,1
PMC4292049A,"However, the tumor-to-blood (T/B) and the tumor-to-liver (T/L) ratios were significantly improved in the pretargeting approach: 7.8 vs. 4.2 and 2.8 vs. 0.8, respectively (29).Besides using a pretargeting approach to detect tumor lesions, the pretargeting approach was also tested to treat tumor lesions.",T,blood,1
PMC5042010A,A synchronous bone marrow sample displayed a distinct TP53 alteration (G108S) as well as alterations in APC (G1447*) and PIK3CA (H1047R).,PIK3CA,bone marrow,1
PMC5042010A,A synchronous bone marrow sample displayed a distinct TP53 alteration (G108S) as well as alterations in APC (G1447*) and PIK3CA (H1047R).,G1447,bone marrow,1
PMC5042010A,A synchronous bone marrow sample displayed a distinct TP53 alteration (G108S) as well as alterations in APC (G1447*) and PIK3CA (H1047R).,TP53,bone marrow,1
PMC5042010A,A synchronous bone marrow sample displayed a distinct TP53 alteration (G108S) as well as alterations in APC (G1447*) and PIK3CA (H1047R).,APC,bone marrow,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",MKRN1,sera,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",MKRN1,sera,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",SCC,sera,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",SCC,sera,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",MKRN1,sera,1
PMC2722670A,"A recent report revealed that MKRN1 is involved in the differentiation of various tissues including osteoblasts, eye epithelial cells and kidney [32].The existence of antibodies against the MKRN1 gene product was examined with 73 sera of patients with esophageal SCC and 43 sera of healthy donors by Western blot analysis.",MKRN1,sera,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",HTB,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",HTB,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",A549,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",A549,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",CRL,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",CRL,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",RNA,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",RNA,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",NSCLC,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",NSCLC,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",CRL,lymph,1
PMC2774741A,"Expression levels of 22,283 gene transcripts were determined on oligonucleotide microarrays using RNA prepared from four NSCLC cell lines [CRL 5807 (bronchoalveolar carcinoma), CRL 5876 (adenocarcinoma derived from metastatic lymph node), A549 (adenocarcinoma), and HTB 177 (large cell carcinoma)], as well as from a pool of 4 normal cervical lymph nodes.",CRL,lymph,1
PMC4188889A,"In the third study, Schultz et al[53] tested the hypothesis that high plasma YKL-40 and IL-6 are associated with PC and short OS.",YKL-40,plasma,-1
PMC4188889A,"In the third study, Schultz et al[53] tested the hypothesis that high plasma YKL-40 and IL-6 are associated with PC and short OS.",PC,plasma,-1
PMC4188889A,"In the third study, Schultz et al[53] tested the hypothesis that high plasma YKL-40 and IL-6 are associated with PC and short OS.",IL-6,plasma,-1
PMC4188889A,"In the third study, Schultz et al[53] tested the hypothesis that high plasma YKL-40 and IL-6 are associated with PC and short OS.",OS,plasma,-1
PMC4202120B,"Capture of CTC presents a technological challenge, such as the frequent EMT observed in CRPC, which eliminates the expression of epithelial markers (antibodies to E-cadherin are frequently used to selectively isolate circulating metastatic cells from whole blood.)",CRPC,blood,-1
PMC4202120B,"Capture of CTC presents a technological challenge, such as the frequent EMT observed in CRPC, which eliminates the expression of epithelial markers (antibodies to E-cadherin are frequently used to selectively isolate circulating metastatic cells from whole blood.)",CTC,blood,-1
PMC4202120B,"Capture of CTC presents a technological challenge, such as the frequent EMT observed in CRPC, which eliminates the expression of epithelial markers (antibodies to E-cadherin are frequently used to selectively isolate circulating metastatic cells from whole blood.)",cadherin,blood,-1
PMC4202120B,"Capture of CTC presents a technological challenge, such as the frequent EMT observed in CRPC, which eliminates the expression of epithelial markers (antibodies to E-cadherin are frequently used to selectively isolate circulating metastatic cells from whole blood.)",EMT,blood,-1
PMC4673178A,"In animal models, the anti-Trop-2 conjugate prepared with the CL2A linker yielded better therapeutic responses than when SN-38 was linked stably, indicating that even antibodies that internalized quickly benefitted when SN-38 was allowed to be released in serum with a half-life of ~1 day [35].",CL2A,serum,-1
PMC4673178A,"In animal models, the anti-Trop-2 conjugate prepared with the CL2A linker yielded better therapeutic responses than when SN-38 was linked stably, indicating that even antibodies that internalized quickly benefitted when SN-38 was allowed to be released in serum with a half-life of ~1 day [35].",Trop-2,serum,-1
PMC4673178A,"In animal models, the anti-Trop-2 conjugate prepared with the CL2A linker yielded better therapeutic responses than when SN-38 was linked stably, indicating that even antibodies that internalized quickly benefitted when SN-38 was allowed to be released in serum with a half-life of ~1 day [35].",SN-38,serum,-1
PMC4673178A,"In animal models, the anti-Trop-2 conjugate prepared with the CL2A linker yielded better therapeutic responses than when SN-38 was linked stably, indicating that even antibodies that internalized quickly benefitted when SN-38 was allowed to be released in serum with a half-life of ~1 day [35].",SN-38,serum,-1
PMC4621003A,The presence of VLP proteins was analyzed (bottom panel) by staining with a 1:1000 dilution of VLP-specific serum from vaccinated mice.,VLP,serum,1
PMC4621003A,The presence of VLP proteins was analyzed (bottom panel) by staining with a 1:1000 dilution of VLP-specific serum from vaccinated mice.,VLP,serum,1
PMC2722670A,"In order to confirm that the antigen reacting with serum antibodies derives from the insert cDNA, protein extracts of IPTG-treated Escherichia coli bearing MKRN1 cDNA expression plasmids or the control empty plasmids were compared with those of non-treated bacteria.",cDNA,serum,1
PMC2722670A,"In order to confirm that the antigen reacting with serum antibodies derives from the insert cDNA, protein extracts of IPTG-treated Escherichia coli bearing MKRN1 cDNA expression plasmids or the control empty plasmids were compared with those of non-treated bacteria.",MKRN1,serum,1
PMC2722670A,"In order to confirm that the antigen reacting with serum antibodies derives from the insert cDNA, protein extracts of IPTG-treated Escherichia coli bearing MKRN1 cDNA expression plasmids or the control empty plasmids were compared with those of non-treated bacteria.",cDNA,serum,1
PMC2722670A,"In order to confirm that the antigen reacting with serum antibodies derives from the insert cDNA, protein extracts of IPTG-treated Escherichia coli bearing MKRN1 cDNA expression plasmids or the control empty plasmids were compared with those of non-treated bacteria.",IPTG,serum,1
PMC5344228A,"Stimulation of monocytes with HGF induced increased matrigel invasion and upregulation of proinflammatory cytokines and chemokines, such as IL-4, Il-1b, GM-CSF, and MIP-1b suggesting a proinflammatory role of HGF [46].",GM,CSF,1
PMC5344228A,"Stimulation of monocytes with HGF induced increased matrigel invasion and upregulation of proinflammatory cytokines and chemokines, such as IL-4, Il-1b, GM-CSF, and MIP-1b suggesting a proinflammatory role of HGF [46].",IL-4,CSF,1
PMC5344228A,"Stimulation of monocytes with HGF induced increased matrigel invasion and upregulation of proinflammatory cytokines and chemokines, such as IL-4, Il-1b, GM-CSF, and MIP-1b suggesting a proinflammatory role of HGF [46].",HGF,CSF,1
PMC5344228A,"Stimulation of monocytes with HGF induced increased matrigel invasion and upregulation of proinflammatory cytokines and chemokines, such as IL-4, Il-1b, GM-CSF, and MIP-1b suggesting a proinflammatory role of HGF [46].",HGF,CSF,1
PMC4803572A,"In contrast, TGFb2-triggered CXCL12-CXCR4 signaling is crucial for the PCa DTC to maintain a slow-cycling state in the bone marrow [48].",DTC,bone marrow,-1
PMC4803572A,"In contrast, TGFb2-triggered CXCL12-CXCR4 signaling is crucial for the PCa DTC to maintain a slow-cycling state in the bone marrow [48].",CXCL12-CXCR4,bone marrow,-1
PMC4803572A,"Global transcriptomic comparison between DTC from these two groups of patients revealed a deregulation in the p38 stress response pathway, suggesting the p38 pathway may play a role in regulating PCa DTC dormancy in the patient bone marrow [6].",p38,bone marrow,1
PMC4803572A,"Global transcriptomic comparison between DTC from these two groups of patients revealed a deregulation in the p38 stress response pathway, suggesting the p38 pathway may play a role in regulating PCa DTC dormancy in the patient bone marrow [6].",DTC,bone marrow,1
PMC4803572A,"Global transcriptomic comparison between DTC from these two groups of patients revealed a deregulation in the p38 stress response pathway, suggesting the p38 pathway may play a role in regulating PCa DTC dormancy in the patient bone marrow [6].",p38,bone marrow,1
PMC4803572A,"Global transcriptomic comparison between DTC from these two groups of patients revealed a deregulation in the p38 stress response pathway, suggesting the p38 pathway may play a role in regulating PCa DTC dormancy in the patient bone marrow [6].",DTC,bone marrow,1
PMC4966842B,"Functional in vivo activity was demonstrated in a mouse challenge study, where DMS5540 provided dose-dependent inhibition of serum IL-6 increases in response to bolus mouse TNF injection.34",DMS5540,serum,1
PMC4966842B,"Functional in vivo activity was demonstrated in a mouse challenge study, where DMS5540 provided dose-dependent inhibition of serum IL-6 increases in response to bolus mouse TNF injection.34",IL-6,serum,1
PMC4966842B,"Functional in vivo activity was demonstrated in a mouse challenge study, where DMS5540 provided dose-dependent inhibition of serum IL-6 increases in response to bolus mouse TNF injection.34",TNF,serum,1
PMC4485845A,No additive toxicity was reported other than grade 1 local reactions.53 Peripheral blood mononuclear cells (PBMCs) showed decreased Treg levels and increased levels of CD28+ memory cytotoxic T-cells (CTLs) that were positively correlated with improved PFS.59 A phase III trial is ongoing.,CD28,blood,1
PMC4485845A,No additive toxicity was reported other than grade 1 local reactions.53 Peripheral blood mononuclear cells (PBMCs) showed decreased Treg levels and increased levels of CD28+ memory cytotoxic T-cells (CTLs) that were positively correlated with improved PFS.59 A phase III trial is ongoing.,T,blood,1
PMC4485845A,No additive toxicity was reported other than grade 1 local reactions.53 Peripheral blood mononuclear cells (PBMCs) showed decreased Treg levels and increased levels of CD28+ memory cytotoxic T-cells (CTLs) that were positively correlated with improved PFS.59 A phase III trial is ongoing.,III,blood,1
PMC4202120B,This test could be used a predictive of responses to ADT.Other possibilities for novel non-invasive tests include mRNA seq in captured CTC [336] and detection of telomerase hTERT mRNA in plasma [337].,hTERT,plasma,-1
PMC4202120B,This test could be used a predictive of responses to ADT.Other possibilities for novel non-invasive tests include mRNA seq in captured CTC [336] and detection of telomerase hTERT mRNA in plasma [337].,mRNA,plasma,-1
PMC4202120B,This test could be used a predictive of responses to ADT.Other possibilities for novel non-invasive tests include mRNA seq in captured CTC [336] and detection of telomerase hTERT mRNA in plasma [337].,CTC,plasma,-1
PMC4202120B,This test could be used a predictive of responses to ADT.Other possibilities for novel non-invasive tests include mRNA seq in captured CTC [336] and detection of telomerase hTERT mRNA in plasma [337].,mRNA,plasma,-1
PMC3128671A,"Indeed, in some USPC cell lines (i.e., USPC-ARK-3) an increase in cell death was detected in the presence of effector cells and non-heat inactivated human serum.",USPC,serum,1
PMC3128671A,"Indeed, in some USPC cell lines (i.e., USPC-ARK-3) an increase in cell death was detected in the presence of effector cells and non-heat inactivated human serum.",USPC,serum,1
PMC3128671A,"Indeed, in some USPC cell lines (i.e., USPC-ARK-3) an increase in cell death was detected in the presence of effector cells and non-heat inactivated human serum.",ARK-3,serum,1
PMC5003214A,"By contrast, serum-containing epithelial growth medium in combination with 3T3-J2 feeder cells and Y-27632 led to the formation of colonies of smaller epithelial cells that retained cell-cell contact and whose morphology did not change with passage (Figure 2A, bottom).",Y-27632,serum,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",III,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",T4,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",XELOX,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",FU,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",III,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",FOLFOX,lymph,1
PMC4430485A,"From the 14th of October 2005 until the 22nd of January 2008 a total of 441 patients with high risk stage II (perforation or obstruction at diagnosis, T4, grade 3, lymphatic or vascular invasion, less than 13 lymph nodes removed) or stage III CRC were enrolled in the HE6C/05 prospective phase III trial randomising between 12 cycles of FOLFOX (folinic acid 200 mg/m2 intravenously, intravenous bolus at 400 mg/m2 and infusional 5-FU at 2400 mg/m2 over 46 hours, oxaliplatin at 85 mg/m2 over two hours intravenously every two weeks) versus 8 cycles of XELOX (capecitabine at 2000 mg/m2 po daily for 14 days, oxaliplatin at 130 mg/m2 intravenously on day 1 every three weeks) adjuvant chemotherapy[9].",CRC,lymph,1
PMC3269833A,"A simplified kinetic model was constructed for the E2F-Rb system [15], in which two genes Myc and CycD (Cyclin D: Cdk4,6) are activated by sufficient growth signal (serum) to induce E2F activation, which then directs the synthesis of downstream factors, such as CycE for DNA replication.",E2F,serum,1
PMC3269833A,"A simplified kinetic model was constructed for the E2F-Rb system [15], in which two genes Myc and CycD (Cyclin D: Cdk4,6) are activated by sufficient growth signal (serum) to induce E2F activation, which then directs the synthesis of downstream factors, such as CycE for DNA replication.",DNA,serum,1
PMC3269833A,"A simplified kinetic model was constructed for the E2F-Rb system [15], in which two genes Myc and CycD (Cyclin D: Cdk4,6) are activated by sufficient growth signal (serum) to induce E2F activation, which then directs the synthesis of downstream factors, such as CycE for DNA replication.",E2F,serum,1
PMC3250983A,The kinetics of 7D4 and B-B4 distribution in the blood and tumors are shown in the same graph to demonstrate the identical blood pharmacokinetics of both antibodies and the specific uptake of BB4 in the tumor.,BB4,blood,-1
PMC3250983A,The kinetics of 7D4 and B-B4 distribution in the blood and tumors are shown in the same graph to demonstrate the identical blood pharmacokinetics of both antibodies and the specific uptake of BB4 in the tumor.,BB4,blood,1
PMC3250983A,The kinetics of 7D4 and B-B4 distribution in the blood and tumors are shown in the same graph to demonstrate the identical blood pharmacokinetics of both antibodies and the specific uptake of BB4 in the tumor.,B4,blood,-1
PMC3250983A,The kinetics of 7D4 and B-B4 distribution in the blood and tumors are shown in the same graph to demonstrate the identical blood pharmacokinetics of both antibodies and the specific uptake of BB4 in the tumor.,B4,blood,1
PMC4882422A,"The gene expression of macrophage markers, proinflammatory cytokines, and profibrogenic factors and the serum GPT levels are shown in the right panel.",GPT,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,PAGE,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,TOF,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,TOF,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,SDS,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,SELDI,serum,1
PMC4188889A,Tissue and serum biomarkers in proteomics are usually determined by: SDS-PAGE followed by LC-MS for identifying the most up- or down-regulated proteins; matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry; and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry.,MALDI,serum,1
PMC2976030A,"1mg glycopeptides from plasma of the retroorbital bleeds before and after chemical-induced cancer, and tumor tissues were dried and resuspended in 20ml of 50% DMF, 40%H2O, 10% pyridine.",DMF,plasma,1
PMC4708083A,"(1999) demonstrated that when they transplanted bone marrow from male rats into female rats, 0.14% of hepatocytes carried the Y chromosome.",Y,bone marrow,1
PMC4803572A,"In BCa, CXCL12-specific miRNAs were proposed to be transported from healthy bone marrow stroma to BCa cells via gap junctions, leading to reduced CXCL12 expression and decreased cell proliferation (Fig. 1) [46].",CXCL12,bone marrow,-1
PMC2976030A,"Plasma (20ml) was added to 90ul 8M urea in 0.4M NH4HCO3, 0.1% (w/v) SDS solution (pH8.3) and 10ml 120mM TCEP in dH2O freshly prepared and incubated at 60degC for 1 hour.",TCEP,Plasma,1
PMC2976030A,"Plasma (20ml) was added to 90ul 8M urea in 0.4M NH4HCO3, 0.1% (w/v) SDS solution (pH8.3) and 10ml 120mM TCEP in dH2O freshly prepared and incubated at 60degC for 1 hour.",dH2O,Plasma,1
PMC2976030A,"Plasma (20ml) was added to 90ul 8M urea in 0.4M NH4HCO3, 0.1% (w/v) SDS solution (pH8.3) and 10ml 120mM TCEP in dH2O freshly prepared and incubated at 60degC for 1 hour.",NH4HCO3,Plasma,1
PMC2976030A,"Plasma (20ml) was added to 90ul 8M urea in 0.4M NH4HCO3, 0.1% (w/v) SDS solution (pH8.3) and 10ml 120mM TCEP in dH2O freshly prepared and incubated at 60degC for 1 hour.",SDS,Plasma,1
PMC4685746A,The majority of definitive HSCs arise in the aorta-gonad-mesonephros (AGM) region after day 9 in the mouse (day 32 in humans) and migrate first to the fetal liver and then to the bone marrow.,AGM,bone marrow,1
PMC4803572A,"In addition, exosomal transfer of miRNAs (e.g. miR-23b) from the bone marrow may promote BCa cell dormancy via suppression of a target cell cycle gene MARCKS [47].",MARCKS,bone marrow,1
PMC5380941A,"After activation, the langerin+ LCs and dDC subsets are able to migrate to the skin-draining lymph nodes, where they activate CD4+ and CD8+ T-cell responses.38,39 The precise function of each subset is still under debate, especially with regard to antigen cross-presentation.",CD8,lymph,1
PMC5380941A,"After activation, the langerin+ LCs and dDC subsets are able to migrate to the skin-draining lymph nodes, where they activate CD4+ and CD8+ T-cell responses.38,39 The precise function of each subset is still under debate, especially with regard to antigen cross-presentation.",dDC,lymph,1
PMC5380941A,"After activation, the langerin+ LCs and dDC subsets are able to migrate to the skin-draining lymph nodes, where they activate CD4+ and CD8+ T-cell responses.38,39 The precise function of each subset is still under debate, especially with regard to antigen cross-presentation.",T,lymph,1
PMC5380941A,"After activation, the langerin+ LCs and dDC subsets are able to migrate to the skin-draining lymph nodes, where they activate CD4+ and CD8+ T-cell responses.38,39 The precise function of each subset is still under debate, especially with regard to antigen cross-presentation.",CD4,lymph,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",BPA,blood,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",BPA,serum,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",LOD,blood,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",LOD,serum,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",BPA,blood,1
PMC3929731A,"Most recently, a study on midgestational umbilical cord blood in 85 patients using a new analytical approach that permitted direct measurement of free and glucuronidated BPA by LC-MS-MS reported free BPA levels ranging from LOD (0.05) to 52 ng/mL with a geometric mean of 0.16 ng/mL in human cord serum (22).",BPA,serum,1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",KRT7,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",TACSTD2,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",KIT,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",CD45,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",THY1,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",ALB,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",DLK1,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",CDH1,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",KRT19,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",HNF4A,blood,-1
PMC4711826A,"(Scale bar, 50 mm.) (C) Immunofluorescent detection in imMob1DKOLP-Tmx cells of the indicated lineage markers: HNF4A and ALB, hepatocytes; KRT19, KRT7 and CDH1, cholangiocytes; TACSTD2, DLK1, KIT and THY1, hepatoblasts/oval cells; CD45 and CD31, blood cells and endothelial cells.",CD31,blood,-1
PMC4882422A,LPS challenge to the PtenDhep mice elevated the serum GPT levels (Fig.,GPT,serum,1
PMC4882422A,LPS challenge to the PtenDhep mice elevated the serum GPT levels (Fig.,LPS,serum,1
PMC2946292A,The results showed that Panc02-mTrop2 cells had a significant increase in proliferation at low serum concentrations when compared to normal Panc02 or Panc02-GFP cells (P  0.01; Fig.,Panc02,serum,-1
PMC4966842B,"Lifastuzumab vedotin consists of a mc-vc-PABA-MMAE linker conjugate that showed preclinical target-directed cytotoxicity in lung and ovarian xenograft models, but also causes toxicity indicated by some bone marrow and hematological changes in a dose-dependent manner.",PABA,bone marrow,1
PMC4966842B,"Lifastuzumab vedotin consists of a mc-vc-PABA-MMAE linker conjugate that showed preclinical target-directed cytotoxicity in lung and ovarian xenograft models, but also causes toxicity indicated by some bone marrow and hematological changes in a dose-dependent manner.",MMAE,bone marrow,1
PMC5363540A,"Thus, AREG expression in body fluid could reflect cellular AREG expression and, in turn, serve as biomarker for tissue malignancy [29].High levels of serum AREG have been shown to activate AKT and ERK signaling and promote early disease progression in cancer patients [30].",AREG,serum,1
PMC5363540A,"Thus, AREG expression in body fluid could reflect cellular AREG expression and, in turn, serve as biomarker for tissue malignancy [29].High levels of serum AREG have been shown to activate AKT and ERK signaling and promote early disease progression in cancer patients [30].",AREG,serum,1
PMC5363540A,"Thus, AREG expression in body fluid could reflect cellular AREG expression and, in turn, serve as biomarker for tissue malignancy [29].High levels of serum AREG have been shown to activate AKT and ERK signaling and promote early disease progression in cancer patients [30].",AREG,serum,1
PMC5363540A,"Thus, AREG expression in body fluid could reflect cellular AREG expression and, in turn, serve as biomarker for tissue malignancy [29].High levels of serum AREG have been shown to activate AKT and ERK signaling and promote early disease progression in cancer patients [30].",AKT,serum,1
PMC5363540A,"Thus, AREG expression in body fluid could reflect cellular AREG expression and, in turn, serve as biomarker for tissue malignancy [29].High levels of serum AREG have been shown to activate AKT and ERK signaling and promote early disease progression in cancer patients [30].",ERK,serum,1
PMC5414739A,"Pb-PRL mice, which present prostate-specific expression of PRL under the control of a short probasin promoter, display normal serum testosterone levels but marked prostate hyperplasia and prostatic intraepithelial neoplasia lesions (99).",PRL,serum,1
PMC5414739A,"Pb-PRL mice, which present prostate-specific expression of PRL under the control of a short probasin promoter, display normal serum testosterone levels but marked prostate hyperplasia and prostatic intraepithelial neoplasia lesions (99).",PRL,serum,1
PMC5480073A,"Parameters evaluated in circulation (serum/plasma)ELISA: The inflammatory and proliferation markers hTERT, IL-6, YKL-40 and TIMP-1 for this GBM patient were analyzed (Table 2) and showed significantly higher levels than control samples.",YKL-40,serum,1
PMC5480073A,"Parameters evaluated in circulation (serum/plasma)ELISA: The inflammatory and proliferation markers hTERT, IL-6, YKL-40 and TIMP-1 for this GBM patient were analyzed (Table 2) and showed significantly higher levels than control samples.",IL-6,serum,1
PMC5480073A,"Parameters evaluated in circulation (serum/plasma)ELISA: The inflammatory and proliferation markers hTERT, IL-6, YKL-40 and TIMP-1 for this GBM patient were analyzed (Table 2) and showed significantly higher levels than control samples.",GBM,serum,1
PMC5480073A,"Parameters evaluated in circulation (serum/plasma)ELISA: The inflammatory and proliferation markers hTERT, IL-6, YKL-40 and TIMP-1 for this GBM patient were analyzed (Table 2) and showed significantly higher levels than control samples.",hTERT,serum,1
PMC5480073A,"Parameters evaluated in circulation (serum/plasma)ELISA: The inflammatory and proliferation markers hTERT, IL-6, YKL-40 and TIMP-1 for this GBM patient were analyzed (Table 2) and showed significantly higher levels than control samples.",TIMP-1,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",A1,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",A1,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",SDS,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",SDS,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",PAGE,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",PAGE,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",GBM,serum,1
PMC5480073A,"A: SDS-PAGE protein profile of serum samples; B: Western blot expression for high mobility group-A1 antibody in control serum sample (Con), GBM and present case.",GBM,serum,1
PMC4106866A,"GBM consists of poorly differentiated, highly invasive neoplastic astrocytes; histopathological features include cellular polymorphism, nuclear atypia, mitotic activity, vascular thrombosis, microvascular proliferation and necrosis [5].",GBM,astrocytes,-1
PMC3718634A,"The serum responses in CRC patients to CDH3 were higher than serum responses in control patients (mean 2.75 +- 0.4 ug/ml vs. 1.58 +- 0.2 ug/ml, p=0.006) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to CDH3 were higher than serum responses in control patients (mean 2.75 +- 0.4 ug/ml vs. 1.58 +- 0.2 ug/ml, p=0.006) (Fig.",CRC,serum,1
PMC3718634A,"The serum responses in CRC patients to CDH3 were higher than serum responses in control patients (mean 2.75 +- 0.4 ug/ml vs. 1.58 +- 0.2 ug/ml, p=0.006) (Fig.",CDH3,serum,1
PMC3718634A,"The serum responses in CRC patients to CDH3 were higher than serum responses in control patients (mean 2.75 +- 0.4 ug/ml vs. 1.58 +- 0.2 ug/ml, p=0.006) (Fig.",CDH3,serum,1
PMC4803572A,"While it is likely that the high level of CXCR4 simply increases the bone propensity of this PCa cell line PC3-NW1 and hence its outgrowth in the bone, whether or not the increase in CXCR4 level in the PCa cell impacts the dormancy switch in DTC that are already in the bone marrow remains unexplored.",CXCR4,bone marrow,1
PMC4803572A,"While it is likely that the high level of CXCR4 simply increases the bone propensity of this PCa cell line PC3-NW1 and hence its outgrowth in the bone, whether or not the increase in CXCR4 level in the PCa cell impacts the dormancy switch in DTC that are already in the bone marrow remains unexplored.",CXCR4,bone marrow,1
PMC4803572A,"While it is likely that the high level of CXCR4 simply increases the bone propensity of this PCa cell line PC3-NW1 and hence its outgrowth in the bone, whether or not the increase in CXCR4 level in the PCa cell impacts the dormancy switch in DTC that are already in the bone marrow remains unexplored.",PC3-NW1,bone marrow,1
PMC4803572A,"While it is likely that the high level of CXCR4 simply increases the bone propensity of this PCa cell line PC3-NW1 and hence its outgrowth in the bone, whether or not the increase in CXCR4 level in the PCa cell impacts the dormancy switch in DTC that are already in the bone marrow remains unexplored.",DTC,bone marrow,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",TA1,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",VLP,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",HER-2,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",VLP,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",VLP,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",SDS,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",PAGE,serum,1
PMC4621003A,"The VLP pellet was then resuspended with Laemmli sample buffer and then subjected to SDS PAGE and western blot analysis to detect VLP and GPI-HER-2 concentrations using anti-VLP serum and TA1 mAb, respectively.",GPI,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",IMMU-132,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",IMMU-132,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",IMMU-132,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",IMMU-132,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",Capan-1,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",Capan-1,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC4673178A,"Constitutive products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice implanted subcutaneously with a human pancreatic cancer xenograft (Capan-1) and then administered irinotecan (773 mg; SN-38 equivalents = 448 mg) and IMMU-132 (1.0 mg; SN-38 equivalents = 16 mg).Irinotecan cleared very rapidly from serum, with conversion to SN-38 and glucuronidated SN-38 (SN-38G) seen within 5 min (Fig 7A).",SN-38,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",NLR,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",NLR,Plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",NLR,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",NLR,plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",NLR,blood,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",HMGA1,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",HMGA1,Plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",HMGA1,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",HMGA1,plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",HMGA1,blood,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",YKL-40,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",YKL-40,Plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",YKL-40,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",YKL-40,plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",YKL-40,blood,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",TIMP-1,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",TIMP-1,Plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",TIMP-1,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",TIMP-1,plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",TIMP-1,blood,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",hTERT,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",hTERT,Plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",hTERT,serum,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",hTERT,plasma,1
PMC5480073A,"Venous blood samples were collected from patient before surgery and centrifuged (Beckman Coulter, United States) at 3000 rpm, for 15 min at 4 degC. Plasma and serum were divided into aliquots and stored at -80 degC. This was followed by assessing levels of NLR, TIMP-1, YKL-40 in plasma as well as that of hTERT and HMGA1 in serum.",hTERT,blood,1
PMC4165776A,"It is well-established that epithelial cells lose their typical epithelial phenotype and gain a mesenchymal signature during epithelia-to-mesenchymal transition (EMT), consequently showing phenotypic heterogeneity.17,18 Herein, we propose a technology using a biotin-doped conductive polypyrrole-deposited microfluidic system (Biotin/Ppy-microfluidic) that can efficiently recognize and isolate multiple CTC types, and readily eliminate white blood cells (WBCs) in the bloodstream (Figure 1a).Current CTC-based methodologies are not sufficiently sensitive for reliable diagnosis or prognosis of cancer due to the co-existence of the very low numbers of isolated CTCs with a relatively large number of WBCs in the resulting cell suspension.19",CTC,blood,-1
PMC4165776A,"It is well-established that epithelial cells lose their typical epithelial phenotype and gain a mesenchymal signature during epithelia-to-mesenchymal transition (EMT), consequently showing phenotypic heterogeneity.17,18 Herein, we propose a technology using a biotin-doped conductive polypyrrole-deposited microfluidic system (Biotin/Ppy-microfluidic) that can efficiently recognize and isolate multiple CTC types, and readily eliminate white blood cells (WBCs) in the bloodstream (Figure 1a).Current CTC-based methodologies are not sufficiently sensitive for reliable diagnosis or prognosis of cancer due to the co-existence of the very low numbers of isolated CTCs with a relatively large number of WBCs in the resulting cell suspension.19",EMT,blood,-1
PMC4165776A,"It is well-established that epithelial cells lose their typical epithelial phenotype and gain a mesenchymal signature during epithelia-to-mesenchymal transition (EMT), consequently showing phenotypic heterogeneity.17,18 Herein, we propose a technology using a biotin-doped conductive polypyrrole-deposited microfluidic system (Biotin/Ppy-microfluidic) that can efficiently recognize and isolate multiple CTC types, and readily eliminate white blood cells (WBCs) in the bloodstream (Figure 1a).Current CTC-based methodologies are not sufficiently sensitive for reliable diagnosis or prognosis of cancer due to the co-existence of the very low numbers of isolated CTCs with a relatively large number of WBCs in the resulting cell suspension.19",CTC,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",DTPA,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",DTPA,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",INCA,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",INCA,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",X,blood,-1
PMC4074497A,"The tumor-to-organ uptake ratios of mice pre-administered cold DTPA-INCA-X were improved in comparison with the mice that only received 111In-DTPA-INCA-X (Table 3), yet the blood concentration increased (Table 1 and Figure 3B).",X,blood,-1
PMC4596896A,A soluble form of CD30 has been reported in the sera of cancer patients but this does not seem to have a deleterious effect on Adcetris (26).,CD30,sera,1
PMC4606116A,"They are CEA, fibrin/fibrinogen degradation product (DR-70), and human hemoglobin (fecal occult blood) [46].",CEA,blood,-1
PMC4606116A,"They are CEA, fibrin/fibrinogen degradation product (DR-70), and human hemoglobin (fecal occult blood) [46].",DR-70,blood,-1
PMC4259449A,"When CTC are able to exit the vasculature and establish residency in distal tissues such as the lung, liver, and bone marrow (BM), they are termed disseminated tumor cells (DTC).",CTC,bone marrow,1
PMC4259449A,"When CTC are able to exit the vasculature and establish residency in distal tissues such as the lung, liver, and bone marrow (BM), they are termed disseminated tumor cells (DTC).",DTC,bone marrow,1
PMC4707334A,"A distinct resident cardiac stem cell population supporting cardiac regeneration, positive for c-kit, and negative for blood lineage markers CD34-, Lin-, and CD45- was reported for the first time by Beltrami et al. [54].",CD34-,blood,-1
PMC4707334A,"A distinct resident cardiac stem cell population supporting cardiac regeneration, positive for c-kit, and negative for blood lineage markers CD34-, Lin-, and CD45- was reported for the first time by Beltrami et al. [54].",CD45-,blood,-1
PMC4366163A,"The C-terminus of Ocln has been shown to bind ZO-1, subsequently mediating its intracellular trafficking to the lateral plasma membrane and TJs [14].",ZO-1,plasma,1
PMC5085135A,". also found that RAN expression increases in colorectal cancer tissues compared with normal colorectal mucosa, and was positively associated with invasion depth, lymph node and distant metastasis, and differentiated degree of the tumors [37].",RAN,lymph,1
PMC3844723A,"Briefly, after trypsinization and washing the cells with medium, 1 x 106 cells were passed through 0.45 mM filters to remove clumps of cells followed by washing with FACS buffer (phosphate saline buffer, 2% fetal bovine serum, and 2 mM ethylenediaminetetraacetic acid (EDTA)).",FACS,serum,1
PMC3844723A,"Briefly, after trypsinization and washing the cells with medium, 1 x 106 cells were passed through 0.45 mM filters to remove clumps of cells followed by washing with FACS buffer (phosphate saline buffer, 2% fetal bovine serum, and 2 mM ethylenediaminetetraacetic acid (EDTA)).",EDTA,serum,1
PMC3561800A,"The asterisk indicates blood vessels, the purple arrow points to high-grade PIN lesions, and red arrows point to invasive adenocarcinomas.",PIN,blood,-1
PMC4306156A,"We demonstrated that combination of WCA with 5-fluorouracil (5-FU) suppressed colon tumor growth and hepatic metastases, reducing the tumor weight and size, the rate of metastases and serum carcinoembryonic antigen levels.",FU,serum,1
PMC4306156A,"We demonstrated that combination of WCA with 5-fluorouracil (5-FU) suppressed colon tumor growth and hepatic metastases, reducing the tumor weight and size, the rate of metastases and serum carcinoembryonic antigen levels.",WCA,serum,1
PMC3135497A,We examined the sero-positivity for s-ECSA-2-Abs in sera from 40 patients with esophageal SCC and 20 healthy donors.,SCC,sera,1
PMC4375832A,"Using anti-human EPCAM+ MACS enrichment followed by growth in Primaria flasks and HPM (plus ROCK inhibitor Y-27632), we were able to demonstrate the ex vivo expansion and maintenance of primary human basal PESCs in the absence of serum and feeder cells.",MACS,serum,1
PMC4375832A,"Using anti-human EPCAM+ MACS enrichment followed by growth in Primaria flasks and HPM (plus ROCK inhibitor Y-27632), we were able to demonstrate the ex vivo expansion and maintenance of primary human basal PESCs in the absence of serum and feeder cells.",ROCK,serum,1
PMC4375832A,"Using anti-human EPCAM+ MACS enrichment followed by growth in Primaria flasks and HPM (plus ROCK inhibitor Y-27632), we were able to demonstrate the ex vivo expansion and maintenance of primary human basal PESCs in the absence of serum and feeder cells.",HPM,serum,1
PMC4375832A,"Using anti-human EPCAM+ MACS enrichment followed by growth in Primaria flasks and HPM (plus ROCK inhibitor Y-27632), we were able to demonstrate the ex vivo expansion and maintenance of primary human basal PESCs in the absence of serum and feeder cells.",Y-27632,serum,1
PMC3135497A,Recognition of ECSA-2 by serum antibodies in patients with esophageal SCC.,ECSA-2,serum,1
PMC3135497A,Recognition of ECSA-2 by serum antibodies in patients with esophageal SCC.,SCC,serum,1
PMC3135497A,"E. coli containing ECSA-2 cDNA expression plasmids was incubated with (+) or without (-) IPTG for 2.5 h, with cell lysates subsequently subjected to Western blot analysis using sera from patient-1 (P#1) and patient-2 (P#2) with esophageal SCC.",cDNA,sera,1
PMC3135497A,"E. coli containing ECSA-2 cDNA expression plasmids was incubated with (+) or without (-) IPTG for 2.5 h, with cell lysates subsequently subjected to Western blot analysis using sera from patient-1 (P#1) and patient-2 (P#2) with esophageal SCC.",SCC,sera,1
PMC3135497A,"E. coli containing ECSA-2 cDNA expression plasmids was incubated with (+) or without (-) IPTG for 2.5 h, with cell lysates subsequently subjected to Western blot analysis using sera from patient-1 (P#1) and patient-2 (P#2) with esophageal SCC.",ECSA-2,sera,1
PMC3135497A,"E. coli containing ECSA-2 cDNA expression plasmids was incubated with (+) or without (-) IPTG for 2.5 h, with cell lysates subsequently subjected to Western blot analysis using sera from patient-1 (P#1) and patient-2 (P#2) with esophageal SCC.",IPTG,sera,1
PMC4790095A,"To specifically identify TFs that could regulate this process, we screened for experimentally validated TFBS over-represented in modules down-regulated after injury--purple, dark red, and green-yellow (candidate transcriptional repressors; Experimental Procedures), which are enriched in genes related to the GO terms plasma membrane, ion/gated channel, ion binding, and synapse/cell junction related (Table S3).",GO,plasma,1
PMC4790095A,"To specifically identify TFs that could regulate this process, we screened for experimentally validated TFBS over-represented in modules down-regulated after injury--purple, dark red, and green-yellow (candidate transcriptional repressors; Experimental Procedures), which are enriched in genes related to the GO terms plasma membrane, ion/gated channel, ion binding, and synapse/cell junction related (Table S3).",S3,plasma,1
PMC4790095A,"To specifically identify TFs that could regulate this process, we screened for experimentally validated TFBS over-represented in modules down-regulated after injury--purple, dark red, and green-yellow (candidate transcriptional repressors; Experimental Procedures), which are enriched in genes related to the GO terms plasma membrane, ion/gated channel, ion binding, and synapse/cell junction related (Table S3).",TFBS,plasma,1
PMC4863686A,"Further, they showed that GO could penetrate the plasma membrane, resulting in altered cell morphology and an augmented number of apoptotic cells.",GO,plasma,1
PMC4966842C,"In the final part of her talk, Dr. Lambson addressed the question if germline IgVH repertoires differ between donors that did and did not develop broadly HIV neutralizing serum activity.",HIV,serum,1
PMC3906064A,The mutation was not detected within 40 PCR cycles in the RBC depleted blood even at the highest input concentration.,RBC,blood,-1
PMC3906064A,The mutation was not detected within 40 PCR cycles in the RBC depleted blood even at the highest input concentration.,PCR,blood,-1
PMC4062414A,Many of the gene family members included in the CIM do not have epithelial-related functions or are expressed at plasma membrane regions other than tight junctions.,CIM,plasma,1
PMC4188889A,"Marker levels were assessed before the start of palliative first-line therapy for advanced PC and during treatment (for CA 19-9 only).In the third study, Boeck et al[43] evaluated pre-treatment (palliative first-line chemotherapy) values and weekly values of cytokeratin 19-fragments (CYFRA 21-1), CA 19-9 and CEA in blood samples from patients with PC.",CEA,blood,-1
PMC4188889A,"Marker levels were assessed before the start of palliative first-line therapy for advanced PC and during treatment (for CA 19-9 only).In the third study, Boeck et al[43] evaluated pre-treatment (palliative first-line chemotherapy) values and weekly values of cytokeratin 19-fragments (CYFRA 21-1), CA 19-9 and CEA in blood samples from patients with PC.",CYFRA,blood,-1
PMC4188889A,"Marker levels were assessed before the start of palliative first-line therapy for advanced PC and during treatment (for CA 19-9 only).In the third study, Boeck et al[43] evaluated pre-treatment (palliative first-line chemotherapy) values and weekly values of cytokeratin 19-fragments (CYFRA 21-1), CA 19-9 and CEA in blood samples from patients with PC.",PC,blood,-1
PMC4188889A,"Marker levels were assessed before the start of palliative first-line therapy for advanced PC and during treatment (for CA 19-9 only).In the third study, Boeck et al[43] evaluated pre-treatment (palliative first-line chemotherapy) values and weekly values of cytokeratin 19-fragments (CYFRA 21-1), CA 19-9 and CEA in blood samples from patients with PC.",PC,blood,-1
PMC3774116A,"Lineage depletion markers PTPRC (lymphoid), PECAM1 (endothelial), glycophorin A (GYPA, red blood cell) and MME (stroma) were utilized to exclude non-epithelial cells from human dissociated endometrial cellular preparations.",PECAM1,blood,-1
PMC3774116A,"Lineage depletion markers PTPRC (lymphoid), PECAM1 (endothelial), glycophorin A (GYPA, red blood cell) and MME (stroma) were utilized to exclude non-epithelial cells from human dissociated endometrial cellular preparations.",GYPA,blood,-1
PMC3774116A,"Lineage depletion markers PTPRC (lymphoid), PECAM1 (endothelial), glycophorin A (GYPA, red blood cell) and MME (stroma) were utilized to exclude non-epithelial cells from human dissociated endometrial cellular preparations.",PTPRC,blood,-1
PMC3774116A,"Lineage depletion markers PTPRC (lymphoid), PECAM1 (endothelial), glycophorin A (GYPA, red blood cell) and MME (stroma) were utilized to exclude non-epithelial cells from human dissociated endometrial cellular preparations.",MME,blood,-1
PMC5042010A,"Tumor cells representing the five major subtypes of breast cancer were recovered from 7.5mL blood samples using the LiquidBiopsy systemThe efficiency of recovery using EpCAM compared to capture with EpCAM, Her2, and Trop2 (top graph) and purity (bottom graph) are shown.",Her2,blood,-1
PMC5042010A,"Tumor cells representing the five major subtypes of breast cancer were recovered from 7.5mL blood samples using the LiquidBiopsy systemThe efficiency of recovery using EpCAM compared to capture with EpCAM, Her2, and Trop2 (top graph) and purity (bottom graph) are shown.",Trop2,blood,-1
PMC4999623A,"In contrast, ductal plate malformations such as extra-hepatic bile duct atresia and congenital hepatic fibrosis are associated with an overexpression of NCAM.140 Activated portal fibroblasts observed in the regenerating livers of rats following partial hepatectomy also express NCAM, further supporting the morphogenesis roles of NCAM.141 Hepatic stem cells have also been known to express NCAM, in addition to EpCAM and Claudin 3.26ICAM-1, a member of the immunoglobulin superfamily,142 is expressed on the surface of various cells at inflammatory and immune reactive sites,143 and is induced by pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-a.144 ICAM1 expression has been observed in various inflammatory liver disorders such as human liver allograft rejection,145 autoimmune liver diseases146,147 and hepatitis B.147,148",NCAM,bile,1
PMC4999623A,"In contrast, ductal plate malformations such as extra-hepatic bile duct atresia and congenital hepatic fibrosis are associated with an overexpression of NCAM.140 Activated portal fibroblasts observed in the regenerating livers of rats following partial hepatectomy also express NCAM, further supporting the morphogenesis roles of NCAM.141 Hepatic stem cells have also been known to express NCAM, in addition to EpCAM and Claudin 3.26ICAM-1, a member of the immunoglobulin superfamily,142 is expressed on the surface of various cells at inflammatory and immune reactive sites,143 and is induced by pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-a.144 ICAM1 expression has been observed in various inflammatory liver disorders such as human liver allograft rejection,145 autoimmune liver diseases146,147 and hepatitis B.147,148",NCAM,bile,1
PMC4999623A,"In contrast, ductal plate malformations such as extra-hepatic bile duct atresia and congenital hepatic fibrosis are associated with an overexpression of NCAM.140 Activated portal fibroblasts observed in the regenerating livers of rats following partial hepatectomy also express NCAM, further supporting the morphogenesis roles of NCAM.141 Hepatic stem cells have also been known to express NCAM, in addition to EpCAM and Claudin 3.26ICAM-1, a member of the immunoglobulin superfamily,142 is expressed on the surface of various cells at inflammatory and immune reactive sites,143 and is induced by pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-a.144 ICAM1 expression has been observed in various inflammatory liver disorders such as human liver allograft rejection,145 autoimmune liver diseases146,147 and hepatitis B.147,148",ICAM1,bile,1
PMC4621003A,"Vaccination with GPI-HER-2-VLPs enhances Th1-type antibody responsesMice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected on day 21.",GPI,serum,1
PMC4621003A,"Vaccination with GPI-HER-2-VLPs enhances Th1-type antibody responsesMice were vaccinated with GPI-HER-2-VLPs (25 mg) on day 0 and day 14, and serum was collected on day 21.",GPI,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",EDTA,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",EDTA,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",EDTA,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",FACS,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",FACS,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",FACS,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",HER-2,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",HER-2,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",HER-2,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",PBS,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",PBS,serum,1
PMC4621003A,"Flow cytometry (FACSCalibur, Becton Dickinson) analysis of serum anti-HER-2 IgG responses was carried out using a 1:200 diluted serum (obtained 7 days post boost) from vaccinated mice as primary antibody and 2.5 x 105 D2F2/E2 cells in 100 ml FACS Buffer (PBS, 5 mM EDTA, 1% cosmic calf serum).",PBS,serum,1
PMC4972371A,Higher levels of FOXC1 expression were associated with lymph node involvement (p  0.001).13Mesothelin and EGFR were the highest ranking tumour markers for the outcome of tumour grade/size/differentiation.,EGFR,lymph,1
PMC4972371A,Higher levels of FOXC1 expression were associated with lymph node involvement (p  0.001).13Mesothelin and EGFR were the highest ranking tumour markers for the outcome of tumour grade/size/differentiation.,FOXC1,lymph,1
PMC4621003A,"Anti-D2F2/E2-specific serum (A) IgG1, (B) IgG2a, and (C) IgG2b subtype antibodies were analyzed by cell ELISA using 1:200 diluted serum from vaccinated mice (n",IgG1,serum,1
PMC4621003A,"Anti-D2F2/E2-specific serum (A) IgG1, (B) IgG2a, and (C) IgG2b subtype antibodies were analyzed by cell ELISA using 1:200 diluted serum from vaccinated mice (n",IgG1,serum,1
PMC4621003A,"Anti-D2F2/E2-specific serum (A) IgG1, (B) IgG2a, and (C) IgG2b subtype antibodies were analyzed by cell ELISA using 1:200 diluted serum from vaccinated mice (n",ELISA,serum,1
PMC4621003A,"Anti-D2F2/E2-specific serum (A) IgG1, (B) IgG2a, and (C) IgG2b subtype antibodies were analyzed by cell ELISA using 1:200 diluted serum from vaccinated mice (n",ELISA,serum,1
PMC5042010A,FFPE and blood was recovered from each donor.,FFPE,blood,-1
PMC4690245A,"In univariate analysis, tumor differentiation (p = 0.008), local progression (p = 0.001), lymph node metastasis (p  0.001), clinical stage (p  0.001), MTA1 and EpCAM high expression (p  0.001) significantly predicted unfavorable overall survival (Table 3).",MTA1,lymph,1
PMC4711826A,(E) Representative images of (Upper) jaundice in the skin and (Lower) yellow-colored serum from the P14 LDKO mice.,LDKO,serum,1
PMC4711826A,(E) Representative images of (Upper) jaundice in the skin and (Lower) yellow-colored serum from the P14 LDKO mice.,P14,serum,1
PMC4558321A,"The linker selected, designated CL2A, resulting in an intermediate conjugate stability in serum, was attached to the hydroxyl group on SN-38's lactone ring, and contains a short polyethylene glycol moiety to enhance solubility (5,7).",SN-38,serum,1
PMC4558321A,"The linker selected, designated CL2A, resulting in an intermediate conjugate stability in serum, was attached to the hydroxyl group on SN-38's lactone ring, and contains a short polyethylene glycol moiety to enhance solubility (5,7).",CL2A,serum,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",Sca1,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",Sca1,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",KTLS,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",KTLS,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC4673473A,"In the first approach, hepatocytes are differentiated directly from bone marrow cells,6, 7, 8, 9, 10, 11, 12 and in the second, the establishment of multipotent stem cells is extended in vitro to allow hepatocyte differentiation.13, 14, 15, 16, 17Two eminent research groups had documented hepatocyte differentiation from bone marrow cells by determining that KTLS (c-KithiThyloLin-Sca1+) hematopoietic stem cells (HSCs), but not c-Kit-, Sca1- and lineage-positive (Lin+) cells, differentiated into hepatocyte-like cells in a FAH-/- (fumarylacetoacetate hydrolase) mouse model.6 Another group corroborated the exclusive capacity of HSC cells to differentiate into hepatocytes using additional functionally rigorous markers that defined the population with higher HSC activity frequency.8 These enriched HSC cells differentiated in vitro into albumin-expressing hepatocyte-like cells with extremely rapid kinetics.9",HSC,bone marrow,1
PMC3039945A,Urokinase receptor (uPAR; CD87) expression in stromal fibroblasts has been implicated in the occurrence of haematogenous metastasis (dissemination via the blood) of CRC [43].,uPAR,blood,-1
PMC3039945A,Urokinase receptor (uPAR; CD87) expression in stromal fibroblasts has been implicated in the occurrence of haematogenous metastasis (dissemination via the blood) of CRC [43].,CRC,blood,-1
PMC3039945A,Urokinase receptor (uPAR; CD87) expression in stromal fibroblasts has been implicated in the occurrence of haematogenous metastasis (dissemination via the blood) of CRC [43].,CD87,blood,-1
PMC3135497A,"E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ).",cDNA,sera,1
PMC3135497A,"E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ).",SDS,sera,1
PMC3135497A,"E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ).",PAGE,sera,1
PMC3135497A,"E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ).",ECSA,sera,1
PMC3135497A,"E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ).",pGEX-4T-3,sera,1
PMC4077671A,"Consistent with these observations, the two bilirubin and bile acid transporters NTCP and OATP1 were repressed in only the DDC diet-fed Car+/+/C3He mice (Figure 3b).",NTCP,bile,1
PMC4077671A,"Consistent with these observations, the two bilirubin and bile acid transporters NTCP and OATP1 were repressed in only the DDC diet-fed Car+/+/C3He mice (Figure 3b).",OATP1,bile,1
PMC4077671A,"Consistent with these observations, the two bilirubin and bile acid transporters NTCP and OATP1 were repressed in only the DDC diet-fed Car+/+/C3He mice (Figure 3b).",DDC,bile,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",TROP2,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",TROP2,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",Ki-67,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",Ki-67,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",TROP2,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",TROP2,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",EBER,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",EBER,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",EBV,lymph,1
PMC4637632A,"When compared TROP2 expression to gender, age, tumor stage, lymph node metastases, distant metastases, Ki-67 and EBER expression, overexpression of TROP2 significantly correlated with patients with distant metastases, proliferation indicator and EBV infection, but not with sex, age and lymph node status (Table 3).",EBV,lymph,1
PMC3110957A,The same patterns were observed in colonies after labeling with bile duct marker cytokeratin 19 (CK19) labeling (Fig.,CK19,bile,1
PMC4606116A,(c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).See full tableTable 1.,BST2,plasma,1
PMC4606116A,(c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).See full tableTable 1.,CEA,plasma,1
PMC4606116A,(c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).See full tableTable 1.,CEA,plasma,1
PMC4606116A,(c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).See full tableTable 1.,BST2,plasma,1
PMC4606116A,(c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).See full tableTable 1.,CRC,plasma,1
PMC3866276A,"Six different cancer cell subpopulations, clonally expanded from a single cell, including CCSP C12 and C13, were derived from the malignant ovarian ascites and propagated in culture as previously described [5,36].",CCSP,ascites,1
PMC3866276A,"Six different cancer cell subpopulations, clonally expanded from a single cell, including CCSP C12 and C13, were derived from the malignant ovarian ascites and propagated in culture as previously described [5,36].",C12,ascites,1
PMC3866276A,"Six different cancer cell subpopulations, clonally expanded from a single cell, including CCSP C12 and C13, were derived from the malignant ovarian ascites and propagated in culture as previously described [5,36].",C13,ascites,1
PMC3126726A,"Although no significant differences were noted for other clinical features (p  0.05), the patients with positive fecal KIAA0247 demonstrated a trend to be diagnosed at an earlier stage (AJCC Stage I; 56.5%, 13 of 23; p = 0.061) and to have lower levels of serum carcinoembryonic antigen (= 5 ng/mL; 53.6%, 15 of 28; p = 0.072).View larger versionFigure 2.",AJCC,serum,1
PMC3126726A,"Although no significant differences were noted for other clinical features (p  0.05), the patients with positive fecal KIAA0247 demonstrated a trend to be diagnosed at an earlier stage (AJCC Stage I; 56.5%, 13 of 23; p = 0.061) and to have lower levels of serum carcinoembryonic antigen (= 5 ng/mL; 53.6%, 15 of 28; p = 0.072).View larger versionFigure 2.",KIAA0247,serum,1
PMC4188889A,"A wide range of serum markers for PC has been reported[2,4] but few of them are exploited in clinical routine since they show low sensitivity and/or specificity in general.",PC,serum,1
PMC4673178A,"Our group explored linkers that released SN-38 from the conjugate with different half-lives in serum, ranging from ~10 h to a highly stable linker, but it was the linker with the intermediate stability that provided the best therapeutic response in mouse-human tumor xenograft models [30, 31].",SN-38,serum,1
PMC4344740A,"(A) Affinity-purified GST-tagged antigens were separated on 12% SDS-polyacrylamide gels stained with Coomassie staining (lane 1), or Western blotted using anti-GST antibody (lane 2) or autologous sera (lane 3) (B).See full tableTable 2.",GST,sera,1
PMC4344740A,"(A) Affinity-purified GST-tagged antigens were separated on 12% SDS-polyacrylamide gels stained with Coomassie staining (lane 1), or Western blotted using anti-GST antibody (lane 2) or autologous sera (lane 3) (B).See full tableTable 2.",SDS,sera,1
PMC4344740A,"(A) Affinity-purified GST-tagged antigens were separated on 12% SDS-polyacrylamide gels stained with Coomassie staining (lane 1), or Western blotted using anti-GST antibody (lane 2) or autologous sera (lane 3) (B).See full tableTable 2.",GST,sera,1
PMC4344740A,"Purified proteins were resolved by SDS-PAGE and then either directly stained with Coomassie Blue (Figure 1B, lane 1) or Western blotted against the anti-GST antibody (Figure 1B, lane 2) or the autologous plasma antibody (Figure 1B, lane 3).",GST,plasma,1
PMC4344740A,"Purified proteins were resolved by SDS-PAGE and then either directly stained with Coomassie Blue (Figure 1B, lane 1) or Western blotted against the anti-GST antibody (Figure 1B, lane 2) or the autologous plasma antibody (Figure 1B, lane 3).",SDS,plasma,1
PMC4344740A,"Purified proteins were resolved by SDS-PAGE and then either directly stained with Coomassie Blue (Figure 1B, lane 1) or Western blotted against the anti-GST antibody (Figure 1B, lane 2) or the autologous plasma antibody (Figure 1B, lane 3).",PAGE,plasma,1
PMC5042010A,"As such, the reasons ctcDNA and ccfDNA are found in blood are different with CTC representing the mobile cellular aspect of a tumor while ccfDNA is produced chiefly as a product of apoptosis [24, 25].In summary, two primary sources of DNA template are available from cancer patient blood samples.",CTC,blood,-1
PMC5042010A,"As such, the reasons ctcDNA and ccfDNA are found in blood are different with CTC representing the mobile cellular aspect of a tumor while ccfDNA is produced chiefly as a product of apoptosis [24, 25].In summary, two primary sources of DNA template are available from cancer patient blood samples.",CTC,blood,-1
PMC5042010A,"As such, the reasons ctcDNA and ccfDNA are found in blood are different with CTC representing the mobile cellular aspect of a tumor while ccfDNA is produced chiefly as a product of apoptosis [24, 25].In summary, two primary sources of DNA template are available from cancer patient blood samples.",DNA,blood,-1
PMC5042010A,"As such, the reasons ctcDNA and ccfDNA are found in blood are different with CTC representing the mobile cellular aspect of a tumor while ccfDNA is produced chiefly as a product of apoptosis [24, 25].In summary, two primary sources of DNA template are available from cancer patient blood samples.",DNA,blood,-1
PMC4673473A,Serum was collected to determine serum alanine aminotransferase levels on day 2 after APAP or after the final treatment with CCl4.,APAP,Serum,1
PMC4673473A,Serum was collected to determine serum alanine aminotransferase levels on day 2 after APAP or after the final treatment with CCl4.,APAP,serum,1
PMC4673473A,Serum was collected to determine serum alanine aminotransferase levels on day 2 after APAP or after the final treatment with CCl4.,CCl4,Serum,1
PMC4673473A,Serum was collected to determine serum alanine aminotransferase levels on day 2 after APAP or after the final treatment with CCl4.,CCl4,serum,1
PMC3090697A,"Sorted cells were fixed for 10 min in 2% paraformaldehyde, washed with 1.5% bovine serum albumin (BSA) in phosphate buffered saline (PBS), then smeared on glass slides and air dried.",PBS,serum,1
PMC3090697A,"Sorted cells were fixed for 10 min in 2% paraformaldehyde, washed with 1.5% bovine serum albumin (BSA) in phosphate buffered saline (PBS), then smeared on glass slides and air dried.",BSA,serum,1
PMC2797899A,"Tissue sections from five independent cases of metastatic prostatic adenocarcinoma to lymph nodes (A, B) or bone (C-F) were stained with an antibody to TRAP-1 (A, B, D-F) or nonbinding IgG (C).",TRAP-1,lymph,1
PMC5042010A,"Furthermore, there has not been a concordance study between ctcDNA, ccfDNA, and formalin fixed, paraffin embedded tissue (FFPE) from the same patient and blood draw using sequencing.",FFPE,blood,-1
PMC4108928A,"The serum CA-125 level of 52 patients was 35 U/ml, whereas that of the other 48 patients was 35 U/ml.",CA-125,serum,1
PMC3981717A,"A recent study has identified that EPCAM-positive cells from whole blood have stem cell-like characteristics and are associated with poor prognosis in HCC patients[12].Single nucleotide polymorphisms (SNPs) represent the most common form of genetic diversity within a species and account for much of the variation in genetic traits between patients [13], including disease susceptibility, prognosis and response to therapy.",HCC,blood,-1
PMC3981717A,"A recent study has identified that EPCAM-positive cells from whole blood have stem cell-like characteristics and are associated with poor prognosis in HCC patients[12].Single nucleotide polymorphisms (SNPs) represent the most common form of genetic diversity within a species and account for much of the variation in genetic traits between patients [13], including disease susceptibility, prognosis and response to therapy.",EPCAM,blood,-1
PMC5042010A,"From the blood samples, germline white blood cell DNA (wbcDNA), ccfDNA, and ctcDNA were isolated.",DNA,blood,-1
PMC5042010A,"From the blood samples, germline white blood cell DNA (wbcDNA), ccfDNA, and ctcDNA were isolated.",DNA,blood,-1
PMC2928967A,"Compared with the vehicle, the shRNA-introduced HCE-T-15 cells exhibited the decreased expression in the CLDN1 and seven proteins and altered subcellular localization from plasma membrane to cytoplasm or nucleus in all of those TJ-related proteins.",T-15,plasma,1
PMC2928967A,"Compared with the vehicle, the shRNA-introduced HCE-T-15 cells exhibited the decreased expression in the CLDN1 and seven proteins and altered subcellular localization from plasma membrane to cytoplasm or nucleus in all of those TJ-related proteins.",CLDN1,plasma,1
PMC2928967A,"Compared with the vehicle, the shRNA-introduced HCE-T-15 cells exhibited the decreased expression in the CLDN1 and seven proteins and altered subcellular localization from plasma membrane to cytoplasm or nucleus in all of those TJ-related proteins.",HCE,plasma,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",PCR,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",OCT-4,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",CD133,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",A549,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",CD326,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",A549,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",CD326,serum,1
PMC5467782A,"(B) The representative image of A549 spheroids in serum-free medium and the CD133+/CD326+ expression. (C) The expression of CD133, CD326, OCT-4 and Nanog in A549 cells and CD133+/CD326+ cells as measured by quantitative real-time PCR (*p0.05).",CD326,serum,1
PMC3478937A,"(C) BM from Axl, Mer, and Tyro3 single and Axl/Mer double KO mice was cultured in the presence of GM-CSF for 7 d and analyzed for TAM receptor expression by Western blot.",Tyro3,CSF,1
PMC3478937A,"(C) BM from Axl, Mer, and Tyro3 single and Axl/Mer double KO mice was cultured in the presence of GM-CSF for 7 d and analyzed for TAM receptor expression by Western blot.",TAM,CSF,1
PMC3478937A,"(C) BM from Axl, Mer, and Tyro3 single and Axl/Mer double KO mice was cultured in the presence of GM-CSF for 7 d and analyzed for TAM receptor expression by Western blot.",GM,CSF,1
PMC3478937A,"(C) BM from Axl, Mer, and Tyro3 single and Axl/Mer double KO mice was cultured in the presence of GM-CSF for 7 d and analyzed for TAM receptor expression by Western blot.",KO,CSF,1
PMC3843273A,"None of the other parameters (patient gender, tumor location, depth of invasion, lymph-node metastasis, vascular invasion, or pathological stage) was associated with positive survivin expression.",survivin,lymph,1
PMC3478937A,"(B) BM was cultured in the presence of GM-CSF and increasing concentrations of TGF-b receptor I kinase inhibitor (SB431542; 0.01, 0.1, 1, and 10 uM) for 7 d and analyzed for TAM receptor expression by Western blot.",SB431542,CSF,1
PMC3478937A,"(B) BM was cultured in the presence of GM-CSF and increasing concentrations of TGF-b receptor I kinase inhibitor (SB431542; 0.01, 0.1, 1, and 10 uM) for 7 d and analyzed for TAM receptor expression by Western blot.",GM,CSF,1
PMC3478937A,"(B) BM was cultured in the presence of GM-CSF and increasing concentrations of TGF-b receptor I kinase inhibitor (SB431542; 0.01, 0.1, 1, and 10 uM) for 7 d and analyzed for TAM receptor expression by Western blot.",TGF,CSF,1
PMC3478937A,"(B) BM was cultured in the presence of GM-CSF and increasing concentrations of TGF-b receptor I kinase inhibitor (SB431542; 0.01, 0.1, 1, and 10 uM) for 7 d and analyzed for TAM receptor expression by Western blot.",TAM,CSF,1
PMC3478937A,(A) BM was cultured in the presence of GM-CSF +- TGF-b1 +- TGF-b receptor I/II kinase inhibitor (LY2109761) for 7 d and analyzed for TAM receptor expression by Western blot.,TGF,CSF,1
PMC3478937A,(A) BM was cultured in the presence of GM-CSF +- TGF-b1 +- TGF-b receptor I/II kinase inhibitor (LY2109761) for 7 d and analyzed for TAM receptor expression by Western blot.,TGF,CSF,1
PMC3478937A,(A) BM was cultured in the presence of GM-CSF +- TGF-b1 +- TGF-b receptor I/II kinase inhibitor (LY2109761) for 7 d and analyzed for TAM receptor expression by Western blot.,LY2109761,CSF,1
PMC3478937A,(A) BM was cultured in the presence of GM-CSF +- TGF-b1 +- TGF-b receptor I/II kinase inhibitor (LY2109761) for 7 d and analyzed for TAM receptor expression by Western blot.,TAM,CSF,1
PMC3478937A,(A) BM was cultured in the presence of GM-CSF +- TGF-b1 +- TGF-b receptor I/II kinase inhibitor (LY2109761) for 7 d and analyzed for TAM receptor expression by Western blot.,GM,CSF,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",ATCC,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",MCF7,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",A549,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",FBS,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",PaCa2,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",T24,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",HCT116,serum,1
PMC4165776A,"EpCAM-positive (HCT116, MCF7, and PC3) and EpCAM-negative (A549, T24, and Mia-PaCa2) cells were obtained from the American Type Culture Collection (ATCC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 and Dulbecco's modified Eagle's medium(DMEM) supplemented with 10% fetal bovine serum (FBS; GenDepot).Cell Capture.",PC3,serum,1
PMC3548755A,"Our unique approach was the quantitative comparison of the levels of serum antibodies using the ELISA, while the approach of others was qualitative analysis.",ELISA,serum,1
PMC3566310A,"First, ligation of the common bile duct (BDL) in mice was used as a model for cholestatic liver disease.",BDL,bile,1
PMC3369609A,"Returning to purified populations of LCs expanded from G-CSF-mobilized, CD34+ HPCs,9 we first compared these with CD34+ HPC-derived DDC-IDCs and moDCs.",CD34,CSF,1
PMC3369609A,"Returning to purified populations of LCs expanded from G-CSF-mobilized, CD34+ HPCs,9 we first compared these with CD34+ HPC-derived DDC-IDCs and moDCs.",DDC,CSF,1
PMC3369609A,"Returning to purified populations of LCs expanded from G-CSF-mobilized, CD34+ HPCs,9 we first compared these with CD34+ HPC-derived DDC-IDCs and moDCs.",HPC,CSF,1
PMC3369609A,"Returning to purified populations of LCs expanded from G-CSF-mobilized, CD34+ HPCs,9 we first compared these with CD34+ HPC-derived DDC-IDCs and moDCs.",CD34,CSF,1
PMC3369609A,"Error bar not shown for the condition without GM-CSF, as lower viability yielded sufficient cells from only 2 independent experiments.",GM,CSF,-1
PMC4370053A,"It should be noted, however, that approximately one-third oflangerin+ DCs in murine nonlymphoid tissues does not express the DC1marker CD103, suggesting expression on additional DC populations that may include someDC2 [20].In vivo experiments with HSCT recipients and patients with DC deficiency show thatlangerin+ DCs and CD1a+ dermal DCs have parallel homeostasiswith blood monocytes and DCs and are not derived from LCs.",CD103,blood,-1
PMC4370053A,"It should be noted, however, that approximately one-third oflangerin+ DCs in murine nonlymphoid tissues does not express the DC1marker CD103, suggesting expression on additional DC populations that may include someDC2 [20].In vivo experiments with HSCT recipients and patients with DC deficiency show thatlangerin+ DCs and CD1a+ dermal DCs have parallel homeostasiswith blood monocytes and DCs and are not derived from LCs.",HSCT,blood,-1
PMC4370053A,"It should be noted, however, that approximately one-third oflangerin+ DCs in murine nonlymphoid tissues does not express the DC1marker CD103, suggesting expression on additional DC populations that may include someDC2 [20].In vivo experiments with HSCT recipients and patients with DC deficiency show thatlangerin+ DCs and CD1a+ dermal DCs have parallel homeostasiswith blood monocytes and DCs and are not derived from LCs.",DC,blood,-1
PMC4370053A,"It should be noted, however, that approximately one-third oflangerin+ DCs in murine nonlymphoid tissues does not express the DC1marker CD103, suggesting expression on additional DC populations that may include someDC2 [20].In vivo experiments with HSCT recipients and patients with DC deficiency show thatlangerin+ DCs and CD1a+ dermal DCs have parallel homeostasiswith blood monocytes and DCs and are not derived from LCs.",DC,blood,-1
PMC3369609A,GM-CSF 1000 IU/mL was added or not to maintain LC viability.21,GM,CSF,1
PMC3369609A,"Apart from mechanical perturbations, these LCs had no exposure to other maturation stimuli, although we did compare cells cultured with or without GM-CSF for enhanced LC viability.21",GM,CSF,1
PMC2722670A,"The cutoff values for serum CEA, CYFRA21-1, and SCC-Ag levels were 4.6 ng/ml, 2.57 ng/ml and 1.5 ng/ml, respectively, in accordance with the manufacturer's instructions.",CYFRA21,serum,1
PMC2722670A,"The cutoff values for serum CEA, CYFRA21-1, and SCC-Ag levels were 4.6 ng/ml, 2.57 ng/ml and 1.5 ng/ml, respectively, in accordance with the manufacturer's instructions.",CEA,serum,1
PMC2722670A,"The cutoff values for serum CEA, CYFRA21-1, and SCC-Ag levels were 4.6 ng/ml, 2.57 ng/ml and 1.5 ng/ml, respectively, in accordance with the manufacturer's instructions.",SCC,serum,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",IL-15R,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",IL-15R,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",CSF,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",GM,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",GM,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",GM,CSF,1
PMC3369609A,"There was no significant difference in intensity of expression between LCs exposed to GM-CSF or not, although the GM-CSF-treated condition appeared to concentrate more of the IL-15R-a at the cell membrane.",GM,CSF,1
PMC4118235A,"Cells were cultured in DMEM supplemented with 10% foetal bovine serum (FBS; Euroclone, Pero, Italy) and 1% antibiotic mixture (Gibco, Invitrogen Life Technologies, S. Giuliano Milanese, Italy).The calcein assay was carried out using the lipophilic, nonfluorescent calcein-acetoxymethylester (calcein-AM), which penetrates cell membranes and is then cleaved by intracellular esterases, yielding the hydrophilic fluorescent dye.",AM,serum,1
PMC4118235A,"Cells were cultured in DMEM supplemented with 10% foetal bovine serum (FBS; Euroclone, Pero, Italy) and 1% antibiotic mixture (Gibco, Invitrogen Life Technologies, S. Giuliano Milanese, Italy).The calcein assay was carried out using the lipophilic, nonfluorescent calcein-acetoxymethylester (calcein-AM), which penetrates cell membranes and is then cleaved by intracellular esterases, yielding the hydrophilic fluorescent dye.",FBS,serum,1
PMC4118235A,"Cells were cultured in DMEM supplemented with 10% foetal bovine serum (FBS; Euroclone, Pero, Italy) and 1% antibiotic mixture (Gibco, Invitrogen Life Technologies, S. Giuliano Milanese, Italy).The calcein assay was carried out using the lipophilic, nonfluorescent calcein-acetoxymethylester (calcein-AM), which penetrates cell membranes and is then cleaved by intracellular esterases, yielding the hydrophilic fluorescent dye.",DMEM,serum,1
PMC4371775A,"CD49f, also designated as integrin-a6 (ITGA6) adhesion molecule, is a cell surface marker that is expressed in stem and progenitor cells from various tissues types including bone marrow, brain, embryo and mammary gland (52,53).",ITGA6,bone marrow,1
PMC4371775A,"CD49f, also designated as integrin-a6 (ITGA6) adhesion molecule, is a cell surface marker that is expressed in stem and progenitor cells from various tissues types including bone marrow, brain, embryo and mammary gland (52,53).",CD49f,bone marrow,1
PMC5485361A,CSCs enriched from patient whole blood would be representative of a CTC subpopulation but may still miss the CSCs developing in the metastatic niche or after therapy.,CTC,blood,-1
PMC5376003A,"354234) for 12 days in WEM with supplements including 2 mM Glutamine, 5% fetal bovine serum, 20 ng/ml epidermal growth factor (In Vitro Technologies), 30 ng/ml insulin-like growth factor-II (PeproTech Inc, Rocky Hill, NJ, USA) as previously described [21].Albumin and urea levels in the cell culture supernatant were determined by ALB ELISA kit and Urea Assay Kit (Abcam) according to the manufacturer's protocol.",ELISA,serum,1
PMC5376003A,"354234) for 12 days in WEM with supplements including 2 mM Glutamine, 5% fetal bovine serum, 20 ng/ml epidermal growth factor (In Vitro Technologies), 30 ng/ml insulin-like growth factor-II (PeproTech Inc, Rocky Hill, NJ, USA) as previously described [21].Albumin and urea levels in the cell culture supernatant were determined by ALB ELISA kit and Urea Assay Kit (Abcam) according to the manufacturer's protocol.",USA,serum,1
PMC5376003A,"354234) for 12 days in WEM with supplements including 2 mM Glutamine, 5% fetal bovine serum, 20 ng/ml epidermal growth factor (In Vitro Technologies), 30 ng/ml insulin-like growth factor-II (PeproTech Inc, Rocky Hill, NJ, USA) as previously described [21].Albumin and urea levels in the cell culture supernatant were determined by ALB ELISA kit and Urea Assay Kit (Abcam) according to the manufacturer's protocol.",WEM,serum,1
PMC5376003A,"354234) for 12 days in WEM with supplements including 2 mM Glutamine, 5% fetal bovine serum, 20 ng/ml epidermal growth factor (In Vitro Technologies), 30 ng/ml insulin-like growth factor-II (PeproTech Inc, Rocky Hill, NJ, USA) as previously described [21].Albumin and urea levels in the cell culture supernatant were determined by ALB ELISA kit and Urea Assay Kit (Abcam) according to the manufacturer's protocol.",ALB,serum,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",RPMI,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",CH,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",T,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",CD28,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",USA,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",FCS,blood,1
PMC4473102A,"The microarray results have been reported according to the MIAME guidelines and deposited in the public repository ArrayExpress http://www.ebi.ac.uk/arrayexpress; accession number E-MTAB-3201.Peripheral blood mononuclear cells (PBMCs) were obtained from 20 healthy donors and 30 patients affected by PsA following a density-gradient centrifugation on Lymphoprep (Nycomed Pharma, Oslo, NO) and two washes with PBS.Cells collected from patients and normal controls were cultured in 2 mL tubes containing 1 mL of RPMI 1640 + FCS 10% (Lonza, Basel, CH) at a concentration of 1*106 cells/mL. Cells were stimulated for 4 hours with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) or with heat-inactivated Candida albicans.",MIAME,blood,1
PMC5000705A,"They used blood samples from metastatic breast cancer patients and breast cancer cell lines to calculate the ratio of CK/vimentin, but especially in the patient samples CK/vimentin ratios varied a lot, displaying again the heterogeneity of CTCs undergoing EMT [90].",EMT,blood,1
PMC2441949A,"As anticipated, we observed a significant association between lymph node metastases and T-stage, pathologic stage, and tissue differentiation (continuous).To evaluate potential prognostic values of the genes, we simply used as an internal reference the mean Ct value of all 15 genes (Figure 2).",T,lymph,1
PMC4807992A,"By inhibiting the AR axis through the release of cytokine CCL5, infiltrating bone marrow mesenchymal stem cells increase prostate CSC population and PC metastatic properties [122].",PC,bone marrow,1
PMC4807992A,"By inhibiting the AR axis through the release of cytokine CCL5, infiltrating bone marrow mesenchymal stem cells increase prostate CSC population and PC metastatic properties [122].",AR,bone marrow,1
PMC4807992A,"By inhibiting the AR axis through the release of cytokine CCL5, infiltrating bone marrow mesenchymal stem cells increase prostate CSC population and PC metastatic properties [122].",CSC,bone marrow,1
PMC4807992A,"By inhibiting the AR axis through the release of cytokine CCL5, infiltrating bone marrow mesenchymal stem cells increase prostate CSC population and PC metastatic properties [122].",CCL5,bone marrow,1
PMC4188889A,PLA is a highly sensitive technique for multiplex detection of biomarkers in plasma with little interfering background signal.,PLA,plasma,1
PMC3369609A,"It is nevertheless important to note that, apart from inflammatory maturation in vitro, the phenotype of CD34+ HPC-derived LCs, generated under culture conditions similar to our own, corresponds closely to LCs isolated from human epidermis,23 but not to so-called monocyte-derived LCs.24,25 Until investigators develop the means to target LCs in situ and selectively activate their migration to and stimulatory capacity in draining lymph nodes, however, well-defined LCs generated in vitro remain suitable candidates for cell-based vaccines.",CD34,lymph,1
PMC3369609A,"It is nevertheless important to note that, apart from inflammatory maturation in vitro, the phenotype of CD34+ HPC-derived LCs, generated under culture conditions similar to our own, corresponds closely to LCs isolated from human epidermis,23 but not to so-called monocyte-derived LCs.24,25 Until investigators develop the means to target LCs in situ and selectively activate their migration to and stimulatory capacity in draining lymph nodes, however, well-defined LCs generated in vitro remain suitable candidates for cell-based vaccines.",HPC,lymph,1
PMC4621003A,A strong anti-D2F2/E2 serum IgG antibody response was detected in GPI-HER-2-VLP-vaccinated mice whereas unmodified VLP-vaccinated mice did not show any detectable levels of anti-D2F2/E2 IgG antibodies (Figure 3A).,HER-2-VLP,serum,1
PMC4621003A,A strong anti-D2F2/E2 serum IgG antibody response was detected in GPI-HER-2-VLP-vaccinated mice whereas unmodified VLP-vaccinated mice did not show any detectable levels of anti-D2F2/E2 IgG antibodies (Figure 3A).,GPI,serum,1
PMC4621003A,A strong anti-D2F2/E2 serum IgG antibody response was detected in GPI-HER-2-VLP-vaccinated mice whereas unmodified VLP-vaccinated mice did not show any detectable levels of anti-D2F2/E2 IgG antibodies (Figure 3A).,VLP,serum,1
PMC4777741A,"After washing, the cells were blocked with 3% normal goat serum (NGS) for 30 min and then incubated with anti-Phospho PKC-I+- antibody (Abcam, Cambridge, MA, USA) for 45 min followed by Alexa Fluor 488 antibody (Life Technologies, Carlsbad, CA, USA).",NGS,serum,1
PMC4777741A,"After washing, the cells were blocked with 3% normal goat serum (NGS) for 30 min and then incubated with anti-Phospho PKC-I+- antibody (Abcam, Cambridge, MA, USA) for 45 min followed by Alexa Fluor 488 antibody (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC4777741A,"After washing, the cells were blocked with 3% normal goat serum (NGS) for 30 min and then incubated with anti-Phospho PKC-I+- antibody (Abcam, Cambridge, MA, USA) for 45 min followed by Alexa Fluor 488 antibody (Life Technologies, Carlsbad, CA, USA).",PKC,serum,1
PMC4777741A,"After washing, the cells were blocked with 3% normal goat serum (NGS) for 30 min and then incubated with anti-Phospho PKC-I+- antibody (Abcam, Cambridge, MA, USA) for 45 min followed by Alexa Fluor 488 antibody (Life Technologies, Carlsbad, CA, USA).",USA,serum,1
PMC3476529A,"To examine this possibility, we added sorted and labeled CD141+ blood DCs to a skin preparation and observed an upregulation of CD1a and CD1c in keeping with the tissue CD141hi DC phenotype (Figure 3D).",DC,blood,-1
PMC3476529A,"To examine this possibility, we added sorted and labeled CD141+ blood DCs to a skin preparation and observed an upregulation of CD1a and CD1c in keeping with the tissue CD141hi DC phenotype (Figure 3D).",CD141,blood,-1
PMC3906064A,"Baseline performance characteristics for the LiquidBiopsy platform were measured by adding MCF7 or H1650 cells into NHD blood at incremental concentrations in triplicate from 3 to 900 cells/mL and measuring the percent error, a measure of accuracy, and percent coefficient of variation (% CV), a measure of precision, at each input (Table 1).",NHD,blood,1
PMC3906064A,"Baseline performance characteristics for the LiquidBiopsy platform were measured by adding MCF7 or H1650 cells into NHD blood at incremental concentrations in triplicate from 3 to 900 cells/mL and measuring the percent error, a measure of accuracy, and percent coefficient of variation (% CV), a measure of precision, at each input (Table 1).",MCF7,blood,1
PMC3906064A,"Baseline performance characteristics for the LiquidBiopsy platform were measured by adding MCF7 or H1650 cells into NHD blood at incremental concentrations in triplicate from 3 to 900 cells/mL and measuring the percent error, a measure of accuracy, and percent coefficient of variation (% CV), a measure of precision, at each input (Table 1).",H1650,blood,1
PMC2722670A,"SCC-Ag levels were measured in serum with an immunoradiometric Assay kit (Dynabott, Tokyo, Japan).",SCC,serum,1
PMC3092219A,"Interestingly, APC hypermethylation was observed more frequently in cases with high Gleason scores and high serum PSA levels.",PSA,serum,1
PMC3092219A,"Interestingly, APC hypermethylation was observed more frequently in cases with high Gleason scores and high serum PSA levels.",APC,serum,1
PMC3476529A,", 2009).Recent progress was made in identifying potential homologs of mouse DC subsets by examining human blood DCs.",DC,blood,-1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",C2,Serum,1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",ICD,Serum,1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",ECD,Serum,1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",Erk2,Serum,1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",RFP,Serum,1
PMC3475800A,"(B) Serum-free medium from TRAMP-C2 cells transduced with RFP lentivirus (control) or mTrop2-Myc tag (mTrop2) was precipitated (precipitated media), followed by Western blot using commercial anti-ECD antibody or anti-Myc tag recognizing the ICD or Erk2 as a marker for cell lysate.",TRAMP,Serum,1
PMC4621003A,"Further, minimum or no serum IgG antibody was detected against the parental HER-2-negative D2F2 (Figure 3B) cells showing that reactivity against D2F2/E2 was from HER-2 specific antibodies.",D2F2,serum,1
PMC4621003A,"Further, minimum or no serum IgG antibody was detected against the parental HER-2-negative D2F2 (Figure 3B) cells showing that reactivity against D2F2/E2 was from HER-2 specific antibodies.",HER-2,serum,1
PMC3478937A,"Indeed, the involvement of the TAM receptor system in human systemic lupus erythematosus has recently been demonstrated by increased soluble Axl and Mer and decreased Protein S serum levels, which are consistent with reduced TAM signaling in patients that display active disease (Suh et al., 2010; Ekman et al., 2011",TAM,serum,1
PMC3478937A,"Indeed, the involvement of the TAM receptor system in human systemic lupus erythematosus has recently been demonstrated by increased soluble Axl and Mer and decreased Protein S serum levels, which are consistent with reduced TAM signaling in patients that display active disease (Suh et al., 2010; Ekman et al., 2011",TAM,serum,1
PMC3561800A,"(D) Percentage of mice that had developed metastatic lesions to lymph nodes, lungs, or liver at the indicated ages (PB-TAg; b4-WT: n = 3 at 2.5 months, n = 16 at 4.5 months, n = 13 at 6.5 months, and n = 7 at 8.5 months; PB-TAg; b4-1355T: n = 3 at 2.5 months, n = 10 at 4.5 months, n = 5 at 6.5 months, and n = 9 at 8.5 months).View larger versionFigure 3.",b4-WT,lymph,-1
PMC3561800A,"(D) Percentage of mice that had developed metastatic lesions to lymph nodes, lungs, or liver at the indicated ages (PB-TAg; b4-WT: n = 3 at 2.5 months, n = 16 at 4.5 months, n = 13 at 6.5 months, and n = 7 at 8.5 months; PB-TAg; b4-1355T: n = 3 at 2.5 months, n = 10 at 4.5 months, n = 5 at 6.5 months, and n = 9 at 8.5 months).View larger versionFigure 3.",T,lymph,-1
PMC5348388A,Membranes were blocked with bovine serum albumin (BSA) and incubated with primary antibodies.,BSA,serum,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",lR1,blood,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",IFN,blood,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",IFN,blood,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",lR1,blood,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",IFN,blood,1
PMC3655979A,"Although blood immune cells express IFN-lR1, they exhibit impaired response to IFN-ls due to the secretion of a short spliced variant of IFN-lR1 that inhibits the effect of IFN-l1 [12].",IFN,blood,1
PMC4188889A,"In the second study, Brand et al[52] investigated 83 circulating proteins in sera of patients diagnosed with PDAC, benign pancreatic conditions and healthy controls.",PDAC,sera,1
PMC3885472A,"The single cells from radical prostatectomy specimens or the small pieces from needle biopsy samples were maintained in complete keratinocyte growth medium (keratinocyte serum-free medium with epidermal growth factor and bovine pituitary extract; Invitrogen), which were also supplemented with 2 ng/ml of leukemia inhibitory factor (LIF, Sigma), 2 ng/ml of stem cell factor (SCF, Sigma), and 100 ng/ml of cholera toxin (Sigma), referring to the method described previously [10].Cells were cultured in the plates or dishes coated with collagen I in a humidified incubator at 37 in an atmosphere of 95% air and 5% carbon dioxide.",SCF,serum,1
PMC3885472A,"The single cells from radical prostatectomy specimens or the small pieces from needle biopsy samples were maintained in complete keratinocyte growth medium (keratinocyte serum-free medium with epidermal growth factor and bovine pituitary extract; Invitrogen), which were also supplemented with 2 ng/ml of leukemia inhibitory factor (LIF, Sigma), 2 ng/ml of stem cell factor (SCF, Sigma), and 100 ng/ml of cholera toxin (Sigma), referring to the method described previously [10].Cells were cultured in the plates or dishes coated with collagen I in a humidified incubator at 37 in an atmosphere of 95% air and 5% carbon dioxide.",LIF,serum,1
PMC3749571A,"Low levels of UGT1A expression were also associated with increased serum PSA levels upon clinical presentation (P=0.003, Mann-Whitney U-test; Figure 4C), consistent with reduced UGT1A expression increasing intracellular testosterone bioavailability and AR activity.",AR,serum,1
PMC3749571A,"Low levels of UGT1A expression were also associated with increased serum PSA levels upon clinical presentation (P=0.003, Mann-Whitney U-test; Figure 4C), consistent with reduced UGT1A expression increasing intracellular testosterone bioavailability and AR activity.",PSA,serum,1
PMC3749571A,"Low levels of UGT1A expression were also associated with increased serum PSA levels upon clinical presentation (P=0.003, Mann-Whitney U-test; Figure 4C), consistent with reduced UGT1A expression increasing intracellular testosterone bioavailability and AR activity.",UGT1A,serum,1
PMC3749571A,"Low levels of UGT1A expression were also associated with increased serum PSA levels upon clinical presentation (P=0.003, Mann-Whitney U-test; Figure 4C), consistent with reduced UGT1A expression increasing intracellular testosterone bioavailability and AR activity.",UGT1A,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",DMEM,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",DMEM,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",F12,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",F12,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",bFGF,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",bFGF,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",BSA,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",BSA,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",EGF,serum,1
PMC3885472A,"Cells were grown in serum-free DMEM/F12 medium (Gibco), which was supplemented with 20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic fibroblast growth factor (bFGF, Sigma), 0.4% bovine serum albumin (BSA, Sigma), 5 mg/ml insulin (Sigma) and 1xN2 nutrition (Stemcell Technologies Inc.).Prostate cancer cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37 degC for 10 days, and collected by gentle centrifugation.",EGF,serum,1
PMC4966842B,"For sipuleucel-T, the vaccine preparatory process involves removing patient DCs and priming these cells with prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells, and granulocyte-macrophage colony stimulating factor (GM-CSF) for maturation of the DCs, and then administering the primed cells back to the patient.",GM,CSF,-1
PMC4966842B,"For sipuleucel-T, the vaccine preparatory process involves removing patient DCs and priming these cells with prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells, and granulocyte-macrophage colony stimulating factor (GM-CSF) for maturation of the DCs, and then administering the primed cells back to the patient.",PAP,CSF,-1
PMC4966842B,"For sipuleucel-T, the vaccine preparatory process involves removing patient DCs and priming these cells with prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells, and granulocyte-macrophage colony stimulating factor (GM-CSF) for maturation of the DCs, and then administering the primed cells back to the patient.",T,CSF,-1
PMC3548755A,Serum antibody level to SH3GL1 was examined by the ELISA as described in the legends of Figure1.,ELISA,Serum,1
PMC3548755A,Serum antibody level to SH3GL1 was examined by the ELISA as described in the legends of Figure1.,SH3GL1,Serum,1
PMC3548755A,Serum antibody level to SH3GL1 was examined by the ELISA as described in the legends of Figure1.,Figure1,Serum,1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",NSCLC,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",PHGDH,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",III,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",pNII,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",PHGDH,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",pN1,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",mRNA,lymph,-1
PMC5143353A,"Similarly, the percentage of tumor with high PHGDH expression increased with the severity of lymph node invasion (pN0, 50.00%; pN1, 57.97%; pNII + III, 71.15%, P = .021, Table 1).Quantitative RT-PCR analysis was conducted to identify differences in PHGDH mRNA expression between NSCLC and matched adjacent normal tissue samples (n = 20).",PCR,lymph,-1
PMC3929731A,"Cells were next incubated in 0.5 mg/mL Hoechst 33342 (Sigma-Aldrich) in Hanks' balance salt solution, 10% fetal bovine serum, 1% d-glucose, and 20 mM HEPES for 30 minutes at 37degC, washed in PBS, and incubated with 1 mg/mL propidium iodide for dead cell exclusion.",HEPES,serum,1
PMC3929731A,"Cells were next incubated in 0.5 mg/mL Hoechst 33342 (Sigma-Aldrich) in Hanks' balance salt solution, 10% fetal bovine serum, 1% d-glucose, and 20 mM HEPES for 30 minutes at 37degC, washed in PBS, and incubated with 1 mg/mL propidium iodide for dead cell exclusion.",PBS,serum,1
PMC3548755A,Serum antibody levels of glioma SEREX antigens.,SEREX,Serum,1
PMC3680444A,"Subsequent studies showed that ATDC was overexpressed in multiple types of cancers including pancreatic, gastric, bladder, colorectal, ovarian and endometrial cancers, as well as in plasma cell myeloma [13]-[21].",ATDC,plasma,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",USA,serum,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",RPMI,serum,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",CO2,serum,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",GIBCO,serum,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",CO2,serum,1
PMC4437992A,"Human cervical cancer cell line HeLa, obtained from the Gynecological Tumor Laboratory of Qilu Hospital of Shandong University, was used in the experiment, which was cultured in RPMI Medium 1640 (GIBCO, Invitrogen Corporation) supplemented with 10 % fetal bovine serum (FBS) (Kangyuan Biology, China) and 1 % penicillin-streptomycin (Solarbio, Beijing Solarbio Science  Technology, China) in water-jacketed CO2 incubators (Thermo Fisher Scientific Forma Series II, USA) at 37 degC with 95 % (v/v) air and 5 % (v/v) CO2.",FBS,serum,1
PMC4606116A,"In agreement with the previous result, the plasma BST2 levels still showed a significant increase in CRC patients as compared to the controls in this independent sample set (2.35 +- 0.13 ng/mL versus 1.04 +- 0.03 ng/mL, p  0.01, independent t-test; Figure 1(b), left panel).",BST2,plasma,1
PMC4606116A,"In agreement with the previous result, the plasma BST2 levels still showed a significant increase in CRC patients as compared to the controls in this independent sample set (2.35 +- 0.13 ng/mL versus 1.04 +- 0.03 ng/mL, p  0.01, independent t-test; Figure 1(b), left panel).",CRC,plasma,1
PMC3476529A,"Reminiscent of this, we found that blood CD141+ DCs are not cycling but 4% of CD141hi DCs are in S, G2, or M phase by DNA content analysis (Figure 3E).CD141hi DCs migrate spontaneously in vitro (Figures 1 and 2) and express CCR7 (Figure 3), suggesting that they may migrate to LNs in vivo.",CCR7,blood,1
PMC3476529A,"Reminiscent of this, we found that blood CD141+ DCs are not cycling but 4% of CD141hi DCs are in S, G2, or M phase by DNA content analysis (Figure 3E).CD141hi DCs migrate spontaneously in vitro (Figures 1 and 2) and express CCR7 (Figure 3), suggesting that they may migrate to LNs in vivo.",DNA,blood,1
PMC3476529A,"Reminiscent of this, we found that blood CD141+ DCs are not cycling but 4% of CD141hi DCs are in S, G2, or M phase by DNA content analysis (Figure 3E).CD141hi DCs migrate spontaneously in vitro (Figures 1 and 2) and express CCR7 (Figure 3), suggesting that they may migrate to LNs in vivo.",CD141,blood,1
PMC3476529A,"Reminiscent of this, we found that blood CD141+ DCs are not cycling but 4% of CD141hi DCs are in S, G2, or M phase by DNA content analysis (Figure 3E).CD141hi DCs migrate spontaneously in vitro (Figures 1 and 2) and express CCR7 (Figure 3), suggesting that they may migrate to LNs in vivo.",G2,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",A2,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",FCS,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",HLA,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",FACS,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",RPMI,blood,1
PMC3476529A,"Proliferation was assessed by CFSE dilution on day 6.4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS.",CFSE,blood,1
PMC3476529A,"Representative data from seven skin donors are shown.(D) Frequency of CD141hi cells as a percent of CD45+ mononuclear cells in skin, liver, and lung relative to peripheral blood.",CD45,blood,-1
PMC4966842A,"This was in contrary to targets such as HER2 and EGFR, which are predominantly present on the plasma membrane.",HER2,plasma,-1
PMC4966842A,"This was in contrary to targets such as HER2 and EGFR, which are predominantly present on the plasma membrane.",EGFR,plasma,-1
PMC3104081A,"The resultant cell suspension was washed twice in RPMI 1640 plus 10% fetal bovine serum (FBS, Invitrogen, Grand Island, NY).",FBS,serum,1
PMC3104081A,"The resultant cell suspension was washed twice in RPMI 1640 plus 10% fetal bovine serum (FBS, Invitrogen, Grand Island, NY).",RPMI,serum,1
PMC3723929A,"Non-serum protein block (Dako, Carpinteria, CA, USA) was applied for 30 min.",USA,serum,1
PMC3476529A,Data shown are from two blood and skin donors.(C) DC migration from skin explants cultured ex vivo over 24 hr in medium alone (-) or with XCL1 or CCL3.,XCL1,blood,-1
PMC3476529A,Data shown are from two blood and skin donors.(C) DC migration from skin explants cultured ex vivo over 24 hr in medium alone (-) or with XCL1 or CCL3.,CCL3,blood,-1
PMC3476529A,Data shown are from two blood and skin donors.(C) DC migration from skin explants cultured ex vivo over 24 hr in medium alone (-) or with XCL1 or CCL3.,DC,blood,-1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",RNA,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",CLEC9A,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",FACS,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",qRT,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",CADM1,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",FACS,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",PCR,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",TLR3,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",HLA,blood,1
PMC3476529A,"CD141hi Tissue DCs Express Markers of Cross-Presenting DCs(A) Lin-HLA-DR+ cells from blood and skin were FACS purified according to gating shown in dot plots.(B) RNA from FACS-purified cells in (A) was analyzed for the expression of XCR1, TLR3, CLEC9A, and CADM1 by qRT-PCR.",XCR1,blood,1
PMC4606475A,"Serum ALT levels were measured using the MaxDiscovery Alanine Transaminase Color Endpoint Assay (Bioo Scientific, Austin, TX, USA).Non-parenchymal cells were isolated by finely dissociating the liver tissue using surgical scissors then passing the fragments through a stainless steel strainer with the addition of 14 ml of Hank's Based Salt Solution (HBSS) containing 1 mg/ml type 4 collagenase (Worthington Biochemical corporation, Lakewood, NJ, USA) 1 mg/ml DNase I (Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin.",TX,Serum,1
PMC4606475A,"Serum ALT levels were measured using the MaxDiscovery Alanine Transaminase Color Endpoint Assay (Bioo Scientific, Austin, TX, USA).Non-parenchymal cells were isolated by finely dissociating the liver tissue using surgical scissors then passing the fragments through a stainless steel strainer with the addition of 14 ml of Hank's Based Salt Solution (HBSS) containing 1 mg/ml type 4 collagenase (Worthington Biochemical corporation, Lakewood, NJ, USA) 1 mg/ml DNase I (Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin.",ALT,Serum,1
PMC4606475A,"Serum ALT levels were measured using the MaxDiscovery Alanine Transaminase Color Endpoint Assay (Bioo Scientific, Austin, TX, USA).Non-parenchymal cells were isolated by finely dissociating the liver tissue using surgical scissors then passing the fragments through a stainless steel strainer with the addition of 14 ml of Hank's Based Salt Solution (HBSS) containing 1 mg/ml type 4 collagenase (Worthington Biochemical corporation, Lakewood, NJ, USA) 1 mg/ml DNase I (Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin.",USA,Serum,1
PMC4606475A,"Serum ALT levels were measured using the MaxDiscovery Alanine Transaminase Color Endpoint Assay (Bioo Scientific, Austin, TX, USA).Non-parenchymal cells were isolated by finely dissociating the liver tissue using surgical scissors then passing the fragments through a stainless steel strainer with the addition of 14 ml of Hank's Based Salt Solution (HBSS) containing 1 mg/ml type 4 collagenase (Worthington Biochemical corporation, Lakewood, NJ, USA) 1 mg/ml DNase I (Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin.",HBSS,Serum,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",VEGF,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",CRC,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",ErbB2,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",IGFR,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",VEGF,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",CRC,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",EGFR,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",EGFR,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",EGFR,lymph,1
PMC3039945A,"Although patients with EGFR expression have a higher risk for disease recurrence compared to those with EGFR negative tumours, there appears to be no relationship between EGFR expression and overall survival [191,192].A significant correlation has been demonstrated between insulin growth factor receptor (IGFR) expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193].Although cytoplasmic over-expression of human epidermal growth factor receptor 2 (CD340, HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous expression of this protein shows no prognostic significance [195].",CD340,lymph,1
PMC3039945A,"Fas-ligand (CD178; CD95L; FasL) expression, however, correlates with lymph node involvement and distant metastases in CRC [207].",FasL,lymph,1
PMC3039945A,"Fas-ligand (CD178; CD95L; FasL) expression, however, correlates with lymph node involvement and distant metastases in CRC [207].",CD95L,lymph,1
PMC3039945A,"Fas-ligand (CD178; CD95L; FasL) expression, however, correlates with lymph node involvement and distant metastases in CRC [207].",CD178,lymph,1
PMC3039945A,"Fas-ligand (CD178; CD95L; FasL) expression, however, correlates with lymph node involvement and distant metastases in CRC [207].",CRC,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",FHCRC,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",OCAMP,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",OCAMP,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",OSCC,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",TCGA,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",GSEA,lymph,1
PMC4096804A,"Three independent datasets of human OSCC (UW/FHCRC (97 patients), MD Anderson (MD, 71 patients (29)) and TCGA (134 patients) were first classified by stage (UW/FHCRC) or regional lymph node metastasis as surrogate markers of tumor aggressiveness and then independently analyzed by GSEA with OCAMP-A. In all cases there was enrichment of OCAMP-A in human tumors (Fig.",FHCRC,lymph,1
PMC5215363A,"In the eye, aberrant anti-retinal T cells are prevented from causing autoimmune disease by the mechanical blood-retina barrier protecting the ocular compartment,20 and both physical barriers and immune regulation mediate ocular immune privilege.26 Analogously, brain-reactive T cells, abundant in the normal immune repertoire, are prevented from initiating autoimmune encephalitis largely by the tight intercellular junctions of the blood-brain barrier.27",T,blood,-1
PMC5215363A,"In the eye, aberrant anti-retinal T cells are prevented from causing autoimmune disease by the mechanical blood-retina barrier protecting the ocular compartment,20 and both physical barriers and immune regulation mediate ocular immune privilege.26 Analogously, brain-reactive T cells, abundant in the normal immune repertoire, are prevented from initiating autoimmune encephalitis largely by the tight intercellular junctions of the blood-brain barrier.27",T,blood,-1
PMC5215363A,"In the eye, aberrant anti-retinal T cells are prevented from causing autoimmune disease by the mechanical blood-retina barrier protecting the ocular compartment,20 and both physical barriers and immune regulation mediate ocular immune privilege.26 Analogously, brain-reactive T cells, abundant in the normal immune repertoire, are prevented from initiating autoimmune encephalitis largely by the tight intercellular junctions of the blood-brain barrier.27",T,blood,-1
PMC5215363A,"In the eye, aberrant anti-retinal T cells are prevented from causing autoimmune disease by the mechanical blood-retina barrier protecting the ocular compartment,20 and both physical barriers and immune regulation mediate ocular immune privilege.26 Analogously, brain-reactive T cells, abundant in the normal immune repertoire, are prevented from initiating autoimmune encephalitis largely by the tight intercellular junctions of the blood-brain barrier.27",T,blood,-1
PMC3509129A,"Hemorrhagic enteritis was apparent in the small intestine of KO mice from day 0 (top, right); black arrows: red blood cells in the intestinal lumen.",KO,blood,-1
PMC5538449A,"CD34+CD19- cells were subfractionated into CD45RAlow/-, CD45RAint, and CD45RAhi subsets (Fig 1, A, initial myelopoiesis).27-30 These subsets were prestimulated with GM-CSF, SCF, FLT3L, and TNF-a for 48 hours to bias their differentiation to monocytes.",GM,CSF,-1
PMC5538449A,"CD34+CD19- cells were subfractionated into CD45RAlow/-, CD45RAint, and CD45RAhi subsets (Fig 1, A, initial myelopoiesis).27-30 These subsets were prestimulated with GM-CSF, SCF, FLT3L, and TNF-a for 48 hours to bias their differentiation to monocytes.",SCF,CSF,-1
PMC5538449A,"CD34+CD19- cells were subfractionated into CD45RAlow/-, CD45RAint, and CD45RAhi subsets (Fig 1, A, initial myelopoiesis).27-30 These subsets were prestimulated with GM-CSF, SCF, FLT3L, and TNF-a for 48 hours to bias their differentiation to monocytes.",TNF,CSF,-1
PMC5538449A,"CD34+CD19- cells were subfractionated into CD45RAlow/-, CD45RAint, and CD45RAhi subsets (Fig 1, A, initial myelopoiesis).27-30 These subsets were prestimulated with GM-CSF, SCF, FLT3L, and TNF-a for 48 hours to bias their differentiation to monocytes.",FLT3L,CSF,-1
PMC5289527A,"Of these, nine variants in four genes were significantly associated with KD in an imputed European descent, KD GWAS dataset (nominal p 0.05), and were differentially expressed in whole blood during acute versus convalescent KD [19, 29].",GWAS,blood,-1
PMC4062414A,"Some of their interactions are included in the molecular interaction map in Figure 14.At the brush border of intestinal epithelial cells, actin fibers are bundled through the action of VIL1/villin-1 (r = 0.68) and PLS1/plastin-1/fimbrin (r = 0.64) (Figure 14). VIL1 links the actin cytoskeleton to the plasma membrane by binding phosphatidylinositol-4,5-bisphosphate and PLCG1/phospholipase C gamma1 [57] (Figure 14).",VIL1,plasma,1
PMC4803572A,"Examining the perivascular niche, breast cancer (BCa) DTC have been demonstrated by Ghajar et al. to reside in a dormant state adjacent to mature blood vessels in the lung, bone marrow, and brain, associated with the local endothelial-derived factors such as thrombospondin-1 produced by the mature blood vessels (Fig",DTC,bone marrow,1
PMC4803572A,"Examining the perivascular niche, breast cancer (BCa) DTC have been demonstrated by Ghajar et al. to reside in a dormant state adjacent to mature blood vessels in the lung, bone marrow, and brain, associated with the local endothelial-derived factors such as thrombospondin-1 produced by the mature blood vessels (Fig",DTC,blood,-1
PMC4803572A,"Examining the perivascular niche, breast cancer (BCa) DTC have been demonstrated by Ghajar et al. to reside in a dormant state adjacent to mature blood vessels in the lung, bone marrow, and brain, associated with the local endothelial-derived factors such as thrombospondin-1 produced by the mature blood vessels (Fig",DTC,blood,-1
PMC4188889A,"In addition, nine features obtained from urine differentiated Ca from both H and CP, combined with high efficiency (SN = 90%, SP = 90%).",SN,urine,-1
PMC4188889A,"In addition, nine features obtained from urine differentiated Ca from both H and CP, combined with high efficiency (SN = 90%, SP = 90%).",CP,urine,-1
PMC5538449A,"KLF4 was also abundantly expressed in CD1a+ moDCs generated in the presence of GM-CSF plus IL-4 (Fig 2, A).IFN-g was previously shown to enhance KLF4 expression in monocytes.35",KLF4,CSF,1
PMC5538449A,"KLF4 was also abundantly expressed in CD1a+ moDCs generated in the presence of GM-CSF plus IL-4 (Fig 2, A).IFN-g was previously shown to enhance KLF4 expression in monocytes.35",KLF4,CSF,1
PMC5538449A,"KLF4 was also abundantly expressed in CD1a+ moDCs generated in the presence of GM-CSF plus IL-4 (Fig 2, A).IFN-g was previously shown to enhance KLF4 expression in monocytes.35",GM,CSF,1
PMC5538449A,"KLF4 was also abundantly expressed in CD1a+ moDCs generated in the presence of GM-CSF plus IL-4 (Fig 2, A).IFN-g was previously shown to enhance KLF4 expression in monocytes.35",IL-4,CSF,1
PMC3104081A,"In this study, we show that ADCC against ovarian carcinoma cells was not significantly decreased by high concentrations (up to 50%) of human serum.",ADCC,serum,1
PMC5332937A,"In adult females, inhibition of AR signaling could also increase mammary ductal branching and mammary epithelial cell proliferation; however, this phenotype was not due to changes in serum estradiol levels or ERa expression, but was attributed to increased AR expression and consequently an increase in the ratio of AR to ERa (as ERa level remained constant) [271].",AR,serum,1
PMC5332937A,"In adult females, inhibition of AR signaling could also increase mammary ductal branching and mammary epithelial cell proliferation; however, this phenotype was not due to changes in serum estradiol levels or ERa expression, but was attributed to increased AR expression and consequently an increase in the ratio of AR to ERa (as ERa level remained constant) [271].",AR,serum,1
PMC5332937A,"In adult females, inhibition of AR signaling could also increase mammary ductal branching and mammary epithelial cell proliferation; however, this phenotype was not due to changes in serum estradiol levels or ERa expression, but was attributed to increased AR expression and consequently an increase in the ratio of AR to ERa (as ERa level remained constant) [271].",AR,serum,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",KLF4,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",IRES,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",TGF,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",DNA,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",GFP,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",GM,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",GFP,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",KLF4DZNF,CSF,1
PMC5538449A,"These characteristics were not observed in GM-CSF/IL-4-dependent p-moDC differentiation cultures, irrespective of the presence or absence of exogenous TGF-b1.CD34+ progenitors were transduced with KLF4-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) or empty control vector and subsequently induced to differentiate for 5 days into monocyte/LC precursors (schematically shown in Fig 2, C).22 Ectopic KLF4 reduced percentages of CD1a+ cells in favor of CD14+CD1a- cells (Fig 5, A), whereas a KLF4 mutant (KLF4DZNF-IRES-GFP), lacking DNA-binding activity but still retaining the transactivation/transrepression domain,35,43 showed the opposite effect (Fig 5, A, right panel).",KLF4,CSF,1
PMC4606116A,"To aid detection and/or monitoring of CRC, carcinoembryonic antigen (CEA), a blood-based tumor marker, has been used extensively in clinic, but it lacks satisfying sensitivity for early tumor [12, 13].In this ""omics"" era, the application of high-throughput genomic and proteomic technologies has enabled the discovery of hundreds to thousands of biomarker candidates.",CEA,blood,1
PMC4606116A,"To aid detection and/or monitoring of CRC, carcinoembryonic antigen (CEA), a blood-based tumor marker, has been used extensively in clinic, but it lacks satisfying sensitivity for early tumor [12, 13].In this ""omics"" era, the application of high-throughput genomic and proteomic technologies has enabled the discovery of hundreds to thousands of biomarker candidates.",CRC,blood,1
PMC3104081A,"Indeed, in one cell line (CC-ARK-2), a consistent increase in cytotoxicity was detected in the presence of effector cells and human serum.",ARK-2,serum,1
PMC4881735A,"For example, overexpression of stomatin-like protein 2 is reported to be associated with invasion depth, tumor node metastasis stage, as well as lymph node and distant metastases, leading to poor prognosis in gastric cancer.6 Notch-1 has also been proven to be correlated with gastric cancer progression and to exert a predictive role for the poor clinical outcome of gastric cancer.7 Li et al8 have found by analyzing microarray data that a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p, and miR-126) is related to the survival and relapse of gastric cancer.",Notch-1,lymph,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",RPMI-1640,serum,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",FBS,serum,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",FBS,serum,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",DMEM,serum,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",FRH0201,serum,1
PMC5385398A,"HIBEpiC was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. QBC939 and FRH0201 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5%",QBC939,serum,1
PMC5000705A,"EMT-characteristic markers like E-cadherin, vimentin, N-cadherin, Twist, and SNAI1/2 were also examined in tissue of lymph node metastases.",cadherin,lymph,1
PMC5000705A,"EMT-characteristic markers like E-cadherin, vimentin, N-cadherin, Twist, and SNAI1/2 were also examined in tissue of lymph node metastases.",EMT,lymph,1
PMC5000705A,"EMT-characteristic markers like E-cadherin, vimentin, N-cadherin, Twist, and SNAI1/2 were also examined in tissue of lymph node metastases.",cadherin,lymph,1
PMC3474961A,"Serum PSA levels, and radiographic scans were used to determine PSA decline and TTP.",PSA,Serum,1
PMC3474961A,"Serum PSA levels, and radiographic scans were used to determine PSA decline and TTP.",TTP,Serum,1
PMC3474961A,"Serum PSA levels, and radiographic scans were used to determine PSA decline and TTP.",PSA,Serum,1
PMC4473102A,"As far as the absence of autoantigens common to skin and joints adduced as evidence for an autoinflammatory origin of the disease we have recently found that PsA is characterized by the presence of serum autoantibodies crossreacting with an epitope shared by skin and joint antigens [171].Finally our work shows that the two genes, SSP1 and GPNMB, encoding for osteopontin and osteoactivin are among the most expressed genes found in the gene array analysis (FC 450 and 147).",SSP1,serum,1
PMC4473102A,"As far as the absence of autoantigens common to skin and joints adduced as evidence for an autoinflammatory origin of the disease we have recently found that PsA is characterized by the presence of serum autoantibodies crossreacting with an epitope shared by skin and joint antigens [171].Finally our work shows that the two genes, SSP1 and GPNMB, encoding for osteopontin and osteoactivin are among the most expressed genes found in the gene array analysis (FC 450 and 147).",GPNMB,serum,1
PMC3474961A,It has been demonstrated that blocking of VEGFR may lead to a transient restoration of functional blood vessels in a variety of tumors.,VEGFR,blood,-1
PMC3474961A,"The second phase III trial will consist of 292 patients, and aims to evaluate the pain palliation benefit of adding custirsen to a taxane-based therapy as second-line chemotherapy in CRPC patients (ClinicalTrials.gov Identifier: NCT01083615) [128].As mentioned earlier, vascularisation in tumerous tissue is disorganized, has lower than normal blood flow, and therefore contributes to impaired drug supply to the tumor cells.",CRPC,blood,-1
PMC3474961A,"The second phase III trial will consist of 292 patients, and aims to evaluate the pain palliation benefit of adding custirsen to a taxane-based therapy as second-line chemotherapy in CRPC patients (ClinicalTrials.gov Identifier: NCT01083615) [128].As mentioned earlier, vascularisation in tumerous tissue is disorganized, has lower than normal blood flow, and therefore contributes to impaired drug supply to the tumor cells.",III,blood,-1
PMC3474961A,"The second phase III trial will consist of 292 patients, and aims to evaluate the pain palliation benefit of adding custirsen to a taxane-based therapy as second-line chemotherapy in CRPC patients (ClinicalTrials.gov Identifier: NCT01083615) [128].As mentioned earlier, vascularisation in tumerous tissue is disorganized, has lower than normal blood flow, and therefore contributes to impaired drug supply to the tumor cells.",NCT01083615,blood,-1
PMC4558321A,"Plasma CEA decreased to 26.5 ng/mL after 18 doses, but thereafter began to increase despite continued radiological evidence (target and non-target lesions) of additional disease reduction or stabilization.",CEA,Plasma,1
PMC2722670A,"Consequently, the sensitivity of serum markers to detect esophageal SCC was improved by using s-MKRN1-Abs in combination with conventional markers.",SCC,serum,1
PMC2722670A,"For this 50-kDa band, 18 of 73 (25%) sera of patients with esophageal SCC were sero-positive (data not shown).",SCC,sera,1
PMC2722670A,"Escherichia coli containing MKRN1 cDNA expression plasmid (MKRN1) or control empty plasmid (Control) was treated with (+) or without (-) IPTG for 2.5 h, and cell lysates were subsequently subjected to Western blot analysis using the sera from healthy donor #1 and esophageal SCC patients #15 as indicated.",cDNA,sera,1
PMC2722670A,"Escherichia coli containing MKRN1 cDNA expression plasmid (MKRN1) or control empty plasmid (Control) was treated with (+) or without (-) IPTG for 2.5 h, and cell lysates were subsequently subjected to Western blot analysis using the sera from healthy donor #1 and esophageal SCC patients #15 as indicated.",SCC,sera,1
PMC2722670A,"Escherichia coli containing MKRN1 cDNA expression plasmid (MKRN1) or control empty plasmid (Control) was treated with (+) or without (-) IPTG for 2.5 h, and cell lysates were subsequently subjected to Western blot analysis using the sera from healthy donor #1 and esophageal SCC patients #15 as indicated.",MKRN1,sera,1
PMC2722670A,"Escherichia coli containing MKRN1 cDNA expression plasmid (MKRN1) or control empty plasmid (Control) was treated with (+) or without (-) IPTG for 2.5 h, and cell lysates were subsequently subjected to Western blot analysis using the sera from healthy donor #1 and esophageal SCC patients #15 as indicated.",MKRN1,sera,1
PMC2722670A,"Escherichia coli containing MKRN1 cDNA expression plasmid (MKRN1) or control empty plasmid (Control) was treated with (+) or without (-) IPTG for 2.5 h, and cell lysates were subsequently subjected to Western blot analysis using the sera from healthy donor #1 and esophageal SCC patients #15 as indicated.",IPTG,sera,1
PMC2722670A,Recognition of MKRN1 by serum antibodies in patients with esophageal SCC.,SCC,serum,1
PMC2722670A,Recognition of MKRN1 by serum antibodies in patients with esophageal SCC.,MKRN1,serum,1
PMC5480073A,"Quantification of fluorescence signals of the identified molecular markers hTERT and HMGA1 was carried out using ImageJ software (National Institute of Health, United States).NLR: The NLR was calculated from a pre-operative whole blood sample count stained with Leishman.",NLR,blood,-1
PMC5480073A,"Quantification of fluorescence signals of the identified molecular markers hTERT and HMGA1 was carried out using ImageJ software (National Institute of Health, United States).NLR: The NLR was calculated from a pre-operative whole blood sample count stained with Leishman.",hTERT,blood,-1
PMC5480073A,"Quantification of fluorescence signals of the identified molecular markers hTERT and HMGA1 was carried out using ImageJ software (National Institute of Health, United States).NLR: The NLR was calculated from a pre-operative whole blood sample count stained with Leishman.",HMGA1,blood,-1
PMC3266428A,"Data were expressed in absolute terms and as SDS (22).For cohort 1, RNA samples, extracted from whole blood from 20 individuals and selected on the basis of their rapid or slow growth and availability of RNA, were sent to ServiceXS (Leiden, the Netherlands) for gene expression analysis.",SDS,blood,-1
PMC3266428A,"Data were expressed in absolute terms and as SDS (22).For cohort 1, RNA samples, extracted from whole blood from 20 individuals and selected on the basis of their rapid or slow growth and availability of RNA, were sent to ServiceXS (Leiden, the Netherlands) for gene expression analysis.",RNA,blood,-1
PMC3266428A,"Data were expressed in absolute terms and as SDS (22).For cohort 1, RNA samples, extracted from whole blood from 20 individuals and selected on the basis of their rapid or slow growth and availability of RNA, were sent to ServiceXS (Leiden, the Netherlands) for gene expression analysis.",RNA,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",Trop-2,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",Trop-2,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",Trop-2,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",Trop-2,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",Trop-2,blood,-1
PMC3224774A,"The difference in Trop-2 surface protein expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression, as tested by flow cytometry, was statistically significant (P = 0.04) as well as mRNA relative expression between cell lines with low/negligible Trop-2 expression and those with positive Trop-2 expression (p  0.05).Each carcinosarcoma cell line was tested for sensitivity to natural killer (NK) cell activity by exposure to peripheral blood lymphocytes (PBLs) collected from several healthy donors.",mRNA,blood,-1
PMC5414739A,"For example, in the hair follicle, PRL contributes to maintain the stem cell pool in quiescence, whereas in the mammary gland and in the brain, it stimulates progenitor proliferation and pushes the progeny towards differentiated (mature) states.",PRL,hair,1
PMC3224774A,Cytotoxicity in the presence of human plasma diluted 1:2 (with or without heat-inactivation) with effector cells and either hRS7 or rituximab control antibody in 5 h 51Cr-release assays.,hRS7,plasma,1
PMC5414739A,"Although opposite, these effects nicely correlate with, and provide a mechanistic rationale for, the physiological actions of PRL observed on these tissues during pregnancy, ie, arrest of hair growth and promotion of mammopoiesis/lactopoiesis and of parental behavior.",PRL,hair,-1
PMC4096804A,MOC2LN was generated from a lymph node bearing metastatic MOC2.,MOC2,lymph,1
PMC4096804A,MOC2LN was generated from a lymph node bearing metastatic MOC2.,MOC2LN,lymph,1
PMC4687932A,"In contrast, efficient adhesion/capturing of EpCAMlow/neg cells (cell line and/or EpCAM-depleted blood fractions) could be achieved by antibodies specific for CD49f, Trop2, c-Met and CK8.",CK8,blood,-1
PMC4687932A,"In contrast, efficient adhesion/capturing of EpCAMlow/neg cells (cell line and/or EpCAM-depleted blood fractions) could be achieved by antibodies specific for CD49f, Trop2, c-Met and CK8.",Trop2,blood,-1
PMC4687932A,"In contrast, efficient adhesion/capturing of EpCAMlow/neg cells (cell line and/or EpCAM-depleted blood fractions) could be achieved by antibodies specific for CD49f, Trop2, c-Met and CK8.",CD49f,blood,-1
PMC4687932A,"In contrast, efficient adhesion/capturing of EpCAMlow/neg cells (cell line and/or EpCAM-depleted blood fractions) could be achieved by antibodies specific for CD49f, Trop2, c-Met and CK8.",Met,blood,-1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",hRS7,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",hRS7,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",ADCC,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",ADCC,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",hRS7,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",hRS7,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",PBL,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",PBL,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",Trop-2,plasma,1
PMC3224774A,"Addition of physiologic concentrations of IgG (heat-inactivated plasma in a 1:2 ratio) to PBL in the presence of hRS7 did not significantly decrease hRS7-mediated killing (P = 0.95) when compared to incubation without plasma (Figure 3), suggesting that the presence of non-specific IgG does not alter the ability of hRS7 to mediate ADCC in Trop-2 expressing carcinosarcoma cells.",Trop-2,plasma,1
PMC3224774A,"However, incubation of plasma with PBL in the presence of hRS7 consistently increased hRS7-mediated cytotoxicity against OMMT-ARK-2 when compared to incubation with PBL alone (P = 0.002, Figure 3).",PBL,plasma,1
PMC3224774A,"However, incubation of plasma with PBL in the presence of hRS7 consistently increased hRS7-mediated cytotoxicity against OMMT-ARK-2 when compared to incubation with PBL alone (P = 0.002, Figure 3).",OMMT,plasma,1
PMC3224774A,"However, incubation of plasma with PBL in the presence of hRS7 consistently increased hRS7-mediated cytotoxicity against OMMT-ARK-2 when compared to incubation with PBL alone (P = 0.002, Figure 3).",hRS7,plasma,1
PMC3224774A,"However, incubation of plasma with PBL in the presence of hRS7 consistently increased hRS7-mediated cytotoxicity against OMMT-ARK-2 when compared to incubation with PBL alone (P = 0.002, Figure 3).",PBL,plasma,1
PMC3224774A,"However, incubation of plasma with PBL in the presence of hRS7 consistently increased hRS7-mediated cytotoxicity against OMMT-ARK-2 when compared to incubation with PBL alone (P = 0.002, Figure 3).",ARK-2,plasma,1
PMC3224774A,Addition of plasma with or without hRS7 was unable to induce significant cytotoxicity against OMMT-ARK-2 cells in the absence of PBL (data not shown).,OMMT,plasma,-1
PMC3224774A,Addition of plasma with or without hRS7 was unable to induce significant cytotoxicity against OMMT-ARK-2 cells in the absence of PBL (data not shown).,hRS7,plasma,1
PMC3224774A,Addition of plasma with or without hRS7 was unable to induce significant cytotoxicity against OMMT-ARK-2 cells in the absence of PBL (data not shown).,ARK-2,plasma,1
PMC3224774A,Addition of plasma with or without hRS7 was unable to induce significant cytotoxicity against OMMT-ARK-2 cells in the absence of PBL (data not shown).,PBL,plasma,1
PMC4606475A,"Interestingly, administration of bone marrow-derived macrophages during ongoing toxic injury was sufficient to ameliorate fibrosis, and this was associated with increased Mmp13 expression [13].",Mmp13,bone marrow,1
PMC3224774A,"The OMMT-ARK-2 cell line was evaluated for sensitivity to complement-mediated cytotoxicity and for possible inhibition of ADCC by physiological concentrations of IgG. Human plasma (with or without heat inactivation) was added in the presence or absence of the effector cells and hRS7 in a 1:2 ratio, with the degree of cell lysis evaluated via 5 h 51Cr-release assays.",OMMT,plasma,1
PMC3224774A,"The OMMT-ARK-2 cell line was evaluated for sensitivity to complement-mediated cytotoxicity and for possible inhibition of ADCC by physiological concentrations of IgG. Human plasma (with or without heat inactivation) was added in the presence or absence of the effector cells and hRS7 in a 1:2 ratio, with the degree of cell lysis evaluated via 5 h 51Cr-release assays.",ARK-2,plasma,1
PMC3224774A,"The OMMT-ARK-2 cell line was evaluated for sensitivity to complement-mediated cytotoxicity and for possible inhibition of ADCC by physiological concentrations of IgG. Human plasma (with or without heat inactivation) was added in the presence or absence of the effector cells and hRS7 in a 1:2 ratio, with the degree of cell lysis evaluated via 5 h 51Cr-release assays.",ADCC,plasma,1
PMC3224774A,"The OMMT-ARK-2 cell line was evaluated for sensitivity to complement-mediated cytotoxicity and for possible inhibition of ADCC by physiological concentrations of IgG. Human plasma (with or without heat inactivation) was added in the presence or absence of the effector cells and hRS7 in a 1:2 ratio, with the degree of cell lysis evaluated via 5 h 51Cr-release assays.",hRS7,plasma,1
PMC3583531A,"Nkx3-1 mRNA is also present in non-urogenital tissues at 16 dpc, including the tooth bud, hair follicle, nasopharyngeal epithelium, and portions of the central nervous system (Tanaka et al., 1999).",mRNA,hair,-1
PMC3583531A,"Nkx3-1 mRNA is also present in non-urogenital tissues at 16 dpc, including the tooth bud, hair follicle, nasopharyngeal epithelium, and portions of the central nervous system (Tanaka et al., 1999).",Nkx3,hair,-1
PMC2928967A,"However, immunoelectron microscopy analysis demonstrated that the subcellular localization of the TACSTD2 protein falls onto the plasma membrane but not the regions where the desmosome apparatus exists (supplemental Figure 3B, see http://ajp.amjpathol.org).",TACSTD2,plasma,1
PMC4188889A,"Paulo et al[63] compared differentially expressed proteins in rat in activated and serum-starved non-proliferating pancreatic stellate cells (PaSC), emerging key mediators in chronic pancreatitis and PC pathogenesis.",PC,serum,1
PMC2800362A,"Tissue recombinants were cultured in DMEM media with 10% fetal bovine serum supplemented with 10-7 M dihydrotestosterone (DHT) overnight, followed by transplantation under the kidney capsules of nude mice.",DMEM,serum,1
PMC2800362A,"Tissue recombinants were cultured in DMEM media with 10% fetal bovine serum supplemented with 10-7 M dihydrotestosterone (DHT) overnight, followed by transplantation under the kidney capsules of nude mice.",DHT,serum,1
PMC5328612A,"A Chinese nomogram predicts individual OS after resection of ICC (Figure 3).43 Prognostic factors in this model included CEA, CA19-9, vascular invasion, presence of lymph node metastases, direct invasion and local metastases, number of tumors, and tumor diameter.",ICC,lymph,1
PMC5328612A,"A Chinese nomogram predicts individual OS after resection of ICC (Figure 3).43 Prognostic factors in this model included CEA, CA19-9, vascular invasion, presence of lymph node metastases, direct invasion and local metastases, number of tumors, and tumor diameter.",OS,lymph,1
PMC5328612A,"A Chinese nomogram predicts individual OS after resection of ICC (Figure 3).43 Prognostic factors in this model included CEA, CA19-9, vascular invasion, presence of lymph node metastases, direct invasion and local metastases, number of tumors, and tumor diameter.",CA19,lymph,1
PMC5328612A,"A Chinese nomogram predicts individual OS after resection of ICC (Figure 3).43 Prognostic factors in this model included CEA, CA19-9, vascular invasion, presence of lymph node metastases, direct invasion and local metastases, number of tumors, and tumor diameter.",CEA,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",G2-G3,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",cadherin,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",Trop-2,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",pT1,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",p53,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",T,lymph,1
PMC4019539A,"The effects of Trop-2 were adjusted for established prognostic factors; i.e., age, grading (G2-G3 versus G1), pathologic T stage (pT2-pT3 versus pT1), number of metastatic lymph nodes (1-3, 4-9 and 9 versus 0), ERa, HER-2/neu, p53, and E-cadherin expression levels.",G1,lymph,1
PMC5437520A,"Foetal Bovine Serum Superior (FBS) was purchased from Biochrom (Berlin, Germany) and trypsin 10-fold was supplied by PAA (Pasching, Austria).",PAA,Serum,1
PMC5437520A,"Foetal Bovine Serum Superior (FBS) was purchased from Biochrom (Berlin, Germany) and trypsin 10-fold was supplied by PAA (Pasching, Austria).",FBS,Serum,1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC3906064A,The equations for percent error and coefficient of variation are as follows: percent error = abs(measured value - expected value)/expected value * 100 and coefficient of variation = standard deviation/mean * 100.Recovery of CTC on the LiquidBiopsy platform relies on fluid phase labeling of whole blood with a functionalized ferrofluid followed by high throughput partitioning of CTC from blood using a CTC sheath flow cell.,CTC,blood,-1
PMC4188889A,"To determine if such arrays can be used to identify novel autoantibodies in the sera from PC patients, Patwa et al[61] resolved proteins from a PDAC cell line (MIAPACA) by 2-D liquid-based separations and then arrayed them on nitrocellulose slides.",PDAC,sera,1
PMC4188889A,"To determine if such arrays can be used to identify novel autoantibodies in the sera from PC patients, Patwa et al[61] resolved proteins from a PDAC cell line (MIAPACA) by 2-D liquid-based separations and then arrayed them on nitrocellulose slides.",PC,sera,1
PMC4188889A,"To determine if such arrays can be used to identify novel autoantibodies in the sera from PC patients, Patwa et al[61] resolved proteins from a PDAC cell line (MIAPACA) by 2-D liquid-based separations and then arrayed them on nitrocellulose slides.",MIAPACA,sera,1
PMC4188889A,The slides were probed with sera from a set of patients diagnosed with PC and compared with age- and sex-matched normal subjects.,PC,sera,1
PMC3369113A,"After extensive washes with PBS without Ca2+/Mg2+, cells were incubated for 30 min in Hepes buffer [20 mM Hepes pH 7.4, 150 mM NaCl, 1% bovine serum albumin, (BSA)].",BSA,serum,1
PMC3369113A,"After extensive washes with PBS without Ca2+/Mg2+, cells were incubated for 30 min in Hepes buffer [20 mM Hepes pH 7.4, 150 mM NaCl, 1% bovine serum albumin, (BSA)].",PBS,serum,1
PMC3369113A,"Briefly, PC3-2/Trop-2, PC3-2/Mock and PC3-2/b5 cell transfectants cultured in complete medium were washed once with PBS without Ca2+/Mg2+, and cultured for 5 h in serum-free medium.",PC3,serum,1
PMC3369113A,"Briefly, PC3-2/Trop-2, PC3-2/Mock and PC3-2/b5 cell transfectants cultured in complete medium were washed once with PBS without Ca2+/Mg2+, and cultured for 5 h in serum-free medium.",PC3,serum,1
PMC3369113A,"Briefly, PC3-2/Trop-2, PC3-2/Mock and PC3-2/b5 cell transfectants cultured in complete medium were washed once with PBS without Ca2+/Mg2+, and cultured for 5 h in serum-free medium.",PC3,serum,1
PMC3369113A,"Briefly, PC3-2/Trop-2, PC3-2/Mock and PC3-2/b5 cell transfectants cultured in complete medium were washed once with PBS without Ca2+/Mg2+, and cultured for 5 h in serum-free medium.",PBS,serum,1
PMC5467782A,"Finally, we compared the expression of miR-181b-5p in peripheral blood of 15 healthy people and 20 patients with NSCLC (patient characteristics are indicated in Table V).",NSCLC,blood,-1
PMC3039945A,"[91] found that high FOXP3(+) Treg density was associated with early tumour stage and independently predicted improved disease-specific survival in MMR-proficient CRCs, but not in MMR-deficient CRCs, though high Treg density correlated with absence of lymph node involvement and vascular invasion in the latter.",MMR,lymph,1
PMC3039945A,"[91] found that high FOXP3(+) Treg density was associated with early tumour stage and independently predicted improved disease-specific survival in MMR-proficient CRCs, but not in MMR-deficient CRCs, though high Treg density correlated with absence of lymph node involvement and vascular invasion in the latter.",MMR,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",UBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",UBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",Spint2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",Spint2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",UBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",UBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",B2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",B2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",TBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",TBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",B2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",B2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",Spint2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",Spint2,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",TBP,lymph,1
PMC2441949A,"In a separate study conducted with a small set of tissues (n=14), we observed that B2M maintained its high prognostic accuracy for lymph node metastases (AUC=0.79) when more classical reference control genes TBP (Ohl et al, 2006) or UBP (Andersen et al, 2004) were substituted for Spint2 (not shown).In this study, we observed that low expression of B2M was a strong prognostic indicator of lymph node metastases regardless of whether the mean expression value of the 15-gene set was used as an internal reference control (AUC=0.85; Table 4), the median expression value of the 15-gene set was used (AUC=0.83), Spint2 was used as a single internal reference gene (AUC=0.87), or classic reference genes such as TBP or UBP were used (AUC=0.79).",TBP,lymph,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",RD,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",RD,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",YKL-40,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",YKL-40,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",YKL-40,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",YKL-40,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",MN,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",MN,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",TIMP-1,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",TIMP-1,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",MN,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",MN,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",RD,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",RD,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",hTERT,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",hTERT,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",ELISA,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",ELISA,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",TIMP-1,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",TIMP-1,plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",ELISA,Plasma,1
PMC5480073A,"The patient did not present any clinical signs of sepsis at that point of time, having been on steroids for the last 24 h.hTERT, TIMP-1 and YKL-40 by ELISA: Plasma concentrations of TIMP-1 (ng/mL, RD Systems, MN, United States), hTERT (ng/L, MyBiosourse, CA, United States) and plasma YKL-40 (ng/mL, RD Systems, MN, United States) were determined by sandwich ELISA assay using commercially available kits as per the manufacturer's protocol.",ELISA,plasma,1
PMC5355237A,"For the CDC assay, ENKTL cells were incubated with LMP1-IgG, and this was followed by the addition of 20% human serum or heat-inactivated human serum.",ENKTL,serum,1
PMC5355237A,"For the CDC assay, ENKTL cells were incubated with LMP1-IgG, and this was followed by the addition of 20% human serum or heat-inactivated human serum.",ENKTL,serum,1
PMC5355237A,"For the CDC assay, ENKTL cells were incubated with LMP1-IgG, and this was followed by the addition of 20% human serum or heat-inactivated human serum.",CDC,serum,1
PMC5355237A,"For the CDC assay, ENKTL cells were incubated with LMP1-IgG, and this was followed by the addition of 20% human serum or heat-inactivated human serum.",CDC,serum,1
PMC3090697A,Viable cells were identified by trypan blue exclusion.1 x 105 irradiated Swiss 3T3 fibroblast cells were plated onto vitrogen-fibronectin (Cohesion Technology and Sigma) coated 24-well plates and cultured in DMEM/F12 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) overnight.,DMEM,serum,1
PMC3090697A,Viable cells were identified by trypan blue exclusion.1 x 105 irradiated Swiss 3T3 fibroblast cells were plated onto vitrogen-fibronectin (Cohesion Technology and Sigma) coated 24-well plates and cultured in DMEM/F12 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) overnight.,F12,serum,1
PMC3090697A,Viable cells were identified by trypan blue exclusion.1 x 105 irradiated Swiss 3T3 fibroblast cells were plated onto vitrogen-fibronectin (Cohesion Technology and Sigma) coated 24-well plates and cultured in DMEM/F12 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) overnight.,FBS,serum,1
PMC4690245A,"In addition, it was significantly positively associated with tumor diameter, clinical stage, and lymph node metastasis, suggesting MTA1 protein is engaged in the progression and aggression of lung cancer.",MTA1,lymph,1
PMC4165776A,"The number of MCF7 cells spiked into lysed blood at concentrations from 3 to 100 cells/mL, captured on anti-EpCAM-coated biotin/Ppy-microfluidics from spiked lysed blood, and subsequently released by applying an electric field at -0.8 V for 15 s. (b) The effect of applied electrical potentials and time on the release efficiency of spiked MCF7 cells.",MCF7,blood,1
PMC4165776A,"The number of MCF7 cells spiked into lysed blood at concentrations from 3 to 100 cells/mL, captured on anti-EpCAM-coated biotin/Ppy-microfluidics from spiked lysed blood, and subsequently released by applying an electric field at -0.8 V for 15 s. (b) The effect of applied electrical potentials and time on the release efficiency of spiked MCF7 cells.",MCF7,blood,-1
PMC4165776A,"The number of MCF7 cells spiked into lysed blood at concentrations from 3 to 100 cells/mL, captured on anti-EpCAM-coated biotin/Ppy-microfluidics from spiked lysed blood, and subsequently released by applying an electric field at -0.8 V for 15 s. (b) The effect of applied electrical potentials and time on the release efficiency of spiked MCF7 cells.",MCF7,blood,1
PMC4165776A,"The number of MCF7 cells spiked into lysed blood at concentrations from 3 to 100 cells/mL, captured on anti-EpCAM-coated biotin/Ppy-microfluidics from spiked lysed blood, and subsequently released by applying an electric field at -0.8 V for 15 s. (b) The effect of applied electrical potentials and time on the release efficiency of spiked MCF7 cells.",MCF7,blood,-1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",ADCC,serum,1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",PBL,serum,1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",USPC,serum,1
PMC3128671A,"To evaluate the eventual inhibition of ADCC against USPC cell lines by physiological human serum concentrations of g-globulin, human serum diluted 1:2 was added in the presence or absence of effector PBL.",USPC,serum,1
PMC5538449A,"These cells can give rise to LCs under inflammatory conditions.9 Congruent with previous observations,12 the Notch ligand Delta-1 cooperates with TGF-b1 to induce LCs from CD14+ blood monocytes (moLCs; CD1a+CD207+ cells).",CD14,blood,-1
PMC5538449A,"These cells can give rise to LCs under inflammatory conditions.9 Congruent with previous observations,12 the Notch ligand Delta-1 cooperates with TGF-b1 to induce LCs from CD14+ blood monocytes (moLCs; CD1a+CD207+ cells).",TGF,blood,-1
PMC5538449A,"These cells can give rise to LCs under inflammatory conditions.9 Congruent with previous observations,12 the Notch ligand Delta-1 cooperates with TGF-b1 to induce LCs from CD14+ blood monocytes (moLCs; CD1a+CD207+ cells).",Delta-1,blood,-1
PMC5385398A,"The membranes were blocked with 5% bovine serum albumin for 2 h and incubated with each primary antibody overnight at 4 degC. The signals from the primary antibody were amplified by HRP conjugated anti-mouse IgG or anti-rabbit IgG, and the bands were visualized with a FluorChem E system (Protein Simple, United States).The shRNA sequences and cDNA of wild-type CUL4A gene were cloned into pLenti-vectors.",cDNA,serum,1
PMC5385398A,"The membranes were blocked with 5% bovine serum albumin for 2 h and incubated with each primary antibody overnight at 4 degC. The signals from the primary antibody were amplified by HRP conjugated anti-mouse IgG or anti-rabbit IgG, and the bands were visualized with a FluorChem E system (Protein Simple, United States).The shRNA sequences and cDNA of wild-type CUL4A gene were cloned into pLenti-vectors.",HRP,serum,1
PMC5385398A,"The membranes were blocked with 5% bovine serum albumin for 2 h and incubated with each primary antibody overnight at 4 degC. The signals from the primary antibody were amplified by HRP conjugated anti-mouse IgG or anti-rabbit IgG, and the bands were visualized with a FluorChem E system (Protein Simple, United States).The shRNA sequences and cDNA of wild-type CUL4A gene were cloned into pLenti-vectors.",CUL4A,serum,1
PMC5042010A,"In brief, the cellular component in the starting blood volume was blocked with FcR block and labelled with a biotinylated antibody cocktail consisting of anti-EpCAM alone, or in combination with anti-HER2, and anti-TROP2 (Cynvenio Biosystems) followed by iMAG streptavidin beads.",iMAG,blood,1
PMC5042010A,"In brief, the cellular component in the starting blood volume was blocked with FcR block and labelled with a biotinylated antibody cocktail consisting of anti-EpCAM alone, or in combination with anti-HER2, and anti-TROP2 (Cynvenio Biosystems) followed by iMAG streptavidin beads.",TROP2,blood,1
PMC5042010A,"In brief, the cellular component in the starting blood volume was blocked with FcR block and labelled with a biotinylated antibody cocktail consisting of anti-EpCAM alone, or in combination with anti-HER2, and anti-TROP2 (Cynvenio Biosystems) followed by iMAG streptavidin beads.",HER2,blood,1
PMC5042010A,The labeled blood was processed in the CTC flow cell on the LiquidBiopsy platform (Cynvenio Biosystems).,CTC,blood,1
PMC4708083A,", 2009).Two growth factors, FGF7 and granulocyte-colony stimulating factor (G-CSF), have been proposed to act as mitogens for HPCs (Piscaglia et al.",FGF7,CSF,1
PMC3981717A,"Logistic regression was used to assess the association of SNPs with and risk of PVTT, which adjusted by age, gender, HBsAg, serum AFP, tumor size and number of tumor.",PVTT,serum,1
PMC3981717A,"Logistic regression was used to assess the association of SNPs with and risk of PVTT, which adjusted by age, gender, HBsAg, serum AFP, tumor size and number of tumor.",AFP,serum,1
PMC4344740A,"Because all the blood samplings in this study were done after the onset of stroke, when the patients were auto-sensitized to RPA2 is to be proved.",RPA2,blood,-1
PMC4469888A,Sections were blocked with blocking buffer (10% donkey serum + 1% BSA in PBST) for 2 h at room temperature.,PBST,serum,1
PMC4469888A,Sections were blocked with blocking buffer (10% donkey serum + 1% BSA in PBST) for 2 h at room temperature.,BSA,serum,1
